1	Comparison	Comparison	B-NP	NN	0	_	_	_	_
2	with	with	B-PP	IN	0	_	_	_	_
3	alkaline	alkaline	B-NP	NN	:::NOCLASS	_	_	_	_
4	phosphatases	phosphatas	I-NP	NNS	:::NOCLASS	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	5	5	B-NP	CD	:::NOCLASS	_	_	_	_
7	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
8	nucleotidase	nucleotidase	I-NP	NN	:::NOCLASS	_	_	_	_

1	Pharmacologic	Pharmacologic	B-NP	JJ	0	_	_	_	_
2	aspects	aspect	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	neonatal	neonatal	B-NP	JJ	UMLS:C0857007:T047:DISO	_	_	_	_
5	hyperbilirubinemia	hyperbilirubinemia	I-NP	NN	UMLS:C0857007:T047:DISO	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	When	When	B-ADVP	WRB	0	_	_	_	_
2	CSF	CSF	B-NP	NN	0	_	_	_	_
3	[	[	O	(	0	_	_	_	_
4	HCO3	HCO3	B-NP	NN	0	_	_	_	_
5	-	-	B-ADJP	HYPH	0	_	_	_	_
6	]	]	O	)	0	_	_	_	_
7	is	be	B-VP	VBZ	0	_	_	_	_
8	shown	show	I-VP	VBN	0	_	_	_	_
9	as	as	B-PP	IN	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	function	function	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	CSF	CSF	B-NP	NN	0	_	_	_	_
14	PCO2	PCO2	I-NP	NN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	data	datum	I-NP	NNS	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	K	K	B-NP	NN	0	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	depleted	deplete	I-NP	VBN	0	_	_	_	_
21	rats	rat	I-NP	NNS	0	_	_	_	_
22	are	be	B-VP	VBP	0	_	_	_	_
23	no	no	I-VP	RB	0	_	_	_	_
24	longer	longer	I-VP	RB	0	_	_	_	_
25	displaced	displace	I-VP	VBD	0	_	_	_	_
26	when	when	B-ADVP	WRB	0	_	_	_	_
27	compared	compare	B-PP	VBN	0	_	_	_	_
28	to	to	B-PP	TO	0	_	_	_	_
29	controls	control	B-NP	NNS	0	_	_	_	_
30	but	but	O	CC	0	_	_	_	_
31	still	still	B-ADVP	RB	0	_	_	_	_
32	have	have	B-VP	VB	0	_	_	_	_
33	a	a	B-NP	DT	0	_	_	_	_
34	significantly	significantly	I-NP	RB	0	_	_	_	_
35	greater	great	I-NP	JJR	0	_	_	_	_
36	slope	slope	I-NP	NN	0	_	_	_	_
37	(	(	O	(	0	_	_	_	_
38	1	1	B-NP	CD	0	_	_	_	_
39	.	.	I-NP	.	0	_	_	_	_
40	21	21	I-NP	CD	0	_	_	_	_
41	+	+	O	SYM	0	_	_	_	_
42	/	/	O	SYM	0	_	_	_	_
43	-	-	B-NP	SYM	0	_	_	_	_
44	0	0	B-NP	CD	0	_	_	_	_
45	.	.	I-NP	SYM	0	_	_	_	_
46	23	23	I-NP	CD	0	_	_	_	_
47	vs	v	I-NP	NNS	0	_	_	_	_
48	.	.	O	.	0	_	_	_	_

1	Flurazepam	Flurazepam	B-NP	NNP	0	_	_	_	_
2	thus	thus	B-ADVP	RB	0	_	_	_	_
3	appears	appear	B-VP	VBZ	0	_	_	_	_
4	to	to	I-VP	TO	0	_	_	_	_
5	be	be	I-VP	VB	0	_	_	_	_
6	an	an	B-NP	DT	0	_	_	_	_
7	effective	effective	I-NP	JJ	0	_	_	_	_
8	hypnotic	hypnotic	I-NP	JJ	0	_	_	_	_
9	drug	drug	I-NP	NN	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	optimum	optimum	I-NP	JJ	0	_	_	_	_
13	dose	dose	I-NP	NN	0	_	_	_	_
14	for	for	B-PP	IN	0	_	_	_	_
15	use	use	B-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	general	general	B-NP	JJ	0	_	_	_	_
18	practice	practice	I-NP	NN	0	_	_	_	_
19	being	be	B-VP	VBG	0	_	_	_	_
20	15	15	B-NP	CD	0	_	_	_	_
21	mg	mg	I-NP	NN	0	_	_	_	_
22	at	at	B-PP	IN	0	_	_	_	_
23	night	night	B-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Beta	Beta	B-NP	NN	0	_	_	_	_
2	blocking	block	I-NP	VBG	0	_	_	_	_
3	agents	agent	I-NP	NNS	0	_	_	_	_
4	.	.	O	.	0	_	_	_	_

1	When	When	B-ADVP	WRB	0	_	_	_	_
2	extracorporeal	extracorporeal	B-NP	JJ	0	_	_	_	_
3	CO2	CO2	I-NP	NN	0	_	_	_	_
4	removal	removal	I-NP	NN	0	_	_	_	_
5	approximated	approximate	B-VP	VBD	0	_	_	_	_
6	CO2	CO2	B-NP	NN	0	_	_	_	_
7	production	production	I-NP	NN	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	VCO2	VCO2	B-NP	NN	0	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	alveolar	alveolar	B-NP	JJ	UMLS:C1440080:T023:ANAT	_	_	_	_
13	ventilation	ventilation	I-NP	NN	0	_	_	_	_
14	almost	almost	B-ADVP	RB	0	_	_	_	_
15	ceased	cease	B-VP	VBD	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Intravenous	Intravenous	B-NP	JJ	0	_	_	_	_
2	administration	administration	I-NP	NN	0	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	25	25	B-NP	CD	0	_	_	_	_
5	mg	mg	I-NP	NN	0	_	_	_	_
6	/	/	B-NP	SYM	0	_	_	_	_
7	kg	kg	I-NP	NN	0	_	_	_	_
8	)	)	O	)	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	carbonic	carbonic	B-NP	JJ	:::NOCLASS	_	_	_	_
11	anhydrase	anhydrase	I-NP	NN	:::NOCLASS	_	_	_	_
12	inhibitors	inhibitor	I-NP	NNS	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	acetazolamide	acetazolamide	B-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	methazolamide	methazolamide	B-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	dichlorphenamide	dichlorphenamide	B-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	sulthiame	sulthiame	B-NP	NN	0	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	induced	induce	B-VP	VBD	0	_	_	_	_
23	an	an	B-NP	DT	0	_	_	_	_
24	early	early	I-NP	JJ	0	_	_	_	_
25	important	important	I-NP	JJ	0	_	_	_	_
26	rise	rise	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	cortical	cortical	B-NP	JJ	UMLS:C0001613:T023:ANAT|UMLS:C0007776:T023:ANAT|UMLS:C0022655:T023:ANAT	_	_	_	_
29	p	p	I-NP	NN	0	_	_	_	_
30	O2	O2	I-NP	NN	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	which	which	B-NP	WDT	0	_	_	_	_
33	is	be	B-VP	VBZ	0	_	_	_	_
34	not	not	O	RB	0	_	_	_	_
35	dependent	dependent	B-ADJP	JJ	0	_	_	_	_
36	on	on	B-PP	IN	0	_	_	_	_
37	increase	increase	B-NP	NN	0	_	_	_	_
38	of	of	B-PP	IN	0	_	_	_	_
39	p	p	B-NP	NN	0	_	_	_	_
40	O2	O2	I-NP	NN	0	_	_	_	_
41	and	and	O	CC	0	_	_	_	_
42	p	p	B-NP	NN	0	_	_	_	_
43	CO2	CO2	I-NP	NN	0	_	_	_	_
44	and	and	O	CC	0	_	_	_	_
45	decrease	decrease	B-NP	NN	0	_	_	_	_
46	of	of	B-PP	IN	0	_	_	_	_
47	pH	pH	B-NP	NN	0	_	_	_	_
48	in	in	B-PP	IN	0	_	_	_	_
49	arterial	arterial	B-NP	JJ	UMLS:C0003842:T023:ANAT	_	_	_	_
50	blood	blood	I-NP	NN	0	_	_	_	_
51	.	.	O	.	0	_	_	_	_

1	Teratological	Teratological	B-NP	JJ	0	_	_	_	_
2	study	study	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	etoperidone	etoperidone	B-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	rat	rat	I-NP	NN	0	_	_	_	_
8	and	and	I-NP	CC	0	_	_	_	_
9	rabbit	rabbit	I-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	Colorectal	Colorectal	B-NP	JJ	0	_	_	_	_
2	polyps	polyp	I-NP	NNS	0	_	_	_	_
3	should	should	B-VP	MD	0	_	_	_	_
4	be	be	I-VP	VB	0	_	_	_	_
5	removed	remove	I-VP	VBN	0	_	_	_	_
6	endoscopically	endoscopically	B-ADVP	RB	0	_	_	_	_
7	whenever	whenever	B-ADVP	WRB	0	_	_	_	_
8	possible	possible	B-ADJP	JJ	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	variable	variable	I-NP	JJ	0	_	_	_	_
3	HMG	HMG	I-NP	NN	:::NOCLASS	_	_	_	_
4	dosage	dosage	I-NP	NN	0	_	_	_	_
5	regimen	regimen	I-NP	NN	0	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	found	find	I-VP	VBN	0	_	_	_	_
8	to	to	I-VP	TO	0	_	_	_	_
9	offer	offer	I-VP	VB	0	_	_	_	_
10	no	no	B-NP	DT	0	_	_	_	_
11	advantages	advantage	I-NP	NNS	0	_	_	_	_
12	when	when	B-ADVP	WRB	0	_	_	_	_
13	compared	compare	B-PP	VBN	0	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	our	our	B-NP	PRP$	0	_	_	_	_
16	standard	standard	I-NP	JJ	0	_	_	_	_
17	daily	daily	I-NP	JJ	0	_	_	_	_
18	dosage	dosage	I-NP	NN	0	_	_	_	_
19	regimen	regimen	I-NP	NN	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	When	When	B-ADVP	WRB	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	CO2	CO2	I-NP	NN	0	_	_	_	_
4	content	content	I-NP	NN	0	_	_	_	_
5	reached	reach	B-VP	VBD	0	_	_	_	_
6	9	9	B-NP	CD	0	_	_	_	_
7	Vol	Vol	I-NP	NN	0	_	_	_	_
8	%	%	I-NP	NN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	animals	animal	I-NP	NNS	0	_	_	_	_
11	became	become	B-VP	VBD	0	_	_	_	_
12	apathic	apathic	B-ADJP	JJ	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	lost	lose	B-VP	VBN	0	_	_	_	_
15	body	body	B-NP	NN	0	_	_	_	_
16	weight	weight	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Serum	Serum	B-NP	NN	:::NOCLASS	_	_	_	_
2	gamma	gamma	I-NP	NN	:::NOCLASS	_	_	_	_
3	glutamyltransferase	glutamyltransferase	I-NP	NN	:::NOCLASS	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	liver	liver	B-NP	NN	UMLS:C0023895:T047:DISO|UMLS:C0023884:T023:ANAT	_	_	_	_
9	disease	disease	I-NP	NN	UMLS:C0023895:T047:DISO	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	cattle	cattle	B-NP	NNS	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	By	By	B-PP	IN	0	_	_	_	_
2	contrast	contrast	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	secretory	secretory	B-NP	JJ	:::NOCLASS	_	_	_	_
5	HI	HI	I-NP	NN	:::NOCLASS	_	_	_	_
6	antibodies	antibody	I-NP	NNS	:::NOCLASS	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	not	not	I-VP	RB	0	_	_	_	_
9	demonstrated	demonstrate	I-VP	VBN	0	_	_	_	_
10	at	at	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	onset	onset	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	illness	illness	B-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	any	any	B-NP	DT	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	patients	patient	I-NP	NNS	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	but	but	O	CC	0	_	_	_	_
22	their	their	B-NP	PRP$	0	_	_	_	_
23	formation	formation	I-NP	NN	0	_	_	_	_
24	started	start	B-VP	VBD	0	_	_	_	_
25	early	early	B-ADVP	RB	0	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	antibodies	antibody	I-NP	NNS	0	_	_	_	_
29	reached	reach	B-VP	VBD	0	_	_	_	_
30	maximal	maximal	B-NP	JJ	0	_	_	_	_
31	levels	level	I-NP	NNS	0	_	_	_	_
32	about	about	B-NP	IN	0	_	_	_	_
33	10	10	I-NP	CD	0	_	_	_	_
34	days	day	I-NP	NNS	0	_	_	_	_
35	after	after	B-PP	IN	0	_	_	_	_
36	onset	onset	B-NP	NN	0	_	_	_	_
37	of	of	B-PP	IN	0	_	_	_	_
38	illness	illness	B-NP	NN	0	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	With	With	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	exception	exception	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	virus	virus	B-NP	NN	0	_	_	_	_
6	assay	assay	I-NP	NN	0	_	_	_	_
7	and	and	I-NP	CC	0	_	_	_	_
8	quantitation	quantitation	I-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	these	these	B-NP	DT	0	_	_	_	_
11	methods	method	I-NP	NNS	0	_	_	_	_
12	are	be	B-VP	VBP	0	_	_	_	_
13	simple	simple	B-ADJP	JJ	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	inexpensive	inexpensive	B-ADJP	JJ	0	_	_	_	_
16	enough	enough	I-ADJP	RB	0	_	_	_	_
17	to	to	B-VP	TO	0	_	_	_	_
18	be	be	I-VP	VB	0	_	_	_	_
19	done	do	I-VP	VBN	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	typical	typical	B-NP	JJ	0	_	_	_	_
22	shellfish	shellfish	I-NP	NN	0	_	_	_	_
23	microbiology	microbiology	I-NP	NN	0	_	_	_	_
24	laboratories	laboratory	I-NP	NNS	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Characteristics	Characteristic	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	lipase	lipase	B-NP	NN	:::NOCLASS	_	_	_	_
4	activity	activity	I-NP	NN	0	_	_	_	_
5	.	.	O	.	0	_	_	_	_

1	Takayasu	Takayasu	B-NP	NNP	UMLS:C0039263:T047:DISO	_	_	_	_
2	's	's	B-NP	POS	UMLS:C0039263:T047:DISO	_	_	_	_
3	disease	disease	I-NP	NN	UMLS:C0039263:T047:DISO	_	_	_	_
4	:	:	O	:	0	_	_	_	_
5	association	association	B-NP	NN	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	HLA	HLA	B-NP	NN	:::NOCLASS	_	_	_	_
8	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
9	B5	B5	I-NP	NN	:::NOCLASS	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	SGPT	SGPT	B-NP	NN	:::NOCLASS	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	SGOT	SGOT	B-NP	NN	:::NOCLASS	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	alkaline	alkaline	B-NP	NN	:::NOCLASS	_	_	_	_
7	phosphatase	phosphatase	I-NP	NN	:::NOCLASS	_	_	_	_
8	concentrations	concentration	I-NP	NNS	0	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	essentially	essentially	B-ADJP	RB	0	_	_	_	_
11	normal	normal	I-ADJP	JJ	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	all	all	B-NP	DT	0	_	_	_	_
14	subjects	subject	I-NP	NNS	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Gamma	Gamma	B-NP	NN	:::NOCLASS	_	_	_	_
2	glutamyl	glutamyl	I-NP	NN	:::NOCLASS	_	_	_	_
3	transpeptidase	transpeptidase	I-NP	NN	:::NOCLASS	_	_	_	_
4	(	(	O	(	0	_	_	_	_
5	GGTP	GGTP	B-NP	NN	:::NOCLASS	_	_	_	_
6	)	)	O	)	0	_	_	_	_
7	activity	activity	B-NP	NN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	seminal	seminal	I-NP	JJ	0	_	_	_	_
11	fluid	fluid	I-NP	NN	0	_	_	_	_

1	Patients	Patient	B-NP	NNS	0	_	_	_	_
2	with	with	B-PP	IN	0	_	_	_	_
3	Parkinson	Parkinson	B-NP	NNP	UMLS:C0030567:T047:DISO	_	_	_	_
4	's	's	B-NP	POS	UMLS:C0030567:T047:DISO	_	_	_	_
5	disease	disease	I-NP	NN	UMLS:C0030567:T047:DISO	_	_	_	_
6	showed	show	B-VP	VBD	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	relatively	relatively	I-NP	RB	0	_	_	_	_
9	high	high	I-NP	JJ	0	_	_	_	_
10	incidence	incidence	I-NP	NN	0	_	_	_	_
11	to	to	B-PP	TO	0	_	_	_	_
12	psychoses	psychos	B-NP	NNS	0	_	_	_	_
13	during	during	B-PP	IN	0	_	_	_	_
14	drug	drug	B-NP	NN	0	_	_	_	_
15	treatment	treatment	I-NP	NN	0	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	51	51	B-NP	CD	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_
19	47	47	B-NP	CD	0	_	_	_	_
20	%	%	I-NP	NN	0	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Selective	Selective	B-NP	JJ	0	_	_	_	_
2	stimulation	stimulation	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	central	central	B-NP	JJ	0	_	_	_	_
5	alpha	alpha	I-NP	SYM	:::NOCLASS	_	_	_	_
6	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
7	autoreceptors	autoreceptor	B-NP	NNS	:::NOCLASS	_	_	_	_
8	following	follow	B-PP	VBG	0	_	_	_	_
9	treatment	treatment	B-NP	NN	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	alpha	alpha	O	SYM	0	_	_	_	_
12	-	-	O	HYPH	0	_	_	_	_
13	methyldopa	methyldopa	B-NP	NN	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	FLA	FLA	B-NP	NN	0	_	_	_	_
16	136	136	I-NP	CD	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Anti	Anti	B-NP	AFX	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	anxiety	anxiety	I-NP	NN	0	_	_	_	_
4	action	action	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	diazepam	diazepam	B-NP	NN	0	_	_	_	_
7	after	after	B-PP	IN	0	_	_	_	_
8	intra	intra	B-NP	AFX	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	amygdaloid	amygdaloid	I-NP	JJ	0	_	_	_	_
11	application	application	I-NP	NN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	rat	rat	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Abstracts	Abstract	B-NP	NNS	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	Removal	Removal	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	thick	thick	B-NP	JJ	0	_	_	_	_
4	,	,	I-NP	,	0	_	_	_	_
5	permanently	permanently	I-NP	RB	0	_	_	_	_
6	altered	alter	I-NP	VBN	0	_	_	_	_
7	mucoas	mucoa	I-NP	NNS	0	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	recommended	recommend	I-VP	VBN	0	_	_	_	_
10	even	even	B-ADVP	RB	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	absence	absence	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	squamous	squamous	B-NP	JJ	0	_	_	_	_
16	epithelium	epithelium	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	An	An	B-NP	DT	0	_	_	_	_
2	IgG	IgG	I-NP	NN	:::NOCLASS	_	_	_	_
3	monoclonal	monoclonal	I-NP	JJ	0	_	_	_	_
4	gammopathy	gammopathy	I-NP	NN	UMLS:C0178650:T047:DISO	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	present	present	B-ADJP	JJ	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	serum	serum	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	4	4	B-NP	CD	0	_	_	_	_
12	patients	patient	I-NP	NNS	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	Bence	Bence	B-NP	NNP	0	_	_	_	_
15	-	-	I-NP	HYPH	0	_	_	_	_
16	Joanes	Joanes	I-NP	NNP	0	_	_	_	_
17	proteinuria	proteinuria	I-NP	NN	0	_	_	_	_
18	was	be	B-VP	VBD	0	_	_	_	_
19	found	find	I-VP	VBN	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	1	1	B-NP	CD	0	_	_	_	_
22	patient	patient	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Studies	Study	B-NP	NNS	0	_	_	_	_
2	on	on	B-PP	IN	0	_	_	_	_
3	immunoglobulin	immunoglobulin	B-NP	NN	:::NOCLASS	_	_	_	_
4	E	E	I-NP	NN	:::NOCLASS	_	_	_	_
5	:	:	O	:	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	impact	impact	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	sojourn	sojourn	I-NP	NN	0	_	_	_	_
11	with	with	B-PP	IN	0	_	_	_	_
12	Professor	Professor	B-NP	NNP	0	_	_	_	_
13	Dan	Dan	I-NP	NNP	0	_	_	_	_
14	H	H	I-NP	NNP	0	_	_	_	_
15	.	.	B-VP	VBD	0	_	_	_	_

1	Peroxydase	Peroxydase	B-NP	NN	:::NOCLASS	_	_	_	_
2	reaction	reaction	I-NP	NN	0	_	_	_	_
3	stains	stain	I-NP	NNS	0	_	_	_	_
4	were	be	B-VP	VBD	0	_	_	_	_
5	negative	negative	B-ADJP	JJ	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	chloroacetate	chloroacetate	B-NP	NN	:::NOCLASS	_	_	_	_
8	esterase	esterase	I-NP	NN	:::NOCLASS	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	strongly	strongly	B-ADJP	RB	0	_	_	_	_
11	positive	positive	I-ADJP	JJ	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	Ten	Ten	B-NP	CD	UMLS:C0014518:T047:DISO	_	_	_	_
2	out	out	B-PRT	RP	0	_	_	_	_
3	-	-	B-NP	HYPH	0	_	_	_	_
4	patients	patient	I-NP	NNS	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	pustulosis	pustulosis	B-NP	NN	UMLS:C0030246:T047:DISO	_	_	_	_
7	palmaris	palmaris	I-NP	NN	UMLS:C0030246:T047:DISO	_	_	_	_
8	et	et	B-ADVP	FW	UMLS:C0030246:T047:DISO	_	_	_	_
9	plantaris	plantaris	I-ADVP	FW	UMLS:C0030246:T047:DISO|UMLS:C0242693:T023:ANAT	_	_	_	_
10	were	be	B-VP	VBD	0	_	_	_	_
11	examined	examine	I-VP	VBN	0	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	direct	direct	B-NP	JJ	0	_	_	_	_
14	immunofluorescence	immunofluorescence	I-NP	NN	0	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	IF	IF	B-NP	NN	0	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	technique	technique	B-NP	NN	0	_	_	_	_
19	for	for	B-PP	IN	0	_	_	_	_
20	deposition	deposition	B-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	fibrinogen	fibrinogen	B-NP	NN	:::NOCLASS	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	fibrin	fibrin	B-NP	NN	:::NOCLASS	_	_	_	_
25	or	or	O	CC	0	_	_	_	_
26	its	its	B-NP	PRP$	0	_	_	_	_
27	degradation	degradation	I-NP	NN	0	_	_	_	_
28	products	product	I-NP	NNS	0	_	_	_	_
29	(	(	O	(	0	_	_	_	_
30	FR	FR	B-NP	NN	:::NOCLASS	_	_	_	_
31	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
32	antigen	antigen	I-NP	NN	:::NOCLASS	_	_	_	_
33	)	)	O	)	0	_	_	_	_
34	in	in	B-PP	IN	0	_	_	_	_
35	affected	affect	B-NP	VBN	0	_	_	_	_
36	and	and	I-NP	CC	0	_	_	_	_
37	unaffected	unaffected	I-NP	JJ	0	_	_	_	_
38	skin	skin	I-NP	NN	0	_	_	_	_
39	,	,	O	,	0	_	_	_	_
40	together	together	B-ADVP	RB	0	_	_	_	_
41	with	with	B-PP	IN	0	_	_	_	_
42	heparin	heparin	B-NP	NN	0	_	_	_	_
43	-	-	B-NP	HYPH	0	_	_	_	_
44	precipitable	precipitable	I-NP	JJ	0	_	_	_	_
45	fraction	fraction	I-NP	NN	0	_	_	_	_
46	(	(	O	(	0	_	_	_	_
47	HPF	HPF	B-NP	NN	0	_	_	_	_
48	)	)	O	)	0	_	_	_	_
49	,	,	O	,	0	_	_	_	_
50	cryoglobulin	cryoglobulin	B-NP	NN	:::NOCLASS	_	_	_	_
51	and	and	O	CC	0	_	_	_	_
52	total	total	B-NP	JJ	0	_	_	_	_
53	plasma	plasma	I-NP	NN	0	_	_	_	_
54	fibrinogen	fibrinogen	I-NP	NN	:::NOCLASS	_	_	_	_
55	in	in	B-PP	IN	0	_	_	_	_
56	the	the	B-NP	DT	0	_	_	_	_
57	blood	blood	I-NP	NN	0	_	_	_	_
58	.	.	O	.	0	_	_	_	_

1	Of	Of	B-PP	IN	0	_	_	_	_
2	600	600	B-NP	CD	0	_	_	_	_
3	mediastinoscopies	mediastinoscopy	I-NP	NNS	0	_	_	_	_
4	carried	carry	B-VP	VBN	0	_	_	_	_
5	out	out	B-PRT	RP	0	_	_	_	_
6	from	from	B-PP	IN	0	_	_	_	_
7	1966	1966	B-NP	CD	0	_	_	_	_
8	to	to	B-PP	TO	0	_	_	_	_
9	1973	1973	B-NP	CD	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	479	479	B-NP	CD	0	_	_	_	_
12	were	be	B-VP	VBD	0	_	_	_	_
13	performed	perform	I-VP	VBN	0	_	_	_	_
14	to	to	B-VP	TO	0	_	_	_	_
15	assess	assess	I-VP	VB	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	operability	operability	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	pulmonary	pulmonary	I-NP	JJ	UMLS:C0024109:T023:ANAT	_	_	_	_
21	carcinoma	carcinoma	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	mixture	mixture	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	human	human	B-NP	JJ	:::NOCLASS	_	_	_	_
5	albumin	albumin	I-NP	NN	:::NOCLASS	_	_	_	_
6	5	5	B-NP	CD	0	_	_	_	_
7	%	%	I-NP	NN	0	_	_	_	_
8	and	and	I-NP	CC	0	_	_	_	_
9	hydroxy	hydroxy	I-NP	NN	0	_	_	_	_
10	-	-	B-NP	HYPH	0	_	_	_	_
11	ethyl	ethyl	I-NP	NN	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	starch	starch	I-NP	NN	0	_	_	_	_
14	was	be	B-VP	VBD	0	_	_	_	_
15	used	use	I-VP	VBN	0	_	_	_	_
16	as	as	B-PP	IN	0	_	_	_	_
17	a	a	B-NP	DT	0	_	_	_	_
18	solution	solution	I-NP	NN	0	_	_	_	_
19	for	for	B-PP	IN	0	_	_	_	_
20	dilution	dilution	B-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	matched	match	I-NP	VBN	0	_	_	_	_
4	control	control	I-NP	NN	0	_	_	_	_
5	group	group	I-NP	NN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	acquisition	acquisition	I-NP	NN	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	rate	rate	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	both	both	B-NP	CC	0	_	_	_	_
12	symptomatic	symptomatic	I-NP	JJ	0	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	asymptomatic	asymptomatic	I-NP	JJ	0	_	_	_	_
15	0acteriuria	0acteriuria	I-NP	NNS	0	_	_	_	_
16	was	be	B-VP	VBD	0	_	_	_	_
17	over	over	B-NP	IN	0	_	_	_	_
18	12	12	I-NP	CD	0	_	_	_	_
19	%	%	I-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	a	a	B-NP	DT	0	_	_	_	_
22	figure	figure	I-NP	NN	0	_	_	_	_
23	similar	similar	B-ADJP	JJ	0	_	_	_	_
24	to	to	B-PP	TO	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	percentage	percentage	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	women	woman	B-NP	NNS	0	_	_	_	_
29	present	present	B-ADJP	JJ	0	_	_	_	_
30	in	in	B-PP	IN	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	practice	practice	I-NP	NN	0	_	_	_	_
33	population	population	I-NP	NN	0	_	_	_	_
34	during	during	B-PP	IN	0	_	_	_	_
35	one	one	B-NP	CD	0	_	_	_	_
36	year	year	I-NP	NN	0	_	_	_	_
37	with	with	B-PP	IN	0	_	_	_	_
38	transient	transient	B-NP	JJ	0	_	_	_	_
39	,	,	I-NP	,	0	_	_	_	_
40	symptomatic	symptomatic	I-NP	JJ	0	_	_	_	_
41	,	,	O	,	0	_	_	_	_
42	and	and	O	CC	0	_	_	_	_
43	persistent	persistent	B-NP	JJ	0	_	_	_	_
44	A	A	I-NP	NN	0	_	_	_	_
45	.	.	O	.	0	_	_	_	_
46	B	B	B-NP	NNP	0	_	_	_	_
47	.	.	O	.	0	_	_	_	_

1	Late	Late	B-NP	JJ	0	_	_	_	_
2	complications	complication	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	catheterisation	catheterisation	B-NP	NN	0	_	_	_	_
5	for	for	B-PP	IN	0	_	_	_	_
6	intravenous	intravenous	B-NP	JJ	0	_	_	_	_
7	nutrition	nutrition	I-NP	NN	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Prenatal	Prenatal	B-NP	JJ	0	_	_	_	_
2	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	galactosaemia	galactosaemia	B-NP	NN	UMLS:C0016952:T047:DISO	_	_	_	_
5	.	.	O	.	0	_	_	_	_

1	Sings	Sing	B-NP	NNS	0	_	_	_	_
2	which	which	B-NP	WDT	0	_	_	_	_
3	are	be	B-VP	VBP	0	_	_	_	_
4	indicative	indicative	B-ADJP	JJ	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	metaplastic	metaplastic	B-NP	JJ	0	_	_	_	_
7	erythropoiesis	erythropoiesis	I-NP	NN	0	_	_	_	_
8	are	be	B-VP	VBP	0	_	_	_	_
9	absent	absent	B-ADJP	JJ	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	False	False	B-NP	JJ	0	_	_	_	_
2	positive	positive	I-NP	JJ	0	_	_	_	_
3	amniotic	amniotic	I-NP	JJ	:::NOCLASS	_	_	_	_
4	fluid	fluid	I-NP	NN	:::NOCLASS	_	_	_	_
5	alpha	alpha	I-NP	NN	:::NOCLASS	_	_	_	_
6	fetoprotein	fetoprotein	I-NP	NN	:::NOCLASS	_	_	_	_
7	levels	level	I-NP	NNS	0	_	_	_	_
8	resulting	result	B-VP	VBG	0	_	_	_	_
9	from	from	B-PP	IN	0	_	_	_	_
10	contamination	contamination	B-NP	NN	0	_	_	_	_
11	with	with	B-PP	IN	0	_	_	_	_
12	fetal	fetal	B-NP	JJ	0	_	_	_	_
13	blood	blood	I-NP	NN	0	_	_	_	_
14	:	:	O	:	0	_	_	_	_
15	results	result	B-NP	NNS	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	an	an	B-NP	DT	0	_	_	_	_
18	experiment	experiment	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Serum	Serum	B-NP	NN	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	ferritin	ferritin	I-NP	NN	:::NOCLASS	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	diagnosis	diagnosis	B-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	haemochromatosis	haemochromatosis	B-NP	NN	UMLS:C0018995:T047:DISO	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	2	2	B-NP	CD	0	_	_	_	_
3	subjects	subject	I-NP	NNS	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	phytomitogen	phytomitogen	I-NP	NN	0	_	_	_	_
6	reactivity	reactivity	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	lymphocytes	lymphocyte	I-NP	NNS	0	_	_	_	_
10	was	be	B-VP	VBD	0	_	_	_	_
11	improved	improve	I-VP	VBN	0	_	_	_	_
12	after	after	B-PP	IN	0	_	_	_	_
13	treatment	treatment	B-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Patients	Patient	B-NP	NNS	0	_	_	_	_
2	at	at	B-PP	IN	0	_	_	_	_
3	risk	risk	B-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	hypothyroidism	hypothyroidism	B-NP	NN	UMLS:C0020676:T047:DISO	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	Albumin	Albumin	B-NP	NN	:::NOCLASS	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	cyclic	cyclic	I-NP	JJ	0	_	_	_	_
4	AMP	AMP	I-NP	NN	0	_	_	_	_
5	levels	level	I-NP	NNS	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	peritoneal	peritoneal	B-NP	JJ	0	_	_	_	_
8	fluids	fluid	I-NP	NNS	0	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	child	child	I-NP	NN	0	_	_	_	_

1	Preface	Preface	B-NP	NNP	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	Thirty	Thirty	B-NP	CD	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	five	five	I-NP	CD	0	_	_	_	_
4	strains	strain	I-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	Legionnaires	Legionnaires	B-NP	NNP	UMLS:C0023241:T047:DISO	_	_	_	_
7	'	'	B-NP	POS	UMLS:C0023241:T047:DISO	_	_	_	_
8	disease	disease	I-NP	NN	UMLS:C0023241:T047:DISO	_	_	_	_
9	bacteria	bacteria	I-NP	NNS	0	_	_	_	_
10	were	be	B-VP	VBD	0	_	_	_	_
11	shown	show	I-VP	VBN	0	_	_	_	_
12	to	to	I-VP	TO	0	_	_	_	_
13	belong	belong	I-VP	VB	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	four	four	B-NP	CD	0	_	_	_	_
16	distinct	distinct	I-NP	JJ	0	_	_	_	_
17	serologic	serologic	I-NP	JJ	0	_	_	_	_
18	groups	group	I-NP	NNS	0	_	_	_	_
19	on	on	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	basis	basis	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	findings	finding	B-NP	NNS	0	_	_	_	_
24	obtained	obtain	B-VP	VBN	0	_	_	_	_
25	with	with	B-PP	IN	0	_	_	_	_
26	direct	direct	B-NP	JJ	0	_	_	_	_
27	fluorescent	fluorescent	I-NP	JJ	0	_	_	_	_
28	antibody	antibody	I-NP	NN	0	_	_	_	_
29	testing	testing	I-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	On	On	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	other	other	I-NP	JJ	0	_	_	_	_
4	hand	hand	I-NP	NN	UMLS:C0018563:T023:ANAT	_	_	_	_
5	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
6	IX	IX	I-NP	CD	:::NOCLASS	_	_	_	_
7	activity	activity	I-NP	NN	0	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	decreased	decrease	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	coumarin	coumarin	B-NP	NN	0	_	_	_	_
12	treatment	treatment	I-NP	NN	0	_	_	_	_
13	with	with	B-PP	IN	0	_	_	_	_
14	factor	factor	B-NP	NN	:::NOCLASS	_	_	_	_
15	IX	IX	I-NP	CD	:::NOCLASS	_	_	_	_
16	antigen	antigen	I-NP	NN	0	_	_	_	_
17	remaining	remain	B-VP	VBG	0	_	_	_	_
18	normal	normal	B-ADJP	JJ	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	concentration	concentration	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	alpha	alpha	B-NP	SYM	:::NOCLASS	_	_	_	_
5	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
6	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
7	macroglobulin	macroglobulin	I-NP	NN	:::NOCLASS	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	alpha	alpha	B-NP	SYM	:::NOCLASS	_	_	_	_
10	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
11	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
12	antitrypsin	antitrypsin	I-NP	NN	:::NOCLASS	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	plasminogen	plasminogen	B-NP	NN	:::NOCLASS	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	C3	C3	B-NP	NN	:::NOCLASS	_	_	_	_
17	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
18	complement	complement	I-NP	NN	:::NOCLASS	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	fibrinogen	fibrinogen	B-NP	NN	:::NOCLASS	_	_	_	_
21	degradation	degradation	I-NP	NN	:::NOCLASS	_	_	_	_
22	products	product	I-NP	NNS	:::NOCLASS	_	_	_	_
23	(	(	O	(	0	_	_	_	_
24	FDP	FDP	B-NP	NN	:::NOCLASS	_	_	_	_
25	)	)	O	)	0	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	fibrinolytic	fibrinolytic	B-NP	JJ	0	_	_	_	_
28	activity	activity	I-NP	NN	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	were	be	B-VP	VBD	0	_	_	_	_
31	studied	study	I-VP	VBN	0	_	_	_	_
32	in	in	B-PP	IN	0	_	_	_	_
33	the	the	B-NP	DT	0	_	_	_	_
34	aqueous	aqueous	I-NP	JJ	0	_	_	_	_
35	humour	humour	I-NP	NN	0	_	_	_	_
36	and	and	I-NP	CC	0	_	_	_	_
37	serum	serum	I-NP	NN	0	_	_	_	_
38	from	from	B-PP	IN	0	_	_	_	_
39	nine	nine	B-NP	CD	0	_	_	_	_
40	patients	patient	I-NP	NNS	0	_	_	_	_
41	with	with	B-PP	IN	0	_	_	_	_
42	Fuchs	Fuchs	B-NP	NNP	UMLS:C0016781:T047:DISO	_	_	_	_
43	'	'	B-NP	POS	UMLS:C0016781:T047:DISO	_	_	_	_
44	endothelial	endothelial	I-NP	JJ	UMLS:C0016781:T047:DISO	_	_	_	_
45	dystrophy	dystrophy	I-NP	NN	UMLS:C0016781:T047:DISO	_	_	_	_
46	,	,	O	,	0	_	_	_	_
47	17	17	B-NP	CD	0	_	_	_	_
48	patients	patient	I-NP	NNS	0	_	_	_	_
49	with	with	B-PP	IN	0	_	_	_	_
50	uncomplicated	uncomplicated	B-NP	JJ	0	_	_	_	_
51	senile	senile	I-NP	JJ	0	_	_	_	_
52	cataract	cataract	I-NP	NN	0	_	_	_	_
53	and	and	B-PP	CC	0	_	_	_	_
54	in	in	B-PP	IN	0	_	_	_	_
55	the	the	B-NP	DT	0	_	_	_	_
56	secondary	secondary	I-NP	JJ	0	_	_	_	_
57	aqueous	aqueous	I-NP	JJ	0	_	_	_	_
58	from	from	B-PP	IN	0	_	_	_	_
59	six	six	B-NP	CD	0	_	_	_	_
60	cataract	cataract	I-NP	NN	0	_	_	_	_
61	patients	patient	I-NP	NNS	0	_	_	_	_
62	.	.	O	.	0	_	_	_	_

1	Only	Only	B-NP	RB	0	_	_	_	_
2	17	17	I-NP	CD	0	_	_	_	_
3	%	%	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	all	all	B-NP	DT	0	_	_	_	_
6	patients	patient	I-NP	NNS	0	_	_	_	_
7	admitted	admit	B-VP	VBD	0	_	_	_	_
8	it	it	B-NP	PRP	0	_	_	_	_
9	at	at	B-PP	IN	0	_	_	_	_
10	all	all	B-NP	DT	0	_	_	_	_
11	times	time	I-NP	NNS	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	Prazosin	Prazosin	B-NP	NN	0	_	_	_	_
2	alone	alone	B-ADVP	RB	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	effective	effective	B-ADJP	JJ	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	volume	volume	B-NP	NN	0	_	_	_	_
7	responsive	responsive	I-NP	JJ	0	_	_	_	_
8	patients	patient	I-NP	NNS	0	_	_	_	_
9	at	at	B-PP	IN	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	dose	dose	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	5	5	B-NP	CD	0	_	_	_	_
14	+	+	B-NP	SYM	0	_	_	_	_
15	/	/	B-VP	SYM	0	_	_	_	_
16	-	-	B-NP	SYM	0	_	_	_	_
17	1	1	I-NP	CD	0	_	_	_	_
18	.	.	I-NP	SYM	0	_	_	_	_
19	0	0	I-NP	CD	0	_	_	_	_
20	mg	mg	I-NP	NN	0	_	_	_	_
21	daily	daily	B-ADVP	RB	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	T4	T4	B-NP	NN	UMLS:C1235738:T023:ANAT	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	FT4I	FT4I	I-NP	NN	0	_	_	_	_
4	followed	follow	B-VP	VBD	0	_	_	_	_
5	parallel	parallel	B-NP	JJ	0	_	_	_	_
6	courses	course	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	both	both	B-NP	DT	0	_	_	_	_
9	groups	group	I-NP	NNS	0	_	_	_	_
10	;	;	O	:	0	_	_	_	_
11	during	during	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	first	first	I-NP	JJ	0	_	_	_	_
14	45	45	I-NP	CD	0	_	_	_	_
15	days	day	I-NP	NNS	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	however	however	B-ADVP	RB	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	values	value	I-NP	NNS	0	_	_	_	_
21	were	be	B-VP	VBD	0	_	_	_	_
22	significantly	significantly	B-ADJP	RB	0	_	_	_	_
23	lower	low	I-ADJP	JJR	0	_	_	_	_
24	in	in	B-PP	IN	0	_	_	_	_
25	premature	premature	B-NP	JJ	0	_	_	_	_
26	infants	infant	I-NP	NNS	0	_	_	_	_
27	under	under	B-PP	IN	0	_	_	_	_
28	34	34	B-NP	CD	0	_	_	_	_
29	weeks	week	I-NP	NNS	0	_	_	_	_
30	'	'	B-NP	POS	0	_	_	_	_
31	EGA	EGA	I-NP	NN	0	_	_	_	_
32	than	than	B-PP	IN	0	_	_	_	_
33	in	in	B-PP	IN	0	_	_	_	_
34	term	term	B-NP	NN	0	_	_	_	_
35	infants	infant	I-NP	NNS	0	_	_	_	_
36	(	(	O	(	0	_	_	_	_
37	P	P	B-NP	NN	0	_	_	_	_
38	less	less	B-NP	JJR	0	_	_	_	_
39	than	than	I-NP	IN	0	_	_	_	_
40	0	0	I-NP	CD	0	_	_	_	_
41	.	.	I-NP	.	0	_	_	_	_
42	001	001	I-NP	CD	0	_	_	_	_
43	)	)	O	)	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	three	three	I-NP	CD	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	phased	phase	I-NP	VBN	0	_	_	_	_
5	analysis	analysis	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	treatment	treatment	B-NP	NN	0	_	_	_	_
8	plans	plan	I-NP	NNS	0	_	_	_	_
9	for	for	B-PP	IN	0	_	_	_	_
10	45	45	B-NP	CD	0	_	_	_	_
11	patients	patient	I-NP	NNS	0	_	_	_	_
12	was	be	B-VP	VBD	0	_	_	_	_
13	undertaken	undertake	I-VP	VBN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Aspirin	Aspirin	B-NP	NN	0	_	_	_	_
2	intolerance	intolerance	I-NP	NN	0	_	_	_	_
3	:	:	O	:	0	_	_	_	_
4	unaltered	unaltered	B-NP	JJ	0	_	_	_	_
5	susceptibility	susceptibility	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	platelet	platelet	B-NP	NN	:::NOCLASS	_	_	_	_
8	cyclo	cyclo	I-NP	NN	:::NOCLASS	_	_	_	_
9	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
10	oxygenase	oxygenase	I-NP	NN	:::NOCLASS	_	_	_	_
11	to	to	B-PP	TO	0	_	_	_	_
12	inhibition	inhibition	B-NP	NN	0	_	_	_	_
13	by	by	B-PP	IN	0	_	_	_	_
14	aspirin	aspirin	B-NP	NN	0	_	_	_	_
15	in	in	B-ADVP	FW	0	_	_	_	_
16	vitro	vitro	I-ADVP	FW	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	indicate	indicate	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	cynomolgus	cynomolgus	B-NP	NN	0	_	_	_	_
6	monkeys	monkey	I-NP	NNS	0	_	_	_	_
7	are	be	B-VP	VBP	0	_	_	_	_
8	either	either	B-ADJP	RB	0	_	_	_	_
9	less	less	I-ADJP	RBR	0	_	_	_	_
10	sensitive	sensitive	I-ADJP	JJ	0	_	_	_	_
11	or	or	O	CC	0	_	_	_	_
12	respond	respond	B-VP	VBP	0	_	_	_	_
13	differently	differently	B-ADVP	RB	0	_	_	_	_
14	than	than	B-PP	IN	0	_	_	_	_
15	rhesus	rhesus	B-NP	NN	0	_	_	_	_
16	monkeys	monkey	I-NP	NNS	0	_	_	_	_
17	to	to	B-PP	TO	0	_	_	_	_
18	some	some	B-NP	DT	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	pharmacological	pharmacological	I-NP	JJ	0	_	_	_	_
22	effects	effect	I-NP	NNS	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	norcocaine	norcocaine	B-NP	NN	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	59	59	B-NP	CD	0	_	_	_	_
2	cases	case	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	surgically	surgically	B-NP	RB	0	_	_	_	_
5	resectable	resectable	I-NP	JJ	0	_	_	_	_
6	cancers	cancer	I-NP	NNS	0	_	_	_	_
7	(	(	O	(	0	_	_	_	_
8	T1	T1	B-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	T2	T2	B-NP	NN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	T3	T3	B-NP	NN	UMLS:C1235740:T023:ANAT	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	N0	N0	B-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	N1	N1	B-NP	NN	0	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	had	have	B-VP	VBD	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	minimum	minimum	I-NP	JJ	0	_	_	_	_
21	followup	followup	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	two	two	B-NP	CD	0	_	_	_	_
24	years	year	I-NP	NNS	0	_	_	_	_
25	(	(	O	(	0	_	_	_	_
26	average	average	B-NP	NN	0	_	_	_	_
27	4	4	B-NP	CD	0	_	_	_	_
28	years	year	I-NP	NNS	0	_	_	_	_
29	+	+	B-NP	SYM	0	_	_	_	_
30	/	/	B-NP	SYM	0	_	_	_	_
31	-	-	B-VP	SYM	0	_	_	_	_
32	3	3	B-NP	CD	0	_	_	_	_
33	months	month	I-NP	NNS	0	_	_	_	_
34	)	)	O	)	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effect	effect	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	CBZ	CBZ	B-NP	NN	0	_	_	_	_
5	and	and	I-NP	CC	0	_	_	_	_
6	DPH	DPH	I-NP	NN	0	_	_	_	_
7	can	can	B-VP	MD	0	_	_	_	_
8	be	be	I-VP	VB	0	_	_	_	_
9	explained	explain	I-VP	VBN	0	_	_	_	_
10	by	by	B-PP	IN	0	_	_	_	_
11	interference	interference	B-NP	NN	0	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	thyroid	thyroid	B-NP	NN	UMLS:C0040132:T023:ANAT	_	_	_	_
14	hormone	hormone	I-NP	NN	0	_	_	_	_
15	binding	bind	B-VP	VBG	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	TBG	TBG	B-NP	NN	:::NOCLASS	_	_	_	_
18	combined	combine	B-VP	VBN	0	_	_	_	_
19	with	with	B-PP	IN	0	_	_	_	_
20	enzyme	enzyme	B-NP	NN	0	_	_	_	_
21	-	-	B-NP	HYPH	0	_	_	_	_
22	induced	induce	I-NP	VBN	0	_	_	_	_
23	increased	increase	I-NP	VBN	0	_	_	_	_
24	metabolic	metabolic	I-NP	JJ	0	_	_	_	_
25	clearance	clearance	I-NP	NN	0	_	_	_	_
26	rate	rate	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	thyroid	thyroid	B-NP	JJ	UMLS:C0040132:T023:ANAT	_	_	_	_
29	hormones	hormone	I-NP	NNS	0	_	_	_	_
30	without	without	B-PP	IN	0	_	_	_	_
31	homeostatic	homeostatic	B-NP	JJ	0	_	_	_	_
32	maintenance	maintenance	I-NP	NN	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	premedication	premedication	B-NP	NN	0	_	_	_	_
35	levels	level	I-NP	NNS	0	_	_	_	_
36	of	of	B-PP	IN	0	_	_	_	_
37	FT4	FT4	B-NP	NN	0	_	_	_	_
38	and	and	I-NP	CC	0	_	_	_	_
39	FT3	FT3	I-NP	NN	0	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	present	present	I-NP	JJ	0	_	_	_	_
3	research	research	I-NP	NN	0	_	_	_	_
4	evaluated	evaluate	B-VP	VBD	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	possibility	possibility	I-NP	NN	0	_	_	_	_
7	that	that	B-SBAR	IN	0	_	_	_	_
8	polyethylene	polyethylene	B-NP	NN	0	_	_	_	_
9	glycol	glycol	I-NP	NN	0	_	_	_	_
10	400	400	I-NP	CD	0	_	_	_	_
11	(	(	O	(	0	_	_	_	_
12	PEG	PEG	B-NP	NN	0	_	_	_	_
13	400	400	I-NP	CD	0	_	_	_	_
14	)	)	O	)	0	_	_	_	_
15	might	might	B-VP	MD	0	_	_	_	_
16	be	be	I-VP	VB	0	_	_	_	_
17	efficacious	efficacious	B-ADJP	JJ	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	toxic	toxic	B-ADJP	JJ	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	or	or	O	CC	0	_	_	_	_
22	both	both	B-NP	DT	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	According	Accord	B-PP	VBG	0	_	_	_	_
2	to	to	B-PP	TO	0	_	_	_	_
3	their	their	B-NP	PRP$	0	_	_	_	_
4	functional	functional	I-NP	JJ	0	_	_	_	_
5	properties	property	I-NP	NNS	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	latter	latter	I-NP	JJ	0	_	_	_	_
8	neurons	neuron	I-NP	NNS	0	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	subdivided	subdivide	I-VP	VBN	0	_	_	_	_
11	into	into	B-PP	IN	0	_	_	_	_
12	:	:	O	:	0	_	_	_	_
13	(	(	B-LST	(	0	_	_	_	_
14	a	a	I-LST	LS	0	_	_	_	_
15	)	)	O	)	0	_	_	_	_
16	neurons	neuron	B-NP	NNS	0	_	_	_	_
17	responding	respond	B-VP	VBG	0	_	_	_	_
18	to	to	B-PP	TO	0	_	_	_	_
19	stimuli	stimulus	B-NP	NNS	0	_	_	_	_
20	near	near	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	eyes	eye	I-NP	NNS	UMLS:C0015392:T023:ANAT	_	_	_	_
23	;	;	O	:	0	_	_	_	_
24	(	(	B-LST	(	0	_	_	_	_
25	b	b	I-LST	LS	0	_	_	_	_
26	)	)	O	)	0	_	_	_	_
27	neurons	neuron	B-NP	NNS	0	_	_	_	_
28	triggered	trigger	B-VP	VBN	0	_	_	_	_
29	by	by	B-PP	IN	0	_	_	_	_
30	complex	complex	B-NP	JJ	0	_	_	_	_
31	visual	visual	I-NP	JJ	0	_	_	_	_
32	stimuli	stimulus	I-NP	NNS	0	_	_	_	_
33	;	;	O	:	0	_	_	_	_
34	(	(	B-LST	(	0	_	_	_	_
35	c	c	I-LST	LS	0	_	_	_	_
36	)	)	O	)	0	_	_	_	_
37	neurons	neuron	B-NP	NNS	0	_	_	_	_
38	inhibited	inhibit	B-VP	VBN	0	_	_	_	_
39	by	by	B-PP	IN	0	_	_	_	_
40	visual	visual	B-NP	JJ	0	_	_	_	_
41	stimuli	stimulus	I-NP	NNS	0	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	Pentobarbital	Pentobarbital	B-NP	NN	0	_	_	_	_
2	(	(	O	(	0	_	_	_	_
3	1	1	B-NP	CD	0	_	_	_	_
4	,	,	I-NP	,	0	_	_	_	_
5	3	3	I-NP	CD	0	_	_	_	_
6	,	,	I-NP	,	0	_	_	_	_
7	10	10	I-NP	CD	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	17	17	B-NP	CD	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_
12	5	5	B-NP	CD	0	_	_	_	_
13	mg	mg	I-NP	NN	0	_	_	_	_
14	/	/	B-NP	SYM	0	_	_	_	_
15	kg	kg	I-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	was	be	B-VP	VBD	0	_	_	_	_
18	also	also	I-VP	RB	0	_	_	_	_
19	tested	test	I-VP	VBN	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	combination	combination	B-NP	NN	0	_	_	_	_
22	with	with	B-PP	IN	0	_	_	_	_
23	rate	rate	B-NP	NN	0	_	_	_	_
24	-	-	O	HYPH	0	_	_	_	_
25	decreasing	decrease	B-VP	VBG	0	_	_	_	_
26	doses	dose	B-NP	NNS	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	normeperidine	normeperidine	B-NP	NN	0	_	_	_	_
29	(	(	O	(	0	_	_	_	_
30	17	17	B-NP	CD	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_
32	5	5	B-NP	CD	0	_	_	_	_
33	mg	mg	I-NP	NN	0	_	_	_	_
34	/	/	B-NP	SYM	0	_	_	_	_
35	kg	kg	I-NP	NN	0	_	_	_	_
36	)	)	O	)	0	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	anileridine	anileridine	B-NP	NN	0	_	_	_	_
39	(	(	O	(	0	_	_	_	_
40	10	10	B-NP	CD	0	_	_	_	_
41	mg	mg	I-NP	NN	0	_	_	_	_
42	/	/	B-NP	SYM	0	_	_	_	_
43	kg	kg	I-NP	NN	0	_	_	_	_
44	)	)	O	)	0	_	_	_	_
45	,	,	O	,	0	_	_	_	_
46	alphaprodine	alphaprodine	B-NP	NN	0	_	_	_	_
47	(	(	O	(	0	_	_	_	_
48	10	10	B-NP	CD	0	_	_	_	_
49	mg	mg	I-NP	NN	0	_	_	_	_
50	/	/	B-NP	SYM	0	_	_	_	_
51	kg	kg	I-NP	NN	0	_	_	_	_
52	)	)	O	)	0	_	_	_	_
53	,	,	O	,	0	_	_	_	_
54	and	and	O	CC	0	_	_	_	_
55	fentanyl	fentanyl	B-NP	NN	0	_	_	_	_
56	(	(	O	(	0	_	_	_	_
57	0	0	B-NP	CD	0	_	_	_	_
58	.	.	O	.	0	_	_	_	_
59	3	3	B-NP	CD	0	_	_	_	_
60	mg	mg	I-NP	NN	0	_	_	_	_
61	/	/	B-NP	SYM	0	_	_	_	_
62	kg	kg	I-NP	NN	0	_	_	_	_
63	)	)	O	)	0	_	_	_	_
64	.	.	O	.	0	_	_	_	_

1	Pb	Pb	B-NP	NN	0	_	_	_	_
2	foil	foil	I-NP	NN	0	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	0	0	B-NP	CD	0	_	_	_	_
5	.	.	O	.	0	_	_	_	_
6	55	55	B-NP	CD	0	_	_	_	_
7	gcm	gcm	I-NP	NN	0	_	_	_	_
8	-	-	B-NP	HYPH	0	_	_	_	_
9	2	2	I-NP	CD	0	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	provided	provide	B-VP	VBD	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	best	good	I-NP	JJS	0	_	_	_	_
14	overall	overall	I-NP	JJ	0	_	_	_	_
15	improvement	improvement	I-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	An	An	B-NP	DT	0	_	_	_	_
2	anatomical	anatomical	I-NP	JJ	0	_	_	_	_
3	and	and	I-NP	CC	0	_	_	_	_
4	histochemical	histochemical	I-NP	JJ	0	_	_	_	_
5	study	study	I-NP	NN	0	_	_	_	_
6	has	have	B-VP	VBZ	0	_	_	_	_
7	been	be	I-VP	VBN	0	_	_	_	_
8	undertaken	undertake	I-VP	VBN	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	as	as	B-PP	IN	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	result	result	I-NP	NN	0	_	_	_	_
13	emphasis	emphasis	I-NP	NN	0	_	_	_	_
14	is	be	B-VP	VBZ	0	_	_	_	_
15	given	give	I-VP	VBN	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	recent	recent	B-NP	JJ	0	_	_	_	_
18	hypotheses	hypothesis	I-NP	NNS	0	_	_	_	_
19	that	that	B-NP	WDT	0	_	_	_	_
20	suggest	suggest	B-VP	VBP	0	_	_	_	_
21	there	there	B-NP	EX	0	_	_	_	_
22	are	be	B-VP	VBP	0	_	_	_	_
23	similarities	similarity	B-NP	NNS	0	_	_	_	_
24	with	with	B-PP	IN	0	_	_	_	_
25	Type	Type	B-NP	NN	UMLS:C0017923:T047:DISO	_	_	_	_
26	IV	IV	I-NP	CD	UMLS:C0017923:T047:DISO	_	_	_	_
27	glycogen	glycogen	I-NP	NN	UMLS:C0017923:T047:DISO	_	_	_	_
28	storage	storage	I-NP	NN	UMLS:C0017923:T047:DISO	_	_	_	_
29	disease	disease	I-NP	NN	UMLS:C0017923:T047:DISO	_	_	_	_
30	(	(	O	(	0	_	_	_	_
31	Andersen	Andersen	B-NP	NNP	UMLS:C0017923:T047:DISO	_	_	_	_
32	's	's	B-NP	POS	UMLS:C0017923:T047:DISO	_	_	_	_
33	disease	disease	I-NP	NN	UMLS:C0017923:T047:DISO	_	_	_	_
34	)	)	O	)	0	_	_	_	_
35	which	which	B-NP	WDT	0	_	_	_	_
36	,	,	O	,	0	_	_	_	_
37	although	although	B-SBAR	IN	0	_	_	_	_
38	clinically	clinically	B-ADJP	RB	0	_	_	_	_
39	distinct	distinct	I-ADJP	JJ	0	_	_	_	_
40	,	,	O	,	0	_	_	_	_
41	has	have	B-VP	VBZ	0	_	_	_	_
42	the	the	B-NP	DT	0	_	_	_	_
43	same	same	I-NP	JJ	0	_	_	_	_
44	enzyme	enzyme	I-NP	NN	0	_	_	_	_
45	defect	defect	I-NP	NN	UMLS:C1861101:T047:DISO	_	_	_	_
46	.	.	O	.	0	_	_	_	_

1	All	All	B-NP	DT	0	_	_	_	_
2	groups	group	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	tested	test	I-VP	VBN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	Hebb	Hebb	I-NP	NNP	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	Williams	Williams	I-NP	NNP	0	_	_	_	_
10	maze	maze	I-NP	NN	0	_	_	_	_
11	at	at	B-PP	IN	0	_	_	_	_
12	100	100	B-NP	CD	0	_	_	_	_
13	approximately	approximately	I-NP	RB	0	_	_	_	_
14	10	10	I-NP	CD	0	_	_	_	_
15	days	day	I-NP	NNS	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	age	age	B-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Erythromycin	Erythromycin	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	clindamycin	clindamycin	I-NP	NN	0	_	_	_	_
4	resistance	resistance	I-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	Corynebacterium	Corynebacterium	B-NP	NNP	0	_	_	_	_
7	diphtheriae	diphtheriae	I-NP	NNP	0	_	_	_	_
8	from	from	B-PP	IN	0	_	_	_	_
9	skin	skin	B-NP	NN	0	_	_	_	_
10	lesions	lesion	I-NP	NNS	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	Imposed	Impose	B-NP	VBN	0	_	_	_	_
2	angular	angular	I-NP	JJ	0	_	_	_	_
3	displacements	displacement	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	monkey	monkey	B-NP	NN	0	_	_	_	_
6	's	's	B-NP	POS	0	_	_	_	_
7	wrist	wrist	I-NP	NN	0	_	_	_	_
8	produce	produce	B-VP	VBP	0	_	_	_	_
9	three	three	B-NP	CD	0	_	_	_	_
10	major	major	I-NP	JJ	0	_	_	_	_
11	peaks	peak	I-NP	NNS	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	activity	activity	B-NP	NN	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	terms	term	B-NP	NNS	0	_	_	_	_
16	M1	M1	I-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	M2	M2	B-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	M3	M3	B-NP	NN	0	_	_	_	_
22	peaks	peak	I-NP	NNS	0	_	_	_	_
23	)	)	O	)	0	_	_	_	_
24	in	in	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	averaged	averaged	I-NP	JJ	0	_	_	_	_
27	gross	gross	I-NP	JJ	0	_	_	_	_
28	EMG	EMG	I-NP	NN	0	_	_	_	_
29	activity	activity	I-NP	NN	0	_	_	_	_
30	ot	ot	B-PP	IN	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	stretched	stretched	I-NP	JJ	0	_	_	_	_
33	muscles	muscle	I-NP	NNS	UMLS:C1995013:T023:ANAT	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Hemolytic	Hemolytic	B-NP	JJ	UMLS:C1263988:T047:DISO	_	_	_	_
2	disease	disease	I-NP	NN	UMLS:C1263988:T047:DISO	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	African	African	B-NP	JJ	0	_	_	_	_
5	newborn	newborn	I-NP	NN	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	this	this	B-NP	DT	0	_	_	_	_
3	animal	animal	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	infected	infect	B-VP	VBN	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	what	what	B-NP	WP	0	_	_	_	_
8	was	be	B-VP	VBD	0	_	_	_	_
9	judged	judge	I-VP	VBN	0	_	_	_	_
10	previously	previously	B-ADVP	RB	0	_	_	_	_
11	to	to	B-VP	TO	0	_	_	_	_
12	be	be	I-VP	VB	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	less	less	I-NP	RBR	0	_	_	_	_
15	virulent	virulent	I-NP	JJ	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	two	two	I-NP	CD	0	_	_	_	_
19	T	T	I-NP	NN	0	_	_	_	_
20	.	.	B-VP	VBD	0	_	_	_	_
21	cruzi	cruzi	B-NP	NN	0	_	_	_	_
22	stocks	stock	I-NP	NNS	0	_	_	_	_
23	used	use	B-VP	VBN	0	_	_	_	_
24	(	(	O	(	0	_	_	_	_
25	'strain	'strain	O	SYM	0	_	_	_	_
26	7	7	O	CD	0	_	_	_	_
27	'	'	O	SYM	0	_	_	_	_
28	)	)	O	)	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	there	there	B-NP	EX	0	_	_	_	_
31	was	be	B-VP	VBD	0	_	_	_	_
32	severe	severe	B-NP	JJ	0	_	_	_	_
33	myocarditis	myocarditis	I-NP	NN	UMLS:C0027059:T047:DISO	_	_	_	_
34	,	,	O	,	0	_	_	_	_
35	with	with	B-PP	IN	0	_	_	_	_
36	myofibre	myofibre	B-NP	NN	0	_	_	_	_
37	degeneration	degeneration	I-NP	NN	0	_	_	_	_
38	,	,	O	,	0	_	_	_	_
39	and	and	O	CC	0	_	_	_	_
40	lesions	lesion	B-NP	NNS	0	_	_	_	_
41	of	of	B-PP	IN	0	_	_	_	_
42	the	the	B-NP	DT	0	_	_	_	_
43	oesophagus	oesophagus	I-NP	NN	UMLS:C0014876:T023:ANAT	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	majority	majority	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	MRF	MRF	B-NP	NN	0	_	_	_	_
5	units	unit	I-NP	NNS	0	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	behaviorally	behaviorally	B-ADJP	RB	0	_	_	_	_
8	incongruent	incongruent	I-ADJP	JJ	0	_	_	_	_
9	;	;	O	:	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	most	most	I-NP	RBS	0	_	_	_	_
13	frequently	frequently	I-NP	RB	0	_	_	_	_
14	observed	observe	I-NP	VBN	0	_	_	_	_
15	case	case	I-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	their	their	B-NP	PRP$	0	_	_	_	_
18	activity	activity	I-NP	NN	0	_	_	_	_
19	failed	fail	B-VP	VBD	0	_	_	_	_
20	to	to	I-VP	TO	0	_	_	_	_
21	change	change	I-VP	VB	0	_	_	_	_
22	reliably	reliably	B-ADVP	RB	0	_	_	_	_
23	when	when	B-ADVP	WRB	0	_	_	_	_
24	behavior	behavior	B-NP	NN	0	_	_	_	_
25	habituated	habituate	B-VP	VBN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	Variability	Variability	B-NP	NN	0	_	_	_	_
2	within	within	B-PP	IN	0	_	_	_	_
3	Down	Down	B-NP	NNP	UMLS:C0013080:T047:DISO	_	_	_	_
4	's	's	B-NP	POS	UMLS:C0013080:T047:DISO	_	_	_	_
5	syndrome	syndrome	I-NP	NN	UMLS:C0013080:T047:DISO	_	_	_	_
6	(	(	O	(	0	_	_	_	_
7	trisomy	trisomy	B-NP	NN	UMLS:C0041107:T047:DISO	_	_	_	_
8	-	-	B-NP	HYPH	0	_	_	_	_
9	21	21	I-NP	CD	0	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	:	:	O	:	0	_	_	_	_
12	empirically	empirically	B-NP	RB	0	_	_	_	_
13	observed	observe	I-NP	VBN	0	_	_	_	_
14	sex	sex	I-NP	NN	0	_	_	_	_
15	differences	difference	I-NP	NNS	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	IQs	IQ	B-NP	NNS	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	VII	VII	B-NP	CD	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	Several	Several	B-NP	JJ	0	_	_	_	_
2	demographic	demographic	I-NP	JJ	0	_	_	_	_
3	indices	index	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	isolated	isolate	B-NP	VBN	0	_	_	_	_
6	populations	population	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	Uzbekistan	Uzbekistan	B-NP	NNP	0	_	_	_	_

1	2	2	B-LST	LS	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_
3	-	-	O	HYPH	0	_	_	_	_
4	-	-	O	HYPH	0	_	_	_	_
5	concepts	concept	B-NP	NNS	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	higher	high	B-NP	JJR	0	_	_	_	_
8	nervous	nervous	I-NP	JJ	0	_	_	_	_
9	function	function	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	USSR	USSR	I-NP	NNP	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	maintenance	maintenance	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	increased	increase	B-NP	VBN	0	_	_	_	_
5	myocardial	myocardial	I-NP	JJ	0	_	_	_	_
6	capillary	capillary	I-NP	JJ	UMLS:C0935624:T023:ANAT|UMLS:C0006901:T023:ANAT	_	_	_	_
7	density	density	I-NP	NN	0	_	_	_	_
8	required	require	B-VP	VBD	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	similar	similar	I-NP	JJ	0	_	_	_	_
11	amount	amount	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	exercise	exercise	B-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	at	at	B-NP	IN	0	_	_	_	_
17	least	least	I-NP	JJS	0	_	_	_	_
18	1	1	I-NP	CD	0	_	_	_	_
19	h	h	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	exercise	exercise	B-NP	NN	0	_	_	_	_
22	once	once	O	RB	0	_	_	_	_
23	a	a	B-NP	DT	0	_	_	_	_
24	week	week	I-NP	NN	0	_	_	_	_
25	was	be	B-VP	VBD	0	_	_	_	_
26	necessary	necessary	B-ADJP	JJ	0	_	_	_	_
27	to	to	B-VP	TO	0	_	_	_	_
28	maintain	maintain	I-VP	VB	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	enlargement	enlargement	I-NP	NN	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	ECA	ECA	B-NP	NN	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_
34	20	20	B-NP	CD	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	observations	observation	I-NP	NNS	0	_	_	_	_
3	have	have	B-VP	VBP	0	_	_	_	_
4	led	lead	I-VP	VBN	0	_	_	_	_
5	us	us	B-NP	PRP	0	_	_	_	_
6	to	to	B-VP	TO	0	_	_	_	_
7	conclude	conclude	I-VP	VB	0	_	_	_	_
8	that	that	B-SBAR	IN	0	_	_	_	_
9	an	an	B-NP	DT	0	_	_	_	_
10	elevated	elevate	I-NP	VBN	0	_	_	_	_
11	VIII	VIII	I-NP	CD	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	ratio	ratio	I-NP	NN	0	_	_	_	_
14	is	be	B-VP	VBZ	0	_	_	_	_
15	a	a	B-NP	DT	0	_	_	_	_
16	very	very	I-NP	RB	0	_	_	_	_
17	sensitive	sensitive	I-NP	JJ	0	_	_	_	_
18	indicator	indicator	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	intravascular	intravascular	B-NP	JJ	0	_	_	_	_
21	coagulation	coagulation	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Eight	Eight	B-NP	CD	0	_	_	_	_
2	hours	hour	I-NP	NNS	0	_	_	_	_
3	after	after	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	administration	administration	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	colchicine	colchicine	B-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	serum	serum	I-NP	NN	:::NOCLASS	_	_	_	_
11	ceruloplasmin	ceruloplasmin	I-NP	NN	:::NOCLASS	_	_	_	_
12	level	level	I-NP	NN	0	_	_	_	_
13	began	begin	B-VP	VBD	0	_	_	_	_
14	to	to	I-VP	TO	0	_	_	_	_
15	rise	rise	I-VP	VB	0	_	_	_	_
16	again	again	B-ADVP	RB	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	female	female	B-NP	JJ	0	_	_	_	_
19	rats	rat	I-NP	NNS	0	_	_	_	_
20	,	,	B-PP	,	0	_	_	_	_
21	but	but	I-PP	CC	0	_	_	_	_
22	not	not	B-PP	RB	0	_	_	_	_
23	in	in	I-PP	IN	0	_	_	_	_
24	male	male	B-NP	JJ	0	_	_	_	_
25	rats	rat	I-NP	NNS	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	Radioimmunoassays	Radioimmunoassay	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	pregnenolone	pregnenolone	B-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	progesterone	progesterone	B-NP	NN	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	dehydroepiandrosterone	dehydroepiandrosterone	B-NP	NN	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	DHA	DHA	B-NP	NN	0	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	16	16	B-NP	CD	0	_	_	_	_
12	alpha	alpha	O	SYM	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	hydroxy	hydroxy	I-NP	NN	0	_	_	_	_
15	-	-	O	HYPH	0	_	_	_	_
16	DHA	DHA	B-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	estriol	estriol	B-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	cortisol	cortisol	B-NP	NN	0	_	_	_	_
22	were	be	B-VP	VBD	0	_	_	_	_
23	performed	perform	I-VP	VBN	0	_	_	_	_
24	on	on	B-PP	IN	0	_	_	_	_
25	a	a	B-NP	DT	0	_	_	_	_
26	total	total	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	0	0	B-NP	CD	0	_	_	_	_
29	;	;	O	:	0	_	_	_	_
30	1	1	B-NP	CD	0	_	_	_	_
31	ml	ml	I-NP	NN	0	_	_	_	_
32	;	;	O	:	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	fetal	fetal	B-NP	JJ	0	_	_	_	_
35	plasma	plasma	I-NP	NN	0	_	_	_	_
36	,	,	O	,	0	_	_	_	_
37	collected	collect	B-VP	VBN	0	_	_	_	_
38	during	during	B-PP	IN	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	course	course	I-NP	NN	0	_	_	_	_
41	of	of	B-PP	IN	0	_	_	_	_
42	normal	normal	B-NP	JJ	0	_	_	_	_
43	vaginal	vaginal	I-NP	JJ	UMLS:C0042232:T023:ANAT	_	_	_	_
44	delivery	delivery	I-NP	NN	0	_	_	_	_
45	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	only	only	B-NP	RB	0	_	_	_	_
3	two	two	I-NP	CD	0	_	_	_	_
4	patients	patient	I-NP	NNS	0	_	_	_	_
5	were	be	B-VP	VBD	0	_	_	_	_
6	we	we	B-NP	PRP	0	_	_	_	_
7	able	able	B-ADJP	JJ	0	_	_	_	_
8	to	to	B-VP	TO	0	_	_	_	_
9	demonstrate	demonstrate	I-VP	VB	0	_	_	_	_
10	changes	change	B-NP	NNS	0	_	_	_	_
11	suggestive	suggestive	B-ADJP	JJ	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	pulmonary	pulmonary	B-NP	JJ	UMLS:C0024109:T023:ANAT	_	_	_	_
14	metastases	metastasis	I-NP	NNS	0	_	_	_	_
15	any	any	B-ADVP	DT	0	_	_	_	_
16	earlier	early	I-ADVP	JJR	0	_	_	_	_
17	with	with	B-PP	IN	0	_	_	_	_
18	a	a	B-NP	DT	0	_	_	_	_
19	99mTc	99mTc	I-NP	NN	0	_	_	_	_
20	-	-	I-NP	HYPH	0	_	_	_	_
21	EHDP	EHDP	I-NP	NN	0	_	_	_	_
22	scan	scan	I-NP	NN	0	_	_	_	_
23	than	than	B-PP	IN	0	_	_	_	_
24	with	with	B-PP	IN	0	_	_	_	_
25	chest	chest	B-NP	NN	0	_	_	_	_
26	radiographs	radiograph	I-NP	NNS	0	_	_	_	_
27	and	and	O	CC	0	_	_	_	_
28	one	one	B-NP	CD	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	these	these	B-NP	DT	0	_	_	_	_
31	resolved	resolve	I-NP	VBN	0	_	_	_	_
32	spontaneously	spontaneously	B-ADVP	RB	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	majority	majority	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	tumors	tumor	B-NP	NNS	0	_	_	_	_
5	occurred	occur	B-VP	VBD	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	nasal	nasal	I-NP	JJ	UMLS:C0028429:T023:ANAT	_	_	_	_
9	cavities	cavity	I-NP	NNS	UMLS:C0011334:T047:DISO	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	although	although	B-SBAR	IN	0	_	_	_	_
12	significant	significant	B-NP	JJ	0	_	_	_	_
13	incidences	incidence	I-NP	NNS	0	_	_	_	_
14	were	be	B-VP	VBD	0	_	_	_	_
15	also	also	I-VP	RB	0	_	_	_	_
16	found	find	I-VP	VBN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	larynx	larynx	I-NP	NN	UMLS:C0023078:T023:ANAT	_	_	_	_
20	,	,	I-NP	,	0	_	_	_	_
21	trachea	trachea	I-NP	NN	UMLS:C0040578:T023:ANAT	_	_	_	_
22	and	and	I-NP	CC	0	_	_	_	_
23	stem	stem	I-NP	NN	UMLS:C1186763:T023:ANAT	_	_	_	_
24	bronchi	bronchi	I-NP	NN	UMLS:C0006255:T023:ANAT	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Prediction	Prediction	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	times	time	I-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	sandfly	sandfly	B-NP	NN	0	_	_	_	_
7	development	development	I-NP	NN	0	_	_	_	_

1	Native	Native	B-NP	JJ	0	_	_	_	_
2	human	human	I-NP	JJ	:::NOCLASS	_	_	_	_
3	fibrinogen	fibrinogen	I-NP	NN	:::NOCLASS	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	brought	bring	I-VP	VBN	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	coagulation	coagulation	B-NP	NN	0	_	_	_	_
8	by	by	B-PP	IN	0	_	_	_	_
9	adding	add	B-VP	VBG	0	_	_	_	_
10	thrombin	thrombin	B-NP	NN	:::NOCLASS	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	No	No	B-NP	DT	0	_	_	_	_
2	post	post	I-NP	AFX	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	operative	operative	I-NP	JJ	0	_	_	_	_
5	haemorrhages	haemorrhage	I-NP	NNS	0	_	_	_	_
6	from	from	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	prostheses	prosthesis	I-NP	NNS	0	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	observed	observe	I-VP	VBN	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	Southern	Southern	I-NP	JJ	0	_	_	_	_
3	technique	technique	I-NP	NN	0	_	_	_	_
4	allowed	allow	B-VP	VBD	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	further	further	I-NP	JJ	0	_	_	_	_
7	localization	localization	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	region	region	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	most	most	B-NP	JJS	0	_	_	_	_
13	extensive	extensive	I-NP	JJ	0	_	_	_	_
14	transcription	transcription	I-NP	NN	0	_	_	_	_
15	to	to	B-PP	TO	0	_	_	_	_
16	a	a	B-NP	DT	0	_	_	_	_
17	1	1	I-NP	CD	0	_	_	_	_
18	.	.	I-NP	.	0	_	_	_	_
19	8	8	I-NP	CD	0	_	_	_	_
20	kb	kb	I-NP	NN	0	_	_	_	_
21	HindIII	HindIII	I-NP	NN	:::NOCLASS	_	_	_	_
22	-	-	B-NP	HYPH	0	_	_	_	_
23	EcoRI	EcoRI	I-NP	NN	:::NOCLASS	_	_	_	_
24	fragment	fragment	I-NP	NN	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Accepting	Accept	B-VP	VBG	0	_	_	_	_
2	arbitrarily	arbitrarily	B-NP	RB	0	_	_	_	_
3	chosen	choose	I-NP	VBN	0	_	_	_	_
4	limits	limit	I-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	maximized	maximized	B-NP	JJ	0	_	_	_	_
7	errors	error	I-NP	NNS	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	+	+	B-NP	SYM	0	_	_	_	_
10	/	/	B-NP	SYM	0	_	_	_	_
11	-	-	B-NP	SYM	0	_	_	_	_
12	10	10	B-NP	CD	0	_	_	_	_
13	%	%	I-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	it	it	B-NP	PRP	0	_	_	_	_
16	could	could	B-VP	MD	0	_	_	_	_
17	be	be	I-VP	VB	0	_	_	_	_
18	shown	show	I-VP	VBN	0	_	_	_	_
19	that	that	B-SBAR	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	system	system	I-NP	NN	0	_	_	_	_
22	did	do	B-VP	VBD	0	_	_	_	_
23	not	not	I-VP	RB	0	_	_	_	_
24	work	work	I-VP	VB	0	_	_	_	_
25	acceptably	acceptably	B-ADVP	RB	0	_	_	_	_
26	when	when	B-ADVP	WRB	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	mean	mean	I-NP	JJ	0	_	_	_	_
29	carbon	carbon	I-NP	NN	0	_	_	_	_
30	dioxide	dioxide	I-NP	NN	0	_	_	_	_
31	concentration	concentration	I-NP	NN	0	_	_	_	_
32	was	be	B-VP	VBD	0	_	_	_	_
33	below	below	B-PP	IN	0	_	_	_	_
34	1	1	B-NP	CD	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_
36	5	5	B-NP	CD	0	_	_	_	_
37	vol	vol	I-NP	NN	0	_	_	_	_
38	.	.	B-NP	.	0	_	_	_	_
39	%	%	I-NP	NN	0	_	_	_	_
40	within	within	B-PP	IN	0	_	_	_	_
41	the	the	B-NP	DT	0	_	_	_	_
42	fresh	fresh	I-NP	JJ	0	_	_	_	_
43	gas	gas	I-NP	NN	0	_	_	_	_
44	flow	flow	I-NP	NN	0	_	_	_	_
45	rates	rate	I-NP	NNS	0	_	_	_	_
46	(	(	O	(	0	_	_	_	_
47	2	2	B-NP	CD	0	_	_	_	_
48	.	.	I-NP	.	0	_	_	_	_
49	2	2	I-NP	CD	0	_	_	_	_
50	-	-	B-NP	HYPH	0	_	_	_	_
51	-	-	I-NP	SYM	0	_	_	_	_
52	7	7	I-NP	CD	0	_	_	_	_
53	.	.	I-NP	.	0	_	_	_	_
54	7	7	I-NP	CD	0	_	_	_	_
55	1	1	I-NP	CD	0	_	_	_	_
56	min	min	I-NP	NN	0	_	_	_	_
57	-	-	B-NP	HYPH	0	_	_	_	_
58	1	1	I-NP	CD	0	_	_	_	_
59	)	)	O	)	0	_	_	_	_
60	and	and	O	CC	0	_	_	_	_
61	the	the	B-NP	DT	0	_	_	_	_
62	range	range	I-NP	NN	0	_	_	_	_
63	of	of	B-PP	IN	0	_	_	_	_
64	minute	minute	B-NP	JJ	0	_	_	_	_
65	ventilation	ventilation	I-NP	NN	0	_	_	_	_
66	(	(	O	(	0	_	_	_	_
67	4	4	B-NP	CD	0	_	_	_	_
68	-	-	O	HYPH	0	_	_	_	_
69	-	-	B-NP	SYM	0	_	_	_	_
70	10	10	I-NP	CD	0	_	_	_	_
71	1	1	I-NP	CD	0	_	_	_	_
72	min	min	I-NP	NN	0	_	_	_	_
73	-	-	B-NP	HYPH	0	_	_	_	_
74	1	1	I-NP	CD	0	_	_	_	_
75	)	)	O	)	0	_	_	_	_
76	employed	employ	B-VP	VBN	0	_	_	_	_
77	.	.	O	.	0	_	_	_	_

1	SV	SV	B-NP	NN	0	_	_	_	_
2	increased	increase	B-VP	VBD	0	_	_	_	_
3	less	less	B-ADVP	RBR	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	SHR	SHR	B-NP	NN	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	mainly	mainly	B-VP	RB	0	_	_	_	_
8	reflecting	reflect	I-VP	VBG	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	reduced	reduce	I-NP	VBN	0	_	_	_	_
11	diastolic	diastolic	I-NP	JJ	0	_	_	_	_
12	compliance	compliance	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	hypertrophied	hypertrophy	I-NP	VBN	0	_	_	_	_
16	SHR	SHR	I-NP	NN	0	_	_	_	_
17	left	leave	B-VP	VBD	UMLS:C0225897:T023:ANAT	_	_	_	_
18	ventricle	ventricle	B-NP	NN	UMLS:C0225897:T023:ANAT	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	consequent	consequent	I-NP	JJ	0	_	_	_	_
22	rightward	rightward	I-NP	JJ	0	_	_	_	_
23	shift	shift	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	its	its	B-NP	PRP$	0	_	_	_	_
26	Frank	Frank	I-NP	NNP	0	_	_	_	_
27	-	-	I-NP	HYPH	0	_	_	_	_
28	Starling	Starling	I-NP	NNP	0	_	_	_	_
29	curve	curve	I-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	carcass	carcass	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	great	great	I-NP	JJ	0	_	_	_	_
6	horned	horned	I-NP	JJ	0	_	_	_	_
7	owl	owl	I-NP	NN	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	Bubo	Bubo	B-NP	NN	UMLS:C0221382:T047:DISO	_	_	_	_
10	virginianus	virginianus	I-NP	NN	0	_	_	_	_
11	)	)	O	)	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	which	which	B-NP	WDT	0	_	_	_	_
14	had	have	B-VP	VBD	0	_	_	_	_
15	been	be	I-VP	VBN	0	_	_	_	_
16	found	find	I-VP	VBN	0	_	_	_	_
17	moribund	moribund	B-NP	NN	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	southern	southern	B-NP	JJ	0	_	_	_	_
20	Ontario	Ontario	I-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	was	be	B-VP	VBD	0	_	_	_	_
23	presented	present	I-VP	VBN	0	_	_	_	_
24	for	for	B-PP	IN	0	_	_	_	_
25	necropsy	necropsy	B-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	inner	inner	I-NP	JJ	UMLS:C0022889:T023:ANAT	_	_	_	_
3	ears	ear	I-NP	NNS	UMLS:C0022889:T023:ANAT	_	_	_	_
4	were	be	B-VP	VBD	0	_	_	_	_
5	exposed	expose	I-VP	VBN	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	microdissection	microdissection	B-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	vestibular	vestibular	I-NP	JJ	0	_	_	_	_
12	sensory	sensory	I-NP	JJ	0	_	_	_	_
13	regions	region	I-NP	NNS	0	_	_	_	_
14	were	be	B-VP	VBD	0	_	_	_	_
15	either	either	I-VP	RB	0	_	_	_	_
16	sectioned	section	I-VP	VBN	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	studied	study	B-VP	VBN	0	_	_	_	_
19	with	with	B-PP	IN	0	_	_	_	_
20	light	light	B-NP	NN	0	_	_	_	_
21	or	or	I-NP	CC	0	_	_	_	_
22	electron	electron	I-NP	NN	0	_	_	_	_
23	microscopy	microscopy	I-NP	NN	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	or	or	O	CC	0	_	_	_	_
26	prepared	prepare	B-VP	VBN	0	_	_	_	_
27	and	and	I-VP	CC	0	_	_	_	_
28	studied	study	I-VP	VBN	0	_	_	_	_
29	with	with	B-PP	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	surface	surface	I-NP	NN	0	_	_	_	_
32	specimen	specimen	I-NP	NN	0	_	_	_	_
33	technique	technique	I-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Patulin	Patulin	B-NP	NN	0	_	_	_	_
2	is	be	B-VP	VBZ	0	_	_	_	_
3	extracted	extract	I-VP	VBN	0	_	_	_	_
4	from	from	B-PP	IN	0	_	_	_	_
5	apple	apple	B-NP	NN	0	_	_	_	_
6	butter	butter	I-NP	NN	0	_	_	_	_
7	samples	sample	I-NP	NNS	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	ethyl	ethyl	B-NP	NN	0	_	_	_	_
10	acetate	acetate	I-NP	NN	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	extract	extract	I-NP	NN	0	_	_	_	_
14	is	be	B-VP	VBZ	0	_	_	_	_
15	cleaned	clean	I-VP	VBN	0	_	_	_	_
16	up	up	B-PRT	RP	0	_	_	_	_
17	on	on	B-PP	IN	0	_	_	_	_
18	a	a	B-NP	DT	0	_	_	_	_
19	silica	silica	I-NP	NN	0	_	_	_	_
20	gel	gel	I-NP	NN	0	_	_	_	_
21	column	column	I-NP	NN	UMLS:C1185738:T023:ANAT	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	using	use	B-VP	VBG	0	_	_	_	_
24	benzene	benzene	B-NP	NN	0	_	_	_	_
25	-	-	O	HYPH	0	_	_	_	_
26	ethyl	ethyl	B-NP	NN	0	_	_	_	_
27	acetate	acetate	I-NP	NN	0	_	_	_	_
28	(	(	O	(	0	_	_	_	_
29	75+25	75+25	B-NP	CD	0	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	as	as	B-SBAR	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	eluant	eluant	I-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Steroid	Steroid	B-NP	JJ	0	_	_	_	_
2	glucuronides	glucuronide	I-NP	NNS	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	amniotic	amniotic	B-NP	JJ	0	_	_	_	_
5	fluid	fluid	I-NP	NN	0	_	_	_	_
6	at	at	B-PP	IN	0	_	_	_	_
7	term	term	B-NP	NN	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	matrix	matrix	I-NP	NN	0	_	_	_	_
3	surrounding	surround	B-VP	VBG	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	clusters	cluster	I-NP	NNS	0	_	_	_	_
6	either	either	O	CC	0	_	_	_	_
7	showed	show	B-VP	VBD	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	normal	normal	I-NP	JJ	0	_	_	_	_
10	morphology	morphology	I-NP	NN	0	_	_	_	_
11	or	or	O	CC	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	homogeneous	homogeneous	I-NP	JJ	0	_	_	_	_
14	appearance	appearance	I-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	within	within	B-PP	IN	0	_	_	_	_
17	which	which	B-NP	WDT	0	_	_	_	_
18	faint	faint	B-NP	JJ	0	_	_	_	_
19	cross	cross	I-NP	NN	0	_	_	_	_
20	striations	striation	I-NP	NNS	0	_	_	_	_
21	but	but	O	CC	0	_	_	_	_
22	no	no	B-NP	DT	0	_	_	_	_
23	distinctly	distinctly	I-NP	RB	0	_	_	_	_
24	fibrillar	fibrillar	I-NP	JJ	0	_	_	_	_
25	outlines	outline	I-NP	NNS	0	_	_	_	_
26	could	could	B-VP	MD	0	_	_	_	_
27	be	be	I-VP	VB	0	_	_	_	_
28	identified	identify	I-VP	VBN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	Riboflavin	Riboflavin	B-NP	NN	0	_	_	_	_
2	did	do	B-VP	VBD	0	_	_	_	_
3	not	not	I-VP	RB	0	_	_	_	_
4	affect	affect	I-VP	VB	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	percentage	percentage	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	aflatoxin	aflatoxin	B-NP	NN	0	_	_	_	_
9	-	-	B-NP	HYPH	0	_	_	_	_
10	treated	treat	I-NP	VBN	0	_	_	_	_
11	animals	animal	I-NP	NNS	0	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	abnormal	abnormal	B-NP	JJ	0	_	_	_	_
14	urinary	urinary	I-NP	JJ	0	_	_	_	_
15	excretion	excretion	I-NP	NN	0	_	_	_	_
16	patterns	pattern	I-NP	NNS	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	but	but	O	CC	0	_	_	_	_
19	did	do	B-VP	VBD	0	_	_	_	_
20	increase	increase	I-VP	VB	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	magnitude	magnitude	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	disturbances	disturbance	I-NP	NNS	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	elimination	elimination	B-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	kynurenic	kynurenic	B-NP	JJ	0	_	_	_	_
30	and	and	I-NP	CC	0	_	_	_	_
31	xanthurenic	xanthurenic	I-NP	JJ	0	_	_	_	_
32	acids	acid	I-NP	NNS	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Polyglactin	Polyglactin	B-NP	NN	0	_	_	_	_
2	910	910	I-NP	CD	0	_	_	_	_
3	suture	suture	I-NP	JJ	0	_	_	_	_
4	absorption	absorption	I-NP	NN	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	role	role	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	cellular	cellular	B-NP	JJ	0	_	_	_	_
10	enzymes	enzyme	I-NP	NNS	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	incidence	incidence	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	DNCB	DNCB	B-NP	NN	0	_	_	_	_
5	reactions	reaction	I-NP	NNS	0	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	78	78	B-NP	CD	0	_	_	_	_
8	per	per	B-PP	IN	0	_	_	_	_
9	cent	cent	B-NP	NN	0	_	_	_	_
10	for	for	B-PP	IN	0	_	_	_	_
11	Stage	Stage	B-NP	NN	0	_	_	_	_
12	I	I	I-NP	CD	0	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	II	II	I-NP	CD	0	_	_	_	_
15	cancers	cancer	I-NP	NNS	0	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	37	37	B-NP	CD	0	_	_	_	_
18	patinets	patinet	I-NP	NNS	0	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	73	73	B-NP	CD	0	_	_	_	_
22	per	per	B-PP	IN	0	_	_	_	_
23	cent	cent	B-NP	NN	0	_	_	_	_
24	for	for	B-PP	IN	0	_	_	_	_
25	resectable	resectable	B-NP	JJ	0	_	_	_	_
26	Stage	Stage	I-NP	NN	0	_	_	_	_
27	III	III	I-NP	CD	0	_	_	_	_
28	cancer	cancer	I-NP	NN	0	_	_	_	_
29	(	(	O	(	0	_	_	_	_
30	22	22	B-NP	CD	0	_	_	_	_
31	patients	patient	I-NP	NNS	0	_	_	_	_
32	)	)	O	)	0	_	_	_	_
33	,	,	O	,	0	_	_	_	_
34	and	and	O	CC	0	_	_	_	_
35	66	66	B-NP	CD	0	_	_	_	_
36	per	per	B-PP	IN	0	_	_	_	_
37	cent	cent	B-NP	NN	0	_	_	_	_
38	in	in	B-PP	IN	0	_	_	_	_
39	patients	patient	B-NP	NNS	0	_	_	_	_
40	with	with	B-PP	IN	0	_	_	_	_
41	unresectable	unresectable	B-NP	JJ	0	_	_	_	_
42	or	or	I-NP	CC	0	_	_	_	_
43	inoperable	inoperable	I-NP	JJ	0	_	_	_	_
44	Stage	Stage	I-NP	NN	0	_	_	_	_
45	III	III	I-NP	CD	0	_	_	_	_
46	cancer	cancer	I-NP	NN	0	_	_	_	_
47	.	.	O	.	0	_	_	_	_

1	Studies	Study	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	lipoproteins	lipoprotein	B-NP	NNS	0	_	_	_	_
4	should	should	B-VP	MD	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	however	however	B-ADVP	RB	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	be	be	B-VP	VB	0	_	_	_	_
9	made	make	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	children	child	B-NP	NNS	0	_	_	_	_
12	from	from	B-PP	IN	0	_	_	_	_
13	families	family	B-NP	NNS	0	_	_	_	_
14	known	know	B-VP	VBN	0	_	_	_	_
15	to	to	I-VP	TO	0	_	_	_	_
16	have	have	I-VP	VB	0	_	_	_	_
17	FH	FH	B-NP	NN	UMLS:C0745103:T047:DISO	_	_	_	_
18	or	or	O	CC	0	_	_	_	_
19	early	early	B-NP	JJ	0	_	_	_	_
20	coronary	coronary	I-NP	JJ	UMLS:C0010068:T047:DISO|UMLS:C0010054:T047:DISO|UMLS:C0018787:T023:ANAT	_	_	_	_
21	heart	heart	I-NP	NN	UMLS:C0010068:T047:DISO|UMLS:C0010054:T047:DISO|UMLS:C0018787:T023:ANAT	_	_	_	_
22	disease	disease	I-NP	NN	UMLS:C0010068:T047:DISO|UMLS:C0010054:T047:DISO	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Sixteen	Sixteen	B-NP	CD	0	_	_	_	_
2	other	other	I-NP	JJ	0	_	_	_	_
3	normal	normal	I-NP	JJ	0	_	_	_	_
4	subjects	subject	I-NP	NNS	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	2	2	B-NP	CD	0	_	_	_	_
7	g	g	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	Metyrapone	Metyrapone	B-NP	NN	0	_	_	_	_
10	are	be	B-VP	VBP	0	_	_	_	_
11	best	good	B-NP	JJS	0	_	_	_	_
12	responses	response	I-NP	NNS	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	EEG	EEG	B-NP	NN	0	_	_	_	_
2	theta	theta	I-NP	NN	0	_	_	_	_
3	waves	wave	I-NP	NNS	0	_	_	_	_
4	and	and	O	CC	0	_	_	_	_
5	psychological	psychological	B-NP	JJ	0	_	_	_	_
6	phenomena	phenomenon	I-NP	NNS	0	_	_	_	_
7	:	:	O	:	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	review	review	I-NP	NN	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	analysis	analysis	I-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	REM	REM	B-NP	NN	0	_	_	_	_
2	dream	dream	I-NP	NN	0	_	_	_	_
3	content	content	I-NP	NN	0	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	scored	score	I-VP	VBN	0	_	_	_	_
6	for	for	B-PP	IN	0	_	_	_	_
7	categories	category	B-NP	NNS	0	_	_	_	_
8	suggesting	suggest	B-VP	VBG	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	predominant	predominant	I-NP	JJ	0	_	_	_	_
11	influence	influence	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	left	left	I-NP	JJ	0	_	_	_	_
15	hemisphere	hemisphere	I-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	e	e	B-NP	NN	0	_	_	_	_
18	.	.	I-NP	.	0	_	_	_	_
19	g	g	I-NP	NN	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	good	good	B-NP	JJ	0	_	_	_	_
23	ego	ego	I-NP	NN	0	_	_	_	_
24	functioning	functioning	I-NP	NN	0	_	_	_	_
25	,	,	O	,	0	_	_	_	_
26	verbalization	verbalization	B-NP	NN	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	or	or	O	CC	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	right	right	I-NP	JJ	0	_	_	_	_
31	hemisphere	hemisphere	I-NP	NN	0	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	e	e	B-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_
35	g	g	B-NP	NN	0	_	_	_	_
36	.	.	I-NP	NN	0	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	music	music	B-NP	NN	0	_	_	_	_
39	,	,	O	,	0	_	_	_	_
40	spatial	spatial	B-NP	JJ	0	_	_	_	_
41	salience	salience	I-NP	NN	0	_	_	_	_
42	,	,	O	,	0	_	_	_	_
43	bizarreness	bizarreness	B-NP	NN	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	Innervation	Innervation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	ventral	ventral	I-NP	JJ	0	_	_	_	_
5	diaphragm	diaphragm	I-NP	NN	UMLS:C0011980:T023:ANAT	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	locust	locust	I-NP	NN	0	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	Locusta	Locusta	B-NP	NNP	0	_	_	_	_
11	migratoria	migratoria	I-NP	NNP	0	_	_	_	_
12	)	)	O	)	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Ectopic	Ectopic	B-NP	JJ	UMLS:C0001231:T047:DISO	_	_	_	_
2	ACTH	ACTH	I-NP	NN	UMLS:C0001231:T047:DISO|:::NOCLASS	_	_	_	_
3	syndrome	syndrome	I-NP	NN	UMLS:C0001231:T047:DISO	_	_	_	_
4	and	and	O	CC	0	_	_	_	_
5	medullary	medullary	B-NP	JJ	UMLS:C0001629:T023:ANAT|UMLS:C0025148:T023:ANAT	_	_	_	_
6	thyroid	thyroid	I-NP	NN	UMLS:C0040132:T023:ANAT	_	_	_	_
7	carcinoma	carcinoma	I-NP	NN	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	striking	striking	I-NP	JJ	0	_	_	_	_
3	finding	finding	I-NP	NN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	all	all	B-NP	DT	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	studies	study	I-NP	NNS	0	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	positive	positive	I-NP	JJ	0	_	_	_	_
12	correlation	correlation	I-NP	NN	0	_	_	_	_
13	between	between	B-PP	IN	0	_	_	_	_
14	PI	PI	B-NP	NN	0	_	_	_	_
15	ACTH	ACTH	I-NP	NN	:::NOCLASS	_	_	_	_
16	and	and	I-NP	CC	0	_	_	_	_
17	MSH	MSH	I-NP	NN	:::NOCLASS	_	_	_	_
18	contents	content	I-NP	NNS	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Chronic	Chronic	B-NP	JJ	0	_	_	_	_
2	hypophosphatemia	hypophosphatemia	I-NP	NN	0	_	_	_	_
3	is	be	B-VP	VBZ	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	most	most	I-NP	RBS	0	_	_	_	_
6	common	common	I-NP	JJ	0	_	_	_	_
7	type	type	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	"	"	B-NP	``	0	_	_	_	_
10	resistant	resistant	I-NP	JJ	0	_	_	_	_
11	"	"	I-NP	''	0	_	_	_	_
12	rickets	ricket	I-NP	NNS	UMLS:C0035579:T047:DISO	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	There	There	B-NP	EX	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	no	no	B-NP	DT	0	_	_	_	_
4	correlation	correlation	I-NP	NN	0	_	_	_	_
5	between	between	B-PP	IN	0	_	_	_	_
6	serum	serum	B-NP	NN	:::NOCLASS	_	_	_	_
7	LH	LH	I-NP	NN	:::NOCLASS	_	_	_	_
8	and	and	O	CC	0	_	_	_	_
9	chronological	chronological	B-NP	JJ	0	_	_	_	_
10	or	or	I-NP	CC	0	_	_	_	_
11	bone	bone	I-NP	NN	UMLS:C0262950:T023:ANAT	_	_	_	_
12	age	age	I-NP	NN	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	this	this	B-NP	DT	0	_	_	_	_
15	age	age	I-NP	NN	0	_	_	_	_
16	group	group	I-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	which	which	B-NP	WDT	0	_	_	_	_
19	suggests	suggest	B-VP	VBZ	0	_	_	_	_
20	that	that	B-SBAR	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	correlation	correlation	I-NP	NN	0	_	_	_	_
23	found	find	B-VP	VBN	0	_	_	_	_
24	is	be	B-VP	VBZ	0	_	_	_	_
25	not	not	O	RB	0	_	_	_	_
26	due	due	B-ADJP	JJ	0	_	_	_	_
27	to	to	B-PP	TO	0	_	_	_	_
28	age	age	B-NP	NN	0	_	_	_	_
29	-	-	I-NP	HYPH	0	_	_	_	_
30	related	relate	B-VP	VBN	0	_	_	_	_
31	parallel	parallel	B-NP	JJ	0	_	_	_	_
32	phenomena	phenomenon	I-NP	NNS	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Molecular	Molecular	B-NP	JJ	0	_	_	_	_
2	neurochemistry	neurochemistry	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	addictive	addictive	B-NP	JJ	0	_	_	_	_
5	drugs	drug	I-NP	NNS	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	Efforts	Effort	B-NP	NNS	0	_	_	_	_
2	were	be	B-VP	VBD	0	_	_	_	_
3	made	make	I-VP	VBN	0	_	_	_	_
4	to	to	B-VP	TO	0	_	_	_	_
5	determine	determine	I-VP	VB	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	amount	amount	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	time	time	B-NP	NN	0	_	_	_	_
10	required	require	B-VP	VBN	0	_	_	_	_
11	for	for	B-PP	IN	0	_	_	_	_
12	kidney	kidney	B-NP	NN	UMLS:C0022646:T023:ANAT|UMLS:C0227665:T023:ANAT	_	_	_	_
13	lesions	lesion	I-NP	NNS	0	_	_	_	_
14	to	to	B-VP	TO	0	_	_	_	_
15	develop	develop	I-VP	VB	0	_	_	_	_
16	and	and	O	CC	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	if	if	B-SBAR	IN	0	_	_	_	_
19	possible	possible	B-ADJP	JJ	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	to	to	B-VP	TO	0	_	_	_	_
22	delineate	delineate	I-VP	VB	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	potential	potential	I-NP	JJ	0	_	_	_	_
25	site	site	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	action	action	B-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	PBB	PBB	B-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Effect	Effect	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	succimer	succimer	B-NP	NN	0	_	_	_	_
4	on	on	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	intensity	intensity	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	tricarboxylic	tricarboxylic	B-NP	JJ	:::NOCLASS	_	_	_	_
9	acid	acid	I-NP	NN	:::NOCLASS	_	_	_	_
10	dehydrogenase	dehydrogenase	I-NP	NN	:::NOCLASS	_	_	_	_
11	reactions	reaction	I-NP	NNS	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	brain	brain	I-NP	NN	UMLS:C0006104:T023:ANAT	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	rats	rat	B-NP	NNS	0	_	_	_	_
17	poisoned	poison	B-VP	VBN	0	_	_	_	_
18	with	with	B-PP	IN	0	_	_	_	_
19	mercuric	mercuric	B-NP	JJ	0	_	_	_	_
20	chloride	chloride	I-NP	NN	0	_	_	_	_

1	Distribution	Distribution	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	correlations	correlation	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	serum	serum	B-NP	NN	0	_	_	_	_
6	uric	uric	I-NP	JJ	0	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	acid	acid	I-NP	NN	0	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	two	two	B-NP	CD	0	_	_	_	_
11	French	French	I-NP	JJ	0	_	_	_	_
12	adult	adult	I-NP	JJ	0	_	_	_	_
13	populations	population	I-NP	NNS	0	_	_	_	_
14	:	:	O	:	0	_	_	_	_
15	13	13	B-NP	CD	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	885	885	B-NP	CD	0	_	_	_	_
18	men	man	I-NP	NNS	0	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	6	6	B-NP	CD	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	861	861	B-NP	CD	0	_	_	_	_
23	women	woman	I-NP	NNS	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	incidence	incidence	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	hepatitis	hepatitis	B-NP	NN	:::NOCLASS|UMLS:C0019163:T047:DISO	_	_	_	_
5	B	B	I-NP	NN	:::NOCLASS|UMLS:C0019163:T047:DISO	_	_	_	_
6	antigen	antigen	I-NP	NN	:::NOCLASS	_	_	_	_
7	following	follow	B-PP	VBG	0	_	_	_	_
8	transfusion	transfusion	B-NP	NN	0	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	about	about	B-NP	RB	0	_	_	_	_
11	2	2	I-NP	CD	0	_	_	_	_
12	.	.	I-NP	.	0	_	_	_	_
13	8	8	I-NP	CD	0	_	_	_	_
14	per	per	B-PP	IN	0	_	_	_	_
15	cent	cent	B-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Technetium	Technetium	B-NP	NN	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	99m	99m	I-NP	CD	0	_	_	_	_
4	stannous	stannous	I-NP	JJ	0	_	_	_	_
5	pyrophosphate	pyrophosphate	I-NP	NN	0	_	_	_	_
6	myocardial	myocardial	I-NP	JJ	0	_	_	_	_
7	scintigrams	scintigram	I-NP	NNS	0	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	obtained	obtain	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	138	138	B-NP	CD	0	_	_	_	_
12	clinically	clinically	I-NP	RB	0	_	_	_	_
13	stable	stable	I-NP	JJ	0	_	_	_	_
14	patients	patient	I-NP	NNS	0	_	_	_	_
15	32	32	B-NP	CD	0	_	_	_	_
16	.	.	I-NP	.	0	_	_	_	_
17	7	7	I-NP	CD	0	_	_	_	_
18	+	+	B-NP	SYM	0	_	_	_	_
19	/	/	I-NP	SYM	0	_	_	_	_
20	-	-	I-NP	SYM	0	_	_	_	_
21	47	47	I-NP	CD	0	_	_	_	_
22	.	.	I-NP	SYM	0	_	_	_	_
23	3	3	I-NP	CD	0	_	_	_	_
24	weeks	week	I-NP	NNS	0	_	_	_	_
25	(	(	O	(	0	_	_	_	_
26	range	range	B-NP	NN	0	_	_	_	_
27	6	6	I-NP	CD	0	_	_	_	_
28	to	to	I-NP	TO	0	_	_	_	_
29	260	260	I-NP	CD	0	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	after	after	B-PP	IN	0	_	_	_	_
32	acute	acute	B-NP	JJ	UMLS:C0155626:T047:DISO	_	_	_	_
33	myocardial	myocardial	I-NP	JJ	UMLS:C0155626:T047:DISO	_	_	_	_
34	infarction	infarction	I-NP	NN	UMLS:C0155626:T047:DISO	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	similar	similar	I-NP	JJ	0	_	_	_	_
3	phenomenon	phenomenon	I-NP	NN	0	_	_	_	_
4	has	have	B-VP	VBZ	0	_	_	_	_
5	been	be	I-VP	VBN	0	_	_	_	_
6	reported	report	I-VP	VBN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	few	few	I-NP	JJ	0	_	_	_	_
10	humans	human	I-NP	NNS	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	decline	decline	I-NP	NN	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	activity	activity	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	cytochrome	cytochrome	B-NP	NN	:::NOCLASS	_	_	_	_
8	oxidase	oxidase	I-NP	NN	:::NOCLASS	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	peroxidase	peroxidase	B-NP	NN	:::NOCLASS	_	_	_	_
11	and	and	B-PP	CC	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	lipid	lipid	I-NP	NN	0	_	_	_	_
15	content	content	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	peripheral	peripheral	B-NP	JJ	0	_	_	_	_
18	neutrophils	neutrophil	I-NP	NNS	0	_	_	_	_
19	was	be	B-VP	VBD	0	_	_	_	_
20	followed	follow	I-VP	VBN	0	_	_	_	_
21	by	by	B-PP	IN	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	decrease	decrease	I-NP	NN	0	_	_	_	_
24	in	in	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	phagocytic	phagocytic	I-NP	JJ	0	_	_	_	_
27	activity	activity	I-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	Treatment	Treatment	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	2	2	B-NP	CD	0	_	_	_	_
4	patients	patient	I-NP	NNS	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	pseudohypoparathyroidism	pseudohypoparathyroidism	B-NP	NN	UMLS:C0033806:T047:DISO	_	_	_	_
7	type	type	I-NP	NN	0	_	_	_	_
8	I	I	I-NP	CD	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	vitamin	vitamin	B-NP	NN	0	_	_	_	_
11	-	-	B-NP	HYPH	0	_	_	_	_
12	D	D	I-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	3	3	I-NP	CD	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	1	1	I-NP	CD	0	_	_	_	_
17	alpha	alpha	O	SYM	0	_	_	_	_
18	-	-	O	HYPH	0	_	_	_	_
19	Hydroxycholecalciferol	Hydroxycholecalciferol	B-NP	NN	0	_	_	_	_
20	consecutively	consecutively	B-ADVP	RB	0	_	_	_	_
21	resulted	result	B-VP	VBD	0	_	_	_	_
22	in	in	B-PP	IN	0	_	_	_	_
23	a	a	B-NP	DT	0	_	_	_	_
24	nonuniform	nonuniform	I-NP	JJ	0	_	_	_	_
25	response	response	I-NP	NN	0	_	_	_	_
26	with	with	B-PP	IN	0	_	_	_	_
27	regard	regard	B-NP	NN	0	_	_	_	_
28	to	to	B-PP	TO	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	normalisation	normalisation	I-NP	NN	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	serum	serum	B-NP	NN	0	_	_	_	_
33	-	-	B-NP	HYPH	0	_	_	_	_
34	calcium	calcium	I-NP	NN	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	Workers	Worker	B-NP	NNS	0	_	_	_	_
2	with	with	B-PP	IN	0	_	_	_	_
3	"	"	O	``	0	_	_	_	_
4	sensitivity	sensitivity	B-NP	NN	0	_	_	_	_
5	"	"	O	''	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	toluene	toluene	B-NP	NN	0	_	_	_	_
8	diisocyanate	diisocyanate	I-NP	NN	0	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	TDI	TDI	B-NP	NN	0	_	_	_	_
11	)	)	O	)	0	_	_	_	_
12	studied	study	B-VP	VBN	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	depth	depth	B-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	an	an	B-NP	DT	0	_	_	_	_
17	attempt	attempt	I-NP	NN	0	_	_	_	_
18	to	to	B-VP	TO	0	_	_	_	_
19	determine	determine	I-VP	VB	0	_	_	_	_
20	mechanisms	mechanism	B-NP	NNS	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	bronchial	bronchial	B-NP	JJ	UMLS:C0085129:T047:DISO|UMLS:C1442216:T023:ANAT|UMLS:C0205039:T023:ANAT	_	_	_	_
23	hyperreactivity	hyperreactivity	I-NP	NN	UMLS:C0085129:T047:DISO	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Total	Total	B-NP	JJ	0	_	_	_	_
2	VO2	VO2	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	decreased	decrease	I-VP	VBN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	both	both	B-NP	DT	0	_	_	_	_
7	groups	group	I-NP	NNS	0	_	_	_	_
8	during	during	B-PP	IN	0	_	_	_	_
9	severe	severe	B-NP	JJ	0	_	_	_	_
10	hypoxia	hypoxia	I-NP	NN	0	_	_	_	_
11	but	but	O	CC	0	_	_	_	_
12	limb	limb	B-NP	NN	UMLS:C0015385:T023:ANAT	_	_	_	_
13	VO2	VO2	I-NP	NN	0	_	_	_	_
14	was	be	B-VP	VBD	0	_	_	_	_
15	maintained	maintain	I-VP	VBN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	beta	beta	I-NP	SYM	0	_	_	_	_
19	-	-	I-NP	HYPH	0	_	_	_	_
20	block	block	I-NP	NN	0	_	_	_	_
21	group	group	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_
23	beta	beta	O	SYM	0	_	_	_	_
24	-	-	B-NP	HYPH	0	_	_	_	_
25	Block	Block	I-NP	NN	0	_	_	_	_
26	prevented	prevent	B-VP	VBD	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	fall	fall	I-NP	NN	0	_	_	_	_
29	in	in	B-PP	IN	0	_	_	_	_
30	total	total	B-NP	NN	0	_	_	_	_
31	and	and	I-NP	CC	0	_	_	_	_
32	limb	limb	I-NP	NN	UMLS:C0015385:T023:ANAT	_	_	_	_
33	peripheral	peripheral	I-NP	JJ	0	_	_	_	_
34	resistance	resistance	I-NP	NN	0	_	_	_	_
35	seen	see	B-VP	VBN	0	_	_	_	_
36	in	in	B-PP	IN	0	_	_	_	_
37	severe	severe	B-NP	JJ	0	_	_	_	_
38	hypoxia	hypoxia	I-NP	NN	0	_	_	_	_
39	but	but	O	CC	0	_	_	_	_
40	did	do	B-VP	VBD	0	_	_	_	_
41	not	not	I-VP	RB	0	_	_	_	_
42	alter	alter	I-VP	VB	0	_	_	_	_
43	the	the	B-NP	DT	0	_	_	_	_
44	consistently	consistently	I-NP	RB	0	_	_	_	_
45	more	more	I-NP	RBR	0	_	_	_	_
46	efficient	efficient	I-NP	JJ	0	_	_	_	_
47	utilization	utilization	I-NP	NN	0	_	_	_	_
48	of	of	B-PP	IN	0	_	_	_	_
49	total	total	B-NP	JJ	0	_	_	_	_
50	O2	O2	I-NP	NN	0	_	_	_	_
51	delivery	delivery	I-NP	NN	0	_	_	_	_
52	shown	show	B-VP	VBN	0	_	_	_	_
53	by	by	B-PP	IN	0	_	_	_	_
54	the	the	B-NP	DT	0	_	_	_	_
55	limb	limb	I-NP	NN	UMLS:C0015385:T023:ANAT	_	_	_	_
56	in	in	B-PP	IN	0	_	_	_	_
57	comparison	comparison	B-NP	NN	0	_	_	_	_
58	to	to	B-PP	TO	0	_	_	_	_
59	the	the	B-NP	DT	0	_	_	_	_
60	whole	whole	I-NP	JJ	0	_	_	_	_
61	body	body	I-NP	NN	0	_	_	_	_
62	by	by	B-PP	IN	0	_	_	_	_
63	higher	high	B-NP	JJR	0	_	_	_	_
64	O2	O2	I-NP	NN	0	_	_	_	_
65	extraction	extraction	I-NP	NN	0	_	_	_	_
66	ratios	ratio	I-NP	NNS	0	_	_	_	_
67	and	and	O	CC	0	_	_	_	_
68	lower	low	B-NP	JJR	0	_	_	_	_
69	venous	venous	I-NP	JJ	UMLS:C0042449:T023:ANAT	_	_	_	_
70	O2	O2	I-NP	NN	0	_	_	_	_
71	pressure	pressure	I-NP	NN	0	_	_	_	_
72	.	.	O	.	0	_	_	_	_
73	beta	beta	B-NP	SYM	:::NOCLASS	_	_	_	_
74	-	-	B-VP	HYPH	:::NOCLASS	_	_	_	_
75	Vasodilator	Vasodilator	B-NP	NN	:::NOCLASS	_	_	_	_
76	receptors	receptor	I-NP	NNS	:::NOCLASS	_	_	_	_
77	evidently	evidently	B-VP	RB	0	_	_	_	_
78	played	play	I-VP	VBD	0	_	_	_	_
79	an	an	B-NP	DT	0	_	_	_	_
80	active	active	I-NP	JJ	0	_	_	_	_
81	part	part	I-NP	NN	0	_	_	_	_
82	in	in	B-PP	IN	0	_	_	_	_
83	the	the	B-NP	DT	0	_	_	_	_
84	vasodilatation	vasodilatation	I-NP	NN	0	_	_	_	_
85	seen	see	B-VP	VBN	0	_	_	_	_
86	during	during	B-PP	IN	0	_	_	_	_
87	severe	severe	B-NP	JJ	0	_	_	_	_
88	hypoxia	hypoxia	I-NP	NN	0	_	_	_	_
89	.	.	O	.	0	_	_	_	_

1	Phenobarbital	Phenobarbital	B-NP	NN	0	_	_	_	_
2	-	-	B-NP	HYPH	0	_	_	_	_
3	induced	induce	I-NP	VBN	0	_	_	_	_
4	alterations	alteration	I-NP	NNS	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	metabolism	metabolism	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	[	[	O	(	0	_	_	_	_
10	3H	3H	B-NP	NN	0	_	_	_	_
11	]	]	O	)	0	_	_	_	_
12	vitamin	vitamin	B-NP	NN	0	_	_	_	_
13	D3	D3	I-NP	NN	0	_	_	_	_
14	by	by	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	perfused	perfuse	I-NP	VBN	0	_	_	_	_
17	rachitic	rachitic	I-NP	JJ	0	_	_	_	_
18	rat	rat	I-NP	NN	UMLS:C1882726:T023:ANAT	_	_	_	_
19	liver	liver	I-NP	NN	UMLS:C1882726:T023:ANAT	_	_	_	_
20	in	in	B-ADVP	FW	0	_	_	_	_
21	vitro	vitro	I-ADVP	FW	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Modulation	Modulation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	25	25	B-NP	CD	:::NOCLASS	_	_	_	_
4	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
5	hydroxyvitamin	hydroxyvitamin	I-NP	NN	:::NOCLASS	_	_	_	_
6	D3	D3	I-NP	NN	:::NOCLASS	_	_	_	_
7	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
8	24	24	I-NP	CD	:::NOCLASS	_	_	_	_
9	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
10	hydroxylase	hydroxylase	I-NP	NN	:::NOCLASS	_	_	_	_
11	by	by	B-PP	IN	0	_	_	_	_
12	aminophylline	aminophylline	B-NP	NN	0	_	_	_	_
13	:	:	O	:	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	cytochrome	cytochrome	I-NP	NN	:::NOCLASS	_	_	_	_
16	P	P	I-NP	NN	:::NOCLASS	_	_	_	_
17	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
18	450	450	I-NP	CD	:::NOCLASS	_	_	_	_
19	monooxygenase	monooxygenase	I-NP	NN	:::NOCLASS	_	_	_	_
20	system	system	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	both	both	B-NP	PDT	0	_	_	_	_
3	these	these	B-NP	DT	0	_	_	_	_
4	respects	respect	I-NP	NNS	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	however	however	B-ADVP	RB	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	DBP	DBP	I-NP	NN	:::NOCLASS	_	_	_	_
10	mRNA	mRNA	I-NP	NN	:::NOCLASS	_	_	_	_
11	resembles	resemble	B-VP	VBZ	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	late	late	I-NP	JJ	0	_	_	_	_
14	messengers	messenger	I-NP	NNS	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	SV40	SV40	B-NP	NN	0	_	_	_	_
17	and	and	I-NP	CC	0	_	_	_	_
18	polyoma	polyoma	I-NP	NN	0	_	_	_	_
19	viruses	virus	I-NP	NNS	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Effect	Effect	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	corticosteroid	corticosteroid	B-NP	NN	0	_	_	_	_
4	-	-	O	HYPH	0	_	_	_	_
5	containing	contain	B-VP	VBG	0	_	_	_	_
6	antirheumatic	antirheumatic	B-NP	JJ	0	_	_	_	_
7	combination	combination	I-NP	NN	0	_	_	_	_
8	drugs	drug	I-NP	NNS	0	_	_	_	_
9	on	on	B-PP	IN	0	_	_	_	_
10	endogenous	endogenous	B-NP	JJ	0	_	_	_	_
11	ACTH	ACTH	I-NP	NN	:::NOCLASS	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	cortisol	cortisol	B-NP	NN	0	_	_	_	_
14	production	production	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Serum	Serum	B-NP	NN	:::NOCLASS	_	_	_	_
2	ACTH	ACTH	I-NP	NN	:::NOCLASS	_	_	_	_
3	did	do	B-VP	VBD	0	_	_	_	_
4	not	not	I-VP	RB	0	_	_	_	_
5	respond	respond	I-VP	VB	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	insulin	insulin	B-NP	NN	:::NOCLASS	_	_	_	_
8	and	and	I-NP	CC	0	_	_	_	_
9	metyrapone	metyrapone	I-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	Anatomy	Anatomy	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	RNA	RNA	I-NP	NN	0	_	_	_	_
5	and	and	I-NP	CC	0	_	_	_	_
6	gene	gene	I-NP	NN	0	_	_	_	_
7	products	product	I-NP	NNS	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	MC29	MC29	B-NP	NN	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	MH2	MH2	I-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	two	two	B-NP	CD	0	_	_	_	_
14	defective	defective	I-NP	JJ	0	_	_	_	_
15	avian	avian	I-NP	JJ	0	_	_	_	_
16	tumor	tumor	I-NP	NN	0	_	_	_	_
17	viruses	virus	I-NP	NNS	0	_	_	_	_
18	causing	cause	B-VP	VBG	0	_	_	_	_
19	acute	acute	B-NP	JJ	0	_	_	_	_
20	leukemia	leukemia	I-NP	NN	0	_	_	_	_
21	and	and	I-NP	CC	0	_	_	_	_
22	carcinoma	carcinoma	I-NP	NN	0	_	_	_	_
23	:	:	O	:	0	_	_	_	_
24	evidence	evidence	B-NP	NN	0	_	_	_	_
25	for	for	B-PP	IN	0	_	_	_	_
26	a	a	B-NP	DT	0	_	_	_	_
27	new	new	I-NP	JJ	0	_	_	_	_
28	class	class	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	transforming	transform	B-VP	VBG	0	_	_	_	_
31	genes	gene	B-NP	NNS	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Bertioga	Bertioga	B-NP	NNP	0	_	_	_	_
2	(	(	O	(	0	_	_	_	_
3	Guama	Guama	B-NP	NNP	0	_	_	_	_
4	group	group	I-NP	NN	0	_	_	_	_
5	)	)	O	)	0	_	_	_	_
6	and	and	O	CC	0	_	_	_	_
7	Anhembi	Anhembi	B-NP	NNP	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	Bunyamwera	Bunyamwera	B-NP	NN	0	_	_	_	_
10	group	group	I-NP	NN	0	_	_	_	_
11	)	)	O	)	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	two	two	B-NP	CD	0	_	_	_	_
14	new	new	I-NP	JJ	0	_	_	_	_
15	arboviruses	arbovirus	I-NP	NNS	0	_	_	_	_
16	isolated	isolate	B-VP	VBN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	Sao	Sao	B-NP	NNP	0	_	_	_	_
19	Paulo	Paulo	I-NP	NNP	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	Brazil	Brazil	B-NP	NNP	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Gamma	Gamma	B-NP	NN	:::NOCLASS	_	_	_	_
2	glutamyl	glutamyl	I-NP	NN	:::NOCLASS	_	_	_	_
3	transpeptidase	transpeptidase	I-NP	NN	:::NOCLASS	_	_	_	_
4	activity	activity	I-NP	NN	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	increased	increase	I-VP	VBN	0	_	_	_	_
7	up	up	B-NP	RB	0	_	_	_	_
8	to	to	I-NP	TO	0	_	_	_	_
9	15	15	I-NP	CD	0	_	_	_	_
10	times	time	I-NP	NNS	0	_	_	_	_
11	above	above	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	upper	upper	I-NP	JJ	0	_	_	_	_
14	normal	normal	I-NP	JJ	0	_	_	_	_
15	limit	limit	I-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	children	child	B-NP	NNS	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	who	who	B-NP	WP	0	_	_	_	_
20	received	receive	B-VP	VBD	0	_	_	_	_
21	aminopyrine	aminopyrine	B-NP	NN	0	_	_	_	_
22	for	for	B-PP	IN	0	_	_	_	_
23	two	two	B-NP	CD	0	_	_	_	_
24	weeks	week	I-NP	NNS	0	_	_	_	_
25	or	or	O	CC	0	_	_	_	_
26	longer	long	B-ADVP	JJR	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	XXI	XXI	B-LST	LS	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	gas	gas	I-NP	NN	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	liquid	liquid	I-NP	NN	0	_	_	_	_
5	chromatographic	chromatographic	I-NP	JJ	0	_	_	_	_
6	method	method	I-NP	NN	0	_	_	_	_
7	for	for	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	determination	determination	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	p	p	B-NP	NN	0	_	_	_	_
12	-	-	B-NP	HYPH	0	_	_	_	_
13	chlorophenoxyisobutyric	chlorophenoxyisobutyric	I-NP	JJ	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	CPIB	CPIB	B-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	acid	acid	B-NP	NN	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	blood	blood	B-NP	NN	0	_	_	_	_
20	plasma	plasma	I-NP	NN	0	_	_	_	_
21	is	be	B-VP	VBZ	0	_	_	_	_
22	described	describe	I-VP	VBN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Dopamine	Dopamine	B-NP	NN	:::NOCLASS	_	_	_	_
2	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
3	blockade	blockade	I-NP	NN	0	_	_	_	_
4	and	and	O	CC	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	neuroleptics	neuroleptic	I-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	crystallographic	crystallographic	I-NP	JJ	0	_	_	_	_
10	study	study	I-NP	NN	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	V	V	B-NP	NN	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	rapid	rapid	I-NP	JJ	0	_	_	_	_
3	fluorimetric	fluorimetric	I-NP	JJ	0	_	_	_	_
4	procedure	procedure	I-NP	NN	0	_	_	_	_
5	for	for	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	determination	determination	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	fungicide	fungicide	I-NP	NN	0	_	_	_	_
11	5	5	I-NP	CD	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	fluorocytosine	fluorocytosine	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	serum	serum	B-NP	NN	0	_	_	_	_
16	is	be	B-VP	VBZ	0	_	_	_	_
17	described	describe	I-VP	VBN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	'field	'field	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	stress	stress	B-NP	NN	0	_	_	_	_
5	'	'	O	''	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	supervisory	supervisory	I-NP	NN	0	_	_	_	_
9	nurse	nurse	I-NP	NN	0	_	_	_	_

1	How	How	B-ADVP	WRB	0	_	_	_	_
2	do	do	O	VBP	0	_	_	_	_
3	graduates	graduate	B-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	different	different	B-NP	JJ	0	_	_	_	_
6	types	type	I-NP	NNS	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	programs	program	B-NP	NNS	0	_	_	_	_
9	perform	perform	B-VP	VBP	0	_	_	_	_
10	on	on	B-PP	IN	0	_	_	_	_
11	state	state	B-NP	NN	0	_	_	_	_
12	boards	board	I-NP	NNS	0	_	_	_	_
13	?	?	O	.	0	_	_	_	_

1	Similarly	Similarly	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	maternal	maternal	B-NP	JJ	:::NOCLASS	_	_	_	_
4	serum	serum	I-NP	NN	:::NOCLASS	_	_	_	_
5	somatomedin	somatomedin	I-NP	NN	:::NOCLASS	_	_	_	_
6	A	A	I-NP	NN	:::NOCLASS	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	significantly	significantly	I-VP	RB	0	_	_	_	_
9	reduced	reduce	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	rats	rat	B-NP	NNS	0	_	_	_	_
12	nursing	nurse	B-VP	VBG	0	_	_	_	_
13	large	large	B-NP	JJ	0	_	_	_	_
14	litters	litter	I-NP	NNS	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	sequences	sequence	I-NP	NNS	0	_	_	_	_
3	following	follow	B-PP	VBG	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	X	X	I-NP	NN	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_
7	borealis	borealis	B-NP	NN	0	_	_	_	_
8	oocyte	oocyte	I-NP	NN	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	somatic	somatic	B-NP	JJ	0	_	_	_	_
11	5S	5S	I-NP	NN	:::NOCLASS	_	_	_	_
12	genes	gene	I-NP	NNS	:::NOCLASS	_	_	_	_
13	are	be	B-VP	VBP	0	_	_	_	_
14	identical	identical	B-ADJP	JJ	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	12	12	B-NP	CD	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	first	first	I-NP	JJ	0	_	_	_	_
20	14	14	I-NP	CD	0	_	_	_	_
21	residues	residue	I-NP	NNS	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	contain	contain	B-VP	VBP	0	_	_	_	_
24	two	two	B-NP	CD	0	_	_	_	_
25	or	or	I-NP	CC	0	_	_	_	_
26	more	more	I-NP	JJR	0	_	_	_	_
27	T	T	I-NP	NN	0	_	_	_	_
28	clusters	cluster	I-NP	NNS	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	as	as	B-SBAR	IN	0	_	_	_	_
31	does	do	O	VBZ	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	corresponding	corresponding	I-NP	JJ	0	_	_	_	_
34	region	region	I-NP	NN	0	_	_	_	_
35	of	of	B-PP	IN	0	_	_	_	_
36	X	X	B-NP	NN	:::NOCLASS	_	_	_	_
37	.	.	O	.	:::NOCLASS	_	_	_	_
38	laevis	laevis	B-NP	NN	:::NOCLASS	_	_	_	_
39	oocyte	oocyte	I-NP	NN	:::NOCLASS	_	_	_	_
40	5S	5S	I-NP	NN	:::NOCLASS	_	_	_	_
41	DNA	DNA	I-NP	NN	:::NOCLASS	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	mechanism	mechanism	I-NP	NN	0	_	_	_	_
3	is	be	B-VP	VBZ	0	_	_	_	_
4	not	not	O	RB	0	_	_	_	_
5	due	due	B-ADJP	JJ	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	observed	observe	I-NP	VBN	0	_	_	_	_
9	grain	grain	I-NP	NN	0	_	_	_	_
10	boundary	boundary	I-NP	JJ	0	_	_	_	_
11	precipitates	precipitate	I-NP	NNS	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	report	report	I-NP	NN	0	_	_	_	_
3	has	have	B-VP	VBZ	0	_	_	_	_
4	reviewed	review	I-VP	VBN	0	_	_	_	_
5	some	some	B-NP	DT	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	reasons	reason	I-NP	NNS	0	_	_	_	_
9	for	for	B-PP	IN	0	_	_	_	_
10	treatment	treatment	B-NP	NN	0	_	_	_	_
11	failures	failure	I-NP	NNS	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	has	have	B-VP	VBZ	0	_	_	_	_
14	presented	present	I-VP	VBN	0	_	_	_	_
15	a	a	B-NP	DT	0	_	_	_	_
16	philosophy	philosophy	I-NP	NN	0	_	_	_	_
17	for	for	B-PP	IN	0	_	_	_	_
18	their	their	B-NP	PRP$	0	_	_	_	_
19	management	management	I-NP	NN	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Diagnosis	Diagnosis	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	treatment	treatment	I-NP	NN	0	_	_	_	_
4	planning	planning	I-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	Class	Class	B-NP	NN	0	_	_	_	_
7	II	II	I-NP	CD	0	_	_	_	_
8	,	,	I-NP	,	0	_	_	_	_
9	division	division	I-NP	NN	0	_	_	_	_
10	2	2	I-NP	CD	0	_	_	_	_

1	Because	Because	B-PP	IN	0	_	_	_	_
2	of	of	I-PP	IN	0	_	_	_	_
3	serious	serious	B-NP	JJ	0	_	_	_	_
4	infections	infection	I-NP	NNS	UMLS:C0021311:T047:DISO|UMLS:C0851162:T047:DISO	_	_	_	_
5	(	(	O	(	0	_	_	_	_
6	fever	fever	B-NP	NN	0	_	_	_	_
7	larger	large	B-ADJP	JJR	0	_	_	_	_
8	than	than	B-PP	IN	0	_	_	_	_
9	or	or	O	CC	0	_	_	_	_
10	equal	equal	B-ADJP	JJ	0	_	_	_	_
11	to	to	B-PP	TO	0	_	_	_	_
12	101	101	B-NP	CD	0	_	_	_	_
13	degrees	degree	I-NP	NNS	0	_	_	_	_
14	F	F	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_
16	granulocytes	granulocyte	B-NP	NNS	0	_	_	_	_
17	less	less	B-NP	JJR	0	_	_	_	_
18	than	than	I-NP	IN	0	_	_	_	_
19	1	1	I-NP	CD	0	_	_	_	_
20	,	,	I-NP	,	0	_	_	_	_
21	000	000	I-NP	CD	0	_	_	_	_
22	/	/	I-NP	SYM	0	_	_	_	_
23	mm	mm	I-NP	NN	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	3	3	B-NP	CD	0	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	hospitalization	hospitalization	B-NP	NN	0	_	_	_	_
28	)	)	O	)	0	_	_	_	_
29	and	and	O	CC	0	_	_	_	_
30	1	1	B-NP	CD	0	_	_	_	_
31	drug	drug	I-NP	NN	0	_	_	_	_
32	death	death	I-NP	NN	0	_	_	_	_
33	in	in	B-PP	IN	0	_	_	_	_
34	the	the	B-NP	DT	0	_	_	_	_
35	first	first	I-NP	JJ	0	_	_	_	_
36	4	4	I-NP	CD	0	_	_	_	_
37	patients	patient	I-NP	NNS	0	_	_	_	_
38	,	,	O	,	0	_	_	_	_
39	oral	oral	B-NP	JJ	0	_	_	_	_
40	calcium	calcium	I-NP	NN	0	_	_	_	_
41	leucovorin	leucovorin	I-NP	NN	0	_	_	_	_
42	,	,	O	,	0	_	_	_	_
43	20	20	B-NP	CD	0	_	_	_	_
44	to	to	I-NP	TO	0	_	_	_	_
45	30	30	I-NP	CD	0	_	_	_	_
46	mg	mg	I-NP	NN	0	_	_	_	_
47	/	/	B-NP	SYM	0	_	_	_	_
48	m2	m2	I-NP	NN	0	_	_	_	_
49	orally	orally	B-ADVP	RB	0	_	_	_	_
50	,	,	O	,	0	_	_	_	_
51	was	be	B-VP	VBD	0	_	_	_	_
52	given	give	I-VP	VBN	0	_	_	_	_
53	2	2	B-NP	CD	0	_	_	_	_
54	days	day	I-NP	NNS	0	_	_	_	_
55	after	after	B-PP	IN	0	_	_	_	_
56	methotrexate	methotrexate	B-NP	NN	0	_	_	_	_
57	in	in	B-PP	IN	0	_	_	_	_
58	subsequent	subsequent	B-NP	JJ	0	_	_	_	_
59	treatment	treatment	I-NP	NN	0	_	_	_	_
60	cycles	cycle	I-NP	NNS	0	_	_	_	_
61	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	seems	seem	B-VP	VBZ	0	_	_	_	_
3	that	that	B-SBAR	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	way	way	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	which	which	B-NP	WDT	0	_	_	_	_
8	drugs	drug	B-NP	NNS	0	_	_	_	_
9	modify	modify	B-VP	VBP	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	patient	patient	I-NP	NN	0	_	_	_	_
12	's	's	B-NP	POS	0	_	_	_	_
13	serum	serum	I-NP	NN	0	_	_	_	_
14	chemistry	chemistry	I-NP	NN	0	_	_	_	_
15	may	may	B-VP	MD	0	_	_	_	_
16	be	be	I-VP	VB	0	_	_	_	_
17	used	use	I-VP	VBN	0	_	_	_	_
18	to	to	B-VP	TO	0	_	_	_	_
19	assess	assess	I-VP	VB	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	efficacy	efficacy	I-NP	NN	0	_	_	_	_
22	with	with	B-PP	IN	0	_	_	_	_
23	which	which	B-NP	WDT	0	_	_	_	_
24	they	they	B-NP	PRP	0	_	_	_	_
25	control	control	B-VP	VBP	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	inflammatory	inflammatory	I-NP	JJ	0	_	_	_	_
28	process	process	I-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	Here	Here	B-ADVP	RB	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	conventional	conventional	I-NP	JJ	0	_	_	_	_
4	tests	test	I-NP	NNS	0	_	_	_	_
5	clearly	clearly	B-ADVP	RB	0	_	_	_	_
6	pointed	point	B-VP	VBD	0	_	_	_	_
7	to	to	B-PP	TO	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	presence	presence	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	retrocochlear	retrocochlear	B-NP	JJ	UMLS:C0035352:T047:DISO	_	_	_	_
12	disease	disease	I-NP	NN	UMLS:C0035352:T047:DISO	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	end	end	I-NP	NN	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	stage	stage	I-NP	NN	0	_	_	_	_
5	or	or	I-NP	CC	0	_	_	_	_
6	involutional	involutional	I-NP	JJ	0	_	_	_	_
7	phase	phase	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	proliferative	proliferative	B-NP	JJ	UMLS:C0154830:T047:DISO	_	_	_	_
10	diabetic	diabetic	I-NP	JJ	UMLS:C0154830:T047:DISO	_	_	_	_
11	retinopathy	retinopathy	I-NP	NN	UMLS:C0154830:T047:DISO	_	_	_	_
12	may	may	B-VP	MD	0	_	_	_	_
13	result	result	I-VP	VB	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	stabilization	stabilization	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	vision	vision	B-NP	NN	0	_	_	_	_
18	for	for	B-PP	IN	0	_	_	_	_
19	long	long	B-NP	JJ	0	_	_	_	_
20	periods	period	I-NP	NNS	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	time	time	B-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	On	On	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	basis	basis	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	serum	serum	B-NP	NN	:::NOCLASS	_	_	_	_
6	alpha1AT	alpha1AT	I-NP	NN	:::NOCLASS	_	_	_	_
7	quantitation	quantitation	I-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	newborn	newborn	B-NP	JJ	0	_	_	_	_
10	infants	infant	I-NP	NNS	0	_	_	_	_
11	may	may	B-VP	MD	0	_	_	_	_
12	be	be	I-VP	VB	0	_	_	_	_
13	separated	separate	I-VP	VBN	0	_	_	_	_
14	into	into	B-PP	IN	0	_	_	_	_
15	two	two	B-NP	CD	0	_	_	_	_
16	groups	group	I-NP	NNS	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	characterized	characterize	B-VP	VBN	0	_	_	_	_
19	respectively	respectively	B-ADVP	RB	0	_	_	_	_
20	by	by	B-PP	IN	0	_	_	_	_
21	concentrations	concentration	B-NP	NNS	0	_	_	_	_
22	above	above	B-PP	IN	0	_	_	_	_
23	or	or	I-PP	CC	0	_	_	_	_
24	below	below	I-PP	IN	0	_	_	_	_
25	150	150	B-NP	CD	0	_	_	_	_
26	mg	mg	I-NP	NN	0	_	_	_	_
27	%	%	I-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	patients	patient	B-NP	NNS	0	_	_	_	_
3	who	who	B-NP	WP	0	_	_	_	_
4	were	be	B-VP	VBD	0	_	_	_	_
5	not	not	I-VP	RB	0	_	_	_	_
6	vented	vent	I-VP	VBN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	there	there	B-NP	EX	0	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	overall	overall	B-NP	JJ	0	_	_	_	_
11	significant	significant	I-NP	JJ	0	_	_	_	_
12	depression	depression	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	function	function	B-NP	NN	0	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	67	67	B-NP	CD	0	_	_	_	_
17	+	+	O	SYM	0	_	_	_	_
18	/	/	O	SYM	0	_	_	_	_
19	-	-	O	SYM	0	_	_	_	_
20	5	5	B-NP	CD	0	_	_	_	_
21	%	%	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	control	control	B-NP	NN	0	_	_	_	_
24	;	;	O	:	0	_	_	_	_
25	range	range	B-NP	NN	0	_	_	_	_
26	,	,	O	,	0	_	_	_	_
27	91	91	B-NP	CD	0	_	_	_	_
28	-	-	I-NP	HYPH	0	_	_	_	_
29	-	-	I-NP	SYM	0	_	_	_	_
30	45	45	B-NP	CD	0	_	_	_	_
31	%	%	I-NP	NN	0	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	p	p	B-NP	NN	0	_	_	_	_
34	less	less	B-NP	JJR	0	_	_	_	_
35	than	than	I-NP	IN	0	_	_	_	_
36	0	0	I-NP	CD	0	_	_	_	_
37	.	.	I-NP	.	0	_	_	_	_
38	01	01	I-NP	CD	0	_	_	_	_
39	)	)	O	)	0	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	Changes	Change	B-NP	NNS	0	_	_	_	_
2	in	in	B-PP	IN	0	_	_	_	_
3	body	body	B-NP	NN	0	_	_	_	_
4	weight	weight	I-NP	NN	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	agonistic	agonistic	B-NP	JJ	0	_	_	_	_
7	behavior	behavior	I-NP	NN	0	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	also	also	I-VP	RB	0	_	_	_	_
10	recorded	record	I-VP	VBN	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	uterine	uterine	I-NP	JJ	UMLS:C0042149:T023:ANAT	_	_	_	_
3	response	response	I-NP	NN	0	_	_	_	_
4	to	to	B-PP	TO	0	_	_	_	_
5	prostaglandin	prostaglandin	B-NP	NN	0	_	_	_	_
6	E2	E2	I-NP	NN	0	_	_	_	_
7	(	(	O	(	0	_	_	_	_
8	PGE2	PGE2	B-NP	NN	0	_	_	_	_
9	)	)	O	)	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	prostaglandin	prostaglandin	B-NP	NN	0	_	_	_	_
12	F2alpha	F2alpha	I-NP	NN	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	administered	administer	B-VP	VBN	0	_	_	_	_
15	by	by	B-PP	IN	0	_	_	_	_
16	intravenous	intravenous	B-NP	JJ	0	_	_	_	_
17	and	and	I-NP	CC	0	_	_	_	_
18	intrauterine	intrauterine	I-NP	JJ	0	_	_	_	_
19	routes	route	I-NP	NNS	0	_	_	_	_
20	)	)	O	)	0	_	_	_	_
21	was	be	B-VP	VBD	0	_	_	_	_
22	evaluated	evaluate	I-VP	VBN	0	_	_	_	_
23	during	during	B-PP	IN	0	_	_	_	_
24	different	different	B-NP	JJ	0	_	_	_	_
25	phases	phase	I-NP	NNS	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	menstrual	menstrual	I-NP	JJ	0	_	_	_	_
29	cycle	cycle	I-NP	NN	0	_	_	_	_
30	in	in	B-PP	IN	0	_	_	_	_
31	five	five	B-NP	CD	0	_	_	_	_
32	functionally	functionally	I-NP	RB	0	_	_	_	_
33	infertile	infertile	I-NP	JJ	UMLS:C0021359:T047:DISO	_	_	_	_
34	women	woman	I-NP	NNS	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	total	total	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	26	26	B-NP	CD	0	_	_	_	_
5	BCG	BCG	I-NP	NN	0	_	_	_	_
6	strains	strain	I-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	out	out	B-PP	IN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	them	them	B-NP	PRP	0	_	_	_	_
11	10	10	B-NP	CD	0	_	_	_	_
12	Czechoslovak	Czechoslovak	I-NP	JJ	0	_	_	_	_
13	strains	strain	I-NP	NNS	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	2	2	B-NP	CD	0	_	_	_	_
16	lyophilized	lyophilize	I-NP	VBN	0	_	_	_	_
17	cultures	culture	I-NP	NNS	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	BCG	BCG	B-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	different	different	B-NP	JJ	0	_	_	_	_
22	batch	batch	I-NP	NN	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	6	6	B-NP	CD	0	_	_	_	_
25	strains	strain	I-NP	NNS	0	_	_	_	_
26	isolated	isolate	B-VP	VBN	0	_	_	_	_
27	from	from	B-PP	IN	0	_	_	_	_
28	abscesses	abscess	B-NP	NNS	UMLS:C0000833:T047:DISO	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	children	child	B-NP	NNS	0	_	_	_	_
31	after	after	B-PP	IN	0	_	_	_	_
32	BCG	BCG	B-NP	NN	0	_	_	_	_
33	-	-	B-NP	HYPH	0	_	_	_	_
34	vaccination	vaccination	I-NP	NN	0	_	_	_	_
35	and	and	O	CC	0	_	_	_	_
36	2	2	B-NP	CD	0	_	_	_	_
37	strains	strain	I-NP	NNS	0	_	_	_	_
38	from	from	B-PP	IN	0	_	_	_	_
39	fatal	fatal	B-NP	JJ	0	_	_	_	_
40	cases	case	I-NP	NNS	0	_	_	_	_
41	after	after	B-PP	IN	0	_	_	_	_
42	BCG	BCG	B-NP	NN	0	_	_	_	_
43	-	-	B-NP	HYPH	0	_	_	_	_
44	vaccination	vaccination	I-NP	NN	0	_	_	_	_
45	)	)	O	)	0	_	_	_	_
46	and	and	O	CC	0	_	_	_	_
47	16	16	B-NP	CD	0	_	_	_	_
48	strains	strain	I-NP	NNS	0	_	_	_	_
49	obtained	obtain	B-VP	VBN	0	_	_	_	_
50	from	from	B-PP	IN	0	_	_	_	_
51	foreign	foreign	B-NP	JJ	0	_	_	_	_
52	laboratories	laboratory	I-NP	NNS	0	_	_	_	_
53	,	,	O	,	0	_	_	_	_
54	were	be	B-VP	VBD	0	_	_	_	_
55	used	use	I-VP	VBN	0	_	_	_	_
56	.	.	O	.	0	_	_	_	_

1	High	High	B-NP	JJ	0	_	_	_	_
2	levels	level	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	serum	serum	B-NP	NN	0	_	_	_	_
5	calcitonin	calcitonin	I-NP	NN	:::NOCLASS	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	found	find	I-VP	VBN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	patients	patient	B-NP	NNS	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	chronic	chronic	B-NP	JJ	UMLS:C0022661:T047:DISO	_	_	_	_
12	renal	renal	I-NP	JJ	UMLS:C0022661:T047:DISO|UMLS:C0022646:T023:ANAT	_	_	_	_
13	failure	failure	I-NP	NN	UMLS:C0022661:T047:DISO	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Detection	Detection	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	anti	anti	B-NP	AFX	0	_	_	_	_
4	-	-	I-NP	HYPH	0	_	_	_	_
5	lymphocyte	lymphocyte	I-NP	NN	0	_	_	_	_
6	antibodies	antibody	I-NP	NNS	0	_	_	_	_
7	using	use	B-VP	VBG	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	immunoperoxidase	immunoperoxidase	I-NP	NN	:::NOCLASS	_	_	_	_
10	antiglobulin	antiglobulin	I-NP	NN	:::NOCLASS	_	_	_	_
11	technic	technic	I-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	response	response	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	serum	serum	B-NP	NN	:::NOCLASS	_	_	_	_
5	GH	GH	I-NP	NN	:::NOCLASS	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	arginine	arginine	B-NP	NN	0	_	_	_	_
8	infusion	infusion	I-NP	NN	0	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	normal	normal	B-ADJP	JJ	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	while	while	B-SBAR	IN	0	_	_	_	_
13	that	that	B-NP	DT	0	_	_	_	_
14	to	to	B-PP	TO	0	_	_	_	_
15	insulin	insulin	B-NP	NN	:::NOCLASS	_	_	_	_
16	-	-	B-NP	HYPH	0	_	_	_	_
17	induced	induce	I-NP	VBN	0	_	_	_	_
18	hypoglycemia	hypoglycemia	I-NP	NN	UMLS:C0020615:T047:DISO	_	_	_	_
19	was	be	B-VP	VBD	0	_	_	_	_
20	poor	poor	B-ADJP	JJ	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	mortality	mortality	I-NP	NN	0	_	_	_	_
3	rate	rate	I-NP	NN	0	_	_	_	_
4	and	and	O	CC	0	_	_	_	_
5	histopathological	histopathological	B-NP	JJ	0	_	_	_	_
6	features	feature	I-NP	NNS	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	Nocardia	Nocardia	B-NP	NNP	0	_	_	_	_
9	asteroides	asteroide	I-NP	NNS	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	Nocardia	Nocardia	B-NP	NNP	0	_	_	_	_
12	brasiliensis	brasiliensis	I-NP	NN	0	_	_	_	_
13	infections	infection	I-NP	NNS	UMLS:C0021311:T047:DISO|UMLS:C0851162:T047:DISO	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	congenitally	congenitally	O	RB	0	_	_	_	_
16	athymic	athymic	O	JJ	0	_	_	_	_
17	(	(	O	(	0	_	_	_	_
18	nude	nude	B-ADJP	JJ	0	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	mice	mouse	B-NP	NNS	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	ICR	ICR	B-NP	NN	0	_	_	_	_
23	and	and	I-NP	CC	0	_	_	_	_
24	C3H	C3H	I-NP	NN	0	_	_	_	_
25	/	/	B-NP	SYM	0	_	_	_	_
26	eB	eB	B-NP	NN	0	_	_	_	_
27	origins	origin	I-NP	NNS	0	_	_	_	_
28	were	be	B-VP	VBD	0	_	_	_	_
29	quite	quite	B-ADJP	RB	0	_	_	_	_
30	different	different	I-ADJP	JJ	0	_	_	_	_
31	from	from	B-PP	IN	0	_	_	_	_
32	what	what	B-NP	WP	0	_	_	_	_
33	we	we	B-NP	PRP	0	_	_	_	_
34	found	find	B-VP	VBD	0	_	_	_	_
35	for	for	B-PP	IN	0	_	_	_	_
36	Swiss	Swiss	B-NP	JJ	0	_	_	_	_
37	white	white	I-NP	JJ	0	_	_	_	_
38	mice	mouse	I-NP	NNS	0	_	_	_	_
39	and	and	O	CC	0	_	_	_	_
40	other	other	B-NP	JJ	0	_	_	_	_
41	inbred	inbred	I-NP	JJ	0	_	_	_	_
42	mouse	mouse	I-NP	NN	0	_	_	_	_
43	strains	strain	I-NP	NNS	0	_	_	_	_
44	(	(	O	(	0	_	_	_	_
45	namely	namely	B-ADVP	RB	0	_	_	_	_
46	,	,	O	,	0	_	_	_	_
47	C57	C57	B-NP	NN	0	_	_	_	_
48	/	/	I-NP	SYM	0	_	_	_	_
49	BL	BL	I-NP	NN	0	_	_	_	_
50	/	/	B-NP	SYM	0	_	_	_	_
51	6J	6J	I-NP	NN	0	_	_	_	_
52	,	,	O	,	0	_	_	_	_
53	New	New	B-NP	NNP	0	_	_	_	_
54	Zealand	Zealand	I-NP	NNP	0	_	_	_	_
55	Black	Black	I-NP	NNP	0	_	_	_	_
56	,	,	O	,	0	_	_	_	_
57	BALB	BALB	B-NP	NN	0	_	_	_	_
58	/	/	I-NP	SYM	0	_	_	_	_
59	c	c	I-NP	NN	0	_	_	_	_
60	,	,	O	,	0	_	_	_	_
61	CBA	CBA	B-NP	NN	0	_	_	_	_
62	/	/	I-NP	SYM	0	_	_	_	_
63	LAC	LAC	I-NP	NN	0	_	_	_	_
64	,	,	O	,	0	_	_	_	_
65	and	and	O	CC	0	_	_	_	_
66	C3H	C3H	B-NP	NN	0	_	_	_	_
67	/	/	B-NP	SYM	0	_	_	_	_
68	eB	eB	I-NP	NN	0	_	_	_	_
69	)	)	O	)	0	_	_	_	_
70	.	.	O	.	0	_	_	_	_

1	Williams	Williams	B-NP	NNP	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	2	2	B-NP	CD	0	_	_	_	_
4	August	August	I-NP	NNP	0	_	_	_	_
5	1977	1977	I-NP	CD	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	Use	Use	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	radioactive	radioactive	B-NP	JJ	0	_	_	_	_
4	isotopes	isotope	I-NP	NNS	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	chemistry	chemistry	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	proteins	protein	B-NP	NNS	0	_	_	_	_

1	(	(	O	(	0	_	_	_	_
2	Emeritus	Emeritus	B-NP	NNP	0	_	_	_	_
3	)	)	O	)	0	_	_	_	_
4	John	John	B-NP	NNP	0	_	_	_	_
5	Henri	Henri	I-NP	NNP	0	_	_	_	_
6	Roosegaarde	Roosegaarde	I-NP	NNP	0	_	_	_	_
7	Bisschop	Bisschop	I-NP	NNP	0	_	_	_	_

1	Disrupted	Disrupted	B-NP	JJ	0	_	_	_	_
2	vaccines	vaccine	I-NP	NNS	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	whole	whole	B-NP	JJ	0	_	_	_	_
5	-	-	I-NP	HYPH	0	_	_	_	_
6	virus	virus	I-NP	NN	0	_	_	_	_
7	vaccines	vaccine	I-NP	NNS	0	_	_	_	_
8	containing	contain	B-VP	VBG	0	_	_	_	_
9	type	type	B-NP	NN	:::NOCLASS	_	_	_	_
10	B	B	I-NP	NN	:::NOCLASS	_	_	_	_
11	antigen	antigen	I-NP	NN	:::NOCLASS	_	_	_	_
12	only	only	B-ADVP	RB	0	_	_	_	_
13	did	do	B-VP	VBD	0	_	_	_	_
14	not	not	I-VP	RB	0	_	_	_	_
15	cause	cause	I-VP	VB	0	_	_	_	_
16	significant	significant	B-NP	JJ	0	_	_	_	_
17	reactivity	reactivity	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	255	255	B-NP	CD	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	61	61	I-NP	CD	0	_	_	_	_
4	.	.	O	.	0	_	_	_	_

1	Antenatal	Antenatal	B-NP	JJ	0	_	_	_	_
2	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	haematological	haematological	B-NP	JJ	UMLS:C0018939:T047:DISO	_	_	_	_
5	disorders	disorder	I-NP	NNS	UMLS:C0018939:T047:DISO	_	_	_	_
6	-	-	B-NP	SYM	0	_	_	_	_
7	-	-	B-NP	SYM	0	_	_	_	_
8	'1978	'1978	B-NP	CD	0	_	_	_	_
9	'	'	B-NP	SYM	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	Hepatic	Hepatic	B-NP	JJ	0	_	_	_	_
2	oxygen	oxygen	I-NP	NN	0	_	_	_	_
3	supply	supply	I-NP	NN	0	_	_	_	_
4	and	and	O	CC	0	_	_	_	_
5	selected	select	B-NP	VBN	0	_	_	_	_
6	blood	blood	I-NP	NN	0	_	_	_	_
7	parameters	parameter	I-NP	NNS	0	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	recorded	record	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	fasted	fast	B-NP	VBN	0	_	_	_	_
12	male	male	I-NP	JJ	0	_	_	_	_
13	rates	rate	I-NP	NNS	0	_	_	_	_
14	given	give	B-VP	VBN	0	_	_	_	_
15	20	20	B-NP	CD	0	_	_	_	_
16	-	-	I-NP	HYPH	0	_	_	_	_
17	-	-	I-NP	SYM	0	_	_	_	_
18	30	30	I-NP	CD	0	_	_	_	_
19	mg	mg	I-NP	NN	0	_	_	_	_
20	/	/	B-NP	SYM	0	_	_	_	_
21	kg	kg	I-NP	NN	0	_	_	_	_
22	Escherichia	Escherichia	B-NP	FW	:::NOCLASS	_	_	_	_
23	coli	coli	I-NP	FW	:::NOCLASS	_	_	_	_
24	endotoxin	endotoxin	I-NP	NN	:::NOCLASS	_	_	_	_
25	intraperitoneally	intraperitoneally	B-ADVP	RB	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	Gonadal	Gonadal	B-NP	JJ	UMLS:C0018067:T023:ANAT	_	_	_	_
2	dysfunction	dysfunction	I-NP	NN	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	patients	patient	B-NP	NNS	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	ataxia	ataxia	B-NP	NN	UMLS:C0004135:T047:DISO	_	_	_	_
7	telangiectasia	telangiectasia	I-NP	NN	UMLS:C0004135:T047:DISO	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	maximum	maximum	I-NP	JJ	0	_	_	_	_
3	period	period	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	treatment	treatment	B-NP	NN	0	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	73	73	B-NP	CD	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	oral	oral	B-ADVP	JJ	0	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	73	73	B-NP	CD	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	intraperitoneal	intraperitoneal	B-ADJP	JJ	0	_	_	_	_
15	)	)	O	)	0	_	_	_	_
16	or	or	O	CC	0	_	_	_	_
17	75	75	B-NP	CD	0	_	_	_	_
18	(	(	O	(	0	_	_	_	_
19	dermal	dermal	O	JJ	0	_	_	_	_
20	)	)	O	)	0	_	_	_	_
21	weeks	week	B-NP	NNS	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	study	study	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	comparative	comparative	I-NP	JJ	0	_	_	_	_
6	efficacy	efficacy	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	diflucortolone	diflucortolone	B-NP	NN	0	_	_	_	_
9	valerate	valerate	I-NP	NN	0	_	_	_	_
10	0	0	I-NP	CD	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_
12	3	3	B-NP	CD	0	_	_	_	_
13	%	%	I-NP	NN	0	_	_	_	_
14	ointment	ointment	I-NP	NN	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	clobetasol	clobetasol	I-NP	NN	0	_	_	_	_
17	propionate	propionate	I-NP	NN	0	_	_	_	_
18	0	0	I-NP	CD	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_
20	05	05	B-NP	CD	0	_	_	_	_
21	%	%	I-NP	NN	0	_	_	_	_
22	ointment	ointment	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Most	Most	B-NP	JJS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	phenomena	phenomena	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	azotaemic	azotaemic	B-NP	JJ	0	_	_	_	_
7	osteodystrophy	osteodystrophy	I-NP	NN	UMLS:C0264009:T047:DISO	_	_	_	_
8	are	be	B-VP	VBP	0	_	_	_	_
9	encountered	encounter	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	simple	simple	B-NP	JJ	0	_	_	_	_
12	vitamin	vitamin	I-NP	NN	UMLS:C0042870:T047:DISO	_	_	_	_
13	D	D	I-NP	NN	UMLS:C0042870:T047:DISO	_	_	_	_
14	deficiency	deficiency	I-NP	NN	UMLS:C0042870:T047:DISO	_	_	_	_
15	;	;	O	:	0	_	_	_	_
16	as	as	B-PP	IN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	that	that	B-NP	DT	0	_	_	_	_
19	condition	condition	I-NP	NN	UMLS:C0012634:T047:DISO	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	deficiency	deficiency	B-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	1	1	B-NP	CD	0	_	_	_	_
24	,	,	I-NP	,	0	_	_	_	_
25	25	25	I-NP	CD	0	_	_	_	_
26	-	-	I-NP	HYPH	0	_	_	_	_
27	dihydroxycholecalciferol	dihydroxycholecalciferol	I-NP	NN	0	_	_	_	_
28	may	may	B-VP	MD	0	_	_	_	_
29	be	be	I-VP	VB	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	primary	primary	B-NP	JJ	0	_	_	_	_
32	significance	significance	I-NP	NN	0	_	_	_	_
33	in	in	B-PP	IN	0	_	_	_	_
34	causing	cause	B-VP	VBG	0	_	_	_	_
35	secondary	secondary	B-NP	JJ	UMLS:C0020503:T047:DISO	_	_	_	_
36	hyperparathyroidism	hyperparathyroidism	I-NP	NN	UMLS:C0020503:T047:DISO	_	_	_	_
37	in	in	B-PP	IN	0	_	_	_	_
38	renal	renal	B-NP	JJ	UMLS:C0341697:T047:DISO|UMLS:C0035078:T047:DISO|UMLS:C0022646:T023:ANAT	_	_	_	_
39	failure	failure	I-NP	NN	UMLS:C0341697:T047:DISO|UMLS:C0035078:T047:DISO	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	Basal	Basal	B-NP	JJ	0	_	_	_	_
2	FSH	FSH	I-NP	NN	:::NOCLASS	_	_	_	_
3	and	and	I-NP	CC	0	_	_	_	_
4	LH	LH	I-NP	NN	:::NOCLASS	_	_	_	_
5	levels	level	I-NP	NNS	0	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	significantly	significantly	B-ADJP	RB	0	_	_	_	_
8	lower	low	I-ADJP	JJR	0	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	addicts	addict	B-NP	NNS	0	_	_	_	_
11	;	;	O	:	0	_	_	_	_
12	after	after	B-PP	IN	0	_	_	_	_
13	GnRH	GnRH	B-NP	NN	:::NOCLASS	_	_	_	_
14	stimulation	stimulation	I-NP	NN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	addicts	addict	I-NP	NNS	0	_	_	_	_
17	'	'	B-NP	POS	0	_	_	_	_
18	FSH	FSH	I-NP	NN	:::NOCLASS	_	_	_	_
19	and	and	I-NP	CC	0	_	_	_	_
20	LH	LH	I-NP	NN	:::NOCLASS	_	_	_	_
21	values	value	I-NP	NNS	0	_	_	_	_
22	increased	increase	B-VP	VBD	0	_	_	_	_
23	but	but	B-VP	CC	0	_	_	_	_
24	not	not	I-VP	RB	0	_	_	_	_
25	significantly	significantly	I-VP	RB	0	_	_	_	_
26	compared	compare	I-VP	VBN	0	_	_	_	_
27	to	to	B-PP	TO	0	_	_	_	_
28	controls	control	B-NP	NNS	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	Adriamycin	Adriamycin	B-NP	NN	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	comparison	comparison	B-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	5	5	I-NP	CD	0	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	week	week	I-NP	NN	0	_	_	_	_
9	schedule	schedule	I-NP	NN	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	3	3	I-NP	CD	0	_	_	_	_
13	-	-	I-NP	HYPH	0	_	_	_	_
14	week	week	I-NP	NN	0	_	_	_	_
15	schedule	schedule	I-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	treatment	treatment	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	breast	breast	B-NP	NN	UMLS:C0006141:T023:ANAT	_	_	_	_
21	cancer	cancer	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Follow	Follow	B-VP	VB	0	_	_	_	_
2	-	-	O	HYPH	0	_	_	_	_
3	up	up	B-PRT	RP	0	_	_	_	_
4	controls	control	B-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	luteinizing	luteinize	B-VP	VBG	:::NOCLASS	_	_	_	_
7	hormone	hormone	B-NP	NN	:::NOCLASS	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	LH	LH	B-NP	NN	:::NOCLASS	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	follicle	follicle	B-NP	NN	:::NOCLASS|UMLS:C0018120:T023:ANAT|UMLS:C1571705:T023:ANAT	_	_	_	_
13	stimulating	stimulate	B-VP	VBG	:::NOCLASS	_	_	_	_
14	hormone	hormone	B-NP	NN	:::NOCLASS	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	FSH	FSH	B-NP	NN	:::NOCLASS	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	prolactin	prolactin	B-NP	NN	:::NOCLASS	_	_	_	_
20	(	(	O	(	0	_	_	_	_
21	HPRL	HPRL	B-NP	NN	:::NOCLASS	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	oestradiol	oestradiol	B-NP	NN	0	_	_	_	_
25	(	(	O	(	0	_	_	_	_
26	E2	E2	B-NP	NN	0	_	_	_	_
27	)	)	O	)	0	_	_	_	_
28	,	,	O	,	0	_	_	_	_
29	progesterone	progesterone	B-NP	NN	0	_	_	_	_
30	(	(	O	(	0	_	_	_	_
31	P	P	B-NP	NN	0	_	_	_	_
32	)	)	O	)	0	_	_	_	_
33	and	and	O	CC	0	_	_	_	_
34	testosterone	testosterone	B-NP	NN	0	_	_	_	_
35	(	(	O	(	0	_	_	_	_
36	T	T	B-NP	NN	0	_	_	_	_
37	)	)	O	)	0	_	_	_	_
38	in	in	B-PP	IN	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	catabolic	catabolic	I-NP	JJ	0	_	_	_	_
41	and	and	I-NP	CC	0	_	_	_	_
42	healing	healing	I-NP	JJ	0	_	_	_	_
43	phase	phase	I-NP	NN	0	_	_	_	_
44	of	of	B-PP	IN	0	_	_	_	_
45	burn	burn	B-NP	NN	0	_	_	_	_
46	disease	disease	I-NP	NN	0	_	_	_	_
47	.	.	O	.	0	_	_	_	_

1	Renin	Renin	B-NP	NN	:::NOCLASS	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	performed	perform	B-VP	VBN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	34	34	B-NP	CD	0	_	_	_	_
6	hypertensive	hypertensive	I-NP	JJ	0	_	_	_	_
7	patients	patient	I-NP	NNS	0	_	_	_	_
8	and	and	B-PP	CC	0	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	control	control	I-NP	NN	0	_	_	_	_
12	group	group	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	11	11	B-NP	CD	0	_	_	_	_
15	recipients	recipient	I-NP	NNS	0	_	_	_	_
16	showed	show	B-VP	VBD	0	_	_	_	_
17	that	that	B-SBAR	IN	0	_	_	_	_
18	elevation	elevation	B-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	plasma	plasma	B-NP	NN	:::NOCLASS	_	_	_	_
21	renin	renin	I-NP	NN	:::NOCLASS	_	_	_	_
22	activity	activity	I-NP	NN	0	_	_	_	_
23	and	and	B-PP	CC	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	plasma	plasma	B-NP	NN	0	_	_	_	_
26	aldosterone	aldosterone	I-NP	NN	0	_	_	_	_
27	level	level	I-NP	NN	0	_	_	_	_
28	is	be	B-VP	VBZ	0	_	_	_	_
29	frequent	frequent	B-ADJP	JJ	0	_	_	_	_
30	but	but	I-ADJP	CC	0	_	_	_	_
31	difficult	difficult	I-ADJP	JJ	0	_	_	_	_
32	to	to	B-VP	TO	0	_	_	_	_
33	interpret	interpret	I-VP	VB	0	_	_	_	_
34	,	,	O	,	0	_	_	_	_
35	particularly	particularly	B-ADVP	RB	0	_	_	_	_
36	when	when	B-ADVP	WRB	0	_	_	_	_
37	a	a	B-NP	DT	0	_	_	_	_
38	renal	renal	I-NP	JJ	UMLS:C0035067:T047:DISO|UMLS:C0035065:T023:ANAT	_	_	_	_
39	artery	artery	I-NP	NN	UMLS:C0035067:T047:DISO|UMLS:C0035065:T023:ANAT	_	_	_	_
40	stenosis	stenosis	I-NP	NN	UMLS:C0035067:T047:DISO	_	_	_	_
41	is	be	B-VP	VBZ	0	_	_	_	_
42	observed	observe	I-VP	VBN	0	_	_	_	_
43	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	randomized	randomize	I-NP	VBN	0	_	_	_	_
3	clinical	clinical	I-NP	JJ	0	_	_	_	_
4	trial	trial	I-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	sixty	sixty	B-NP	CD	0	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	two	two	I-NP	CD	0	_	_	_	_
9	adult	adult	I-NP	JJ	0	_	_	_	_
10	patients	patient	I-NP	NNS	0	_	_	_	_
11	suffering	suffer	B-VP	VBG	0	_	_	_	_
12	from	from	B-PP	IN	0	_	_	_	_
13	typhoid	typhoid	B-NP	JJ	UMLS:C0041466:T047:DISO	_	_	_	_
14	fever	fever	I-NP	NN	UMLS:C0041466:T047:DISO	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	proved	prove	B-VP	VBN	0	_	_	_	_
17	by	by	B-PP	IN	0	_	_	_	_
18	blood	blood	B-NP	NN	0	_	_	_	_
19	and	and	I-NP	CC	0	_	_	_	_
20	marrow	marrow	I-NP	NN	UMLS:C0376152:T023:ANAT	_	_	_	_
21	culture	culture	I-NP	NN	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	showed	show	B-VP	VBD	0	_	_	_	_
24	that	that	B-SBAR	IN	0	_	_	_	_
25	amoxycillin	amoxycillin	B-NP	NN	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	a	a	B-NP	DT	0	_	_	_	_
28	dosage	dosage	I-NP	NN	0	_	_	_	_
29	schedule	schedule	I-NP	NN	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	1	1	B-NP	CD	0	_	_	_	_
32	g	g	I-NP	NN	0	_	_	_	_
33	8	8	B-NP	CD	0	_	_	_	_
34	-	-	I-NP	HYPH	0	_	_	_	_
35	hourly	hourly	B-ADVP	RB	0	_	_	_	_
36	orally	orally	I-ADVP	RB	0	_	_	_	_
37	for	for	B-PP	IN	0	_	_	_	_
38	fourteen	fourteen	B-NP	CD	0	_	_	_	_
39	days	day	I-NP	NNS	0	_	_	_	_
40	was	be	B-VP	VBD	0	_	_	_	_
41	better	good	B-ADJP	JJR	0	_	_	_	_
42	than	than	B-PP	IN	0	_	_	_	_
43	chloramphenicol	chloramphenicol	B-NP	NN	0	_	_	_	_
44	with	with	B-PP	IN	0	_	_	_	_
45	regard	regard	B-NP	NN	0	_	_	_	_
46	to	to	B-PP	TO	0	_	_	_	_
47	clinical	clinical	B-NP	JJ	0	_	_	_	_
48	and	and	I-NP	CC	0	_	_	_	_
49	temperature	temperature	I-NP	NN	0	_	_	_	_
50	response	response	I-NP	NN	0	_	_	_	_
51	and	and	B-PP	CC	0	_	_	_	_
52	in	in	B-PP	IN	0	_	_	_	_
53	respect	respect	B-NP	NN	0	_	_	_	_
54	of	of	B-PP	IN	0	_	_	_	_
55	carriers	carrier	B-NP	NNS	0	_	_	_	_
56	and	and	O	CC	0	_	_	_	_
57	relapse	relapse	B-NP	NN	UMLS:C0277556:T047:DISO	_	_	_	_
58	rates	rate	I-NP	NNS	0	_	_	_	_
59	.	.	O	.	0	_	_	_	_

1	202	202	B-NP	CD	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	8	8	I-NP	CD	0	_	_	_	_
4	.	.	O	.	0	_	_	_	_

1	Bone	Bone	B-NP	NN	UMLS:C0262950:T023:ANAT	_	_	_	_
2	marrow	marrow	I-NP	NN	UMLS:C0376152:T023:ANAT	_	_	_	_
3	transplantation	transplantation	I-NP	NN	0	_	_	_	_
4	-	-	B-NP	HYPH	0	_	_	_	_
5	1979	1979	I-NP	CD	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	this	this	B-NP	DT	0	_	_	_	_
3	article	article	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	clinical	clinical	I-NP	JJ	0	_	_	_	_
7	actions	action	I-NP	NNS	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	principal	principal	I-NP	JJ	0	_	_	_	_
11	dopamine	dopamine	I-NP	NN	:::NOCLASS	_	_	_	_
12	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
13	stimulating	stimulate	B-VP	VBG	0	_	_	_	_
14	agents	agent	B-NP	NNS	0	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	apomorphine	apomorphine	B-NP	NN	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	its	its	B-NP	PRP$	0	_	_	_	_
19	derivatives	derivative	I-NP	NNS	0	_	_	_	_
20	;	;	O	:	0	_	_	_	_
21	piribedil	piribedil	B-NP	NN	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	rye	rye	B-NP	NN	0	_	_	_	_
24	-	-	O	HYPH	0	_	_	_	_
25	ergot	ergot	B-NP	VBN	0	_	_	_	_
26	derivatives	derivative	I-NP	NNS	0	_	_	_	_
27	)	)	O	)	0	_	_	_	_
28	are	be	B-VP	VBP	0	_	_	_	_
29	discussed	discuss	I-VP	VBN	0	_	_	_	_
30	on	on	B-PP	IN	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	basis	basis	I-NP	NN	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	their	their	B-NP	PRP$	0	_	_	_	_
35	biochemical	biochemical	I-NP	JJ	0	_	_	_	_
36	and	and	I-NP	CC	0	_	_	_	_
37	pharmacological	pharmacological	I-NP	JJ	0	_	_	_	_
38	properties	property	I-NP	NNS	0	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	unilateral	unilateral	I-NP	JJ	0	_	_	_	_
3	vestibular	vestibular	I-NP	JJ	0	_	_	_	_
4	hypofunction	hypofunction	I-NP	NN	0	_	_	_	_
5	.	.	O	.	0	_	_	_	_

1	Thus	Thus	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	inhibition	inhibition	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	pepsin	pepsin	B-NP	NN	:::NOCLASS	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	human	human	B-NP	JJ	0	_	_	_	_
9	gastric	gastric	I-NP	JJ	UMLS:C0038351:T023:ANAT	_	_	_	_
10	juice	juice	I-NP	NN	0	_	_	_	_
11	does	do	B-VP	VBZ	0	_	_	_	_
12	not	not	I-VP	RB	0	_	_	_	_
13	appear	appear	I-VP	VB	0	_	_	_	_
14	to	to	I-VP	TO	0	_	_	_	_
15	have	have	I-VP	VB	0	_	_	_	_
16	a	a	B-NP	DT	0	_	_	_	_
17	major	major	I-NP	JJ	0	_	_	_	_
18	influence	influence	I-NP	NN	0	_	_	_	_
19	on	on	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	healing	healing	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	duodenal	duodenal	B-NP	JJ	UMLS:C0013295:T047:DISO	_	_	_	_
24	ulcer	ulcer	I-NP	NN	UMLS:C0013295:T047:DISO	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	IDF	IDF	I-NP	NN	0	_	_	_	_
3	standard	standard	I-NP	JJ	0	_	_	_	_
4	method	method	I-NP	NN	0	_	_	_	_
5	for	for	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	detection	detection	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	penicillin	penicillin	B-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	milk	milk	B-NP	NN	0	_	_	_	_
12	is	be	B-VP	VBZ	0	_	_	_	_
13	not	not	O	RB	0	_	_	_	_
14	suitable	suitable	B-ADJP	JJ	0	_	_	_	_
15	for	for	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	detection	detection	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	sulphonamide	sulphonamide	B-NP	NN	0	_	_	_	_
20	residues	residue	I-NP	NNS	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	milk	milk	B-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Capsular	Capsular	B-NP	JJ	0	_	_	_	_
2	antigens	antigen	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	Staphylococcus	Staphylococcus	B-NP	NNP	0	_	_	_	_
5	aureus	aureus	I-NP	NN	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	course	course	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	endotoxin	endotoxin	B-NP	NN	0	_	_	_	_
5	fever	fever	I-NP	NN	0	_	_	_	_
6	remained	remain	B-VP	VBD	0	_	_	_	_
7	uninfluenced	uninfluenced	B-ADJP	JJ	0	_	_	_	_
8	by	by	B-PP	IN	0	_	_	_	_
9	ALS	ALS	B-NP	NN	UMLS:C0002736:T047:DISO	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	2	2	B-NP	CD	0	_	_	_	_
2	new	new	I-NP	JJ	0	_	_	_	_
3	Algerian	Algerian	I-NP	JJ	0	_	_	_	_
4	cases	case	I-NP	NNS	0	_	_	_	_

1	Seventy	Seventy	B-NP	CD	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	one	one	I-NP	CD	0	_	_	_	_
4	percent	percent	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	patients	patient	B-NP	NNS	0	_	_	_	_
7	treated	treat	B-VP	VBN	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	ticarcillin	ticarcillin	B-NP	NN	0	_	_	_	_
10	alone	alone	B-ADVP	RB	0	_	_	_	_
11	responded	respond	B-VP	VBD	0	_	_	_	_
12	favorably	favorably	B-ADVP	RB	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Accurate	Accurate	B-NP	JJ	0	_	_	_	_
2	pathologic	pathologic	I-NP	JJ	0	_	_	_	_
3	staging	staging	I-NP	NN	0	_	_	_	_
4	identifies	identify	B-VP	VBZ	0	_	_	_	_
5	patients	patient	B-NP	NNS	0	_	_	_	_
6	who	who	B-NP	WP	0	_	_	_	_
7	are	be	B-VP	VBP	0	_	_	_	_
8	potentially	potentially	B-ADJP	RB	0	_	_	_	_
9	curable	curable	I-ADJP	JJ	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	radiotherapy	radiotherapy	B-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	Inherent	Inherent	B-NP	JJ	0	_	_	_	_
2	hematology	hematology	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	old	old	B-NP	JJ	0	_	_	_	_
5	age	age	I-NP	NN	0	_	_	_	_

1	Neomycin	Neomycin	B-NP	NN	0	_	_	_	_
2	is	be	B-VP	VBZ	0	_	_	_	_
3	fairly	fairly	B-ADJP	RB	0	_	_	_	_
4	effective	effective	I-ADJP	JJ	0	_	_	_	_
5	against	against	B-PP	IN	0	_	_	_	_
6	staphylococci	staphylococci	B-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	less	less	B-ADJP	RBR	0	_	_	_	_
9	effective	effective	I-ADJP	JJ	0	_	_	_	_
10	against	against	B-PP	IN	0	_	_	_	_
11	streptococci	streptococci	B-NP	NNS	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	fairly	fairly	B-ADJP	RB	0	_	_	_	_
15	effective	effective	I-ADJP	JJ	0	_	_	_	_
16	against	against	B-PP	IN	0	_	_	_	_
17	gram	gram	B-NP	NN	0	_	_	_	_
18	-	-	B-NP	HYPH	0	_	_	_	_
19	negative	negative	I-NP	JJ	0	_	_	_	_
20	intestinal	intestinal	I-NP	JJ	UMLS:C0021853:T023:ANAT	_	_	_	_
21	organisms	organism	I-NP	NNS	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	concluded	conclude	I-VP	VBN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	that	that	B-ADVP	IN	0	_	_	_	_
6	on	on	B-PP	IN	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	given	give	I-NP	VBN	0	_	_	_	_
9	section	section	I-NP	NN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	75	75	B-NP	CD	0	_	_	_	_
12	,	,	I-NP	,	0	_	_	_	_
13	7	7	I-NP	CD	0	_	_	_	_
14	per	per	B-PP	IN	0	_	_	_	_
15	cent	cent	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	trabeculae	trabecula	I-NP	NNS	0	_	_	_	_
19	were	be	B-VP	VBD	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	contact	contact	B-NP	NN	0	_	_	_	_
22	with	with	B-PP	IN	0	_	_	_	_
23	vascular	vascular	B-NP	JJ	UMLS:C0005847:T023:ANAT	_	_	_	_
24	cavities	cavity	I-NP	NNS	UMLS:C0011334:T047:DISO	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	2	2	B-LST	LS	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	Changes	Change	B-NP	NNS	0	_	_	_	_
2	in	in	B-PP	IN	0	_	_	_	_
3	tissue	tissue	B-NP	NN	0	_	_	_	_
4	PCO2	PCO2	I-NP	NN	0	_	_	_	_
5	were	be	B-VP	VBD	0	_	_	_	_
6	less	less	B-ADJP	RBR	0	_	_	_	_
7	dramatic	dramatic	I-ADJP	JJ	0	_	_	_	_
8	and	and	O	CC	0	_	_	_	_
9	did	do	B-VP	VBD	0	_	_	_	_
10	not	not	I-VP	RB	0	_	_	_	_
11	vary	vary	I-VP	VB	0	_	_	_	_
12	significantly	significantly	B-ADVP	RB	0	_	_	_	_
13	from	from	B-PP	IN	0	_	_	_	_
14	those	those	B-NP	DT	0	_	_	_	_
15	recorded	record	B-VP	VBN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	venous	venous	B-NP	JJ	UMLS:C0042449:T023:ANAT	_	_	_	_
18	blood	blood	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Ultrasonic	Ultrasonic	B-NP	JJ	0	_	_	_	_
2	evaluation	evaluation	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	renal	renal	B-NP	JJ	UMLS:C0022646:T023:ANAT	_	_	_	_
5	calculi	calculus	I-NP	NNS	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	Recognition	Recognition	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	emphysema	emphysema	B-NP	NN	UMLS:C0034067:T047:DISO	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	poor	poor	B-ADJP	JJ	0	_	_	_	_
6	when	when	B-ADVP	WRB	0	_	_	_	_
7	radiographs	radiograph	B-NP	NNS	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	inadequate	inadequate	B-NP	JJ	0	_	_	_	_
10	quality	quality	I-NP	NN	0	_	_	_	_
11	were	be	B-VP	VBD	0	_	_	_	_
12	included	include	I-VP	VBN	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	anteroposterior	anteroposterior	B-NP	JJ	0	_	_	_	_
15	films	film	I-NP	NNS	0	_	_	_	_
16	or	or	O	CC	0	_	_	_	_
17	films	film	B-NP	NNS	0	_	_	_	_
18	from	from	B-PP	IN	0	_	_	_	_
19	patients	patient	B-NP	NNS	0	_	_	_	_
20	with	with	B-PP	IN	0	_	_	_	_
21	acute	acute	B-NP	JJ	0	_	_	_	_
22	or	or	I-NP	CC	0	_	_	_	_
23	chronic	chronic	I-NP	JJ	UMLS:C0746102:T047:DISO	_	_	_	_
24	lung	lung	I-NP	NN	UMLS:C0746102:T047:DISO|UMLS:C0024109:T023:ANAT	_	_	_	_
25	disease	disease	I-NP	NN	UMLS:C0746102:T047:DISO	_	_	_	_
26	)	)	O	)	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Isolation	Isolation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	T	T	B-NP	NN	0	_	_	_	_
4	.	.	I-NP	SYM	0	_	_	_	_
5	gambiense	gambiense	I-NP	NN	0	_	_	_	_
6	strains	strain	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	Zaire	Zaire	B-NP	NN	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	their	their	B-NP	PRP$	0	_	_	_	_
11	adaptation	adaptation	I-NP	NN	0	_	_	_	_
12	to	to	B-PP	TO	0	_	_	_	_
13	laboratory	laboratory	B-NP	NN	0	_	_	_	_
14	animals	animal	I-NP	NNS	0	_	_	_	_

1	Pharmacokinetic	Pharmacokinetic	B-NP	JJ	0	_	_	_	_
2	profile	profile	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	clonazepam	clonazepam	B-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	rhesus	rhesus	B-NP	NN	0	_	_	_	_
7	monkeys	monkey	I-NP	NNS	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Immunologic	Immunologic	B-NP	JJ	0	_	_	_	_
2	mechanisms	mechanism	I-NP	NNS	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	chronic	chronic	B-NP	JJ	0	_	_	_	_
5	brucellosis	brucellosis	I-NP	NN	UMLS:C0006309:T047:DISO	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	humans	human	B-NP	NNS	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Intestinal	Intestinal	B-NP	JJ	UMLS:C0021853:T023:ANAT	_	_	_	_
2	adaptation	adaptation	I-NP	NN	0	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	first	first	B-ADVP	JJ	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	two	two	B-NP	CD	0	_	_	_	_
7	parts	part	I-NP	NNS	0	_	_	_	_
8	)	)	O	)	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	patients	patient	B-NP	NNS	0	_	_	_	_
3	who	who	B-NP	WP	0	_	_	_	_
4	had	have	B-VP	VBD	0	_	_	_	_
5	received	receive	I-VP	VBN	0	_	_	_	_
6	no	no	B-NP	DT	0	_	_	_	_
7	previous	previous	I-NP	JJ	0	_	_	_	_
8	drug	drug	I-NP	NN	0	_	_	_	_
9	treatment	treatment	I-NP	NN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	log	log	B-NP	NN	0	_	_	_	_
12	baseline	baseline	I-NP	NN	0	_	_	_	_
13	plasma	plasma	I-NP	NN	:::NOCLASS	_	_	_	_
14	renin	renin	I-NP	NN	:::NOCLASS	_	_	_	_
15	activity	activity	I-NP	NN	0	_	_	_	_
16	and	and	O	CC	0	_	_	_	_
17	change	change	B-NP	NN	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	mean	mean	B-NP	JJ	0	_	_	_	_
20	blood	blood	I-NP	NN	0	_	_	_	_
21	pressure	pressure	I-NP	NN	0	_	_	_	_
22	after	after	B-PP	IN	0	_	_	_	_
23	SQ	SQ	B-NP	NN	0	_	_	_	_
24	20881	20881	I-NP	CD	0	_	_	_	_
25	correlated	correlate	B-VP	VBD	0	_	_	_	_
26	significantly	significantly	B-ADVP	RB	0	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	r	r	B-NP	NN	0	_	_	_	_
29	=	=	B-VP	SYM	0	_	_	_	_
30	0	0	B-NP	CD	0	_	_	_	_
31	.	.	I-NP	SYM	0	_	_	_	_
32	651	651	I-NP	CD	0	_	_	_	_
33	,	,	O	,	0	_	_	_	_
34	P	P	B-NP	NN	0	_	_	_	_
35	less	less	B-NP	JJR	0	_	_	_	_
36	than	than	I-NP	IN	0	_	_	_	_
37	0	0	I-NP	CD	0	_	_	_	_
38	.	.	I-NP	.	0	_	_	_	_
39	05	05	I-NP	CD	0	_	_	_	_
40	)	)	O	)	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	techniques	technique	I-NP	NNS	0	_	_	_	_
3	have	have	B-VP	VBP	0	_	_	_	_
4	been	be	I-VP	VBN	0	_	_	_	_
5	used	use	I-VP	VBN	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	many	many	B-NP	JJ	0	_	_	_	_
8	people	people	I-NP	NNS	0	_	_	_	_
9	for	for	B-PP	IN	0	_	_	_	_
10	many	many	B-NP	JJ	0	_	_	_	_
11	years	year	I-NP	NNS	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	no	no	B-NP	DT	0	_	_	_	_
14	claim	claim	I-NP	NN	0	_	_	_	_
15	is	be	B-VP	VBZ	0	_	_	_	_
16	being	be	I-VP	VBG	0	_	_	_	_
17	made	make	I-VP	VBN	0	_	_	_	_
18	for	for	B-PP	IN	0	_	_	_	_
19	any	any	B-NP	DT	0	_	_	_	_
20	innovation	innovation	I-NP	NN	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	this	this	B-NP	DT	0	_	_	_	_
23	regard	regard	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	40	40	B-NP	CD	0	_	_	_	_
2	patients	patient	I-NP	NNS	0	_	_	_	_
3	with	with	B-PP	IN	0	_	_	_	_
4	chronic	chronic	B-NP	JJ	UMLS:C0008707:T047:DISO	_	_	_	_
5	osteomyelitis	osteomyelitis	I-NP	NN	UMLS:C0008707:T047:DISO	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	treated	treat	I-VP	VBN	0	_	_	_	_
8	per	per	B-PP	IN	0	_	_	_	_
9	os	o	B-NP	NNS	UMLS:C2936904:T047:DISO|UMLS:C0262950:T023:ANAT	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	bactericidal	bactericidal	I-NP	JJ	0	_	_	_	_
13	beta	beta	I-NP	SYM	0	_	_	_	_
14	-	-	I-NP	HYPH	0	_	_	_	_
15	lactam	lactam	I-NP	NN	0	_	_	_	_
16	-	-	I-NP	HYPH	0	_	_	_	_
17	antibiotic	antibiotic	I-NP	JJ	0	_	_	_	_
18	cephalexin	cephalexin	I-NP	NN	0	_	_	_	_
19	during	during	B-PP	IN	0	_	_	_	_
20	3	3	B-NP	CD	0	_	_	_	_
21	to	to	I-NP	TO	0	_	_	_	_
22	60	60	I-NP	CD	0	_	_	_	_
23	weeks	week	I-NP	NNS	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	total	total	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	57	57	B-NP	CD	0	_	_	_	_
5	patients	patient	I-NP	NNS	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	Hodgkin	Hodgkin	B-NP	NN	0	_	_	_	_
8	's	's	B-NP	POS	0	_	_	_	_
9	disease	disease	I-NP	NN	0	_	_	_	_
10	limited	limit	B-VP	VBN	0	_	_	_	_
11	to	to	B-VP	TO	0	_	_	_	_
12	above	above	I-VP	VB	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	diaphragm	diaphragm	I-NP	NN	UMLS:C0011980:T023:ANAT	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	Stages	Stage	B-NP	NNS	0	_	_	_	_
17	I	I	B-NP	CD	0	_	_	_	_
18	and	and	I-NP	CC	0	_	_	_	_
19	II	II	I-NP	CD	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	A	A	B-NP	NN	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	B	B	B-NP	NN	0	_	_	_	_
24	)	)	O	)	0	_	_	_	_
25	were	be	B-VP	VBD	0	_	_	_	_
26	treated	treat	I-VP	VBN	0	_	_	_	_
27	with	with	B-PP	IN	0	_	_	_	_
28	radiation	radiation	B-NP	NN	0	_	_	_	_
29	therapy	therapy	I-NP	NN	0	_	_	_	_
30	alone	alone	B-ADVP	RB	0	_	_	_	_
31	at	at	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	University	University	I-NP	NNP	0	_	_	_	_
34	of	of	B-PP	IN	0	_	_	_	_
35	Florida	Florida	B-NP	NNP	0	_	_	_	_
36	between	between	B-PP	IN	0	_	_	_	_
37	1964	1964	B-NP	CD	0	_	_	_	_
38	and	and	I-NP	CC	0	_	_	_	_
39	1974	1974	I-NP	CD	0	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	Year	Year	B-NP	NN	0	_	_	_	_
2	one	one	I-NP	CD	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	first	first	I-NP	JJ	0	_	_	_	_
6	general	general	I-NP	JJ	0	_	_	_	_
7	practitioner	practitioner	I-NP	NN	0	_	_	_	_
8	medical	medical	I-NP	JJ	0	_	_	_	_
9	unit	unit	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	greater	great	I-NP	JJR	0	_	_	_	_
13	Glasgow	Glasgow	I-NP	NNP	0	_	_	_	_
14	area	area	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	multiple	multiple	I-NP	JJ	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	electrode	electrode	I-NP	NN	0	_	_	_	_
5	array	array	I-NP	NN	0	_	_	_	_
6	for	for	B-PP	IN	0	_	_	_	_
7	round	round	B-NP	NN	0	_	_	_	_
8	window	window	I-NP	NN	0	_	_	_	_
9	cochlear	cochlear	I-NP	JJ	UMLS:C0009195:T023:ANAT	_	_	_	_
10	implantation	implantation	I-NP	NN	0	_	_	_	_
11	is	be	B-VP	VBZ	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	robust	robust	I-NP	JJ	0	_	_	_	_
14	,	,	I-NP	,	0	_	_	_	_
15	reliable	reliable	I-NP	JJ	0	_	_	_	_
16	system	system	I-NP	NN	0	_	_	_	_
17	for	for	B-PP	IN	0	_	_	_	_
18	inserting	insert	B-VP	VBG	0	_	_	_	_
19	20	20	B-NP	CD	0	_	_	_	_
20	mm	mm	I-NP	NN	0	_	_	_	_
21	along	along	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	scala	scala	I-NP	NN	UMLS:C0036264:T023:ANAT	_	_	_	_
24	tympani	tympani	I-NP	NNS	UMLS:C0036264:T023:ANAT	_	_	_	_
25	with	with	B-PP	IN	0	_	_	_	_
26	a	a	B-NP	DT	0	_	_	_	_
27	minimum	minimum	I-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	trauma	trauma	B-NP	NN	0	_	_	_	_
30	and	and	O	CC	0	_	_	_	_
31	can	can	B-VP	MD	0	_	_	_	_
32	provide	provide	I-VP	VB	0	_	_	_	_
33	for	for	B-PP	IN	0	_	_	_	_
34	bipolar	bipolar	B-NP	JJ	0	_	_	_	_
35	stimulation	stimulation	I-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	As	As	B-SBAR	IN	0	_	_	_	_
2	authorized	authorize	B-VP	VBN	0	_	_	_	_
3	by	by	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	World	World	I-NP	NNP	0	_	_	_	_
6	Health	Health	I-NP	NNP	0	_	_	_	_
7	Organization	Organization	I-NP	NNP	0	_	_	_	_
8	29th	29th	I-NP	NNP	0	_	_	_	_
9	Expert	Expert	I-NP	NNP	0	_	_	_	_
10	Committee	Committee	I-NP	NNP	0	_	_	_	_
11	on	on	B-PP	IN	0	_	_	_	_
12	Biological	Biological	B-NP	NNP	0	_	_	_	_
13	Standardization	Standardization	I-NP	NNP	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	preparation	preparation	I-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	human	human	B-NP	JJ	:::NOCLASS	_	_	_	_
19	prolactin	prolactin	I-NP	NN	:::NOCLASS	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	ampoules	ampoule	B-NP	NNS	0	_	_	_	_
22	coded	cod	B-VP	VBD	0	_	_	_	_
23	75	75	B-NP	CD	0	_	_	_	_
24	/	/	I-NP	SYM	0	_	_	_	_
25	504	504	I-NP	CD	0	_	_	_	_
26	has	have	B-VP	VBZ	0	_	_	_	_
27	been	be	I-VP	VBN	0	_	_	_	_
28	established	establish	I-VP	VBN	0	_	_	_	_
29	as	as	B-SBAR	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	International	International	I-NP	NNP	0	_	_	_	_
32	Reference	Reference	I-NP	NNP	0	_	_	_	_
33	Preparation	Preparation	I-NP	NNP	0	_	_	_	_
34	(	(	O	(	0	_	_	_	_
35	IRP	IRP	B-NP	NN	0	_	_	_	_
36	)	)	O	)	0	_	_	_	_
37	of	of	B-PP	IN	0	_	_	_	_
38	human	human	B-NP	JJ	:::NOCLASS	_	_	_	_
39	prolactin	prolactin	I-NP	NN	:::NOCLASS	_	_	_	_
40	for	for	B-PP	IN	0	_	_	_	_
41	immunoassay	immunoassay	B-NP	NN	0	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	i	i	B-LST	LS	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	Biliary	Biliary	B-NP	JJ	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	enteric	enteric	I-NP	JJ	0	_	_	_	_
4	fistulas	fistula	I-NP	NNS	0	_	_	_	_

1	Plasma	Plasma	B-NP	NN	0	_	_	_	_
2	ion	ion	I-NP	NN	0	_	_	_	_
3	changes	change	I-NP	NNS	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	venous	venous	B-NP	JJ	UMLS:C0042449:T023:ANAT	_	_	_	_
6	blood	blood	I-NP	NN	0	_	_	_	_
7	incubated	incubate	B-VP	VBN	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	beta	beta	B-NP	NN	:::NOCLASS	_	_	_	_
10	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
11	blockers	blocker	I-NP	NNS	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	subjected	subject	B-VP	VBN	0	_	_	_	_
14	to	to	B-PP	TO	0	_	_	_	_
15	tonometry	tonometry	B-NP	NN	0	_	_	_	_
16	in	in	B-ADVP	FW	0	_	_	_	_
17	vitro	vitro	I-ADVP	FW	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Such	Such	B-NP	JJ	0	_	_	_	_
2	marked	marked	I-NP	JJ	0	_	_	_	_
3	differences	difference	I-NP	NNS	0	_	_	_	_
4	are	be	B-VP	VBP	0	_	_	_	_
5	found	find	I-VP	VBN	0	_	_	_	_
6	occasionally	occasionally	B-ADVP	RB	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	literature	literature	I-NP	NN	0	_	_	_	_
10	:	:	O	:	0	_	_	_	_
11	heterophile	heterophile	B-NP	JJ	0	_	_	_	_
12	antibodies	antibody	I-NP	NNS	0	_	_	_	_
13	against	against	B-PP	IN	0	_	_	_	_
14	bovine	bovine	B-NP	JJ	:::NOCLASS	_	_	_	_
15	gammaglobulin	gammaglobulin	I-NP	NN	:::NOCLASS	_	_	_	_
16	are	be	B-VP	VBP	0	_	_	_	_
17	regarded	regard	I-VP	VBN	0	_	_	_	_
18	as	as	B-PP	IN	0	_	_	_	_
19	responsible	responsible	B-ADJP	JJ	0	_	_	_	_
20	for	for	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	interference	interference	I-NP	NN	0	_	_	_	_
23	in	in	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	Sephadex	Sephadex	I-NP	NN	0	_	_	_	_
26	system	system	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	RIST	RIST	B-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	"	"	O	''	0	_	_	_	_
2	Let	Let	B-VP	VBD	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	hundred	hundred	I-NP	CD	0	_	_	_	_
5	flowers	flower	I-NP	NNS	0	_	_	_	_
6	bloom	bloom	I-NP	NN	0	_	_	_	_
7	"	"	O	''	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Various	Various	B-NP	JJ	0	_	_	_	_
2	treatment	treatment	I-NP	NN	0	_	_	_	_
3	modalities	modality	I-NP	NNS	0	_	_	_	_
4	are	be	B-VP	VBP	0	_	_	_	_
5	reviewed	review	I-VP	VBN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	context	context	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	psychology	psychology	I-NP	NN	0	_	_	_	_
12	as	as	B-CONJP	RB	0	_	_	_	_
13	well	well	I-CONJP	RB	0	_	_	_	_
14	as	as	I-CONJP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	physiology	physiology	I-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	severe	severe	B-NP	JJ	0	_	_	_	_
19	intractable	intractable	I-NP	JJ	0	_	_	_	_
20	pain	pain	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Lethal	Lethal	B-NP	JJ	0	_	_	_	_
2	Tachmalcor	Tachmalcor	I-NP	NNP	0	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	4	4	B-NP	CD	0	_	_	_	_
5	-	-	O	HYPH	0	_	_	_	_
6	(	(	O	(	0	_	_	_	_
7	3	3	B-NP	CD	0	_	_	_	_
8	'	'	I-NP	SYM	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	diethylamino	diethylamino	I-NP	NN	0	_	_	_	_
11	-	-	I-NP	HYPH	0	_	_	_	_
12	2	2	I-NP	CD	0	_	_	_	_
13	'	'	I-NP	SYM	0	_	_	_	_
14	-	-	I-NP	HYPH	0	_	_	_	_
15	hydroxypropyl	hydroxypropyl	I-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	-	-	B-NP	HYPH	0	_	_	_	_
18	ajmaline	ajmaline	I-NP	NN	0	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	poisoning	poisoning	B-NP	NN	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	childhood	childhood	B-NP	NN	0	_	_	_	_

1	Ophthalmosonographic	Ophthalmosonographic	B-NP	JJ	0	_	_	_	_
2	evaluation	evaluation	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	blood	blood	B-NP	NN	0	_	_	_	_
5	flow	flow	I-NP	NN	0	_	_	_	_
6	velocity	velocity	I-NP	NN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	arteriocavernous	arteriocavernous	B-NP	JJ	0	_	_	_	_
9	fistula	fistula	I-NP	NNS	0	_	_	_	_

1	Serum	Serum	B-NP	NN	0	_	_	_	_
2	ferritin	ferritin	I-NP	NN	:::NOCLASS	_	_	_	_
3	concentration	concentration	I-NP	NN	0	_	_	_	_
4	and	and	O	CC	0	_	_	_	_
5	bone	bone	B-NP	NN	UMLS:C0262950:T023:ANAT	_	_	_	_
6	marrow	marrow	I-NP	NN	UMLS:C0376152:T023:ANAT	_	_	_	_
7	iron	iron	I-NP	NN	0	_	_	_	_
8	stores	store	I-NP	NNS	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	systolic	systolic	I-NP	JJ	0	_	_	_	_
3	pressure	pressure	I-NP	NN	0	_	_	_	_
4	gradient	gradient	I-NP	NN	0	_	_	_	_
5	(	(	O	(	0	_	_	_	_
6	SPG	SPG	B-NP	NN	0	_	_	_	_
7	)	)	O	)	0	_	_	_	_
8	between	between	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	left	left	I-NP	JJ	UMLS:C0225897:T023:ANAT	_	_	_	_
11	ventricle	ventricle	I-NP	NN	UMLS:C0225897:T023:ANAT	_	_	_	_
12	(	(	O	(	0	_	_	_	_
13	LV	LV	B-NP	NN	0	_	_	_	_
14	)	)	O	)	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	left	left	B-NP	JJ	UMLS:C0225860:T023:ANAT	_	_	_	_
17	atrium	atrium	I-NP	NN	UMLS:C0225860:T023:ANAT	_	_	_	_
18	(	(	O	(	0	_	_	_	_
19	LA	LA	B-NP	NN	0	_	_	_	_
20	)	)	O	)	0	_	_	_	_
21	was	be	B-VP	VBD	0	_	_	_	_
22	obtained	obtain	I-VP	VBN	0	_	_	_	_
23	from	from	B-PP	IN	0	_	_	_	_
24	high	high	B-NP	JJ	0	_	_	_	_
25	-	-	I-NP	HYPH	0	_	_	_	_
26	fidelity	fidelity	I-NP	NN	0	_	_	_	_
27	pressure	pressure	I-NP	NN	0	_	_	_	_
28	transducers	transducer	I-NP	NNS	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	prospective	prospective	I-NP	JJ	0	_	_	_	_
3	trail	trail	I-NP	NN	0	_	_	_	_
4	comparing	compare	B-VP	VBG	0	_	_	_	_
5	hysterectomy	hysterectomy	B-NP	NN	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	hysterectomy	hysterectomy	B-NP	NN	0	_	_	_	_
8	plus	plus	O	CC	0	_	_	_	_
9	vaginal	vaginal	B-NP	JJ	UMLS:C0042232:T023:ANAT	_	_	_	_
10	radium	radium	I-NP	NN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	uterine	uterine	B-NP	JJ	UMLS:C0042149:T023:ANAT	_	_	_	_
14	radium	radium	I-NP	NN	0	_	_	_	_
15	plus	plus	O	CC	0	_	_	_	_
16	hysterectomy	hysterectomy	B-NP	NN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	stage	stage	B-NP	NN	0	_	_	_	_
19	I	I	I-NP	CD	0	_	_	_	_
20	endometrial	endometrial	I-NP	JJ	0	_	_	_	_
21	carcinoma	carcinoma	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	On	On	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	basis	basis	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	patient	patient	I-NP	NN	0	_	_	_	_
7	's	's	B-NP	POS	0	_	_	_	_
8	report	report	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	one	one	B-NP	CD	0	_	_	_	_
11	inaccurate	inaccurate	I-NP	JJ	0	_	_	_	_
12	Clinitemp	Clinitemp	I-NP	NNP	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	we	we	B-NP	PRP	0	_	_	_	_
15	undertook	undertake	B-VP	VBD	0	_	_	_	_
16	to	to	I-VP	TO	0	_	_	_	_
17	investigate	investigate	I-VP	VB	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	accuracy	accuracy	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	this	this	B-NP	DT	0	_	_	_	_
22	thermometer	thermometer	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Cryoglobulinemia	Cryoglobulinemia	B-NP	NN	UMLS:C0010403:T047:DISO	_	_	_	_
2	in	in	B-PP	IN	0	_	_	_	_
3	Raynaud	Raynaud	B-NP	NNP	UMLS:C0034734:T047:DISO|UMLS:C0034735:T047:DISO	_	_	_	_
4	's	's	B-NP	POS	UMLS:C0034734:T047:DISO|UMLS:C0034735:T047:DISO	_	_	_	_
5	syndrome	syndrome	I-NP	NN	UMLS:C0034734:T047:DISO|UMLS:C0034735:T047:DISO	_	_	_	_

1	Data	Datum	B-NP	NNS	0	_	_	_	_
2	were	be	B-VP	VBD	0	_	_	_	_
3	processed	process	I-VP	VBN	0	_	_	_	_
4	with	with	B-PP	IN	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	semi	semi	I-NP	AFX	0	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	automatic	automatic	I-NP	JJ	0	_	_	_	_
9	computer	computer	I-NP	NN	0	_	_	_	_
10	program	program	I-NP	NN	0	_	_	_	_
11	which	which	B-NP	WDT	0	_	_	_	_
12	develops	develop	B-VP	VBZ	0	_	_	_	_
13	an	an	B-NP	DT	0	_	_	_	_
14	averaged	averaged	I-NP	JJ	0	_	_	_	_
15	-	-	I-NP	HYPH	0	_	_	_	_
16	volume	volume	I-NP	NN	0	_	_	_	_
17	curve	curve	I-NP	NN	0	_	_	_	_
18	from	from	B-PP	IN	0	_	_	_	_
19	an	an	B-NP	DT	0	_	_	_	_
20	assigned	assign	I-NP	VBN	0	_	_	_	_
21	LV	LV	I-NP	NN	0	_	_	_	_
22	region	region	I-NP	NN	0	_	_	_	_
23	-	-	B-NP	HYPH	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	-	-	B-NP	HYPH	0	_	_	_	_
26	interest	interest	I-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	preferential	preferential	I-NP	JJ	0	_	_	_	_
3	serum	serum	I-NP	NN	:::NOCLASS	_	_	_	_
4	IgA	IgA	I-NP	NN	:::NOCLASS	_	_	_	_
5	response	response	I-NP	NN	0	_	_	_	_
6	observed	observe	B-VP	VBN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	patient	patient	I-NP	NN	0	_	_	_	_
10	population	population	I-NP	NN	0	_	_	_	_
11	suggests	suggest	B-VP	VBZ	0	_	_	_	_
12	that	that	B-SBAR	IN	0	_	_	_	_
13	bronchial	bronchial	B-NP	JJ	UMLS:C1442216:T023:ANAT|UMLS:C0205039:T023:ANAT	_	_	_	_
14	associated	associate	I-NP	VBN	0	_	_	_	_
15	lymphoid	lymphoid	I-NP	JJ	0	_	_	_	_
16	tissue	tissue	I-NP	NN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	diseased	diseased	I-NP	JJ	0	_	_	_	_
20	lung	lung	I-NP	NN	UMLS:C0024109:T023:ANAT	_	_	_	_
21	is	be	B-VP	VBZ	0	_	_	_	_
22	an	an	B-NP	DT	0	_	_	_	_
23	important	important	I-NP	JJ	0	_	_	_	_
24	source	source	I-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	circulating	circulate	B-VP	VBG	0	_	_	_	_
27	IgA	IgA	B-NP	NN	:::NOCLASS	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	Ultimate	Ultimate	B-NP	JJ	0	_	_	_	_
2	strengthes	strengthe	I-NP	NNS	0	_	_	_	_
3	seem	seem	B-VP	VBP	0	_	_	_	_
4	to	to	I-VP	TO	0	_	_	_	_
5	be	be	I-VP	VB	0	_	_	_	_
6	reached	reach	I-VP	VBN	0	_	_	_	_
7	for	for	B-PP	IN	0	_	_	_	_
8	cast	cast	B-NP	VBN	0	_	_	_	_
9	cobalt	cobalt	I-NP	NN	0	_	_	_	_
10	alloys	alloy	I-NP	NNS	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	whereas	whereas	O	IN	0	_	_	_	_
13	titanium	titanium	B-NP	NN	0	_	_	_	_
14	alloys	alloy	I-NP	NNS	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	such	such	B-PP	JJ	0	_	_	_	_
17	as	as	I-PP	IN	0	_	_	_	_
18	Ta	Ta	B-NP	NN	0	_	_	_	_
19	6	6	I-NP	CD	0	_	_	_	_
20	V	V	I-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	present	present	B-VP	VBP	0	_	_	_	_
23	very	very	B-NP	RB	0	_	_	_	_
24	high	high	I-NP	JJ	0	_	_	_	_
25	fatigue	fatigue	I-NP	NN	0	_	_	_	_
26	limit	limit	I-NP	NN	0	_	_	_	_
27	under	under	B-PP	IN	0	_	_	_	_
28	corrosion	corrosion	B-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effects	effect	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	intracisternal	intracisternal	B-NP	JJ	0	_	_	_	_
5	injection	injection	I-NP	NN	0	_	_	_	_
6	(	(	O	(	0	_	_	_	_
7	i	i	B-NP	NN	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_
9	c	c	B-NP	NN	0	_	_	_	_
10	.	.	I-NP	.	0	_	_	_	_
11	i	i	I-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	clonidine	clonidine	B-NP	NN	0	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	1	1	B-NP	CD	0	_	_	_	_
18	microgram	microgram	I-NP	NN	0	_	_	_	_
19	kg	kg	I-NP	NN	0	_	_	_	_
20	-	-	B-NP	HYPH	0	_	_	_	_
21	1	1	I-NP	CD	0	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	on	on	B-PP	IN	0	_	_	_	_
24	blood	blood	B-NP	NN	0	_	_	_	_
25	pressure	pressure	I-NP	NN	0	_	_	_	_
26	and	and	I-NP	CC	0	_	_	_	_
27	heart	heart	I-NP	NN	UMLS:C0018787:T023:ANAT	_	_	_	_
28	rate	rate	I-NP	NN	0	_	_	_	_
29	were	be	B-VP	VBD	0	_	_	_	_
30	studied	study	I-VP	VBN	0	_	_	_	_
31	in	in	B-PP	IN	0	_	_	_	_
32	conscious	conscious	B-NP	JJ	0	_	_	_	_
33	rabbits	rabbit	I-NP	NNS	0	_	_	_	_
34	with	with	B-PP	IN	0	_	_	_	_
35	an	an	B-NP	DT	0	_	_	_	_
36	implanted	implant	I-NP	VBN	0	_	_	_	_
37	catheter	catheter	I-NP	NN	0	_	_	_	_
38	in	in	B-PP	IN	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	cisterna	cisterna	I-NP	NN	0	_	_	_	_
41	magna	magna	I-NP	NN	0	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	Platelet	Platelet	B-NP	NN	0	_	_	_	_
2	number	number	I-NP	NN	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	life	life	B-NP	NN	0	_	_	_	_
5	span	span	I-NP	NN	0	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	determined	determine	I-VP	VBN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	last	last	I-NP	JJ	0	_	_	_	_
11	trimester	trimester	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	pregnancy	pregnancy	B-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	22	22	B-NP	CD	0	_	_	_	_
16	women	woman	I-NP	NNS	0	_	_	_	_
17	who	who	B-NP	WP	0	_	_	_	_
18	were	be	B-VP	VBD	0	_	_	_	_
19	delivered	deliver	I-VP	VBN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	small	small	B-NP	JJ	0	_	_	_	_
22	-	-	I-NP	HYPH	0	_	_	_	_
23	for	for	B-PP	IN	0	_	_	_	_
24	-	-	B-NP	HYPH	0	_	_	_	_
25	gestational	gestational	I-NP	JJ	0	_	_	_	_
26	age	age	I-NP	NN	0	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	SGA	SGA	B-NP	NN	0	_	_	_	_
29	)	)	O	)	0	_	_	_	_
30	infants	infant	B-NP	NNS	0	_	_	_	_
31	and	and	O	CC	0	_	_	_	_
32	in	in	B-PP	IN	0	_	_	_	_
33	21	21	B-NP	CD	0	_	_	_	_
34	women	woman	I-NP	NNS	0	_	_	_	_
35	with	with	B-PP	IN	0	_	_	_	_
36	infants	infant	B-NP	NNS	0	_	_	_	_
37	having	have	B-VP	VBG	0	_	_	_	_
38	normal	normal	B-NP	JJ	0	_	_	_	_
39	birth	birth	I-NP	NN	0	_	_	_	_
40	weights	weight	I-NP	NNS	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	Serial	Serial	B-NP	JJ	0	_	_	_	_
2	measurements	measurement	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	total	total	B-NP	JJ	0	_	_	_	_
5	serum	serum	I-NP	NN	0	_	_	_	_
6	IgE	IgE	I-NP	NN	UMLS:C0270850:T047:DISO|:::NOCLASS	_	_	_	_
7	appears	appear	B-VP	VBZ	0	_	_	_	_
8	to	to	I-VP	TO	0	_	_	_	_
9	be	be	I-VP	VB	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	useful	useful	I-NP	JJ	0	_	_	_	_
12	index	index	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	disease	disease	B-NP	NN	0	_	_	_	_
15	activity	activity	I-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	ABPA	ABPA	B-NP	NNP	UMLS:C0004031:T047:DISO	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	8	8	I-NP	CD	0	_	_	_	_
4	patients	patient	I-NP	NNS	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	difference	difference	I-NP	NN	0	_	_	_	_
7	betweent	betweent	B-SBAR	IN	0	_	_	_	_
8	he	he	B-NP	PRP	0	_	_	_	_
9	mean	mean	B-VP	VB	0	_	_	_	_
10	diastolic	diastolic	B-NP	JJ	0	_	_	_	_
11	values	value	I-NP	NNS	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	delta	delta	B-NP	NN	0	_	_	_	_
14	PU	PU	I-NP	NN	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	delta	delta	I-NP	NN	0	_	_	_	_
17	PM	PM	I-NP	NN	0	_	_	_	_
18	was	be	B-VP	VBD	0	_	_	_	_
19	-	-	B-ADJP	SYM	0	_	_	_	_
20	0	0	B-NP	CD	0	_	_	_	_
21	.	.	I-NP	SYM	0	_	_	_	_
22	54	54	I-NP	CD	0	_	_	_	_
23	+	+	O	SYM	0	_	_	_	_
24	/	/	B-NP	SYM	0	_	_	_	_
25	-	-	B-NP	SYM	0	_	_	_	_
26	1	1	I-NP	CD	0	_	_	_	_
27	.	.	I-NP	SYM	0	_	_	_	_
28	0	0	I-NP	CD	0	_	_	_	_
29	(	(	O	(	0	_	_	_	_
30	SD	SD	B-NP	NN	UMLS:C1096903:T047:DISO	_	_	_	_
31	)	)	O	)	0	_	_	_	_
32	mmHg	mmHg	B-NP	NN	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	rise	rise	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	hemoglobin	hemoglobin	B-NP	NN	:::NOCLASS	_	_	_	_
5	concentration	concentration	I-NP	NN	0	_	_	_	_
6	accompanied	accompany	B-VP	VBN	0	_	_	_	_
7	by	by	B-PP	IN	0	_	_	_	_
8	an	an	B-NP	DT	0	_	_	_	_
9	increase	increase	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	total	total	I-NP	JJ	0	_	_	_	_
13	iron	iron	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	blood	blood	I-NP	NN	0	_	_	_	_
17	serum	serum	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	white	white	B-NP	JJ	0	_	_	_	_
20	mice	mouse	I-NP	NNS	0	_	_	_	_
21	was	be	B-VP	VBD	0	_	_	_	_
22	found	find	I-VP	VBN	0	_	_	_	_
23	under	under	B-PP	IN	0	_	_	_	_
24	oxygen	oxygen	B-NP	NN	0	_	_	_	_
25	pressure	pressure	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	4	4	B-NP	CD	0	_	_	_	_
28	atm	atm	I-NP	NN	0	_	_	_	_
29	for	for	B-PP	IN	0	_	_	_	_
30	an	an	B-NP	DT	0	_	_	_	_
31	hour	hour	I-NP	NN	0	_	_	_	_
32	(	(	O	(	0	_	_	_	_
33	preconvulsive	preconvulsive	B-NP	JJ	0	_	_	_	_
34	state	state	I-NP	NN	0	_	_	_	_
35	)	)	O	)	0	_	_	_	_
36	and	and	O	CC	0	_	_	_	_
37	6	6	B-NP	CD	0	_	_	_	_
38	atm	atm	I-NP	NN	0	_	_	_	_
39	(	(	O	(	0	_	_	_	_
40	convulsive	convulsive	B-NP	JJ	0	_	_	_	_
41	state	state	I-NP	NN	0	_	_	_	_
42	)	)	O	)	0	_	_	_	_
43	.	.	O	.	0	_	_	_	_

1	Nernst	Nernst	B-NP	NN	0	_	_	_	_
2	-	-	O	HYPH	0	_	_	_	_
3	-	-	B-NP	HYPH	0	_	_	_	_
4	Planck	Planck	I-NP	NN	0	_	_	_	_
5	analog	analog	I-NP	NN	0	_	_	_	_
6	equations	equation	I-NP	NNS	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	stationary	stationary	B-NP	JJ	0	_	_	_	_
9	state	state	I-NP	NN	0	_	_	_	_
10	membrane	membrane	I-NP	NN	0	_	_	_	_
11	electric	electric	I-NP	JJ	0	_	_	_	_
12	potentials	potential	I-NP	NNS	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Effects	Effect	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	methylene	methylene	B-NP	NN	0	_	_	_	_
4	chloride	chloride	I-NP	NN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	trichloroethane	trichloroethane	B-NP	NN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	trichloroethylene	trichloroethylene	B-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	tetrachloroethylene	tetrachloroethylene	B-NP	NN	0	_	_	_	_
11	and	and	I-NP	CC	0	_	_	_	_
12	toluene	toluene	I-NP	NN	0	_	_	_	_
13	on	on	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	development	development	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	chick	chick	B-NP	NN	0	_	_	_	_
18	embryos	embryo	I-NP	NNS	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Effect	Effect	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	intraventricular	intraventricular	B-NP	JJ	0	_	_	_	_
4	administration	administration	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	streptolysin	streptolysin	B-NP	NN	:::NOCLASS	_	_	_	_
7	O	O	I-NP	NN	:::NOCLASS	_	_	_	_
8	on	on	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	electroencephalogram	electroencephalogram	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	rabbits	rabbit	B-NP	NNS	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	this	this	B-NP	DT	0	_	_	_	_
3	situation	situation	I-NP	NN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	convlusion	convlusion	I-NP	NN	0	_	_	_	_
6	threshold	threshold	I-NP	NN	0	_	_	_	_
7	for	for	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	8	8	I-NP	CD	0	_	_	_	_
10	substances	substance	I-NP	NNS	0	_	_	_	_
11	is	be	B-VP	VBZ	0	_	_	_	_
12	as	as	B-SBAR	IN	0	_	_	_	_
13	follows	follow	B-VP	VBZ	0	_	_	_	_
14	:	:	O	:	0	_	_	_	_
15	pethidine	pethidine	B-NP	NN	0	_	_	_	_
16	20	20	I-NP	CD	0	_	_	_	_
17	mg	mg	I-NP	NN	0	_	_	_	_
18	.	.	I-NP	SYM	0	_	_	_	_
19	kg	kg	I-NP	NN	0	_	_	_	_
20	-	-	B-NP	HYPH	0	_	_	_	_
21	1	1	I-NP	CD	0	_	_	_	_
22	I	I	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_
24	V	V	B-NP	NNP	0	_	_	_	_
25	.	.	I-NP	NN	0	_	_	_	_
26	,	,	O	,	0	_	_	_	_
27	piritramide	piritramide	B-NP	NN	0	_	_	_	_
28	30	30	I-NP	CD	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	morphine	morphine	B-NP	NN	0	_	_	_	_
31	180	180	I-NP	CD	0	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	phenoperidine	phenoperidine	B-NP	NN	0	_	_	_	_
34	4	4	I-NP	CD	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	R	R	B-NP	NN	0	_	_	_	_
37	39	39	I-NP	CD	0	_	_	_	_
38	209	209	I-NP	CD	0	_	_	_	_
39	5	5	I-NP	CD	0	_	_	_	_
40	,	,	O	,	0	_	_	_	_
41	fentanyl	fentanyl	B-NP	NN	0	_	_	_	_
42	4	4	I-NP	CD	0	_	_	_	_
43	,	,	O	,	0	_	_	_	_
44	sufentanil	sufentanil	B-NP	NN	0	_	_	_	_
45	4	4	I-NP	CD	0	_	_	_	_
46	and	and	O	CC	0	_	_	_	_
47	R	R	B-NP	NN	0	_	_	_	_
48	34	34	I-NP	CD	0	_	_	_	_
49	995	995	I-NP	CD	0	_	_	_	_
50	10	10	I-NP	CD	0	_	_	_	_
51	mg	mg	I-NP	NN	0	_	_	_	_
52	.	.	I-NP	SYM	0	_	_	_	_
53	kg	kg	I-NP	NN	0	_	_	_	_
54	-	-	B-NP	HYPH	0	_	_	_	_
55	1	1	I-NP	CD	0	_	_	_	_
56	I	I	I-NP	NN	0	_	_	_	_
57	.	.	O	.	0	_	_	_	_
58	V	V	B-NP	NNP	0	_	_	_	_
59	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	biochemistry	biochemistry	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	amniotic	amniotic	B-NP	JJ	0	_	_	_	_
5	fluid	fluid	I-NP	NN	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	poor	poor	B-NP	JJ	0	_	_	_	_
8	fetal	fetal	I-NP	JJ	0	_	_	_	_
9	growth	growth	I-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	Roentgenographically	Roentgenographically	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	lesion	lesion	I-NP	NN	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	usually	usually	B-ADVP	RB	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	well	well	I-NP	RB	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	defined	define	I-NP	VBN	0	_	_	_	_
11	and	and	I-NP	CC	0	_	_	_	_
12	benign	benign	I-NP	JJ	0	_	_	_	_
13	appearing	appear	I-NP	VBG	0	_	_	_	_
14	one	one	I-NP	CD	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	either	either	O	CC	0	_	_	_	_
17	purely	purely	B-ADJP	RB	0	_	_	_	_
18	lytic	lytic	I-ADJP	JJ	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	3	3	B-NP	CD	0	_	_	_	_
21	cases	case	I-NP	NNS	0	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	or	or	O	CC	0	_	_	_	_
24	with	with	B-PP	IN	0	_	_	_	_
25	central	central	B-NP	JJ	0	_	_	_	_
26	radiodensity	radiodensity	I-NP	NN	0	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	2	2	B-NP	CD	0	_	_	_	_
29	cases	case	I-NP	NNS	0	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Effects	Effect	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	chronic	chronic	B-NP	JJ	0	_	_	_	_
4	descending	descend	I-NP	VBG	0	_	_	_	_
5	tractotomy	tractotomy	I-NP	NN	0	_	_	_	_
6	on	on	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	response	response	I-NP	NN	0	_	_	_	_
9	patterns	pattern	I-NP	NNS	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	neurons	neuron	B-NP	NNS	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	trigeminal	trigeminal	I-NP	JJ	UMLS:C0040999:T023:ANAT	_	_	_	_
15	nuclei	nucleus	I-NP	NNS	UMLS:C0040999:T023:ANAT	_	_	_	_
16	principalis	principalis	I-NP	NN	0	_	_	_	_
17	and	and	I-NP	CC	0	_	_	_	_
18	oralis	oralis	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Efficacy	Efficacy	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	three	three	I-NP	CD	0	_	_	_	_
5	-	-	I-NP	HYPH	0	_	_	_	_
6	versus	versus	B-PP	IN	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	five	five	I-NP	CD	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	week	week	I-NP	NN	0	_	_	_	_
11	alcohol	alcohol	I-NP	NN	0	_	_	_	_
12	treatment	treatment	I-NP	NN	0	_	_	_	_
13	program	program	I-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Resistance	Resistance	B-NP	NN	0	_	_	_	_
2	to	to	B-PP	TO	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	simulated	simulated	I-NP	JJ	0	_	_	_	_
5	physiologic	physiologic	I-NP	JJ	0	_	_	_	_
6	environment	environment	I-NP	NN	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	tested	test	I-VP	VBN	0	_	_	_	_
9	by	by	B-PP	IN	0	_	_	_	_
10	measured	measure	B-NP	VBN	0	_	_	_	_
11	retention	retention	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	mechanical	mechanical	B-NP	JJ	0	_	_	_	_
14	properties	property	I-NP	NNS	0	_	_	_	_
15	after	after	B-PP	IN	0	_	_	_	_
16	immersion	immersion	B-NP	NN	0	_	_	_	_
17	times	time	I-NP	NNS	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	pseudo	pseudo	B-NP	AFX	0	_	_	_	_
20	-	-	I-NP	HYPH	0	_	_	_	_
21	extracellular	extracellular	I-NP	JJ	0	_	_	_	_
22	fluid	fluid	I-NP	NN	0	_	_	_	_
23	(	(	O	(	0	_	_	_	_
24	PECF	PECF	B-NP	NN	0	_	_	_	_
25	)	)	O	)	0	_	_	_	_
26	at	at	B-PP	IN	0	_	_	_	_
27	37	37	B-NP	CD	0	_	_	_	_
28	degrees	degree	I-NP	NNS	0	_	_	_	_
29	C	C	I-NP	NN	0	_	_	_	_
30	for	for	B-PP	IN	0	_	_	_	_
31	as	as	B-ADVP	RB	0	_	_	_	_
32	long	long	I-ADVP	JJ	0	_	_	_	_
33	as	as	B-PP	IN	0	_	_	_	_
34	three	three	B-NP	CD	0	_	_	_	_
35	years	year	I-NP	NNS	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	Isolated	Isolate	B-NP	VBN	0	_	_	_	_
2	calcaneal	calcaneal	I-NP	JJ	UMLS:C0006655:T023:ANAT	_	_	_	_
3	tuberculous	tuberculous	I-NP	JJ	UMLS:C0275922:T047:DISO	_	_	_	_
4	osteomyelitis	osteomyelitis	I-NP	NN	UMLS:C0275922:T047:DISO	_	_	_	_
5	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	is	be	B-VP	VBZ	0	_	_	_	_
3	concluded	conclude	I-VP	VBN	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	opiate	opiate	B-NP	JJ	:::NOCLASS	_	_	_	_
6	receptors	receptor	I-NP	NNS	:::NOCLASS	_	_	_	_
7	bordering	border	B-VP	VBG	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	fourth	fourth	I-NP	JJ	0	_	_	_	_
10	cerebral	cerebral	I-NP	JJ	UMLS:C0228174:T023:ANAT|UMLS:C0006104:T023:ANAT	_	_	_	_
11	ventricle	ventricle	I-NP	NN	UMLS:C2355627:T023:ANAT|UMLS:C0018827:T023:ANAT	_	_	_	_
12	mediate	mediate	B-VP	VBP	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	cardiovascular	cardiovascular	I-NP	JJ	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	hypnotic	hypnotic	I-NP	JJ	0	_	_	_	_
17	action	action	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	fentanyl	fentanyl	B-NP	NN	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	case	case	B-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	pathologically	pathologically	I-NP	RB	0	_	_	_	_
6	convoluted	convolute	I-NP	VBN	0	_	_	_	_
7	internal	internal	I-NP	JJ	UMLS:C0741978:T023:ANAT	_	_	_	_
8	carotid	carotid	I-NP	NN	UMLS:C0741978:T023:ANAT	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	common	common	I-NP	JJ	UMLS:C0162859:T023:ANAT	_	_	_	_
11	carotid	carotid	I-NP	NN	UMLS:C0162859:T023:ANAT	_	_	_	_
12	artery	artery	I-NP	NN	UMLS:C0162859:T023:ANAT	_	_	_	_
13	was	be	B-VP	VBD	0	_	_	_	_
14	resected	resecte	I-VP	VBN	0	_	_	_	_
15	with	with	B-PP	IN	0	_	_	_	_
16	an	an	B-NP	DT	0	_	_	_	_
17	end	end	I-NP	NN	0	_	_	_	_
18	-	-	B-ADJP	HYPH	0	_	_	_	_
19	to	to	B-PP	TO	0	_	_	_	_
20	-	-	B-NP	HYPH	0	_	_	_	_
21	end	end	I-NP	NN	0	_	_	_	_
22	anastomosis	anastomosis	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	expression	expression	I-NP	NN	0	_	_	_	_
3	assumes	assume	I-NP	NNS	0	_	_	_	_
4	:	:	O	:	0	_	_	_	_
5	(	(	B-LST	(	0	_	_	_	_
6	1	1	I-LST	LS	0	_	_	_	_
7	)	)	O	)	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	laminar	laminar	I-NP	JJ	0	_	_	_	_
10	flow	flow	I-NP	NN	0	_	_	_	_
11	regimen	regimen	I-NP	NN	0	_	_	_	_
12	during	during	B-PP	IN	0	_	_	_	_
13	expiration	expiration	B-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	(	(	B-LST	(	0	_	_	_	_
17	2	2	I-LST	LS	0	_	_	_	_
18	)	)	O	)	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	constant	constant	I-NP	JJ	0	_	_	_	_
21	CT	CT	I-NP	NN	0	_	_	_	_
22	value	value	I-NP	NN	0	_	_	_	_
23	over	over	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	range	range	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	VT	VT	B-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	data	datum	I-NP	NNS	0	_	_	_	_
3	confirm	confirm	B-VP	VBP	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	existence	existence	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	hyperlipemic	hyperlipemic	B-NP	JJ	0	_	_	_	_
8	abdominal	abdominal	I-NP	JJ	0	_	_	_	_
9	crisis	crisis	I-NP	NN	0	_	_	_	_
10	as	as	B-PP	IN	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	distinct	distinct	I-NP	JJ	0	_	_	_	_
13	entity	entity	I-NP	NN	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	testify	testify	B-VP	VB	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	importance	importance	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	recognizing	recognize	B-VP	VBG	0	_	_	_	_
21	this	this	B-NP	DT	0	_	_	_	_
22	syndrome	syndrome	I-NP	NN	UMLS:C0039082:T047:DISO	_	_	_	_
23	in	in	B-SBAR	IN	0	_	_	_	_
24	order	order	O	NN	0	_	_	_	_
25	to	to	B-VP	TO	0	_	_	_	_
26	avoid	avoid	I-VP	VB	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	occurrence	occurrence	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	acute	acute	B-NP	JJ	UMLS:C0001339:T047:DISO	_	_	_	_
31	pancreatitis	pancreatitis	I-NP	NN	UMLS:C0001339:T047:DISO	_	_	_	_
32	and	and	O	CC	0	_	_	_	_
33	the	the	B-NP	DT	0	_	_	_	_
34	performance	performance	I-NP	NN	0	_	_	_	_
35	of	of	B-PP	IN	0	_	_	_	_
36	unnecessary	unnecessary	B-NP	JJ	0	_	_	_	_
37	and	and	I-NP	CC	0	_	_	_	_
38	potentially	potentially	I-NP	RB	0	_	_	_	_
39	harmful	harmful	I-NP	JJ	0	_	_	_	_
40	surgery	surgery	I-NP	NN	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	addition	addition	B-NP	NN	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	significant	significant	I-NP	JJ	0	_	_	_	_
5	Treatment	Treatment	I-NP	NN	0	_	_	_	_
6	X	X	I-NP	NN	0	_	_	_	_
7	Strain	Strain	I-NP	NN	0	_	_	_	_
8	interaction	interaction	I-NP	NN	0	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	due	due	B-ADJP	JJ	0	_	_	_	_
11	to	to	B-PP	TO	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	larger	large	I-NP	JJR	0	_	_	_	_
14	defecation	defecation	I-NP	NN	0	_	_	_	_
15	numbers	number	I-NP	NNS	0	_	_	_	_
16	displayed	display	B-VP	VBN	0	_	_	_	_
17	by	by	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	taurine	taurine	I-NP	NN	0	_	_	_	_
20	-	-	B-VP	HYPH	0	_	_	_	_
21	injected	inject	B-NP	VBN	0	_	_	_	_
22	MR	MR	I-NP	NN	0	_	_	_	_
23	rats	rat	I-NP	NNS	0	_	_	_	_
24	relative	relative	B-ADVP	JJ	0	_	_	_	_
25	to	to	B-PP	TO	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	saline	saline	I-NP	NN	0	_	_	_	_
28	-	-	B-VP	HYPH	0	_	_	_	_
29	injected	inject	B-NP	VBN	0	_	_	_	_
30	MR	MR	I-NP	NN	0	_	_	_	_
31	rats	rat	I-NP	NNS	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Their	Their	B-NP	PRP$	0	_	_	_	_
2	conduction	conduction	I-NP	NN	0	_	_	_	_
3	velocity	velocity	I-NP	NN	0	_	_	_	_
4	ranged	range	B-VP	VBD	0	_	_	_	_
5	from	from	B-PP	IN	0	_	_	_	_
6	0	0	B-NP	CD	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_
8	23	23	B-NP	CD	0	_	_	_	_
9	to	to	B-PP	TO	0	_	_	_	_
10	0	0	B-NP	CD	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_
12	98	98	B-NP	CD	0	_	_	_	_
13	m	m	I-NP	NN	0	_	_	_	_
14	/	/	B-NP	SYM	0	_	_	_	_
15	sec	sec	B-NP	NN	0	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	group	group	B-NP	NN	0	_	_	_	_
18	C	C	I-NP	NN	0	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	failures	failure	I-NP	NNS	0	_	_	_	_
3	frequently	frequently	B-ADVP	RB	0	_	_	_	_
4	were	be	B-VP	VBD	0	_	_	_	_
5	related	relate	I-VP	VBN	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	patient	patient	B-NP	NN	0	_	_	_	_
8	intolerance	intolerance	I-NP	NN	0	_	_	_	_
9	or	or	O	CC	0	_	_	_	_
10	poor	poor	B-NP	JJ	0	_	_	_	_
11	mechanical	mechanical	I-NP	JJ	0	_	_	_	_
12	fit	fit	I-NP	NN	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	occurred	occur	B-VP	VBD	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	first	first	I-NP	JJ	0	_	_	_	_
18	few	few	I-NP	JJ	0	_	_	_	_
19	days	day	I-NP	NNS	0	_	_	_	_
20	or	or	O	CC	0	_	_	_	_
21	first	first	B-NP	JJ	0	_	_	_	_
22	few	few	I-NP	JJ	0	_	_	_	_
23	months	month	I-NP	NNS	0	_	_	_	_
24	after	after	B-PP	IN	0	_	_	_	_
25	insertion	insertion	B-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	major	major	I-NP	JJ	0	_	_	_	_
3	urinary	urinary	I-NP	JJ	0	_	_	_	_
4	metabolites	metabolite	I-NP	NNS	0	_	_	_	_
5	were	be	B-VP	VBD	0	_	_	_	_
6	3	3	B-NP	CD	0	_	_	_	_
7	-	-	O	HYPH	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	3	3	B-NP	CD	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	carboxyphenyl	carboxyphenyl	I-NP	NN	0	_	_	_	_
12	)	)	O	)	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	5	5	I-NP	CD	0	_	_	_	_
15	-	-	I-NP	HYPH	0	_	_	_	_
16	hydroxymethyl	hydroxymethyl	I-NP	NN	0	_	_	_	_
17	-	-	B-NP	HYPH	0	_	_	_	_
18	2	2	I-NP	CD	0	_	_	_	_
19	-	-	I-NP	HYPH	0	_	_	_	_
20	oxazolidinone	oxazolidinone	I-NP	NN	0	_	_	_	_
21	and	and	O	CC	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	glucuronide	glucuronide	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	toloxatone	toloxatone	B-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	characteristics	characteristic	I-NP	NNS	0	_	_	_	_
3	indicated	indicate	B-VP	VBD	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	pronounced	pronounced	I-NP	JJ	0	_	_	_	_
6	activity	activity	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	collagenous	collagenous	B-NP	JJ	0	_	_	_	_
9	fiber	fiber	I-NP	NN	0	_	_	_	_
10	synthesis	synthesis	I-NP	NN	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	matrix	matrix	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	osteoid	osteoid	I-NP	JJ	0	_	_	_	_
17	tissue	tissue	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	ventilation	ventilation	I-NP	NN	0	_	_	_	_
3	did	do	B-VP	VBD	0	_	_	_	_
4	not	not	I-VP	RB	0	_	_	_	_
5	increase	increase	I-VP	VB	0	_	_	_	_
6	when	when	B-ADVP	WRB	0	_	_	_	_
7	PACO2	PACO2	B-NP	NN	0	_	_	_	_
8	was	be	B-VP	VBD	0	_	_	_	_
9	increased	increase	I-VP	VBN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	Carbohydrate	Carbohydrate	B-NP	NN	0	_	_	_	_
2	metabolism	metabolism	I-NP	NN	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	semen	seman	I-NP	NNS	0	_	_	_	_
6	profile	profile	I-NP	NN	0	_	_	_	_
7	:	:	O	:	0	_	_	_	_
8	glucose	glucose	B-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	insulin	insulin	B-NP	NN	:::NOCLASS	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	sperm	sperm	B-NP	NN	0	_	_	_	_
14	studies	study	I-NP	NNS	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	has	have	B-VP	VBZ	0	_	_	_	_
3	come	come	I-VP	VBN	0	_	_	_	_
4	out	out	B-PRT	RP	0	_	_	_	_
5	that	that	B-SBAR	IN	0	_	_	_	_
6	CAEC	CAEC	B-NP	NN	0	_	_	_	_
7	is	be	B-VP	VBZ	0	_	_	_	_
8	between	between	B-PP	IN	0	_	_	_	_
9	CC	CC	B-NP	NN	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	CIEC	CIEC	I-NP	NN	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	that	that	B-SBAR	IN	0	_	_	_	_
14	attacks	attack	B-NP	NNS	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	biliary	biliary	B-NP	JJ	0	_	_	_	_
17	fever	fever	I-NP	NN	0	_	_	_	_
18	and	and	O	CC	0	_	_	_	_
19	high	high	B-NP	JJ	0	_	_	_	_
20	levels	level	I-NP	NNS	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	alkaline	alkaline	B-NP	NN	:::NOCLASS	_	_	_	_
23	phosphatase	phosphatase	I-NP	NN	:::NOCLASS	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	transaminases	transaminase	B-NP	NNS	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	serum	serum	I-NP	NN	0	_	_	_	_
29	are	be	B-VP	VBP	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	helpful	helpful	I-NP	JJ	0	_	_	_	_
32	findings	finding	I-NP	NNS	0	_	_	_	_
33	for	for	B-PP	IN	0	_	_	_	_
34	preoperative	preoperative	B-NP	JJ	0	_	_	_	_
35	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	sub	sub	I-NP	AFX	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	acute	acute	I-NP	JJ	0	_	_	_	_
5	inhalation	inhalation	I-NP	NN	0	_	_	_	_
6	toxicity	toxicity	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	furfural	furfural	B-NP	JJ	0	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	studied	study	I-VP	VBN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	Syrian	Syrian	B-NP	JJ	0	_	_	_	_
13	golden	golden	I-NP	JJ	0	_	_	_	_
14	hamsters	hamster	I-NP	NNS	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Changes	Change	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	thirtynine	thirtynine	B-NP	NN	0	_	_	_	_
4	serum	serum	I-NP	NN	0	_	_	_	_
5	protein	protein	I-NP	NN	0	_	_	_	_
6	components	component	I-NP	NNS	0	_	_	_	_
7	following	follow	B-PP	VBG	0	_	_	_	_
8	surgical	surgical	B-NP	JJ	0	_	_	_	_
9	stress	stress	I-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	differences	difference	I-NP	NNS	0	_	_	_	_
3	are	be	B-VP	VBP	0	_	_	_	_
4	smaller	small	B-ADJP	JJR	0	_	_	_	_
5	than	than	B-PP	IN	0	_	_	_	_
6	those	those	B-NP	DT	0	_	_	_	_
7	described	describe	B-VP	VBN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	standard	standard	B-NP	JJ	0	_	_	_	_
10	textbooks	textbook	I-NP	NNS	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	study	study	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	E	E	I-NP	NNP	0	_	_	_	_
6	.	.	I-NP	.	0	_	_	_	_
7	O	O	I-NP	NNP	0	_	_	_	_
8	.	.	I-NP	.	0	_	_	_	_
9	R	R	I-NP	NNP	0	_	_	_	_
10	.	.	I-NP	.	0	_	_	_	_
11	T	T	I-NP	NNP	0	_	_	_	_
12	.	.	B-VP	VBD	0	_	_	_	_
13	C	C	B-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	present	present	I-NP	JJ	0	_	_	_	_
3	study	study	I-NP	NN	0	_	_	_	_
4	examined	examine	B-VP	VBD	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	dependence	dependence	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	difference	difference	B-NP	NN	0	_	_	_	_
9	tone	tone	I-NP	NN	0	_	_	_	_
10	level	level	I-NP	NN	0	_	_	_	_
11	[	[	O	(	0	_	_	_	_
12	L	L	B-NP	NN	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	f2	f2	B-NP	NN	0	_	_	_	_
15	-	-	O	HYPH	0	_	_	_	_
16	f1	f1	B-NP	NN	0	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	]	]	O	)	0	_	_	_	_
19	on	on	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	following	follow	I-NP	VBG	0	_	_	_	_
22	parameters	parameter	I-NP	NNS	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	two	two	I-NP	CD	0	_	_	_	_
26	-	-	I-NP	HYPH	0	_	_	_	_
27	tone	tone	I-NP	NN	0	_	_	_	_
28	input	input	I-NP	NN	0	_	_	_	_
29	:	:	O	:	0	_	_	_	_
30	f1	f1	B-NP	NN	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	f2	f2	B-NP	NN	0	_	_	_	_
33	/	/	O	SYM	0	_	_	_	_
34	f1	f1	B-NP	NN	0	_	_	_	_
35	(	(	O	(	0	_	_	_	_
36	f2	f2	B-NP	NN	0	_	_	_	_
37	greater	great	B-ADJP	JJR	0	_	_	_	_
38	than	than	B-PP	IN	0	_	_	_	_
39	f1	f1	B-NP	NN	0	_	_	_	_
40	)	)	O	)	0	_	_	_	_
41	,	,	O	,	0	_	_	_	_
42	L1	L1	B-NP	NN	0	_	_	_	_
43	,	,	O	,	0	_	_	_	_
44	L2	L2	B-NP	NN	0	_	_	_	_
45	,	,	O	,	0	_	_	_	_
46	and	and	O	CC	0	_	_	_	_
47	L1	L1	B-NP	NN	0	_	_	_	_
48	=	=	I-NP	JJ	0	_	_	_	_
49	L2	L2	I-NP	NN	0	_	_	_	_
50	.	.	O	.	0	_	_	_	_

1	An	An	B-NP	DT	0	_	_	_	_
2	intravenous	intravenous	I-NP	JJ	0	_	_	_	_
3	preparation	preparation	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	doxycycline	doxycycline	B-NP	NN	0	_	_	_	_
6	(	(	O	(	0	_	_	_	_
7	DOTC	DOTC	B-NP	NNP	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	Vibramycin	Vibramycin	B-NP	NNP	0	_	_	_	_
10	'Pfizer	'Pfizer	I-NP	NNP	0	_	_	_	_
11	'	'	B-NP	POS	0	_	_	_	_
12	)	)	O	)	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	long	long	I-NP	RB	0	_	_	_	_
16	-	-	I-NP	HYPH	0	_	_	_	_
17	lasting	last	B-VP	VBG	0	_	_	_	_
18	tetracycline	tetracycline	B-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	was	be	B-VP	VBD	0	_	_	_	_
21	administered	administer	I-VP	VBN	0	_	_	_	_
22	mainly	mainly	B-ADVP	RB	0	_	_	_	_
23	by	by	B-PP	IN	0	_	_	_	_
24	drip	drip	B-NP	NN	0	_	_	_	_
25	infusion	infusion	I-NP	NN	0	_	_	_	_
26	for	for	B-PP	IN	0	_	_	_	_
27	a	a	B-NP	DT	0	_	_	_	_
28	series	series	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	study	study	B-NP	NN	0	_	_	_	_
31	in	in	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	pediatrics	pediatric	I-NP	NNS	0	_	_	_	_
34	field	field	I-NP	NN	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	and	and	O	CC	0	_	_	_	_
37	the	the	B-NP	DT	0	_	_	_	_
38	results	result	I-NP	NNS	0	_	_	_	_
39	were	be	B-VP	VBD	0	_	_	_	_
40	as	as	B-SBAR	IN	0	_	_	_	_
41	follows	follow	B-VP	VBZ	0	_	_	_	_
42	:	:	O	:	0	_	_	_	_
43	1	1	B-LST	LS	0	_	_	_	_
44	)	)	O	)	0	_	_	_	_
45	DOTC	DOTC	B-NP	NN	0	_	_	_	_
46	(	(	O	(	0	_	_	_	_
47	100	100	B-NP	CD	0	_	_	_	_
48	mg	mg	I-NP	NN	0	_	_	_	_
49	)	)	O	)	0	_	_	_	_
50	was	be	B-VP	VBD	0	_	_	_	_
51	dissolved	dissolve	I-VP	VBN	0	_	_	_	_
52	in	in	B-PP	IN	0	_	_	_	_
53	a	a	B-NP	DT	0	_	_	_	_
54	100	100	I-NP	CD	0	_	_	_	_
55	ml	ml	I-NP	NN	0	_	_	_	_
56	of	of	B-PP	IN	0	_	_	_	_
57	glucose	glucose	B-NP	NN	0	_	_	_	_
58	solution	solution	I-NP	NN	0	_	_	_	_
59	and	and	O	CC	0	_	_	_	_
60	2	2	B-NP	CD	0	_	_	_	_
61	-	-	I-NP	HYPH	0	_	_	_	_
62	-	-	I-NP	SYM	0	_	_	_	_
63	3	3	I-NP	CD	0	_	_	_	_
64	mg	mg	I-NP	NN	0	_	_	_	_
65	/	/	B-NP	SYM	0	_	_	_	_
66	kg	kg	I-NP	NN	0	_	_	_	_
67	was	be	B-VP	VBD	0	_	_	_	_
68	administered	administer	I-VP	VBN	0	_	_	_	_
69	intravenously	intravenously	B-ADVP	RB	0	_	_	_	_
70	.	.	O	.	0	_	_	_	_

1	5	5	B-LST	LS	0	_	_	_	_
2	)	)	O	)	0	_	_	_	_
3	Before	Before	B-ADVP	IN	0	_	_	_	_
4	and	and	O	CC	0	_	_	_	_
5	ten	ten	B-NP	CD	UMLS:C0014518:T047:DISO	_	_	_	_
6	days	day	I-NP	NNS	0	_	_	_	_
7	after	after	B-PP	IN	0	_	_	_	_
8	DOTC	DOTC	B-NP	NN	0	_	_	_	_
9	infusion	infusion	I-NP	NN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	laboratory	laboratory	B-NP	NN	0	_	_	_	_
12	tests	test	I-NP	NNS	0	_	_	_	_
13	for	for	B-PP	IN	0	_	_	_	_
14	liver	liver	B-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	renal	renal	I-NP	JJ	UMLS:C0022646:T023:ANAT	_	_	_	_
17	functions	function	I-NP	NNS	0	_	_	_	_
18	and	and	I-NP	CC	0	_	_	_	_
19	blood	blood	I-NP	NN	0	_	_	_	_
20	were	be	B-VP	VBD	0	_	_	_	_
21	performed	perform	I-VP	VBN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Structural	Structural	B-NP	JJ	0	_	_	_	_
2	characteristics	characteristic	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	erythrocyte	erythrocyte	I-NP	NN	0	_	_	_	_
6	membrane	membrane	I-NP	NN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	peroxidation	peroxidation	B-NP	NN	0	_	_	_	_
9	processes	process	I-NP	NNS	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	antioxidant	antioxidant	B-NP	JJ	0	_	_	_	_
12	function	function	I-NP	NN	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	children	child	B-NP	NNS	0	_	_	_	_
15	with	with	B-PP	IN	0	_	_	_	_
16	diffuse	diffuse	B-NP	JJ	UMLS:C0859036:T047:DISO	_	_	_	_
17	glomerulonephritis	glomerulonephritis	I-NP	NN	UMLS:C0859036:T047:DISO	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	enteric	enteric	I-NP	JJ	0	_	_	_	_
3	route	route	I-NP	NN	0	_	_	_	_
4	is	be	B-VP	VBZ	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	principal	principal	I-NP	JJ	0	_	_	_	_
7	mode	mode	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	transmission	transmission	B-NP	NN	0	_	_	_	_
10	for	for	B-PP	IN	0	_	_	_	_
11	hepatitis	hepatitis	B-NP	NN	UMLS:C0019159:T047:DISO	_	_	_	_
12	A	A	I-NP	NN	UMLS:C0019159:T047:DISO	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	but	but	O	CC	0	_	_	_	_
15	maximal	maximal	B-NP	JJ	0	_	_	_	_
16	levels	level	I-NP	NNS	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	hepatitis	hepatitis	B-NP	NN	UMLS:C0019159:T047:DISO	_	_	_	_
19	A	A	I-NP	NN	UMLS:C0019159:T047:DISO	_	_	_	_
20	virus	virus	I-NP	NN	0	_	_	_	_
21	excretion	excretion	I-NP	NN	0	_	_	_	_
22	occur	occur	B-VP	VBP	0	_	_	_	_
23	before	before	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	onset	onset	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	jaundice	jaundice	B-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	All	All	B-NP	DT	0	_	_	_	_
2	13	13	I-NP	CD	0	_	_	_	_
3	patients	patient	I-NP	NNS	0	_	_	_	_
4	showed	show	B-VP	VBD	0	_	_	_	_
5	endoscopic	endoscopic	B-NP	JJ	0	_	_	_	_
6	evidence	evidence	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	oesophagitis	oesophagitis	B-NP	NN	UMLS:C0014868:T047:DISO	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	moderate	moderate	B-ADJP	JJ	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	4	4	B-NP	CD	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	severe	severe	B-ADJP	JJ	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	9	9	B-NP	CD	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Urinary	Urinary	B-NP	JJ	0	_	_	_	_
2	excretion	excretion	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	oestrone	oestrone	B-NP	NN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	oestradiol	oestradiol	B-NP	NN	0	_	_	_	_
7	-	-	O	HYPH	0	_	_	_	_
8	17	17	B-NP	CD	0	_	_	_	_
9	beta	beta	I-NP	SYM	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	oestriol	oestriol	I-NP	NN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	pregnancies	pregnancy	B-NP	NNS	0	_	_	_	_
14	complicated	complicate	B-VP	VBN	0	_	_	_	_
15	by	by	B-PP	IN	0	_	_	_	_
16	steroid	steroid	B-NP	NN	:::NOCLASS	_	_	_	_
17	sulphatase	sulphatase	I-NP	NN	:::NOCLASS|UMLS:C1283601:T047:DISO	_	_	_	_
18	deficiency	deficiency	I-NP	NN	UMLS:C1283601:T047:DISO	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Both	Both	B-NP	DT	0	_	_	_	_
2	reduced	reduce	B-VP	VBD	0	_	_	_	_
3	spontaneous	spontaneous	B-NP	JJ	0	_	_	_	_
4	locomotor	locomotor	I-NP	NN	0	_	_	_	_
5	activity	activity	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	mice	mouse	B-NP	NNS	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	protected	protect	B-VP	VBD	0	_	_	_	_
10	them	them	B-NP	PRP	0	_	_	_	_
11	from	from	B-PP	IN	0	_	_	_	_
12	death	death	B-NP	NN	0	_	_	_	_
13	from	from	B-PP	IN	0	_	_	_	_
14	amphetamine	amphetamine	B-NP	NN	0	_	_	_	_
15	induced	induce	B-VP	VBD	0	_	_	_	_
16	toxicity	toxicity	B-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	prolonged	prolong	B-VP	VBD	0	_	_	_	_
19	hexobarbitone	hexobarbitone	B-NP	NN	0	_	_	_	_
20	sleeping	sleeping	I-NP	NN	0	_	_	_	_
21	time	time	I-NP	NN	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	caused	cause	B-VP	VBD	0	_	_	_	_
24	a	a	B-NP	DT	0	_	_	_	_
25	depletion	depletion	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	catecholamines	catecholamine	B-NP	NNS	0	_	_	_	_
28	from	from	B-PP	IN	0	_	_	_	_
29	various	various	B-NP	JJ	0	_	_	_	_
30	organs	organ	I-NP	NNS	UMLS:C0178784:T023:ANAT	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	rat	rat	I-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	On	On	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	role	role	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	transferrin	transferrin	B-NP	NN	:::NOCLASS	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	uptake	uptake	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	gallium	gallium	B-NP	NN	0	_	_	_	_
11	by	by	B-PP	IN	0	_	_	_	_
12	tumor	tumor	B-NP	NN	0	_	_	_	_
13	cells	cell	I-NP	NNS	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Irradiation	Irradiation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	human	human	B-NP	JJ	0	_	_	_	_
4	blood	blood	I-NP	NN	0	_	_	_	_
5	platelets	platelet	I-NP	NNS	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	UV	UV	B-NP	NN	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	A	A	I-NP	NN	0	_	_	_	_
10	in	in	B-ADVP	FW	0	_	_	_	_
11	vitro	vitro	I-ADVP	FW	0	_	_	_	_
12	impairs	impair	B-VP	VBZ	0	_	_	_	_
13	their	their	B-NP	PRP$	0	_	_	_	_
14	ability	ability	I-NP	NN	0	_	_	_	_
15	to	to	B-VP	TO	0	_	_	_	_
16	aggregate	aggregate	I-VP	VB	0	_	_	_	_
17	after	after	B-PP	IN	0	_	_	_	_
18	challenge	challenge	B-NP	NN	0	_	_	_	_
19	with	with	B-PP	IN	0	_	_	_	_
20	collagen	collagen	B-NP	NN	:::NOCLASS	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	With	With	B-PP	IN	0	_	_	_	_
2	certain	certain	B-NP	JJ	0	_	_	_	_
3	exceptions	exception	I-NP	NNS	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	method	method	I-NP	NN	0	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	considered	consider	I-VP	VBN	0	_	_	_	_
8	suitable	suitable	B-ADJP	JJ	0	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	routine	routine	I-NP	JJ	0	_	_	_	_
12	intravenous	intravenous	I-NP	JJ	0	_	_	_	_
13	cholangiography	cholangiography	I-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Following	Follow	B-PP	VBG	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	satisfactory	satisfactory	I-NP	JJ	0	_	_	_	_
4	results	result	I-NP	NNS	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	taking	take	B-VP	VBG	0	_	_	_	_
7	into	into	B-PP	IN	0	_	_	_	_
8	account	account	B-NP	NN	0	_	_	_	_
9	that	that	B-SBAR	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	complications	complication	I-NP	NNS	0	_	_	_	_
12	had	have	B-VP	VBD	0	_	_	_	_
13	reduced	reduce	I-VP	VBN	0	_	_	_	_
14	to	to	B-PP	TO	0	_	_	_	_
15	a	a	B-NP	DT	0	_	_	_	_
16	very	very	I-NP	RB	0	_	_	_	_
17	low	low	I-NP	JJ	0	_	_	_	_
18	rate	rate	I-NP	NN	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	2	2	B-NP	CD	0	_	_	_	_
22	cases	case	I-NP	NNS	0	_	_	_	_
23	lead	lead	B-VP	VBP	0	_	_	_	_
24	tip	tip	B-NP	NN	0	_	_	_	_
25	displacement	displacement	I-NP	NN	0	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	pouch	pouch	B-NP	NN	0	_	_	_	_
28	haematoma	haematoma	I-NP	NN	0	_	_	_	_
29	occurred	occur	B-VP	VBD	0	_	_	_	_
30	respectively	respectively	B-ADVP	RB	0	_	_	_	_
31	)	)	O	)	0	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	the	the	B-NP	DT	0	_	_	_	_
34	Authors	Author	I-NP	NNS	0	_	_	_	_
35	consider	consider	B-VP	VBP	0	_	_	_	_
36	the	the	B-NP	DT	0	_	_	_	_
37	adopted	adopt	I-NP	VBN	0	_	_	_	_
38	method	method	I-NP	NN	0	_	_	_	_
39	an	an	B-NP	DT	0	_	_	_	_
40	useful	useful	I-NP	JJ	0	_	_	_	_
41	approach	approach	I-NP	NN	0	_	_	_	_
42	for	for	B-PP	IN	0	_	_	_	_
43	PMK	PMK	B-NP	NN	0	_	_	_	_
44	implantation	implantation	I-NP	NN	0	_	_	_	_
45	particularly	particularly	B-ADVP	RB	0	_	_	_	_
46	when	when	B-ADVP	WRB	0	_	_	_	_
47	the	the	B-NP	DT	0	_	_	_	_
48	use	use	I-NP	NN	0	_	_	_	_
49	of	of	B-PP	IN	0	_	_	_	_
50	the	the	B-NP	DT	0	_	_	_	_
51	vena	vena	I-NP	NN	UMLS:C0226802:T023:ANAT	_	_	_	_
52	cephalica	cephalica	I-NP	NN	UMLS:C0226802:T023:ANAT	_	_	_	_
53	is	be	B-VP	VBZ	0	_	_	_	_
54	deemed	deem	I-VP	VBN	0	_	_	_	_
55	impossible	impossible	B-ADJP	JJ	0	_	_	_	_
56	.	.	O	.	0	_	_	_	_

1	When	When	B-ADVP	WRB	0	_	_	_	_
2	two	two	B-NP	CD	0	_	_	_	_
3	determinations	determination	I-NP	NNS	0	_	_	_	_
4	were	be	B-VP	VBD	0	_	_	_	_
5	performed	perform	I-VP	VBN	0	_	_	_	_
6	on	on	B-PP	IN	0	_	_	_	_
7	12	12	B-NP	CD	0	_	_	_	_
8	samples	sample	I-NP	NNS	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	plasma	plasma	B-NP	NN	0	_	_	_	_
11	taken	take	B-VP	VBN	0	_	_	_	_
12	from	from	B-PP	IN	0	_	_	_	_
13	normal	normal	B-NP	JJ	0	_	_	_	_
14	adults	adult	I-NP	NNS	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	October	October	B-NP	NNP	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	values	value	I-NP	NNS	0	_	_	_	_
20	were	be	B-VP	VBD	0	_	_	_	_
21	22	22	B-NP	CD	0	_	_	_	_
22	.	.	I-NP	.	0	_	_	_	_
23	6	6	I-NP	CD	0	_	_	_	_
24	+	+	B-NP	SYM	0	_	_	_	_
25	/	/	I-NP	SYM	0	_	_	_	_
26	-	-	I-NP	SYM	0	_	_	_	_
27	4	4	I-NP	CD	0	_	_	_	_
28	.	.	I-NP	SYM	0	_	_	_	_
29	8	8	I-NP	CD	0	_	_	_	_
30	and	and	I-NP	CC	0	_	_	_	_
31	21	21	I-NP	CD	0	_	_	_	_
32	.	.	I-NP	.	0	_	_	_	_
33	0	0	I-NP	CD	0	_	_	_	_
34	+	+	O	SYM	0	_	_	_	_
35	/	/	B-NP	SYM	0	_	_	_	_
36	-	-	B-NP	SYM	0	_	_	_	_
37	3	3	I-NP	CD	0	_	_	_	_
38	.	.	I-NP	SYM	0	_	_	_	_
39	6	6	I-NP	CD	0	_	_	_	_
40	(	(	O	(	0	_	_	_	_
41	mean	mean	B-NP	NN	0	_	_	_	_
42	+	+	O	SYM	0	_	_	_	_
43	/	/	B-NP	SYM	0	_	_	_	_
44	-	-	B-NP	HYPH	0	_	_	_	_
45	SD	SD	I-NP	NN	UMLS:C1096903:T047:DISO	_	_	_	_
46	)	)	O	)	0	_	_	_	_
47	ng	ng	B-NP	NN	0	_	_	_	_
48	/	/	B-VP	SYM	0	_	_	_	_
49	ml	ml	B-NP	NN	0	_	_	_	_
50	,	,	O	,	0	_	_	_	_
51	respectively	respectively	B-ADVP	RB	0	_	_	_	_
52	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	six	six	I-NP	CD	0	_	_	_	_
3	commonest	commonest	I-NP	JJ	0	_	_	_	_
4	causes	cause	I-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	death	death	B-NP	NN	0	_	_	_	_
7	varied	vary	B-VP	VBD	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	three	three	I-NP	CD	0	_	_	_	_
11	ethnic	ethnic	I-NP	JJ	0	_	_	_	_
12	groups	group	I-NP	NNS	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Although	Although	B-SBAR	IN	0	_	_	_	_
2	Grice	Grice	B-NP	NNP	0	_	_	_	_
3	's	's	B-NP	POS	0	_	_	_	_
4	operation	operation	I-NP	NN	0	_	_	_	_
5	has	have	B-VP	VBZ	0	_	_	_	_
6	been	be	I-VP	VBN	0	_	_	_	_
7	used	use	I-VP	VBN	0	_	_	_	_
8	all	all	B-ADVP	DT	0	_	_	_	_
9	over	over	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	world	world	I-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	no	no	B-NP	DT	0	_	_	_	_
14	systematic	systematic	I-NP	JJ	0	_	_	_	_
15	account	account	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	it	it	B-NP	PRP	0	_	_	_	_
18	has	have	B-VP	VBZ	0	_	_	_	_
19	been	be	I-VP	VBN	0	_	_	_	_
20	found	find	I-VP	VBN	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	literature	literature	I-NP	NN	0	_	_	_	_
24	(	(	O	(	0	_	_	_	_
25	including	include	B-PP	VBG	0	_	_	_	_
26	publications	publication	B-NP	NNS	0	_	_	_	_
27	dealing	deal	B-VP	VBG	0	_	_	_	_
28	with	with	B-PP	IN	0	_	_	_	_
29	technique	technique	B-NP	NN	0	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	which	which	B-NP	WDT	0	_	_	_	_
33	presents	present	B-VP	VBZ	0	_	_	_	_
34	it	it	B-NP	PRP	0	_	_	_	_
35	in	in	B-PP	IN	0	_	_	_	_
36	terms	term	B-NP	NNS	0	_	_	_	_
37	related	relate	B-VP	VBN	0	_	_	_	_
38	to	to	B-PP	TO	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	basic	basic	I-NP	JJ	0	_	_	_	_
41	"	"	I-NP	``	0	_	_	_	_
42	classical	classical	I-NP	JJ	0	_	_	_	_
43	"	"	I-NP	''	0	_	_	_	_
44	principles	principle	I-NP	NNS	0	_	_	_	_
45	on	on	B-PP	IN	0	_	_	_	_
46	which	which	B-NP	WDT	0	_	_	_	_
47	the	the	B-NP	DT	0	_	_	_	_
48	operation	operation	I-NP	NN	0	_	_	_	_
49	was	be	B-VP	VBD	0	_	_	_	_
50	conceived	conceive	I-VP	VBN	0	_	_	_	_
51	.	.	O	.	0	_	_	_	_

1	(	(	B-LST	(	0	_	_	_	_
2	5	5	I-LST	LS	0	_	_	_	_
3	)	)	O	)	0	_	_	_	_
4	No	No	B-NP	DT	0	_	_	_	_
5	changes	change	I-NP	NNS	0	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	observed	observe	I-VP	VBN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	gastric	gastric	I-NP	JJ	UMLS:C0038351:T023:ANAT	_	_	_	_
11	venous	venous	I-NP	JJ	UMLS:C0042449:T023:ANAT	_	_	_	_
12	blood	blood	I-NP	NN	0	_	_	_	_
13	flow	flow	I-NP	NN	0	_	_	_	_
14	by	by	B-PP	IN	0	_	_	_	_
15	continuous	continuous	B-NP	JJ	0	_	_	_	_
16	intravenous	intravenous	I-NP	JJ	0	_	_	_	_
17	injection	injection	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	cimetidine	cimetidine	B-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	but	but	O	CC	0	_	_	_	_
22	by	by	B-PP	IN	0	_	_	_	_
23	rapid	rapid	B-NP	JJ	0	_	_	_	_
24	injection	injection	I-NP	NN	0	_	_	_	_
25	both	both	O	CC	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	flow	flow	I-NP	NN	0	_	_	_	_
28	was	be	B-VP	VBD	0	_	_	_	_
29	augmented	augmented	B-ADJP	JJ	0	_	_	_	_
30	and	and	O	CC	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	systemic	systemic	I-NP	JJ	0	_	_	_	_
33	blood	blood	I-NP	NN	0	_	_	_	_
34	pressure	pressure	I-NP	NN	0	_	_	_	_
35	decreased	decrease	B-VP	VBD	0	_	_	_	_
36	transiently	transiently	B-ADVP	RB	0	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	Study	Study	B-NP	NN	0	_	_	_	_
2	on	on	B-PP	IN	0	_	_	_	_
3	re	re	B-NP	AFX	UMLS:C0228327:T023:ANAT	_	_	_	_
4	-	-	I-NP	HYPH	0	_	_	_	_
5	establishment	establishment	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	ovulation	ovulation	B-NP	NN	0	_	_	_	_
8	after	after	B-PP	IN	0	_	_	_	_
9	termination	termination	B-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	sex	sex	B-NP	NN	0	_	_	_	_
12	-	-	O	HYPH	0	_	_	_	_
13	steroidal	steroidal	B-NP	JJ	0	_	_	_	_
14	treatment	treatment	I-NP	NN	0	_	_	_	_
15	-	-	B-VP	HYPH	0	_	_	_	_
16	-	-	B-ADJP	HYPH	0	_	_	_	_
17	compared	compare	B-PP	VBN	0	_	_	_	_
18	with	with	B-PP	IN	0	_	_	_	_
19	re	re	B-NP	AFX	UMLS:C0228327:T023:ANAT	_	_	_	_
20	-	-	I-NP	HYPH	0	_	_	_	_
21	appearance	appearance	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	ovulation	ovulation	B-NP	NN	0	_	_	_	_
24	after	after	B-PP	IN	0	_	_	_	_
25	abortion	abortion	B-NP	NN	0	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	premature	premature	B-NP	JJ	0	_	_	_	_
28	delivery	delivery	I-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	Pharmacokinetics	Pharmacokinetic	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	Carbamazepine	Carbamazepine	B-NP	NN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	man	man	B-NP	NN	0	_	_	_	_
6	:	:	O	:	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	review	review	I-NP	NN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Of	Of	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	compounds	compound	I-NP	NNS	0	_	_	_	_
4	tested	test	B-VP	VBN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	alpha	alpha	O	SYM	0	_	_	_	_
7	-	-	O	HYPH	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	3	3	B-NP	CD	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	methyl	methyl	I-NP	NN	0	_	_	_	_
12	-	-	B-NP	HYPH	0	_	_	_	_
13	2	2	I-NP	CD	0	_	_	_	_
14	-	-	I-NP	HYPH	0	_	_	_	_
15	quinoxalinyl	quinoxalinyl	I-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	-	-	B-NP	HYPH	0	_	_	_	_
18	N	N	I-NP	NN	0	_	_	_	_
19	-	-	O	HYPH	0	_	_	_	_
20	methylnitrone	methylnitrone	B-NP	NN	0	_	_	_	_
21	1	1	I-NP	CD	0	_	_	_	_
22	,	,	I-NP	,	0	_	_	_	_
23	4	4	I-NP	CD	0	_	_	_	_
24	-	-	I-NP	HYPH	0	_	_	_	_
25	dioxide	dioxide	I-NP	NN	0	_	_	_	_
26	(	(	O	(	0	_	_	_	_
27	2	2	B-NP	CD	0	_	_	_	_
28	)	)	O	)	0	_	_	_	_
29	was	be	B-VP	VBD	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	most	most	I-NP	RBS	0	_	_	_	_
32	active	active	I-NP	JJ	0	_	_	_	_
33	agent	agent	I-NP	NN	0	_	_	_	_
34	in	in	B-ADVP	FW	0	_	_	_	_
35	vivo	vivo	I-ADVP	FW	0	_	_	_	_
36	against	against	B-PP	IN	0	_	_	_	_
37	the	the	B-NP	DT	0	_	_	_	_
38	gram	gram	I-NP	NN	0	_	_	_	_
39	-	-	B-VP	HYPH	0	_	_	_	_
40	negative	negative	B-ADJP	JJ	0	_	_	_	_
41	and	and	O	CC	0	_	_	_	_
42	the	the	B-NP	DT	0	_	_	_	_
43	gram	gram	I-NP	NN	0	_	_	_	_
44	-	-	B-NP	HYPH	0	_	_	_	_
45	positive	positive	I-NP	JJ	0	_	_	_	_
46	organisms	organism	I-NP	NNS	0	_	_	_	_
47	.	.	O	.	0	_	_	_	_

1	Changes	Change	B-NP	NNS	0	_	_	_	_
2	in	in	B-PP	IN	0	_	_	_	_
3	ionic	ionic	B-NP	JJ	0	_	_	_	_
4	content	content	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	mucous	mucous	I-NP	NN	0	_	_	_	_
8	suggest	suggest	B-VP	VBP	0	_	_	_	_
9	that	that	B-SBAR	IN	0	_	_	_	_
10	cholinergic	cholinergic	B-NP	JJ	0	_	_	_	_
11	mechanisms	mechanism	I-NP	NNS	0	_	_	_	_
12	affect	affect	B-VP	VBP	0	_	_	_	_
13	pressure	pressure	B-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	excretory	excretory	I-NP	JJ	0	_	_	_	_
17	duct	duct	I-NP	NN	UMLS:C0687028:T023:ANAT|UMLS:C1550227:T023:ANAT	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	gland	gland	I-NP	NN	UMLS:C1285092:T023:ANAT	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Calves	Calf	B-NP	NNS	0	_	_	_	_
2	fed	feed	B-NP	VBN	UMLS:C0342895:T047:DISO	_	_	_	_
3	MCT	MCT	I-NP	NN	0	_	_	_	_
4	-	-	B-NP	HYPH	0	_	_	_	_
5	milk	milk	I-NP	NN	0	_	_	_	_
6	had	have	B-VP	VBD	0	_	_	_	_
7	significantly	significantly	B-NP	RB	0	_	_	_	_
8	lower	low	I-NP	JJR	0	_	_	_	_
9	blood	blood	I-NP	NN	0	_	_	_	_
10	cholesterol	cholesterol	I-NP	NN	0	_	_	_	_
11	than	than	B-PP	IN	0	_	_	_	_
12	calves	calf	B-NP	NNS	0	_	_	_	_
13	fed	feed	B-NP	VBN	UMLS:C0342895:T047:DISO	_	_	_	_
14	T	T	I-NP	NN	0	_	_	_	_
15	-	-	B-NP	HYPH	0	_	_	_	_
16	or	or	I-NP	CC	0	_	_	_	_
17	SBO	SBO	I-NP	NN	0	_	_	_	_
18	-	-	I-NP	HYPH	0	_	_	_	_
19	milk	milk	I-NP	NN	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Delayed	Delay	B-NP	VBN	0	_	_	_	_
2	mortality	mortality	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	mice	mouse	B-NP	NNS	0	_	_	_	_
5	following	follow	B-PP	VBG	0	_	_	_	_
6	inhalation	inhalation	B-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	acute	acute	B-NP	JJ	0	_	_	_	_
9	doses	dose	I-NP	NNS	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	CH2O	CH2O	B-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	SO2Cl2	SO2Cl2	B-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	Br2	Br2	B-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Guinea	Guinea	B-NP	NN	0	_	_	_	_
2	pigs	pig	I-NP	NNS	0	_	_	_	_
3	weighing	weigh	B-VP	VBG	0	_	_	_	_
4	300	300	B-NP	CD	0	_	_	_	_
5	approximately	approximately	I-NP	RB	0	_	_	_	_
6	350	350	I-NP	CD	0	_	_	_	_
7	g	g	I-NP	NN	0	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	used	use	I-VP	VBN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	Under	Under	B-PP	IN	0	_	_	_	_
2	halothane	halothane	B-NP	NN	0	_	_	_	_
3	anesthesia	anesthesia	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	flow	flow	I-NP	NN	0	_	_	_	_
7	pneumocardiogram	pneumocardiogram	I-NP	NN	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	PnCG	PnCG	B-NP	NN	0	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	its	its	B-NP	PRP$	0	_	_	_	_
13	time	time	I-NP	NN	0	_	_	_	_
14	derivative	derivative	I-NP	NN	0	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	acceleration	acceleration	B-NP	NN	0	_	_	_	_
17	pneumocardiogram	pneumocardiogram	I-NP	NN	0	_	_	_	_
18	or	or	O	CC	0	_	_	_	_
19	dPn	dPn	B-NP	NN	0	_	_	_	_
20	/	/	B-NP	SYM	0	_	_	_	_
21	dt	dt	I-NP	NN	0	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	were	be	B-VP	VBD	0	_	_	_	_
24	transduced	transduce	I-VP	VBN	0	_	_	_	_
25	during	during	B-PP	IN	0	_	_	_	_
26	apnea	apnea	B-NP	NN	0	_	_	_	_
27	by	by	B-PP	IN	0	_	_	_	_
28	a	a	B-NP	DT	0	_	_	_	_
29	small	small	I-NP	JJ	0	_	_	_	_
30	high	high	I-NP	JJ	0	_	_	_	_
31	-	-	I-NP	HYPH	0	_	_	_	_
32	gain	gain	I-NP	NN	0	_	_	_	_
33	pneumotachograph	pneumotachograph	I-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Sensory	Sensory	B-NP	JJ	0	_	_	_	_
2	kindling	kindling	I-NP	NN	0	_	_	_	_
3	:	:	O	:	0	_	_	_	_
4	implications	implication	B-NP	NNS	0	_	_	_	_
5	for	for	B-PP	IN	0	_	_	_	_
6	development	development	B-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	sensory	sensory	B-NP	JJ	0	_	_	_	_
9	prostheses	prosthesis	I-NP	NNS	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	is	be	B-VP	VBZ	0	_	_	_	_
3	concluded	conclude	I-VP	VBN	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	stereotypy	stereotypy	B-NP	NN	0	_	_	_	_
6	can	can	B-VP	MD	0	_	_	_	_
7	be	be	I-VP	VB	0	_	_	_	_
8	evoked	evoke	I-VP	VBN	0	_	_	_	_
9	also	also	B-ADVP	RB	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	case	case	I-NP	NN	0	_	_	_	_
13	when	when	B-ADVP	WRB	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	striatal	striatal	I-NP	JJ	0	_	_	_	_
16	dopaminergic	dopaminergic	I-NP	JJ	0	_	_	_	_
17	tone	tone	I-NP	NN	0	_	_	_	_
18	is	be	B-VP	VBZ	0	_	_	_	_
19	normal	normal	B-ADJP	JJ	0	_	_	_	_
20	or	or	O	CC	0	_	_	_	_
21	even	even	B-ADVP	RB	0	_	_	_	_
22	below	below	B-PP	IN	0	_	_	_	_
23	normal	normal	B-ADJP	JJ	0	_	_	_	_
24	:	:	O	:	0	_	_	_	_
25	it	it	B-NP	PRP	0	_	_	_	_
26	is	be	B-VP	VBZ	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	equilibrium	equilibrium	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	striatal	striatal	I-NP	JJ	0	_	_	_	_
32	cholinergic	cholinergic	I-NP	JJ	0	_	_	_	_
33	-	-	I-NP	HYPH	0	_	_	_	_
34	dopaminergic	dopaminergic	I-NP	JJ	0	_	_	_	_
35	systems	system	I-NP	NNS	0	_	_	_	_
36	which	which	B-NP	WDT	0	_	_	_	_
37	must	must	B-VP	MD	0	_	_	_	_
38	be	be	I-VP	VB	0	_	_	_	_
39	shifted	shift	I-VP	VBN	0	_	_	_	_
40	towards	towards	B-PP	IN	0	_	_	_	_
41	dopamine	dopamine	B-NP	NN	0	_	_	_	_
42	,	,	O	,	0	_	_	_	_
43	which	which	B-NP	WDT	0	_	_	_	_
44	is	be	B-VP	VBZ	0	_	_	_	_
45	necessary	necessary	B-ADJP	JJ	0	_	_	_	_
46	for	for	B-PP	IN	0	_	_	_	_
47	the	the	B-NP	DT	0	_	_	_	_
48	development	development	I-NP	NN	0	_	_	_	_
49	of	of	B-PP	IN	0	_	_	_	_
50	this	this	B-NP	DT	0	_	_	_	_
51	behavioral	behavioral	I-NP	JJ	0	_	_	_	_
52	manifestation	manifestation	I-NP	NN	0	_	_	_	_
53	.	.	O	.	0	_	_	_	_

1	None	None	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	cystometrograms	cystometrogram	I-NP	NNS	0	_	_	_	_
5	showed	show	B-VP	VBD	0	_	_	_	_
6	uninhibited	uninhibited	B-NP	JJ	0	_	_	_	_
7	detrusor	detrusor	I-NP	NN	UMLS:C1180419:T023:ANAT	_	_	_	_
8	contractions	contraction	I-NP	NNS	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	duodenum	duodenum	I-NP	NN	UMLS:C0013303:T023:ANAT	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	small	small	I-NP	JJ	0	_	_	_	_
6	part	part	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	administered	administer	I-NP	VBN	0	_	_	_	_
10	dose	dose	I-NP	NN	0	_	_	_	_
11	was	be	B-VP	VBD	0	_	_	_	_
12	transformed	transform	I-VP	VBN	0	_	_	_	_
13	to	to	B-PP	TO	0	_	_	_	_
14	3H	3H	B-NP	NN	0	_	_	_	_
15	-	-	O	HYPH	0	_	_	_	_
16	alpha	alpha	O	SYM	0	_	_	_	_
17	-	-	O	HYPH	0	_	_	_	_
18	acetyldigoxin	acetyldigoxin	B-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Functional	Functional	B-NP	JJ	0	_	_	_	_
2	effects	effect	I-NP	NNS	0	_	_	_	_
3	following	follow	B-PP	VBG	0	_	_	_	_
4	subacute	subacute	B-NP	JJ	0	_	_	_	_
5	administration	administration	I-NP	NN	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	Treatment	Treatment	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	Graves	Graves	B-NP	NN	UMLS:C0018213:T047:DISO	_	_	_	_
4	'	'	B-NP	POS	UMLS:C0018213:T047:DISO	_	_	_	_
5	disease	disease	I-NP	NN	UMLS:C0018213:T047:DISO	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	Although	Although	B-SBAR	IN	0	_	_	_	_
2	it	it	B-NP	PRP	0	_	_	_	_
3	has	have	B-VP	VBZ	0	_	_	_	_
4	been	be	I-VP	VBN	0	_	_	_	_
5	shown	show	I-VP	VBN	0	_	_	_	_
6	that	that	B-SBAR	IN	0	_	_	_	_
7	it	it	B-NP	PRP	0	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	possible	possible	B-ADJP	JJ	0	_	_	_	_
10	to	to	B-VP	TO	0	_	_	_	_
11	use	use	I-VP	VB	0	_	_	_	_
12	orally	orally	B-NP	RB	0	_	_	_	_
13	administered	administer	I-NP	VBN	0	_	_	_	_
14	testosterone	testosterone	I-NP	NN	0	_	_	_	_
15	to	to	B-VP	TO	0	_	_	_	_
16	maintain	maintain	I-VP	VB	0	_	_	_	_
17	se	se	B-NP	NN	0	_	_	_	_
18	-	-	I-NP	HYPH	0	_	_	_	_
19	T	T	I-NP	NN	0	_	_	_	_
20	levels	level	I-NP	NNS	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	normal	normal	I-NP	JJ	0	_	_	_	_
24	male	male	I-NP	JJ	0	_	_	_	_
25	range	range	I-NP	NN	0	_	_	_	_
26	,	,	O	,	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	convenience	convenience	I-NP	NN	0	_	_	_	_
29	to	to	B-PP	TO	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	patient	patient	I-NP	NN	0	_	_	_	_
32	must	must	B-VP	MD	0	_	_	_	_
33	be	be	I-VP	VB	0	_	_	_	_
34	balanced	balance	I-VP	VBN	0	_	_	_	_
35	against	against	B-PP	IN	0	_	_	_	_
36	the	the	B-NP	DT	0	_	_	_	_
37	cost	cost	I-NP	NN	0	_	_	_	_
38	and	and	I-NP	CC	0	_	_	_	_
39	possible	possible	I-NP	JJ	0	_	_	_	_
40	side	side	I-NP	NN	0	_	_	_	_
41	effects	effect	I-NP	NNS	0	_	_	_	_
42	of	of	B-PP	IN	0	_	_	_	_
43	the	the	B-NP	DT	0	_	_	_	_
44	large	large	I-NP	JJ	0	_	_	_	_
45	doses	dose	I-NP	NNS	0	_	_	_	_
46	required	require	B-VP	VBN	0	_	_	_	_
47	.	.	O	.	0	_	_	_	_

1	Contrary	Contrary	B-ADJP	JJ	0	_	_	_	_
2	to	to	B-PP	TO	0	_	_	_	_
3	1	1	B-NP	CD	0	_	_	_	_
4	,	,	I-NP	,	0	_	_	_	_
5	8	8	I-NP	CD	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	dihydroxy	dihydroxy	I-NP	NN	0	_	_	_	_
8	-	-	B-NP	HYPH	0	_	_	_	_
9	9	9	I-NP	CD	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	anthrone	anthrone	I-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	1	1	B-NP	CD	0	_	_	_	_
14	,	,	I-NP	,	0	_	_	_	_
15	8	8	I-NP	CD	0	_	_	_	_
16	,	,	I-NP	,	0	_	_	_	_
17	9	9	I-NP	CD	0	_	_	_	_
18	-	-	I-NP	HYPH	0	_	_	_	_
19	triacetoxyanthracene	triacetoxyanthracene	I-NP	NN	0	_	_	_	_
20	and	and	I-NP	CC	0	_	_	_	_
21	1	1	I-NP	CD	0	_	_	_	_
22	,	,	I-NP	,	0	_	_	_	_
23	8	8	I-NP	CD	0	_	_	_	_
24	-	-	I-NP	HYPH	0	_	_	_	_
25	diacetoxy	diacetoxy	I-NP	NN	0	_	_	_	_
26	-	-	B-NP	HYPH	0	_	_	_	_
27	9	9	I-NP	CD	0	_	_	_	_
28	-	-	I-NP	HYPH	0	_	_	_	_
29	anthrone	anthrone	I-NP	NN	0	_	_	_	_
30	are	be	B-VP	VBP	0	_	_	_	_
31	effective	effective	B-ADJP	JJ	0	_	_	_	_
32	against	against	B-PP	IN	0	_	_	_	_
33	psoriatic	psoriatic	B-NP	JJ	0	_	_	_	_
34	lesions	lesion	I-NP	NNS	0	_	_	_	_
35	without	without	B-PP	IN	0	_	_	_	_
36	accompanying	accompany	B-VP	VBG	0	_	_	_	_
37	inflammations	inflammation	B-NP	NNS	0	_	_	_	_
38	of	of	B-PP	IN	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	skin	skin	I-NP	NN	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	Etiopathogenetic	Etiopathogenetic	B-NP	JJ	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	therapeutic	therapeutic	I-NP	JJ	0	_	_	_	_
4	problems	problem	I-NP	NNS	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	acute	acute	B-NP	JJ	0	_	_	_	_
7	orbital	orbital	I-NP	JJ	0	_	_	_	_
8	inflammation	inflammation	I-NP	NN	0	_	_	_	_

1	Nursing	Nurse	B-VP	VBG	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	patients	patient	B-NP	NNS	0	_	_	_	_
4	with	with	B-PP	IN	0	_	_	_	_
5	gynecological	gynecological	B-NP	JJ	0	_	_	_	_
6	diseases	disease	I-NP	NNS	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	measured	measure	B-VP	VBD	0	_	_	_	_
3	basal	basal	B-NP	JJ	0	_	_	_	_
4	plasma	plasma	I-NP	NN	0	_	_	_	_
5	prolactin	prolactin	I-NP	NN	:::NOCLASS	_	_	_	_
6	concentrations	concentration	I-NP	NNS	0	_	_	_	_
7	(	(	O	(	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	samples	sample	B-NP	NNS	0	_	_	_	_
10	obtained	obtain	B-VP	VBN	0	_	_	_	_
11	during	during	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	early	early	I-NP	JJ	0	_	_	_	_
14	follicular	follicular	I-NP	JJ	UMLS:C1571705:T023:ANAT	_	_	_	_
15	phase	phase	I-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	25	25	B-NP	CD	0	_	_	_	_
19	normal	normal	I-NP	JJ	0	_	_	_	_
20	(	(	O	(	0	_	_	_	_
21	control	control	O	NN	0	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	women	woman	B-NP	NNS	0	_	_	_	_
24	and	and	B-PP	CC	0	_	_	_	_
25	in	in	B-PP	IN	0	_	_	_	_
26	a	a	B-NP	DT	0	_	_	_	_
27	similar	similar	I-NP	JJ	0	_	_	_	_
28	group	group	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	40	40	B-NP	CD	0	_	_	_	_
31	patients	patient	I-NP	NNS	0	_	_	_	_
32	with	with	B-PP	IN	0	_	_	_	_
33	a	a	B-NP	DT	0	_	_	_	_
34	long	long	I-NP	JJ	0	_	_	_	_
35	-	-	I-NP	HYPH	0	_	_	_	_
36	standing	stand	B-VP	VBG	0	_	_	_	_
37	history	history	B-NP	NN	0	_	_	_	_
38	of	of	B-PP	IN	0	_	_	_	_
39	infertility	infertility	B-NP	NN	UMLS:C0021359:T047:DISO	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	Ovarian	Ovarian	B-NP	JJ	UMLS:C0205065:T023:ANAT	_	_	_	_
2	allotransplantation	allotransplantation	I-NP	NN	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	human	human	B-NP	NN	0	_	_	_	_
5	.	.	O	.	0	_	_	_	_

1	Allergic	Allergic	B-NP	JJ	0	_	_	_	_
2	reaction	reaction	I-NP	NN	0	_	_	_	_
3	to	to	B-PP	TO	0	_	_	_	_
4	Patent	Patent	B-NP	NNP	0	_	_	_	_
5	Blue	Blue	I-NP	NNP	0	_	_	_	_
6	Violet	Violet	I-NP	NNP	0	_	_	_	_
7	during	during	B-PP	IN	0	_	_	_	_
8	lymphography	lymphography	B-NP	NN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Screening	Screening	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	asthma	asthma	B-NP	NN	UMLS:C0004096:T047:DISO	_	_	_	_
4	patients	patient	I-NP	NNS	0	_	_	_	_
5	by	by	B-PP	IN	0	_	_	_	_
6	determination	determination	B-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	IgE	IgE	B-NP	NN	UMLS:C0270850:T047:DISO|:::NOCLASS	_	_	_	_
9	and	and	B-PP	CC	0	_	_	_	_
10	by	by	B-PP	IN	0	_	_	_	_
11	comprehension	comprehension	B-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	spectrum	spectrum	B-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	allergospecific	allergospecific	B-NP	JJ	:::NOCLASS	_	_	_	_
16	IgE	IgE	I-NP	NN	:::NOCLASS|UMLS:C0270850:T047:DISO	_	_	_	_
17	antibodies	antibody	I-NP	NNS	:::NOCLASS	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	induction	induction	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	seizures	seizure	B-NP	NNS	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	"	"	O	``	0	_	_	_	_
7	Papio	Papio	B-NP	NNP	0	_	_	_	_
8	papio	papio	I-NP	NN	0	_	_	_	_
9	"	"	O	''	0	_	_	_	_
10	following	follow	B-VP	VBG	0	_	_	_	_
11	allylglycine	allylglycine	B-NP	NN	0	_	_	_	_
12	alone	alone	B-ADVP	RB	0	_	_	_	_
13	or	or	O	CC	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	combination	combination	B-NP	NN	0	_	_	_	_
16	with	with	B-PP	IN	0	_	_	_	_
17	intermittent	intermittent	B-NP	JJ	0	_	_	_	_
18	photic	photic	I-NP	JJ	0	_	_	_	_
19	stimulation	stimulation	I-NP	NN	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	highly	highly	I-NP	RB	0	_	_	_	_
3	significant	significant	I-NP	JJ	0	_	_	_	_
4	correlation	correlation	I-NP	NN	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	found	find	I-VP	VBN	0	_	_	_	_
7	between	between	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	presence	presence	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	fibrinolytic	fibrinolytic	B-NP	JJ	0	_	_	_	_
12	degradation	degradation	I-NP	NN	0	_	_	_	_
13	products	product	I-NP	NNS	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	FDP	FDP	B-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	incidence	incidence	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	nephropathy	nephropathy	B-NP	NN	UMLS:C0022658:T047:DISO	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	renal	renal	B-NP	JJ	UMLS:C1565489:T047:DISO|UMLS:C0022646:T023:ANAT	_	_	_	_
24	insufficiency	insufficiency	I-NP	NN	UMLS:C1565489:T047:DISO	_	_	_	_
25	,	,	O	,	0	_	_	_	_
26	as	as	B-CONJP	RB	0	_	_	_	_
27	well	well	I-CONJP	RB	0	_	_	_	_
28	as	as	I-CONJP	IN	0	_	_	_	_
29	between	between	B-PP	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	presence	presence	I-NP	NN	0	_	_	_	_
32	of	of	B-PP	IN	0	_	_	_	_
33	fibrin	fibrin	B-NP	NN	:::NOCLASS	_	_	_	_
34	monomers	monomer	I-NP	NNS	:::NOCLASS	_	_	_	_
35	(	(	O	(	0	_	_	_	_
36	Godal	Godal	B-NP	NNP	0	_	_	_	_
37	's	's	B-NP	POS	0	_	_	_	_
38	ethanol	ethanol	I-NP	NN	0	_	_	_	_
39	-	-	I-NP	HYPH	0	_	_	_	_
40	gelification	gelification	I-NP	NN	0	_	_	_	_
41	test	test	I-NP	NN	0	_	_	_	_
42	)	)	O	)	0	_	_	_	_
43	and	and	O	CC	0	_	_	_	_
44	the	the	B-NP	DT	0	_	_	_	_
45	evolutive	evolutive	I-NP	JJ	0	_	_	_	_
46	signs	sign	I-NP	NNS	0	_	_	_	_
47	of	of	B-PP	IN	0	_	_	_	_
48	the	the	B-NP	DT	0	_	_	_	_
49	primary	primary	I-NP	JJ	0	_	_	_	_
50	disease	disease	I-NP	NN	0	_	_	_	_
51	(	(	O	(	0	_	_	_	_
52	fever	fever	B-NP	NN	0	_	_	_	_
53	,	,	O	,	0	_	_	_	_
54	accelerated	accelerate	B-VP	VBD	0	_	_	_	_
55	ESR	ESR	B-NP	NNP	0	_	_	_	_
56	)	)	O	)	0	_	_	_	_
57	.	.	O	.	0	_	_	_	_

1	One	One	B-NP	CD	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	third	third	I-NP	JJ	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	men	man	I-NP	NNS	0	_	_	_	_
7	with	with	B-PP	IN	0	_	_	_	_
8	azoospermia	azoospermia	B-NP	NN	UMLS:C1321542:T047:DISO|UMLS:C0004509:T047:DISO	_	_	_	_
9	and	and	B-PP	CC	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	sperm	sperm	B-NP	NN	0	_	_	_	_
12	density	density	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	less	less	B-NP	JJR	0	_	_	_	_
15	than	than	I-NP	IN	0	_	_	_	_
16	10	10	I-NP	CD	0	_	_	_	_
17	million	million	I-NP	CD	0	_	_	_	_
18	had	have	B-VP	VBD	0	_	_	_	_
19	marked	mark	I-VP	VBN	0	_	_	_	_
20	FSH	FSH	B-NP	NN	:::NOCLASS	_	_	_	_
21	elevation	elevation	I-NP	NN	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	our	our	B-NP	PRP$	0	_	_	_	_
24	experience	experience	I-NP	NN	0	_	_	_	_
25	confirms	confirm	B-VP	VBZ	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	work	work	I-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	others	other	B-NP	NNS	0	_	_	_	_
30	that	that	B-SBAR	IN	0	_	_	_	_
31	this	this	B-NP	DT	0	_	_	_	_
32	indicates	indicate	B-VP	VBZ	0	_	_	_	_
33	a	a	B-NP	DT	0	_	_	_	_
34	poor	poor	I-NP	JJ	0	_	_	_	_
35	prognosis	prognosis	I-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	girls	girl	B-NP	NNS	0	_	_	_	_
3	prolactin	prolactin	I-NP	NN	:::NOCLASS	_	_	_	_
4	levels	level	I-NP	NNS	0	_	_	_	_
5	rise	rise	B-VP	VBP	0	_	_	_	_
6	at	at	B-PP	IN	0	_	_	_	_
7	stage	stage	B-NP	NN	0	_	_	_	_
8	2	2	I-NP	CD	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	are	be	B-VP	VBP	0	_	_	_	_
12	higher	high	B-ADJP	JJR	0	_	_	_	_
13	after	after	B-PP	IN	0	_	_	_	_
14	menarche	menarche	B-NP	NN	0	_	_	_	_
15	;	;	O	:	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	boys	boy	B-NP	NNS	0	_	_	_	_
18	there	there	B-NP	EX	0	_	_	_	_
19	is	be	B-VP	VBZ	0	_	_	_	_
20	no	no	B-NP	DT	0	_	_	_	_
21	change	change	I-NP	NN	0	_	_	_	_
22	in	in	B-PP	IN	0	_	_	_	_
23	prolactin	prolactin	B-NP	NN	:::NOCLASS	_	_	_	_
24	levels	level	I-NP	NNS	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	concluded	conclude	I-VP	VBN	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	both	both	B-NP	DT	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	these	these	B-NP	DT	0	_	_	_	_
8	surgical	surgical	I-NP	JJ	0	_	_	_	_
9	procedures	procedure	I-NP	NNS	0	_	_	_	_
10	were	be	B-VP	VBD	0	_	_	_	_
11	as	as	B-ADJP	RB	0	_	_	_	_
12	effective	effective	I-ADJP	JJ	0	_	_	_	_
13	as	as	B-PP	IN	0	_	_	_	_
14	pinealectomy	pinealectomy	B-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	reversing	reverse	B-VP	VBG	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	pineal	pineal	I-NP	NN	UMLS:C0031939:T023:ANAT	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	induced	induce	I-NP	VBN	0	_	_	_	_
21	alterations	alteration	I-NP	NNS	0	_	_	_	_
22	in	in	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	reproductive	reproductive	I-NP	JJ	0	_	_	_	_
25	physiology	physiology	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	blind	blind	I-NP	JJ	UMLS:C0456909:T047:DISO	_	_	_	_
29	-	-	I-NP	HYPH	0	_	_	_	_
30	anosmic	anosmic	I-NP	JJ	0	_	_	_	_
31	female	female	I-NP	JJ	0	_	_	_	_
32	rat	rat	I-NP	NN	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	2	2	B-NP	CD	0	_	_	_	_
2	cases	case	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	toxic	toxic	B-NP	JJ	0	_	_	_	_
5	lymphomononucleosis	lymphomononucleosis	I-NP	NN	0	_	_	_	_

1	Such	Such	B-NP	PDT	0	_	_	_	_
2	an	an	I-NP	DT	0	_	_	_	_
3	hemoglobin	hemoglobin	I-NP	NN	:::NOCLASS	_	_	_	_
4	solution	solution	I-NP	NN	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	shown	show	I-VP	VBN	0	_	_	_	_
7	to	to	I-VP	TO	0	_	_	_	_
8	exhibit	exhibit	I-VP	VB	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	high	high	I-NP	JJ	0	_	_	_	_
11	affinity	affinity	I-NP	NN	0	_	_	_	_
12	for	for	B-PP	IN	0	_	_	_	_
13	oxygen	oxygen	B-NP	NN	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	a	a	B-NP	DT	0	_	_	_	_
16	low	low	I-NP	JJ	0	_	_	_	_
17	Bohr	Bohr	I-NP	NN	0	_	_	_	_
18	effect	effect	I-NP	NN	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	assessed	assess	B-VP	VBN	0	_	_	_	_
21	from	from	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	delta	delta	I-NP	NN	0	_	_	_	_
24	log	log	I-NP	NN	0	_	_	_	_
25	Po2	Po2	I-NP	NN	0	_	_	_	_
26	/	/	O	SYM	0	_	_	_	_
27	delta	delta	O	SYM	0	_	_	_	_
28	pH	pH	B-NP	NN	0	_	_	_	_
29	ratio	ratio	I-NP	NN	0	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	one	one	I-NP	CD	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	week	week	I-NP	NN	0	_	_	_	_
5	ulcer	ulcer	I-NP	NN	0	_	_	_	_
6	therapy	therapy	I-NP	NN	0	_	_	_	_
7	with	with	B-PP	IN	0	_	_	_	_
8	atropine	atropine	B-NP	NN	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	Vikalin	Vikalin	B-NP	NN	0	_	_	_	_
11	(	(	O	(	0	_	_	_	_
12	Roter	Roter	B-NP	NN	0	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	led	lead	B-VP	VBD	0	_	_	_	_
15	to	to	B-PP	TO	0	_	_	_	_
16	a	a	B-NP	DT	0	_	_	_	_
17	significant	significant	I-NP	JJ	0	_	_	_	_
18	(	(	O	(	0	_	_	_	_
19	p	p	B-NP	NN	0	_	_	_	_
20	less	less	B-ADJP	JJR	0	_	_	_	_
21	than	than	B-PP	IN	0	_	_	_	_
22	0	0	B-NP	CD	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_
24	01	01	O	CD	0	_	_	_	_
25	)	)	O	)	0	_	_	_	_
26	reduction	reduction	B-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	nocturnal	nocturnal	I-NP	JJ	0	_	_	_	_
30	proteolytic	proteolytic	I-NP	JJ	0	_	_	_	_
31	activity	activity	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	one	one	B-NP	CD	0	_	_	_	_
3	patient	patient	I-NP	NN	0	_	_	_	_
4	with	with	B-PP	IN	0	_	_	_	_
5	severe	severe	B-NP	JJ	0	_	_	_	_
6	diarrhea	diarrhea	I-NP	NN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	estriol	estriol	I-NP	NN	0	_	_	_	_
9	concentration	concentration	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	serum	serum	B-NP	NN	0	_	_	_	_
12	was	be	B-VP	VBD	0	_	_	_	_
13	low	low	B-ADJP	JJ	0	_	_	_	_
14	until	until	B-SBAR	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	intestinal	intestinal	I-NP	JJ	UMLS:C0021853:T023:ANAT	_	_	_	_
17	function	function	I-NP	NN	0	_	_	_	_
18	normalised	normalise	B-VP	VBD	0	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	estriol	estriol	I-NP	NN	0	_	_	_	_
22	concentration	concentration	I-NP	NN	0	_	_	_	_
23	went	go	B-VP	VBD	0	_	_	_	_
24	up	up	B-PRT	RP	0	_	_	_	_
25	exactly	exactly	B-ADVP	RB	0	_	_	_	_
26	when	when	B-ADVP	WRB	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	diarrhea	diarrhea	I-NP	NN	0	_	_	_	_
29	stopped	stop	B-VP	VBD	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Serum	Serum	B-NP	NN	0	_	_	_	_
2	levels	level	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	IgG	IgG	B-NP	NN	:::NOCLASS	_	_	_	_
5	and	and	I-NP	CC	0	_	_	_	_
6	IgM	IgM	I-NP	NN	:::NOCLASS	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	also	also	I-VP	RB	0	_	_	_	_
9	raised	raise	I-VP	VBN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	but	but	O	CC	0	_	_	_	_
12	contrary	contrary	B-ADJP	JJ	0	_	_	_	_
13	to	to	B-PP	TO	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	findings	finding	I-NP	NNS	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	other	other	B-NP	JJ	0	_	_	_	_
18	observers	observer	I-NP	NNS	0	_	_	_	_
19	IgA	IgA	I-NP	NN	:::NOCLASS	_	_	_	_
20	levels	level	I-NP	NNS	0	_	_	_	_
21	were	be	B-VP	VBD	0	_	_	_	_
22	normal	normal	B-ADJP	JJ	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Experimental	Experimental	B-NP	JJ	0	_	_	_	_
2	ischemic	ischemic	I-NP	JJ	UMLS:C0151744:T047:DISO	_	_	_	_
3	heart	heart	I-NP	NN	UMLS:C0151744:T047:DISO|UMLS:C0018787:T023:ANAT	_	_	_	_
4	disease	disease	I-NP	NN	UMLS:C0151744:T047:DISO	_	_	_	_
5	induced	induce	B-VP	VBN	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	thromboxane	thromboxane	B-NP	NN	0	_	_	_	_
8	A2	A2	I-NP	NN	UMLS:C0935080:T023:ANAT	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	rabbits	rabbit	B-NP	NNS	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	Vitrectomy	Vitrectomy	B-NP	NN	0	_	_	_	_
2	in	in	B-PP	IN	0	_	_	_	_
3	ocular	ocular	B-NP	JJ	UMLS:C0015392:T023:ANAT	_	_	_	_
4	traumatology	traumatology	I-NP	NN	0	_	_	_	_

1	To	To	B-VP	TO	0	_	_	_	_
2	study	study	I-VP	VB	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	sensitivity	sensitivity	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	some	some	B-NP	DT	0	_	_	_	_
7	central	central	I-NP	JJ	0	_	_	_	_
8	brain	brain	I-NP	NN	UMLS:C0006104:T023:ANAT	_	_	_	_
9	structures	structure	I-NP	NNS	0	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	action	action	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	an	an	B-NP	DT	0	_	_	_	_
15	electromagnetic	electromagnetic	I-NP	JJ	0	_	_	_	_
16	field	field	I-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	decimeter	decimeter	B-NP	NN	0	_	_	_	_
19	waves	wave	I-NP	NNS	0	_	_	_	_
20	(	(	O	(	0	_	_	_	_
21	EMF	EMF	B-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	DW	DW	B-NP	NN	0	_	_	_	_
24	)	)	O	)	0	_	_	_	_
25	a	a	B-NP	DT	0	_	_	_	_
26	dynamic	dynamic	I-NP	JJ	0	_	_	_	_
27	investigation	investigation	I-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	single	single	B-NP	JJ	0	_	_	_	_
30	unit	unit	I-NP	NN	0	_	_	_	_
31	activity	activity	I-NP	NN	0	_	_	_	_
32	was	be	B-VP	VBD	0	_	_	_	_
33	undertaken	undertake	I-VP	VBN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	No	No	B-NP	DT	0	_	_	_	_
2	systematic	systematic	I-NP	JJ	0	_	_	_	_
3	L	L	I-NP	NN	0	_	_	_	_
4	-	-	B-NP	HYPH	0	_	_	_	_
5	R	R	I-NP	NN	0	_	_	_	_
6	differences	difference	I-NP	NNS	0	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	observed	observe	I-VP	VBN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	decrease	decrease	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	lysozyme	lysozyme	I-NP	NN	:::NOCLASS	_	_	_	_
6	activity	activity	I-NP	NN	0	_	_	_	_
7	coincided	coincide	B-VP	VBD	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	clinical	clinical	I-NP	JJ	0	_	_	_	_
11	improvement	improvement	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	bacterial	bacterial	I-NP	JJ	UMLS:C0085437:T047:DISO	_	_	_	_
15	meningitis	meningitis	I-NP	NN	UMLS:C0085437:T047:DISO	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	implies	imply	B-VP	VBZ	0	_	_	_	_
3	that	that	B-SBAR	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	groups	group	I-NP	NNS	0	_	_	_	_
6	do	do	B-VP	VBP	0	_	_	_	_
7	not	not	I-VP	RB	0	_	_	_	_
8	just	just	I-VP	RB	0	_	_	_	_
9	differ	differ	I-VP	VB	0	_	_	_	_
10	along	along	B-PP	IN	0	_	_	_	_
11	one	one	B-NP	CD	0	_	_	_	_
12	dimension	dimension	I-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	but	but	O	CC	0	_	_	_	_
15	along	along	B-PP	IN	0	_	_	_	_
16	three	three	B-NP	CD	0	_	_	_	_
17	dimensions	dimension	I-NP	NNS	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Deep	Deep	B-NP	NN	0	_	_	_	_
2	tans	tan	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	induced	induce	I-VP	VBN	0	_	_	_	_
5	over	over	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	backs	back	I-NP	NNS	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	volunteers	volunteer	B-NP	NNS	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	repeated	repeat	B-NP	VBN	0	_	_	_	_
12	exposure	exposure	I-NP	NN	0	_	_	_	_
13	to	to	B-VP	TO	0	_	_	_	_
14	longwave	longwave	I-VP	VB	0	_	_	_	_
15	ultraviolet	ultraviolet	B-NP	JJ	0	_	_	_	_
16	radiation	radiation	I-NP	NN	0	_	_	_	_
17	(	(	O	(	0	_	_	_	_
18	UV	UV	B-NP	NN	0	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	A	A	I-NP	NN	0	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	1	1	B-LST	LS	0	_	_	_	_
2	The	The	B-NP	DT	0	_	_	_	_
3	effects	effect	I-NP	NNS	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	normal	normal	B-NP	JJ	0	_	_	_	_
6	subjects	subject	I-NP	NNS	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	single	single	I-NP	JJ	0	_	_	_	_
10	oral	oral	I-NP	JJ	0	_	_	_	_
11	dose	dose	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	Motival	Motival	B-NP	NNP	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	one	one	B-NP	CD	0	_	_	_	_
16	tablet	tablet	I-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	containing	contain	B-VP	VBG	0	_	_	_	_
19	fluphenazine	fluphenazine	B-NP	NN	0	_	_	_	_
20	0	0	I-NP	CD	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_
22	5	5	B-NP	CD	0	_	_	_	_
23	mg	mg	I-NP	NN	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	nortriptyline	nortriptyline	B-NP	NN	0	_	_	_	_
26	10	10	I-NP	CD	0	_	_	_	_
27	mg	mg	I-NP	NN	0	_	_	_	_
28	)	)	O	)	0	_	_	_	_
29	on	on	B-PP	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	contingent	contingent	I-NP	JJ	0	_	_	_	_
32	negative	negative	I-NP	JJ	0	_	_	_	_
33	variation	variation	I-NP	NN	0	_	_	_	_
34	(	(	O	(	0	_	_	_	_
35	CNV	CNV	B-NP	NN	0	_	_	_	_
36	)	)	O	)	0	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	reaction	reaction	B-NP	NN	0	_	_	_	_
39	time	time	I-NP	NN	0	_	_	_	_
40	,	,	O	,	0	_	_	_	_
41	heart	heart	B-NP	NN	UMLS:C0018787:T023:ANAT	_	_	_	_
42	rate	rate	I-NP	NN	0	_	_	_	_
43	,	,	O	,	0	_	_	_	_
44	blood	blood	B-NP	NN	0	_	_	_	_
45	pressure	pressure	I-NP	NN	0	_	_	_	_
46	and	and	I-NP	CC	0	_	_	_	_
47	self	self	I-NP	NN	0	_	_	_	_
48	-	-	O	HYPH	0	_	_	_	_
49	rating	rat	B-VP	VBG	0	_	_	_	_
50	scales	scale	B-NP	NNS	0	_	_	_	_
51	for	for	B-PP	IN	0	_	_	_	_
52	alertness	alertness	B-NP	NN	0	_	_	_	_
53	,	,	I-NP	,	0	_	_	_	_
54	anxiety	anxiety	I-NP	NN	0	_	_	_	_
55	,	,	I-NP	,	0	_	_	_	_
56	tension	tension	I-NP	NN	0	_	_	_	_
57	,	,	I-NP	,	0	_	_	_	_
58	detachment	detachment	I-NP	NN	0	_	_	_	_
59	and	and	I-NP	CC	0	_	_	_	_
60	depression	depression	I-NP	NN	0	_	_	_	_
61	were	be	B-VP	VBD	0	_	_	_	_
62	compared	compare	I-VP	VBN	0	_	_	_	_
63	with	with	B-PP	IN	0	_	_	_	_
64	those	those	B-NP	DT	0	_	_	_	_
65	of	of	B-PP	IN	0	_	_	_	_
66	diazepam	diazepam	B-NP	NN	0	_	_	_	_
67	(	(	O	(	0	_	_	_	_
68	5	5	B-NP	CD	0	_	_	_	_
69	mg	mg	I-NP	NN	0	_	_	_	_
70	and	and	O	CC	0	_	_	_	_
71	7	7	B-NP	CD	0	_	_	_	_
72	.	.	O	.	0	_	_	_	_
73	5	5	B-NP	CD	0	_	_	_	_
74	mg	mg	I-NP	NN	0	_	_	_	_
75	)	)	O	)	0	_	_	_	_
76	and	and	O	CC	0	_	_	_	_
77	placebo	placebo	B-NP	NN	0	_	_	_	_
78	or	or	I-NP	CC	0	_	_	_	_
79	propranolol	propranolol	I-NP	NN	0	_	_	_	_
80	(	(	O	(	0	_	_	_	_
81	60	60	B-NP	CD	0	_	_	_	_
82	mg	mg	I-NP	NN	0	_	_	_	_
83	)	)	O	)	0	_	_	_	_
84	.	.	O	.	0	_	_	_	_

1	Stress	Stress	B-NP	NN	0	_	_	_	_
2	effects	effect	I-NP	NNS	0	_	_	_	_
3	on	on	B-PP	IN	0	_	_	_	_
4	affiliation	affiliation	B-NP	NN	0	_	_	_	_
5	preferences	preference	I-NP	NNS	0	_	_	_	_
6	among	among	B-PP	IN	0	_	_	_	_
7	subjects	subject	B-NP	NNS	0	_	_	_	_
8	possessing	possess	B-VP	VBG	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	type	type	I-NP	NN	0	_	_	_	_
11	A	A	I-NP	NN	0	_	_	_	_
12	coronary	coronary	I-NP	JJ	UMLS:C0018787:T023:ANAT	_	_	_	_
13	-	-	I-NP	HYPH	0	_	_	_	_
14	prone	prone	I-NP	JJ	0	_	_	_	_
15	behavior	behavior	I-NP	NN	0	_	_	_	_
16	pattern	pattern	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	show	show	B-VP	VBP	0	_	_	_	_
3	that	that	B-SBAR	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	collagen	collagen	I-NP	NN	:::NOCLASS	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	this	this	B-NP	DT	0	_	_	_	_
8	tissue	tissue	I-NP	NN	0	_	_	_	_
9	is	be	B-VP	VBZ	0	_	_	_	_
10	modified	modify	I-VP	VBN	0	_	_	_	_
11	compared	compare	B-PP	VBN	0	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	that	that	B-NP	DT	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	tendon	tendon	B-NP	NN	UMLS:C0039508:T023:ANAT	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Smoking	Smoking	B-NP	NN	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	regarded	regard	I-VP	VBN	0	_	_	_	_
4	as	as	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	major	major	I-NP	JJ	0	_	_	_	_
7	contribution	contribution	I-NP	NN	0	_	_	_	_
8	to	to	B-PP	TO	0	_	_	_	_
9	pulmonary	pulmonary	B-NP	JJ	UMLS:C0024109:T023:ANAT	_	_	_	_
10	dysfunction	dysfunction	I-NP	NN	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	malignity	malignity	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	nevoid	nevoid	B-NP	JJ	0	_	_	_	_
5	lentigo	lentigo	I-NP	NN	UMLS:C0023321:T047:DISO	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	Elimination	Elimination	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	bagassosis	bagassosis	B-NP	NN	UMLS:C0004681:T047:DISO	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	Louisiana	Louisiana	B-NP	NNP	0	_	_	_	_
6	paper	paper	I-NP	NN	0	_	_	_	_
7	manufacturing	manufacturing	I-NP	NN	0	_	_	_	_
8	plant	plant	I-NP	NN	0	_	_	_	_
9	workers	worker	I-NP	NNS	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	responses	response	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	compared	compare	I-VP	VBN	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	others	other	B-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	same	same	I-NP	JJ	0	_	_	_	_
10	subjects	subject	I-NP	NNS	0	_	_	_	_
11	under	under	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	same	same	I-NP	JJ	0	_	_	_	_
14	conditions	condition	I-NP	NNS	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	it	it	B-NP	PRP	0	_	_	_	_
17	was	be	B-VP	VBD	0	_	_	_	_
18	concluded	conclude	I-VP	VBN	0	_	_	_	_
19	that	that	B-SBAR	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	antihypertensive	antihypertensive	I-NP	JJ	0	_	_	_	_
22	effect	effect	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	labetalol	labetalol	B-NP	NN	0	_	_	_	_
25	is	be	B-VP	VBZ	0	_	_	_	_
26	explained	explain	I-VP	VBN	0	_	_	_	_
27	by	by	B-PP	IN	0	_	_	_	_
28	concurrent	concurrent	B-NP	JJ	0	_	_	_	_
29	blockade	blockade	I-NP	NN	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	alpha	alpha	B-NP	SYM	:::NOCLASS	_	_	_	_
32	-	-	B-ADJP	HYPH	:::NOCLASS	_	_	_	_
33	and	and	O	CC	:::NOCLASS	_	_	_	_
34	beta	beta	B-NP	SYM	:::NOCLASS	_	_	_	_
35	-	-	B-VP	HYPH	:::NOCLASS	_	_	_	_
36	adrenoceptors	adrenoceptor	B-NP	NNS	:::NOCLASS	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	Diuretics	Diuretic	B-NP	NNS	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	basic	basic	B-NP	JJ	0	_	_	_	_
4	clinical	clinical	I-NP	JJ	0	_	_	_	_
5	pharmacology	pharmacology	I-NP	NN	0	_	_	_	_
6	and	and	O	CC	0	_	_	_	_
7	therapeutic	therapeutic	B-NP	JJ	0	_	_	_	_
8	use	use	I-NP	NN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Three	Three	B-NP	CD	0	_	_	_	_
2	patients	patient	I-NP	NNS	0	_	_	_	_
3	with	with	B-PP	IN	0	_	_	_	_
4	four	four	B-NP	CD	0	_	_	_	_
5	renoureteral	renoureteral	I-NP	JJ	0	_	_	_	_
6	units	unit	I-NP	NNS	0	_	_	_	_
7	have	have	B-VP	VBP	0	_	_	_	_
8	undergone	undergo	I-VP	VBN	0	_	_	_	_
9	single	single	B-NP	JJ	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	stage	stage	I-NP	NN	0	_	_	_	_
12	reconstruction	reconstruction	I-NP	NN	0	_	_	_	_
13	involving	involve	B-VP	VBG	0	_	_	_	_
14	ureteroureterostomy	ureteroureterostomy	B-NP	NN	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	ipsilateral	ipsilateral	B-NP	JJ	0	_	_	_	_
17	ureteroneocystostomy	ureteroneocystostomy	I-NP	NN	0	_	_	_	_
18	following	follow	B-PP	VBG	0	_	_	_	_
19	temporary	temporary	B-NP	JJ	0	_	_	_	_
20	loop	loop	I-NP	NN	0	_	_	_	_
21	cutaneous	cutaneous	I-NP	JJ	0	_	_	_	_
22	ureterostomy	ureterostomy	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Evaluation	Evaluation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	Du	Du	I-NP	NNP	0	_	_	_	_
5	Pont	Pont	I-NP	NNP	0	_	_	_	_
6	aca	aca	I-NP	NN	UMLS:C0149561:T023:ANAT	_	_	_	_
7	ammonia	ammonia	I-NP	NN	0	_	_	_	_
8	procedure	procedure	I-NP	NN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Internally	Internally	B-NP	RB	0	_	_	_	_
2	oriented	orient	I-NP	VBN	0	_	_	_	_
3	patients	patient	I-NP	NNS	0	_	_	_	_
4	'	'	B-NP	POS	0	_	_	_	_
5	scores	score	I-NP	NNS	0	_	_	_	_
6	on	on	B-PP	IN	0	_	_	_	_
7	Rotter	Rotter	B-NP	NNP	0	_	_	_	_
8	's	's	B-NP	POS	0	_	_	_	_
9	Internal	Internal	I-NP	NNP	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	External	External	I-NP	NNP	0	_	_	_	_
12	Locus	Locus	I-NP	NNP	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	Control	Control	B-NP	NNP	0	_	_	_	_
15	Scale	Scale	I-NP	NNP	0	_	_	_	_
16	remained	remain	B-VP	VBD	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	same	same	I-NP	JJ	0	_	_	_	_
19	over	over	B-PP	IN	0	_	_	_	_
20	treatment	treatment	B-NP	NN	0	_	_	_	_
21	but	but	O	CC	0	_	_	_	_
22	those	those	B-NP	DT	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	externally	externally	B-NP	RB	0	_	_	_	_
25	oriented	orient	I-NP	VBN	0	_	_	_	_
26	patients	patient	I-NP	NNS	0	_	_	_	_
27	shifted	shift	B-VP	VBD	0	_	_	_	_
28	toward	toward	B-PP	IN	0	_	_	_	_
29	greater	great	B-NP	JJR	0	_	_	_	_
30	internal	internal	I-NP	JJ	0	_	_	_	_
31	control	control	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Action	Action	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	strontium	strontium	B-NP	NN	0	_	_	_	_
4	-	-	O	HYPH	0	_	_	_	_
5	90	90	B-NP	CD	0	_	_	_	_
6	and	and	O	CC	0	_	_	_	_
7	metaphos	metapho	B-NP	NNS	0	_	_	_	_
8	on	on	B-PP	IN	0	_	_	_	_
9	Cyprinus	Cyprinus	B-NP	NN	0	_	_	_	_
10	carpio	carpio	I-NP	NN	0	_	_	_	_

1	Kodak	Kodak	B-NP	NNP	0	_	_	_	_
2	XV	XV	I-NP	NNP	0	_	_	_	_
3	-	-	B-NP	HYPH	0	_	_	_	_
4	2	2	I-NP	CD	0	_	_	_	_
5	film	film	I-NP	NN	0	_	_	_	_
6	is	be	B-VP	VBZ	0	_	_	_	_
7	wrapped	wrap	I-VP	VBN	0	_	_	_	_
8	around	around	B-PP	IN	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	cylindrical	cylindrical	I-NP	JJ	0	_	_	_	_
11	water	water	I-NP	NN	0	_	_	_	_
12	-	-	B-VP	HYPH	0	_	_	_	_
13	filled	fill	B-NP	VBN	0	_	_	_	_
14	phantom	phantom	I-NP	NN	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	dose	dose	I-NP	NN	0	_	_	_	_
18	distribution	distribution	I-NP	NN	0	_	_	_	_
19	is	be	B-VP	VBZ	0	_	_	_	_
20	recorded	record	I-VP	VBN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Diagnosis	Diagnosis	B-NP	NN	0	_	_	_	_
2	and	and	O	CC	0	_	_	_	_
3	differential	differential	B-NP	JJ	0	_	_	_	_
4	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	multiple	multiple	I-NP	JJ	0	_	_	_	_
3	factors	factor	I-NP	NNS	0	_	_	_	_
4	affecting	affect	B-VP	VBG	0	_	_	_	_
5	plasma	plasma	B-NP	NN	0	_	_	_	_
6	renin	renin	I-NP	NN	:::NOCLASS	_	_	_	_
7	activity	activity	I-NP	NN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	essential	essential	B-NP	JJ	UMLS:C0085580:T047:DISO	_	_	_	_
10	hypertension	hypertension	I-NP	NN	UMLS:C0085580:T047:DISO	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	Cortisone	Cortisone	B-NP	NN	0	_	_	_	_
2	induced	induce	B-VP	VBD	0	_	_	_	_
3	bone	bone	B-NP	NN	UMLS:C0262950:T023:ANAT	_	_	_	_
4	changes	change	I-NP	NNS	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	its	its	B-NP	PRP$	0	_	_	_	_
7	response	response	I-NP	NN	0	_	_	_	_
8	to	to	B-PP	TO	0	_	_	_	_
9	lipid	lipid	B-NP	NN	0	_	_	_	_
10	clearing	clearing	I-NP	NN	0	_	_	_	_
11	agents	agent	I-NP	NNS	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	2	2	B-LST	LS	0	_	_	_	_
2	)	)	O	)	0	_	_	_	_
3	The	The	B-NP	DT	0	_	_	_	_
4	time	time	I-NP	NN	0	_	_	_	_
5	-	-	O	HYPH	0	_	_	_	_
6	sharing	share	B-VP	VBG	0	_	_	_	_
7	principle	principle	B-NP	NN	0	_	_	_	_
8	was	be	B-VP	VBD	0	_	_	_	_
9	applied	apply	I-VP	VBN	0	_	_	_	_
10	to	to	I-VP	TO	0	_	_	_	_
11	gain	gain	I-VP	VB	0	_	_	_	_
12	high	high	B-NP	JJ	0	_	_	_	_
13	stability	stability	I-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	When	When	B-ADVP	WRB	0	_	_	_	_
2	blood	blood	B-NP	NN	0	_	_	_	_
3	samples	sample	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	patients	patient	B-NP	NNS	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	hyperbilirubinemia	hyperbilirubinemia	B-NP	NN	UMLS:C0020433:T047:DISO	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	analyzed	analyze	I-VP	VBN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	direct	direct	B-NP	JJ	0	_	_	_	_
12	measurement	measurement	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	ZPP	ZPP	B-NP	NN	0	_	_	_	_
15	by	by	B-PP	IN	0	_	_	_	_
16	this	this	B-NP	DT	0	_	_	_	_
17	fluorimeter	fluorimeter	I-NP	NN	0	_	_	_	_
18	yielded	yield	B-VP	VBD	0	_	_	_	_
19	significantly	significantly	B-NP	RB	0	_	_	_	_
20	higher	high	I-NP	JJR	0	_	_	_	_
21	levels	level	I-NP	NNS	0	_	_	_	_
22	than	than	B-SBAR	IN	0	_	_	_	_
23	did	do	B-VP	VBD	0	_	_	_	_
24	an	an	B-NP	DT	0	_	_	_	_
25	alternate	alternate	I-NP	JJ	0	_	_	_	_
26	extraction	extraction	I-NP	NN	0	_	_	_	_
27	method	method	I-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	Delayed	Delay	B-NP	VBN	0	_	_	_	_
2	hypersensitivity	hypersensitivity	I-NP	NN	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	man	man	B-NP	NN	0	_	_	_	_
5	:	:	O	:	0	_	_	_	_
6	effects	effect	B-NP	NNS	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	systemic	systemic	B-NP	JJ	0	_	_	_	_
9	anticoagulation	anticoagulation	I-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	three	three	B-NP	CD	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	seven	seven	I-NP	CD	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	inhalation	inhalation	B-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	2	2	B-NP	CD	0	_	_	_	_
10	ml	ml	I-NP	NN	0	_	_	_	_
11	normal	normal	I-NP	JJ	0	_	_	_	_
12	saline	saline	I-NP	NN	0	_	_	_	_
13	produced	produce	B-VP	VBD	0	_	_	_	_
14	FEV1	FEV1	B-NP	NN	0	_	_	_	_
15	falls	fall	I-NP	NNS	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	25	25	B-NP	CD	0	_	_	_	_
18	%	%	I-NP	NN	0	_	_	_	_
19	to	to	I-NP	TO	0	_	_	_	_
20	30	30	I-NP	CD	0	_	_	_	_
21	%	%	I-NP	NN	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	but	but	O	CC	0	_	_	_	_
24	these	these	B-NP	DT	0	_	_	_	_
25	falls	fall	I-NP	NNS	0	_	_	_	_
26	were	be	B-VP	VBD	0	_	_	_	_
27	not	not	O	RB	0	_	_	_	_
28	as	as	B-ADJP	RB	0	_	_	_	_
29	great	great	I-ADJP	JJ	0	_	_	_	_
30	as	as	B-PP	IN	0	_	_	_	_
31	each	each	B-NP	DT	0	_	_	_	_
32	subject	subject	I-NP	NN	0	_	_	_	_
33	's	's	B-NP	POS	0	_	_	_	_
34	reactions	reaction	I-NP	NNS	0	_	_	_	_
35	to	to	B-PP	TO	0	_	_	_	_
36	the	the	B-NP	DT	0	_	_	_	_
37	test	test	I-NP	NN	0	_	_	_	_
38	solutions	solution	I-NP	NNS	0	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	Experimental	Experimental	B-NP	JJ	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	on	on	B-PP	IN	0	_	_	_	_
4	virus	virus	B-NP	NN	0	_	_	_	_
5	excretion	excretion	I-NP	NN	0	_	_	_	_
6	and	and	O	CC	0	_	_	_	_
7	non	non	B-NP	AFX	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	arthropod	arthropod	I-NP	NN	0	_	_	_	_
10	transmission	transmission	I-NP	NN	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	Potency	Potency	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	enflurane	enflurane	B-NP	NN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	dogs	dog	B-NP	NNS	0	_	_	_	_
6	:	:	O	:	0	_	_	_	_
7	comparison	comparison	B-NP	NN	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	halothane	halothane	B-NP	NN	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	isoflurane	isoflurane	I-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	Prevention	Prevention	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	acute	acute	B-NP	JJ	0	_	_	_	_
4	paraquat	paraquat	I-NP	NN	0	_	_	_	_
5	toxicity	toxicity	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	rats	rat	B-NP	NNS	0	_	_	_	_
8	by	by	B-PP	IN	0	_	_	_	_
9	superoxide	superoxide	B-NP	NN	:::NOCLASS	_	_	_	_
10	dismutase	dismutase	I-NP	NN	:::NOCLASS	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	Measurement	Measurement	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	magnesium	magnesium	B-NP	NN	0	_	_	_	_
4	absorption	absorption	I-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	man	man	B-NP	NN	0	_	_	_	_
7	using	use	B-VP	VBG	0	_	_	_	_
8	stable	stable	B-NP	JJ	0	_	_	_	_
9	26Mg	26Mg	I-NP	NN	0	_	_	_	_
10	as	as	B-PP	IN	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	tracer	tracer	I-NP	NN	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Increased	Increase	B-NP	VBN	0	_	_	_	_
2	urinary	urinary	I-NP	JJ	0	_	_	_	_
3	riboflavin	riboflavin	I-NP	NN	0	_	_	_	_
4	excretion	excretion	I-NP	NN	0	_	_	_	_
5	resulting	result	B-VP	VBG	0	_	_	_	_
6	from	from	B-PP	IN	0	_	_	_	_
7	boric	boric	B-NP	JJ	0	_	_	_	_
8	acid	acid	I-NP	NN	0	_	_	_	_
9	ingestion	ingestion	I-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	Radionuclide	Radionuclide	B-NP	NN	0	_	_	_	_
2	angiography	angiography	I-NP	NN	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	static	static	B-NP	JJ	0	_	_	_	_
5	whole	whole	I-NP	JJ	0	_	_	_	_
6	body	body	I-NP	NN	0	_	_	_	_
7	imaging	imaging	I-NP	NN	0	_	_	_	_
8	performed	perform	B-VP	VBN	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	technetium	technetium	B-NP	NN	0	_	_	_	_
11	-	-	B-NP	HYPH	0	_	_	_	_
12	99m	99m	I-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	labeled	label	I-NP	VBN	0	_	_	_	_
15	particulates	particulate	I-NP	NNS	0	_	_	_	_
16	can	can	B-VP	MD	0	_	_	_	_
17	clearly	clearly	I-VP	RB	0	_	_	_	_
18	demonstrate	demonstrate	I-VP	VB	0	_	_	_	_
19	differential	differential	B-NP	JJ	0	_	_	_	_
20	shunting	shunting	I-NP	NN	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	patients	patient	B-NP	NNS	0	_	_	_	_
23	with	with	B-PP	IN	0	_	_	_	_
24	patent	patent	B-NP	NN	0	_	_	_	_
25	ductus	ductus	I-NP	NN	0	_	_	_	_
26	arteriosus	arteriosus	I-NP	NN	0	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	PDA	PDA	B-NP	NN	UMLS:C0226047:T023:ANAT	_	_	_	_
29	)	)	O	)	0	_	_	_	_
30	with	with	B-PP	IN	0	_	_	_	_
31	Eisenmenger	Eisenmenger	B-NP	NN	0	_	_	_	_
32	physiology	physiology	I-NP	NN	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Looming	Loom	B-VP	VBG	0	_	_	_	_
2	detectors	detector	B-NP	NNS	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	human	human	I-NP	JJ	0	_	_	_	_
6	visual	visual	I-NP	JJ	UMLS:C0587900:T023:ANAT|UMLS:C0042829:T023:ANAT	_	_	_	_
7	pathway	pathway	I-NP	NN	UMLS:C0587900:T023:ANAT|UMLS:C0042829:T023:ANAT	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Escherichia	Escherichia	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	single	single	I-NP	JJ	0	_	_	_	_
5	sero	sero	I-NP	AFX	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	anzymatic	anzymatic	I-NP	JJ	0	_	_	_	_
8	type	type	I-NP	NN	0	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	06a6b	06a6b	B-NP	NN	0	_	_	_	_
11	:	:	O	:	0	_	_	_	_
12	K13	K13	B-NP	NN	0	_	_	_	_
13	:	:	O	:	0	_	_	_	_
14	H1	H1	B-NP	NN	0	_	_	_	_
15	)	)	O	)	0	_	_	_	_
16	were	be	B-VP	VBD	0	_	_	_	_
17	isolated	isolate	I-VP	VBN	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	group	group	I-NP	NN	0	_	_	_	_
21	affection	affection	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	method	method	I-NP	NN	0	_	_	_	_
3	described	describe	B-VP	VBN	0	_	_	_	_
4	may	may	B-VP	MD	0	_	_	_	_
5	prove	prove	I-VP	VB	0	_	_	_	_
6	useful	useful	B-ADJP	JJ	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	studying	study	B-VP	VBG	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	physiology	physiology	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	nasal	nasal	I-NP	JJ	UMLS:C0028429:T023:ANAT	_	_	_	_
14	cycle	cycle	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	At	At	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	same	same	I-NP	JJ	0	_	_	_	_
4	time	time	I-NP	NN	0	_	_	_	_
5	we	we	B-NP	PRP	0	_	_	_	_
6	obtained	obtain	B-VP	VBD	0	_	_	_	_
7	easily	easily	B-NP	RB	0	_	_	_	_
8	understandable	understandable	I-NP	JJ	0	_	_	_	_
9	EEG	EEG	I-NP	NN	0	_	_	_	_
10	-	-	B-NP	HYPH	0	_	_	_	_
11	information	information	I-NP	NN	0	_	_	_	_
12	which	which	B-NP	WDT	0	_	_	_	_
13	has	have	B-VP	VBZ	0	_	_	_	_
14	never	never	I-VP	RB	0	_	_	_	_
15	previously	previously	I-VP	RB	0	_	_	_	_
16	been	be	I-VP	VBN	0	_	_	_	_
17	available	available	B-ADJP	JJ	0	_	_	_	_
18	to	to	B-PP	TO	0	_	_	_	_
19	us	us	B-NP	PRP	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Analysis	Analysis	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	liver	liver	B-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
4	biopsy	biopsy	I-NP	NN	0	_	_	_	_
5	specimens	specimen	I-NP	NNS	0	_	_	_	_
6	from	from	B-PP	IN	0	_	_	_	_
7	patients	patient	B-NP	NNS	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	hepatitis	hepatitis	B-NP	NN	UMLS:C0019159:T047:DISO|UMLS:C0019158:T047:DISO	_	_	_	_
10	showed	show	B-VP	VBD	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	large	large	I-NP	JJ	0	_	_	_	_
13	variation	variation	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	mean	mean	I-NP	JJ	0	_	_	_	_
17	iron	iron	I-NP	NN	0	_	_	_	_
18	content	content	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	liver	liver	I-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
22	ferritin	ferritin	I-NP	NN	:::NOCLASS	_	_	_	_
23	molecules	molecule	I-NP	NNS	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Female	Female	B-NP	JJ	0	_	_	_	_
2	mice	mouse	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	significantly	significantly	B-ADJP	RB	0	_	_	_	_
5	more	more	I-ADJP	RBR	0	_	_	_	_
6	resistant	resistant	I-ADJP	JJ	0	_	_	_	_
7	to	to	B-PP	TO	0	_	_	_	_
8	infection	infection	B-NP	NN	UMLS:C0021311:T047:DISO|UMLS:C0009450:T047:DISO	_	_	_	_
9	than	than	B-PP	IN	0	_	_	_	_
10	males	male	B-NP	NNS	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	During	During	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	following	follow	I-NP	VBG	0	_	_	_	_
4	9	9	I-NP	CD	0	_	_	_	_
5	1	1	I-NP	CD	0	_	_	_	_
6	/	/	B-NP	SYM	0	_	_	_	_
7	2	2	B-NP	CD	0	_	_	_	_
8	years	year	I-NP	NNS	0	_	_	_	_
9	three	three	B-NP	CD	0	_	_	_	_
10	sequential	sequential	I-NP	JJ	0	_	_	_	_
11	liver	liver	I-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
12	biopsies	biopsy	I-NP	NNS	0	_	_	_	_
13	were	be	B-VP	VBD	0	_	_	_	_
14	performed	perform	I-VP	VBN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Angiotensin	Angiotensin	B-NP	NN	:::NOCLASS	_	_	_	_
2	effect	effect	I-NP	NN	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	human	human	I-NP	JJ	0	_	_	_	_
6	kidney	kidney	I-NP	NN	UMLS:C0022646:T023:ANAT|UMLS:C0227665:T023:ANAT	_	_	_	_
7	.	.	O	.	0	_	_	_	_

1	Procion	Procion	B-NP	NN	0	_	_	_	_
2	yellow	yellow	I-NP	JJ	0	_	_	_	_
3	dye	dye	I-NP	NN	0	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	injected	inject	I-VP	VBN	0	_	_	_	_
6	intracellularly	intracellularly	B-ADVP	RB	0	_	_	_	_
7	into	into	B-PP	IN	0	_	_	_	_
8	large	large	B-NP	JJ	0	_	_	_	_
9	auditory	auditory	I-NP	JJ	0	_	_	_	_
10	fibers	fiber	I-NP	NNS	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	goldfish	goldfish	B-NP	NN	0	_	_	_	_
13	to	to	B-VP	TO	0	_	_	_	_
14	investigate	investigate	I-VP	VB	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	relationship	relationship	I-NP	NN	0	_	_	_	_
17	between	between	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	response	response	I-NP	NN	0	_	_	_	_
20	type	type	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	these	these	B-NP	DT	0	_	_	_	_
23	fibers	fiber	I-NP	NNS	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	their	their	B-NP	PRP$	0	_	_	_	_
26	site	site	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	termination	termination	B-NP	NN	0	_	_	_	_
29	in	in	B-PP	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	saccular	saccular	I-NP	JJ	0	_	_	_	_
32	macula	macula	I-NP	NN	UMLS:C0227662:T023:ANAT|UMLS:C0450295:T023:ANAT	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Incidental	Incidental	B-NP	JJ	0	_	_	_	_
2	findings	finding	I-NP	NNS	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	epidermis	epidermis	I-NP	NN	0	_	_	_	_
6	and	and	B-PP	CC	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	intraepidermal	intraepidermal	I-NP	JJ	0	_	_	_	_
10	eccrine	eccrine	I-NP	JJ	0	_	_	_	_
11	sweat	sweat	I-NP	NN	0	_	_	_	_
12	duct	duct	I-NP	NN	UMLS:C0687028:T023:ANAT|UMLS:C1550227:T023:ANAT	_	_	_	_
13	units	unit	I-NP	NNS	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Silicosis	Silicosis	B-NP	NN	UMLS:C0037116:T047:DISO	_	_	_	_
2	mortality	mortality	I-NP	NN	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	consisted	consist	B-VP	VBD	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	beading	bead	B-NP	VBG	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	strictures	stricture	B-VP	VBZ	0	_	_	_	_
7	mainly	mainly	B-ADVP	RB	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	intrahepatic	intrahepatic	I-NP	JJ	UMLS:C0682625:T023:ANAT	_	_	_	_
11	biliary	biliary	I-NP	JJ	UMLS:C0682625:T023:ANAT	_	_	_	_
12	tree	tree	I-NP	NN	UMLS:C0682625:T023:ANAT	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	IHB	IHB	B-NP	NN	0	_	_	_	_
15	)	)	O	)	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Pentane	Pentane	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	ethane	ethane	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	which	which	B-NP	WDT	0	_	_	_	_
6	arise	arise	B-VP	VBP	0	_	_	_	_
7	during	during	B-PP	IN	0	_	_	_	_
8	lipid	lipid	B-NP	NN	0	_	_	_	_
9	peroxidation	peroxidation	I-NP	NN	0	_	_	_	_
10	in	in	B-ADVP	FW	0	_	_	_	_
11	vivo	vivo	I-ADVP	FW	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	were	be	B-VP	VBD	0	_	_	_	_
14	measured	measure	I-VP	VBN	0	_	_	_	_
15	by	by	B-PP	IN	0	_	_	_	_
16	gas	gas	B-NP	NN	0	_	_	_	_
17	chromatography	chromatography	I-NP	NN	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	breath	breath	B-NP	NN	0	_	_	_	_
20	samples	sample	I-NP	NNS	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	rats	rat	B-NP	NNS	0	_	_	_	_
23	fed	feed	B-VP	VBN	UMLS:C0342895:T047:DISO	_	_	_	_
24	for	for	B-PP	IN	0	_	_	_	_
25	8	8	B-NP	CD	0	_	_	_	_
26	weeks	week	I-NP	NNS	0	_	_	_	_
27	a	a	B-NP	DT	0	_	_	_	_
28	vitamin	vitamin	I-NP	NN	0	_	_	_	_
29	E	E	I-NP	NN	0	_	_	_	_
30	-	-	B-NP	HYPH	0	_	_	_	_
31	deficient	deficient	I-NP	JJ	0	_	_	_	_
32	diet	diet	I-NP	NN	0	_	_	_	_
33	to	to	B-PP	TO	0	_	_	_	_
34	which	which	B-NP	WDT	0	_	_	_	_
35	had	have	B-VP	VBD	0	_	_	_	_
36	been	be	I-VP	VBN	0	_	_	_	_
37	added	add	I-VP	VBN	0	_	_	_	_
38	0	0	B-NP	CD	0	_	_	_	_
39	,	,	I-NP	,	0	_	_	_	_
40	11	11	I-NP	CD	0	_	_	_	_
41	,	,	O	,	0	_	_	_	_
42	or	or	O	CC	0	_	_	_	_
43	40	40	B-NP	CD	0	_	_	_	_
44	IU	IU	I-NP	NN	0	_	_	_	_
45	vitamin	vitamin	I-NP	NN	0	_	_	_	_
46	E	E	I-NP	NN	0	_	_	_	_
47	acetate	acetate	I-NP	NN	0	_	_	_	_
48	per	per	B-PP	IN	0	_	_	_	_
49	kg	kg	B-NP	NN	0	_	_	_	_
50	.	.	O	.	0	_	_	_	_

1	Thromboplastic	Thromboplastic	B-NP	JJ	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	fibrynolytic	fibrynolytic	I-NP	JJ	0	_	_	_	_
4	activity	activity	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	blood	blood	I-NP	NN	0	_	_	_	_
8	after	after	B-PP	IN	0	_	_	_	_
9	administration	administration	B-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	intralipid	intralipid	B-NP	NN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	men	man	B-NP	NNS	0	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	history	history	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	myocardial	myocardial	B-NP	JJ	UMLS:C0027051:T047:DISO	_	_	_	_
18	infarction	infarction	I-NP	NN	UMLS:C0027051:T047:DISO	_	_	_	_
19	up	up	B-NP	IN	0	_	_	_	_
20	to	to	I-NP	TO	0	_	_	_	_
21	45	45	I-NP	CD	0	_	_	_	_
22	year	year	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	life	life	B-NP	NN	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	authors	author	I-NP	NNS	0	_	_	_	_
3	report	report	B-VP	VBP	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	clinicopathologic	clinicopathologic	I-NP	JJ	0	_	_	_	_
6	findings	finding	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	four	four	B-NP	CD	0	_	_	_	_
9	cases	case	I-NP	NNS	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	adult	adult	B-NP	JJ	0	_	_	_	_
12	women	woman	I-NP	NNS	0	_	_	_	_
13	with	with	B-PP	IN	0	_	_	_	_
14	rhabdomyosarcomas	rhabdomyosarcoma	B-NP	NNS	0	_	_	_	_
15	that	that	B-NP	WDT	0	_	_	_	_
16	originated	originate	B-VP	VBD	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	endometrium	endometrium	I-NP	NN	UMLS:C0014180:T023:ANAT	_	_	_	_
20	or	or	I-NP	CC	0	_	_	_	_
21	cervix	cervix	I-NP	NN	UMLS:C0007874:T023:ANAT	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	or	or	O	CC	0	_	_	_	_
24	both	both	B-NP	DT	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effect	effect	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	pure	pure	B-NP	JJ	0	_	_	_	_
5	natural	natural	I-NP	JJ	0	_	_	_	_
6	porcine	porcine	I-NP	JJ	:::NOCLASS	_	_	_	_
7	secretin	secretin	I-NP	NN	:::NOCLASS	_	_	_	_
8	on	on	B-PP	IN	0	_	_	_	_
9	endocrine	endocrine	B-NP	JJ	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	exocrine	exocrine	I-NP	JJ	0	_	_	_	_
12	pancreatic	pancreatic	I-NP	JJ	UMLS:C0030274:T023:ANAT	_	_	_	_
13	secretion	secretion	I-NP	NN	0	_	_	_	_
14	was	be	B-VP	VBD	0	_	_	_	_
15	studied	study	I-VP	VBN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	totally	totally	I-NP	RB	0	_	_	_	_
19	isolated	isolate	I-NP	VBN	0	_	_	_	_
20	perfused	perfuse	I-NP	VBN	0	_	_	_	_
21	porcine	porcine	I-NP	JJ	0	_	_	_	_
22	pancreas	pancreas	I-NP	NN	UMLS:C0030274:T023:ANAT	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Biometric	Biometric	B-NP	JJ	0	_	_	_	_
2	analysis	analysis	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	intraocular	intraocular	B-NP	JJ	0	_	_	_	_
5	lens	lens	I-NP	NN	UMLS:C0023317:T023:ANAT	_	_	_	_
6	power	power	I-NP	NN	0	_	_	_	_
7	required	require	B-VP	VBN	0	_	_	_	_
8	to	to	I-VP	TO	0	_	_	_	_
9	produce	produce	I-VP	VB	0	_	_	_	_
10	emmetropia	emmetropia	B-NP	NN	0	_	_	_	_
11	:	:	O	:	0	_	_	_	_
12	results	result	B-NP	NNS	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	450	450	B-NP	CD	0	_	_	_	_
15	implants	implant	I-NP	NNS	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Urine	Urine	B-NP	NN	0	_	_	_	_
2	antibodies	antibody	I-NP	NNS	0	_	_	_	_
3	could	could	B-VP	MD	0	_	_	_	_
4	not	not	I-VP	RB	0	_	_	_	_
5	be	be	I-VP	VB	0	_	_	_	_
6	demonstrated	demonstrate	I-VP	VBN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	any	any	B-NP	DT	0	_	_	_	_
9	other	other	I-NP	JJ	0	_	_	_	_
10	cases	case	I-NP	NNS	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	Althoug	Althoug	B-NP	NN	0	_	_	_	_
2	RBF	RBF	I-NP	NN	0	_	_	_	_
3	tended	tend	B-VP	VBD	0	_	_	_	_
4	to	to	I-VP	TO	0	_	_	_	_
5	increase	increase	I-VP	VB	0	_	_	_	_
6	after	after	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	therapy	therapy	I-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	there	there	B-NP	EX	0	_	_	_	_
11	was	be	B-VP	VBD	0	_	_	_	_
12	no	no	B-NP	DT	0	_	_	_	_
13	statistically	statistically	I-NP	RB	0	_	_	_	_
14	significant	significant	I-NP	JJ	0	_	_	_	_
15	change	change	I-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	RBF	RBF	B-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	GFR	GFR	B-NP	NN	0	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	cardiac	cardiac	B-NP	JJ	UMLS:C0018787:T023:ANAT	_	_	_	_
22	output	output	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	99mTc	99mTc	B-NP	NN	0	_	_	_	_
2	phytate	phytate	I-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	198Au	198Au	B-NP	NNP	0	_	_	_	_
5	colloid	colloid	I-NP	NN	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	99mTc	99mTc	B-NP	NN	0	_	_	_	_
9	antimony	antimony	I-NP	JJ	0	_	_	_	_
10	sulfide	sulfide	I-NP	NN	0	_	_	_	_
11	have	have	B-VP	VBP	0	_	_	_	_
12	been	be	I-VP	VBN	0	_	_	_	_
13	used	use	I-VP	VBN	0	_	_	_	_
14	;	;	O	:	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	last	last	I-NP	JJ	0	_	_	_	_
17	appears	appear	B-VP	VBZ	0	_	_	_	_
18	to	to	I-VP	TO	0	_	_	_	_
19	have	have	I-VP	VB	0	_	_	_	_
20	been	be	I-VP	VBN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	most	most	I-NP	RBS	0	_	_	_	_
23	satisfactory	satisfactory	I-NP	JJ	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Six	Six	B-NP	CD	0	_	_	_	_
2	patients	patient	I-NP	NNS	0	_	_	_	_
3	with	with	B-PP	IN	0	_	_	_	_
4	glomerulonephritis	glomerulonephritis	B-NP	NN	UMLS:C0017658:T047:DISO	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	association	association	B-NP	NN	0	_	_	_	_
7	with	with	B-PP	IN	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	ventriculovascular	ventriculovascular	I-NP	JJ	0	_	_	_	_
10	shunt	shunt	I-NP	NN	0	_	_	_	_
11	were	be	B-VP	VBD	0	_	_	_	_
12	treated	treat	I-VP	VBN	0	_	_	_	_
13	with	with	B-PP	IN	0	_	_	_	_
14	three	three	B-NP	CD	0	_	_	_	_
15	basic	basic	I-NP	JJ	0	_	_	_	_
16	modes	mode	I-NP	NNS	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	therapy	therapy	B-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	mass	mass	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	UO2	UO2	B-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	extrapulmonary	extrapulmonary	I-NP	JJ	0	_	_	_	_
8	bronchi	bronchi	I-NP	NN	UMLS:C0006255:T023:ANAT	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	first	first	B-NP	JJ	0	_	_	_	_
11	bifurcation	bifurcation	I-NP	NN	0	_	_	_	_
12	decreased	decrease	B-VP	VBD	0	_	_	_	_
13	more	more	B-ADVP	RBR	0	_	_	_	_
14	slowly	slowly	I-ADVP	RB	0	_	_	_	_
15	over	over	B-NP	IN	0	_	_	_	_
16	0	0	I-NP	CD	0	_	_	_	_
17	-	-	I-NP	HYPH	0	_	_	_	_
18	-	-	I-NP	SYM	0	_	_	_	_
19	8	8	I-NP	CD	0	_	_	_	_
20	d	d	I-NP	NN	0	_	_	_	_
21	after	after	B-PP	IN	0	_	_	_	_
22	inhalation	inhalation	B-NP	NN	0	_	_	_	_
23	than	than	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	corresponding	correspond	I-NP	VBG	0	_	_	_	_
26	mass	mass	I-NP	NN	0	_	_	_	_
27	on	on	B-PP	IN	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	trachea	trachea	I-NP	NN	UMLS:C0040578:T023:ANAT	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Synovial	Synovial	B-NP	JJ	UMLS:C0085648:T047:DISO	_	_	_	_
2	cysts	cyst	I-NP	NNS	UMLS:C0085648:T047:DISO	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	hip	hip	I-NP	NN	UMLS:C0019552:T023:ANAT|UMLS:C0022122:T023:ANAT	_	_	_	_
6	joint	joint	I-NP	NN	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	suspected	suspect	I-NP	VBN	0	_	_	_	_
3	hypothalamic	hypothalamic	I-NP	JJ	UMLS:C0751230:T047:DISO|UMLS:C0020663:T023:ANAT	_	_	_	_
4	dysfunction	dysfunction	I-NP	NN	UMLS:C0751230:T047:DISO	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	slightly	slightly	I-NP	RB	0	_	_	_	_
8	impaired	impaired	I-NP	JJ	0	_	_	_	_
9	pituitary	pituitary	I-NP	JJ	UMLS:C0032005:T023:ANAT	_	_	_	_
10	function	function	I-NP	NN	0	_	_	_	_
11	manifested	manifest	B-VP	VBN	0	_	_	_	_
12	as	as	B-PP	IN	0	_	_	_	_
13	GH	GH	B-NP	NN	:::NOCLASS	_	_	_	_
14	deficiency	deficiency	I-NP	NN	0	_	_	_	_
15	were	be	B-VP	VBD	0	_	_	_	_
16	their	their	B-NP	PRP$	0	_	_	_	_
17	common	common	I-NP	JJ	0	_	_	_	_
18	endocrinological	endocrinological	I-NP	JJ	0	_	_	_	_
19	features	feature	I-NP	NNS	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	sharp	sharp	I-NP	JJ	0	_	_	_	_
3	outbreak	outbreak	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	influenza	influenza	B-NP	NN	UMLS:C0021400:T047:DISO	_	_	_	_
6	A	A	I-NP	NN	0	_	_	_	_
7	occurred	occur	B-VP	VBD	0	_	_	_	_
8	on	on	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	base	base	I-NP	NN	0	_	_	_	_
11	during	during	B-PP	IN	0	_	_	_	_
12	February	February	B-NP	NNP	0	_	_	_	_
13	that	that	B-NP	WDT	0	_	_	_	_
14	was	be	B-VP	VBD	0	_	_	_	_
15	due	due	B-ADJP	JJ	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	an	an	B-NP	DT	0	_	_	_	_
18	A	A	I-NP	NN	0	_	_	_	_
19	/	/	I-NP	SYM	0	_	_	_	_
20	Texas	Texas	I-NP	NN	0	_	_	_	_
21	/	/	B-NP	SYM	0	_	_	_	_
22	1	1	I-NP	CD	0	_	_	_	_
23	/	/	I-NP	SYM	0	_	_	_	_
24	77	77	I-NP	CD	0	_	_	_	_
25	-	-	I-NP	HYPH	0	_	_	_	_
26	like	like	I-NP	JJ	0	_	_	_	_
27	virus	virus	I-NP	NN	0	_	_	_	_
28	,	,	O	,	0	_	_	_	_
29	a	a	B-NP	DT	0	_	_	_	_
30	variant	variant	I-NP	NN	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	A	A	I-NP	NN	0	_	_	_	_
34	/	/	I-NP	SYM	0	_	_	_	_
35	Victoria	Victoria	I-NP	NN	0	_	_	_	_
36	/	/	B-NP	SYM	0	_	_	_	_
37	3	3	I-NP	CD	0	_	_	_	_
38	/	/	I-NP	SYM	0	_	_	_	_
39	75	75	I-NP	CD	0	_	_	_	_
40	prototpye	prototpye	I-NP	NN	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	Because	Because	B-SBAR	IN	0	_	_	_	_
2	decreases	decrease	B-NP	NNS	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	disfluency	disfluency	I-NP	NN	0	_	_	_	_
6	rates	rate	I-NP	NNS	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	stutterers	stutterer	B-NP	NNS	0	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	observed	observe	I-VP	VBN	0	_	_	_	_
11	during	during	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	presentation	presentation	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	all	all	B-NP	DT	0	_	_	_	_
16	three	three	I-NP	CD	0	_	_	_	_
17	stimulus	stimulus	I-NP	NN	0	_	_	_	_
18	words	word	I-NP	NNS	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	data	datum	I-NP	NNS	0	_	_	_	_
22	failed	fail	B-VP	VBD	0	_	_	_	_
23	to	to	I-VP	TO	0	_	_	_	_
24	support	support	I-VP	VB	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	operant	operant	I-NP	JJ	0	_	_	_	_
27	model	model	I-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	Effect	Effect	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	time	time	B-NP	NN	0	_	_	_	_
4	and	and	I-NP	CC	0	_	_	_	_
5	dose	dose	I-NP	NN	0	_	_	_	_
6	on	on	B-PP	IN	0	_	_	_	_
7	alterations	alteration	B-NP	NNS	0	_	_	_	_
8	following	follow	B-PP	VBG	0	_	_	_	_
9	inhalation	inhalation	B-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	plutonium	plutonium	B-NP	NN	0	_	_	_	_
12	-	-	B-NP	HYPH	0	_	_	_	_
13	239	239	I-NP	CD	0	_	_	_	_
14	dioxide	dioxide	I-NP	NN	0	_	_	_	_
15	aerosol	aerosol	I-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	rat	rat	B-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	biopsies	biopsy	B-NP	NNS	0	_	_	_	_
3	CK	CK	I-NP	NN	:::NOCLASS	_	_	_	_
4	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
5	MB	MB	I-NP	NN	:::NOCLASS	_	_	_	_
6	fraction	fraction	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	total	total	B-NP	JJ	0	_	_	_	_
9	myocardial	myocardial	I-NP	JJ	0	_	_	_	_
10	CPK	CPK	I-NP	NN	:::NOCLASS	_	_	_	_
11	was	be	B-VP	VBD	0	_	_	_	_
12	37	37	B-NP	CD	0	_	_	_	_
13	%	%	I-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	total	total	I-NP	JJ	:::NOCLASS	_	_	_	_
17	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
18	CPK	CPK	I-NP	NN	:::NOCLASS	_	_	_	_
19	activity	activity	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	human	human	B-NP	JJ	0	_	_	_	_
22	skeletal	skeletal	I-NP	JJ	UMLS:C0242692:T023:ANAT	_	_	_	_
23	muscles	muscle	I-NP	NNS	UMLS:C0242692:T023:ANAT	_	_	_	_
24	still	still	B-ADVP	RB	0	_	_	_	_
25	shows	show	B-VP	VBZ	0	_	_	_	_
26	a	a	B-NP	DT	0	_	_	_	_
27	5	5	I-NP	CD	0	_	_	_	_
28	%	%	I-NP	NN	0	_	_	_	_
29	fraction	fraction	I-NP	NN	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	CK	CK	B-NP	NN	:::NOCLASS	_	_	_	_
32	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
33	MB	MB	I-NP	NN	:::NOCLASS	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Value	Value	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	determination	determination	B-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	alkaline	alkaline	B-NP	NN	:::NOCLASS	_	_	_	_
6	phosphatase	phosphatase	I-NP	NN	:::NOCLASS	_	_	_	_
7	isoenzymes	isoenzyme	I-NP	NNS	:::NOCLASS	_	_	_	_
8	for	for	B-PP	IN	0	_	_	_	_
9	differential	differential	B-NP	JJ	0	_	_	_	_
10	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	obstructive	obstructive	B-NP	JJ	UMLS:C0022354:T047:DISO	_	_	_	_
13	jaundice	jaundice	I-NP	NN	UMLS:C0022354:T047:DISO	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	biliary	biliary	B-NP	JJ	UMLS:C0023892:T047:DISO	_	_	_	_
16	liver	liver	I-NP	NN	UMLS:C0023892:T047:DISO|UMLS:C0023884:T023:ANAT	_	_	_	_
17	cirrhosis	cirrhosis	I-NP	NN	UMLS:C0023892:T047:DISO	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	one	one	I-NP	CD	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	way	way	I-NP	NN	0	_	_	_	_
5	analysis	analysis	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	variance	variance	B-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	performed	perform	B-VP	VBN	0	_	_	_	_
10	separately	separately	B-ADVP	RB	0	_	_	_	_
11	for	for	B-PP	IN	0	_	_	_	_
12	men	man	B-NP	NNS	0	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	women	woman	I-NP	NNS	0	_	_	_	_
15	for	for	B-PP	IN	0	_	_	_	_
16	differences	difference	B-NP	NNS	0	_	_	_	_
17	among	among	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	three	three	I-NP	CD	0	_	_	_	_
20	phobic	phobic	I-NP	JJ	0	_	_	_	_
21	groups	group	I-NP	NNS	0	_	_	_	_
22	on	on	B-PP	IN	0	_	_	_	_
23	field	field	B-NP	NN	0	_	_	_	_
24	dependence	dependence	I-NP	NN	0	_	_	_	_
25	,	,	O	,	0	_	_	_	_
26	showed	show	B-VP	VBD	0	_	_	_	_
27	significance	significance	B-NP	NN	0	_	_	_	_
28	(	(	O	(	0	_	_	_	_
29	rho	rho	B-NP	NN	0	_	_	_	_
30	less	less	B-ADJP	JJR	0	_	_	_	_
31	than	than	B-PP	IN	0	_	_	_	_
32	.	.	B-NP	.	0	_	_	_	_
33	05	05	I-NP	CD	0	_	_	_	_
34	)	)	O	)	0	_	_	_	_
35	for	for	B-PP	IN	0	_	_	_	_
36	the	the	B-NP	DT	0	_	_	_	_
37	females	female	I-NP	NNS	0	_	_	_	_
38	,	,	O	,	0	_	_	_	_
39	with	with	B-PP	IN	0	_	_	_	_
40	the	the	B-NP	DT	0	_	_	_	_
41	famale	famale	I-NP	JJ	0	_	_	_	_
42	agoraphobic	agoraphobic	I-NP	JJ	0	_	_	_	_
43	being	be	B-VP	VBG	0	_	_	_	_
44	more	more	B-NP	JJR	0	_	_	_	_
45	field	field	I-NP	NN	0	_	_	_	_
46	dependent	dependent	B-ADJP	JJ	0	_	_	_	_
47	than	than	B-PP	IN	0	_	_	_	_
48	the	the	B-NP	DT	0	_	_	_	_
49	female	female	I-NP	JJ	0	_	_	_	_
50	simple	simple	I-NP	JJ	0	_	_	_	_
51	phobic	phobic	I-NP	JJ	0	_	_	_	_
52	groups	group	I-NP	NNS	0	_	_	_	_
53	,	,	O	,	0	_	_	_	_
54	but	but	O	CC	0	_	_	_	_
55	not	not	O	RB	0	_	_	_	_
56	for	for	B-PP	IN	0	_	_	_	_
57	the	the	B-NP	DT	0	_	_	_	_
58	males	male	I-NP	NNS	0	_	_	_	_
59	.	.	O	.	0	_	_	_	_

1	Several	Several	B-NP	JJ	0	_	_	_	_
2	free	free	I-NP	JJ	0	_	_	_	_
3	2nd	2nd	I-NP	CD	0	_	_	_	_
4	-	-	I-NP	HYPH	0	_	_	_	_
5	generation	generation	I-NP	NN	0	_	_	_	_
6	schizonts	schizont	I-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	which	which	B-NP	WDT	0	_	_	_	_
9	varied	vary	B-VP	VBD	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	diameter	diameter	B-NP	NN	0	_	_	_	_
12	from	from	B-PP	IN	0	_	_	_	_
13	11	11	B-NP	CD	0	_	_	_	_
14	to	to	B-PP	TO	0	_	_	_	_
15	21	21	B-NP	CD	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_
17	6	6	B-NP	CD	0	_	_	_	_
18	micrometer	micrometer	I-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	were	be	B-VP	VBD	0	_	_	_	_
21	found	find	I-VP	VBN	0	_	_	_	_
22	on	on	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	epithelial	epithelial	I-NP	JJ	0	_	_	_	_
25	surface	surface	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	cecum	cecum	I-NP	NN	UMLS:C0007531:T023:ANAT	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	calculated	calculate	I-NP	VBN	0	_	_	_	_
3	pD2	pD2	I-NP	NN	0	_	_	_	_
4	values	value	I-NP	NNS	0	_	_	_	_
5	were	be	B-VP	VBD	0	_	_	_	_
6	8	8	B-NP	CD	0	_	_	_	_
7	.	.	I-NP	.	0	_	_	_	_
8	8	8	I-NP	CD	0	_	_	_	_
9	for	for	B-PP	IN	0	_	_	_	_
10	E	E	B-NP	NN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	8	8	B-NP	CD	0	_	_	_	_
13	.	.	I-NP	.	0	_	_	_	_
14	6	6	I-NP	CD	0	_	_	_	_
15	for	for	B-PP	IN	0	_	_	_	_
16	DHE	DHE	B-NP	NN	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	6	6	B-NP	CD	0	_	_	_	_
19	.	.	I-NP	.	0	_	_	_	_
20	6	6	I-NP	CD	0	_	_	_	_
21	for	for	B-PP	IN	0	_	_	_	_
22	M	M	B-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Newcastle	Newcastle	B-NP	JJ	UMLS:C0027983:T047:DISO	_	_	_	_
2	disease	disease	I-NP	NN	UMLS:C0027983:T047:DISO	_	_	_	_
3	virus	virus	I-NP	NN	0	_	_	_	_
4	surveillance	surveillance	I-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	Hong	Hong	B-NP	NNP	0	_	_	_	_
7	Kong	Kong	I-NP	NNP	0	_	_	_	_
8	on	on	B-PP	IN	0	_	_	_	_
9	local	local	B-NP	JJ	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	imported	import	I-NP	VBN	0	_	_	_	_
12	poultry	poultry	I-NP	NN	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	postulated	postulate	I-VP	VBN	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	persistent	persistent	B-NP	JJ	0	_	_	_	_
6	challenge	challenge	I-NP	NN	0	_	_	_	_
7	by	by	B-PP	IN	0	_	_	_	_
8	M	M	B-NP	NN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_
10	leprae	leprae	B-NP	NN	0	_	_	_	_
11	or	or	O	CC	0	_	_	_	_
12	its	its	B-NP	PRP$	0	_	_	_	_
13	antigens	antigen	I-NP	NNS	0	_	_	_	_
14	to	to	B-PP	TO	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	IgA	IgA	I-NP	NN	:::NOCLASS	_	_	_	_
17	immunocytes	immunocyte	I-NP	NNS	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	intestinal	intestinal	I-NP	JJ	UMLS:C0021853:T023:ANAT	_	_	_	_
21	epithelium	epithelium	I-NP	NN	0	_	_	_	_
22	might	might	B-VP	MD	0	_	_	_	_
23	have	have	I-VP	VB	0	_	_	_	_
24	induced	induce	I-VP	VBN	0	_	_	_	_
25	tolerance	tolerance	B-NP	NN	0	_	_	_	_
26	leading	lead	B-VP	VBG	0	_	_	_	_
27	to	to	B-PP	TO	0	_	_	_	_
28	IgA	IgA	B-NP	NN	UMLS:C0162538:T047:DISO|:::NOCLASS	_	_	_	_
29	deficiency	deficiency	I-NP	NN	UMLS:C0162538:T047:DISO	_	_	_	_
30	and	and	O	CC	0	_	_	_	_
31	subsequent	subsequent	B-NP	JJ	0	_	_	_	_
32	subtotal	subtotal	I-NP	JJ	0	_	_	_	_
33	atrophy	atrophy	I-NP	NN	0	_	_	_	_
34	of	of	B-PP	IN	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	intestinal	intestinal	I-NP	JJ	UMLS:C0227266:T023:ANAT	_	_	_	_
37	villi	villus	I-NP	NNS	UMLS:C0227266:T023:ANAT	_	_	_	_
38	in	in	B-PP	IN	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	patients	patient	I-NP	NNS	0	_	_	_	_
41	with	with	B-PP	IN	0	_	_	_	_
42	lepromatous	lepromatous	B-NP	JJ	UMLS:C0023348:T047:DISO	_	_	_	_
43	leprosy	leprosy	I-NP	NN	UMLS:C0023348:T047:DISO	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	Treatment	Treatment	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	hypertension	hypertension	B-NP	NN	UMLS:C0020538:T047:DISO	_	_	_	_
4	with	with	B-PP	IN	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	combination	combination	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	adrenergic	adrenergic	I-NP	JJ	:::NOCLASS	_	_	_	_
10	beta	beta	I-NP	NN	:::NOCLASS	_	_	_	_
11	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
12	blockader	blockader	I-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	obsidan	obsidan	B-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	and	and	O	CC	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	vasodilator	vasodilator	I-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	apressin	apressin	B-NP	NN	0	_	_	_	_

1	Orthop	Orthop	B-NP	NNP	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	Thyroid	Thyroid	B-NP	JJ	UMLS:C0040128:T047:DISO|UMLS:C0040132:T023:ANAT	_	_	_	_
2	disease	disease	I-NP	NN	UMLS:C0040128:T047:DISO	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	pregnancy	pregnancy	B-NP	NN	0	_	_	_	_
5	.	.	O	.	0	_	_	_	_

1	Residues	Residue	B-NP	NNS	0	_	_	_	_
2	removed	remove	B-VP	VBN	0	_	_	_	_
3	from	from	B-PP	IN	0	_	_	_	_
4	transcripts	transcript	B-NP	NNS	0	_	_	_	_
5	by	by	B-PP	IN	0	_	_	_	_
6	splicing	splicing	B-NP	NN	0	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	identified	identify	I-VP	VBN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	To	To	B-VP	TO	0	_	_	_	_
2	minimize	minimize	I-VP	VB	0	_	_	_	_
3	reflux	reflux	B-NP	NN	UMLS:C0017168:T047:DISO	_	_	_	_
4	into	into	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	blind	blind	I-NP	JJ	UMLS:C0456909:T047:DISO	_	_	_	_
7	loop	loop	I-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	number	number	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	technical	technical	B-NP	JJ	0	_	_	_	_
13	steps	step	I-NP	NNS	0	_	_	_	_
14	are	be	B-VP	VBP	0	_	_	_	_
15	considered	consider	I-VP	VBN	0	_	_	_	_
16	indispensable	indispensable	B-ADJP	JJ	0	_	_	_	_
17	:	:	O	:	0	_	_	_	_
18	1	1	B-LST	LS	0	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	fluted	fluted	B-NP	JJ	0	_	_	_	_
21	section	section	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	jejunal	jejunal	I-NP	JJ	UMLS:C0022378:T023:ANAT	_	_	_	_
25	stump	stump	I-NP	NN	0	_	_	_	_
26	;	;	O	:	0	_	_	_	_
27	2	2	B-LST	LS	0	_	_	_	_
28	)	)	O	)	0	_	_	_	_
29	isoperistaltic	isoperistaltic	B-NP	JJ	0	_	_	_	_
30	construction	construction	I-NP	NN	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	anastomosis	anastomosis	I-NP	NN	0	_	_	_	_
34	and	and	O	CC	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	particularly	particularly	B-ADVP	RB	0	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	3	3	B-LST	LS	0	_	_	_	_
39	)	)	O	)	0	_	_	_	_
40	the	the	B-NP	DT	0	_	_	_	_
41	creation	creation	I-NP	NN	0	_	_	_	_
42	of	of	B-PP	IN	0	_	_	_	_
43	a	a	B-NP	DT	0	_	_	_	_
44	single	single	I-NP	JJ	0	_	_	_	_
45	or	or	I-NP	CC	0	_	_	_	_
46	double	double	I-NP	JJ	0	_	_	_	_
47	valve	valve	I-NP	NN	UMLS:C1186983:T023:ANAT	_	_	_	_
48	system	system	I-NP	NN	0	_	_	_	_
49	upstream	upstream	B-ADJP	JJ	0	_	_	_	_
50	from	from	B-PP	IN	0	_	_	_	_
51	the	the	B-NP	DT	0	_	_	_	_
52	anastomosis	anastomosis	I-NP	NN	0	_	_	_	_
53	by	by	B-PP	IN	0	_	_	_	_
54	spiral	spiral	B-NP	JJ	0	_	_	_	_
55	introflexion	introflexion	I-NP	NN	0	_	_	_	_
56	of	of	B-PP	IN	0	_	_	_	_
57	the	the	B-NP	DT	0	_	_	_	_
58	mucosa	mucosa	I-NP	NN	0	_	_	_	_
59	using	use	B-VP	VBG	0	_	_	_	_
60	seroserous	seroserous	B-NP	JJ	0	_	_	_	_
61	stitches	stitch	I-NP	NNS	0	_	_	_	_
62	parallel	parallel	B-ADJP	JJ	0	_	_	_	_
63	and	and	O	CC	0	_	_	_	_
64	perpendicular	perpendicular	B-ADJP	JJ	0	_	_	_	_
65	to	to	B-PP	TO	0	_	_	_	_
66	the	the	B-NP	DT	0	_	_	_	_
67	ileal	ileal	I-NP	JJ	UMLS:C0020885:T023:ANAT	_	_	_	_
68	lumen	lumen	I-NP	NN	0	_	_	_	_
69	.	.	O	.	0	_	_	_	_

1	At	At	B-PP	IN	0	_	_	_	_
2	this	this	B-NP	DT	0	_	_	_	_
3	stage	stage	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	eventual	eventual	I-NP	JJ	0	_	_	_	_
7	high	high	I-NP	JJ	0	_	_	_	_
8	mortality	mortality	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	acute	acute	B-NP	JJ	0	_	_	_	_
11	ischemia	ischemia	I-NP	NN	UMLS:C0022116:T047:DISO	_	_	_	_
12	is	be	B-VP	VBZ	0	_	_	_	_
13	established	establish	I-VP	VBN	0	_	_	_	_
14	whatever	whatever	B-NP	WDT	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	urgency	urgency	I-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	operation	operation	I-NP	NN	0	_	_	_	_
20	or	or	O	CC	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	skill	skill	I-NP	NN	0	_	_	_	_
23	with	with	B-PP	IN	0	_	_	_	_
24	which	which	B-NP	WDT	0	_	_	_	_
25	it	it	B-NP	PRP	0	_	_	_	_
26	is	be	B-VP	VBZ	0	_	_	_	_
27	performed	perform	I-VP	VBN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	Pathogens	Pathogen	B-NP	NNS	0	_	_	_	_
2	(	(	O	(	0	_	_	_	_
3	Staphylococcus	Staphylococcus	B-NP	FW	0	_	_	_	_
4	aureus	aureus	I-NP	FW	0	_	_	_	_
5	or	or	O	CC	0	_	_	_	_
6	Gram	Gram	B-NP	NN	0	_	_	_	_
7	-	-	B-NP	HYPH	0	_	_	_	_
8	negative	negative	I-NP	JJ	0	_	_	_	_
9	bacilli	bacilli	I-NP	NNS	0	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	were	be	B-VP	VBD	0	_	_	_	_
12	isolated	isolate	I-VP	VBN	0	_	_	_	_
13	from	from	B-PP	IN	0	_	_	_	_
14	only	only	B-NP	RB	0	_	_	_	_
15	one	one	I-NP	CD	0	_	_	_	_
16	member	member	I-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	staff	staff	B-NP	NN	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	small	small	B-NP	JJ	0	_	_	_	_
21	numbers	number	I-NP	NNS	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	irregularly	irregularly	B-VP	RB	0	_	_	_	_
24	and	and	I-VP	CC	0	_	_	_	_
25	rarely	rarely	I-VP	RB	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	large	large	B-NP	JJ	0	_	_	_	_
28	numbers	number	I-NP	NNS	0	_	_	_	_
29	from	from	B-PP	IN	0	_	_	_	_
30	patients	patient	B-NP	NNS	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	histochemistry	histochemistry	I-NP	NN	0	_	_	_	_
3	and	and	I-NP	CC	0	_	_	_	_
4	ultrastructure	ultrastructure	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	calcified	calcify	B-NP	VBN	0	_	_	_	_
7	cerebellar	cerebellar	I-NP	JJ	UMLS:C0007765:T023:ANAT	_	_	_	_
8	deposits	deposit	I-NP	NNS	0	_	_	_	_
9	described	describe	B-VP	VBN	0	_	_	_	_
10	by	by	B-PP	IN	0	_	_	_	_
11	Tonge	Tonge	B-NP	NNP	0	_	_	_	_
12	et	et	I-NP	FW	0	_	_	_	_
13	al	al	I-NP	FW	UMLS:C0268381:T047:DISO	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	36	36	I-NP	CD	0	_	_	_	_
3	year	year	I-NP	NN	0	_	_	_	_
4	-	-	O	HYPH	0	_	_	_	_
5	old	old	B-NP	JJ	0	_	_	_	_
6	woman	woman	I-NP	NN	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	given	give	I-VP	VBN	0	_	_	_	_
9	Ergotamine	Ergotamine	B-NP	NN	0	_	_	_	_
10	Tartrate	Tartrate	I-NP	NN	0	_	_	_	_
11	4	4	I-NP	CD	0	_	_	_	_
12	.	.	I-NP	.	0	_	_	_	_
13	5	5	I-NP	CD	0	_	_	_	_
14	mg	mg	I-NP	NN	0	_	_	_	_
15	p	p	I-NP	NN	0	_	_	_	_
16	.	.	I-NP	.	0	_	_	_	_
17	d	d	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_
19	during	during	B-PP	IN	0	_	_	_	_
20	seven	seven	B-NP	CD	0	_	_	_	_
21	days	day	I-NP	NNS	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	after	after	B-PP	IN	0	_	_	_	_
24	an	an	B-NP	DT	0	_	_	_	_
25	abortion	abortion	I-NP	NN	0	_	_	_	_
26	(	(	O	(	0	_	_	_	_
27	a	a	B-NP	DT	0	_	_	_	_
28	still	still	I-NP	RB	0	_	_	_	_
29	birth	birth	I-NP	NN	0	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Reaction	Reaction	B-NP	NN	0	_	_	_	_
2	times	time	I-NP	NNS	0	_	_	_	_
3	to	to	B-PP	TO	0	_	_	_	_
4	tachistoscopically	tachistoscopically	B-NP	RB	0	_	_	_	_
5	presented	present	I-NP	VBN	0	_	_	_	_
6	stimuli	stimulus	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	diabetics	diabetic	B-NP	NNS	0	_	_	_	_

1	Two	Two	B-NP	CD	0	_	_	_	_
2	out	out	B-PP	IN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	five	five	B-NP	CD	0	_	_	_	_
5	patients	patient	I-NP	NNS	0	_	_	_	_
6	undergoing	undergo	B-VP	VBG	0	_	_	_	_
7	selective	selective	B-NP	JJ	0	_	_	_	_
8	spinal	spinal	I-NP	JJ	0	_	_	_	_
9	arteriography	arteriography	I-NP	NN	0	_	_	_	_
10	developed	develop	B-VP	VBD	0	_	_	_	_
11	transient	transient	B-NP	JJ	0	_	_	_	_
12	neurological	neurological	I-NP	JJ	0	_	_	_	_
13	complications	complication	I-NP	NNS	0	_	_	_	_
14	during	during	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	injection	injection	I-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	Urografin	Urografin	B-NP	NN	0	_	_	_	_
19	310	310	I-NP	CD	0	_	_	_	_
20	M	M	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	data	datum	I-NP	NNS	0	_	_	_	_
3	indicate	indicate	B-VP	VBP	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	three	three	I-NP	CD	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	phase	phase	I-NP	NN	0	_	_	_	_
8	reaction	reaction	I-NP	NN	0	_	_	_	_
9	after	after	B-PP	IN	0	_	_	_	_
10	B1	B1	B-NP	NN	UMLS:C0507112:T023:ANAT	_	_	_	_
11	injection	injection	I-NP	NN	0	_	_	_	_
12	:	:	O	:	0	_	_	_	_
13	Phase	Phase	B-NP	NN	0	_	_	_	_
14	1	1	I-NP	CD	0	_	_	_	_
15	-	-	O	HYPH	0	_	_	_	_
16	-	-	O	HYPH	0	_	_	_	_
17	shortly	shortly	B-ADVP	RB	0	_	_	_	_
18	after	after	B-PP	IN	0	_	_	_	_
19	injection	injection	B-NP	NN	0	_	_	_	_
20	there	there	B-NP	EX	0	_	_	_	_
21	is	be	B-VP	VBZ	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	drop	drop	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	all	all	B-NP	DT	0	_	_	_	_
26	parameters	parameter	I-NP	NNS	0	_	_	_	_
27	lasting	last	B-VP	VBG	0	_	_	_	_
28	for	for	B-PP	IN	0	_	_	_	_
29	30	30	B-NP	CD	0	_	_	_	_
30	sec	sec	I-NP	NN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Serum	Serum	B-NP	NN	:::NOCLASS	_	_	_	_
2	relaxin	relaxin	I-NP	NN	:::NOCLASS	_	_	_	_
3	levels	level	I-NP	NNS	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	prostaglandin	prostaglandin	B-NP	NN	0	_	_	_	_
6	E2	E2	I-NP	NN	0	_	_	_	_
7	induced	induced	I-NP	JJ	0	_	_	_	_
8	abortions	abortion	I-NP	NNS	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	-	-	I-NP	SYM	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	A	A	I-NP	DT	0	_	_	_	_
5	natural	natural	I-NP	JJ	0	_	_	_	_
6	hydrostatic	hydrostatic	I-NP	JJ	0	_	_	_	_
7	phenomenon	phenomenon	I-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	at	at	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	level	level	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	ends	end	I-NP	NNS	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	plantar	plantar	I-NP	NN	0	_	_	_	_
18	arcs	arc	I-NP	NNS	UMLS:C1859722:T047:DISO	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	diffuses	diffuse	B-VP	VBZ	0	_	_	_	_
21	body	body	B-NP	NN	0	_	_	_	_
22	weight	weight	I-NP	NN	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	as	as	B-SBAR	IN	0	_	_	_	_
25	PAIN	PAIN	B-NP	NN	0	_	_	_	_
26	plays	play	B-VP	VBZ	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	role	role	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	outsentry	outsentry	B-NP	NN	0	_	_	_	_
31	(	(	O	(	0	_	_	_	_
32	fig	fig	B-NP	NN	0	_	_	_	_
33	.	.	O	SYM	0	_	_	_	_
34	-	-	O	SYM	0	_	_	_	_
35	-	-	B-NP	SYM	0	_	_	_	_
36	1	1	I-NP	CD	0	_	_	_	_
37	)	)	O	)	0	_	_	_	_
38	(	(	O	(	0	_	_	_	_
39	5	5	B-NP	CD	0	_	_	_	_
40	)	)	O	)	0	_	_	_	_
41	;	;	O	:	0	_	_	_	_
42	B	B	B-NP	NN	0	_	_	_	_
43	-	-	O	HYPH	0	_	_	_	_
44	-	-	O	HYPH	0	_	_	_	_
45	Plantar	Plantar	B-NP	NN	0	_	_	_	_
46	perforating	perforate	B-VP	VBG	0	_	_	_	_
47	ulceration	ulceration	B-NP	NN	0	_	_	_	_
48	(	(	O	(	0	_	_	_	_
49	PPU	PPU	B-NP	NN	0	_	_	_	_
50	)	)	O	)	0	_	_	_	_
51	is	be	B-VP	VBZ	0	_	_	_	_
52	caused	cause	I-VP	VBN	0	_	_	_	_
53	by	by	B-PP	IN	0	_	_	_	_
54	a	a	B-NP	DT	0	_	_	_	_
55	combination	combination	I-NP	NN	0	_	_	_	_
56	of	of	B-PP	IN	0	_	_	_	_
57	INSENSITIVITY	INSENSITIVITY	B-NP	NN	0	_	_	_	_
58	and	and	I-NP	CC	0	_	_	_	_
59	TRAUMATIS	TRAUMATIS	I-NP	NN	0	_	_	_	_
60	(	(	O	(	0	_	_	_	_
61	1	1	B-NP	CD	0	_	_	_	_
62	)	)	O	)	0	_	_	_	_
63	;	;	O	:	0	_	_	_	_
64	C	C	B-NP	NN	0	_	_	_	_
65	-	-	O	HYPH	0	_	_	_	_
66	-	-	O	HYPH	0	_	_	_	_
67	The	The	B-NP	DT	0	_	_	_	_
68	patient	patient	I-NP	NN	0	_	_	_	_
69	reposing	repose	B-VP	VBG	0	_	_	_	_
70	,	,	O	,	0	_	_	_	_
71	as	as	B-SBAR	IN	0	_	_	_	_
72	body	body	B-NP	NN	0	_	_	_	_
73	weight	weight	I-NP	NN	0	_	_	_	_
74	(	(	O	(	0	_	_	_	_
75	traumatism	traumatism	B-NP	NN	0	_	_	_	_
76	)	)	O	)	0	_	_	_	_
77	effects	effect	B-NP	NNS	0	_	_	_	_
78	disappear	disappear	B-VP	VBP	0	_	_	_	_
79	,	,	O	,	0	_	_	_	_
80	cicatrization	cicatrization	B-NP	NN	0	_	_	_	_
81	process	process	I-NP	NN	0	_	_	_	_
82	can	can	B-VP	MD	0	_	_	_	_
83	be	be	I-VP	VB	0	_	_	_	_
84	easily	easily	I-VP	RB	0	_	_	_	_
85	observed	observe	I-VP	VBN	0	_	_	_	_
86	;	;	O	:	0	_	_	_	_
87	D	D	B-NP	NN	0	_	_	_	_
88	-	-	O	HYPH	0	_	_	_	_
89	-	-	B-NP	HYPH	0	_	_	_	_
90	PNEUMATIC	PNEUMATIC	I-NP	NN	0	_	_	_	_
91	INSOLE	INSOLE	I-NP	NN	0	_	_	_	_
92	,	,	O	,	0	_	_	_	_
93	being	be	B-VP	VBG	0	_	_	_	_
94	elastic	elastic	B-ADJP	JJ	0	_	_	_	_
95	,	,	O	,	0	_	_	_	_
96	diffuses	diffuse	B-VP	VBZ	0	_	_	_	_
97	localized	localized	B-NP	JJ	0	_	_	_	_
98	compression	compression	I-NP	NN	0	_	_	_	_
99	at	at	B-PP	IN	0	_	_	_	_
100	the	the	B-NP	DT	0	_	_	_	_
101	ends	end	I-NP	NNS	0	_	_	_	_
102	of	of	B-PP	IN	0	_	_	_	_
103	the	the	B-NP	DT	0	_	_	_	_
104	plantar	plantar	I-NP	NN	0	_	_	_	_
105	arcs	arc	I-NP	NNS	UMLS:C1859722:T047:DISO	_	_	_	_
106	,	,	O	,	0	_	_	_	_
107	reduces	reduce	B-VP	VBZ	0	_	_	_	_
108	attrition	attrition	B-NP	NN	UMLS:C0004277:T047:DISO	_	_	_	_
109	,	,	O	,	0	_	_	_	_
110	makes	make	B-VP	VBZ	0	_	_	_	_
111	easier	easy	B-NP	JJR	0	_	_	_	_
112	blood	blood	I-NP	NN	0	_	_	_	_
113	circulation	circulation	I-NP	NN	0	_	_	_	_
114	,	,	O	,	0	_	_	_	_
115	as	as	B-CONJP	RB	0	_	_	_	_
116	well	well	I-CONJP	RB	0	_	_	_	_
117	as	as	I-CONJP	IN	0	_	_	_	_
118	cure	cure	B-NP	NN	0	_	_	_	_
119	and	and	I-NP	CC	0	_	_	_	_
120	prophylaxis	prophylaxis	I-NP	NN	0	_	_	_	_
121	of	of	B-PP	IN	0	_	_	_	_
122	PPU	PPU	B-NP	NN	0	_	_	_	_
123	(	(	O	(	0	_	_	_	_
124	fig	fig	B-NP	NN	0	_	_	_	_
125	.	.	O	SYM	0	_	_	_	_
126	-	-	O	SYM	0	_	_	_	_
127	-	-	O	SYM	0	_	_	_	_
128	6	6	B-NP	CD	0	_	_	_	_
129	)	)	O	)	0	_	_	_	_
130	(	(	O	(	0	_	_	_	_
131	3	3	B-NP	CD	0	_	_	_	_
132	)	)	O	)	0	_	_	_	_
133	.	.	O	.	0	_	_	_	_

1	Effect	Effect	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	indoramin	indoramin	B-NP	NN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	small	small	B-NP	JJ	0	_	_	_	_
6	doses	dose	I-NP	NNS	0	_	_	_	_
7	on	on	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	central	central	I-NP	JJ	0	_	_	_	_
10	vasomotor	vasomotor	I-NP	NN	0	_	_	_	_
11	loci	locus	I-NP	NNS	0	_	_	_	_
12	has	have	B-VP	VBZ	0	_	_	_	_
13	been	be	I-VP	VBN	0	_	_	_	_
14	studied	study	I-VP	VBN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	chloralose	chloralose	B-NP	NN	0	_	_	_	_
17	anesthetized	anesthetize	B-VP	VBD	0	_	_	_	_
18	cats	cat	B-NP	NNS	0	_	_	_	_
19	by	by	B-PP	IN	0	_	_	_	_
20	localizing	localize	B-VP	VBG	0	_	_	_	_
21	it	it	B-NP	PRP	0	_	_	_	_
22	to	to	B-PP	TO	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	central	central	I-NP	JJ	0	_	_	_	_
25	sites	site	I-NP	NNS	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	As	As	B-SBAR	IN	0	_	_	_	_
2	expected	expect	B-VP	VBN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	heparin	heparin	I-NP	NN	0	_	_	_	_
6	did	do	B-VP	VBD	0	_	_	_	_
7	produce	produce	I-VP	VB	0	_	_	_	_
8	increased	increase	B-NP	VBN	0	_	_	_	_
9	recalcification	recalcification	I-NP	NN	0	_	_	_	_
10	times	time	I-NP	NNS	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	development	development	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	occasional	occasional	B-NP	JJ	0	_	_	_	_
16	subcutaneous	subcutaneous	I-NP	JJ	0	_	_	_	_
17	hematomas	hematoma	I-NP	NNS	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Contingency	Contingency	B-NP	NN	0	_	_	_	_
2	contracting	contracting	I-NP	NN	0	_	_	_	_
3	between	between	B-PP	IN	0	_	_	_	_
4	clients	client	B-NP	NNS	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	their	their	B-NP	PRP$	0	_	_	_	_
7	parents	parent	I-NP	NNS	0	_	_	_	_
8	/	/	O	SYM	0	_	_	_	_
9	caregivers	caregiver	B-NP	NNS	0	_	_	_	_
10	was	be	B-VP	VBD	0	_	_	_	_
11	used	use	I-VP	VBN	0	_	_	_	_
12	to	to	B-VP	TO	0	_	_	_	_
13	specify	specify	I-VP	VB	0	_	_	_	_
14	consequences	consequence	B-NP	NNS	0	_	_	_	_
15	for	for	B-PP	IN	0	_	_	_	_
16	daily	daily	B-NP	JJ	0	_	_	_	_
17	self	self	I-NP	AFX	0	_	_	_	_
18	-	-	I-NP	HYPH	0	_	_	_	_
19	monitoring	monitoring	I-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	reduced	reduce	B-VP	VBD	0	_	_	_	_
22	caloric	caloric	B-NP	JJ	0	_	_	_	_
23	intake	intake	I-NP	NN	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	weight	weight	B-NP	NN	0	_	_	_	_
26	loss	loss	I-NP	NN	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	and	and	O	CC	0	_	_	_	_
29	exercise	exercise	B-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Dietetics	Dietetic	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	childhood	childhood	B-NP	NN	0	_	_	_	_
4	-	-	B-NP	HYPH	0	_	_	_	_
5	and	and	I-NP	CC	0	_	_	_	_
6	juvenile	juvenile	I-NP	JJ	UMLS:C0011854:T047:DISO	_	_	_	_
7	diabetes	diabete	I-NP	NNS	UMLS:C0011854:T047:DISO	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	quantitative	quantitative	I-NP	JJ	0	_	_	_	_
6	study	study	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	vasculosyncytial	vasculosyncytial	B-NP	JJ	0	_	_	_	_
9	membranes	membrane	I-NP	NNS	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	123	123	B-NP	CD	0	_	_	_	_
12	placentas	placenta	I-NP	NNS	0	_	_	_	_
13	are	be	B-VP	VBP	0	_	_	_	_
14	presented	present	I-VP	VBN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	micromethod	micromethod	I-NP	NN	0	_	_	_	_
3	uses	use	B-VP	VBZ	0	_	_	_	_
4	microcuvettes	microcuvette	B-NP	NNS	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	substitutes	substitute	B-VP	VBZ	0	_	_	_	_
7	ferrozine	ferrozine	B-NP	NN	0	_	_	_	_
8	for	for	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	bathophenanthroline	bathophenanthroline	I-NP	NN	0	_	_	_	_
11	chromogen	chromogen	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	ICSH	ICSH	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Platelet	Platelet	B-NP	NN	0	_	_	_	_
2	serotonin	serotonin	I-NP	NN	0	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	5	5	B-NP	CD	0	_	_	_	_
5	-	-	I-NP	HYPH	0	_	_	_	_
6	HT	HT	I-NP	NN	UMLS:C0677607:T047:DISO	_	_	_	_
7	)	)	O	)	0	_	_	_	_
8	and	and	O	CC	0	_	_	_	_
9	5	5	B-NP	CD	:::NOCLASS	_	_	_	_
10	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
11	HT	HT	I-NP	NN	:::NOCLASS|UMLS:C0677607:T047:DISO	_	_	_	_
12	releasing	release	B-VP	VBG	:::NOCLASS	_	_	_	_
13	factor	factor	B-NP	NN	:::NOCLASS	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	plasma	plasma	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	migrainous	migrainous	B-NP	JJ	0	_	_	_	_
18	patients	patient	I-NP	NNS	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	overall	overall	I-NP	JJ	0	_	_	_	_
3	incidence	incidence	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	SIDS	SIDS	B-NP	NN	UMLS:C0038644:T047:DISO	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	1	1	B-NP	CD	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_
9	43	43	O	CD	0	_	_	_	_
10	per	per	B-PP	IN	0	_	_	_	_
11	1	1	B-NP	CD	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	000	000	B-NP	CD	0	_	_	_	_
14	live	live	I-NP	JJ	0	_	_	_	_
15	births	birth	I-NP	NNS	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	vigilance	vigilance	I-NP	NN	0	_	_	_	_
3	task	task	I-NP	NN	0	_	_	_	_
4	and	and	O	CC	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	measurement	measurement	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	attentional	attentional	B-NP	JJ	0	_	_	_	_
9	deficits	deficit	I-NP	NNS	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	December	December	I-NP	NNP	0	_	_	_	_
3	armed	arm	B-VP	VBD	0	_	_	_	_
4	revolt	revolt	B-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	Moscow	Moscow	B-NP	NNP	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	paramedical	paramedical	I-NP	JJ	0	_	_	_	_
10	personnel	personnel	I-NP	NNS	0	_	_	_	_

1	Significant	Significant	B-NP	JJ	0	_	_	_	_
2	increases	increase	I-NP	NNS	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	mean	mean	B-NP	JJ	0	_	_	_	_
5	serum	serum	I-NP	NN	0	_	_	_	_
6	E2	E2	I-NP	NN	0	_	_	_	_
7	concentration	concentration	I-NP	NN	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	100	100	B-NP	CD	0	_	_	_	_
10	to	to	I-NP	TO	0	_	_	_	_
11	150	150	I-NP	CD	0	_	_	_	_
12	pg	pg	I-NP	NN	0	_	_	_	_
13	/	/	B-NP	SYM	0	_	_	_	_
14	ml	ml	I-NP	NN	0	_	_	_	_
15	)	)	O	)	0	_	_	_	_
16	were	be	B-VP	VBD	0	_	_	_	_
17	noted	note	I-VP	VBN	0	_	_	_	_
18	at	at	B-PP	IN	0	_	_	_	_
19	6	6	B-NP	CD	0	_	_	_	_
20	and	and	I-NP	CC	0	_	_	_	_
21	8	8	I-NP	CD	0	_	_	_	_
22	hours	hour	I-NP	NNS	0	_	_	_	_
23	after	after	B-PP	IN	0	_	_	_	_
24	administration	administration	B-NP	NN	0	_	_	_	_
25	on	on	B-PP	IN	0	_	_	_	_
26	day	day	B-NP	NN	0	_	_	_	_
27	1	1	I-NP	CD	0	_	_	_	_
28	and	and	O	CC	0	_	_	_	_
29	at	at	B-PP	IN	0	_	_	_	_
30	8	8	B-NP	CD	0	_	_	_	_
31	hours	hour	I-NP	NNS	0	_	_	_	_
32	on	on	B-PP	IN	0	_	_	_	_
33	day	day	B-NP	NN	0	_	_	_	_
34	4	4	I-NP	CD	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	motor	motor	I-NP	NN	UMLS:C0231502:T023:ANAT	_	_	_	_
3	unit	unit	I-NP	NN	UMLS:C0231502:T023:ANAT	_	_	_	_
4	viewed	view	B-VP	VBN	0	_	_	_	_
5	from	from	B-PP	IN	0	_	_	_	_
6	above	above	B-ADVP	RB	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_

1	Avian	Avian	B-NP	JJ	0	_	_	_	_
2	reproductive	reproductive	I-NP	JJ	0	_	_	_	_
3	system	system	I-NP	NN	0	_	_	_	_
4	:	:	O	:	0	_	_	_	_
5	daily	daily	B-NP	JJ	0	_	_	_	_
6	variations	variation	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	responses	response	B-NP	NNS	0	_	_	_	_
9	to	to	B-PP	TO	0	_	_	_	_
10	hormones	hormone	B-NP	NNS	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	Biological	Biological	B-NP	JJ	0	_	_	_	_
2	properties	property	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	sumithion	sumithion	B-NP	NN	0	_	_	_	_
5	.	.	O	.	0	_	_	_	_

1	Serological	Serological	B-NP	JJ	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	antibodies	antibody	B-NP	NNS	0	_	_	_	_
5	to	to	B-PP	TO	0	_	_	_	_
6	Epstein	Epstein	B-NP	NNP	UMLS:C1396851:T047:DISO	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	Barr	Barr	I-NP	NNP	0	_	_	_	_
9	virus	virus	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	infectious	infectious	B-NP	JJ	UMLS:C0021345:T047:DISO	_	_	_	_
12	mononucleosis	mononucleosis	I-NP	NN	UMLS:C0021345:T047:DISO	_	_	_	_

1	Carcinoembryonic	Carcinoembryonic	B-NP	JJ	:::NOCLASS	_	_	_	_
2	antigen	antigen	I-NP	NN	:::NOCLASS	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	CEA	CEA	B-NP	NN	:::NOCLASS	_	_	_	_
5	)	)	O	)	0	_	_	_	_
6	procedures	procedure	B-NP	NNS	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	clinical	clinical	B-NP	JJ	0	_	_	_	_
9	evaluation	evaluation	I-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	remain	remain	B-VP	VBP	0	_	_	_	_
3	convinced	convinced	B-ADJP	JJ	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	antilymphocyte	antilymphocyte	B-NP	NN	:::NOCLASS	_	_	_	_
6	globulin	globulin	I-NP	NN	:::NOCLASS	_	_	_	_
7	(	(	O	(	0	_	_	_	_
8	ALG	ALG	B-NP	NN	:::NOCLASS	_	_	_	_
9	)	)	O	)	0	_	_	_	_
10	is	be	B-VP	VBZ	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	potent	potent	I-NP	JJ	0	_	_	_	_
13	immunosuppressive	immunosuppressive	I-NP	JJ	0	_	_	_	_
14	agent	agent	I-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	humans	human	B-NP	NNS	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	On	On	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	basis	basis	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	global	global	I-NP	JJ	0	_	_	_	_
7	assessment	assessment	I-NP	NN	0	_	_	_	_
8	patients	patient	I-NP	NNS	0	_	_	_	_
9	showed	show	B-VP	VBD	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	highly	highly	I-NP	RB	0	_	_	_	_
12	significant	significant	I-NP	JJ	0	_	_	_	_
13	preference	preference	I-NP	NN	0	_	_	_	_
14	for	for	B-PP	IN	0	_	_	_	_
15	imipramine	imipramine	B-NP	NN	0	_	_	_	_
16	compared	compare	B-PP	VBN	0	_	_	_	_
17	with	with	B-PP	IN	0	_	_	_	_
18	placebo	placebo	B-NP	NN	0	_	_	_	_
19	as	as	B-PP	IN	0	_	_	_	_
20	adjunctive	adjunctive	B-NP	JJ	0	_	_	_	_
21	therapy	therapy	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	39	39	B-NP	CD	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	47	47	I-NP	CD	0	_	_	_	_
4	.	.	O	.	0	_	_	_	_

1	Patients	Patient	B-NP	NNS	0	_	_	_	_
2	were	be	B-VP	VBD	0	_	_	_	_
3	subclassified	subclassifie	I-VP	VBN	0	_	_	_	_
4	into	into	B-PP	IN	0	_	_	_	_
5	age	age	B-NP	NN	0	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	matched	match	I-NP	VBN	0	_	_	_	_
8	groups	group	I-NP	NNS	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	primary	primary	B-NP	JJ	0	_	_	_	_
11	untreated	untreated	I-NP	JJ	0	_	_	_	_
12	cancer	cancer	I-NP	NN	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	21	21	B-NP	CD	0	_	_	_	_
15	)	)	O	)	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	recurrent	recurrent	B-NP	JJ	0	_	_	_	_
18	cancer	cancer	I-NP	NN	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	18	18	B-NP	CD	0	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	and	and	O	CC	0	_	_	_	_
24	"	"	O	``	0	_	_	_	_
25	cured	cure	B-VP	VBN	0	_	_	_	_
26	"	"	O	''	0	_	_	_	_
27	patients	patient	B-NP	NNS	0	_	_	_	_
28	who	who	B-NP	WP	0	_	_	_	_
29	had	have	B-VP	VBD	0	_	_	_	_
30	been	be	I-VP	VBN	0	_	_	_	_
31	free	free	B-ADJP	JJ	0	_	_	_	_
32	of	of	B-PP	IN	0	_	_	_	_
33	disease	disease	B-NP	NN	0	_	_	_	_
34	for	for	B-PP	IN	0	_	_	_	_
35	at	at	B-NP	IN	0	_	_	_	_
36	least	least	I-NP	JJS	0	_	_	_	_
37	9	9	I-NP	CD	0	_	_	_	_
38	months	month	I-NP	NNS	0	_	_	_	_
39	(	(	O	(	0	_	_	_	_
40	16	16	B-NP	CD	0	_	_	_	_
41	)	)	O	)	0	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	Absorption	Absorption	B-NP	NN	0	_	_	_	_
2	varied	vary	B-VP	VBD	0	_	_	_	_
3	between	between	B-PP	IN	0	_	_	_	_
4	65	65	B-NP	CD	0	_	_	_	_
5	and	and	I-NP	CC	0	_	_	_	_
6	95	95	I-NP	CD	0	_	_	_	_
7	per	per	B-PP	IN	0	_	_	_	_
8	cent	cent	B-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	mean	mean	I-NP	JJ	0	_	_	_	_
13	absorption	absorption	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	80	80	B-NP	CD	0	_	_	_	_
16	per	per	B-PP	IN	0	_	_	_	_
17	cent	cent	B-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	both	both	B-NP	CC	0	_	_	_	_
21	pregnant	pregnant	I-NP	JJ	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	non	non	B-NP	AFX	0	_	_	_	_
24	-	-	I-NP	HYPH	0	_	_	_	_
25	pregnant	pregnant	I-NP	JJ	0	_	_	_	_
26	subjects	subject	I-NP	NNS	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Bacteriostatic	Bacteriostatic	B-NP	JJ	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	bacteriacidal	bacteriacidal	I-NP	JJ	0	_	_	_	_
4	activity	activity	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	hydroxy	hydroxy	B-NP	NN	0	_	_	_	_
7	-	-	O	HYPH	0	_	_	_	_
8	9	9	B-NP	CD	0	_	_	_	_
9	ellipticine	ellipticine	I-NP	NN	0	_	_	_	_
10	in	in	B-ADVP	FW	0	_	_	_	_
11	vitro	vitro	I-ADVP	FW	0	_	_	_	_

1	Advances	Advance	B-NP	NNS	0	_	_	_	_
2	in	in	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	management	management	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	gynecologic	gynecologic	B-NP	JJ	0	_	_	_	_
7	cancer	cancer	I-NP	NN	0	_	_	_	_
8	-	-	O	HYPH	0	_	_	_	_
9	-	-	B-NP	HYPH	0	_	_	_	_
10	radiation	radiation	I-NP	NN	0	_	_	_	_
11	therapy	therapy	I-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	clinico	clinico	I-NP	AFX	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	pathological	pathological	I-NP	JJ	0	_	_	_	_
5	data	datum	I-NP	NNS	0	_	_	_	_
6	from	from	B-PP	IN	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	patient	patient	I-NP	NN	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	irreversible	irreversible	B-NP	JJ	0	_	_	_	_
11	post	post	I-NP	AFX	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	partum	partum	I-NP	NN	0	_	_	_	_
14	renal	renal	I-NP	JJ	UMLS:C0341697:T047:DISO|UMLS:C0035078:T047:DISO|UMLS:C0022646:T023:ANAT	_	_	_	_
15	failure	failure	I-NP	NN	UMLS:C0341697:T047:DISO|UMLS:C0035078:T047:DISO	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	IPRF	IPRF	B-NP	NN	0	_	_	_	_
18	)	)	O	)	0	_	_	_	_
19	are	be	B-VP	VBP	0	_	_	_	_
20	presented	present	I-VP	VBN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Personal	Personal	B-NP	JJ	0	_	_	_	_
2	satisfaction	satisfaction	I-NP	NN	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	nursing	nursing	B-NP	NN	0	_	_	_	_
5	:	:	O	:	0	_	_	_	_
6	an	an	B-NP	DT	0	_	_	_	_
7	encounter	encounter	I-NP	NN	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	extremely	extremely	B-NP	RB	0	_	_	_	_
10	hostile	hostile	I-NP	JJ	0	_	_	_	_
11	patients	patient	I-NP	NNS	0	_	_	_	_

1	Dialyzable	Dialyzable	B-NP	JJ	0	_	_	_	_
2	transfer	transfer	I-NP	NN	:::NOCLASS	_	_	_	_
3	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
4	.	.	O	.	0	_	_	_	_

1	19	19	B-NP	CD	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	32	32	I-NP	CD	0	_	_	_	_
4	.	.	O	.	0	_	_	_	_

1	Rheumatoid	Rheumatoid	B-NP	JJ	:::NOCLASS	_	_	_	_
2	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	antinuclear	antinuclear	B-NP	JJ	0	_	_	_	_
5	antibody	antibody	I-NP	NN	0	_	_	_	_
6	tests	test	I-NP	NNS	0	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	frequently	frequently	B-ADJP	RB	0	_	_	_	_
9	positive	positive	I-ADJP	JJ	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	reactions	reaction	B-NP	NNS	0	_	_	_	_
13	to	to	B-PP	TO	0	_	_	_	_
14	gold	gold	B-NP	NN	0	_	_	_	_
15	therapy	therapy	I-NP	NN	0	_	_	_	_
16	were	be	B-VP	VBD	0	_	_	_	_
17	more	more	B-ADJP	RBR	0	_	_	_	_
18	frequent	frequent	I-ADJP	JJ	0	_	_	_	_
19	than	than	B-PP	IN	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	other	other	B-NP	JJ	0	_	_	_	_
22	rheumatoid	rheumatoid	I-NP	JJ	0	_	_	_	_
23	populations	population	I-NP	NNS	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effect	effect	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	hydrostatic	hydrostatic	B-NP	JJ	0	_	_	_	_
5	pressure	pressure	I-NP	NN	0	_	_	_	_
6	on	on	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	swimming	swimming	I-NP	NN	0	_	_	_	_
9	activity	activity	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	three	three	B-NP	CD	0	_	_	_	_
12	hyponeustonic	hyponeustonic	I-NP	JJ	0	_	_	_	_
13	crustacea	crustacea	I-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	Anomalocera	Anomalocera	B-NP	NNP	0	_	_	_	_
16	patersoni	patersoni	I-NP	NNS	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	Pontella	Pontella	B-NP	NNP	0	_	_	_	_
19	mediterranea	mediterranea	I-NP	NNP	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	Labidocera	Labidocera	B-NP	NNP	0	_	_	_	_
22	wollastoni	wollastoni	I-NP	NNS	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	report	report	I-NP	NN	0	_	_	_	_
3	presents	present	B-VP	VBZ	0	_	_	_	_
4	an	an	B-NP	DT	0	_	_	_	_
5	analysis	analysis	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	vocal	vocal	I-NP	JJ	0	_	_	_	_
9	repertoire	repertoire	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	howler	howler	B-NP	NN	0	_	_	_	_
12	monkeys	monkey	I-NP	NNS	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	Alouatta	Alouatta	B-NP	NN	0	_	_	_	_
15	palliata	palliata	I-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	observed	observe	B-VP	VBN	0	_	_	_	_
18	during	during	B-PP	IN	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	field	field	I-NP	NN	0	_	_	_	_
21	study	study	I-NP	NN	0	_	_	_	_
22	in	in	B-PP	IN	0	_	_	_	_
23	southwestern	southwestern	B-NP	JJ	0	_	_	_	_
24	Panama	Panama	I-NP	NNP	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Up	Up	B-PP	IN	0	_	_	_	_
2	to	to	B-PP	TO	0	_	_	_	_
3	now	now	B-ADVP	RB	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	number	number	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	patients	patient	B-NP	NNS	0	_	_	_	_
8	examined	examine	B-VP	VBN	0	_	_	_	_
9	is	be	B-VP	VBZ	0	_	_	_	_
10	about	about	B-NP	IN	0	_	_	_	_
11	300	300	I-NP	CD	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	additionally	additionally	B-NP	RB	0	_	_	_	_
14	6	6	I-NP	CD	0	_	_	_	_
15	persons	person	I-NP	NNS	0	_	_	_	_
16	who	who	B-NP	WP	0	_	_	_	_
17	underwent	undergo	B-VP	VBD	0	_	_	_	_
18	binephrectomy	binephrectomy	B-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Deflunia	Deflunia	B-NP	NNP	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	well	well	I-VP	RB	0	_	_	_	_
4	tolerated	tolerate	I-VP	VBN	0	_	_	_	_
5	by	by	B-PP	IN	0	_	_	_	_
6	25	25	B-NP	CD	0	_	_	_	_
7	patients	patient	I-NP	NNS	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	very	very	B-VP	RB	0	_	_	_	_
10	well	well	I-VP	RB	0	_	_	_	_
11	tolerated	tolerate	I-VP	VBN	0	_	_	_	_
12	by	by	B-PP	IN	0	_	_	_	_
13	2	2	B-NP	CD	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	III	III	B-NP	CD	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	new	new	I-NP	JJ	0	_	_	_	_
3	instrument	instrument	I-NP	NN	0	_	_	_	_
4	has	have	B-VP	VBZ	0	_	_	_	_
5	been	be	I-VP	VBN	0	_	_	_	_
6	designed	design	I-VP	VBN	0	_	_	_	_
7	for	for	B-PP	IN	0	_	_	_	_
8	freeze	freeze	B-NP	NN	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	fracturing	fracturing	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	biological	biological	B-NP	JJ	0	_	_	_	_
13	material	material	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	ultra	ultra	B-NP	JJ	0	_	_	_	_
16	high	high	I-NP	JJ	0	_	_	_	_
17	vacuum	vacuum	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Pancreatic	Pancreatic	B-NP	JJ	UMLS:C0030274:T023:ANAT	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	biliary	biliary	I-NP	JJ	0	_	_	_	_
4	secretion	secretion	I-NP	NN	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	gastric	gastric	B-NP	JJ	UMLS:C0038351:T023:ANAT	_	_	_	_
7	emptying	emptying	I-NP	NN	0	_	_	_	_
8	rates	rate	I-NP	NNS	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	liquid	liquid	I-NP	JJ	0	_	_	_	_
12	test	test	I-NP	NN	0	_	_	_	_
13	meal	meal	I-NP	NN	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	LTM	LTM	B-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	were	be	B-VP	VBD	0	_	_	_	_
18	determined	determine	I-VP	VBN	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	normal	normal	B-NP	JJ	0	_	_	_	_
21	persons	person	I-NP	NNS	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	in	in	B-PP	IN	0	_	_	_	_
24	patients	patient	B-NP	NNS	0	_	_	_	_
25	with	with	B-PP	IN	0	_	_	_	_
26	subtotal	subtotal	B-NP	JJ	0	_	_	_	_
27	gastrectomy	gastrectomy	I-NP	NN	0	_	_	_	_
28	with	with	B-PP	IN	0	_	_	_	_
29	gastroduodenostomy	gastroduodenostomy	B-NP	NN	0	_	_	_	_
30	(	(	O	(	0	_	_	_	_
31	STG	STG	B-NP	NN	0	_	_	_	_
32	-	-	B-NP	HYPH	0	_	_	_	_
33	BI	BI	I-NP	NN	0	_	_	_	_
34	)	)	O	)	0	_	_	_	_
35	or	or	O	CC	0	_	_	_	_
36	with	with	B-PP	IN	0	_	_	_	_
37	gastrojejunostomy	gastrojejunostomy	B-NP	NN	0	_	_	_	_
38	(	(	O	(	0	_	_	_	_
39	STG	STG	B-NP	NN	0	_	_	_	_
40	-	-	B-NP	HYPH	0	_	_	_	_
41	BII	BII	I-NP	NN	0	_	_	_	_
42	)	)	O	)	0	_	_	_	_
43	,	,	O	,	0	_	_	_	_
44	and	and	O	CC	0	_	_	_	_
45	in	in	B-PP	IN	0	_	_	_	_
46	patients	patient	B-NP	NNS	0	_	_	_	_
47	with	with	B-PP	IN	0	_	_	_	_
48	truncal	truncal	B-NP	JJ	0	_	_	_	_
49	vagotomy	vagotomy	I-NP	NN	0	_	_	_	_
50	and	and	O	CC	0	_	_	_	_
51	pyloroplasty	pyloroplasty	B-NP	NN	0	_	_	_	_
52	(	(	O	(	0	_	_	_	_
53	V	V	B-NP	NN	0	_	_	_	_
54	&	&	I-NP	CC	0	_	_	_	_
55	P	P	I-NP	NN	0	_	_	_	_
56	)	)	O	)	0	_	_	_	_
57	.	.	O	.	0	_	_	_	_

1	Abnormal	Abnormal	B-NP	JJ	0	_	_	_	_
2	calcium	calcium	I-NP	NN	0	_	_	_	_
3	metabolism	metabolism	I-NP	NN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	normocalcaemic	normocalcaemic	B-NP	JJ	0	_	_	_	_
6	sarcoidosis	sarcoidosis	I-NP	NN	UMLS:C0036202:T047:DISO	_	_	_	_
7	.	.	O	.	0	_	_	_	_

1	Also	Also	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	except	except	B-PP	IN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	one	one	B-NP	CD	0	_	_	_	_
6	patient	patient	I-NP	NN	0	_	_	_	_
7	who	who	B-NP	WP	0	_	_	_	_
8	developed	develop	B-VP	VBD	0	_	_	_	_
9	gallstones	gallstone	B-NP	NNS	UMLS:C0008350:T047:DISO	_	_	_	_
10	following	follow	B-PP	VBG	0	_	_	_	_
11	institution	institution	B-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	colestipol	colestipol	B-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	saturation	saturation	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	gallbladder	gallbladder	B-NP	NN	UMLS:C0016976:T023:ANAT	_	_	_	_
18	bile	bile	I-NP	NN	0	_	_	_	_
19	with	with	B-PP	IN	0	_	_	_	_
20	cholesterol	cholesterol	B-NP	NN	0	_	_	_	_
21	was	be	B-VP	VBD	0	_	_	_	_
22	not	not	I-VP	RB	0	_	_	_	_
23	markedly	markedly	I-VP	RB	0	_	_	_	_
24	increased	increase	I-VP	VBN	0	_	_	_	_
25	by	by	B-PP	IN	0	_	_	_	_
26	this	this	B-NP	DT	0	_	_	_	_
27	drug	drug	I-NP	NN	0	_	_	_	_
28	alone	alone	B-ADVP	RB	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	five	five	I-NP	CD	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	phase	phase	I-NP	NN	0	_	_	_	_
5	experiment	experiment	I-NP	NN	0	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	designed	design	I-VP	VBN	0	_	_	_	_
8	to	to	B-VP	TO	0	_	_	_	_
9	investigate	investigate	I-VP	VB	0	_	_	_	_
10	(	(	O	(	0	_	_	_	_
11	a	a	O	DT	0	_	_	_	_
12	)	)	O	)	0	_	_	_	_
13	whether	whether	B-SBAR	IN	0	_	_	_	_
14	contingent	contingent	B-NP	JJ	0	_	_	_	_
15	music	music	I-NP	NN	0	_	_	_	_
16	-	-	B-NP	HYPH	0	_	_	_	_
17	listening	listening	I-NP	NN	0	_	_	_	_
18	would	would	B-VP	MD	0	_	_	_	_
19	act	act	I-VP	VB	0	_	_	_	_
20	as	as	B-PP	IN	0	_	_	_	_
21	a	a	B-NP	DT	0	_	_	_	_
22	reinforcer	reinforcer	I-NP	NN	0	_	_	_	_
23	to	to	B-VP	TO	0	_	_	_	_
24	increase	increase	I-VP	VB	0	_	_	_	_
25	arithmetic	arithmetic	B-NP	JJ	0	_	_	_	_
26	performance	performance	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	EMR	EMR	B-NP	NN	0	_	_	_	_
29	children	child	I-NP	NNS	0	_	_	_	_
30	and	and	O	CC	0	_	_	_	_
31	(	(	O	(	0	_	_	_	_
32	b	b	O	NN	0	_	_	_	_
33	)	)	O	)	0	_	_	_	_
34	whether	whether	B-SBAR	IN	0	_	_	_	_
35	this	this	B-NP	DT	0	_	_	_	_
36	contingent	contingent	I-NP	JJ	0	_	_	_	_
37	reinforcement	reinforcement	I-NP	NN	0	_	_	_	_
38	would	would	B-VP	MD	0	_	_	_	_
39	affect	affect	I-VP	VB	0	_	_	_	_
40	preference	preference	B-NP	NN	0	_	_	_	_
41	for	for	B-PP	IN	0	_	_	_	_
42	that	that	B-NP	DT	0	_	_	_	_
43	reinforcer	reinforcer	I-NP	NN	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	responsiveness	responsiveness	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	visual	visual	B-NP	JJ	UMLS:C0042817:T023:ANAT	_	_	_	_
5	cortex	cortex	I-NP	NN	UMLS:C0042817:T023:ANAT	_	_	_	_
6	(	(	O	(	0	_	_	_	_
7	VC	VC	B-NP	NN	0	_	_	_	_
8	)	)	O	)	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	superior	superior	B-NP	JJ	UMLS:C0228405:T023:ANAT	_	_	_	_
11	colliculus	colliculus	I-NP	NN	UMLS:C0228405:T023:ANAT	_	_	_	_
12	(	(	O	(	0	_	_	_	_
13	SC	SC	B-NP	NN	0	_	_	_	_
14	)	)	O	)	0	_	_	_	_
15	was	be	B-VP	VBD	0	_	_	_	_
16	simultaneously	simultaneously	I-VP	RB	0	_	_	_	_
17	compared	compare	I-VP	VBN	0	_	_	_	_
18	following	follow	B-PP	VBG	0	_	_	_	_
19	conditioning	condition	B-VP	VBG	0	_	_	_	_
20	"	"	O	``	0	_	_	_	_
21	ON	ON	B-NP	NNP	0	_	_	_	_
22	"	"	O	''	0	_	_	_	_
23	or	or	O	CC	0	_	_	_	_
24	"	"	B-NP	``	0	_	_	_	_
25	OFF	OFF	I-NP	NN	0	_	_	_	_
26	"	"	I-NP	''	0	_	_	_	_
27	stimulation	stimulation	I-NP	NN	0	_	_	_	_
28	,	,	O	,	0	_	_	_	_
29	in	in	B-PP	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	rabbit	rabbit	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	MS	MS	B-NP	NN	UMLS:C0026269:T047:DISO|UMLS:C0026769:T047:DISO	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	made	make	I-VP	VBN	0	_	_	_	_
7	based	base	B-PP	VBN	0	_	_	_	_
8	on	on	B-PP	IN	0	_	_	_	_
9	subtle	subtle	B-NP	JJ	0	_	_	_	_
10	neurologic	neurologic	I-NP	JJ	0	_	_	_	_
11	signs	sign	I-NP	NNS	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	spinal	spinal	B-NP	JJ	0	_	_	_	_
14	fluid	fluid	I-NP	NN	0	_	_	_	_
15	gamma	gamma	I-NP	NN	:::NOCLASS	_	_	_	_
16	globulin	globulin	I-NP	NN	:::NOCLASS	_	_	_	_
17	elevations	elevation	I-NP	NNS	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	abnormalities	abnormality	B-NP	NNS	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	neuropsychological	neuropsychological	B-NP	JJ	0	_	_	_	_
23	testing	testing	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	If	If	B-SBAR	IN	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	however	however	B-ADVP	RB	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	mean	mean	I-NP	JJ	0	_	_	_	_
7	temperature	temperature	I-NP	NN	0	_	_	_	_
8	rise	rise	I-NP	NN	0	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	higher	high	B-ADJP	JJR	0	_	_	_	_
11	(	(	O	(	0	_	_	_	_
12	0	0	B-NP	CD	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_
14	57	57	B-NP	CD	0	_	_	_	_
15	degrees	degree	I-NP	NNS	0	_	_	_	_
16	C	C	B-ADJP	JJ	0	_	_	_	_
17	or	or	O	CC	0	_	_	_	_
18	0	0	B-NP	CD	0	_	_	_	_
19	.	.	I-NP	.	0	_	_	_	_
20	69	69	I-NP	CD	0	_	_	_	_
21	degrees	degree	I-NP	NNS	0	_	_	_	_
22	C	C	I-NP	NN	0	_	_	_	_
23	)	)	O	)	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	such	such	B-NP	PDT	0	_	_	_	_
26	a	a	I-NP	DT	0	_	_	_	_
27	selection	selection	I-NP	NN	0	_	_	_	_
28	practically	practically	B-ADVP	RB	0	_	_	_	_
29	resulted	result	B-VP	VBD	0	_	_	_	_
30	in	in	B-PP	IN	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	disappearance	disappearance	I-NP	NN	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	'passable	'passable	B-NP	JJ	0	_	_	_	_
35	'	'	I-NP	''	0	_	_	_	_
36	qualifications	qualification	I-NP	NNS	0	_	_	_	_
37	in	in	B-PP	IN	0	_	_	_	_
38	the	the	B-NP	DT	0	_	_	_	_
39	triplet	triplet	I-NP	JJ	0	_	_	_	_
40	groups	group	I-NP	NNS	0	_	_	_	_
41	and	and	O	CC	0	_	_	_	_
42	a	a	B-NP	DT	0	_	_	_	_
43	great	great	I-NP	JJ	0	_	_	_	_
44	predominance	predominance	I-NP	NN	0	_	_	_	_
45	of	of	B-PP	IN	0	_	_	_	_
46	'to	'to	B-VP	MD	0	_	_	_	_
47	be	be	I-VP	VB	0	_	_	_	_
48	rejected	reject	I-VP	VBN	0	_	_	_	_
49	'	'	O	''	0	_	_	_	_
50	qualifications	qualification	B-NP	NNS	0	_	_	_	_
51	in	in	B-PP	IN	0	_	_	_	_
52	the	the	B-NP	DT	0	_	_	_	_
53	large	large	I-NP	JJ	0	_	_	_	_
54	groups	group	I-NP	NNS	0	_	_	_	_
55	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	elevated	elevate	I-NP	VBN	0	_	_	_	_
3	Viso	Viso	I-NP	NNP	0	_	_	_	_
4	V	V	I-NP	NNP	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	RDS	RDS	I-NP	NN	UMLS:C1704437:T047:DISO	_	_	_	_
8	group	group	I-NP	NN	0	_	_	_	_
9	suggests	suggest	B-VP	VBZ	0	_	_	_	_
10	an	an	B-NP	DT	0	_	_	_	_
11	increase	increase	I-NP	NN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	small	small	B-NP	JJ	0	_	_	_	_
14	airway	airway	I-NP	NN	UMLS:C0458827:T023:ANAT	_	_	_	_
15	resistance	resistance	I-NP	NN	0	_	_	_	_
16	secondary	secondary	B-ADJP	JJ	0	_	_	_	_
17	to	to	B-PP	TO	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	disease	disease	I-NP	NN	0	_	_	_	_
20	or	or	B-PP	CC	0	_	_	_	_
21	to	to	B-PP	TO	0	_	_	_	_
22	its	its	B-NP	PRP$	0	_	_	_	_
23	therapy	therapy	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	psychological	psychological	I-NP	JJ	0	_	_	_	_
3	tests	test	I-NP	NNS	0	_	_	_	_
4	consisted	consist	B-VP	VBD	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	free	free	I-NP	JJ	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	recall	recall	I-NP	NN	0	_	_	_	_
10	task	task	I-NP	NN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	test	test	I-NP	NN	0	_	_	_	_
14	for	for	B-PP	IN	0	_	_	_	_
15	visuomotor	visuomotor	B-NP	NN	0	_	_	_	_
16	coordination	coordination	I-NP	NN	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	a	a	B-NP	DT	0	_	_	_	_
19	recognition	recognition	I-NP	NN	0	_	_	_	_
20	task	task	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Selective	Selective	B-NP	JJ	0	_	_	_	_
2	bronchial	bronchial	I-NP	JJ	UMLS:C1442216:T023:ANAT|UMLS:C0205039:T023:ANAT	_	_	_	_
3	intubation	intubation	I-NP	NN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	management	management	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	unilateral	unilateral	B-NP	JJ	0	_	_	_	_
9	pulmonary	pulmonary	I-NP	JJ	UMLS:C0013994:T047:DISO|UMLS:C0024109:T023:ANAT	_	_	_	_
10	interstitial	interstitial	I-NP	JJ	UMLS:C0013994:T047:DISO	_	_	_	_
11	emphysema	emphysema	I-NP	NN	UMLS:C0013994:T047:DISO	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	background	background	I-NP	NN	0	_	_	_	_
3	processes	process	I-NP	NNS	0	_	_	_	_
4	depending	depend	B-PP	VBG	0	_	_	_	_
5	on	on	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	etiological	etiological	I-NP	JJ	0	_	_	_	_
8	factor	factor	I-NP	NN	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	character	character	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	lesion	lesion	B-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	epithelium	epithelium	I-NP	NN	0	_	_	_	_
17	are	be	B-VP	VBP	0	_	_	_	_
18	divided	divide	I-VP	VBN	0	_	_	_	_
19	into	into	B-PP	IN	0	_	_	_	_
20	dyshormonal	dyshormonal	B-NP	JJ	0	_	_	_	_
21	,	,	I-NP	,	0	_	_	_	_
22	inflammatory	inflammatory	I-NP	JJ	0	_	_	_	_
23	,	,	I-NP	,	0	_	_	_	_
24	and	and	I-NP	CC	0	_	_	_	_
25	posttraumatic	posttraumatic	I-NP	JJ	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	sense	sense	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	self	self	B-NP	NN	0	_	_	_	_
5	.	.	O	.	0	_	_	_	_

1	Eleven	Eleven	B-NP	CD	0	_	_	_	_
2	strains	strain	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	Fusarium	Fusarium	B-NP	NNP	0	_	_	_	_
5	poae	poae	I-NP	NN	0	_	_	_	_
6	and	and	I-NP	CC	0	_	_	_	_
7	F	F	I-NP	NN	0	_	_	_	_
8	.	.	I-NP	.	0	_	_	_	_
9	sporotrichioides	sporotrichioide	I-NP	NNS	0	_	_	_	_
10	from	from	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	U	U	I-NP	NNP	0	_	_	_	_
13	.	.	I-NP	.	0	_	_	_	_
14	S	S	I-NP	NNP	0	_	_	_	_
15	.	.	I-NP	.	0	_	_	_	_
16	S	S	I-NP	NNP	0	_	_	_	_
17	.	.	I-NP	.	0	_	_	_	_
18	R	R	I-NP	NNP	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	7	7	B-NP	CD	0	_	_	_	_
22	strains	strain	I-NP	NNS	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	these	these	B-NP	DT	0	_	_	_	_
25	species	specie	I-NP	NNS	0	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	one	one	B-NP	CD	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	F	F	B-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_
31	sporotrichioides	sporotrichioide	B-NP	NNS	0	_	_	_	_
32	var	var	B-VP	VBP	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_
34	tricinctum	tricinctum	B-NP	NN	0	_	_	_	_
35	from	from	B-PP	IN	0	_	_	_	_
36	U	U	B-NP	NNP	0	_	_	_	_
37	.	.	I-NP	.	0	_	_	_	_
38	S	S	I-NP	NNP	0	_	_	_	_
39	.	.	I-NP	.	0	_	_	_	_
40	A	A	I-NP	NNP	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_
42	and	and	O	CC	0	_	_	_	_
43	France	France	B-NP	NNP	0	_	_	_	_
44	have	have	B-VP	VBP	0	_	_	_	_
45	been	be	I-VP	VBN	0	_	_	_	_
46	compared	compare	I-VP	VBN	0	_	_	_	_
47	as	as	B-PP	IN	0	_	_	_	_
48	to	to	B-PP	TO	0	_	_	_	_
49	their	their	B-NP	PRP$	0	_	_	_	_
50	capacity	capacity	I-NP	NN	0	_	_	_	_
51	to	to	B-VP	TO	0	_	_	_	_
52	yield	yield	I-VP	VB	0	_	_	_	_
53	T	T	B-NP	NN	:::NOCLASS	_	_	_	_
54	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
55	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
56	toxin	toxin	I-NP	NN	:::NOCLASS	_	_	_	_
57	.	.	O	.	0	_	_	_	_

1	Current	Current	B-NP	JJ	0	_	_	_	_
2	diagnostic	diagnostic	I-NP	JJ	0	_	_	_	_
3	uses	use	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	computerized	computerized	B-NP	JJ	0	_	_	_	_
6	tomography	tomography	I-NP	NN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	clinical	clinical	B-NP	JJ	0	_	_	_	_
9	medicine	medicine	I-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	follow	follow	B-VP	VB	0	_	_	_	_
3	-	-	O	HYPH	0	_	_	_	_
4	up	up	B-PRT	RP	0	_	_	_	_
5	study	study	B-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	22	22	B-NP	CD	0	_	_	_	_
8	patients	patient	I-NP	NNS	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	Ebstein	Ebstein	B-NP	NNP	0	_	_	_	_
11	's	's	B-NP	POS	0	_	_	_	_
12	anomaly	anomaly	B-ADVP	RB	0	_	_	_	_
13	has	have	B-VP	VBZ	0	_	_	_	_
14	been	be	I-VP	VBN	0	_	_	_	_
15	performed	perform	I-VP	VBN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Deaths	Death	B-NP	NNS	0	_	_	_	_
2	stopped	stop	B-VP	VBD	0	_	_	_	_
3	11	11	B-NP	CD	0	_	_	_	_
4	hours	hour	I-NP	NNS	0	_	_	_	_
5	after	after	B-PP	IN	0	_	_	_	_
6	copper	copper	B-NP	NN	0	_	_	_	_
7	concentrations	concentration	I-NP	NNS	0	_	_	_	_
8	decreased	decrease	B-VP	VBD	0	_	_	_	_
9	below	below	B-PP	IN	0	_	_	_	_
10	0	0	B-NP	CD	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_
12	2	2	B-NP	CD	0	_	_	_	_
13	ppm	ppm	I-NP	NN	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	signs	sign	B-NP	NNS	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	distress	distress	B-NP	NN	0	_	_	_	_
18	stopped	stop	B-VP	VBD	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	surviving	survive	B-VP	VBG	0	_	_	_	_
21	pinfish	pinfish	B-NP	NN	0	_	_	_	_
22	by	by	B-PP	IN	0	_	_	_	_
23	approximately	approximately	B-NP	RB	0	_	_	_	_
24	6	6	I-NP	CD	0	_	_	_	_
25	hours	hour	I-NP	NNS	0	_	_	_	_
26	after	after	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	last	last	I-NP	JJ	0	_	_	_	_
29	death	death	I-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Recurrence	Recurrence	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	bladder	bladder	B-NP	NN	UMLS:C0005682:T023:ANAT	_	_	_	_
4	tumors	tumor	I-NP	NNS	0	_	_	_	_
5	among	among	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	original	original	I-NP	JJ	0	_	_	_	_
8	9	9	I-NP	CD	0	_	_	_	_
9	cases	case	I-NP	NNS	0	_	_	_	_
10	has	have	B-VP	VBZ	0	_	_	_	_
11	occurred	occur	I-VP	VBN	0	_	_	_	_
12	only	only	B-ADVP	RB	0	_	_	_	_
13	among	among	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	5	5	I-NP	CD	0	_	_	_	_
16	whose	whose	I-NP	WP$	0	_	_	_	_
17	properdin	properdin	I-NP	NN	:::NOCLASS	_	_	_	_
18	levels	level	I-NP	NNS	0	_	_	_	_
19	remained	remain	B-VP	VBD	0	_	_	_	_
20	below	below	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	median	median	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Adaptation	Adaptation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	taurocholate	taurocholate	B-NP	JJ	0	_	_	_	_
4	transport	transport	I-NP	NN	0	_	_	_	_
5	maximum	maximum	I-NP	NN	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	increased	increase	B-NP	VBN	0	_	_	_	_
8	secretory	secretory	I-NP	JJ	0	_	_	_	_
9	load	load	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	rat	rat	I-NP	NN	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Dangers	Danger	B-NP	NNS	0	_	_	_	_
2	in	in	B-PP	IN	0	_	_	_	_
3	use	use	B-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	live	live	B-NP	JJ	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	virus	virus	I-NP	NN	0	_	_	_	_
8	vaccines	vaccine	I-NP	NNS	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Treatment	Treatment	B-NP	NN	0	_	_	_	_
2	with	with	B-PP	IN	0	_	_	_	_
3	heparin	heparin	B-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	plasminogen	plasminogen	B-NP	NN	:::NOCLASS	_	_	_	_
6	activators	activator	I-NP	NNS	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	fibrinogenolytic	fibrinogenolytic	B-NP	JJ	0	_	_	_	_
9	agents	agent	I-NP	NNS	0	_	_	_	_
10	was	be	B-VP	VBD	0	_	_	_	_
11	disappointing	disappointing	B-ADJP	JJ	0	_	_	_	_
12	although	although	B-SBAR	IN	0	_	_	_	_
13	renal	renal	B-NP	JJ	UMLS:C0022646:T023:ANAT	_	_	_	_
14	function	function	I-NP	NN	0	_	_	_	_
15	has	have	B-VP	VBZ	0	_	_	_	_
16	stabilized	stabilize	I-VP	VBN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	one	one	B-NP	CD	0	_	_	_	_
19	patient	patient	I-NP	NN	0	_	_	_	_
20	on	on	B-PP	IN	0	_	_	_	_
21	long	long	B-NP	JJ	0	_	_	_	_
22	term	term	I-NP	NN	0	_	_	_	_
23	oral	oral	I-NP	JJ	0	_	_	_	_
24	anticoagulant	anticoagulant	I-NP	JJ	0	_	_	_	_
25	therapy	therapy	I-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	diethyl	diethyl	B-NP	NN	0	_	_	_	_
3	ether	ether	I-NP	NN	0	_	_	_	_
4	solution	solution	I-NP	NN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	main	main	I-NP	JJ	0	_	_	_	_
7	peak	peak	I-NP	NN	0	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	that	that	O	DT	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	2	2	B-NP	CD	0	_	_	_	_
12	-	-	O	HYPH	0	_	_	_	_
13	benzylidenamio	benzylidenamio	O	AFX	0	_	_	_	_
14	-	-	B-NP	HYPH	0	_	_	_	_
15	1	1	I-NP	CD	0	_	_	_	_
16	-	-	I-NP	HYPH	0	_	_	_	_
17	phenylpropane	phenylpropane	I-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	which	which	B-NP	WDT	0	_	_	_	_
20	has	have	B-VP	VBZ	0	_	_	_	_
21	a	a	B-NP	DT	0	_	_	_	_
22	retention	retention	I-NP	NN	0	_	_	_	_
23	time	time	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	23	23	B-NP	CD	0	_	_	_	_
26	,	,	O	,	0	_	_	_	_
27	2	2	B-NP	CD	0	_	_	_	_
28	minutes	minute	I-NP	NNS	0	_	_	_	_
29	under	under	B-PP	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	condition	condition	I-NP	NN	UMLS:C0012634:T047:DISO	_	_	_	_
32	delineated	delineate	B-VP	VBN	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Amikacin	Amikacin	B-NP	NN	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	used	use	I-VP	VBN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	treatment	treatment	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	56	56	B-NP	CD	0	_	_	_	_
9	serious	serious	I-NP	JJ	0	_	_	_	_
10	gram	gram	I-NP	NN	0	_	_	_	_
11	-	-	B-NP	HYPH	0	_	_	_	_
12	negative	negative	I-NP	JJ	0	_	_	_	_
13	infections	infection	I-NP	NNS	UMLS:C0021311:T047:DISO|UMLS:C0851162:T047:DISO	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	54	54	B-NP	CD	0	_	_	_	_
16	patients	patient	I-NP	NNS	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	whom	whom	B-NP	WP	0	_	_	_	_
19	47	47	B-NP	CD	0	_	_	_	_
20	survived	survive	B-VP	VBD	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	data	datum	I-NP	NNS	0	_	_	_	_
3	normally	normally	B-ADJP	RB	0	_	_	_	_
4	available	available	I-ADJP	JJ	0	_	_	_	_
5	are	be	B-VP	VBP	0	_	_	_	_
6	insufficient	insufficient	B-ADJP	JJ	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	take	take	B-VP	VB	0	_	_	_	_
9	no	no	B-NP	DT	0	_	_	_	_
10	account	account	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	direction	direction	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	recirculation	recirculation	B-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	which	which	B-NP	WDT	0	_	_	_	_
18	may	may	B-VP	MD	0	_	_	_	_
19	be	be	I-VP	VB	0	_	_	_	_
20	a	a	B-NP	DT	0	_	_	_	_
21	determining	determining	I-NP	JJ	0	_	_	_	_
22	factor	factor	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	During	During	B-PP	IN	0	_	_	_	_
2	activity	activity	B-NP	NN	0	_	_	_	_
3	III	III	I-NP	CD	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	one	one	B-NP	CD	0	_	_	_	_
6	patient	patient	I-NP	NN	0	_	_	_	_
7	developed	develop	B-VP	VBD	0	_	_	_	_
8	angina	angina	B-NP	NN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Estimation	Estimation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	L	L	B-NP	NN	0	_	_	_	_
4	-	-	O	HYPH	0	_	_	_	_
5	alanine	alanine	B-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	serum	serum	B-NP	NN	0	_	_	_	_
8	or	or	I-NP	CC	0	_	_	_	_
9	plasma	plasma	I-NP	NN	0	_	_	_	_
10	using	use	B-VP	VBG	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	LKB	LKB	I-NP	NN	0	_	_	_	_
13	reaction	reaction	I-NP	NN	0	_	_	_	_
14	rate	rate	I-NP	NN	0	_	_	_	_
15	analyser	analyser	I-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	acids	acid	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	obtained	obtain	I-VP	VBN	0	_	_	_	_
5	by	by	B-PP	IN	0	_	_	_	_
6	hydrolysis	hydrolysis	B-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	corresponding	corresponding	I-NP	JJ	0	_	_	_	_
10	esters	ester	I-NP	NNS	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	their	their	B-NP	PRP$	0	_	_	_	_
14	anti	anti	I-NP	AFX	0	_	_	_	_
15	-	-	I-NP	HYPH	0	_	_	_	_
16	inflammatory	inflammatory	I-NP	JJ	0	_	_	_	_
17	activity	activity	I-NP	NN	0	_	_	_	_
18	was	be	B-VP	VBD	0	_	_	_	_
19	tested	test	I-VP	VBN	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Unrecognized	Unrecognized	B-NP	JJ	0	_	_	_	_
2	amnionitis	amnionitis	I-NP	NN	UMLS:C0002631:T047:DISO	_	_	_	_
3	and	and	I-NP	CC	0	_	_	_	_
4	prematurity	prematurity	I-NP	NN	UMLS:C0728731:T047:DISO	_	_	_	_
5	:	:	O	:	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	preliminary	preliminary	I-NP	JJ	0	_	_	_	_
8	report	report	I-NP	NN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Evaluation	Evaluation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	new	new	I-NP	JJ	0	_	_	_	_
5	Gravigard	Gravigard	I-NP	NNP	0	_	_	_	_
6	IUCD	IUCD	I-NP	NN	0	_	_	_	_
7	inserter	inserter	I-NP	NN	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Bacterial	Bacterial	B-NP	JJ	UMLS:C0085437:T047:DISO	_	_	_	_
2	meningitis	meningitis	I-NP	NN	UMLS:C0085437:T047:DISO	_	_	_	_
3	secondary	secondary	B-ADJP	JJ	0	_	_	_	_
4	to	to	B-PP	TO	0	_	_	_	_
5	abscess	abscess	B-NP	NN	UMLS:C0000833:T047:DISO	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	nasal	nasal	I-NP	JJ	UMLS:C0027432:T023:ANAT	_	_	_	_
9	septum	septum	I-NP	NN	UMLS:C0027432:T023:ANAT	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	Serum	Serum	B-NP	NN	:::NOCLASS	_	_	_	_
2	amylase	amylase	I-NP	NN	:::NOCLASS	_	_	_	_
3	became	become	B-VP	VBD	0	_	_	_	_
4	markedly	markedly	B-ADJP	RB	0	_	_	_	_
5	elevated	elevate	I-ADJP	VBN	0	_	_	_	_
6	(	(	O	(	0	_	_	_	_
7	2	2	B-NP	CD	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	624	624	B-NP	CD	0	_	_	_	_
10	CU	CU	I-NP	NN	0	_	_	_	_
11	/	/	B-NP	SYM	0	_	_	_	_
12	100	100	B-NP	CD	0	_	_	_	_
13	ml	ml	I-NP	NN	0	_	_	_	_
14	)	)	O	)	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	as	as	B-SBAR	IN	0	_	_	_	_
17	did	do	O	VBD	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	serum	serum	I-NP	NN	0	_	_	_	_
20	FFA	FFA	I-NP	NN	0	_	_	_	_
21	(	(	O	(	0	_	_	_	_
22	29	29	B-NP	CD	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_
24	19	19	B-NP	CD	0	_	_	_	_
25	mEq	mEq	I-NP	NN	0	_	_	_	_
26	/	/	B-NP	SYM	0	_	_	_	_
27	liter	liter	I-NP	NN	0	_	_	_	_
28	)	)	O	)	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	control	control	I-NP	NN	0	_	_	_	_
4	preparation	preparation	I-NP	NN	0	_	_	_	_
5	before	before	B-PP	IN	0	_	_	_	_
6	weight	weight	B-NP	NN	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	allowed	allow	I-VP	VBN	0	_	_	_	_
9	to	to	I-VP	TO	0	_	_	_	_
10	increase	increase	I-VP	VB	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	isogravimetric	isogravimetric	B-NP	JJ	0	_	_	_	_
13	capillary	capillary	I-NP	JJ	UMLS:C0935624:T023:ANAT|UMLS:C0006901:T023:ANAT	_	_	_	_
14	pressure	pressure	I-NP	NN	0	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	Pci	Pci	B-NP	NN	0	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	averaged	average	B-VP	VBD	0	_	_	_	_
19	8	8	B-NP	CD	0	_	_	_	_
20	mmHg	mmHg	I-NP	NN	0	_	_	_	_
21	lower	low	B-ADJP	JJR	0	_	_	_	_
22	than	than	B-PP	IN	0	_	_	_	_
23	colloid	colloid	B-NP	JJ	0	_	_	_	_
24	osmotic	osmotic	I-NP	JJ	0	_	_	_	_
25	pressure	pressure	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	plasma	plasma	I-NP	NN	0	_	_	_	_
29	(	(	O	(	0	_	_	_	_
30	IIp	IIp	B-NP	NN	0	_	_	_	_
31	)	)	O	)	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Infants	Infant	B-NP	NNS	0	_	_	_	_
2	who	who	B-NP	WP	0	_	_	_	_
3	died	die	B-VP	VBD	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	first	first	I-NP	JJ	0	_	_	_	_
7	12	12	I-NP	CD	0	_	_	_	_
8	hours	hour	I-NP	NNS	0	_	_	_	_
9	from	from	B-PP	IN	0	_	_	_	_
10	'IVH	'IVH	B-NP	NN	0	_	_	_	_
11	only	only	B-ADVP	RB	0	_	_	_	_
12	'	'	O	''	0	_	_	_	_
13	had	have	B-VP	VBD	0	_	_	_	_
14	suffered	suffer	I-VP	VBN	0	_	_	_	_
15	severe	severe	B-NP	JJ	0	_	_	_	_
16	birth	birth	I-NP	NN	UMLS:C0004045:T047:DISO	_	_	_	_
17	asphyxia	asphyxia	I-NP	NN	UMLS:C0004045:T047:DISO	_	_	_	_
18	but	but	B-PP	CC	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	those	those	B-NP	DT	0	_	_	_	_
21	who	who	B-NP	WP	0	_	_	_	_
22	died	die	B-VP	VBD	0	_	_	_	_
23	later	later	B-ADVP	RB	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	main	main	I-NP	JJ	0	_	_	_	_
26	symptom	symptom	I-NP	NN	0	_	_	_	_
27	was	be	B-VP	VBD	0	_	_	_	_
28	recurrent	recurrent	B-NP	JJ	0	_	_	_	_
29	apnoea	apnoea	I-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	morphological	morphological	I-NP	JJ	0	_	_	_	_
3	effects	effect	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	two	two	B-NP	CD	0	_	_	_	_
6	snake	snake	I-NP	NN	0	_	_	_	_
7	venoms	venom	I-NP	NNS	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	N	N	B-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_
11	naja	naja	B-NP	NN	0	_	_	_	_
12	and	and	I-NP	CC	0	_	_	_	_
13	A	A	I-NP	NN	0	_	_	_	_
14	.	.	I-NP	.	0	_	_	_	_
15	piscivorus	piscivorus	I-NP	NN	0	_	_	_	_
16	,	,	B-PP	,	0	_	_	_	_
17	and	and	I-PP	CC	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	Direct	Direct	I-NP	JJ	:::NOCLASS	_	_	_	_
21	Lytic	Lytic	I-NP	JJ	:::NOCLASS	_	_	_	_
22	Factor	Factor	I-NP	NN	:::NOCLASS	_	_	_	_
23	and	and	I-NP	CC	0	_	_	_	_
24	Phospholipase	Phospholipase	I-NP	NN	:::NOCLASS	_	_	_	_
25	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
26	A	A	I-NP	NN	:::NOCLASS	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	compounds	compound	B-NP	NNS	0	_	_	_	_
29	purified	purify	B-VP	VBN	0	_	_	_	_
30	from	from	B-PP	IN	0	_	_	_	_
31	N	N	B-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_
33	naja	naja	B-NP	NN	0	_	_	_	_
34	crude	crude	I-NP	JJ	0	_	_	_	_
35	venom	venom	I-NP	NN	0	_	_	_	_
36	,	,	O	,	0	_	_	_	_
37	were	be	B-VP	VBD	0	_	_	_	_
38	investigated	investigate	I-VP	VBN	0	_	_	_	_
39	on	on	B-PP	IN	0	_	_	_	_
40	lung	lung	B-NP	NN	UMLS:C0024109:T023:ANAT	_	_	_	_
41	and	and	I-NP	CC	0	_	_	_	_
42	cremaster	cremaster	I-NP	NN	UMLS:C0224377:T023:ANAT	_	_	_	_
43	vessels	vessel	I-NP	NNS	UMLS:C0005847:T023:ANAT	_	_	_	_
44	of	of	B-PP	IN	0	_	_	_	_
45	rats	rat	B-NP	NNS	0	_	_	_	_
46	.	.	O	.	0	_	_	_	_

1	Since	Since	B-SBAR	IN	0	_	_	_	_
2	GAGs	GAG	B-NP	NNS	0	_	_	_	_
3	are	be	B-VP	VBP	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	components	component	I-NP	NNS	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	cartilage	cartilage	B-NP	NN	0	_	_	_	_
8	matrix	matrix	I-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	depletion	depletion	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	which	which	B-NP	WDT	0	_	_	_	_
14	is	be	B-VP	VBZ	0	_	_	_	_
15	associated	associate	I-VP	VBN	0	_	_	_	_
16	with	with	B-PP	IN	0	_	_	_	_
17	osteoarthrosis	osteoarthrosis	B-NP	NN	UMLS:C0029408:T047:DISO	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	method	method	I-NP	NN	0	_	_	_	_
21	for	for	B-PP	IN	0	_	_	_	_
22	measuring	measure	B-VP	VBG	0	_	_	_	_
23	sulphated	sulphate	B-NP	VBN	0	_	_	_	_
24	GAG	GAG	I-NP	NN	0	_	_	_	_
25	synthesis	synthesis	I-NP	NN	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	culture	culture	B-NP	NN	0	_	_	_	_
28	has	have	B-VP	VBZ	0	_	_	_	_
29	been	be	I-VP	VBN	0	_	_	_	_
30	investigated	investigate	I-VP	VBN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	length	length	I-NP	NN	0	_	_	_	_
3	scales	scale	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	turbulence	turbulence	I-NP	NN	0	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	also	also	I-VP	RB	0	_	_	_	_
9	estimated	estimate	I-VP	VBN	0	_	_	_	_
10	:	:	O	:	0	_	_	_	_
11	at	at	B-PP	IN	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	Reynolds	Reynolds	I-NP	NNP	0	_	_	_	_
14	number	number	I-NP	NN	0	_	_	_	_
15	near	near	B-PP	IN	0	_	_	_	_
16	4	4	B-NP	CD	0	_	_	_	_
17	,	,	I-NP	,	0	_	_	_	_
18	000	000	I-NP	CD	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	macroscale	macroscale	I-NP	NN	0	_	_	_	_
21	is	be	B-VP	VBZ	0	_	_	_	_
22	about	about	B-NP	IN	0	_	_	_	_
23	1	1	I-NP	CD	0	_	_	_	_
24	.	.	I-NP	.	0	_	_	_	_
25	25	25	I-NP	CD	0	_	_	_	_
26	mm	mm	I-NP	NN	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	Taylor	Taylor	I-NP	NNP	0	_	_	_	_
30	microscale	microscale	I-NP	NN	0	_	_	_	_
31	is	be	B-VP	VBZ	0	_	_	_	_
32	about	about	B-NP	IN	0	_	_	_	_
33	0	0	I-NP	CD	0	_	_	_	_
34	.	.	I-NP	.	0	_	_	_	_
35	85	85	I-NP	CD	0	_	_	_	_
36	mm	mm	I-NP	NN	0	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	and	and	O	CC	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	Kolmogoroff	Kolmogoroff	I-NP	NNP	0	_	_	_	_
41	scale	scale	I-NP	NN	0	_	_	_	_
42	is	be	B-VP	VBZ	0	_	_	_	_
43	near	near	B-PP	IN	0	_	_	_	_
44	0	0	B-NP	CD	0	_	_	_	_
45	.	.	O	.	0	_	_	_	_
46	075	075	B-NP	CD	0	_	_	_	_
47	mm	mm	I-NP	NN	0	_	_	_	_
48	.	.	O	.	0	_	_	_	_

1	Well	Well	B-ADVP	RB	0	_	_	_	_
2	-	-	B-NP	HYPH	0	_	_	_	_
3	visualised	visualise	I-NP	VBN	0	_	_	_	_
4	arteriograms	arteriogram	I-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	limbs	limb	I-NP	NNS	UMLS:C0015385:T023:ANAT	_	_	_	_
8	can	can	B-VP	MD	0	_	_	_	_
9	be	be	I-VP	VB	0	_	_	_	_
10	obtained	obtain	I-VP	VBN	0	_	_	_	_
11	by	by	B-PP	IN	0	_	_	_	_
12	xeroradiography	xeroradiography	B-NP	NN	0	_	_	_	_
13	after	after	B-PP	IN	0	_	_	_	_
14	rapid	rapid	B-NP	JJ	0	_	_	_	_
15	manual	manual	I-NP	JJ	0	_	_	_	_
16	injection	injection	I-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	contrast	contrast	B-NP	NN	0	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	medium	medium	I-NP	NN	0	_	_	_	_
21	into	into	B-PP	IN	0	_	_	_	_
22	an	an	B-NP	DT	0	_	_	_	_
23	arm	arm	I-NP	NN	UMLS:C0226792:T023:ANAT	_	_	_	_
24	vein	vein	I-NP	NN	UMLS:C0226792:T023:ANAT	_	_	_	_
25	,	,	O	,	0	_	_	_	_
26	as	as	B-SBAR	IN	0	_	_	_	_
27	demonstrated	demonstrate	B-VP	VBN	0	_	_	_	_
28	in	in	B-PP	IN	0	_	_	_	_
29	28	28	B-NP	CD	0	_	_	_	_
30	patients	patient	I-NP	NNS	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	No	No	B-NP	DT	0	_	_	_	_
2	hypotension	hypotension	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	noted	note	I-VP	VBN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	patients	patient	B-NP	NNS	0	_	_	_	_
7	with	with	B-PP	IN	0	_	_	_	_
8	toxemia	toxemia	B-NP	NN	UMLS:C0040524:T047:DISO|UMLS:C0036690:T047:DISO	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	only	only	B-NP	RB	0	_	_	_	_
11	2	2	I-NP	CD	0	_	_	_	_
12	ran	run	B-VP	VBD	0	_	_	_	_
13	a	a	B-NP	DT	0	_	_	_	_
14	fever	fever	I-NP	NN	0	_	_	_	_
15	above	above	B-PP	IN	0	_	_	_	_
16	37	37	B-NP	CD	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_
18	5	5	B-NP	CD	0	_	_	_	_
19	degrees	degree	I-NP	NNS	0	_	_	_	_
20	C	C	B-ADJP	JJ	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	sera	serum	I-NP	NNS	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	nasal	nasal	B-NP	JJ	UMLS:C0028429:T023:ANAT	_	_	_	_
5	secretions	secretion	I-NP	NNS	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	142	142	B-NP	CD	0	_	_	_	_
8	patients	patient	I-NP	NNS	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	who	who	B-NP	WP	0	_	_	_	_
11	were	be	B-VP	VBD	0	_	_	_	_
12	positive	positive	B-ADJP	JJ	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	HD	HD	B-NP	NN	UMLS:C0020179:T047:DISO	_	_	_	_
15	or	or	I-NP	CC	0	_	_	_	_
16	mites	mite	I-NP	NNS	0	_	_	_	_
17	skin	skin	I-NP	NN	0	_	_	_	_
18	test	test	I-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	were	be	B-VP	VBD	0	_	_	_	_
21	subjected	subject	I-VP	VBN	0	_	_	_	_
22	to	to	B-PP	TO	0	_	_	_	_
23	a	a	B-NP	DT	0	_	_	_	_
24	radioallergosorbent	radioallergosorbent	I-NP	JJ	0	_	_	_	_
25	test	test	I-NP	NN	0	_	_	_	_
26	(	(	O	(	0	_	_	_	_
27	RAST	RAST	B-NP	NN	0	_	_	_	_
28	)	)	O	)	0	_	_	_	_
29	for	for	B-PP	IN	0	_	_	_	_
30	estimating	estimate	B-VP	VBG	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	specific	specific	I-NP	JJ	0	_	_	_	_
33	IgE	IgE	I-NP	NN	:::NOCLASS|UMLS:C0270850:T047:DISO	_	_	_	_
34	antibody	antibody	I-NP	NN	:::NOCLASS	_	_	_	_
35	activity	activity	I-NP	NN	0	_	_	_	_
36	to	to	B-PP	TO	0	_	_	_	_
37	mites	mite	B-NP	NNS	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_

1	Wherever	Wherever	B-ADVP	WRB	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	site	site	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	conditioning	condition	I-NP	VBG	0	_	_	_	_
7	stimulation	stimulation	I-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	these	these	B-NP	DT	0	_	_	_	_
10	modifications	modification	I-NP	NNS	0	_	_	_	_
11	disappeared	disappear	B-VP	VBD	0	_	_	_	_
12	after	after	B-PP	IN	0	_	_	_	_
13	ischaemia	ischaemia	B-NP	NN	UMLS:C0022116:T047:DISO	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	leg	leg	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Diallylnitrosamine	Diallylnitrosamine	B-NP	NN	0	_	_	_	_
2	(	(	O	(	0	_	_	_	_
3	DAN	DAN	B-NP	NN	0	_	_	_	_
4	)	)	O	)	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	one	one	B-NP	CD	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	few	few	I-NP	JJ	0	_	_	_	_
10	nitrosamines	nitrosamine	I-NP	NNS	0	_	_	_	_
11	tested	test	B-VP	VBN	0	_	_	_	_
12	thus	thus	B-ADVP	RB	0	_	_	_	_
13	far	far	I-ADVP	RB	0	_	_	_	_
14	that	that	B-NP	DT	0	_	_	_	_
15	has	have	B-VP	VBZ	0	_	_	_	_
16	not	not	I-VP	RB	0	_	_	_	_
17	induced	induce	I-VP	VBN	0	_	_	_	_
18	neoplasms	neoplasm	B-NP	NNS	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	rats	rat	B-NP	NNS	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	caused	cause	B-VP	VBD	0	_	_	_	_
23	a	a	B-NP	DT	0	_	_	_	_
24	high	high	I-NP	JJ	0	_	_	_	_
25	incidence	incidence	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	respiratory	respiratory	B-NP	JJ	UMLS:C0282335:T023:ANAT	_	_	_	_
28	tract	tract	I-NP	NN	UMLS:C0282335:T023:ANAT	_	_	_	_
29	tumors	tumor	I-NP	NNS	0	_	_	_	_
30	in	in	B-PP	IN	0	_	_	_	_
31	Syrian	Syrian	B-NP	JJ	0	_	_	_	_
32	golden	golden	I-NP	JJ	0	_	_	_	_
33	hamsters	hamster	I-NP	NNS	0	_	_	_	_
34	treated	treat	B-VP	VBN	0	_	_	_	_
35	sc	sc	B-NP	NN	0	_	_	_	_
36	with	with	B-PP	IN	0	_	_	_	_
37	single	single	B-NP	JJ	0	_	_	_	_
38	or	or	I-NP	CC	0	_	_	_	_
39	weekly	weekly	I-NP	JJ	0	_	_	_	_
40	doses	dose	I-NP	NNS	0	_	_	_	_
41	of	of	B-PP	IN	0	_	_	_	_
42	the	the	B-NP	DT	0	_	_	_	_
43	compound	compound	I-NP	NN	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	Near	Near	B-NP	JJ	0	_	_	_	_
2	term	term	I-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	under	under	B-PP	IN	0	_	_	_	_
5	experimental	experimental	B-NP	JJ	0	_	_	_	_
6	conditions	condition	I-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	maternal	maternal	B-NP	JJ	0	_	_	_	_
9	and	and	I-NP	CC	0	_	_	_	_
10	fetal	fetal	I-NP	JJ	0	_	_	_	_
11	blood	blood	I-NP	NN	0	_	_	_	_
12	gases	gas	I-NP	NNS	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	pH	pH	B-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	uterine	uterine	B-NP	JJ	UMLS:C0042149:T023:ANAT	_	_	_	_
17	and	and	I-NP	CC	0	_	_	_	_
18	umbilical	umbilical	I-NP	JJ	0	_	_	_	_
19	blood	blood	I-NP	NN	0	_	_	_	_
20	flows	flow	I-NP	NNS	0	_	_	_	_
21	were	be	B-VP	VBD	0	_	_	_	_
22	measured	measure	I-VP	VBN	0	_	_	_	_
23	or	or	I-VP	CC	0	_	_	_	_
24	calculated	calculate	I-VP	VBN	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Haemodynamic	Haemodynamic	B-NP	JJ	0	_	_	_	_
2	responses	response	I-NP	NNS	0	_	_	_	_
3	to	to	B-PP	TO	0	_	_	_	_
4	antagonism	antagonism	B-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	bocurarine	bocurarine	B-NP	NN	0	_	_	_	_
7	block	block	I-NP	NN	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	atropine	atropine	B-NP	NN	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	neostigmine	neostigmine	I-NP	NN	0	_	_	_	_
12	mixture	mixture	I-NP	NN	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	children	child	B-NP	NNS	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	mechanism	mechanism	I-NP	NN	0	_	_	_	_
3	by	by	B-PP	IN	0	_	_	_	_
4	which	which	B-NP	WDT	0	_	_	_	_
5	large	large	B-NP	JJ	0	_	_	_	_
6	molecules	molecule	I-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	such	such	B-PP	JJ	0	_	_	_	_
9	as	as	I-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	diphosphonate	diphosphonate	I-NP	NN	0	_	_	_	_
12	99mTc	99mTc	I-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	labeled	label	I-NP	VBN	0	_	_	_	_
15	EHDP	EHDP	I-NP	NN	0	_	_	_	_
16	or	or	I-NP	CC	0	_	_	_	_
17	99mTc	99mTc	I-NP	NN	0	_	_	_	_
18	-	-	O	HYPH	0	_	_	_	_
19	labeled	label	B-VP	VBN	0	_	_	_	_
20	pyrophosphate	pyrophosphate	B-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	pass	pass	B-VP	VBP	0	_	_	_	_
23	through	through	B-PP	IN	0	_	_	_	_
24	capillaries	capillary	B-NP	NNS	UMLS:C0006901:T023:ANAT	_	_	_	_
25	in	in	B-PP	IN	0	_	_	_	_
26	bone	bone	B-NP	NN	UMLS:C0262950:T023:ANAT	_	_	_	_
27	is	be	B-VP	VBZ	0	_	_	_	_
28	by	by	B-PP	IN	0	_	_	_	_
29	passive	passive	B-NP	JJ	0	_	_	_	_
30	diffusion	diffusion	I-NP	NN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Twenty	Twenty	B-NP	CD	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	nine	nine	I-NP	CD	0	_	_	_	_
4	days	day	I-NP	NNS	0	_	_	_	_
5	after	after	B-PP	IN	0	_	_	_	_
6	injection	injection	B-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	5	5	B-NP	CD	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_
10	8	8	B-NP	CD	0	_	_	_	_
11	mCi	mCi	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	Tc	Tc	B-NP	NN	0	_	_	_	_
14	-	-	B-NP	HYPH	0	_	_	_	_
15	99m	99m	I-NP	CD	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	which	which	B-NP	WDT	0	_	_	_	_
18	gives	give	B-VP	VBZ	0	_	_	_	_
19	28	28	B-NP	CD	0	_	_	_	_
20	rads	rad	I-NP	NNS	0	_	_	_	_
21	to	to	B-PP	TO	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	testis	testis	I-NP	NN	UMLS:C0039597:T023:ANAT	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	number	number	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	sperm	sperm	B-NP	NN	0	_	_	_	_
29	hads	had	I-NP	NNS	0	_	_	_	_
30	decreased	decrease	B-VP	VBD	0	_	_	_	_
31	to	to	B-PP	TO	0	_	_	_	_
32	70	70	B-NP	CD	0	_	_	_	_
33	%	%	I-NP	NN	0	_	_	_	_
34	of	of	B-PP	IN	0	_	_	_	_
35	control	control	B-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	Self	Self	B-NP	NN	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	emasculation	emasculation	I-NP	NN	0	_	_	_	_
4	is	be	B-VP	VBZ	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	end	end	I-NP	NN	0	_	_	_	_
7	result	result	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	an	an	B-NP	DT	0	_	_	_	_
10	unusual	unusual	I-NP	JJ	0	_	_	_	_
11	psychiatric	psychiatric	I-NP	JJ	0	_	_	_	_
12	disorder	disorder	I-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	which	which	B-NP	WDT	0	_	_	_	_
15	initially	initially	B-ADVP	RB	0	_	_	_	_
16	requires	require	B-VP	VBZ	0	_	_	_	_
17	surgical	surgical	B-NP	JJ	0	_	_	_	_
18	treatment	treatment	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Possibility	Possibility	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	TSH	TSH	I-NP	NN	:::NOCLASS	_	_	_	_
5	-	-	B-NP	HYPH	0	_	_	_	_
6	Screening	Screening	I-NP	NN	0	_	_	_	_
7	method	method	I-NP	NN	0	_	_	_	_
8	for	for	B-PP	IN	0	_	_	_	_
9	detection	detection	B-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	hypothyroidism	hypothyroidism	B-NP	NN	UMLS:C0020676:T047:DISO	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	newborn	newborn	I-NP	NN	0	_	_	_	_

1	Thus	Thus	B-NP	RB	0	_	_	_	_
2	analysis	analysis	I-NP	NN	0	_	_	_	_
3	indicated	indicate	B-VP	VBD	0	_	_	_	_
4	no	no	B-NP	DT	0	_	_	_	_
5	reliable	reliable	I-NP	JJ	0	_	_	_	_
6	evidence	evidence	I-NP	NN	0	_	_	_	_
7	that	that	B-SBAR	IN	0	_	_	_	_
8	conscious	conscious	B-NP	JJ	0	_	_	_	_
9	presleep	presleep	I-NP	NN	0	_	_	_	_
10	suggestions	suggestion	I-NP	NNS	0	_	_	_	_
11	become	become	B-VP	VBP	0	_	_	_	_
12	incorporated	incorporate	I-VP	VBN	0	_	_	_	_
13	into	into	B-PP	IN	0	_	_	_	_
14	dream	dream	B-NP	NN	0	_	_	_	_
15	content	content	I-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	prevalence	prevalence	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	hepatitis	hepatitis	B-NP	NN	:::NOCLASS|UMLS:C0019163:T047:DISO	_	_	_	_
5	B	B	I-NP	NN	:::NOCLASS|UMLS:C0019163:T047:DISO	_	_	_	_
6	surface	surface	I-NP	NN	:::NOCLASS	_	_	_	_
7	antigen	antigen	I-NP	NN	:::NOCLASS	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	HBsAg	HBsAg	B-NP	NN	:::NOCLASS	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	anti	anti	B-NP	AFX	:::NOCLASS	_	_	_	_
13	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
14	HBs	HB	B-NP	NNS	:::NOCLASS	_	_	_	_
15	was	be	B-VP	VBD	0	_	_	_	_
16	determined	determine	I-VP	VBN	0	_	_	_	_
17	by	by	B-PP	IN	0	_	_	_	_
18	a	a	B-NP	DT	0	_	_	_	_
19	sensitive	sensitive	I-NP	JJ	0	_	_	_	_
20	double	double	I-NP	JJ	0	_	_	_	_
21	-	-	I-NP	HYPH	0	_	_	_	_
22	antibody	antibody	I-NP	NN	0	_	_	_	_
23	radio	radio	B-NP	AFX	0	_	_	_	_
24	-	-	I-NP	HYPH	0	_	_	_	_
25	immunoassay	immunoassay	I-NP	NN	0	_	_	_	_
26	technique	technique	I-NP	NN	0	_	_	_	_
27	in	in	B-PP	IN	0	_	_	_	_
28	a	a	B-NP	DT	0	_	_	_	_
29	series	series	I-NP	NN	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	patients	patient	B-NP	NNS	0	_	_	_	_
32	with	with	B-PP	IN	0	_	_	_	_
33	chronic	chronic	B-NP	JJ	0	_	_	_	_
34	liver	liver	I-NP	NN	UMLS:C0023895:T047:DISO|UMLS:C0023884:T023:ANAT	_	_	_	_
35	diseases	disease	I-NP	NNS	UMLS:C0023895:T047:DISO	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	concluded	conclude	I-VP	VBN	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	patients	patient	B-NP	NNS	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	acute	acute	B-NP	JJ	UMLS:C0264490:T047:DISO	_	_	_	_
8	respiratory	respiratory	I-NP	JJ	UMLS:C0264490:T047:DISO	_	_	_	_
9	failure	failure	I-NP	NN	UMLS:C0264490:T047:DISO	_	_	_	_
10	requiring	require	B-VP	VBG	0	_	_	_	_
11	artificial	artificial	B-NP	JJ	0	_	_	_	_
12	ventilation	ventilation	I-NP	NN	0	_	_	_	_
13	have	have	B-VP	VBP	0	_	_	_	_
14	two	two	B-NP	CD	0	_	_	_	_
15	componenents	componenent	I-NP	NNS	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	pulmonary	pulmonary	I-NP	JJ	UMLS:C0024109:T023:ANAT	_	_	_	_
19	shunt	shunt	I-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	one	one	B-NP	CD	0	_	_	_	_
22	parallel	parallel	I-NP	NN	0	_	_	_	_
23	with	with	B-PP	IN	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	other	other	I-NP	JJ	0	_	_	_	_
27	inversely	inversely	B-ADJP	RB	0	_	_	_	_
28	related	related	I-ADJP	JJ	0	_	_	_	_
29	with	with	B-PP	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	PAO2	PAO2	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Decreased	Decrease	B-NP	VBN	0	_	_	_	_
2	cardiac	cardiac	I-NP	JJ	UMLS:C0018787:T023:ANAT	_	_	_	_
3	glycogen	glycogen	I-NP	NN	0	_	_	_	_
4	following	follow	B-PP	VBG	0	_	_	_	_
5	phenformin	phenformin	B-NP	NN	0	_	_	_	_
6	injection	injection	I-NP	NN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	hyperglycemic	hyperglycemic	B-NP	JJ	0	_	_	_	_
9	,	,	I-NP	,	0	_	_	_	_
10	hyperinsulinemic	hyperinsulinemic	I-NP	JJ	0	_	_	_	_
11	anaesthetized	anaesthetize	I-NP	VBN	0	_	_	_	_
12	rats	rat	I-NP	NNS	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Biological	Biological	B-NP	JJ	0	_	_	_	_
2	evaluation	evaluation	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	mibolerone	mibolerone	B-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	female	female	I-NP	JJ	0	_	_	_	_
8	Beagle	Beagle	I-NP	NNP	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Levels	Level	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	both	both	O	CC	0	_	_	_	_
4	PGF	PGF	B-NP	NN	0	_	_	_	_
5	and	and	I-NP	CC	0	_	_	_	_
6	PGFM	PGFM	I-NP	NN	0	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	significantly	significantly	B-ADJP	RB	0	_	_	_	_
9	higher	high	I-ADJP	JJR	0	_	_	_	_
10	during	during	B-PP	IN	0	_	_	_	_
11	early	early	B-NP	JJ	0	_	_	_	_
12	spontaneous	spontaneous	I-NP	JJ	0	_	_	_	_
13	labour	labour	I-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	at	at	B-PP	IN	0	_	_	_	_
16	a	a	B-NP	DT	0	_	_	_	_
17	cervical	cervical	I-NP	JJ	0	_	_	_	_
18	dilatation	dilatation	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	less	less	B-NP	JJR	0	_	_	_	_
21	than	than	I-NP	IN	0	_	_	_	_
22	4	4	I-NP	CD	0	_	_	_	_
23	cm	cm	I-NP	NN	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	than	than	B-PP	IN	0	_	_	_	_
26	before	before	O	RB	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	onset	onset	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	labour	labour	B-NP	NN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	most	most	I-NP	RBS	0	_	_	_	_
3	common	common	I-NP	JJ	0	_	_	_	_
4	cause	cause	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	renal	renal	B-NP	JJ	UMLS:C0022646:T023:ANAT	_	_	_	_
7	deterioration	deterioration	I-NP	NN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	spinal	spinal	I-NP	JJ	UMLS:C0037925:T023:ANAT	_	_	_	_
11	cord	cord	I-NP	NN	UMLS:C0037925:T023:ANAT|UMLS:C0035334:T047:DISO	_	_	_	_
12	injured	injured	I-NP	JJ	0	_	_	_	_
13	patient	patient	I-NP	NN	0	_	_	_	_
14	is	be	B-VP	VBZ	0	_	_	_	_
15	irreversible	irreversible	B-NP	JJ	0	_	_	_	_
16	vesicoureteral	vesicoureteral	I-NP	JJ	UMLS:C0042580:T047:DISO	_	_	_	_
17	reflux	reflux	I-NP	NN	UMLS:C0042580:T047:DISO	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Propranolol	Propranolol	B-NP	NN	0	_	_	_	_
2	(	(	O	(	0	_	_	_	_
3	Inderal	Inderal	B-ADJP	JJ	0	_	_	_	_
4	)	)	O	)	0	_	_	_	_
5	administered	administer	B-VP	VBN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	dose	dose	I-NP	NN	0	_	_	_	_
9	which	which	B-NP	WDT	0	_	_	_	_
10	blocks	block	B-VP	VBZ	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	beta	beta	I-NP	SYM	0	_	_	_	_
13	-	-	I-NP	HYPH	0	_	_	_	_
14	adrenergic	adrenergic	I-NP	JJ	0	_	_	_	_
15	apparatus	apparatus	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	heart	heart	I-NP	NN	UMLS:C0018787:T023:ANAT	_	_	_	_
19	prevents	prevent	B-VP	VBZ	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	development	development	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	positive	positive	I-NP	JJ	0	_	_	_	_
25	inotropic	inotropic	I-NP	JJ	0	_	_	_	_
26	effect	effect	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	therapeutic	therapeutic	B-NP	JJ	0	_	_	_	_
29	doses	dose	I-NP	NNS	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	strophanthin	strophanthin	B-NP	JJ	0	_	_	_	_
32	K	K	I-NP	NN	0	_	_	_	_
33	on	on	B-PP	IN	0	_	_	_	_
34	a	a	B-NP	DT	0	_	_	_	_
35	hypodynamic	hypodynamic	I-NP	JJ	0	_	_	_	_
36	left	left	I-NP	JJ	UMLS:C0225899:T023:ANAT	_	_	_	_
37	ventricular	ventricular	I-NP	JJ	UMLS:C0225899:T023:ANAT	_	_	_	_
38	myocardium	myocardium	I-NP	NN	UMLS:C0225899:T023:ANAT	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	Recent	Recent	B-NP	JJ	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	have	have	B-VP	VBP	0	_	_	_	_
4	shown	show	I-VP	VBN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	rat	rat	I-NP	NN	UMLS:C1882718:T023:ANAT	_	_	_	_
7	larynx	larynx	I-NP	NN	UMLS:C1882718:T023:ANAT	_	_	_	_
8	to	to	B-VP	TO	0	_	_	_	_
9	be	be	I-VP	VB	0	_	_	_	_
10	an	an	B-NP	DT	0	_	_	_	_
11	important	important	I-NP	JJ	0	_	_	_	_
12	organ	organ	I-NP	NN	UMLS:C0178784:T023:ANAT	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	evaluation	evaluation	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	irritancy	irritancy	B-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	inhaled	inhale	B-NP	VBN	0	_	_	_	_
20	materials	material	I-NP	NNS	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Scanning	Scan	B-NP	VBG	0	_	_	_	_
2	electron	electron	I-NP	NN	0	_	_	_	_
3	microscopic	microscopic	I-NP	JJ	0	_	_	_	_
4	investigations	investigation	I-NP	NNS	0	_	_	_	_
5	on	on	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	formation	formation	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	Reissner	Reissner	B-NP	NNP	0	_	_	_	_
10	's	's	B-NP	POS	0	_	_	_	_
11	fiber	fiber	I-NP	NN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	Rattus	Rattus	B-NP	NNP	0	_	_	_	_
14	rattus	rattus	I-NP	NN	0	_	_	_	_

1	Feeding	Feed	B-NP	VBG	0	_	_	_	_
2	behavior	behavior	I-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	circannual	circannual	B-NP	JJ	0	_	_	_	_
5	body	body	I-NP	NN	0	_	_	_	_
6	weight	weight	I-NP	NN	0	_	_	_	_
7	and	and	I-NP	CC	0	_	_	_	_
8	hibernation	hibernation	I-NP	NN	0	_	_	_	_
9	rhythms	rhythm	I-NP	NNS	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	European	European	B-NP	JJ	0	_	_	_	_
12	hamsters	hamster	I-NP	NNS	0	_	_	_	_
13	lesioned	lesione	B-VP	VBN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	noradrenergic	noradrenergic	I-NP	JJ	0	_	_	_	_
17	ascending	ascend	I-NP	VBG	0	_	_	_	_
18	bundles	bundle	I-NP	NNS	0	_	_	_	_

1	Role	Role	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	infectious	infectious	I-NP	JJ	UMLS:C0009450:T047:DISO	_	_	_	_
5	-	-	I-NP	HYPH	0	_	_	_	_
6	disease	disease	I-NP	NN	0	_	_	_	_
7	specialist	specialist	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	polyclinic	polyclinic	I-NP	NN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	reducing	reduce	B-VP	VBG	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	incidence	incidence	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	communicable	communicable	B-NP	JJ	UMLS:C0009450:T047:DISO	_	_	_	_
17	diseases	disease	I-NP	NNS	UMLS:C0009450:T047:DISO	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	observed	observe	I-NP	VBN	0	_	_	_	_
3	drug	drug	I-NP	NN	0	_	_	_	_
4	interactions	interaction	I-NP	NNS	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	plus	plus	O	CC	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	known	know	I-NP	VBN	0	_	_	_	_
9	effect	effect	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	probenecid	probenecid	B-NP	NN	0	_	_	_	_
12	to	to	B-VP	TO	0	_	_	_	_
13	block	block	I-VP	VB	0	_	_	_	_
14	secretion	secretion	B-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	PZA	PZA	B-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	have	have	B-VP	VBP	0	_	_	_	_
19	to	to	I-VP	TO	0	_	_	_	_
20	be	be	I-VP	VB	0	_	_	_	_
21	considered	consider	I-VP	VBN	0	_	_	_	_
22	in	in	B-PP	IN	0	_	_	_	_
23	evaluating	evaluate	B-VP	VBG	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	effect	effect	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	two	two	I-NP	CD	0	_	_	_	_
29	drugs	drug	I-NP	NNS	0	_	_	_	_
30	given	give	B-VP	VBN	0	_	_	_	_
31	together	together	B-ADVP	RB	0	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	compared	compare	B-PP	VBN	0	_	_	_	_
34	to	to	B-PP	TO	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	effect	effect	I-NP	NN	0	_	_	_	_
37	of	of	B-PP	IN	0	_	_	_	_
38	each	each	B-NP	DT	0	_	_	_	_
39	drug	drug	I-NP	NN	0	_	_	_	_
40	given	give	B-VP	VBN	0	_	_	_	_
41	separately	separately	B-ADVP	RB	0	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	Circulatory	Circulatory	B-NP	JJ	UMLS:C0444720:T047:DISO	_	_	_	_
2	arrest	arrest	I-NP	NN	UMLS:C0444720:T047:DISO	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	operating	operating	I-NP	NN	0	_	_	_	_
6	room	room	I-NP	NN	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_

1	At	At	B-PP	IN	0	_	_	_	_
2	a	a	B-NP	DT	0	_	_	_	_
3	systolic	systolic	I-NP	JJ	0	_	_	_	_
4	blood	blood	I-NP	NN	0	_	_	_	_
5	pressure	pressure	I-NP	NN	0	_	_	_	_
6	(	(	O	(	0	_	_	_	_
7	BP	BP	B-NP	NN	0	_	_	_	_
8	)	)	O	)	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	60	60	B-NP	CD	0	_	_	_	_
11	mmHg	mmHg	I-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	C02	C02	B-NP	NN	0	_	_	_	_
14	responsiveness	responsiveness	I-NP	NN	0	_	_	_	_
15	was	be	B-VP	VBD	0	_	_	_	_
16	abolished	abolish	I-VP	VBN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	but	but	O	CC	0	_	_	_	_
19	was	be	B-VP	VBD	0	_	_	_	_
20	maintained	maintain	I-VP	VBN	0	_	_	_	_
21	at	at	B-PP	IN	0	_	_	_	_
22	higher	high	B-NP	JJR	0	_	_	_	_
23	levels	level	I-NP	NNS	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	BP	BP	B-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	Iodine	Iodine	B-NP	NN	0	_	_	_	_
2	-	-	O	HYPH	0	_	_	_	_
3	123	123	B-NP	CD	0	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	satisfactorily	satisfactorily	I-VP	RB	0	_	_	_	_
6	imaged	image	I-VP	VBN	0	_	_	_	_
7	only	only	B-ADVP	RB	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	MEC	MEC	I-NP	NN	0	_	_	_	_
11	and	and	I-NP	CC	0	_	_	_	_
12	pinhole	pinhole	I-NP	NN	0	_	_	_	_
13	collimators	collimator	I-NP	NNS	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	which	which	B-NP	WDT	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	turn	turn	B-NP	NN	0	_	_	_	_
18	yielded	yield	B-VP	VBD	0	_	_	_	_
19	MTF	MTF	B-NP	NN	0	_	_	_	_
20	values	value	I-NP	NNS	0	_	_	_	_
21	comparable	comparable	B-ADJP	JJ	0	_	_	_	_
22	to	to	B-PP	TO	0	_	_	_	_
23	those	those	B-NP	DT	0	_	_	_	_
24	measured	measure	B-VP	VBN	0	_	_	_	_
25	for	for	B-PP	IN	0	_	_	_	_
26	99mTc	99mTc	B-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Petrous	Petrous	B-NP	JJ	0	_	_	_	_
2	meningioma	meningioma	I-NP	NN	0	_	_	_	_
3	en	en	B-PP	IN	0	_	_	_	_
4	plaque	plaque	B-NP	NN	UMLS:C0011389:T047:DISO	_	_	_	_
5	presenting	present	B-VP	VBG	0	_	_	_	_
6	as	as	B-PP	IN	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	right	right	I-NP	JJ	UMLS:C0229353:T023:ANAT	_	_	_	_
9	middle	middle	I-NP	JJ	UMLS:C0229353:T023:ANAT	_	_	_	_
10	ear	ear	I-NP	JJ	UMLS:C0229353:T023:ANAT	_	_	_	_
11	tumor	tumor	I-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	difficulties	difficulty	I-NP	NNS	0	_	_	_	_
3	to	to	B-VP	TO	0	_	_	_	_
4	analyse	analyse	I-VP	VB	0	_	_	_	_
5	prostaglandins	prostaglandin	B-NP	NNS	0	_	_	_	_
6	(	(	O	(	0	_	_	_	_
7	PG	PG	B-NP	NN	0	_	_	_	_
8	)	)	O	)	0	_	_	_	_
9	by	by	B-PP	IN	0	_	_	_	_
10	gas	gas	B-NP	NN	0	_	_	_	_
11	-	-	I-NP	HYPH	0	_	_	_	_
12	liquid	liquid	I-NP	NN	0	_	_	_	_
13	chromatography	chromatography	I-NP	NN	0	_	_	_	_
14	are	be	B-VP	VBP	0	_	_	_	_
15	mainly	mainly	B-ADJP	RB	0	_	_	_	_
16	due	due	I-ADJP	JJ	0	_	_	_	_
17	to	to	B-PP	TO	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	lack	lack	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	sensitivity	sensitivity	B-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	gas	gas	I-NP	NN	0	_	_	_	_
25	-	-	I-NP	HYPH	0	_	_	_	_
26	chromatograph	chromatograph	I-NP	NN	0	_	_	_	_
27	itself	itself	B-NP	PRP	0	_	_	_	_
28	(	(	O	(	0	_	_	_	_
29	higher	high	B-NP	JJR	0	_	_	_	_
30	than	than	I-NP	IN	0	_	_	_	_
31	200	200	I-NP	CD	0	_	_	_	_
32	ng	ng	I-NP	NN	0	_	_	_	_
33	)	)	O	)	0	_	_	_	_
34	and	and	B-PP	CC	0	_	_	_	_
35	to	to	B-PP	TO	0	_	_	_	_
36	the	the	B-NP	DT	0	_	_	_	_
37	poor	poor	I-NP	JJ	0	_	_	_	_
38	resolution	resolution	I-NP	NN	0	_	_	_	_
39	of	of	B-PP	IN	0	_	_	_	_
40	the	the	B-NP	DT	0	_	_	_	_
41	packed	packed	I-NP	JJ	0	_	_	_	_
42	columns	column	I-NP	NNS	0	_	_	_	_
43	.	.	O	.	0	_	_	_	_

1	On	On	B-PP	IN	0	_	_	_	_
2	cessation	cessation	B-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	steroid	steroid	B-NP	NN	0	_	_	_	_
5	therapy	therapy	I-NP	NN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	patient	patient	I-NP	NN	0	_	_	_	_
8	was	be	B-VP	VBD	0	_	_	_	_
9	noted	note	I-VP	VBN	0	_	_	_	_
10	to	to	I-VP	TO	0	_	_	_	_
11	have	have	I-VP	VB	0	_	_	_	_
12	radiologic	radiologic	B-NP	JJ	0	_	_	_	_
13	manifestations	manifestation	I-NP	NNS	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	hypertrophic	hypertrophic	B-NP	JJ	UMLS:C0178703:T047:DISO	_	_	_	_
16	osteoarthropathy	osteoarthropathy	I-NP	NN	UMLS:C0178703:T047:DISO	_	_	_	_
17	(	(	O	(	0	_	_	_	_
18	HOA	HOA	B-NP	NN	UMLS:C0409957:T047:DISO	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	as	as	B-CONJP	RB	0	_	_	_	_
21	well	well	I-CONJP	RB	0	_	_	_	_
22	as	as	I-CONJP	IN	0	_	_	_	_
23	clinical	clinical	B-NP	JJ	0	_	_	_	_
24	and	and	I-NP	CC	0	_	_	_	_
25	laboratory	laboratory	I-NP	NN	0	_	_	_	_
26	features	feature	I-NP	NNS	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	rheumatoid	rheumatoid	B-NP	JJ	UMLS:C0003873:T047:DISO	_	_	_	_
29	arthritis	arthritis	I-NP	NN	UMLS:C0003873:T047:DISO	_	_	_	_
30	(	(	O	(	0	_	_	_	_
31	RA	RA	B-NP	NN	UMLS:C0003873:T047:DISO	_	_	_	_
32	)	)	O	)	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effect	effect	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	food	food	B-NP	NN	0	_	_	_	_
5	on	on	B-PP	IN	0	_	_	_	_
6	procainamide	procainamide	B-NP	NN	0	_	_	_	_
7	absorption	absorption	I-NP	NN	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	After	After	B-PP	IN	0	_	_	_	_
2	giving	give	B-VP	VBG	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	survey	survey	I-NP	NN	0	_	_	_	_
5	on	on	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	situation	situation	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	antibiotic	antibiotic	B-NP	JJ	0	_	_	_	_
10	resistance	resistance	I-NP	NN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	region	region	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	Northern	Northern	B-NP	NNP	0	_	_	_	_
16	Bavaria	Bavaria	I-NP	NNP	0	_	_	_	_
17	during	during	B-PP	IN	0	_	_	_	_
18	1973	1973	B-NP	CD	0	_	_	_	_
19	/	/	I-NP	SYM	0	_	_	_	_
20	74	74	I-NP	CD	0	_	_	_	_
21	and	and	O	CC	0	_	_	_	_
22	comparing	compare	B-VP	VBG	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	activity	activity	I-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	a	a	B-NP	DT	0	_	_	_	_
27	sulfamethoxazole	sulfamethoxazole	I-NP	NN	0	_	_	_	_
28	(	(	O	(	0	_	_	_	_
29	SMZ	SMZ	B-NP	NN	0	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	trimethoprim	trimethoprim	B-NP	NN	0	_	_	_	_
32	(	(	O	(	0	_	_	_	_
33	TMP	TMP	B-NP	NN	0	_	_	_	_
34	)	)	O	)	0	_	_	_	_
35	combination	combination	B-NP	NN	0	_	_	_	_
36	to	to	B-PP	TO	0	_	_	_	_
37	other	other	B-NP	JJ	0	_	_	_	_
38	commonly	commonly	I-NP	RB	0	_	_	_	_
39	used	use	I-NP	VBN	0	_	_	_	_
40	antibiotics	antibiotic	I-NP	NNS	0	_	_	_	_
41	and	and	O	CC	0	_	_	_	_
42	chemotherapeutic	chemotherapeutic	B-NP	JJ	0	_	_	_	_
43	agents	agent	I-NP	NNS	0	_	_	_	_
44	,	,	O	,	0	_	_	_	_
45	the	the	B-NP	DT	0	_	_	_	_
46	results	result	I-NP	NNS	0	_	_	_	_
47	of	of	B-PP	IN	0	_	_	_	_
48	tests	test	B-NP	NNS	0	_	_	_	_
49	with	with	B-PP	IN	0	_	_	_	_
50	the	the	B-NP	DT	0	_	_	_	_
51	new	new	I-NP	JJ	0	_	_	_	_
52	combination	combination	I-NP	NN	0	_	_	_	_
53	of	of	B-PP	IN	0	_	_	_	_
54	N1	N1	B-NP	NN	0	_	_	_	_
55	-	-	O	HYPH	0	_	_	_	_
56	(	(	O	(	0	_	_	_	_
57	4	4	B-NP	CD	0	_	_	_	_
58	,	,	O	,	0	_	_	_	_
59	5	5	B-NP	CD	0	_	_	_	_
60	-	-	I-NP	HYPH	0	_	_	_	_
61	dimethyl	dimethyl	I-NP	NN	0	_	_	_	_
62	-	-	B-NP	HYPH	0	_	_	_	_
63	2	2	I-NP	CD	0	_	_	_	_
64	-	-	I-NP	HYPH	0	_	_	_	_
65	oxazolyl	oxazolyl	I-NP	NN	0	_	_	_	_
66	)	)	O	)	0	_	_	_	_
67	-	-	B-NP	HYPH	0	_	_	_	_
68	sulfanilamide	sulfanilamide	I-NP	NN	0	_	_	_	_
69	)	)	O	)	0	_	_	_	_
70	(	(	O	(	0	_	_	_	_
71	sulfamoxole	sulfamoxole	B-NP	NN	0	_	_	_	_
72	)	)	O	)	0	_	_	_	_
73	and	and	O	CC	0	_	_	_	_
74	2	2	B-NP	CD	0	_	_	_	_
75	,	,	I-NP	,	0	_	_	_	_
76	4	4	I-NP	CD	0	_	_	_	_
77	-	-	I-NP	HYPH	0	_	_	_	_
78	diamino	diamino	I-NP	NN	0	_	_	_	_
79	-	-	B-NP	HYPH	0	_	_	_	_
80	5	5	I-NP	CD	0	_	_	_	_
81	-	-	B-NP	HYPH	0	_	_	_	_
82	(	(	I-NP	(	0	_	_	_	_
83	3	3	I-NP	CD	0	_	_	_	_
84	,	,	I-NP	,	0	_	_	_	_
85	4	4	I-NP	CD	0	_	_	_	_
86	,	,	I-NP	,	0	_	_	_	_
87	5	5	I-NP	CD	0	_	_	_	_
88	-	-	I-NP	HYPH	0	_	_	_	_
89	trimethoxy	trimethoxy	I-NP	AFX	0	_	_	_	_
90	-	-	I-NP	HYPH	0	_	_	_	_
91	benzyl	benzyl	I-NP	NN	0	_	_	_	_
92	)	)	O	)	0	_	_	_	_
93	-	-	O	HYPH	0	_	_	_	_
94	pyrimidine	pyrimidine	B-NP	NN	0	_	_	_	_
95	(	(	O	(	0	_	_	_	_
96	trimethoprim	trimethoprim	B-NP	NN	0	_	_	_	_
97	)	)	O	)	0	_	_	_	_
98	at	at	B-PP	IN	0	_	_	_	_
99	a	a	B-NP	DT	0	_	_	_	_
100	ratio	ratio	I-NP	NN	0	_	_	_	_
101	of	of	B-PP	IN	0	_	_	_	_
102	5	5	B-NP	CD	0	_	_	_	_
103	:	:	I-NP	SYM	0	_	_	_	_
104	1	1	I-NP	CD	0	_	_	_	_
105	(	(	O	(	0	_	_	_	_
106	CN	CN	B-NP	NN	0	_	_	_	_
107	3123	3123	I-NP	CD	0	_	_	_	_
108	;	;	O	:	0	_	_	_	_
109	Nevin	Nevin	B-NP	NN	0	_	_	_	_
110	,	,	I-NP	,	0	_	_	_	_
111	Supristol	Supristol	I-NP	NN	0	_	_	_	_
112	)	)	O	)	0	_	_	_	_
113	are	be	B-VP	VBP	0	_	_	_	_
114	compared	compare	I-VP	VBN	0	_	_	_	_
115	to	to	B-PP	TO	0	_	_	_	_
116	those	those	B-NP	DT	0	_	_	_	_
117	of	of	B-PP	IN	0	_	_	_	_
118	tests	test	B-NP	NNS	0	_	_	_	_
119	with	with	B-PP	IN	0	_	_	_	_
120	TMP	TMP	B-NP	NN	0	_	_	_	_
121	/	/	I-NP	SYM	0	_	_	_	_
122	SMZ	SMZ	I-NP	NN	0	_	_	_	_
123	.	.	O	.	0	_	_	_	_

1	RESULTS	RESULTS	B-NP	NNS	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	Total	Total	B-NP	JJ	0	_	_	_	_
4	IgE	IgE	I-NP	NN	UMLS:C0270850:T047:DISO|:::NOCLASS	_	_	_	_
5	levels	level	I-NP	NNS	0	_	_	_	_
6	showed	show	B-VP	VBD	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	tendency	tendency	I-NP	NN	0	_	_	_	_
9	to	to	B-VP	TO	0	_	_	_	_
10	diminish	diminish	I-VP	VB	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	Does	Do	O	VBZ	0	_	_	_	_
2	afferent	afferent	B-NP	JJ	UMLS:C0001727:T047:DISO	_	_	_	_
3	loop	loop	I-NP	NN	UMLS:C0001727:T047:DISO	_	_	_	_
4	syndrome	syndrome	I-NP	NN	UMLS:C0001727:T047:DISO	_	_	_	_
5	exist	exist	B-VP	VB	0	_	_	_	_
6	?	?	O	.	0	_	_	_	_
7	]	]	O	)	0	_	_	_	_
8	It	It	B-NP	PRP	0	_	_	_	_
9	is	be	B-VP	VBZ	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	author	author	I-NP	NN	0	_	_	_	_
12	's	's	B-NP	POS	0	_	_	_	_
13	opinion	opinion	I-NP	NN	0	_	_	_	_
14	that	that	B-SBAR	IN	0	_	_	_	_
15	diagnosis	diagnosis	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	"	"	I-NP	``	0	_	_	_	_
19	adducent	adducent	I-NP	JJ	0	_	_	_	_
20	loop	loop	I-NP	NN	0	_	_	_	_
21	syndrome	syndrome	I-NP	NN	UMLS:C0039082:T047:DISO	_	_	_	_
22	"	"	O	''	0	_	_	_	_
23	is	be	B-VP	VBZ	0	_	_	_	_
24	unlikely	unlikely	B-ADJP	JJ	0	_	_	_	_
25	to	to	B-VP	TO	0	_	_	_	_
26	be	be	I-VP	VB	0	_	_	_	_
27	correct	correct	B-ADJP	JJ	0	_	_	_	_
28	in	in	B-PP	IN	0	_	_	_	_
29	patients	patient	B-NP	NNS	0	_	_	_	_
30	subjected	subject	B-VP	VBN	0	_	_	_	_
31	to	to	B-PP	TO	0	_	_	_	_
32	Billroth	Billroth	B-NP	NNP	UMLS:C0741496:T047:DISO	_	_	_	_
33	-	-	B-NP	HYPH	0	_	_	_	_
34	II	II	I-NP	CD	0	_	_	_	_
35	gastrectomy	gastrectomy	I-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	Letter	Letter	B-NP	NNP	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	Is	Be	O	VBZ	0	_	_	_	_
4	actinic	actinic	O	JJ	0	_	_	_	_
5	(	(	O	(	0	_	_	_	_
6	solar	solar	B-ADJP	JJ	0	_	_	_	_
7	)	)	O	)	0	_	_	_	_
8	damage	damage	B-VP	VBP	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	provoking	provoke	I-NP	VBG	0	_	_	_	_
11	cause	cause	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	'post	'post	B-NP	AFX	0	_	_	_	_
14	-	-	I-NP	HYPH	0	_	_	_	_
15	inflammatory	inflammatory	I-NP	JJ	0	_	_	_	_
16	elastolysis	elastolysis	I-NP	NN	UMLS:C0010495:T047:DISO	_	_	_	_
17	and	and	I-NP	CC	0	_	_	_	_
18	cutis	cutis	I-NP	NN	UMLS:C0010495:T047:DISO	_	_	_	_
19	laxa	laxa	I-NP	NN	UMLS:C0010495:T047:DISO	_	_	_	_
20	(	(	O	(	0	_	_	_	_
21	PECL	PECL	B-NP	NN	0	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	'	'	O	''	0	_	_	_	_
24	?	?	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	data	datum	I-NP	NNS	0	_	_	_	_
3	suggest	suggest	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	spontaneous	spontaneous	B-NP	JJ	0	_	_	_	_
6	recovery	recovery	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	central	central	B-NP	JJ	0	_	_	_	_
9	respiratory	respiratory	I-NP	JJ	0	_	_	_	_
10	function	function	I-NP	NN	0	_	_	_	_
11	after	after	B-PP	IN	0	_	_	_	_
12	intoxication	intoxication	B-NP	NN	0	_	_	_	_
13	with	with	B-PP	IN	0	_	_	_	_
14	Soman	Soman	B-NP	NN	0	_	_	_	_
15	or	or	I-NP	CC	0	_	_	_	_
16	Sarin	Sarin	I-NP	NN	0	_	_	_	_
17	may	may	B-VP	MD	0	_	_	_	_
18	not	not	I-VP	RB	0	_	_	_	_
19	be	be	I-VP	VB	0	_	_	_	_
20	related	relate	I-VP	VBN	0	_	_	_	_
21	to	to	B-PP	TO	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	return	return	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	AChE	AChE	B-NP	NN	:::NOCLASS	_	_	_	_
26	activity	activity	I-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Batch	Batch	B-NP	NN	0	_	_	_	_
2	cultures	culture	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	S	S	B-NP	NN	0	_	_	_	_
5	.	.	O	.	0	_	_	_	_
6	mutans	mutan	B-NP	NNS	0	_	_	_	_
7	serotype	serotype	B-VP	VBP	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	demonstrated	demonstrate	I-NP	VBN	0	_	_	_	_
10	no	no	I-NP	DT	0	_	_	_	_
11	growth	growth	I-NP	NN	0	_	_	_	_
12	on	on	B-PP	IN	0	_	_	_	_
13	MSB	MSB	B-NP	NN	0	_	_	_	_
14	agar	agar	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Also	Also	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	samples	sample	B-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	serum	serum	B-NP	NN	0	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	absorbed	absorb	I-VP	VBN	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	various	various	I-NP	JJ	0	_	_	_	_
11	solid	solid	I-NP	JJ	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	phase	phase	I-NP	NN	0	_	_	_	_
14	allergens	allergen	I-NP	NNS	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	reactivity	reactivity	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	remaining	remain	I-NP	VBG	0	_	_	_	_
21	IgE	IgE	I-NP	NN	:::NOCLASS|UMLS:C0270850:T047:DISO	_	_	_	_
22	antibodies	antibody	I-NP	NNS	:::NOCLASS	_	_	_	_
23	was	be	B-VP	VBD	0	_	_	_	_
24	determined	determine	I-VP	VBN	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Crisis	Crisis	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	therapeutic	therapeutic	I-NP	JJ	0	_	_	_	_
5	community	community	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	Great	Great	B-NP	NNP	0	_	_	_	_
8	Britain	Britain	I-NP	NNP	0	_	_	_	_

1	Pregnant	Pregnant	B-NP	JJ	0	_	_	_	_
2	women	woman	I-NP	NNS	0	_	_	_	_
3	at	at	B-PP	IN	0	_	_	_	_
4	term	term	B-NP	NN	0	_	_	_	_
5	had	have	B-VP	VBD	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	lowest	low	I-NP	JJS	0	_	_	_	_
8	levels	level	I-NP	NNS	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	antithrombin	antithrombin	B-NP	NN	:::NOCLASS	_	_	_	_
11	III	III	I-NP	CD	:::NOCLASS	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	Hematology	Hematology	B-NP	NN	0	_	_	_	_
2	problem	problem	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	month	month	I-NP	NN	0	_	_	_	_
6	:	:	O	:	0	_	_	_	_
7	band	band	B-NP	NN	0	_	_	_	_
8	or	or	I-NP	CC	0	_	_	_	_
9	seg	seg	I-NP	NN	0	_	_	_	_
10	?	?	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	is	be	B-VP	VBZ	0	_	_	_	_
3	possible	possible	B-ADJP	JJ	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	cyclic	cyclic	B-NP	JJ	0	_	_	_	_
6	variations	variation	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	heme	heme	B-NP	NN	0	_	_	_	_
9	turnover	turnover	I-NP	NN	0	_	_	_	_
10	are	be	B-VP	VBP	0	_	_	_	_
11	related	relate	I-VP	VBN	0	_	_	_	_
12	to	to	B-PP	TO	0	_	_	_	_
13	changes	change	B-NP	NNS	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	erythrocyte	erythrocyte	B-NP	NN	0	_	_	_	_
16	characteristics	characteristic	I-NP	NNS	0	_	_	_	_
17	during	during	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	progesterone	progesterone	I-NP	NN	0	_	_	_	_
20	phase	phase	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Haemodilution	Haemodilution	B-NP	NN	0	_	_	_	_
2	in	in	B-PP	IN	0	_	_	_	_
3	cardiopulmonary	cardiopulmonary	B-NP	JJ	0	_	_	_	_
4	bypass	bypass	I-NP	NN	0	_	_	_	_
5	using	use	B-VP	VBG	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	gelatine	gelatine	I-NP	NN	0	_	_	_	_
8	derivative	derivative	I-NP	NN	0	_	_	_	_
9	for	for	B-PP	IN	0	_	_	_	_
10	priming	priming	B-NP	NN	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	Extramedullary	Extramedullary	B-NP	JJ	0	_	_	_	_
2	plasmacytoma	plasmacytoma	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	parotid	parotid	I-NP	NN	UMLS:C0030580:T023:ANAT	_	_	_	_
6	gland	gland	I-NP	NN	UMLS:C0030580:T023:ANAT	_	_	_	_

1	I	I	B-NP	PRP	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	recovered	recover	I-NP	VBN	0	_	_	_	_
3	calves	calf	I-NP	NNS	0	_	_	_	_
4	were	be	B-VP	VBD	0	_	_	_	_
5	tested	test	I-VP	VBN	0	_	_	_	_
6	for	for	B-PP	IN	0	_	_	_	_
7	immunity	immunity	B-NP	NN	0	_	_	_	_
8	to	to	B-PP	TO	0	_	_	_	_
9	homologous	homologous	B-NP	JJ	0	_	_	_	_
10	severe	severe	I-NP	JJ	0	_	_	_	_
11	challenge	challenge	I-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	50	50	B-NP	CD	0	_	_	_	_
14	or	or	I-NP	CC	0	_	_	_	_
15	73	73	I-NP	CD	0	_	_	_	_
16	days	day	I-NP	NNS	0	_	_	_	_
17	after	after	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	first	first	I-NP	JJ	0	_	_	_	_
20	infection	infection	I-NP	NN	UMLS:C0021311:T047:DISO|UMLS:C0009450:T047:DISO	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	performance	performance	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	three	three	B-NP	CD	0	_	_	_	_
5	commonly	commonly	I-NP	RB	0	_	_	_	_
6	used	use	I-NP	VBN	0	_	_	_	_
7	chemical	chemical	I-NP	JJ	0	_	_	_	_
8	cartridge	cartridge	I-NP	NN	0	_	_	_	_
9	respirators	respirator	I-NP	NNS	0	_	_	_	_
10	for	for	B-PP	IN	0	_	_	_	_
11	SO2	SO2	B-NP	NN	0	_	_	_	_
12	was	be	B-VP	VBD	0	_	_	_	_
13	measured	measure	I-VP	VBN	0	_	_	_	_
14	under	under	B-PP	IN	0	_	_	_	_
15	working	work	B-NP	VBG	0	_	_	_	_
16	conditions	condition	I-NP	NNS	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	a	a	B-NP	DT	0	_	_	_	_
19	copper	copper	I-NP	NN	0	_	_	_	_
20	smelter	smelter	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	neuroleptic	neuroleptic	I-NP	JJ	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	induced	induce	I-NP	VBN	0	_	_	_	_
5	increase	increase	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	central	central	B-NP	JJ	0	_	_	_	_
8	DA	DA	I-NP	NN	0	_	_	_	_
9	turnover	turnover	I-NP	NN	0	_	_	_	_
10	(	(	O	(	0	_	_	_	_
11	an	an	B-NP	DT	0	_	_	_	_
12	indicator	indicator	I-NP	NN	0	_	_	_	_
13	for	for	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	degree	degree	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	DA	DA	B-NP	NN	:::NOCLASS	_	_	_	_
18	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
19	blocking	blocking	I-NP	NN	0	_	_	_	_
20	)	)	O	)	0	_	_	_	_
21	was	be	B-VP	VBD	0	_	_	_	_
22	found	find	I-VP	VBN	0	_	_	_	_
23	to	to	I-VP	TO	0	_	_	_	_
24	be	be	I-VP	VB	0	_	_	_	_
25	positively	positively	I-VP	RB	0	_	_	_	_
26	correlated	correlate	I-VP	VBN	0	_	_	_	_
27	with	with	B-PP	IN	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	therapeutic	therapeutic	I-NP	JJ	0	_	_	_	_
30	effect	effect	I-NP	NN	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	neuroleptics	neuroleptic	B-NP	NNS	0	_	_	_	_
33	and	and	O	CC	0	_	_	_	_
34	the	the	B-NP	DT	0	_	_	_	_
35	development	development	I-NP	NN	0	_	_	_	_
36	of	of	B-PP	IN	0	_	_	_	_
37	hypokinetic	hypokinetic	B-NP	JJ	0	_	_	_	_
38	-	-	I-NP	HYPH	0	_	_	_	_
39	rigid	rigid	I-NP	JJ	0	_	_	_	_
40	symptoms	symptom	I-NP	NNS	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	Rainbow	Rainbow	B-NP	NN	0	_	_	_	_
2	trout	trout	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	obtained	obtain	I-VP	VBN	0	_	_	_	_
5	from	from	B-PP	IN	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	commercial	commercial	I-NP	JJ	0	_	_	_	_
8	trout	trout	I-NP	NN	0	_	_	_	_
9	farm	farm	I-NP	NN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	kept	keep	B-VP	VBD	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	running	running	B-NP	JJ	0	_	_	_	_
14	water	water	I-NP	NN	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	feeding	feeding	I-NP	NN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	experimental	experimental	B-NP	JJ	0	_	_	_	_
19	pellets	pellet	I-NP	NNS	0	_	_	_	_
20	for	for	B-PP	IN	0	_	_	_	_
21	4	4	B-NP	CD	0	_	_	_	_
22	to	to	I-NP	TO	0	_	_	_	_
23	8	8	I-NP	CD	0	_	_	_	_
24	weeks	week	I-NP	NNS	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Stimulation	Stimulation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	macrophage	macrophage	B-NP	NN	0	_	_	_	_
4	function	function	I-NP	NN	0	_	_	_	_
5	by	by	B-PP	IN	0	_	_	_	_
6	killed	kill	B-NP	VBN	0	_	_	_	_
7	Bordetella	Bordetella	I-NP	NNP	0	_	_	_	_
8	pertussis	pertussis	I-NP	NN	UMLS:C0043167:T047:DISO	_	_	_	_
9	cells	cell	I-NP	NNS	0	_	_	_	_
10	did	do	B-VP	VBD	0	_	_	_	_
11	not	not	I-VP	RB	0	_	_	_	_
12	show	show	I-VP	VB	0	_	_	_	_
13	any	any	B-NP	DT	0	_	_	_	_
14	beneficial	beneficial	I-NP	JJ	0	_	_	_	_
15	effect	effect	I-NP	NN	0	_	_	_	_
16	as	as	B-PP	IN	0	_	_	_	_
17	an	an	B-NP	DT	0	_	_	_	_
18	increased	increase	I-NP	VBN	0	_	_	_	_
19	susceptibility	susceptibility	I-NP	NN	0	_	_	_	_
20	became	become	B-VP	VBD	0	_	_	_	_
21	apparent	apparent	B-ADJP	JJ	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Primary	Primary	B-NP	JJ	UMLS:C0232939:T047:DISO	_	_	_	_
2	amenorrhoea	amenorrhoea	I-NP	NN	UMLS:C0232939:T047:DISO	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	phenotypically	phenotypically	I-NP	RB	0	_	_	_	_
6	female	female	I-NP	JJ	0	_	_	_	_
7	individual	individual	I-NP	NN	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	karyotype	karyotype	I-NP	NN	0	_	_	_	_
11	46	46	I-NP	CD	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	xy	xy	B-NP	NN	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	bilateral	bilateral	B-NP	JJ	0	_	_	_	_
16	gonadoblastoma	gonadoblastoma	I-NP	NN	0	_	_	_	_

1	Toward	Toward	B-PP	IN	0	_	_	_	_
2	absolute	absolute	B-NP	JJ	0	_	_	_	_
3	methods	method	I-NP	NNS	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	clinical	clinical	B-NP	JJ	0	_	_	_	_
6	chemistry	chemistry	I-NP	NN	0	_	_	_	_
7	:	:	O	:	0	_	_	_	_
8	application	application	B-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	mass	mass	B-NP	NN	0	_	_	_	_
11	fragmentography	fragmentography	I-NP	NN	0	_	_	_	_
12	to	to	B-PP	TO	0	_	_	_	_
13	high	high	B-NP	JJ	0	_	_	_	_
14	-	-	I-NP	HYPH	0	_	_	_	_
15	accuracy	accuracy	I-NP	NN	0	_	_	_	_
16	analyses	analysis	I-NP	NNS	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Application	Application	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	2	2	I-NP	CD	0	_	_	_	_
5	-	-	I-NP	HYPH	0	_	_	_	_
6	deoxy	deoxy	I-NP	NN	0	_	_	_	_
7	-	-	B-NP	HYPH	0	_	_	_	_
8	D	D	I-NP	NN	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	glucose	glucose	I-NP	NN	0	_	_	_	_
11	method	method	I-NP	NN	0	_	_	_	_
12	to	to	B-PP	TO	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	coupling	coupling	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	cerebral	cerebral	B-NP	JJ	UMLS:C0228174:T023:ANAT|UMLS:C0006104:T023:ANAT	_	_	_	_
17	metabolism	metabolism	I-NP	NN	0	_	_	_	_
18	and	and	I-NP	CC	0	_	_	_	_
19	blood	blood	I-NP	NN	0	_	_	_	_
20	flow	flow	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Serum	Serum	B-NP	NN	0	_	_	_	_
2	gastrin	gastrin	I-NP	NN	:::NOCLASS	_	_	_	_
3	levels	level	I-NP	NNS	0	_	_	_	_
4	did	do	B-VP	VBD	0	_	_	_	_
5	not	not	I-VP	RB	0	_	_	_	_
6	change	change	I-VP	VB	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	either	either	O	CC	0	_	_	_	_
9	group	group	B-NP	NN	0	_	_	_	_
10	;	;	O	:	0	_	_	_	_
11	however	however	B-ADVP	RB	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	background	background	B-NP	NN	0	_	_	_	_
14	serum	serum	I-NP	NN	0	_	_	_	_
15	gastrin	gastrin	I-NP	NN	:::NOCLASS	_	_	_	_
16	concentrations	concentration	I-NP	NNS	0	_	_	_	_
17	were	be	B-VP	VBD	0	_	_	_	_
18	significantly	significantly	B-ADJP	RB	0	_	_	_	_
19	greater	great	I-ADJP	JJR	0	_	_	_	_
20	for	for	B-PP	IN	0	_	_	_	_
21	V	V	B-NP	NNP	0	_	_	_	_
22	&	&	I-NP	CC	0	_	_	_	_
23	P	P	I-NP	NN	0	_	_	_	_
24	patients	patient	I-NP	NNS	0	_	_	_	_
25	than	than	B-PP	IN	0	_	_	_	_
26	V	V	B-NP	NNP	0	_	_	_	_
27	&	&	I-NP	CC	0	_	_	_	_
28	A	A	I-NP	NNP	0	_	_	_	_
29	patients	patient	I-NP	NNS	0	_	_	_	_
30	throughout	throughout	B-PP	IN	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	study	study	I-NP	NN	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Efferent	Efferent	B-NP	JJ	0	_	_	_	_
2	projections	projection	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	ventral	ventral	I-NP	JJ	0	_	_	_	_
6	portion	portion	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	putamen	putaman	I-NP	NNS	UMLS:C0034169:T023:ANAT	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	frontal	frontal	I-NP	JJ	0	_	_	_	_
13	,	,	I-NP	,	0	_	_	_	_
14	parietal	parietal	I-NP	JJ	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	temporal	temporal	I-NP	JJ	0	_	_	_	_
17	regions	region	I-NP	NNS	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	cat	cat	I-NP	NN	0	_	_	_	_
21	cerebral	cerebral	I-NP	JJ	UMLS:C0007776:T023:ANAT	_	_	_	_
22	cortex	cortex	I-NP	NN	UMLS:C0007776:T023:ANAT	_	_	_	_

1	Preflight	Preflight	B-NP	NN	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	inflight	inflight	B-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	postflight	postflight	B-NP	JJ	0	_	_	_	_
7	exercise	exercise	I-NP	NN	0	_	_	_	_
8	response	response	I-NP	NN	0	_	_	_	_
9	tests	test	I-NP	NNS	0	_	_	_	_
10	were	be	B-VP	VBD	0	_	_	_	_
11	conducted	conduct	I-VP	VBN	0	_	_	_	_
12	on	on	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	astronauts	astronaut	I-NP	NNS	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	second	second	I-NP	JJ	0	_	_	_	_
18	Skylab	Skylab	I-NP	NN	0	_	_	_	_
19	mission	mission	I-NP	NN	0	_	_	_	_
20	(	(	O	(	0	_	_	_	_
21	Skylab	Skylab	B-NP	NN	0	_	_	_	_
22	3	3	I-NP	CD	0	_	_	_	_
23	)	)	O	)	0	_	_	_	_
24	as	as	B-PP	IN	0	_	_	_	_
25	part	part	B-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	an	an	B-NP	DT	0	_	_	_	_
28	evaluation	evaluation	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	physiological	physiological	B-NP	JJ	0	_	_	_	_
31	adaptation	adaptation	I-NP	NN	0	_	_	_	_
32	to	to	B-PP	TO	0	_	_	_	_
33	long	long	B-NP	JJ	0	_	_	_	_
34	-	-	I-NP	HYPH	0	_	_	_	_
35	term	term	I-NP	NN	0	_	_	_	_
36	weightlessness	weightlessness	I-NP	NN	0	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	Mean	Mean	B-NP	JJ	0	_	_	_	_
2	corpuscular	corpuscular	I-NP	JJ	:::NOCLASS	_	_	_	_
3	hemoglobin	hemoglobin	I-NP	NN	:::NOCLASS	_	_	_	_
4	concentrations	concentration	I-NP	NNS	0	_	_	_	_
5	remained	remain	B-VP	VBD	0	_	_	_	_
6	normal	normal	B-ADJP	JJ	0	_	_	_	_
7	for	for	B-PP	IN	0	_	_	_	_
8	48	48	B-NP	CD	0	_	_	_	_
9	h	h	I-NP	NN	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	then	then	B-VP	RB	0	_	_	_	_
12	decreased	decrease	I-VP	VBD	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	both	both	B-NP	DT	0	_	_	_	_
15	groups	group	I-NP	NNS	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	CO2	CO2	I-NP	NN	0	_	_	_	_
19	group	group	I-NP	NN	0	_	_	_	_
20	showing	show	B-VP	VBG	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	larger	large	I-NP	JJR	0	_	_	_	_
23	decrease	decrease	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	All	All	B-NP	DT	0	_	_	_	_
2	Cu	Cu	I-NP	NN	0	_	_	_	_
3	values	value	I-NP	NNS	0	_	_	_	_
4	obtained	obtain	B-VP	VBN	0	_	_	_	_
5	from	from	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	organs	organ	I-NP	NNS	UMLS:C0178784:T023:ANAT	_	_	_	_
8	investigated	investigate	B-VP	VBN	0	_	_	_	_
9	had	have	B-VP	VBD	0	_	_	_	_
10	reached	reach	I-VP	VBN	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	saturation	saturation	I-NP	NN	0	_	_	_	_
13	level	level	I-NP	NN	0	_	_	_	_
14	at	at	B-PP	IN	0	_	_	_	_
15	8	8	B-NP	CD	0	_	_	_	_
16	mug	mug	I-NP	NN	0	_	_	_	_
17	Cu	Cu	I-NP	NN	0	_	_	_	_
18	/	/	B-NP	SYM	0	_	_	_	_
19	g	g	I-NP	NN	0	_	_	_	_
20	diet	diet	I-NP	NN	0	_	_	_	_
21	with	with	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	exception	exception	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	values	value	I-NP	NNS	0	_	_	_	_
27	for	for	B-PP	IN	0	_	_	_	_
28	body	body	B-NP	NN	0	_	_	_	_
29	Cu	Cu	I-NP	NN	0	_	_	_	_
30	found	find	B-VP	VBN	0	_	_	_	_
31	in	in	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	dams	dam	I-NP	NNS	0	_	_	_	_
34	that	that	B-NP	WDT	0	_	_	_	_
35	were	be	B-VP	VBD	0	_	_	_	_
36	killed	kill	I-VP	VBN	0	_	_	_	_
37	on	on	B-PP	IN	0	_	_	_	_
38	the	the	B-NP	DT	0	_	_	_	_
39	day	day	I-NP	NN	0	_	_	_	_
40	of	of	B-PP	IN	0	_	_	_	_
41	delivery	delivery	B-NP	NN	0	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effect	effect	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	calcitonin	calcitonin	B-NP	NN	:::NOCLASS	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	large	large	I-NP	JJ	0	_	_	_	_
8	amount	amount	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	calcium	calcium	B-NP	NN	0	_	_	_	_
11	given	give	B-VP	VBN	0	_	_	_	_
12	orally	orally	B-ADVP	RB	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	pentagastrin	pentagastrin	B-NP	NN	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	glucagon	glucagon	I-NP	NN	:::NOCLASS	_	_	_	_
17	on	on	B-PP	IN	0	_	_	_	_
18	plasma	plasma	B-NP	NN	0	_	_	_	_
19	47Ca	47Ca	I-NP	NN	0	_	_	_	_
20	radioactivity	radioactivity	I-NP	NN	0	_	_	_	_
21	curves	curve	I-NP	NNS	0	_	_	_	_
22	in	in	B-PP	IN	0	_	_	_	_
23	subjects	subject	B-NP	NNS	0	_	_	_	_
24	pretreated	pretreate	B-VP	VBN	0	_	_	_	_
25	with	with	B-PP	IN	0	_	_	_	_
26	47Ca	47Ca	B-NP	NN	0	_	_	_	_
27	was	be	B-VP	VBD	0	_	_	_	_
28	examined	examine	I-VP	VBN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	State	State	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	body	body	I-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	disorders	disorder	B-NP	NNS	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	diurnal	diurnal	B-NP	JJ	0	_	_	_	_
9	physiological	physiological	I-NP	JJ	0	_	_	_	_
10	rhythms	rhythm	I-NP	NNS	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	long	long	B-NP	JJ	0	_	_	_	_
13	-	-	I-NP	HYPH	0	_	_	_	_
14	term	term	I-NP	NN	0	_	_	_	_
15	hypokinesia	hypokinesia	I-NP	NN	0	_	_	_	_

1	Oxygen	Oxygen	B-NP	NN	0	_	_	_	_
2	tension	tension	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	small	small	I-NP	JJ	0	_	_	_	_
6	lymph	lymph	I-NP	NN	UMLS:C0229889:T023:ANAT	_	_	_	_
7	vessels	vessel	I-NP	NNS	UMLS:C0229889:T023:ANAT	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	PLO2	PLO2	B-NP	NN	0	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	rabbit	rabbit	I-NP	NN	0	_	_	_	_
14	hind	hind	I-NP	NN	0	_	_	_	_
15	limb	limb	I-NP	NN	UMLS:C0015385:T023:ANAT	_	_	_	_
16	was	be	B-VP	VBD	0	_	_	_	_
17	measured	measure	I-VP	VBN	0	_	_	_	_
18	with	with	B-PP	IN	0	_	_	_	_
19	both	both	O	CC	0	_	_	_	_
20	a	a	B-NP	DT	0	_	_	_	_
21	flow	flow	I-NP	NN	0	_	_	_	_
22	-	-	B-VP	HYPH	0	_	_	_	_
23	through	through	B-PP	IN	0	_	_	_	_
24	micro	micro	B-NP	NN	0	_	_	_	_
25	chamber	chamber	I-NP	NN	UMLS:C0935616:T023:ANAT	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	a	a	B-NP	DT	0	_	_	_	_
28	polarographic	polarographic	I-NP	JJ	0	_	_	_	_
29	catheter	catheter	I-NP	NN	0	_	_	_	_
30	-	-	I-NP	HYPH	0	_	_	_	_
31	tip	tip	I-NP	NN	0	_	_	_	_
32	oxygen	oxygen	I-NP	NN	0	_	_	_	_
33	electrode	electrode	I-NP	NN	0	_	_	_	_
34	to	to	B-VP	TO	0	_	_	_	_
35	obtain	obtain	I-VP	VB	0	_	_	_	_
36	experimental	experimental	B-NP	JJ	0	_	_	_	_
37	data	datum	I-NP	NNS	0	_	_	_	_
38	on	on	B-PP	IN	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	source	source	I-NP	NN	0	_	_	_	_
41	of	of	B-PP	IN	0	_	_	_	_
42	oxygen	oxygen	B-NP	NN	0	_	_	_	_
43	in	in	B-PP	IN	0	_	_	_	_
44	the	the	B-NP	DT	0	_	_	_	_
45	lymph	lymph	I-NP	NN	0	_	_	_	_
46	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	response	response	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	plasma	plasma	I-NP	NN	:::NOCLASS	_	_	_	_
6	fibrinogen	fibrinogen	I-NP	NN	:::NOCLASS	_	_	_	_
7	level	level	I-NP	NN	0	_	_	_	_
8	to	to	B-PP	TO	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	subucutaneous	subucutaneous	I-NP	JJ	0	_	_	_	_
11	injection	injection	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	turpentine	turpentine	B-NP	NN	0	_	_	_	_
14	and	and	B-PP	CC	0	_	_	_	_
15	to	to	B-PP	TO	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	intravenous	intravenous	I-NP	JJ	0	_	_	_	_
18	injection	injection	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	endotoxin	endotoxin	B-NP	NN	0	_	_	_	_
21	was	be	B-VP	VBD	0	_	_	_	_
22	measured	measure	I-VP	VBN	0	_	_	_	_
23	in	in	B-PP	IN	0	_	_	_	_
24	normal	normal	B-NP	JJ	0	_	_	_	_
25	rabbits	rabbit	I-NP	NNS	0	_	_	_	_
26	and	and	B-PP	CC	0	_	_	_	_
27	in	in	B-PP	IN	0	_	_	_	_
28	rabbits	rabbit	B-NP	NNS	0	_	_	_	_
29	made	make	B-VP	VBN	0	_	_	_	_
30	granulocytopenic	granulocytopenic	B-ADJP	JJ	0	_	_	_	_
31	and	and	I-ADJP	CC	0	_	_	_	_
32	thrombocytopenic	thrombocytopenic	I-ADJP	JJ	0	_	_	_	_
33	with	with	B-PP	IN	0	_	_	_	_
34	busulfan	busulfan	B-NP	NN	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	Constantly	Constantly	B-ADVP	RB	0	_	_	_	_
2	rectilinear	rectilinear	B-VP	VB	0	_	_	_	_
3	pressure	pressure	B-NP	NN	0	_	_	_	_
4	curves	curve	I-NP	NNS	0	_	_	_	_
5	without	without	B-PP	IN	0	_	_	_	_
6	uterine	uterine	B-NP	JJ	UMLS:C0042149:T023:ANAT	_	_	_	_
7	activities	activity	I-NP	NNS	0	_	_	_	_
8	are	be	B-VP	VBP	0	_	_	_	_
9	interpreted	interpret	I-VP	VBN	0	_	_	_	_
10	as	as	B-PP	IN	0	_	_	_	_
11	characteristic	characteristic	B-NP	JJ	0	_	_	_	_
12	tocographic	tocographic	I-NP	JJ	0	_	_	_	_
13	criteria	criterion	I-NP	NNS	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	an	an	B-NP	DT	0	_	_	_	_
16	advanced	advanced	I-NP	JJ	0	_	_	_	_
17	ectopic	ectopic	I-NP	JJ	0	_	_	_	_
18	gravidity	gravidity	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Since	Since	B-SBAR	IN	0	_	_	_	_
2	myoglobin	myoglobin	B-NP	NN	:::NOCLASS	_	_	_	_
3	is	be	B-VP	VBZ	0	_	_	_	_
4	co	co	B-ADJP	AFX	0	_	_	_	_
5	-	-	O	HYPH	0	_	_	_	_
6	extracted	extract	B-VP	VBN	0	_	_	_	_
7	with	with	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	hemoglobin	hemoglobin	I-NP	NN	:::NOCLASS	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	2	2	I-NP	CD	0	_	_	_	_
13	heme	heme	I-NP	NN	0	_	_	_	_
14	pigments	pigment	I-NP	NNS	0	_	_	_	_
15	are	be	B-VP	VBP	0	_	_	_	_
16	separated	separate	I-VP	VBN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	one	one	B-NP	CD	0	_	_	_	_
19	portion	portion	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	extract	extract	I-NP	NN	0	_	_	_	_
23	by	by	B-PP	IN	0	_	_	_	_
24	precipitating	precipitate	B-VP	VBG	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	hemoglobin	hemoglobin	I-NP	NN	:::NOCLASS	_	_	_	_
27	in	in	B-PP	IN	0	_	_	_	_
28	an	an	B-NP	DT	0	_	_	_	_
29	85	85	I-NP	CD	0	_	_	_	_
30	%	%	I-NP	NN	0	_	_	_	_
31	(	(	O	(	0	_	_	_	_
32	NH4	NH4	B-NP	NN	0	_	_	_	_
33	)	)	O	)	0	_	_	_	_
34	2SO4	2SO4	B-NP	NN	0	_	_	_	_
35	solution	solution	I-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	Considering	Consider	B-VP	VBG	0	_	_	_	_
2	these	these	B-NP	DT	0	_	_	_	_
3	sources	source	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	error	error	B-NP	NN	0	_	_	_	_
6	some	some	B-NP	DT	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	variability	variability	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	present	present	I-NP	JJ	0	_	_	_	_
13	investigation	investigation	I-NP	NN	0	_	_	_	_
14	might	might	B-VP	MD	0	_	_	_	_
15	be	be	I-VP	VB	0	_	_	_	_
16	avoided	avoid	I-VP	VBN	0	_	_	_	_
17	by	by	B-PP	IN	0	_	_	_	_
18	systematic	systematic	B-NP	JJ	0	_	_	_	_
19	instructions	instruction	I-NP	NNS	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	E	E	B-NP	NN	0	_	_	_	_
2	50	50	I-NP	CD	0	_	_	_	_
3	,	,	I-NP	,	0	_	_	_	_
4	843	843	I-NP	CD	0	_	_	_	_
5	(	(	O	(	0	_	_	_	_
6	1994	1994	B-NP	CD	0	_	_	_	_
7	)	)	O	)	0	_	_	_	_
8	]	]	O	)	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Six	Six	B-NP	CD	0	_	_	_	_
2	patients	patient	I-NP	NNS	0	_	_	_	_
3	with	with	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	acute	acute	B-NP	JJ	0	_	_	_	_
8	mania	mania	I-NP	NN	0	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	treated	treat	I-VP	VBN	0	_	_	_	_
11	with	with	B-PP	IN	0	_	_	_	_
12	high	high	B-NP	JJ	0	_	_	_	_
13	doses	dose	I-NP	NNS	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	beta	beta	I-NP	SYM	0	_	_	_	_
17	-	-	I-NP	HYPH	0	_	_	_	_
18	adrenergic	adrenergic	I-NP	JJ	0	_	_	_	_
19	blocking	block	I-NP	VBG	0	_	_	_	_
20	agent	agent	I-NP	NN	0	_	_	_	_
21	propranolol	propranolol	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Effect	Effect	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	trauma	trauma	B-NP	NN	0	_	_	_	_
4	on	on	B-PP	IN	0	_	_	_	_
5	plasma	plasma	B-NP	NN	:::NOCLASS	_	_	_	_
6	glucagon	glucagon	I-NP	NN	:::NOCLASS	_	_	_	_
7	and	and	I-NP	CC	0	_	_	_	_
8	insulin	insulin	I-NP	NN	:::NOCLASS	_	_	_	_
9	concentrations	concentration	I-NP	NNS	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	sheep	sheep	B-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	With	With	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	help	help	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	nomogram	nomogram	I-NP	NN	0	_	_	_	_
7	one	one	I-NP	NN	0	_	_	_	_
8	can	can	B-VP	MD	0	_	_	_	_
9	read	read	I-VP	VB	0	_	_	_	_
10	off	off	B-PRT	RP	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	refraction	refraction	I-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	when	when	B-ADVP	WRB	0	_	_	_	_
15	axis	axis	B-NP	NN	UMLS:C0004457:T023:ANAT	_	_	_	_
16	length	length	I-NP	NN	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	corneal	corneal	B-NP	JJ	0	_	_	_	_
19	curvature	curvature	I-NP	NN	0	_	_	_	_
20	are	be	B-VP	VBP	0	_	_	_	_
21	known	know	I-VP	VBN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	up	up	B-ADVP	RB	0	_	_	_	_
3	-	-	O	HYPH	0	_	_	_	_
4	grading	grading	B-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	final	final	I-NP	JJ	0	_	_	_	_
8	score	score	I-NP	NN	0	_	_	_	_
9	by	by	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	CA	CA	I-NP	NN	UMLS:C0019564:T023:ANAT	_	_	_	_
12	component	component	I-NP	NN	0	_	_	_	_
13	is	be	B-VP	VBZ	0	_	_	_	_
14	greater	great	B-ADJP	JJR	0	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	3	3	B-NP	CD	0	_	_	_	_
17	-	-	I-NP	HYPH	0	_	_	_	_
18	8	8	I-NP	CD	0	_	_	_	_
19	%	%	I-NP	NN	0	_	_	_	_
20	)	)	O	)	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	less	less	I-NP	RBR	0	_	_	_	_
24	able	able	I-NP	JJ	0	_	_	_	_
25	students	student	I-NP	NNS	0	_	_	_	_
26	with	with	B-PP	IN	0	_	_	_	_
27	scores	score	B-NP	NNS	0	_	_	_	_
28	below	below	B-PP	IN	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	mean	mean	I-NP	JJ	0	_	_	_	_
31	level	level	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Compared	Compare	B-PP	VBN	0	_	_	_	_
2	to	to	B-PP	TO	0	_	_	_	_
3	controls	control	B-NP	NNS	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	both	both	O	CC	0	_	_	_	_
6	UB	UB	B-NP	NN	0	_	_	_	_
7	and	and	I-NP	CC	0	_	_	_	_
8	OCS	OCS	I-NP	NN	0	_	_	_	_
9	rats	rat	I-NP	NNS	0	_	_	_	_
10	showed	show	B-VP	VBD	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	small	small	I-NP	JJ	0	_	_	_	_
13	but	but	I-NP	CC	0	_	_	_	_
14	significant	significant	I-NP	JJ	0	_	_	_	_
15	post	post	I-NP	AFX	0	_	_	_	_
16	-	-	I-NP	HYPH	0	_	_	_	_
17	operative	operative	I-NP	JJ	0	_	_	_	_
18	reduction	reduction	I-NP	NN	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	nocturnality	nocturnality	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	drinking	drinking	B-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Effect	Effect	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	indomethacin	indomethacin	B-NP	NN	0	_	_	_	_
4	on	on	B-PP	IN	0	_	_	_	_
5	coronary	coronary	B-NP	JJ	UMLS:C0018787:T023:ANAT	_	_	_	_
6	circulation	circulation	I-NP	NN	0	_	_	_	_
7	:	:	O	:	0	_	_	_	_
8	effect	effect	B-NP	NN	0	_	_	_	_
9	on	on	B-PP	IN	0	_	_	_	_
10	ECG	ECG	B-NP	NN	0	_	_	_	_
11	tracing	tracing	I-NP	NN	0	_	_	_	_

1	Dual	Dual	B-NP	JJ	0	_	_	_	_
2	innervation	innervation	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	fast	fast	B-NP	JJ	0	_	_	_	_
5	fibers	fiber	I-NP	NNS	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	trunk	trunk	B-NP	NN	UMLS:C0581755:T023:ANAT	_	_	_	_
8	muscles	muscle	I-NP	NNS	UMLS:C0581755:T023:ANAT	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	lamprey	lamprey	B-NP	NN	0	_	_	_	_
11	larvae	larva	I-NP	NNS	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	feed	feed	I-NP	NN	0	_	_	_	_
3	consumed	consume	B-VP	VBD	0	_	_	_	_
4	which	which	B-NP	WDT	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	lowered	lower	I-VP	VBN	0	_	_	_	_
7	by	by	B-PP	IN	0	_	_	_	_
8	25	25	B-NP	CD	0	_	_	_	_
9	%	%	I-NP	NN	0	_	_	_	_
10	initially	initially	B-ADVP	RB	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	did	do	B-VP	VBD	0	_	_	_	_
13	not	not	I-VP	RB	0	_	_	_	_
14	alter	alter	I-VP	VB	0	_	_	_	_
15	later	later	B-ADVP	RB	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Certain	Certain	B-NP	JJ	0	_	_	_	_
2	characteristics	characteristic	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	eye	eye	B-NP	NN	UMLS:C0015392:T023:ANAT	_	_	_	_
5	changes	change	I-NP	NNS	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	patients	patient	B-NP	NNS	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	pheochromocytoma	pheochromocytoma	B-NP	NN	0	_	_	_	_
10	including	include	B-PP	VBG	0	_	_	_	_
11	Sipple	Sipple	B-NP	NNP	0	_	_	_	_
12	's	's	B-NP	POS	0	_	_	_	_
13	syndrome	syndrome	I-NP	NN	UMLS:C0039082:T047:DISO	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	color	color	I-NP	NN	0	_	_	_	_
3	-	-	I-NP	HYPH	0	_	_	_	_
4	word	word	I-NP	NN	0	_	_	_	_
5	interference	interference	I-NP	NN	0	_	_	_	_
6	effect	effect	I-NP	NN	0	_	_	_	_
7	previously	previously	B-VP	RB	0	_	_	_	_
8	reported	report	I-VP	VBN	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	normal	normal	B-NP	JJ	0	_	_	_	_
11	populations	population	I-NP	NNS	0	_	_	_	_
12	when	when	B-ADVP	WRB	0	_	_	_	_
13	given	give	B-PP	VBN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	Stroop	Stroop	I-NP	NNP	0	_	_	_	_
16	test	test	I-NP	NN	0	_	_	_	_
17	was	be	B-VP	VBD	0	_	_	_	_
18	demonstrated	demonstrate	I-VP	VBN	0	_	_	_	_
19	for	for	B-PP	IN	0	_	_	_	_
20	this	this	B-NP	DT	0	_	_	_	_
21	retarded	retard	I-NP	VBN	0	_	_	_	_
22	sample	sample	I-NP	NN	0	_	_	_	_
23	using	use	B-VP	VBG	0	_	_	_	_
24	a	a	B-NP	DT	0	_	_	_	_
25	special	special	I-NP	JJ	0	_	_	_	_
26	format	format	I-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	found	find	I-VP	VBN	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	under	under	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	selected	select	I-NP	VBN	0	_	_	_	_
8	conditions	condition	I-NP	NNS	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	linear	linear	I-NP	JJ	0	_	_	_	_
11	dependence	dependence	I-NP	NN	0	_	_	_	_
12	exists	exist	B-VP	VBZ	0	_	_	_	_
13	between	between	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	betaI	betaI	I-NP	NN	0	_	_	_	_
16	%	%	I-NP	NN	0	_	_	_	_
17	value	value	I-NP	NN	0	_	_	_	_
18	and	and	I-NP	CC	0	_	_	_	_
19	lgC	lgC	I-NP	NN	0	_	_	_	_
20	within	within	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	range	range	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	0	0	B-NP	CD	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_
26	5	5	B-NP	CD	0	_	_	_	_
27	-	-	I-NP	HYPH	0	_	_	_	_
28	-	-	I-NP	SYM	0	_	_	_	_
29	10	10	I-NP	CD	0	_	_	_	_
30	mug	mug	I-NP	NN	0	_	_	_	_
31	ruscogenin	ruscogenin	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	influence	influence	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	adrenergic	adrenergic	B-NP	JJ	0	_	_	_	_
5	nerves	nerve	I-NP	NNS	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	response	response	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	blood	blood	B-NP	NN	UMLS:C0005847:T023:ANAT	_	_	_	_
11	vessels	vessel	I-NP	NNS	UMLS:C0005847:T023:ANAT	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	rabbit	rabbit	I-NP	NN	0	_	_	_	_
15	ear	ear	I-NP	NN	UMLS:C0013443:T023:ANAT	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	2	2	B-NP	CD	:::NOCLASS	_	_	_	_
18	-	-	O	HYPH	:::NOCLASS	_	_	_	_
19	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
20	phenylalanine	phenylalanine	I-NP	NN	:::NOCLASS	_	_	_	_
21	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
22	8	8	I-NP	CD	:::NOCLASS	_	_	_	_
23	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
24	lysine	lysine	I-NP	NN	:::NOCLASS	_	_	_	_
25	vasopressin	vasopressin	I-NP	NN	:::NOCLASS	_	_	_	_
26	(	(	O	(	0	_	_	_	_
27	Octapressin	Octapressin	B-NP	NN	:::NOCLASS	_	_	_	_
28	)	)	O	)	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	Potscoital	Potscoital	B-NP	JJ	0	_	_	_	_
2	test	test	I-NP	NN	0	_	_	_	_

1	I	I	B-NP	PRP	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	When	When	B-ADVP	WRB	0	_	_	_	_
2	a	a	B-NP	DT	0	_	_	_	_
3	tumour	tumour	I-NP	NN	0	_	_	_	_
4	is	be	B-VP	VBZ	0	_	_	_	_
5	present	present	B-NP	JJ	0	_	_	_	_
6	nipple	nipple	I-NP	NN	UMLS:C0028109:T023:ANAT	_	_	_	_
7	discharge	discharge	I-NP	NN	0	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	little	little	B-NP	JJ	0	_	_	_	_
11	importance	importance	I-NP	NN	0	_	_	_	_
12	for	for	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	treatment	treatment	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Studies	Study	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	biochemical	biochemical	B-NP	JJ	0	_	_	_	_
4	and	and	I-NP	CC	0	_	_	_	_
5	morphological	morphological	I-NP	JJ	0	_	_	_	_
6	changes	change	I-NP	NNS	0	_	_	_	_
7	(	(	O	(	0	_	_	_	_
8	between	between	B-PP	IN	0	_	_	_	_
9	normal	normal	B-NP	JJ	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	treated	treat	I-NP	VBN	0	_	_	_	_
12	animals	animal	I-NP	NNS	0	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	show	show	B-VP	VBP	0	_	_	_	_
15	that	that	B-SBAR	IN	0	_	_	_	_
16	chrysotile	chrysotile	B-NP	NN	0	_	_	_	_
17	induces	induce	B-VP	VBZ	0	_	_	_	_
18	an	an	B-NP	DT	0	_	_	_	_
19	increase	increase	I-NP	NN	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	lung	lung	I-NP	NN	UMLS:C0024109:T023:ANAT	_	_	_	_
23	free	free	I-NP	JJ	0	_	_	_	_
24	cell	cell	I-NP	NN	0	_	_	_	_
25	population	population	I-NP	NN	0	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	pulmonary	pulmonary	B-NP	JJ	UMLS:C0024109:T023:ANAT	_	_	_	_
28	surfactant	surfactant	I-NP	JJ	0	_	_	_	_
29	levels	level	I-NP	NNS	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Infrared	Infrared	B-NP	JJ	0	_	_	_	_
2	measurements	measurement	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	temperature	temperature	B-NP	NN	0	_	_	_	_
5	changes	change	I-NP	NNS	0	_	_	_	_
6	and	and	I-NP	CC	0	_	_	_	_
7	estimates	estimate	I-NP	NNS	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	heating	heating	I-NP	NN	0	_	_	_	_
11	produced	produce	B-VP	VBN	0	_	_	_	_
12	at	at	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	mical	mical	I-NP	JJ	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Who	Who	B-NP	WP	0	_	_	_	_
2	says	say	B-VP	VBZ	0	_	_	_	_
3	'National	'National	B-NP	NNP	0	_	_	_	_
4	Health	Health	I-NP	NNP	0	_	_	_	_
5	Dis	Dis	I-NP	NNP	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	service	service	I-NP	NN	0	_	_	_	_
8	'	'	O	''	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Is	Be	O	VBZ	0	_	_	_	_
2	criticism	criticism	B-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	patient	patient	B-NP	NN	0	_	_	_	_
5	care	care	I-NP	NN	0	_	_	_	_
6	justified	justified	B-ADJP	JJ	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	does	do	O	VBZ	0	_	_	_	_
9	it	it	B-NP	PRP	0	_	_	_	_
10	have	have	B-VP	VB	0	_	_	_	_
11	educational	educational	B-NP	JJ	0	_	_	_	_
12	value	value	I-NP	NN	0	_	_	_	_
13	?	?	O	.	0	_	_	_	_
14	Patients	Patient	B-NP	NNS	0	_	_	_	_
15	'	'	I-NP	''	0	_	_	_	_
16	criticism	criticism	I-NP	NN	0	_	_	_	_
17	contributes	contribute	B-VP	VBZ	0	_	_	_	_
18	to	to	B-PP	TO	0	_	_	_	_
19	improved	improve	B-NP	VBN	0	_	_	_	_
20	patient	patient	I-NP	NN	0	_	_	_	_
21	care	care	I-NP	NN	0	_	_	_	_

1	Critique	Critique	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	"	"	O	``	0	_	_	_	_
4	Interactive	Interactive	B-NP	JJ	0	_	_	_	_
5	Effects	Effect	I-NP	NNS	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	Test	Test	B-NP	NN	0	_	_	_	_
8	Anxiety	Anxiety	I-NP	NN	0	_	_	_	_
9	and	and	I-NP	CC	0	_	_	_	_
10	Credit	Credit	I-NP	NN	0	_	_	_	_
11	/	/	I-NP	SYM	0	_	_	_	_
12	No	No	I-NP	NN	0	_	_	_	_
13	Credit	Credit	I-NP	NN	0	_	_	_	_
14	or	or	I-NP	CC	0	_	_	_	_
15	A	A	I-NP	NN	0	_	_	_	_
16	-	-	I-NP	HYPH	0	_	_	_	_
17	F	F	I-NP	NN	0	_	_	_	_
18	Grade	Grade	I-NP	NN	0	_	_	_	_
19	Condition	Condition	I-NP	NN	UMLS:C0012634:T047:DISO	_	_	_	_
20	upon	upon	B-PP	IN	0	_	_	_	_
21	Short	Short	B-NP	JJ	0	_	_	_	_
22	-	-	I-NP	HYPH	0	_	_	_	_
23	term	term	I-NP	NN	0	_	_	_	_
24	and	and	I-NP	CC	0	_	_	_	_
25	Long	Long	I-NP	JJ	0	_	_	_	_
26	-	-	I-NP	HYPH	0	_	_	_	_
27	term	term	I-NP	NN	0	_	_	_	_
28	Recall	Recall	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	Course	Course	B-NP	NN	0	_	_	_	_
31	Information	Information	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	have	have	B-VP	VBP	0	_	_	_	_
4	shown	show	I-VP	VBN	0	_	_	_	_
5	that	that	B-SBAR	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	majority	majority	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	tested	test	B-NP	VBN	0	_	_	_	_
10	staphylococci	staphylococci	I-NP	NNS	0	_	_	_	_
11	were	be	B-VP	VBD	0	_	_	_	_
12	resistant	resistant	B-ADJP	JJ	0	_	_	_	_
13	to	to	B-PP	TO	0	_	_	_	_
14	penicillin	penicillin	B-NP	NN	0	_	_	_	_
15	G	G	I-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	erythromycin	erythromycin	B-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	produced	produce	B-VP	VBD	0	_	_	_	_
21	beta	beta	B-NP	SYM	:::NOCLASS	_	_	_	_
22	-	-	B-VP	HYPH	:::NOCLASS	_	_	_	_
23	lactamase	lactamase	B-NP	NN	:::NOCLASS	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Since	Since	B-PP	IN	0	_	_	_	_
2	1968	1968	B-NP	CD	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	steep	steep	I-NP	JJ	0	_	_	_	_
6	decrease	decrease	I-NP	NN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	number	number	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	strains	strain	B-NP	NNS	0	_	_	_	_
12	resistant	resistant	B-ADJP	JJ	0	_	_	_	_
13	to	to	B-PP	TO	0	_	_	_	_
14	three	three	B-NP	CD	0	_	_	_	_
15	or	or	I-NP	CC	0	_	_	_	_
16	more	more	I-NP	JJR	0	_	_	_	_
17	antibiotics	antibiotic	I-NP	NNS	0	_	_	_	_
18	(	(	O	(	0	_	_	_	_
19	multiple	multiple	B-NP	JJ	0	_	_	_	_
20	-	-	I-NP	HYPH	0	_	_	_	_
21	resistant	resistant	B-ADJP	JJ	0	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	and	and	O	CC	0	_	_	_	_
24	in	in	B-PP	IN	0	_	_	_	_
25	strains	strain	B-NP	NNS	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	83A	83A	I-NP	NN	0	_	_	_	_
29	complex	complex	I-NP	NN	0	_	_	_	_
30	was	be	B-VP	VBD	0	_	_	_	_
31	noticed	notice	I-VP	VBN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Improvement	Improvement	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	nursing	nurse	B-VP	VBG	0	_	_	_	_
4	instruction	instruction	B-NP	NN	0	_	_	_	_
5	to	to	B-VP	TO	0	_	_	_	_
6	be	be	I-VP	VB	0	_	_	_	_
7	given	give	I-VP	VBN	0	_	_	_	_
8	at	at	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	time	time	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	discharge	discharge	B-NP	NN	0	_	_	_	_
13	from	from	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	ward	ward	I-NP	NN	0	_	_	_	_
16	for	for	B-PP	IN	0	_	_	_	_
17	premature	premature	B-NP	JJ	0	_	_	_	_
18	infants	infant	I-NP	NNS	0	_	_	_	_

1	No	No	B-NP	DT	0	_	_	_	_
2	difference	difference	I-NP	NN	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	clinical	clinical	I-NP	JJ	0	_	_	_	_
6	acceptability	acceptability	I-NP	NN	0	_	_	_	_
7	could	could	B-VP	MD	0	_	_	_	_
8	be	be	I-VP	VB	0	_	_	_	_
9	ascertained	ascertain	I-VP	VBN	0	_	_	_	_
10	between	between	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	two	two	I-NP	CD	0	_	_	_	_
13	groups	group	I-NP	NNS	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	After	After	B-PP	IN	0	_	_	_	_
2	90	90	B-NP	CD	0	_	_	_	_
3	d	d	I-NP	NN	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	subsurface	subsurface	I-NP	NN	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	radiolucent	radiolucent	B-NP	JJ	0	_	_	_	_
8	caries	cary	I-NP	NNS	UMLS:C0333519:T047:DISO|UMLS:C0011334:T047:DISO	_	_	_	_
9	-	-	O	HYPH	0	_	_	_	_
10	like	like	B-NP	JJ	0	_	_	_	_
11	lesion	lesion	I-NP	NN	0	_	_	_	_
12	was	be	B-VP	VBD	0	_	_	_	_
13	observed	observe	I-VP	VBN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	two	two	B-NP	CD	0	_	_	_	_
16	specimens	specimen	I-NP	NNS	0	_	_	_	_
17	only	only	B-ADVP	RB	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	contraceptive	contraceptive	I-NP	JJ	0	_	_	_	_
3	pattern	pattern	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	157	157	B-NP	CD	0	_	_	_	_
6	women	woman	I-NP	NNS	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	analysed	analyse	I-VP	VBN	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	13	13	B-NP	CD	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_
12	8	8	B-NP	CD	0	_	_	_	_
13	percent	percent	I-NP	NN	0	_	_	_	_
14	were	be	B-VP	VBD	0	_	_	_	_
15	using	use	I-VP	VBG	0	_	_	_	_
16	inefficient	inefficient	B-NP	JJ	0	_	_	_	_
17	methods	method	I-NP	NNS	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Plethysmographic	Plethysmographic	B-NP	JJ	0	_	_	_	_
2	technique	technique	I-NP	NN	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	indirect	indirect	B-NP	JJ	0	_	_	_	_
5	blood	blood	I-NP	NN	0	_	_	_	_
6	pressure	pressure	I-NP	NN	0	_	_	_	_
7	recordings	recording	I-NP	NNS	0	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	used	use	I-VP	VBN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	I	I	B-NP	PRP	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	second	second	I-NP	JJ	0	_	_	_	_
3	and	and	I-NP	CC	0	_	_	_	_
4	third	third	I-NP	JJ	0	_	_	_	_
5	responded	respond	B-VP	VBD	0	_	_	_	_
6	similarly	similarly	B-ADVP	RB	0	_	_	_	_
7	to	to	B-PP	TO	0	_	_	_	_
8	either	either	O	CC	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	combined	combine	I-NP	VBN	0	_	_	_	_
11	cyclophosphamide	cyclophosphamide	I-NP	NN	0	_	_	_	_
12	+	+	O	SYM	0	_	_	_	_
13	antilymphocyte	antilymphocyte	B-NP	NN	:::NOCLASS	_	_	_	_
14	globulin	globulin	I-NP	NN	:::NOCLASS	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	ALG	ALG	B-NP	NN	:::NOCLASS	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	treatment	treatment	B-NP	NN	0	_	_	_	_
19	or	or	B-PP	CC	0	_	_	_	_
20	to	to	B-PP	TO	0	_	_	_	_
21	ALG	ALG	B-NP	NN	:::NOCLASS	_	_	_	_
22	administration	administration	I-NP	NN	0	_	_	_	_
23	preceded	precede	B-VP	VBN	0	_	_	_	_
24	by	by	B-PP	IN	0	_	_	_	_
25	a	a	B-NP	DT	0	_	_	_	_
26	small	small	I-NP	JJ	0	_	_	_	_
27	dosage	dosage	I-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	cyclophosphamide	cyclophosphamide	B-NP	NN	0	_	_	_	_
30	,	,	O	,	0	_	_	_	_
31	which	which	B-NP	WDT	0	_	_	_	_
32	had	have	B-VP	VBD	0	_	_	_	_
33	proved	prove	I-VP	VBN	0	_	_	_	_
34	ineffective	ineffective	B-ADJP	JJ	0	_	_	_	_
35	when	when	B-ADVP	WRB	0	_	_	_	_
36	administered	administer	B-VP	VBN	0	_	_	_	_
37	alone	alone	B-ADVP	RB	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_

1	Evidence	Evidence	B-NP	NN	0	_	_	_	_
2	is	be	B-VP	VBZ	0	_	_	_	_
3	presented	present	I-VP	VBN	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	Leber	Leber	B-NP	NNP	0	_	_	_	_
6	's	's	B-NP	POS	0	_	_	_	_
7	military	military	I-NP	JJ	0	_	_	_	_
8	aneurysm	aneurysm	I-NP	NN	UMLS:C0002940:T047:DISO	_	_	_	_
9	retinitis	retinitis	I-NP	NN	UMLS:C0035333:T047:DISO	_	_	_	_
10	is	be	B-VP	VBZ	0	_	_	_	_
11	not	not	O	RB	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	separate	separate	I-NP	JJ	0	_	_	_	_
14	entity	entity	I-NP	NN	0	_	_	_	_
15	but	but	O	CC	0	_	_	_	_
16	a	a	B-NP	DT	0	_	_	_	_
17	special	special	I-NP	JJ	0	_	_	_	_
18	form	form	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	Coats	Coats	B-NP	NNP	UMLS:C0154832:T047:DISO	_	_	_	_
21	'	'	B-NP	POS	UMLS:C0154832:T047:DISO	_	_	_	_
22	disease	disease	I-NP	NN	UMLS:C0154832:T047:DISO	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Fibrin	Fibrin	B-NP	NN	:::NOCLASS	_	_	_	_
2	cloaking	cloak	B-VP	VBG	0	_	_	_	_
3	along	along	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	catheter	catheter	I-NP	NN	0	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	found	find	I-VP	VBN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	20	20	B-NP	CD	0	_	_	_	_
10	patients	patient	I-NP	NNS	0	_	_	_	_
11	studied	study	B-VP	VBN	0	_	_	_	_
12	by	by	B-PP	IN	0	_	_	_	_
13	pull	pull	B-VP	VB	0	_	_	_	_
14	-	-	O	HYPH	0	_	_	_	_
15	out	out	B-PRT	RP	0	_	_	_	_
16	arteriography	arteriography	B-NP	NN	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	was	be	B-VP	VBD	0	_	_	_	_
19	unassociated	unassociated	B-ADJP	JJ	0	_	_	_	_
20	with	with	B-PP	IN	0	_	_	_	_
21	clinical	clinical	B-NP	JJ	0	_	_	_	_
22	symptoms	symptom	I-NP	NNS	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	influence	influence	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	mobile	mobile	I-NP	JJ	0	_	_	_	_
6	pupil	pupil	I-NP	NN	UMLS:C0034121:T023:ANAT	_	_	_	_
7	on	on	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	response	response	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	DC	DC	I-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	ERG	ERG	I-NP	NN	0	_	_	_	_
15	is	be	B-VP	VBZ	0	_	_	_	_
16	demonstrated	demonstrate	I-VP	VBN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	newly	newly	I-NP	RB	0	_	_	_	_
3	synthesized	synthesize	I-NP	VBN	0	_	_	_	_
4	anti	anti	I-NP	AFX	0	_	_	_	_
5	-	-	I-NP	HYPH	0	_	_	_	_
6	inflammatory	inflammatory	I-NP	JJ	0	_	_	_	_
7	agent	agent	I-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	Y	Y	B-NP	NN	0	_	_	_	_
10	-	-	O	HYPH	0	_	_	_	_
11	8004	8004	B-NP	CD	0	_	_	_	_
12	demonstrated	demonstrate	B-VP	VBD	0	_	_	_	_
13	a	a	B-NP	DT	0	_	_	_	_
14	greater	great	I-NP	JJR	0	_	_	_	_
15	inhibition	inhibition	I-NP	NN	0	_	_	_	_
16	than	than	B-SBAR	IN	0	_	_	_	_
17	did	do	O	VBD	0	_	_	_	_
18	indomethacin	indomethacin	B-NP	NN	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	IM	IM	B-NP	NN	0	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_
23	on	on	B-PP	IN	0	_	_	_	_
24	inflammatory	inflammatory	B-NP	JJ	0	_	_	_	_
25	response	response	I-NP	NN	0	_	_	_	_
26	such	such	B-PP	JJ	0	_	_	_	_
27	as	as	I-PP	IN	0	_	_	_	_
28	ultraviolet	ultraviolet	B-NP	JJ	0	_	_	_	_
29	erythema	erythema	I-NP	NN	0	_	_	_	_
30	in	in	B-PP	IN	0	_	_	_	_
31	guinea	guinea	B-NP	NN	0	_	_	_	_
32	pigs	pig	I-NP	NNS	0	_	_	_	_
33	,	,	O	,	0	_	_	_	_
34	carrageenin	carrageenin	B-NP	NN	0	_	_	_	_
35	edema	edema	I-NP	NN	0	_	_	_	_
36	,	,	O	,	0	_	_	_	_
37	evans	evan	B-NP	NNS	0	_	_	_	_
38	blue	blue	B-ADJP	JJ	0	_	_	_	_
39	and	and	O	CC	0	_	_	_	_
40	carrageenin	carrageenin	B-NP	NN	0	_	_	_	_
41	-	-	O	HYPH	0	_	_	_	_
42	induced	induce	B-NP	VBN	0	_	_	_	_
43	pleuritis	pleuritis	I-NP	NN	UMLS:C0032231:T047:DISO	_	_	_	_
44	and	and	O	CC	0	_	_	_	_
45	acetic	acetic	B-NP	JJ	0	_	_	_	_
46	acid	acid	I-NP	NN	0	_	_	_	_
47	-	-	B-NP	HYPH	0	_	_	_	_
48	induced	induce	I-NP	VBN	0	_	_	_	_
49	peritonitis	peritonitis	I-NP	NN	UMLS:C0031154:T047:DISO	_	_	_	_
50	in	in	B-PP	IN	0	_	_	_	_
51	rats	rat	B-NP	NNS	0	_	_	_	_
52	.	.	O	.	0	_	_	_	_

1	As	As	B-SBAR	IN	0	_	_	_	_
2	stands	stand	B-NP	NNS	0	_	_	_	_
3	shifted	shift	B-VP	VBN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	dominance	dominance	B-NP	NN	0	_	_	_	_
6	from	from	B-PP	IN	0	_	_	_	_
7	pine	pine	B-NP	NN	0	_	_	_	_
8	to	to	B-VP	TO	0	_	_	_	_
9	fir	fir	I-VP	VB	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	age	age	B-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	subalpine	subalpine	B-NP	NN	0	_	_	_	_
14	fir	fir	I-NP	NN	0	_	_	_	_
15	appeared	appear	B-VP	VBD	0	_	_	_	_
16	to	to	I-VP	TO	0	_	_	_	_
17	maintain	maintain	I-VP	VB	0	_	_	_	_
18	gradually	gradually	B-ADVP	RB	0	_	_	_	_
19	increasing	increase	B-VP	VBG	0	_	_	_	_
20	rates	rate	B-NP	NNS	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	whole	whole	B-NP	JJ	0	_	_	_	_
23	-	-	I-NP	HYPH	0	_	_	_	_
24	forest	forest	I-NP	NN	0	_	_	_	_
25	productivity	productivity	I-NP	NN	0	_	_	_	_
26	until	until	B-SBAR	IN	0	_	_	_	_
27	stands	stand	B-NP	NNS	0	_	_	_	_
28	were	be	B-VP	VBD	0	_	_	_	_
29	approximately	approximately	B-NP	RB	0	_	_	_	_
30	400	400	I-NP	CD	0	_	_	_	_
31	years	year	I-NP	NNS	0	_	_	_	_
32	old	old	B-ADJP	JJ	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Alpha	Alpha	B-NP	NN	:::NOCLASS	_	_	_	_
2	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
3	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
4	antitrypsin	antitrypsin	I-NP	NN	:::NOCLASS	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	Indian	Indian	B-NP	JJ	UMLS:C0268074:T047:DISO	_	_	_	_
7	childhood	childhood	I-NP	NN	UMLS:C0268074:T047:DISO	_	_	_	_
8	cirrhosis	cirrhosis	I-NP	NN	UMLS:C0268074:T047:DISO	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Lymphocyte	Lymphocyte	B-NP	NN	0	_	_	_	_
2	subpopulations	subpopulation	I-NP	NNS	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	serum	serum	B-NP	NN	:::NOCLASS	_	_	_	_
5	IgE	IgE	I-NP	NN	:::NOCLASS|UMLS:C0270850:T047:DISO	_	_	_	_
6	and	and	O	CC	0	_	_	_	_
7	total	total	B-NP	JJ	0	_	_	_	_
8	eosinophil	eosinophil	I-NP	NN	0	_	_	_	_
9	counts	count	I-NP	NNS	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	patients	patient	B-NP	NNS	0	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	bronchial	bronchial	B-NP	JJ	UMLS:C0004096:T047:DISO|UMLS:C1442216:T023:ANAT|UMLS:C0205039:T023:ANAT	_	_	_	_
14	asthma	asthma	I-NP	NN	UMLS:C0004096:T047:DISO	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	range	range	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	normal	normal	B-NP	JJ	0	_	_	_	_
5	ventricular	ventricular	I-NP	JJ	UMLS:C0018827:T023:ANAT	_	_	_	_
6	measurements	measurement	I-NP	NNS	0	_	_	_	_
7	for	for	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	EMI	EMI	I-NP	NN	0	_	_	_	_
10	scan	scan	I-NP	NN	0	_	_	_	_
11	is	be	B-VP	VBZ	0	_	_	_	_
12	suggested	suggest	I-VP	VBN	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	comparison	comparison	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	physical	physical	B-NP	JJ	0	_	_	_	_
5	and	and	I-NP	CC	0	_	_	_	_
6	cytogenetic	cytogenetic	I-NP	JJ	0	_	_	_	_
7	estimates	estimate	I-NP	NNS	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	radiation	radiation	B-NP	NN	0	_	_	_	_
10	dose	dose	I-NP	NN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	patients	patient	B-NP	NNS	0	_	_	_	_
13	treated	treat	B-VP	VBN	0	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	iodine	iodine	B-NP	NN	0	_	_	_	_
16	-	-	B-NP	HYPH	0	_	_	_	_
17	131	131	I-NP	NN	0	_	_	_	_
18	for	for	B-PP	IN	0	_	_	_	_
19	thyroid	thyroid	B-NP	JJ	UMLS:C0040132:T023:ANAT	_	_	_	_
20	carcinoma	carcinoma	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Technique	Technique	B-NP	NN	0	_	_	_	_
2	for	for	B-PP	IN	0	_	_	_	_
3	obtaining	obtain	B-VP	VBG	0	_	_	_	_
4	refined	refined	B-NP	JJ	0	_	_	_	_
5	ceramics	ceramic	I-NP	NNS	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	dense	dense	B-NP	JJ	0	_	_	_	_
8	mass	mass	I-NP	NN	0	_	_	_	_

1	Mean	Mean	B-NP	JJ	0	_	_	_	_
2	total	total	I-NP	JJ	0	_	_	_	_
3	lung	lung	I-NP	NN	UMLS:C0024109:T023:ANAT	_	_	_	_
4	capacity	capacity	I-NP	NN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	functional	functional	B-NP	JJ	0	_	_	_	_
7	residual	residual	I-NP	JJ	0	_	_	_	_
8	capacity	capacity	I-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	residual	residual	B-NP	JJ	0	_	_	_	_
12	volume	volume	I-NP	NN	0	_	_	_	_
13	increased	increase	B-VP	VBD	0	_	_	_	_
14	significantly	significantly	B-ADVP	RB	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	and	and	O	CC	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	mean	mean	I-NP	JJ	0	_	_	_	_
19	closing	closing	I-NP	NN	0	_	_	_	_
20	volume	volume	I-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	lung	lung	I-NP	NN	UMLS:C0024109:T023:ANAT	_	_	_	_
24	volume	volume	I-NP	NN	0	_	_	_	_
25	above	above	B-PP	IN	0	_	_	_	_
26	residual	residual	B-NP	JJ	0	_	_	_	_
27	volume	volume	I-NP	NN	0	_	_	_	_
28	at	at	B-PP	IN	0	_	_	_	_
29	which	which	B-NP	WDT	0	_	_	_	_
30	phase	phase	B-NP	NN	0	_	_	_	_
31	IV	IV	I-NP	CD	0	_	_	_	_
32	begins	begin	B-VP	VBZ	0	_	_	_	_
33	,	,	O	,	0	_	_	_	_
34	decreased	decrease	B-VP	VBN	0	_	_	_	_
35	significantly	significantly	B-ADVP	RB	0	_	_	_	_
36	with	with	B-PP	IN	0	_	_	_	_
37	11	11	B-NP	CD	0	_	_	_	_
38	cm	cm	I-NP	NN	0	_	_	_	_
39	H20	H20	I-NP	NN	0	_	_	_	_
40	continuous	continuous	I-NP	JJ	0	_	_	_	_
41	positive	positive	I-NP	JJ	0	_	_	_	_
42	airway	airway	I-NP	NN	UMLS:C0458827:T023:ANAT	_	_	_	_
43	pressure	pressure	I-NP	NN	0	_	_	_	_
44	;	;	O	:	0	_	_	_	_
45	differences	difference	B-NP	NNS	0	_	_	_	_
46	at	at	B-PP	IN	0	_	_	_	_
47	5	5	B-NP	CD	0	_	_	_	_
48	cm	cm	I-NP	NN	0	_	_	_	_
49	H20	H20	I-NP	NN	0	_	_	_	_
50	were	be	B-VP	VBD	0	_	_	_	_
51	not	not	O	RB	0	_	_	_	_
52	significant	significant	B-ADJP	JJ	0	_	_	_	_
53	.	.	O	.	0	_	_	_	_

1	Current	Current	B-NP	JJ	0	_	_	_	_
2	status	status	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	zinc	zinc	B-NP	NN	UMLS:C0235950:T047:DISO	_	_	_	_
5	deficiency	deficiency	I-NP	NN	UMLS:C0235950:T047:DISO	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	pathogenesis	pathogenesis	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	neurological	neurological	B-NP	JJ	0	_	_	_	_
11	,	,	I-NP	,	0	_	_	_	_
12	dermatological	dermatological	I-NP	JJ	0	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	musculoskeletal	musculoskeletal	I-NP	JJ	UMLS:C0026857:T047:DISO	_	_	_	_
15	disorders	disorder	I-NP	NNS	UMLS:C0026857:T047:DISO	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Calcium	Calcium	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	phosphorus	phosphorus	I-NP	NN	0	_	_	_	_
4	metabolism	metabolism	I-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	chronic	chronic	B-NP	JJ	UMLS:C1579029:T047:DISO	_	_	_	_
7	uremia	uremia	I-NP	NN	UMLS:C1579029:T047:DISO	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Modern	Modern	B-NP	JJ	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	conducted	conduct	B-VP	VBN	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	Delta	Delta	B-NP	NN	0	_	_	_	_
7	-	-	B-NP	HYPH	0	_	_	_	_
8	9	9	I-NP	CD	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	THC	THC	I-NP	NN	UMLS:C1839163:T047:DISO	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	healthy	healthy	B-NP	JJ	0	_	_	_	_
14	voluntaries	voluntary	I-NP	NNS	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	again	again	B-ADVP	RB	0	_	_	_	_
17	suggest	suggest	B-VP	VBP	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	comparison	comparison	I-NP	NN	0	_	_	_	_
20	or	or	O	CC	0	_	_	_	_
21	even	even	B-ADVP	RB	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	identity	identity	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	modifications	modification	I-NP	NNS	0	_	_	_	_
27	caused	cause	B-VP	VBN	0	_	_	_	_
28	by	by	B-PP	IN	0	_	_	_	_
29	cannabis	cannabis	B-NP	NN	0	_	_	_	_
30	with	with	B-PP	IN	0	_	_	_	_
31	sleep	sleep	B-NP	NN	0	_	_	_	_
32	and	and	I-NP	CC	0	_	_	_	_
33	dream	dream	I-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	correcting	correct	I-NP	VBG	0	_	_	_	_
3	action	action	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	tropatepine	tropatepine	B-NP	NN	0	_	_	_	_
6	hydrochloride	hydrochloride	I-NP	NN	0	_	_	_	_
7	upon	upon	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	extrapyramidal	extrapyramidal	I-NP	JJ	0	_	_	_	_
10	effects	effect	I-NP	NNS	0	_	_	_	_
11	induced	induce	B-VP	VBN	0	_	_	_	_
12	by	by	B-PP	IN	0	_	_	_	_
13	neuroleptics	neuroleptic	B-NP	NNS	0	_	_	_	_
14	has	have	B-VP	VBZ	0	_	_	_	_
15	been	be	I-VP	VBN	0	_	_	_	_
16	studied	study	I-VP	VBN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	32	32	B-NP	CD	0	_	_	_	_
19	acute	acute	I-NP	JJ	0	_	_	_	_
20	psychotic	psychotic	I-NP	JJ	0	_	_	_	_
21	states	state	I-NP	NNS	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Epididymal	Epididymal	B-NP	JJ	UMLS:C0014533:T023:ANAT	_	_	_	_
2	growth	growth	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	retarded	retard	I-VP	VBN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	animals	animal	B-NP	NNS	0	_	_	_	_
7	maintained	maintain	B-VP	VBN	0	_	_	_	_
8	solely	solely	B-ADVP	RB	0	_	_	_	_
9	on	on	B-PP	IN	0	_	_	_	_
10	chickpea	chickpea	B-NP	NN	0	_	_	_	_
11	haulm	haulm	I-NP	NN	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	improved	improve	B-VP	VBN	0	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	supplementation	supplementation	B-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Two	Two	B-NP	CD	0	_	_	_	_
2	patients	patient	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	treated	treat	I-VP	VBN	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	both	both	B-NP	DT	0	_	_	_	_
7	regimens	regimen	I-NP	NNS	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Results	Result	B-NP	NNS	0	_	_	_	_
2	obtained	obtain	B-VP	VBN	0	_	_	_	_
3	for	for	B-PP	IN	0	_	_	_	_
4	chloramphenicol	chloramphenicol	B-NP	NN	0	_	_	_	_
5	-	-	O	HYPH	0	_	_	_	_
6	containing	contain	B-VP	VBG	0	_	_	_	_
7	preparations	preparation	B-NP	NNS	0	_	_	_	_
8	are	be	B-VP	VBP	0	_	_	_	_
9	presented	present	I-VP	VBN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	both	both	B-NP	DT	0	_	_	_	_
13	dissolution	dissolution	I-NP	NN	0	_	_	_	_
14	curves	curve	I-NP	NNS	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	cup	cup	B-NP	NN	0	_	_	_	_
17	-	-	I-NP	HYPH	0	_	_	_	_
18	plate	plate	B-NP	NN	0	_	_	_	_
19	assays	assay	I-NP	NNS	0	_	_	_	_
20	demonstrate	demonstrate	B-VP	VBP	0	_	_	_	_
21	that	that	B-SBAR	IN	0	_	_	_	_
22	chloramphenicol	chloramphenicol	B-NP	NN	0	_	_	_	_
23	has	have	B-VP	VBZ	0	_	_	_	_
24	far	far	B-NP	RB	0	_	_	_	_
25	superior	superior	I-NP	JJ	0	_	_	_	_
26	release	release	I-NP	NN	0	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	and	and	O	CC	0	_	_	_	_
29	hence	hence	B-ADVP	RB	0	_	_	_	_
30	activity	activity	B-NP	NN	0	_	_	_	_
31	)	)	O	)	0	_	_	_	_
32	from	from	B-PP	IN	0	_	_	_	_
33	creams	cream	B-NP	NNS	0	_	_	_	_
34	than	than	B-PP	IN	0	_	_	_	_
35	from	from	B-PP	IN	0	_	_	_	_
36	ophthalmic	ophthalmic	B-NP	JJ	UMLS:C0015392:T023:ANAT	_	_	_	_
37	ointments	ointment	I-NP	NNS	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_

1	IgG	IgG	B-NP	NN	:::NOCLASS	_	_	_	_
2	levels	level	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	1	1	B-NP	CD	0	_	_	_	_
5	/	/	I-NP	SYM	0	_	_	_	_
6	100	100	I-NP	CD	0	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	present	present	B-ADJP	JJ	0	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	only	only	B-NP	RB	0	_	_	_	_
11	four	four	I-NP	CD	0	_	_	_	_
12	out	out	I-NP	IN	0	_	_	_	_
13	of	of	I-NP	IN	0	_	_	_	_
14	ten	ten	I-NP	CD	UMLS:C0014518:T047:DISO	_	_	_	_
15	samples	sample	I-NP	NNS	0	_	_	_	_
16	obtained	obtain	B-VP	VBD	0	_	_	_	_
17	150	150	B-NP	CD	0	_	_	_	_
18	days	day	I-NP	NNS	0	_	_	_	_
19	after	after	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	clinical	clinical	I-NP	JJ	0	_	_	_	_
22	onset	onset	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Letter	Letter	B-NP	NNP	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	Perspectives	Perspective	B-NP	NNS	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	bone	bone	B-NP	NN	UMLS:C0262950:T023:ANAT	_	_	_	_
6	marrow	marrow	I-NP	NN	UMLS:C0376152:T023:ANAT	_	_	_	_
7	transplantation	transplantation	I-NP	NN	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Assessment	Assessment	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	carcinogenicity	carcinogenicity	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	non	non	B-NP	AFX	0	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	nutritive	nutritive	B-NP	JJ	0	_	_	_	_
9	sweetners	sweetner	I-NP	NNS	0	_	_	_	_
10	II	II	B-NP	CD	0	_	_	_	_
11	:	:	O	:	0	_	_	_	_
12	Cyclamates	Cyclamate	B-NP	NNS	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	cyclohexylamine	cyclohexylamine	B-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	discordant	discordant	I-NP	JJ	0	_	_	_	_
3	behaviour	behaviour	I-NP	NN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	weakly	weakly	B-NP	RB	0	_	_	_	_
6	infected	infected	I-NP	JJ	0	_	_	_	_
7	mice	mouse	I-NP	NNS	0	_	_	_	_
8	was	be	B-VP	VBD	0	_	_	_	_
9	due	due	B-ADJP	JJ	0	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	occurrence	occurrence	I-NP	NN	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	some	some	B-NP	DT	0	_	_	_	_
15	animals	animal	I-NP	NNS	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	a	a	B-NP	DT	0	_	_	_	_
18	second	second	I-NP	JJ	0	_	_	_	_
19	phase	phase	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	more	more	B-NP	RBR	0	_	_	_	_
22	rapid	rapid	I-NP	JJ	0	_	_	_	_
23	increase	increase	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	parasitemia	parasitemia	I-NP	NN	UMLS:C0242723:T047:DISO	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Residual	Residual	B-NP	JJ	0	_	_	_	_
2	amphotericin	amphotericin	I-NP	NN	0	_	_	_	_
3	B	B	I-NP	NN	0	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	detected	detect	I-VP	VBN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	feces	fece	I-NP	NNS	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	mice	mouse	I-NP	NNS	0	_	_	_	_
12	only	only	B-ADVP	RB	0	_	_	_	_
13	while	while	B-SBAR	IN	0	_	_	_	_
14	they	they	B-NP	PRP	0	_	_	_	_
15	were	be	B-VP	VBD	0	_	_	_	_
16	receiving	receive	I-VP	VBG	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	0	0	I-NP	CD	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_
20	3	3	B-NP	CD	0	_	_	_	_
21	mg	mg	I-NP	NN	0	_	_	_	_
22	/	/	B-NP	SYM	0	_	_	_	_
23	ml	ml	I-NP	NN	0	_	_	_	_
24	dose	dose	I-NP	NN	0	_	_	_	_
25	level	level	I-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	There	There	B-NP	EX	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	slight	slight	I-NP	JJ	0	_	_	_	_
5	increase	increase	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	total	total	B-NP	JJ	0	_	_	_	_
8	transferrin	transferrin	I-NP	NN	:::NOCLASS	_	_	_	_
9	2	2	I-NP	CD	0	_	_	_	_
10	hr	hr	I-NP	NN	0	_	_	_	_
11	after	after	B-PP	IN	0	_	_	_	_
12	1	1	B-NP	CD	0	_	_	_	_
13	tablet	tablet	I-NP	NN	0	_	_	_	_
14	and	and	I-NP	CC	0	_	_	_	_
15	values	value	I-NP	NNS	0	_	_	_	_
16	remained	remain	B-VP	VBD	0	_	_	_	_
17	high	high	B-ADJP	JJ	0	_	_	_	_
18	throughout	throughout	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	experiment	experiment	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Following	Follow	B-VP	VBG	0	_	_	_	_
2	intravenous	intravenous	B-NP	JJ	0	_	_	_	_
3	administration	administration	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	myocardial	myocardial	I-NP	JJ	0	_	_	_	_
7	concentration	concentration	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	tracer	tracer	B-NP	NN	0	_	_	_	_
10	thallium	thallium	I-NP	NN	0	_	_	_	_
11	-	-	O	HYPH	0	_	_	_	_
12	201	201	B-NP	CD	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	potassium	potassium	B-NP	NN	0	_	_	_	_
15	-	-	O	HYPH	0	_	_	_	_
16	43	43	B-NP	CD	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	and	and	O	CC	0	_	_	_	_
19	rubidium	rubidium	B-NP	NN	0	_	_	_	_
20	-	-	B-NP	HYPH	0	_	_	_	_
21	81	81	I-NP	CD	0	_	_	_	_
22	were	be	B-VP	VBD	0	_	_	_	_
23	determined	determine	I-VP	VBN	0	_	_	_	_
24	in	in	B-PP	IN	0	_	_	_	_
25	mice	mouse	B-NP	NNS	0	_	_	_	_
26	;	;	O	:	0	_	_	_	_
27	thallium	thallium	B-NP	NN	0	_	_	_	_
28	was	be	B-VP	VBD	0	_	_	_	_
29	present	present	B-ADJP	JJ	0	_	_	_	_
30	in	in	B-PP	IN	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	greatest	great	I-NP	JJS	0	_	_	_	_
33	concentration	concentration	I-NP	NN	0	_	_	_	_
34	in	in	B-PP	IN	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	myocardium	myocardium	I-NP	NN	0	_	_	_	_
37	(	(	O	(	0	_	_	_	_
38	2	2	B-NP	CD	0	_	_	_	_
39	.	.	O	.	0	_	_	_	_
40	08	08	B-NP	CD	0	_	_	_	_
41	%	%	I-NP	NN	0	_	_	_	_
42	compared	compare	B-PP	VBN	0	_	_	_	_
43	1	1	B-NP	CD	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_
45	25	25	B-NP	CD	0	_	_	_	_
46	%	%	I-NP	NN	0	_	_	_	_
47	for	for	B-PP	IN	0	_	_	_	_
48	potassium	potassium	B-NP	NN	0	_	_	_	_
49	and	and	O	CC	0	_	_	_	_
50	1	1	B-NP	CD	0	_	_	_	_
51	.	.	O	.	0	_	_	_	_
52	15	15	B-NP	CD	0	_	_	_	_
53	%	%	I-NP	NN	0	_	_	_	_
54	for	for	B-PP	IN	0	_	_	_	_
55	rubidium	rubidium	B-NP	NN	0	_	_	_	_
56	at	at	B-PP	IN	0	_	_	_	_
57	10	10	B-NP	CD	0	_	_	_	_
58	minutes	minute	I-NP	NNS	0	_	_	_	_
59	)	)	O	)	0	_	_	_	_
60	.	.	O	.	0	_	_	_	_

1	Thromboplastin	Thromboplastin	B-NP	NN	:::NOCLASS	_	_	_	_
2	time	time	I-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	partial	partial	B-NP	JJ	0	_	_	_	_
5	thromboplastin	thromboplastin	I-NP	NN	:::NOCLASS	_	_	_	_
6	time	time	I-NP	NN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	thrombin	thrombin	B-NP	NN	:::NOCLASS	_	_	_	_
9	time	time	I-NP	NN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	heat	heat	B-NP	NN	0	_	_	_	_
12	-	-	B-NP	HYPH	0	_	_	_	_
13	dependent	dependent	I-NP	JJ	0	_	_	_	_
14	fibrin	fibrin	I-NP	NN	:::NOCLASS	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	clot	clot	B-NP	NN	0	_	_	_	_
17	retraction	retraction	I-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	clotting	clot	B-VP	VBG	:::NOCLASS	_	_	_	_
21	factors	factor	B-NP	NNS	:::NOCLASS	_	_	_	_
22	II	II	I-NP	CD	:::NOCLASS	_	_	_	_
23	,	,	I-NP	,	:::NOCLASS	_	_	_	_
24	V	V	I-NP	CD	:::NOCLASS	_	_	_	_
25	,	,	I-NP	,	:::NOCLASS	_	_	_	_
26	VIII	VIII	I-NP	CD	:::NOCLASS	_	_	_	_
27	,	,	I-NP	,	:::NOCLASS	_	_	_	_
28	IX	IX	I-NP	CD	:::NOCLASS	_	_	_	_
29	,	,	O	,	:::NOCLASS	_	_	_	_
30	X	X	B-NP	NN	:::NOCLASS	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	and	and	O	CC	0	_	_	_	_
33	the	the	B-NP	DT	0	_	_	_	_
34	platelet	platelet	I-NP	NN	0	_	_	_	_
35	count	count	I-NP	NN	0	_	_	_	_
36	were	be	B-VP	VBD	0	_	_	_	_
37	determined	determine	I-VP	VBN	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	data	datum	I-NP	NNS	0	_	_	_	_
3	support	support	B-VP	VBP	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	notion	notion	I-NP	NN	0	_	_	_	_
6	that	that	B-SBAR	IN	0	_	_	_	_
7	suppression	suppression	B-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	images	image	B-NP	NNS	0	_	_	_	_
10	during	during	B-PP	IN	0	_	_	_	_
11	binocular	binocular	B-NP	JJ	0	_	_	_	_
12	rivalry	rivalry	I-NP	NN	0	_	_	_	_
13	is	be	B-VP	VBZ	0	_	_	_	_
14	independent	independent	B-ADJP	JJ	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	both	both	B-NP	DT	0	_	_	_	_
17	eyes	eye	I-NP	NNS	UMLS:C0015392:T023:ANAT	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Glycogen	Glycogen	B-NP	NN	0	_	_	_	_
2	utilization	utilization	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	increased	increase	I-VP	VBN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	but	but	O	CC	0	_	_	_	_
7	tissue	tissue	B-NP	NN	0	_	_	_	_
8	levels	level	I-NP	NNS	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	creatine	creatine	B-NP	NN	0	_	_	_	_
11	phosphate	phosphate	I-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	ATP	ATP	B-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	lactate	lactate	B-NP	NN	0	_	_	_	_
17	were	be	B-VP	VBD	0	_	_	_	_
18	similar	similar	B-ADJP	JJ	0	_	_	_	_
19	to	to	B-PP	TO	0	_	_	_	_
20	those	those	B-NP	DT	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	hearts	heart	B-NP	NNS	UMLS:C0018787:T023:ANAT	_	_	_	_
23	receiving	receive	B-VP	VBG	0	_	_	_	_
24	normal	normal	B-NP	JJ	0	_	_	_	_
25	flow	flow	I-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	records	record	I-NP	NNS	0	_	_	_	_
3	from	from	B-PP	IN	0	_	_	_	_
4	1948	1948	B-NP	CD	0	_	_	_	_
5	through	through	B-PP	IN	0	_	_	_	_
6	1967	1967	B-NP	CD	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	344	344	B-NP	CD	0	_	_	_	_
9	previously	previously	I-NP	RB	0	_	_	_	_
10	untreated	untreated	I-NP	JJ	0	_	_	_	_
11	patients	patient	I-NP	NNS	0	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	squamous	squamous	B-NP	JJ	0	_	_	_	_
14	cell	cell	I-NP	NN	0	_	_	_	_
15	carcinoma	carcinoma	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	oral	oral	I-NP	JJ	0	_	_	_	_
19	cavity	cavity	I-NP	NN	UMLS:C0011334:T047:DISO	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	oropharynx	oropharynx	B-NP	NN	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	supraglottic	supraglottic	B-NP	JJ	0	_	_	_	_
24	larynx	larynx	I-NP	NN	UMLS:C0023078:T023:ANAT	_	_	_	_
25	and	and	I-NP	CC	0	_	_	_	_
26	hypopharynx	hypopharynx	I-NP	NN	0	_	_	_	_
27	who	who	B-NP	WP	0	_	_	_	_
28	had	have	B-VP	VBD	0	_	_	_	_
29	clinically	clinically	B-NP	RB	0	_	_	_	_
30	positive	positive	I-NP	JJ	0	_	_	_	_
31	cervical	cervical	I-NP	JJ	UMLS:C0588054:T023:ANAT	_	_	_	_
32	lymph	lymph	I-NP	NN	UMLS:C0588054:T023:ANAT	_	_	_	_
33	node	node	I-NP	NN	UMLS:C0588054:T023:ANAT	_	_	_	_
34	metastases	metastasis	I-NP	NNS	0	_	_	_	_
35	staged	stag	B-VP	VBD	0	_	_	_	_
36	N1	N1	B-NP	NN	0	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	N2A	N2A	B-NP	NN	0	_	_	_	_
39	,	,	O	,	0	_	_	_	_
40	or	or	O	CC	0	_	_	_	_
41	N2B	N2B	B-NP	NN	0	_	_	_	_
42	,	,	O	,	0	_	_	_	_
43	and	and	O	CC	0	_	_	_	_
44	whose	whose	B-NP	WP$	0	_	_	_	_
45	initial	initial	I-NP	JJ	0	_	_	_	_
46	neck	neck	I-NP	NN	0	_	_	_	_
47	treatment	treatment	I-NP	NN	0	_	_	_	_
48	consisted	consist	B-VP	VBD	0	_	_	_	_
49	of	of	B-PP	IN	0	_	_	_	_
50	external	external	B-NP	JJ	0	_	_	_	_
51	radiation	radiation	I-NP	NN	0	_	_	_	_
52	therapy	therapy	I-NP	NN	0	_	_	_	_
53	alone	alone	B-ADVP	RB	0	_	_	_	_
54	were	be	B-VP	VBD	0	_	_	_	_
55	reviewed	review	I-VP	VBN	0	_	_	_	_
56	.	.	O	.	0	_	_	_	_

1	With	With	B-PP	IN	0	_	_	_	_
2	0	0	B-NP	CD	0	_	_	_	_
3	.	.	O	.	0	_	_	_	_
4	5	5	B-NP	CD	0	_	_	_	_
5	vol	vol	I-NP	NN	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_
7	-	-	B-NP	HYPH	0	_	_	_	_
8	%	%	I-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	corresponding	correspond	I-NP	VBG	0	_	_	_	_
12	values	value	I-NP	NNS	0	_	_	_	_
13	were	be	B-VP	VBD	0	_	_	_	_
14	345	345	B-NP	CD	0	_	_	_	_
15	mumol	mumol	I-NP	NN	0	_	_	_	_
16	/	/	B-NP	SYM	0	_	_	_	_
17	1	1	I-NP	CD	0	_	_	_	_
18	(	(	O	(	0	_	_	_	_
19	5	5	B-NP	CD	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_
21	72	72	B-NP	CD	0	_	_	_	_
22	mg	mg	I-NP	NN	0	_	_	_	_
23	/	/	B-NP	SYM	0	_	_	_	_
24	100	100	B-NP	CD	0	_	_	_	_
25	ml	ml	I-NP	NN	0	_	_	_	_
26	)	)	O	)	0	_	_	_	_
27	and	and	O	CC	0	_	_	_	_
28	137	137	B-NP	CD	0	_	_	_	_
29	mumol	mumol	I-NP	NN	0	_	_	_	_
30	/	/	B-NP	SYM	0	_	_	_	_
31	1	1	I-NP	CD	0	_	_	_	_
32	(	(	O	(	0	_	_	_	_
33	2	2	B-NP	CD	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_
35	25	25	B-NP	CD	0	_	_	_	_
36	mg	mg	I-NP	NN	0	_	_	_	_
37	/	/	B-NP	SYM	0	_	_	_	_
38	100	100	B-NP	CD	0	_	_	_	_
39	ml	ml	I-NP	NN	0	_	_	_	_
40	)	)	O	)	0	_	_	_	_
41	respectively	respectively	B-ADVP	RB	0	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	authors	author	I-NP	NNS	0	_	_	_	_
3	describe	describe	B-VP	VBP	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	technique	technique	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	transverse	transverse	B-NP	JJ	0	_	_	_	_
8	axial	axial	I-NP	JJ	0	_	_	_	_
9	tomography	tomography	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	spine	spine	I-NP	NN	UMLS:C0037949:T023:ANAT	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	give	give	B-VP	VB	0	_	_	_	_
15	a	a	B-NP	DT	0	_	_	_	_
16	detailed	detailed	I-NP	JJ	0	_	_	_	_
17	description	description	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	axial	axial	I-NP	JJ	0	_	_	_	_
21	anatomy	anatomy	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	normal	normal	I-NP	JJ	0	_	_	_	_
25	lumbar	lumbar	I-NP	NN	UMLS:C0024091:T023:ANAT	_	_	_	_
26	spine	spine	I-NP	NN	UMLS:C0024091:T023:ANAT	_	_	_	_
27	from	from	B-PP	IN	0	_	_	_	_
28	L	L	B-NP	NN	0	_	_	_	_
29	-	-	B-ADVP	HYPH	0	_	_	_	_
30	4	4	B-NP	CD	0	_	_	_	_
31	to	to	B-PP	TO	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	sacrum	sacrum	I-NP	NN	UMLS:C0036037:T023:ANAT	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Owing	Owe	B-VP	VBG	0	_	_	_	_
2	to	to	B-PP	TO	0	_	_	_	_
3	parental	parental	B-NP	JJ	0	_	_	_	_
4	attitude	attitude	I-NP	NN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	low	low	I-NP	JJ	0	_	_	_	_
8	protein	protein	I-NP	NN	0	_	_	_	_
9	diet	diet	I-NP	NN	0	_	_	_	_
10	(	(	O	(	0	_	_	_	_
11	1	1	B-NP	CD	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	5	5	I-NP	CD	0	_	_	_	_
14	g	g	I-NP	NN	0	_	_	_	_
15	/	/	B-NP	SYM	0	_	_	_	_
16	kg	kg	I-NP	NN	0	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	was	be	B-VP	VBD	0	_	_	_	_
19	introduced	introduce	I-VP	VBN	0	_	_	_	_
20	only	only	B-ADVP	RB	0	_	_	_	_
21	late	late	I-ADVP	RB	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	none	none	B-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	44	44	I-NP	CD	0	_	_	_	_
6	type	type	I-NP	NN	0	_	_	_	_
7	I	I	B-NP	CD	0	_	_	_	_
8	attacks	attack	I-NP	NNS	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	29	29	B-NP	CD	0	_	_	_	_
11	type	type	I-NP	NN	0	_	_	_	_
12	II	II	B-NP	CD	0	_	_	_	_
13	attacks	attack	I-NP	NNS	0	_	_	_	_
14	which	which	B-NP	WDT	0	_	_	_	_
15	were	be	B-VP	VBD	0	_	_	_	_
16	recorded	record	I-VP	VBN	0	_	_	_	_
17	did	do	B-VP	VBD	0	_	_	_	_
18	circulatory	circulatory	B-NP	JJ	0	_	_	_	_
19	changes	change	I-NP	NNS	0	_	_	_	_
20	;	;	O	:	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	latter	latter	I-NP	JJ	0	_	_	_	_
23	were	be	B-VP	VBD	0	_	_	_	_
24	different	different	B-ADJP	JJ	0	_	_	_	_
25	in	in	B-PP	IN	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	two	two	I-NP	CD	0	_	_	_	_
28	groups	group	I-NP	NNS	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	clinically	clinically	I-NP	RB	0	_	_	_	_
3	useful	useful	I-NP	JJ	0	_	_	_	_
4	diagnostic	diagnostic	I-NP	JJ	0	_	_	_	_
5	method	method	I-NP	NN	0	_	_	_	_
6	has	have	B-VP	VBZ	0	_	_	_	_
7	been	be	I-VP	VBN	0	_	_	_	_
8	developed	develop	I-VP	VBN	0	_	_	_	_
9	for	for	B-PP	IN	0	_	_	_	_
10	detecting	detect	B-VP	VBG	0	_	_	_	_
11	and	and	I-VP	CC	0	_	_	_	_
12	quantitating	quantitate	I-VP	VBG	0	_	_	_	_
13	periods	period	B-NP	NNS	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	apnea	apnea	B-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	pediatric	pediatric	B-NP	JJ	0	_	_	_	_
18	patients	patient	I-NP	NNS	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	other	other	I-NP	JJ	0	_	_	_	_
3	hypoglycaemic	hypoglycaemic	I-NP	JJ	0	_	_	_	_
4	patient	patient	I-NP	NN	0	_	_	_	_
5	showed	show	B-VP	VBD	0	_	_	_	_
6	an	an	B-NP	DT	0	_	_	_	_
7	exaggerated	exaggerated	I-NP	JJ	0	_	_	_	_
8	insulin	insulin	I-NP	NN	:::NOCLASS	_	_	_	_
9	release	release	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	response	response	I-PP	NN	0	_	_	_	_
12	to	to	I-PP	TO	0	_	_	_	_
13	tolbutamide	tolbutamide	B-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Nerve	Nerve	B-NP	NN	0	_	_	_	_
2	stimulation	stimulation	I-NP	NN	0	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	1	1	B-NP	CD	0	_	_	_	_
5	.	.	O	.	0	_	_	_	_
6	5	5	B-NP	CD	0	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	12	12	I-NP	CD	0	_	_	_	_
9	cycles	cycle	I-NP	NNS	0	_	_	_	_
10	/	/	B-NP	SYM	0	_	_	_	_
11	s	s	I-NP	NNS	0	_	_	_	_
12	)	)	O	)	0	_	_	_	_
13	produced	produce	B-VP	VBD	0	_	_	_	_
14	frequency	frequency	B-NP	NN	0	_	_	_	_
15	-	-	O	HYPH	0	_	_	_	_
16	dependent	dependent	B-NP	JJ	0	_	_	_	_
17	reductions	reduction	I-NP	NNS	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	CBF	CBF	B-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	a	a	B-NP	DT	0	_	_	_	_
22	decrease	decrease	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	50	50	B-NP	CD	0	_	_	_	_
25	percent	percent	I-NP	NN	0	_	_	_	_
26	occurring	occur	B-VP	VBG	0	_	_	_	_
27	with	with	B-PP	IN	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	highest	high	I-NP	JJS	0	_	_	_	_
30	frequency	frequency	I-NP	NN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Effect	Effect	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	ingestion	ingestion	B-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	Norbiogest	Norbiogest	B-NP	NNP	0	_	_	_	_
6	during	during	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	quiescent	quiescent	I-NP	JJ	0	_	_	_	_
9	period	period	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	genital	genital	I-NP	JJ	UMLS:C0017420:T023:ANAT	_	_	_	_
13	organs	organ	I-NP	NNS	UMLS:C0017420:T023:ANAT	_	_	_	_

1	Risk	Risk	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	infection	infection	B-NP	NN	UMLS:C0021311:T047:DISO|UMLS:C0009450:T047:DISO	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	treatment	treatment	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	fractures	fracture	B-NP	NNS	0	_	_	_	_

1	Bulbar	Bulbar	B-NP	NN	0	_	_	_	_
2	pouches	pouch	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	perfused	perfuse	I-VP	VBN	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	solutions	solution	B-NP	NNS	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	0	0	B-NP	CD	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_
10	9	9	B-NP	CD	0	_	_	_	_
11	%	%	I-NP	NN	0	_	_	_	_
12	Na	Na	I-NP	NN	0	_	_	_	_
13	C1	C1	I-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	0	0	B-NP	CD	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_
17	1	1	B-NP	CD	0	_	_	_	_
18	N	N	I-NP	NN	0	_	_	_	_
19	HC1	HC1	I-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	40	40	B-NP	CD	0	_	_	_	_
22	%	%	I-NP	NN	0	_	_	_	_
23	glucose	glucose	I-NP	NN	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	40	40	B-NP	CD	0	_	_	_	_
26	%	%	I-NP	NN	0	_	_	_	_
27	NaC1	NaC1	I-NP	NN	0	_	_	_	_
28	,	,	O	,	0	_	_	_	_
29	and	and	O	CC	0	_	_	_	_
30	40	40	B-NP	CD	0	_	_	_	_
31	%	%	I-NP	NN	0	_	_	_	_
32	peptone	peptone	I-NP	NN	0	_	_	_	_
33	or	or	B-PP	CC	0	_	_	_	_
34	with	with	B-PP	IN	0	_	_	_	_
35	0	0	B-NP	CD	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_
37	1	1	B-NP	CD	0	_	_	_	_
38	%	%	I-NP	NN	0	_	_	_	_
39	solutions	solution	I-NP	NNS	0	_	_	_	_
40	of	of	B-PP	IN	0	_	_	_	_
41	acetylcholine	acetylcholine	B-NP	NN	0	_	_	_	_
42	chloride	chloride	I-NP	NN	0	_	_	_	_
43	.	.	O	.	0	_	_	_	_

1	Liver	Liver	B-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
2	microsomes	microsome	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	shag	shag	I-NP	NN	0	_	_	_	_
6	showed	show	B-VP	VBD	0	_	_	_	_
7	smaller	small	B-NP	JJR	0	_	_	_	_
8	than	than	I-NP	IN	0	_	_	_	_
9	8	8	I-NP	CD	0	_	_	_	_
10	%	%	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	epoxide	epoxide	I-NP	NN	:::NOCLASS	_	_	_	_
14	hydrase	hydrase	I-NP	NN	:::NOCLASS	_	_	_	_
15	activity	activity	I-NP	NN	0	_	_	_	_
16	and	and	O	CC	0	_	_	_	_
17	smaller	small	B-ADJP	JJR	0	_	_	_	_
18	than	than	B-PP	IN	0	_	_	_	_
19	14	14	B-NP	CD	0	_	_	_	_
20	%	%	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	hydroxylating	hydroxylate	I-NP	VBG	0	_	_	_	_
24	capacity	capacity	I-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	liver	liver	B-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
27	microsomes	microsome	I-NP	NNS	0	_	_	_	_
28	from	from	B-PP	IN	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	rat	rat	I-NP	NN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Prolonged	Prolong	B-NP	VBN	0	_	_	_	_
2	heavy	heavy	I-NP	JJ	0	_	_	_	_
3	work	work	I-NP	NN	0	_	_	_	_
4	effected	effect	B-VP	VBD	0	_	_	_	_
5	an	an	B-NP	DT	0	_	_	_	_
6	increase	increase	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	10	10	B-NP	CD	0	_	_	_	_
9	.	.	I-NP	.	0	_	_	_	_
10	3	3	I-NP	CD	0	_	_	_	_
11	plus	plus	B-NP	CC	0	_	_	_	_
12	or	or	O	CC	0	_	_	_	_
13	minus	minus	O	CC	0	_	_	_	_
14	0	0	B-NP	CD	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_
16	9	9	B-NP	CD	0	_	_	_	_
17	mmHg	mmHg	I-NP	NN	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	in	in	B-NP	FW	0	_	_	_	_
20	vivo	vivo	I-NP	FW	0	_	_	_	_
21	P50	P50	I-NP	NN	0	_	_	_	_
22	(	(	O	(	0	_	_	_	_
23	7	7	B-NP	CD	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_
25	30	30	B-NP	CD	0	_	_	_	_
26	PH	PH	I-NP	NN	0	_	_	_	_
27	-	-	B-NP	HYPH	0	_	_	_	_
28	v	v	I-NP	NN	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	41	41	B-NP	CD	0	_	_	_	_
31	degrees	degree	I-NP	NNS	0	_	_	_	_
32	C	C	B-NP	JJ	0	_	_	_	_
33	-	-	I-NP	HYPH	0	_	_	_	_
34	v	v	I-NP	NN	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	and	and	O	CC	0	_	_	_	_
37	45	45	B-NP	CD	0	_	_	_	_
38	Pv	Pv	I-NP	NN	0	_	_	_	_
39	-	-	B-NP	HYPH	0	_	_	_	_
40	CO2	CO2	I-NP	NN	0	_	_	_	_
41	)	)	O	)	0	_	_	_	_
42	;	;	O	:	0	_	_	_	_
43	due	due	B-ADJP	JJ	0	_	_	_	_
44	entirely	entirely	I-ADJP	RB	0	_	_	_	_
45	to	to	B-PP	TO	0	_	_	_	_
46	the	the	B-NP	DT	0	_	_	_	_
47	additive	additive	I-NP	JJ	0	_	_	_	_
48	effects	effect	I-NP	NNS	0	_	_	_	_
49	of	of	B-PP	IN	0	_	_	_	_
50	increased	increase	B-NP	VBN	0	_	_	_	_
51	venous	venous	I-NP	JJ	UMLS:C0042449:T023:ANAT	_	_	_	_
52	temperature	temperature	I-NP	NN	0	_	_	_	_
53	and	and	O	CC	0	_	_	_	_
54	[	[	O	(	0	_	_	_	_
55	H+	H+	B-NP	NN	0	_	_	_	_
56	]	]	O	)	0	_	_	_	_
57	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	clinical	clinical	I-NP	JJ	0	_	_	_	_
3	,	,	I-NP	,	0	_	_	_	_
4	serological	serological	I-NP	JJ	0	_	_	_	_
5	and	and	I-NP	CC	0	_	_	_	_
6	prognostic	prognostic	I-NP	JJ	0	_	_	_	_
7	study	study	I-NP	NN	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	American	American	I-NP	NNP	0	_	_	_	_
3	Burkitt	Burkitt	I-NP	NNP	0	_	_	_	_
4	Lymphoma	Lymphoma	I-NP	NNP	0	_	_	_	_
5	Registry	Registry	I-NP	NNP	0	_	_	_	_
6	:	:	O	:	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	progress	progress	I-NP	NN	0	_	_	_	_
9	report	report	I-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	Vitrectomy	Vitrectomy	B-NP	NN	0	_	_	_	_
2	with	with	B-PP	IN	0	_	_	_	_
3	an	an	B-NP	DT	0	_	_	_	_
4	alternative	alternative	I-NP	JJ	0	_	_	_	_
5	instrument	instrument	I-NP	NN	0	_	_	_	_
6	system	system	I-NP	NN	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	metabolic	metabolic	I-NP	JJ	0	_	_	_	_
3	clearance	clearance	I-NP	NN	0	_	_	_	_
4	rate	rate	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	progesterone	progesterone	B-NP	NN	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	295	295	B-NP	CD	0	_	_	_	_
9	+	+	O	SYM	0	_	_	_	_
10	/	/	O	SYM	0	_	_	_	_
11	-	-	O	SYM	0	_	_	_	_
12	49	49	B-NP	CD	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	S	S	B-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_
16	E	E	B-NP	NNP	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_
18	)	)	O	)	0	_	_	_	_
19	1	1	B-NP	CD	0	_	_	_	_
20	/	/	I-NP	SYM	0	_	_	_	_
21	day	day	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	sequence	sequence	I-NP	NN	0	_	_	_	_
3	is	be	B-VP	VBZ	0	_	_	_	_
4	almost	almost	B-ADJP	RB	0	_	_	_	_
5	identical	identical	I-ADJP	JJ	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	that	that	B-NP	DT	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	human	human	B-NP	JJ	:::NOCLASS	_	_	_	_
10	luteinizing	luteinizing	I-NP	NN	:::NOCLASS	_	_	_	_
11	hormone	hormone	I-NP	NN	:::NOCLASS	_	_	_	_
12	(	(	O	(	0	_	_	_	_
13	Sairam	Sairam	B-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	M	M	B-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	mean	mean	I-NP	JJ	0	_	_	_	_
3	plasma	plasma	I-NP	NN	0	_	_	_	_
4	sodium	sodium	I-NP	NN	0	_	_	_	_
5	concentration	concentration	I-NP	NN	0	_	_	_	_
6	which	which	B-NP	WDT	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	135	135	B-NP	CD	0	_	_	_	_
9	.	.	I-NP	.	0	_	_	_	_
10	95	95	I-NP	CD	0	_	_	_	_
11	(	(	O	(	0	_	_	_	_
12	+	+	B-NP	SYM	0	_	_	_	_
13	/	/	O	SYM	0	_	_	_	_
14	-	-	O	SYM	0	_	_	_	_
15	SD	SD	B-NP	NN	UMLS:C1096903:T047:DISO	_	_	_	_
16	4	4	I-NP	CD	0	_	_	_	_
17	.	.	I-NP	.	0	_	_	_	_
18	14	14	I-NP	CD	0	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	mEq	mEq	B-NP	NN	0	_	_	_	_
21	/	/	B-NP	SYM	0	_	_	_	_
22	kg	kg	I-NP	NN	0	_	_	_	_
23	before	before	B-PP	IN	0	_	_	_	_
24	diuretic	diuretic	B-NP	JJ	0	_	_	_	_
25	treatment	treatment	I-NP	NN	0	_	_	_	_
26	was	be	B-VP	VBD	0	_	_	_	_
27	significantly	significantly	I-VP	RB	0	_	_	_	_
28	decreased	decrease	I-VP	VBN	0	_	_	_	_
29	during	during	B-PP	IN	0	_	_	_	_
30	treatment	treatment	B-NP	NN	0	_	_	_	_
31	to	to	B-PP	TO	0	_	_	_	_
32	129	129	B-NP	CD	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_
34	19	19	O	CD	0	_	_	_	_
35	(	(	O	(	0	_	_	_	_
36	+	+	O	SYM	0	_	_	_	_
37	/	/	O	SYM	0	_	_	_	_
38	-	-	O	SYM	0	_	_	_	_
39	SD	SD	B-NP	NN	UMLS:C1096903:T047:DISO	_	_	_	_
40	2	2	I-NP	CD	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_
42	77	77	O	CD	0	_	_	_	_
43	)	)	O	)	0	_	_	_	_
44	mEq	mEq	B-NP	NN	0	_	_	_	_
45	/	/	B-VP	SYM	0	_	_	_	_
46	kg	kg	B-NP	NN	0	_	_	_	_
47	,	,	O	,	0	_	_	_	_
48	P	P	B-NP	NN	0	_	_	_	_
49	less	less	B-NP	JJR	0	_	_	_	_
50	than	than	I-NP	IN	0	_	_	_	_
51	0	0	I-NP	CD	0	_	_	_	_
52	.	.	I-NP	.	0	_	_	_	_
53	001	001	I-NP	CD	0	_	_	_	_
54	.	.	O	.	0	_	_	_	_

1	Editorial	Editorial	B-NP	NNP	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	Low	Low	B-NP	JJ	0	_	_	_	_
4	-	-	I-NP	HYPH	0	_	_	_	_
5	dose	dose	I-NP	NN	0	_	_	_	_
6	heparin	heparin	I-NP	NN	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	prevention	prevention	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	venous	venous	B-NP	JJ	UMLS:C0042449:T023:ANAT	_	_	_	_
12	thromboembolic	thromboembolic	I-NP	JJ	UMLS:C0040038:T047:DISO	_	_	_	_
13	disease	disease	I-NP	NN	UMLS:C0040038:T047:DISO	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	At	At	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	very	very	I-NP	RB	0	_	_	_	_
4	high	high	I-NP	JJ	0	_	_	_	_
5	dose	dose	I-NP	NN	0	_	_	_	_
6	levels	level	I-NP	NNS	0	_	_	_	_
7	used	use	B-VP	VBN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	sodium	sodium	B-NP	NN	0	_	_	_	_
10	saccharin	saccharin	I-NP	NN	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	sodium	sodium	B-NP	NN	0	_	_	_	_
13	cyclamate	cyclamate	I-NP	NN	0	_	_	_	_
14	were	be	B-VP	VBD	0	_	_	_	_
15	weak	weak	B-NP	JJ	0	_	_	_	_
16	solitary	solitary	I-NP	JJ	0	_	_	_	_
17	carcinogens	carcinogen	I-NP	NNS	0	_	_	_	_
18	producing	produce	B-VP	VBG	0	_	_	_	_
19	4	4	B-NP	CD	0	_	_	_	_
20	/	/	I-NP	SYM	0	_	_	_	_
21	253	253	I-NP	CD	0	_	_	_	_
22	and	and	I-NP	CC	0	_	_	_	_
23	3	3	I-NP	CD	0	_	_	_	_
24	/	/	I-NP	SYM	0	_	_	_	_
25	228	228	I-NP	CD	0	_	_	_	_
26	bladder	bladder	I-NP	NN	UMLS:C0005682:T023:ANAT	_	_	_	_
27	tumours	tumour	I-NP	NNS	0	_	_	_	_
28	respectively	respectively	B-ADVP	RB	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	and	and	O	CC	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	first	first	I-NP	JJ	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	these	these	B-NP	DT	0	_	_	_	_
35	tumours	tumour	I-NP	NNS	0	_	_	_	_
36	did	do	B-VP	VBD	0	_	_	_	_
37	not	not	I-VP	RB	0	_	_	_	_
38	appear	appear	I-VP	VB	0	_	_	_	_
39	for	for	B-PP	IN	0	_	_	_	_
40	more	more	B-NP	JJR	0	_	_	_	_
41	than	than	I-NP	IN	0	_	_	_	_
42	80	80	I-NP	CD	0	_	_	_	_
43	weeks	week	I-NP	NNS	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	Effects	Effect	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	perceptual	perceptual	B-NP	JJ	0	_	_	_	_
4	salience	salience	I-NP	NN	0	_	_	_	_
5	on	on	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	matrix	matrix	I-NP	NN	0	_	_	_	_
8	task	task	I-NP	NN	0	_	_	_	_
9	performance	performance	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	four	four	B-NP	CD	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	six	six	I-NP	CD	0	_	_	_	_
15	-	-	I-NP	HYPH	0	_	_	_	_
16	year	year	I-NP	NN	0	_	_	_	_
17	-	-	O	HYPH	0	_	_	_	_
18	old	old	B-NP	JJ	0	_	_	_	_
19	children	child	I-NP	NNS	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Glucose	Glucose	B-NP	NN	:::NOCLASS	_	_	_	_
2	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
3	6	6	I-NP	CD	:::NOCLASS	_	_	_	_
4	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
5	phosphate	phosphate	I-NP	NN	:::NOCLASS	_	_	_	_
6	dehydrogenase	dehydrogenase	I-NP	NN	:::NOCLASS	_	_	_	_
7	(	(	O	(	0	_	_	_	_
8	G	G	B-NP	NN	:::NOCLASS	_	_	_	_
9	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
10	6	6	I-NP	CD	:::NOCLASS	_	_	_	_
11	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
12	PD	PD	I-NP	NN	:::NOCLASS|UMLS:C3160718:T047:DISO	_	_	_	_
13	)	)	I-NP	)	0	_	_	_	_
14	deficiency	deficiency	I-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	newborn	newborn	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	eluting	elute	I-NP	VBG	0	_	_	_	_
3	solvent	solvent	I-NP	NN	0	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	methanol	methanol	B-NP	NN	0	_	_	_	_
6	-	-	O	HYPH	0	_	_	_	_
7	chloroform	chloroform	B-NP	NN	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	10+90	10+90	B-NP	CD	0	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	at	at	B-PP	IN	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	flow	flow	I-NP	NN	0	_	_	_	_
14	rate	rate	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	2	2	B-NP	CD	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_
18	0	0	B-NP	CD	0	_	_	_	_
19	ml	ml	I-NP	NN	0	_	_	_	_
20	/	/	B-NP	SYM	0	_	_	_	_
21	min	min	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	bronchial	bronchial	I-NP	JJ	UMLS:C1442216:T023:ANAT|UMLS:C0205039:T023:ANAT	_	_	_	_
3	epithelia	epithelia	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	all	all	B-NP	DT	0	_	_	_	_
6	smoke	smoke	I-NP	NN	0	_	_	_	_
7	-	-	B-NP	HYPH	0	_	_	_	_
8	exposed	expose	I-NP	VBN	0	_	_	_	_
9	animals	animal	I-NP	NNS	0	_	_	_	_
10	were	be	B-VP	VBD	0	_	_	_	_
11	hyperplastic	hyperplastic	B-ADJP	JJ	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	their	their	B-NP	PRP$	0	_	_	_	_
15	ultrastructure	ultrastructure	I-NP	NN	0	_	_	_	_
16	showed	show	B-VP	VBD	0	_	_	_	_
17	invaginations	invagination	B-NP	NNS	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	tilt	tilt	B-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	nuclear	nuclear	B-NP	JJ	0	_	_	_	_
22	axes	ax	I-NP	NNS	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	an	an	B-NP	DT	0	_	_	_	_
25	increase	increase	I-NP	NN	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	number	number	I-NP	NN	0	_	_	_	_
29	and	and	I-NP	CC	0	_	_	_	_
30	size	size	I-NP	NN	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	lysosomes	lysosome	B-NP	NNS	0	_	_	_	_
33	and	and	O	CC	0	_	_	_	_
34	multivesiculated	multivesiculated	B-NP	JJ	0	_	_	_	_
35	bodies	body	I-NP	NNS	0	_	_	_	_
36	,	,	O	,	0	_	_	_	_
37	and	and	O	CC	0	_	_	_	_
38	increased	increase	B-NP	VBN	0	_	_	_	_
39	numbers	number	I-NP	NNS	0	_	_	_	_
40	of	of	B-PP	IN	0	_	_	_	_
41	enlarged	enlarged	B-NP	JJ	0	_	_	_	_
42	intramitochondrial	intramitochondrial	I-NP	JJ	0	_	_	_	_
43	granules	granule	I-NP	NNS	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	routine	routine	I-NP	JJ	0	_	_	_	_
3	administration	administration	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	fat	fat	B-NP	NN	0	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	soluble	soluble	I-NP	JJ	0	_	_	_	_
8	vitamins	vitamin	I-NP	NNS	0	_	_	_	_
9	appears	appear	B-VP	VBZ	0	_	_	_	_
10	unnecessary	unnecessary	B-ADJP	JJ	0	_	_	_	_
11	but	but	O	CC	0	_	_	_	_
12	it	it	B-NP	PRP	0	_	_	_	_
13	is	be	B-VP	VBZ	0	_	_	_	_
14	prudent	prudent	B-ADJP	JJ	0	_	_	_	_
15	to	to	B-VP	TO	0	_	_	_	_
16	measure	measure	I-VP	VB	0	_	_	_	_
17	prothrombin	prothrombin	B-NP	NN	:::NOCLASS	_	_	_	_
18	time	time	I-NP	NN	0	_	_	_	_
19	and	and	I-NP	CC	0	_	_	_	_
20	serum	serum	I-NP	NN	0	_	_	_	_
21	vitamins	vitamin	I-NP	NNS	0	_	_	_	_
22	A	A	I-NP	NN	0	_	_	_	_
23	and	and	I-NP	CC	0	_	_	_	_
24	E	E	I-NP	NN	0	_	_	_	_
25	at	at	B-PP	IN	0	_	_	_	_
26	intervals	interval	B-NP	NNS	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Prostaglandins	Prostaglandin	B-NP	NNS	0	_	_	_	_
2	F	F	I-NP	NN	0	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	PGF	PGF	B-NP	NN	0	_	_	_	_
5	)	)	O	)	0	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	measured	measure	I-VP	VBN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	uterine	uterine	B-NP	JJ	UMLS:C0226787:T023:ANAT	_	_	_	_
10	vein	vein	I-NP	NN	UMLS:C0226787:T023:ANAT	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	ovarian	ovarian	B-NP	JJ	UMLS:C0226411:T023:ANAT	_	_	_	_
13	artery	artery	I-NP	NN	UMLS:C0226411:T023:ANAT	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	jugular	jugular	B-NP	JJ	UMLS:C0022427:T023:ANAT	_	_	_	_
17	vein	vein	I-NP	NN	UMLS:C0022427:T023:ANAT	_	_	_	_
18	plasma	plasma	I-NP	NN	0	_	_	_	_
19	and	and	B-PP	CC	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	endometrial	endometrial	I-NP	JJ	0	_	_	_	_
23	tissues	tissue	I-NP	NNS	0	_	_	_	_
24	at	at	B-PP	IN	0	_	_	_	_
25	various	various	B-NP	JJ	0	_	_	_	_
26	times	time	I-NP	NNS	0	_	_	_	_
27	during	during	B-PP	IN	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	bovine	bovine	I-NP	JJ	0	_	_	_	_
30	estrous	estrous	I-NP	JJ	0	_	_	_	_
31	cycle	cycle	I-NP	NN	0	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	and	and	O	CC	0	_	_	_	_
34	were	be	B-VP	VBD	0	_	_	_	_
35	compared	compare	I-VP	VBN	0	_	_	_	_
36	to	to	B-PP	TO	0	_	_	_	_
37	peripheral	peripheral	B-NP	JJ	0	_	_	_	_
38	plasma	plasma	I-NP	NN	0	_	_	_	_
39	progesterone	progesterone	I-NP	NN	0	_	_	_	_
40	levels	level	I-NP	NNS	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	Before	Before	B-SBAR	IN	0	_	_	_	_
2	this	this	B-NP	DT	0	_	_	_	_
3	date	date	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	drug	drug	I-NP	NN	0	_	_	_	_
7	directly	directly	B-VP	RB	0	_	_	_	_
8	inhibits	inhibit	I-VP	VBZ	0	_	_	_	_
9	fetal	fetal	B-NP	JJ	0	_	_	_	_
10	weight	weight	I-NP	NN	0	_	_	_	_
11	gain	gain	I-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	whereas	whereas	O	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	sensitivity	sensitivity	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	placenta	placenta	I-NP	NN	0	_	_	_	_
19	is	be	B-VP	VBZ	0	_	_	_	_
20	only	only	B-ADJP	RB	0	_	_	_	_
21	transient	transient	I-ADJP	JJ	0	_	_	_	_
22	at	at	B-PP	IN	0	_	_	_	_
23	day	day	B-NP	NN	0	_	_	_	_
24	16	16	I-NP	CD	0	_	_	_	_
25	resulting	result	B-VP	VBG	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	maximum	maximum	B-NP	JJ	0	_	_	_	_
28	weight	weight	I-NP	NN	0	_	_	_	_
29	decrease	decrease	I-NP	NN	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	this	this	B-NP	DT	0	_	_	_	_
32	organ	organ	I-NP	NN	UMLS:C0178784:T023:ANAT	_	_	_	_
33	24	24	I-NP	CD	0	_	_	_	_
34	h	h	I-NP	NN	0	_	_	_	_
35	later	later	B-ADVP	RB	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	Groups	Group	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	ten	ten	B-NP	CD	UMLS:C0014518:T047:DISO	_	_	_	_
4	dependent	dependent	I-NP	JJ	0	_	_	_	_
5	and	and	O	CC	0	_	_	_	_
6	ten	ten	B-NP	CD	UMLS:C0014518:T047:DISO	_	_	_	_
7	saline	saline	I-NP	NN	0	_	_	_	_
8	mice	mouse	I-NP	NNS	0	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	singly	singly	I-VP	RB	0	_	_	_	_
11	tested	test	I-VP	VBN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	both	both	B-NP	CC	0	_	_	_	_
14	light	light	I-NP	JJ	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	dark	dark	I-NP	JJ	0	_	_	_	_
17	conditions	condition	I-NP	NNS	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	each	each	B-NP	DT	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	five	five	B-NP	CD	0	_	_	_	_
22	covered	cover	I-NP	VBN	0	_	_	_	_
23	cylinders	cylinder	I-NP	NNS	0	_	_	_	_
24	(	(	O	(	0	_	_	_	_
25	2	2	B-NP	CD	0	_	_	_	_
26	-	-	O	HYPH	0	_	_	_	_
27	23	23	B-NP	CD	0	_	_	_	_
28	in	in	B-PP	IN	0	_	_	_	_
29	high	high	B-NP	JJ	0	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effects	effect	I-NP	NNS	0	_	_	_	_
3	initiated	initiate	B-VP	VBN	0	_	_	_	_
4	from	from	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	nucleus	nucleus	I-NP	NN	UMLS:C0028633:T023:ANAT	_	_	_	_
7	accumbens	accumbens	I-NP	NN	UMLS:C0028633:T023:ANAT	_	_	_	_
8	septi	septi	I-NP	NNS	UMLS:C0028633:T023:ANAT	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	most	most	B-ADJP	RBS	0	_	_	_	_
11	marked	marked	I-ADJP	JJ	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	appearance	appearance	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	dyskinetic	dyskinetic	B-NP	JJ	0	_	_	_	_
5	movement	movement	I-NP	NN	UMLS:C0026650:T047:DISO	_	_	_	_
6	disorders	disorder	I-NP	NNS	UMLS:C0026650:T047:DISO	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	humans	human	B-NP	NNS	0	_	_	_	_
9	following	follow	B-PP	VBG	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	chronic	chronic	I-NP	JJ	0	_	_	_	_
12	use	use	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	levodopa	levodopa	B-NP	NN	0	_	_	_	_
15	or	or	I-NP	CC	0	_	_	_	_
16	amphetamine	amphetamine	I-NP	NN	0	_	_	_	_
17	may	may	B-VP	MD	0	_	_	_	_
18	be	be	I-VP	VB	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	manifestation	manifestation	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	similarly	similarly	B-NP	RB	0	_	_	_	_
23	increased	increase	I-NP	VBN	0	_	_	_	_
24	dopamine	dopamine	I-NP	NN	:::NOCLASS	_	_	_	_
25	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
26	site	site	I-NP	NN	:::NOCLASS	_	_	_	_
27	sensitivity	sensitivity	I-NP	NN	0	_	_	_	_
28	within	within	B-PP	IN	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	striatum	striatum	I-NP	NN	UMLS:C0162512:T023:ANAT|UMLS:C0010097:T023:ANAT	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Association	Association	B-NP	NN	0	_	_	_	_
2	with	with	B-PP	IN	0	_	_	_	_
3	HL	HL	B-NP	NN	:::NOCLASS	_	_	_	_
4	-	-	O	HYPH	:::NOCLASS	_	_	_	_
5	A	A	B-NP	NN	:::NOCLASS	_	_	_	_
6	W	W	I-NP	NN	:::NOCLASS	_	_	_	_
7	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
8	27	27	I-NP	CD	:::NOCLASS	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Letter	Letter	B-NP	NNP	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	Lactose	Lactose	B-NP	NN	0	_	_	_	_
4	tolerance	tolerance	I-NP	NN	0	_	_	_	_
5	tests	test	I-NP	NNS	0	_	_	_	_
6	as	as	B-PP	IN	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	predictor	predictor	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	milk	milk	B-NP	NN	0	_	_	_	_
11	tolerance	tolerance	I-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	Retinoblastoma	Retinoblastoma	B-NP	NN	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	study	study	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	natural	natural	B-NP	JJ	0	_	_	_	_
7	history	history	I-NP	NN	0	_	_	_	_
8	and	and	I-NP	CC	0	_	_	_	_
9	prognosis	prognosis	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	268	268	B-NP	CD	0	_	_	_	_
12	cases	case	I-NP	NNS	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Like	Like	B-PP	IN	0	_	_	_	_
2	pineal	pineal	B-NP	JJ	UMLS:C0031939:T023:ANAT	_	_	_	_
3	melatonin	melatonin	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	serum	serum	B-NP	NN	0	_	_	_	_
6	melatonin	melatonin	I-NP	NN	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	high	high	B-ADJP	JJ	0	_	_	_	_
9	at	at	B-PP	IN	0	_	_	_	_
10	mid	mid	B-NP	JJ	0	_	_	_	_
11	-	-	I-NP	HYPH	0	_	_	_	_
12	dark	dark	I-NP	JJ	0	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	low	low	I-NP	JJ	0	_	_	_	_
15	at	at	B-PP	IN	0	_	_	_	_
16	mid	mid	B-NP	JJ	0	_	_	_	_
17	-	-	I-NP	HYPH	0	_	_	_	_
18	light	light	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	D	D	B-NP	NN	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	Atherosclerosis	Atherosclerosis	B-NP	NNP	UMLS:C0004153:T047:DISO	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	authors	author	I-NP	NNS	0	_	_	_	_
3	concluded	conclude	B-VP	VBD	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	ultrasonic	ultrasonic	B-NP	JJ	0	_	_	_	_
6	Doppler	Doppler	I-NP	NNP	0	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	cardiography	cardiography	I-NP	NN	0	_	_	_	_
9	can	can	B-VP	MD	0	_	_	_	_
10	be	be	I-VP	VB	0	_	_	_	_
11	used	use	I-VP	VBN	0	_	_	_	_
12	for	for	B-PP	IN	0	_	_	_	_
13	measuring	measure	B-VP	VBG	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	relative	relative	I-NP	JJ	0	_	_	_	_
16	changes	change	I-NP	NNS	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	stroke	stroke	I-NP	NN	UMLS:C0038454:T047:DISO	_	_	_	_
20	volume	volume	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	attainment	attainment	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	sexual	sexual	B-NP	JJ	0	_	_	_	_
5	maturity	maturity	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	terms	term	B-NP	NNS	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	secondary	secondary	B-NP	JJ	0	_	_	_	_
10	sexual	sexual	I-NP	JJ	0	_	_	_	_
11	characteristics	characteristic	I-NP	NNS	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	production	production	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	spermatozoa	spermatozoa	B-NP	NN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	male	male	I-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	and	and	O	CC	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	cyclical	cyclical	I-NP	JJ	0	_	_	_	_
24	female	female	I-NP	JJ	0	_	_	_	_
25	pattern	pattern	I-NP	NN	0	_	_	_	_
26	with	with	B-PP	IN	0	_	_	_	_
27	release	release	B-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	ova	ova	B-NP	NN	0	_	_	_	_
30	are	be	B-VP	VBP	0	_	_	_	_
31	end	end	B-NP	NN	0	_	_	_	_
32	-	-	B-VP	HYPH	0	_	_	_	_
33	points	point	B-NP	NNS	0	_	_	_	_
34	of	of	B-PP	IN	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	developmental	developmental	I-NP	JJ	0	_	_	_	_
37	process	process	I-NP	NN	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_

1	However	However	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	10	10	I-NP	CD	0	_	_	_	_
5	-	-	I-NP	HYPH	0	_	_	_	_
6	-	-	I-NP	SYM	0	_	_	_	_
7	15	15	I-NP	CD	0	_	_	_	_
8	%	%	I-NP	NN	0	_	_	_	_
9	lengthening	lengthening	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	partial	partial	I-NP	JJ	0	_	_	_	_
13	thromboplastin	thromboplastin	I-NP	NN	:::NOCLASS	_	_	_	_
14	time	time	I-NP	NN	0	_	_	_	_
15	is	be	B-VP	VBZ	0	_	_	_	_
16	evident	evident	B-ADJP	JJ	0	_	_	_	_
17	after	after	B-PP	IN	0	_	_	_	_
18	24	24	B-NP	CD	0	_	_	_	_
19	hours	hour	I-NP	NNS	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	storage	storage	B-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Caution	Caution	B-NP	NN	0	_	_	_	_
2	should	should	B-VP	MD	0	_	_	_	_
3	be	be	I-VP	VB	0	_	_	_	_
4	exercised	exercise	I-VP	VBN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	use	use	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	these	these	B-NP	DT	0	_	_	_	_
10	dyes	dye	I-NP	NNS	0	_	_	_	_
11	for	for	B-PP	IN	0	_	_	_	_
12	lymphograms	lymphogram	B-NP	NNS	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	reveals	reveal	B-VP	VBZ	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	new	new	I-NP	JJ	0	_	_	_	_
5	test	test	I-NP	NN	0	_	_	_	_
6	for	for	B-PP	IN	0	_	_	_	_
7	short	short	B-NP	JJ	0	_	_	_	_
8	saphenous	saphenous	I-NP	JJ	0	_	_	_	_
9	incompetence	incompetence	I-NP	NN	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	shows	show	B-VP	VBZ	0	_	_	_	_
12	that	that	B-SBAR	IN	0	_	_	_	_
13	14	14	B-NP	CD	0	_	_	_	_
14	per	per	B-PP	IN	0	_	_	_	_
15	cent	cent	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	varices	varix	B-NP	NNS	UMLS:C0042345:T047:DISO	_	_	_	_
18	stem	stem	B-VP	VBP	UMLS:C1186763:T023:ANAT	_	_	_	_
19	from	from	B-PP	IN	0	_	_	_	_
20	a	a	B-NP	DT	0	_	_	_	_
21	saphenopopliteal	saphenopopliteal	I-NP	JJ	0	_	_	_	_
22	reflux	reflux	I-NP	NN	UMLS:C0017168:T047:DISO	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Three	Three	B-NP	CD	0	_	_	_	_
2	groups	group	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	patients	patient	B-NP	NNS	0	_	_	_	_
5	who	who	B-NP	WP	0	_	_	_	_
6	had	have	B-VP	VBD	0	_	_	_	_
7	undergone	undergo	I-VP	VBN	0	_	_	_	_
8	subtotal	subtotal	B-NP	JJ	0	_	_	_	_
9	thyroidectomy	thyroidectomy	I-NP	NN	0	_	_	_	_
10	for	for	B-PP	IN	0	_	_	_	_
11	Graves	Graves	B-NP	NN	0	_	_	_	_
12	's	's	B-NP	POS	0	_	_	_	_
13	disease	disease	I-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	toxic	toxic	B-NP	JJ	UMLS:C0154143:T047:DISO	_	_	_	_
16	multinodular	multinodular	I-NP	JJ	UMLS:C0154143:T047:DISO	_	_	_	_
17	goitre	goitre	I-NP	NN	UMLS:C0154143:T047:DISO	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	or	or	O	CC	0	_	_	_	_
20	euthyroid	euthyroid	B-NP	JJ	0	_	_	_	_
21	multinodular	multinodular	I-NP	JJ	UMLS:C0342208:T047:DISO	_	_	_	_
22	goitre	goitre	I-NP	NN	UMLS:C0342208:T047:DISO	_	_	_	_
23	12	12	I-NP	CD	0	_	_	_	_
24	to	to	I-NP	TO	0	_	_	_	_
25	15	15	I-NP	CD	0	_	_	_	_
26	years	year	I-NP	NNS	0	_	_	_	_
27	before	before	B-PP	IN	0	_	_	_	_
28	and	and	I-PP	CC	0	_	_	_	_
29	in	in	I-PP	IN	0	_	_	_	_
30	whom	whom	B-NP	WP	0	_	_	_	_
31	a	a	B-NP	DT	0	_	_	_	_
32	normal	normal	I-NP	JJ	0	_	_	_	_
33	serum	serum	I-NP	NN	0	_	_	_	_
34	thyroxine	thyroxine	I-NP	NN	0	_	_	_	_
35	(	(	O	(	0	_	_	_	_
36	T	T	B-NP	NN	0	_	_	_	_
37	-	-	O	HYPH	0	_	_	_	_
38	4	4	O	CD	0	_	_	_	_
39	)	)	O	)	0	_	_	_	_
40	level	level	B-NP	NN	0	_	_	_	_
41	was	be	B-VP	VBD	0	_	_	_	_
42	found	find	I-VP	VBN	0	_	_	_	_
43	were	be	B-VP	VBD	0	_	_	_	_
44	each	each	O	DT	0	_	_	_	_
45	divided	divide	B-VP	VBN	0	_	_	_	_
46	into	into	B-PP	IN	0	_	_	_	_
47	two	two	B-NP	CD	0	_	_	_	_
48	subgroups	subgroup	I-NP	NNS	0	_	_	_	_
49	on	on	B-PP	IN	0	_	_	_	_
50	the	the	B-NP	DT	0	_	_	_	_
51	basis	basis	I-NP	NN	0	_	_	_	_
52	of	of	B-PP	IN	0	_	_	_	_
53	a	a	B-NP	DT	0	_	_	_	_
54	normal	normal	I-NP	JJ	0	_	_	_	_
55	or	or	O	CC	0	_	_	_	_
56	a	a	B-NP	DT	0	_	_	_	_
57	raised	raise	I-NP	VBN	0	_	_	_	_
58	serum	serum	I-NP	NN	0	_	_	_	_
59	thyrotrophin	thyrotrophin	I-NP	NN	:::NOCLASS	_	_	_	_
60	concentration	concentration	I-NP	NN	0	_	_	_	_
61	.	.	O	.	0	_	_	_	_

1	Routine	Routine	B-NP	NN	0	_	_	_	_
2	isotope	isotope	I-NP	NN	0	_	_	_	_
3	cystography	cystography	I-NP	NN	0	_	_	_	_
4	using	use	B-VP	VBG	0	_	_	_	_
5	99M	99M	B-NP	NN	0	_	_	_	_
6	Tc	Tc	I-NP	NN	0	_	_	_	_
7	sulfur	sulfur	I-NP	NN	0	_	_	_	_
8	colloid	colloid	I-NP	NN	0	_	_	_	_
9	for	for	B-PP	IN	0	_	_	_	_
10	detection	detection	B-NP	NN	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	follow	follow	B-VP	VB	0	_	_	_	_
13	-	-	O	HYPH	0	_	_	_	_
14	up	up	B-PRT	RP	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	vesico	vesico	B-NP	AFX	UMLS:C0042580:T047:DISO	_	_	_	_
17	-	-	I-NP	HYPH	UMLS:C0042580:T047:DISO	_	_	_	_
18	ureteral	ureteral	I-NP	JJ	UMLS:C0042580:T047:DISO	_	_	_	_
19	reflux	reflux	I-NP	NN	UMLS:C0042580:T047:DISO	_	_	_	_

1	Air	Air	B-NP	NN	0	_	_	_	_
2	ion	ion	I-NP	NN	0	_	_	_	_
3	action	action	I-NP	NN	0	_	_	_	_
4	on	on	B-PP	IN	0	_	_	_	_
5	bacteria	bacteria	B-NP	NNS	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	No	No	B-NP	DT	0	_	_	_	_
2	evidence	evidence	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	either	either	B-NP	CC	0	_	_	_	_
5	positive	positive	I-NP	JJ	0	_	_	_	_
6	or	or	I-NP	CC	0	_	_	_	_
7	negative	negative	I-NP	JJ	0	_	_	_	_
8	chemography	chemography	I-NP	NN	0	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	found	find	I-VP	VBN	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	interpretation	interpretation	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	antibiotic	antibiotic	B-NP	JJ	0	_	_	_	_
5	disc	disc	I-NP	NN	UMLS:C1556138:T023:ANAT	_	_	_	_
6	sensitivities	sensitivity	I-NP	NNS	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_

1	Following	Follow	B-PP	VBG	0	_	_	_	_
2	retransfusion	retransfusion	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	affected	affect	I-NP	VBN	0	_	_	_	_
6	epithelial	epithelial	I-NP	JJ	0	_	_	_	_
7	lining	lining	I-NP	NN	0	_	_	_	_
8	appeared	appear	B-VP	VBD	0	_	_	_	_
9	greatly	greatly	I-VP	RB	0	_	_	_	_
10	distended	distend	I-VP	VBN	0	_	_	_	_
11	over	over	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	oedematous	oedematous	I-NP	JJ	0	_	_	_	_
14	lamina	lamina	I-NP	NN	UMLS:C0920995:T023:ANAT|UMLS:C2330124:T023:ANAT	_	_	_	_
15	propria	propria	I-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	with	with	B-PP	IN	0	_	_	_	_
18	almost	almost	B-NP	RB	0	_	_	_	_
19	complete	complete	I-NP	JJ	0	_	_	_	_
20	loss	loss	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	structural	structural	B-NP	JJ	0	_	_	_	_
23	detail	detail	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	study	study	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	chromosomes	chromosome	B-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	lymphocytes	lymphocyte	B-NP	NNS	0	_	_	_	_
7	from	from	B-PP	IN	0	_	_	_	_
8	patients	patient	B-NP	NNS	0	_	_	_	_
9	treated	treat	B-VP	VBN	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	hycanthone	hycanthone	B-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	Characteristics	Characteristic	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	anesthesia	anesthesia	B-NP	NN	0	_	_	_	_
4	and	and	I-NP	CC	0	_	_	_	_
5	resuscitation	resuscitation	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	emergency	emergency	B-NP	NN	0	_	_	_	_
8	lung	lung	I-NP	NN	UMLS:C0024109:T023:ANAT	_	_	_	_
9	surgery	surgery	I-NP	NN	0	_	_	_	_

1	Study	Study	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	physico	physico	I-NP	NN	0	_	_	_	_
5	-	-	B-NP	HYPH	0	_	_	_	_
6	chemical	chemical	I-NP	JJ	0	_	_	_	_
7	state	state	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	plutonium	plutonium	B-NP	NN	0	_	_	_	_
10	-	-	B-NP	HYPH	0	_	_	_	_
11	239	239	I-NP	CD	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	a	a	B-NP	DT	0	_	_	_	_
14	citrate	citrate	I-NP	NN	0	_	_	_	_
15	solution	solution	I-NP	NN	0	_	_	_	_
16	-	-	B-NP	HYPH	0	_	_	_	_
17	blood	blood	I-NP	NN	0	_	_	_	_
18	system	system	I-NP	NN	0	_	_	_	_

1	Tobramycin	Tobramycin	B-NP	NN	0	_	_	_	_
2	60	60	I-NP	CD	0	_	_	_	_
3	mg	mg	I-NP	NN	0	_	_	_	_
4	did	do	B-VP	VBD	0	_	_	_	_
5	not	not	I-VP	RB	0	_	_	_	_
6	show	show	I-VP	VB	0	_	_	_	_
7	any	any	B-NP	DT	0	_	_	_	_
8	remarkable	remarkable	I-NP	JJ	0	_	_	_	_
9	effect	effect	I-NP	NN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	but	but	O	CC	0	_	_	_	_
12	dibecacin	dibecacin	B-NP	NN	0	_	_	_	_
13	100	100	I-NP	CD	0	_	_	_	_
14	mg	mg	I-NP	NN	0	_	_	_	_
15	produced	produce	B-VP	VBD	0	_	_	_	_
16	a	a	B-NP	DT	0	_	_	_	_
17	slight	slight	I-NP	JJ	0	_	_	_	_
18	potentiating	potentiating	I-NP	NN	0	_	_	_	_
19	effect	effect	I-NP	NN	0	_	_	_	_
20	on	on	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	action	action	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	d	d	B-NP	NN	0	_	_	_	_
25	-	-	B-NP	HYPH	0	_	_	_	_
26	tubocurarine	tubocurarine	I-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	about	about	B-NP	IN	0	_	_	_	_
3	one	one	I-NP	CD	0	_	_	_	_
4	third	third	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	cases	case	I-NP	NNS	0	_	_	_	_
8	this	this	B-NP	DT	0	_	_	_	_
9	operation	operation	I-NP	NN	0	_	_	_	_
10	results	result	B-VP	VBZ	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	tonal	tonal	B-NP	JJ	0	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	vocal	vocal	I-NP	JJ	0	_	_	_	_
15	improvement	improvement	I-NP	NN	0	_	_	_	_
16	for	for	B-PP	IN	0	_	_	_	_
17	patients	patient	B-NP	NNS	0	_	_	_	_
18	suffering	suffer	B-VP	VBG	0	_	_	_	_
19	from	from	B-PP	IN	0	_	_	_	_
20	progressive	progressive	B-NP	JJ	0	_	_	_	_
21	perceptive	perceptive	I-NP	JJ	UMLS:C0018784:T047:DISO	_	_	_	_
22	deafness	deafness	I-NP	NN	UMLS:C0018784:T047:DISO	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	specific	specific	I-NP	JJ	0	_	_	_	_
3	electrical	electrical	I-NP	JJ	0	_	_	_	_
4	resistance	resistance	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	cerebrospinal	cerebrospinal	I-NP	JJ	0	_	_	_	_
8	fluid	fluid	I-NP	NN	0	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	measured	measure	I-VP	VBN	0	_	_	_	_
11	by	by	B-PP	IN	0	_	_	_	_
12	means	mean	B-NP	NNS	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	conductometry	conductometry	B-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	14	14	B-NP	CD	0	_	_	_	_
17	cases	case	I-NP	NNS	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	meningitis	meningitis	B-NP	NN	UMLS:C0025289:T047:DISO	_	_	_	_
20	purulenta	purulenta	I-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	17	17	B-NP	CD	0	_	_	_	_
23	cases	case	I-NP	NNS	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	meningitis	meningitis	B-NP	NN	UMLS:C0025289:T047:DISO	_	_	_	_
26	serosa	serosa	I-NP	NN	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	10	10	B-NP	CD	0	_	_	_	_
29	cases	case	I-NP	NNS	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	encephalitis	encephalitis	B-NP	NN	UMLS:C0014038:T047:DISO	_	_	_	_
32	and	and	O	CC	0	_	_	_	_
33	in	in	B-PP	IN	0	_	_	_	_
34	32	32	B-NP	CD	0	_	_	_	_
35	control	control	I-NP	JJ	0	_	_	_	_
36	subjects	subject	I-NP	NNS	0	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	2	2	B-NP	CD	0	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	Chemical	Chemical	I-NP	JJ	0	_	_	_	_
4	occlusion	occlusion	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	vas	vas	B-NP	NN	0	_	_	_	_
7	is	be	B-VP	VBZ	0	_	_	_	_
8	quite	quite	B-ADJP	RB	0	_	_	_	_
9	effective	effective	I-ADJP	JJ	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	producing	produce	B-VP	VBG	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	block	block	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	vas	vas	I-NP	NN	UMLS:C0042360:T023:ANAT	_	_	_	_
17	deferens	deferen	I-NP	NNS	UMLS:C0042360:T023:ANAT	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	dogs	dog	B-NP	NNS	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Besides	Besides	B-ADVP	IN	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	we	we	B-NP	PRP	0	_	_	_	_
4	found	find	B-VP	VBD	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	3	3	B-NP	CD	0	_	_	_	_
7	patients	patient	I-NP	NNS	0	_	_	_	_
8	increased	increase	B-VP	VBD	0	_	_	_	_
9	serum	serum	B-NP	NN	:::NOCLASS	_	_	_	_
10	immunoglobulins	immunoglobulin	I-NP	NNS	:::NOCLASS	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	chiefly	chiefly	B-NP	RB	0	_	_	_	_
13	IgG	IgG	I-NP	NN	:::NOCLASS	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	as	as	B-SBAR	IN	0	_	_	_	_
16	first	first	B-NP	JJ	0	_	_	_	_
17	Russe	Russe	I-NP	NNP	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	Busey	Busey	B-NP	NNP	0	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	Barbeau	Barbeau	B-NP	NNP	0	_	_	_	_
22	demonstrated	demonstrate	B-VP	VBD	0	_	_	_	_
23	in	in	B-PP	IN	0	_	_	_	_
24	a	a	B-NP	DT	0	_	_	_	_
25	large	large	I-NP	JJ	0	_	_	_	_
26	French	French	I-NP	JJ	0	_	_	_	_
27	-	-	I-NP	HYPH	0	_	_	_	_
28	Canadian	Canadian	I-NP	JJ	0	_	_	_	_
29	family	family	I-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	suggest	suggest	B-VP	VBP	0	_	_	_	_
3	that	that	B-SBAR	IN	0	_	_	_	_
4	such	such	B-NP	JJ	0	_	_	_	_
5	occlusions	occlusion	I-NP	NNS	0	_	_	_	_
6	occurred	occur	B-VP	VBD	0	_	_	_	_
7	at	at	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	time	time	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	infarction	infarction	I-NP	NN	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Streptococcal	Streptococcal	B-NP	JJ	0	_	_	_	_
2	preparation	preparation	I-NP	NN	0	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	OK	OK	B-NP	NN	0	_	_	_	_
5	-	-	O	HYPH	0	_	_	_	_
6	432	432	B-NP	CD	0	_	_	_	_
7	)	)	O	)	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	new	new	I-NP	JJ	0	_	_	_	_
11	type	type	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	anti	anti	B-NP	AFX	0	_	_	_	_
14	-	-	I-NP	HYPH	0	_	_	_	_
15	cancer	cancer	I-NP	NN	0	_	_	_	_
16	agent	agent	I-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	was	be	B-VP	VBD	0	_	_	_	_
19	given	give	I-VP	VBN	0	_	_	_	_
20	to	to	B-PP	TO	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	patients	patient	I-NP	NNS	0	_	_	_	_
23	with	with	B-PP	IN	0	_	_	_	_
24	advanced	advance	B-NP	VBN	0	_	_	_	_
25	cancer	cancer	I-NP	NN	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	combination	combination	B-NP	NN	0	_	_	_	_
28	with	with	B-PP	IN	0	_	_	_	_
29	Mitomycin	Mitomycin	B-NP	NN	0	_	_	_	_
30	-	-	I-NP	HYPH	0	_	_	_	_
31	C	C	I-NP	NN	0	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	5	5	B-NP	CD	0	_	_	_	_
34	-	-	I-NP	HYPH	0	_	_	_	_
35	FU	FU	I-NP	NN	0	_	_	_	_
36	and	and	I-NP	CC	0	_	_	_	_
37	Cytosine	Cytosine	I-NP	NN	0	_	_	_	_
38	arabinoside	arabinoside	I-NP	NN	0	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	Generally	Generally	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	correlation	correlation	I-NP	NN	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	observed	observe	I-VP	VBN	0	_	_	_	_
7	between	between	B-PP	IN	0	_	_	_	_
8	highest	high	B-NP	JJS	0	_	_	_	_
9	concentrations	concentration	I-NP	NNS	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	CSF	CSF	B-NP	NN	:::NOCLASS	_	_	_	_
12	immunoglobulins	immunoglobulin	I-NP	NNS	:::NOCLASS	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	degree	degree	B-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	meningeal	meningeal	B-NP	JJ	0	_	_	_	_
17	inflammatory	inflammatory	I-NP	JJ	0	_	_	_	_
18	response	response	I-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	even	even	B-SBAR	RB	0	_	_	_	_
21	if	if	I-SBAR	IN	0	_	_	_	_
22	this	this	B-NP	DT	0	_	_	_	_
23	was	be	B-VP	VBD	0	_	_	_	_
24	a	a	B-NP	DT	0	_	_	_	_
25	component	component	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	other	other	B-NP	JJ	0	_	_	_	_
28	neurological	neurological	I-NP	JJ	0	_	_	_	_
29	diseases	disease	I-NP	NNS	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Maternal	Maternal	B-NP	JJ	0	_	_	_	_
2	lactation	lactation	I-NP	NN	0	_	_	_	_

1	Experimental	Experimental	B-NP	JJ	0	_	_	_	_
2	cardiotoxicity	cardiotoxicity	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	adriamycin	adriamycin	B-NP	NN	0	_	_	_	_

1	Muscular	Muscular	B-NP	JJ	0	_	_	_	_
2	pathology	pathology	I-NP	NN	0	_	_	_	_

1	Demonstration	Demonstration	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	agent	agent	I-NP	NN	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	performed	perform	I-VP	VBN	0	_	_	_	_
7	from	from	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	6th	6th	I-NP	NN	0	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	11th	11th	I-NP	JJ	0	_	_	_	_
13	day	day	I-NP	NN	0	_	_	_	_
14	p	p	I-NP	NN	0	_	_	_	_
15	.	.	I-NP	.	0	_	_	_	_
16	i	i	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_
18	by	by	B-PP	IN	0	_	_	_	_
19	direct	direct	B-NP	JJ	0	_	_	_	_
20	microscopic	microscopic	I-NP	JJ	0	_	_	_	_
21	methods	method	I-NP	NNS	0	_	_	_	_
22	(	(	O	(	0	_	_	_	_
23	Stamp	Stamp	B-NP	NN	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	auramine	auramine	B-NP	NN	0	_	_	_	_
26	staining	staining	I-NP	NN	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	fluorescent	fluorescent	B-NP	JJ	0	_	_	_	_
29	antibody	antibody	I-NP	NN	0	_	_	_	_
30	technique	technique	I-NP	NN	0	_	_	_	_
31	)	)	O	)	0	_	_	_	_
32	;	;	O	:	0	_	_	_	_
33	the	the	B-NP	DT	0	_	_	_	_
34	Coxiella	Coxiella	I-NP	NNP	0	_	_	_	_
35	content	content	I-NP	NN	0	_	_	_	_
36	was	be	B-VP	VBD	0	_	_	_	_
37	determined	determine	I-VP	VBN	0	_	_	_	_
38	by	by	B-PP	IN	0	_	_	_	_
39	titration	titration	B-NP	NN	0	_	_	_	_
40	in	in	B-PP	IN	0	_	_	_	_
41	embryonated	embryonate	B-NP	VBN	0	_	_	_	_
42	hen	hen	I-NP	NN	0	_	_	_	_
43	's	's	B-NP	POS	0	_	_	_	_
44	eggs	egg	I-NP	NNS	0	_	_	_	_
45	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	patients	patient	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	divided	divide	I-VP	VBN	0	_	_	_	_
5	into	into	B-PP	IN	0	_	_	_	_
6	4	4	B-NP	CD	0	_	_	_	_
7	groups	group	I-NP	NNS	0	_	_	_	_
8	receiving	receive	B-VP	VBG	0	_	_	_	_
9	NLA	NLA	B-NP	NN	0	_	_	_	_
10	II	II	I-NP	CD	0	_	_	_	_
11	with	with	B-PP	IN	0	_	_	_	_
12	or	or	B-PP	CC	0	_	_	_	_
13	without	without	B-PP	IN	0	_	_	_	_
14	nalorphine	nalorphine	B-NP	NN	0	_	_	_	_
15	,	,	I-NP	,	0	_	_	_	_
16	morphine	morphine	I-NP	NN	0	_	_	_	_
17	or	or	I-NP	CC	0	_	_	_	_
18	Micoren	Micoren	I-NP	NNS	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	alterations	alteration	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	5	5	B-NP	CD	0	_	_	_	_
5	-	-	I-NP	HYPH	0	_	_	_	_
6	HT	HT	I-NP	NN	UMLS:C0677607:T047:DISO	_	_	_	_
7	and	and	I-NP	CC	0	_	_	_	_
8	5	5	I-NP	CD	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	HIAA	HIAA	I-NP	NN	0	_	_	_	_
11	levels	level	I-NP	NNS	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	several	several	B-NP	JJ	0	_	_	_	_
14	regions	region	I-NP	NNS	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	brain	brain	I-NP	NN	UMLS:C0006104:T023:ANAT	_	_	_	_
18	under	under	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	conditions	condition	I-NP	NNS	0	_	_	_	_
21	examined	examine	B-VP	VBN	0	_	_	_	_
22	may	may	B-VP	MD	0	_	_	_	_
23	indicate	indicate	I-VP	VB	0	_	_	_	_
24	that	that	B-SBAR	IN	0	_	_	_	_
25	IDPN	IDPN	B-NP	NN	0	_	_	_	_
26	's	's	B-NP	POS	0	_	_	_	_
27	neurotoxicity	neurotoxicity	I-NP	NN	0	_	_	_	_
28	primarily	primarily	B-ADVP	RB	0	_	_	_	_
29	affects	affect	B-VP	VBZ	0	_	_	_	_
30	5	5	B-NP	CD	0	_	_	_	_
31	-	-	I-NP	HYPH	0	_	_	_	_
32	HT	HT	I-NP	NN	UMLS:C0677607:T047:DISO	_	_	_	_
33	-	-	O	HYPH	0	_	_	_	_
34	containing	contain	B-VP	VBG	0	_	_	_	_
35	neurones	neurone	B-NP	NNS	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	(	(	B-LST	(	0	_	_	_	_
2	5	5	I-LST	LS	0	_	_	_	_
3	)	)	O	)	0	_	_	_	_
4	An	An	B-NP	DT	0	_	_	_	_
5	increase	increase	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	leukocyte	leukocyte	B-NP	NN	0	_	_	_	_
8	-	-	B-NP	HYPH	0	_	_	_	_
9	counts	count	I-NP	NNS	0	_	_	_	_
10	occurred	occur	B-VP	VBD	0	_	_	_	_
11	on	on	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	administration	administration	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	serum	serum	B-NP	NN	0	_	_	_	_
16	obtained	obtain	B-VP	VBN	0	_	_	_	_
17	from	from	B-PP	IN	0	_	_	_	_
18	rabbit	rabbit	B-NP	NN	0	_	_	_	_
19	during	during	B-PP	IN	0	_	_	_	_
20	phase	phase	B-NP	NN	0	_	_	_	_
21	-	-	B-NP	HYPH	0	_	_	_	_
22	2	2	I-NP	CD	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	obtained	obtain	B-VP	VBN	0	_	_	_	_
4	tend	tend	B-VP	VBP	0	_	_	_	_
5	to	to	I-VP	TO	0	_	_	_	_
6	prove	prove	I-VP	VB	0	_	_	_	_
7	that	that	B-SBAR	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	reticuloendothelial	reticuloendothelial	I-NP	JJ	0	_	_	_	_
10	system	system	I-NP	NN	0	_	_	_	_
11	mainly	mainly	B-ADVP	RB	0	_	_	_	_
12	participated	participate	B-VP	VBD	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	beryllium	beryllium	B-NP	NN	0	_	_	_	_
15	retention	retention	I-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	both	both	B-NP	DT	0	_	_	_	_
3	cases	case	I-NP	NNS	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	at	at	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	end	end	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	exposure	exposure	B-NP	NN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	same	same	I-NP	JJ	0	_	_	_	_
12	level	level	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	blood	blood	B-NP	NN	0	_	_	_	_
15	carboxyhemoglobin	carboxyhemoglobin	I-NP	NN	:::NOCLASS	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	COHb	COHb	B-NP	NN	:::NOCLASS	_	_	_	_
18	)	)	O	)	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	about	about	B-NP	RB	0	_	_	_	_
21	50	50	I-NP	CD	0	_	_	_	_
22	%	%	I-NP	NN	0	_	_	_	_
23	)	)	O	)	0	_	_	_	_
24	was	be	B-VP	VBD	0	_	_	_	_
25	reached	reach	I-VP	VBN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	indicate	indicate	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	increased	increase	B-NP	VBN	0	_	_	_	_
6	pulmonary	pulmonary	I-NP	JJ	UMLS:C0024109:T023:ANAT	_	_	_	_
7	blood	blood	I-NP	NN	0	_	_	_	_
8	flow	flow	I-NP	NN	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	decreased	decrease	B-VP	VBD	0	_	_	_	_
11	pulmonary	pulmonary	B-NP	JJ	UMLS:C0024109:T023:ANAT	_	_	_	_
12	vascular	vascular	I-NP	JJ	UMLS:C0005847:T023:ANAT	_	_	_	_
13	resistance	resistance	I-NP	NN	0	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	advancing	advance	B-VP	VBG	0	_	_	_	_
16	gestation	gestation	B-NP	NN	0	_	_	_	_
17	are	be	B-VP	VBP	0	_	_	_	_
18	due	due	B-PP	JJ	0	_	_	_	_
19	to	to	B-PP	TO	0	_	_	_	_
20	an	an	B-NP	DT	0	_	_	_	_
21	increase	increase	I-NP	NN	0	_	_	_	_
22	in	in	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	total	total	I-NP	JJ	0	_	_	_	_
25	number	number	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	vessels	vessel	B-NP	NNS	UMLS:C0005847:T023:ANAT	_	_	_	_
28	and	and	O	CC	0	_	_	_	_
29	increased	increase	B-NP	VBN	0	_	_	_	_
30	vasomotor	vasomotor	I-NP	NN	0	_	_	_	_
31	reactivity	reactivity	I-NP	NN	0	_	_	_	_
32	is	be	B-VP	VBZ	0	_	_	_	_
33	related	related	B-ADJP	JJ	0	_	_	_	_
34	to	to	B-PP	TO	0	_	_	_	_
35	an	an	B-NP	DT	0	_	_	_	_
36	increase	increase	I-NP	NN	0	_	_	_	_
37	in	in	B-PP	IN	0	_	_	_	_
38	the	the	B-NP	DT	0	_	_	_	_
39	total	total	I-NP	JJ	0	_	_	_	_
40	amount	amount	I-NP	NN	0	_	_	_	_
41	of	of	B-PP	IN	0	_	_	_	_
42	smooth	smooth	B-NP	JJ	0	_	_	_	_
43	muscle	muscle	I-NP	NN	0	_	_	_	_
44	while	while	B-SBAR	IN	0	_	_	_	_
45	the	the	B-NP	DT	0	_	_	_	_
46	thickness	thickness	I-NP	NN	0	_	_	_	_
47	of	of	B-PP	IN	0	_	_	_	_
48	muscle	muscle	B-NP	NN	0	_	_	_	_
49	in	in	B-PP	IN	0	_	_	_	_
50	individual	individual	B-NP	JJ	0	_	_	_	_
51	vessels	vessel	I-NP	NNS	UMLS:C0005847:T023:ANAT	_	_	_	_
52	remains	remain	B-VP	VBZ	0	_	_	_	_
53	constant	constant	B-ADJP	JJ	0	_	_	_	_
54	.	.	O	.	0	_	_	_	_

1	Reduction	Reduction	B-NP	NN	0	_	_	_	_
2	in	in	B-PP	IN	0	_	_	_	_
3	dosage	dosage	B-NP	NN	0	_	_	_	_
4	restored	restore	B-VP	VBD	0	_	_	_	_
5	normal	normal	B-NP	JJ	0	_	_	_	_
6	taste	taste	I-NP	NN	0	_	_	_	_
7	sense	sense	I-NP	NN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	all	all	B-NP	DT	0	_	_	_	_
10	three	three	I-NP	CD	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	but	but	O	CC	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	two	two	B-NP	CD	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	drug	drug	I-NP	NN	0	_	_	_	_
17	had	have	B-VP	VBD	0	_	_	_	_
18	to	to	I-VP	TO	0	_	_	_	_
19	be	be	I-VP	VB	0	_	_	_	_
20	discontinued	discontinue	I-VP	VBN	0	_	_	_	_
21	because	because	B-PP	RB	0	_	_	_	_
22	of	of	I-PP	IN	0	_	_	_	_
23	persisting	persist	B-VP	VBG	0	_	_	_	_
24	high	high	B-NP	JJ	0	_	_	_	_
25	transaminase	transaminase	I-NP	NN	0	_	_	_	_
26	levels	level	I-NP	NNS	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	calcium	calcium	I-NP	NN	0	_	_	_	_
3	ratio	ratio	I-NP	NN	0	_	_	_	_
4	(	(	O	(	0	_	_	_	_
5	mean	mean	B-NP	JJ	0	_	_	_	_
6	ratio	ratio	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	predicted	predict	I-NP	VBN	0	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	measured	measure	B-NP	VBN	0	_	_	_	_
12	TBCa	TBCa	I-NP	NN	0	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	men	man	B-NP	NNS	0	_	_	_	_
16	was	be	B-VP	VBD	0	_	_	_	_
17	1	1	B-NP	CD	0	_	_	_	_
18	.	.	I-NP	.	0	_	_	_	_
19	000	000	I-NP	CD	0	_	_	_	_
20	+	+	B-VP	SYM	0	_	_	_	_
21	/	/	B-ADVP	SYM	0	_	_	_	_
22	-	-	B-NP	SYM	0	_	_	_	_
23	7	7	B-NP	CD	0	_	_	_	_
24	.	.	I-NP	SYM	0	_	_	_	_
25	8	8	I-NP	CD	0	_	_	_	_
26	%	%	I-NP	NN	0	_	_	_	_
27	and	and	B-PP	CC	0	_	_	_	_
28	in	in	B-PP	IN	0	_	_	_	_
29	women	woman	B-NP	NNS	0	_	_	_	_
30	0	0	B-NP	CD	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_
32	996	996	B-NP	CD	0	_	_	_	_
33	+	+	B-NP	SYM	0	_	_	_	_
34	/	/	B-ADVP	SYM	0	_	_	_	_
35	-	-	B-NP	SYM	0	_	_	_	_
36	7	7	B-NP	CD	0	_	_	_	_
37	.	.	I-NP	SYM	0	_	_	_	_
38	1	1	I-NP	CD	0	_	_	_	_
39	%	%	I-NP	NN	0	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	late	late	I-NP	JJ	0	_	_	_	_
3	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	retinoblastoma	retinoblastoma	B-NP	NN	0	_	_	_	_
6	is	be	B-VP	VBZ	0	_	_	_	_
7	an	an	B-NP	DT	0	_	_	_	_
8	unquestionable	unquestionable	I-NP	JJ	0	_	_	_	_
9	fact	fact	I-NP	NN	0	_	_	_	_
10	that	that	B-NP	WDT	0	_	_	_	_
11	allows	allow	B-VP	VBZ	0	_	_	_	_
12	its	its	B-NP	PRP$	0	_	_	_	_
13	growth	growth	I-NP	NN	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	leads	lead	B-VP	VBZ	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	a	a	B-NP	DT	0	_	_	_	_
18	deterioration	deterioration	I-NP	NN	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	outlook	outlook	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Total	Total	B-NP	JJ	0	_	_	_	_
2	cholesterol	cholesterol	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	measured	measure	I-VP	VBN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	amniotic	amniotic	B-NP	JJ	0	_	_	_	_
7	fluids	fluid	I-NP	NNS	0	_	_	_	_
8	collected	collect	B-VP	VBN	0	_	_	_	_
9	at	at	B-PP	IN	0	_	_	_	_
10	different	different	B-NP	JJ	0	_	_	_	_
11	stages	stage	I-NP	NNS	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	gestation	gestation	B-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Her	Her	B-NP	PRP$	0	_	_	_	_
2	serum	serum	I-NP	NN	0	_	_	_	_
3	FT3	FT3	I-NP	NN	0	_	_	_	_
4	concentration	concentration	I-NP	NN	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	however	however	B-ADVP	RB	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	much	much	B-ADJP	RB	0	_	_	_	_
10	higher	high	I-ADJP	JJR	0	_	_	_	_
11	than	than	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	ranges	range	I-NP	NNS	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	normal	normal	B-NP	JJ	0	_	_	_	_
16	pregnancy	pregnancy	I-NP	NN	0	_	_	_	_
17	or	or	B-PP	CC	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	GTD	GTD	B-NP	NN	0	_	_	_	_
20	patients	patient	I-NP	NNS	0	_	_	_	_
21	without	without	B-PP	IN	0	_	_	_	_
22	clinical	clinical	B-NP	JJ	0	_	_	_	_
23	hyperthyroidism	hyperthyroidism	I-NP	NN	UMLS:C0020550:T047:DISO	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	authors	author	I-NP	NNS	0	_	_	_	_
3	found	find	B-VP	VBD	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	except	except	B-PP	IN	0	_	_	_	_
6	for	for	B-PP	IN	0	_	_	_	_
7	fear	fear	B-NP	NN	0	_	_	_	_
8	and	and	I-NP	CC	0	_	_	_	_
9	pugnacity	pugnacity	I-NP	NN	0	_	_	_	_
10	all	all	B-NP	DT	0	_	_	_	_
11	husband	husband	I-NP	NN	0	_	_	_	_
12	-	-	B-NP	HYPH	0	_	_	_	_
13	wife	wife	I-NP	NN	0	_	_	_	_
14	trait	trait	I-NP	NN	0	_	_	_	_
15	correlations	correlation	I-NP	NNS	0	_	_	_	_
16	were	be	B-VP	VBD	0	_	_	_	_
17	positive	positive	B-ADJP	JJ	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	contrast	contrast	B-NP	NN	0	_	_	_	_
21	to	to	B-PP	TO	0	_	_	_	_
22	Winch	Winch	B-NP	NNP	0	_	_	_	_
23	's	's	B-NP	POS	0	_	_	_	_
24	principle	principle	I-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	type	type	B-NP	NN	0	_	_	_	_
27	I	I	I-NP	CD	0	_	_	_	_
28	complementarity	complementarity	I-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	note	note	I-NP	NN	0	_	_	_	_
3	on	on	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	phase	phase	I-NP	NN	0	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	plane	plane	I-NP	NN	0	_	_	_	_
8	technique	technique	I-NP	NN	0	_	_	_	_
9	representation	representation	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	cardiac	cardiac	B-NP	JJ	UMLS:C0018787:T023:ANAT	_	_	_	_
12	action	action	I-NP	NN	0	_	_	_	_
13	potentials	potential	I-NP	NNS	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	3	3	B-NP	CD	0	_	_	_	_
2	activities	activity	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
6	II	II	I-NP	CD	:::NOCLASS	_	_	_	_
7	molecule	molecule	I-NP	NN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	newborn	newborn	I-NP	JJ	0	_	_	_	_
11	infant	infant	I-NP	NN	0	_	_	_	_
12	at	at	B-PP	IN	0	_	_	_	_
13	term	term	B-NP	NN	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	concept	concept	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	"	"	O	``	0	_	_	_	_
5	structural	structural	B-NP	JJ	0	_	_	_	_
6	identifiability	identifiability	I-NP	NN	0	_	_	_	_
7	"	"	O	''	0	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	employed	employ	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	this	this	B-NP	DT	0	_	_	_	_
12	analysis	analysis	I-NP	NN	0	_	_	_	_
13	to	to	B-VP	TO	0	_	_	_	_
14	determine	determine	I-VP	VB	0	_	_	_	_
15	which	which	B-NP	WDT	0	_	_	_	_
16	model	model	I-NP	NN	0	_	_	_	_
17	parameters	parameter	I-NP	NNS	0	_	_	_	_
18	can	can	B-VP	MD	0	_	_	_	_
19	be	be	I-VP	VB	0	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	which	which	B-NP	WDT	0	_	_	_	_
22	cannot	cannot	B-VP	MD	0	_	_	_	_
23	be	be	I-VP	VB	0	_	_	_	_
24	determined	determine	I-VP	VBN	0	_	_	_	_
25	"	"	O	``	0	_	_	_	_
26	uniquely	uniquely	B-ADVP	RB	0	_	_	_	_
27	"	"	O	''	0	_	_	_	_
28	from	from	B-PP	IN	0	_	_	_	_
29	given	give	B-NP	VBN	0	_	_	_	_
30	input	input	I-NP	NN	0	_	_	_	_
31	-	-	B-NP	HYPH	0	_	_	_	_
32	output	output	I-NP	NN	0	_	_	_	_
33	data	datum	I-NP	NNS	0	_	_	_	_
34	;	;	O	:	0	_	_	_	_
35	a	a	B-NP	DT	0	_	_	_	_
36	step	step	I-NP	NN	0	_	_	_	_
37	-	-	B-ADJP	HYPH	0	_	_	_	_
38	by	by	B-PP	IN	0	_	_	_	_
39	-	-	B-NP	HYPH	0	_	_	_	_
40	step	step	I-NP	NN	0	_	_	_	_
41	procedure	procedure	I-NP	NN	0	_	_	_	_
42	based	base	B-VP	VBN	0	_	_	_	_
43	on	on	B-PP	IN	0	_	_	_	_
44	an	an	B-NP	DT	0	_	_	_	_
45	extension	extension	I-NP	NN	0	_	_	_	_
46	of	of	B-PP	IN	0	_	_	_	_
47	this	this	B-NP	DT	0	_	_	_	_
48	concept	concept	I-NP	NN	0	_	_	_	_
49	is	be	B-VP	VBZ	0	_	_	_	_
50	presented	present	I-VP	VBN	0	_	_	_	_
51	for	for	B-PP	IN	0	_	_	_	_
52	adapting	adapt	B-VP	VBG	0	_	_	_	_
53	the	the	B-NP	DT	0	_	_	_	_
54	overall	overall	I-NP	JJ	0	_	_	_	_
55	approach	approach	I-NP	NN	0	_	_	_	_
56	to	to	B-PP	TO	0	_	_	_	_
57	the	the	B-NP	DT	0	_	_	_	_
58	experimental	experimental	I-NP	JJ	0	_	_	_	_
59	design	design	I-NP	NN	0	_	_	_	_
60	problem	problem	I-NP	NN	0	_	_	_	_
61	.	.	O	.	0	_	_	_	_

1	However	However	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	we	we	B-NP	PRP	0	_	_	_	_
4	did	do	B-VP	VBD	0	_	_	_	_
5	detect	detect	I-VP	VB	0	_	_	_	_
6	lot	lot	B-NP	NN	0	_	_	_	_
7	-	-	B-ADVP	HYPH	0	_	_	_	_
8	to	to	B-PP	TO	0	_	_	_	_
9	-	-	B-NP	HYPH	0	_	_	_	_
10	lot	lot	I-NP	NN	0	_	_	_	_
11	variation	variation	I-NP	NN	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	differences	difference	B-NP	NNS	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	performance	performance	B-NP	NN	0	_	_	_	_
16	between	between	B-PP	IN	0	_	_	_	_
17	narrow	narrow	B-NP	JJ	0	_	_	_	_
18	bandpass	bandpass	I-NP	NN	0	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	wide	wide	B-NP	JJ	0	_	_	_	_
21	bandpass	bandpass	I-NP	NN	0	_	_	_	_
22	spectrophotometers	spectrophotometer	I-NP	NNS	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	cochlear	cochlear	I-NP	JJ	UMLS:C0009195:T023:ANAT	_	_	_	_
3	compromise	compromise	I-NP	NN	0	_	_	_	_
4	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	case	case	I-NP	NN	0	_	_	_	_
3	observed	observe	B-VP	VBN	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	Saigon	Saigon	B-NP	NNP	0	_	_	_	_

1	Hypertonic	Hypertonic	B-NP	JJ	0	_	_	_	_
2	glucose	glucose	I-NP	NN	0	_	_	_	_
3	administered	administer	B-VP	VBN	0	_	_	_	_
4	intrajejunally	intrajejunally	B-ADVP	RB	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	Heidenhain	Heidenhain	B-NP	NNP	0	_	_	_	_
7	pouch	pouch	I-NP	NN	0	_	_	_	_
8	dogs	dog	I-NP	NNS	0	_	_	_	_
9	resulted	result	B-VP	VBD	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	an	an	B-NP	DT	0	_	_	_	_
12	equal	equal	I-NP	JJ	0	_	_	_	_
13	inhibition	inhibition	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	pentagastrin	pentagastrin	B-NP	NN	0	_	_	_	_
16	-	-	B-NP	HYPH	0	_	_	_	_
17	induced	induce	I-NP	VBN	0	_	_	_	_
18	acid	acid	I-NP	NN	0	_	_	_	_
19	secretion	secretion	I-NP	NN	0	_	_	_	_
20	from	from	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	pouch	pouch	I-NP	NN	0	_	_	_	_
23	and	and	O	CC	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	main	main	I-NP	JJ	0	_	_	_	_
26	stomach	stomach	I-NP	NN	UMLS:C0038351:T023:ANAT	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	whereas	whereas	O	IN	0	_	_	_	_
29	hypertonic	hypertonic	B-NP	JJ	0	_	_	_	_
30	saline	saline	I-NP	NN	0	_	_	_	_
31	had	have	B-VP	VBD	0	_	_	_	_
32	no	no	B-NP	DT	0	_	_	_	_
33	effect	effect	I-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Acquired	Acquire	B-NP	VBN	0	_	_	_	_
2	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
3	VIII	VIII	I-NP	CD	:::NOCLASS	_	_	_	_
4	inhibitor	inhibitor	I-NP	NN	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	non	non	B-NP	AFX	0	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	hemophilic	hemophilic	I-NP	JJ	0	_	_	_	_
9	patients	patient	I-NP	NNS	0	_	_	_	_

1	Biohydrogenation	Biohydrogenation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	linoleic	linoleic	B-NP	JJ	0	_	_	_	_
4	acid	acid	I-NP	NN	0	_	_	_	_
5	into	into	B-PP	IN	0	_	_	_	_
6	octadecenoic	octadecenoic	B-NP	JJ	0	_	_	_	_
7	acid	acid	I-NP	NN	0	_	_	_	_
8	was	be	B-VP	VBD	0	_	_	_	_
9	observed	observe	I-VP	VBN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	study	study	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	calcium	calcium	B-NP	NN	0	_	_	_	_
5	metabolism	metabolism	I-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	ten	ten	B-NP	CD	UMLS:C0014518:T047:DISO	_	_	_	_
8	thalassaemic	thalassaemic	I-NP	JJ	0	_	_	_	_
9	children	child	I-NP	NNS	0	_	_	_	_
10	comperatively	comperatively	B-ADVP	RB	0	_	_	_	_
11	with	with	B-PP	IN	0	_	_	_	_
12	controls	control	B-NP	NNS	0	_	_	_	_
13	after	after	B-PP	IN	0	_	_	_	_
14	oral	oral	B-NP	JJ	0	_	_	_	_
15	administration	administration	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	47Ca	47Ca	B-NP	NN	0	_	_	_	_
18	has	have	B-VP	VBZ	0	_	_	_	_
19	shown	show	I-VP	VBN	0	_	_	_	_
20	diminished	diminish	I-VP	VBN	0	_	_	_	_
21	intestinal	intestinal	B-NP	JJ	UMLS:C0021853:T023:ANAT	_	_	_	_
22	absorption	absorption	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Chlamydial	Chlamydial	B-NP	NN	0	_	_	_	_
2	agents	agent	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	isolated	isolate	I-VP	VBN	0	_	_	_	_
5	from	from	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	semen	seman	I-NP	NNS	0	_	_	_	_
8	near	near	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	end	end	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	chlamydemic	chlamydemic	I-NP	JJ	0	_	_	_	_
14	phase	phase	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Because	Because	B-PP	IN	0	_	_	_	_
2	of	of	I-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	increased	increase	I-NP	VBN	0	_	_	_	_
5	CPK	CPK	I-NP	NN	:::NOCLASS	_	_	_	_
6	activity	activity	I-NP	NN	0	_	_	_	_
7	found	find	B-VP	VBN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	normal	normal	B-NP	JJ	0	_	_	_	_
10	newborns	newborn	I-NP	NNS	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	screening	screen	B-VP	VBG	0	_	_	_	_
13	for	for	B-PP	IN	0	_	_	_	_
14	Duchenne	Duchenne	B-NP	NNP	0	_	_	_	_
15	-	-	I-NP	HYPH	0	_	_	_	_
16	type	type	I-NP	NN	0	_	_	_	_
17	muscular	muscular	I-NP	JJ	UMLS:C0026850:T047:DISO	_	_	_	_
18	dystrophy	dystrophy	I-NP	NN	UMLS:C0026850:T047:DISO	_	_	_	_
19	should	should	B-VP	MD	0	_	_	_	_
20	be	be	I-VP	VB	0	_	_	_	_
21	postponed	postpone	I-VP	VBN	0	_	_	_	_
22	for	for	B-PP	IN	0	_	_	_	_
23	a	a	B-NP	DT	0	_	_	_	_
24	few	few	I-NP	JJ	0	_	_	_	_
25	weeks	week	I-NP	NNS	0	_	_	_	_
26	after	after	B-PP	IN	0	_	_	_	_
27	delivery	delivery	B-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	contrast	contrast	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	insulin	insulin	I-NP	NN	:::NOCLASS	_	_	_	_
6	response	response	I-NP	NN	0	_	_	_	_
7	had	have	B-VP	VBD	0	_	_	_	_
8	returned	return	I-VP	VBN	0	_	_	_	_
9	to	to	B-PP	TO	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	non	non	I-NP	AFX	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	pregnant	pregnant	I-NP	JJ	0	_	_	_	_
14	value	value	I-NP	NN	0	_	_	_	_
15	by	by	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	second	second	I-NP	JJ	0	_	_	_	_
18	day	day	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	puerperium	puerperium	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	authors	author	I-NP	NNS	0	_	_	_	_
3	report	report	B-VP	VBP	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	results	result	I-NP	NNS	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	series	series	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	toxicological	toxicological	B-NP	JJ	0	_	_	_	_
11	tests	test	I-NP	NNS	0	_	_	_	_
12	conducted	conduct	B-VP	VBN	0	_	_	_	_
13	on	on	B-PP	IN	0	_	_	_	_
14	plastic	plastic	B-NP	JJ	0	_	_	_	_
15	materials	material	I-NP	NNS	0	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	polyethylene	polyethylene	B-NP	NN	0	_	_	_	_
18	)	)	O	)	0	_	_	_	_
19	activated	activate	B-VP	VBN	0	_	_	_	_
20	with	with	B-PP	IN	0	_	_	_	_
21	tetraphenylbutadiene	tetraphenylbutadiene	B-NP	NN	0	_	_	_	_
22	(	(	O	(	0	_	_	_	_
23	TPB	TPB	B-NP	NN	0	_	_	_	_
24	)	)	O	)	0	_	_	_	_
25	an	an	B-NP	DT	0	_	_	_	_
26	additive	additive	I-NP	JJ	0	_	_	_	_
27	recently	recently	I-NP	RB	0	_	_	_	_
28	proposed	propose	I-NP	VBN	0	_	_	_	_
29	as	as	B-PP	IN	0	_	_	_	_
30	a	a	B-NP	DT	0	_	_	_	_
31	sensitizer	sensitizer	I-NP	NN	0	_	_	_	_
32	capable	capable	B-ADJP	JJ	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	photodegrading	photodegrade	B-VP	VBG	0	_	_	_	_
35	plastic	plastic	B-NP	JJ	0	_	_	_	_
36	materials	material	I-NP	NNS	0	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	Mutational	Mutational	B-NP	JJ	0	_	_	_	_
2	analysis	analysis	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	major	major	I-NP	JJ	0	_	_	_	_
6	homology	homology	I-NP	NN	0	_	_	_	_
7	region	region	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	Mason	Mason	B-NP	NNP	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	Pfizer	Pfizer	I-NP	NNP	0	_	_	_	_
12	monkey	monkey	I-NP	NN	0	_	_	_	_
13	virus	virus	I-NP	NN	0	_	_	_	_
14	by	by	B-PP	IN	0	_	_	_	_
15	use	use	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	saturation	saturation	B-NP	NN	0	_	_	_	_
18	mutagenesis	mutagenesis	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	One	One	B-NP	CD	0	_	_	_	_
2	site	site	I-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	PAL	PAL	B-NP	NN	UMLS:C1186982:T023:ANAT|:::NOCLASS	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	occurs	occur	B-VP	VBZ	0	_	_	_	_
7	within	within	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	10	10	I-NP	CD	0	_	_	_	_
10	bp	bp	I-NP	NN	0	_	_	_	_
11	sequence	sequence	I-NP	NN	0	_	_	_	_
12	GGGGAGGAGG	GGGGAGGAGG	I-NP	NN	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Nuclear	Nuclear	B-NP	JJ	0	_	_	_	_
2	extracts	extract	I-NP	NNS	0	_	_	_	_
3	prepared	prepare	B-VP	VBN	0	_	_	_	_
4	from	from	B-PP	IN	0	_	_	_	_
5	both	both	B-NP	CC	0	_	_	_	_
6	neural	neural	I-NP	JJ	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	non	non	B-NP	AFX	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	neural	neural	I-NP	JJ	0	_	_	_	_
11	cell	cell	I-NP	NN	0	_	_	_	_
12	lines	line	I-NP	NNS	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	mouse	mouse	B-NP	NN	0	_	_	_	_
15	brain	brain	I-NP	NN	UMLS:C0006104:T023:ANAT	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	mouse	mouse	B-NP	NN	0	_	_	_	_
19	liver	liver	I-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
20	contain	contain	B-VP	VBP	0	_	_	_	_
21	proteins	protein	B-NP	NNS	0	_	_	_	_
22	that	that	B-NP	WDT	0	_	_	_	_
23	recognize	recognize	B-VP	VBP	0	_	_	_	_
24	and	and	I-VP	CC	0	_	_	_	_
25	bind	bind	I-VP	VBP	0	_	_	_	_
26	to	to	B-PP	TO	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	PROX	PROX	I-NP	NN	0	_	_	_	_
29	and	and	I-NP	CC	0	_	_	_	_
30	PAL	PAL	I-NP	NN	UMLS:C1186982:T023:ANAT	_	_	_	_
31	sequences	sequence	I-NP	NNS	0	_	_	_	_
32	indicating	indicate	B-VP	VBG	0	_	_	_	_
33	that	that	B-SBAR	IN	0	_	_	_	_
34	proteins	protein	B-NP	NNS	0	_	_	_	_
35	which	which	B-NP	WDT	0	_	_	_	_
36	bind	bind	B-VP	VBP	0	_	_	_	_
37	to	to	B-PP	TO	0	_	_	_	_
38	these	these	B-NP	DT	0	_	_	_	_
39	target	target	I-NP	NN	0	_	_	_	_
40	sequences	sequence	I-NP	NNS	0	_	_	_	_
41	are	be	B-VP	VBP	0	_	_	_	_
42	widespread	widespread	B-ADJP	JJ	0	_	_	_	_
43	.	.	O	.	0	_	_	_	_

1	To	To	B-VP	TO	0	_	_	_	_
2	determine	determine	I-VP	VB	0	_	_	_	_
3	if	if	B-SBAR	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	NF	NF	I-NP	NN	:::NOCLASS	_	_	_	_
6	(	(	O	(	:::NOCLASS	_	_	_	_
7	H	H	B-NP	NN	:::NOCLASS	_	_	_	_
8	)	)	O	)	:::NOCLASS	_	_	_	_
9	promoter	promoter	B-NP	NN	:::NOCLASS	_	_	_	_
10	can	can	B-VP	MD	0	_	_	_	_
11	be	be	I-VP	VB	0	_	_	_	_
12	activated	activate	I-VP	VBN	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	tissue	tissue	I-NP	NN	0	_	_	_	_
16	specific	specific	I-NP	JJ	0	_	_	_	_
17	manner	manner	I-NP	NN	0	_	_	_	_
18	during	during	B-PP	IN	0	_	_	_	_
19	development	development	B-NP	NN	0	_	_	_	_
20	transgenic	transgenic	I-NP	JJ	0	_	_	_	_
21	mice	mouse	I-NP	NNS	0	_	_	_	_
22	containing	contain	B-VP	VBG	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	promoter	promoter	I-NP	NN	0	_	_	_	_
25	region	region	I-NP	NN	0	_	_	_	_
26	linked	link	B-VP	VBN	0	_	_	_	_
27	to	to	B-PP	TO	0	_	_	_	_
28	a	a	B-NP	DT	0	_	_	_	_
29	beta	beta	I-NP	SYM	:::NOCLASS	_	_	_	_
30	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
31	galactosidase	galactosidase	I-NP	NN	:::NOCLASS	_	_	_	_
32	reporter	reporter	I-NP	NN	:::NOCLASS	_	_	_	_
33	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
34	were	be	B-VP	VBD	0	_	_	_	_
35	generated	generate	I-VP	VBN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	Here	Here	B-ADVP	RB	0	_	_	_	_
2	we	we	B-NP	PRP	0	_	_	_	_
3	describe	describe	B-VP	VBP	0	_	_	_	_
4	and	and	I-VP	CC	0	_	_	_	_
5	map	map	I-VP	VBP	0	_	_	_	_
6	two	two	B-NP	CD	0	_	_	_	_
7	more	more	I-NP	RBR	0	_	_	_	_
8	new	new	I-NP	JJ	0	_	_	_	_
9	genes	gene	I-NP	NNS	0	_	_	_	_
10	identified	identify	B-VP	VBN	0	_	_	_	_
11	as	as	B-PP	IN	0	_	_	_	_
12	allele	allele	B-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	specific	specific	I-NP	JJ	0	_	_	_	_
15	suppressors	suppressor	I-NP	NNS	0	_	_	_	_
16	that	that	B-NP	WDT	0	_	_	_	_
17	compensate	compensate	B-VP	VBP	0	_	_	_	_
18	for	for	B-PP	IN	0	_	_	_	_
19	carboxy	carboxy	B-NP	NN	0	_	_	_	_
20	-	-	B-NP	HYPH	0	_	_	_	_
21	terminal	terminal	I-NP	JJ	0	_	_	_	_
22	truncation	truncation	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	PET122	PET122	B-NP	NN	:::NOCLASS	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Previous	Previous	B-NP	JJ	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	have	have	B-VP	VBP	0	_	_	_	_
4	shown	show	I-VP	VBN	0	_	_	_	_
5	[	[	O	(	0	_	_	_	_
6	Hisanaga	Hisanaga	B-NP	NNP	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	S	S	B-NP	NNP	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	Kusubata	Kusubata	B-NP	NNP	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	M	M	B-NP	NNP	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	Okumura	Okumura	B-NP	NNP	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	E	E	B-NP	NNP	0	_	_	_	_
19	.	.	I-NP	.	0	_	_	_	_
20	&	&	I-NP	CC	0	_	_	_	_
21	Kishimoto	Kishimoto	I-NP	NNP	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	T	T	B-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Treatment	Treatment	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	staining	staining	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	smears	smear	B-NP	NNS	0	_	_	_	_
6	and	and	I-NP	CC	0	_	_	_	_
7	sections	section	I-NP	NNS	0	_	_	_	_
8	for	for	B-PP	IN	0	_	_	_	_
9	detection	detection	B-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	microorganisms	microorganism	B-NP	NNS	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	apparent	apparent	I-NP	JJ	0	_	_	_	_
3	Kd	Kd	I-NP	NN	UMLS:C1839259:T047:DISO|UMLS:C0026691:T047:DISO	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	MetRS	MetRS	I-NP	NN	:::NOCLASS	_	_	_	_
7	/	/	B-NP	SYM	:::NOCLASS	_	_	_	_
8	CAU	CAU	I-NP	NN	:::NOCLASS	_	_	_	_
9	operator	operator	I-NP	NN	:::NOCLASS	_	_	_	_
10	complex	complex	I-NP	NN	:::NOCLASS	_	_	_	_
11	is	be	B-VP	VBZ	0	_	_	_	_
12	one	one	B-NP	CD	0	_	_	_	_
13	order	order	I-NP	NN	0	_	_	_	_
14	magnitude	magnitude	I-NP	NN	0	_	_	_	_
15	higher	high	B-ADJP	JJR	0	_	_	_	_
16	than	than	B-PP	IN	0	_	_	_	_
17	that	that	B-NP	DT	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	ThrRS	ThrRS	I-NP	NN	:::NOCLASS	_	_	_	_
21	/	/	B-NP	SYM	:::NOCLASS	_	_	_	_
22	CGU	CGU	I-NP	NN	:::NOCLASS	_	_	_	_
23	operator	operator	I-NP	NN	:::NOCLASS	_	_	_	_
24	complex	complex	I-NP	NN	:::NOCLASS	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	significant	significant	I-NP	JJ	0	_	_	_	_
3	direct	direct	I-NP	JJ	0	_	_	_	_
4	relationship	relationship	I-NP	NN	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	observed	observe	I-VP	VBN	0	_	_	_	_
7	between	between	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	percent	percent	I-NP	NN	0	_	_	_	_
10	area	area	I-NP	NN	0	_	_	_	_
11	density	density	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	smooth	smooth	B-NP	JJ	0	_	_	_	_
14	muscle	muscle	I-NP	NN	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	percent	percent	I-NP	NN	0	_	_	_	_
18	change	change	I-NP	NN	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	peak	peak	B-NP	NN	0	_	_	_	_
21	urinary	urinary	I-NP	JJ	0	_	_	_	_
22	flow	flow	I-NP	NN	0	_	_	_	_
23	rate	rate	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Rabbit	Rabbit	B-NP	NN	:::NOCLASS	_	_	_	_
2	skeletal	skeletal	I-NP	JJ	:::NOCLASS|UMLS:C0242692:T023:ANAT	_	_	_	_
3	muscle	muscle	I-NP	NN	:::NOCLASS|UMLS:C0242692:T023:ANAT	_	_	_	_
4	glycogenin	glycogenin	I-NP	NN	:::NOCLASS	_	_	_	_
5	.	.	O	.	0	_	_	_	_

1	Characterization	Characterization	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	human	human	I-NP	JJ	:::NOCLASS	_	_	_	_
5	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
6	encoding	encode	B-VP	VBG	:::NOCLASS	_	_	_	_
7	cytokeratin	cytokeratin	B-NP	NN	:::NOCLASS	_	_	_	_
8	17	17	I-NP	CD	:::NOCLASS	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	its	its	B-NP	PRP$	0	_	_	_	_
11	expression	expression	I-NP	NN	0	_	_	_	_
12	pattern	pattern	I-NP	NN	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Animals	Animal	B-NP	NNS	0	_	_	_	_
2	that	that	B-NP	WDT	0	_	_	_	_
3	received	receive	B-VP	VBD	0	_	_	_	_
4	DSP	DSP	B-NP	NN	0	_	_	_	_
5	-	-	B-NP	HYPH	0	_	_	_	_
6	4	4	I-NP	CD	0	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	significantly	significantly	I-VP	RB	0	_	_	_	_
9	retarded	retard	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	motor	motor	B-NP	NN	0	_	_	_	_
12	recovery	recovery	I-NP	NN	0	_	_	_	_
13	compared	compare	B-PP	VBN	0	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	saline	saline	I-NP	NN	0	_	_	_	_
17	group	group	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	prophylactic	prophylactic	I-NP	JJ	0	_	_	_	_
3	use	use	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	new	new	B-NP	JJ	0	_	_	_	_
6	medication	medication	I-NP	NN	0	_	_	_	_
7	for	for	B-PP	IN	0	_	_	_	_
8	patients	patient	B-NP	NNS	0	_	_	_	_
9	between	between	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	first	first	I-NP	JJ	0	_	_	_	_
12	and	and	I-NP	CC	0	_	_	_	_
13	second	second	I-NP	JJ	0	_	_	_	_
14	cycle	cycle	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	chemotherapy	chemotherapy	B-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	agreement	agreement	B-NP	NN	0	_	_	_	_
20	with	with	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	estimates	estimate	I-NP	NNS	0	_	_	_	_
23	calculated	calculate	B-VP	VBN	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	does	do	B-VP	VBZ	0	_	_	_	_
26	not	not	I-VP	RB	0	_	_	_	_
27	save	save	I-VP	VB	0	_	_	_	_
28	health	health	B-NP	NN	0	_	_	_	_
29	care	care	I-NP	NN	0	_	_	_	_
30	costs	cost	I-NP	NNS	0	_	_	_	_
31	but	but	O	CC	0	_	_	_	_
32	may	may	B-VP	MD	0	_	_	_	_
33	improve	improve	I-VP	VB	0	_	_	_	_
34	the	the	B-NP	DT	0	_	_	_	_
35	quality	quality	I-NP	NN	0	_	_	_	_
36	of	of	B-PP	IN	0	_	_	_	_
37	life	life	B-NP	NN	0	_	_	_	_
38	in	in	B-PP	IN	0	_	_	_	_
39	these	these	B-NP	DT	0	_	_	_	_
40	patients	patient	I-NP	NNS	0	_	_	_	_
41	and	and	O	CC	0	_	_	_	_
42	permit	permit	B-VP	VB	0	_	_	_	_
43	the	the	B-NP	DT	0	_	_	_	_
44	continuation	continuation	I-NP	NN	0	_	_	_	_
45	of	of	B-PP	IN	0	_	_	_	_
46	a	a	B-NP	DT	0	_	_	_	_
47	therapeutic	therapeutic	I-NP	JJ	0	_	_	_	_
48	schedule	schedule	I-NP	NN	0	_	_	_	_
49	without	without	B-PP	IN	0	_	_	_	_
50	interruption	interruption	B-NP	NN	0	_	_	_	_
51	which	which	B-NP	WDT	0	_	_	_	_
52	may	may	B-VP	MD	0	_	_	_	_
53	improve	improve	I-VP	VB	0	_	_	_	_
54	the	the	B-NP	DT	0	_	_	_	_
55	life	life	I-NP	NN	0	_	_	_	_
56	expectancy	expectancy	I-NP	NN	0	_	_	_	_
57	of	of	B-PP	IN	0	_	_	_	_
58	the	the	B-NP	DT	0	_	_	_	_
59	patient	patient	I-NP	NN	0	_	_	_	_
60	.	.	O	.	0	_	_	_	_

1	AP	AP	B-NP	NN	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	induced	induce	I-VP	VBN	0	_	_	_	_
4	by	by	B-PP	IN	0	_	_	_	_
5	intraductal	intraductal	B-NP	JJ	0	_	_	_	_
6	infusion	infusion	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	two	two	B-NP	CD	0	_	_	_	_
9	different	different	I-NP	JJ	0	_	_	_	_
10	concentrations	concentration	I-NP	NNS	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	glycodeoxycholic	glycodeoxycholic	B-NP	JJ	0	_	_	_	_
13	acid	acid	I-NP	NN	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	GDOC	GDOC	B-NP	NN	0	_	_	_	_
16	17	17	I-NP	CD	0	_	_	_	_
17	mmol	mmol	I-NP	NN	0	_	_	_	_
18	and	and	O	CC	0	_	_	_	_
19	34	34	B-NP	CD	0	_	_	_	_
20	mmol	mmol	I-NP	NN	0	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	isolation	isolation	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	this	this	B-NP	DT	0	_	_	_	_
5	gene	gene	I-NP	NN	0	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	based	base	I-VP	VBN	0	_	_	_	_
8	on	on	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	identification	identification	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	Y	Y	I-NP	NN	0	_	_	_	_
14	-	-	B-NP	HYPH	0	_	_	_	_
15	231	231	I-NP	CD	0	_	_	_	_
16	cosmid	cosmid	I-NP	NN	0	_	_	_	_
17	that	that	B-NP	WDT	0	_	_	_	_
18	contains	contain	B-VP	VBZ	0	_	_	_	_
19	CpG	CpG	B-NP	NN	0	_	_	_	_
20	rich	rich	I-NP	JJ	0	_	_	_	_
21	sequences	sequence	I-NP	NNS	0	_	_	_	_
22	(	(	O	(	0	_	_	_	_
23	HTF	HTF	B-NP	NN	0	_	_	_	_
24	islands	island	I-NP	NNS	0	_	_	_	_
25	)	)	O	)	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	its	its	B-NP	PRP$	0	_	_	_	_
28	human	human	I-NP	JJ	0	_	_	_	_
29	insert	insert	I-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Tissue	Tissue	B-NP	NN	:::NOCLASS	_	_	_	_
2	plasminogen	plasminogen	I-NP	NN	:::NOCLASS	_	_	_	_
3	activator	activator	I-NP	NN	:::NOCLASS	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	its	its	B-NP	PRP$	0	_	_	_	_
6	inhibitor	inhibitor	I-NP	NN	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	other	other	B-NP	JJ	0	_	_	_	_
9	parameters	parameter	I-NP	NNS	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	fibrinolysis	fibrinolysis	B-NP	NN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	blood	blood	B-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	patients	patient	B-NP	NNS	0	_	_	_	_
16	operated	operate	B-VP	VBN	0	_	_	_	_
17	for	for	B-PP	IN	0	_	_	_	_
18	mild	mild	B-NP	JJ	0	_	_	_	_
19	hypertrophy	hypertrophy	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	prostate	prostate	I-NP	NN	UMLS:C0033572:T023:ANAT	_	_	_	_

1	Gene	Gene	B-NP	NN	0	_	_	_	_
2	constructs	construct	I-NP	NNS	0	_	_	_	_
3	consisting	consist	B-VP	VBG	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	human	human	B-NP	JJ	:::NOCLASS	_	_	_	_
6	growth	growth	I-NP	NN	:::NOCLASS	_	_	_	_
7	hormone	hormone	I-NP	NN	:::NOCLASS	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	hGH	hGH	B-NP	NN	:::NOCLASS	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	gene	gene	B-NP	NN	0	_	_	_	_
12	driven	drive	B-VP	VBN	0	_	_	_	_
13	by	by	B-PP	IN	0	_	_	_	_
14	promoter	promoter	B-NP	NN	0	_	_	_	_
15	/	/	B-NP	SYM	0	_	_	_	_
16	regulatory	regulatory	I-NP	JJ	0	_	_	_	_
17	sequence	sequence	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	mouse	mouse	B-NP	NN	:::NOCLASS	_	_	_	_
20	metallothionein	metallothionein	I-NP	NN	:::NOCLASS	_	_	_	_
21	(	(	O	(	0	_	_	_	_
22	mMT	mMT	B-NP	NN	:::NOCLASS	_	_	_	_
23	)	)	O	)	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	viral	viral	B-NP	JJ	:::NOCLASS	_	_	_	_
26	thymidine	thymidine	I-NP	NN	:::NOCLASS	_	_	_	_
27	kinase	kinase	I-NP	NN	:::NOCLASS	_	_	_	_
28	(	(	O	(	0	_	_	_	_
29	vTK	vTK	B-NP	NN	:::NOCLASS	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	rat	rat	B-NP	NN	:::NOCLASS	_	_	_	_
33	cholecystokinin	cholecystokinin	I-NP	NN	:::NOCLASS	_	_	_	_
34	(	(	O	(	0	_	_	_	_
35	rCCK	rCCK	B-NP	NN	:::NOCLASS	_	_	_	_
36	)	)	O	)	0	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	or	or	O	CC	0	_	_	_	_
39	chicken	chicken	B-NP	NN	:::NOCLASS	_	_	_	_
40	beta	beta	O	SYM	0	_	_	_	_
41	-	-	O	HYPH	0	_	_	_	_
42	actin	actin	B-NP	NN	0	_	_	_	_
43	(	(	O	(	0	_	_	_	_
44	cBA	cBA	B-NP	NN	:::NOCLASS	_	_	_	_
45	)	)	O	)	0	_	_	_	_
46	gene	gene	B-NP	NN	0	_	_	_	_
47	were	be	B-VP	VBD	0	_	_	_	_
48	injected	inject	I-VP	VBN	0	_	_	_	_
49	into	into	B-PP	IN	0	_	_	_	_
50	the	the	B-NP	DT	0	_	_	_	_
51	cytoplasm	cytoplasm	I-NP	NN	0	_	_	_	_
52	of	of	B-PP	IN	0	_	_	_	_
53	fertilized	fertilize	B-NP	VBN	0	_	_	_	_
54	medaka	medaka	I-NP	NN	0	_	_	_	_
55	eggs	egg	I-NP	NNS	0	_	_	_	_
56	via	via	B-PP	IN	0	_	_	_	_
57	the	the	B-NP	DT	0	_	_	_	_
58	micropyle	micropyle	I-NP	NN	0	_	_	_	_
59	.	.	O	.	0	_	_	_	_

1	Serum	Serum	B-NP	NN	0	_	_	_	_
2	gastrin	gastrin	I-NP	NN	:::NOCLASS	_	_	_	_
3	and	and	I-NP	CC	0	_	_	_	_
4	AFP	AFP	I-NP	NN	:::NOCLASS	_	_	_	_
5	levels	level	I-NP	NNS	0	_	_	_	_
6	had	have	B-VP	VBD	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	same	same	I-NP	JJ	0	_	_	_	_
9	evolution	evolution	I-NP	NN	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	appear	appear	B-VP	VBP	0	_	_	_	_
12	to	to	I-VP	TO	0	_	_	_	_
13	have	have	I-VP	VB	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	same	same	I-NP	JJ	0	_	_	_	_
16	interest	interest	I-NP	NN	0	_	_	_	_
17	to	to	B-VP	TO	0	_	_	_	_
18	follow	follow	I-VP	VB	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	course	course	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	disease	disease	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Prospects	Prospect	B-NP	NNS	0	_	_	_	_
2	for	for	B-PP	IN	0	_	_	_	_
3	controlled	control	B-NP	VBN	0	_	_	_	_
4	-	-	I-NP	HYPH	0	_	_	_	_
5	delivery	delivery	I-NP	NN	0	_	_	_	_
6	systems	system	I-NP	NNS	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	mean	mean	I-NP	JJ	0	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	+	+	O	SYM	0	_	_	_	_
5	/	/	O	SYM	0	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	SD	SD	I-NP	NN	UMLS:C1096903:T047:DISO	_	_	_	_
8	)	)	O	)	0	_	_	_	_
9	PaO2	PaO2	B-NP	NN	0	_	_	_	_
10	increased	increase	B-VP	VBD	0	_	_	_	_
11	from	from	B-PP	IN	0	_	_	_	_
12	80	80	B-NP	CD	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_
14	8	8	B-NP	CD	0	_	_	_	_
15	+	+	O	SYM	0	_	_	_	_
16	/	/	O	SYM	0	_	_	_	_
17	-	-	B-NP	SYM	0	_	_	_	_
18	26	26	B-NP	CD	0	_	_	_	_
19	.	.	I-NP	SYM	0	_	_	_	_
20	9	9	I-NP	CD	0	_	_	_	_
21	mmHg	mmHg	I-NP	NN	0	_	_	_	_
22	before	before	B-PP	IN	0	_	_	_	_
23	to	to	B-PP	TO	0	_	_	_	_
24	89	89	B-NP	CD	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_
26	8	8	B-NP	CD	0	_	_	_	_
27	+	+	B-NP	SYM	0	_	_	_	_
28	/	/	I-NP	SYM	0	_	_	_	_
29	-	-	I-NP	SYM	0	_	_	_	_
30	27	27	I-NP	CD	0	_	_	_	_
31	.	.	I-NP	SYM	0	_	_	_	_
32	3	3	I-NP	CD	0	_	_	_	_
33	mmHg	mmHg	I-NP	NN	0	_	_	_	_
34	after	after	B-PP	IN	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	infusion	infusion	I-NP	NN	0	_	_	_	_
37	(	(	O	(	0	_	_	_	_
38	P	P	B-NP	NN	0	_	_	_	_
39	<	<	B-ADJP	SYM	0	_	_	_	_
40	0	0	B-NP	CD	0	_	_	_	_
41	.	.	I-NP	.	0	_	_	_	_
42	05	05	I-NP	CD	0	_	_	_	_
43	)	)	O	)	0	_	_	_	_
44	and	and	O	CC	0	_	_	_	_
45	the	the	B-NP	DT	0	_	_	_	_
46	PaCO2	PaCO2	I-NP	NN	0	_	_	_	_
47	decreased	decrease	B-VP	VBD	0	_	_	_	_
48	from	from	B-PP	IN	0	_	_	_	_
49	42	42	B-NP	CD	0	_	_	_	_
50	.	.	O	.	0	_	_	_	_
51	4	4	B-NP	CD	0	_	_	_	_
52	+	+	B-NP	SYM	0	_	_	_	_
53	/	/	I-NP	SYM	0	_	_	_	_
54	-	-	I-NP	SYM	0	_	_	_	_
55	8	8	I-NP	CD	0	_	_	_	_
56	.	.	I-NP	SYM	0	_	_	_	_
57	3	3	I-NP	CD	0	_	_	_	_
58	to	to	B-PP	TO	0	_	_	_	_
59	39	39	B-NP	CD	0	_	_	_	_
60	.	.	O	.	0	_	_	_	_
61	6	6	B-NP	CD	0	_	_	_	_
62	+	+	B-NP	SYM	0	_	_	_	_
63	/	/	I-NP	SYM	0	_	_	_	_
64	-	-	I-NP	SYM	0	_	_	_	_
65	7	7	I-NP	CD	0	_	_	_	_
66	.	.	I-NP	SYM	0	_	_	_	_
67	9	9	I-NP	CD	0	_	_	_	_
68	mmHg	mmHg	I-NP	NN	0	_	_	_	_
69	(	(	O	(	0	_	_	_	_
70	P	P	B-NP	NN	0	_	_	_	_
71	<	<	B-ADJP	SYM	0	_	_	_	_
72	0	0	B-NP	CD	0	_	_	_	_
73	.	.	I-NP	.	0	_	_	_	_
74	05	05	I-NP	CD	0	_	_	_	_
75	)	)	O	)	0	_	_	_	_
76	.	.	O	.	0	_	_	_	_

1	Though	Though	B-SBAR	IN	0	_	_	_	_
2	hepatomegaly	hepatomegaly	B-NP	NN	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	mild	mild	B-NP	JJ	0	_	_	_	_
5	elevation	elevation	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	enzymes	enzyme	B-NP	NNS	0	_	_	_	_
8	can	can	B-VP	MD	0	_	_	_	_
9	be	be	I-VP	VB	0	_	_	_	_
10	observed	observe	I-VP	VBN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	significant	significant	I-NP	JJ	0	_	_	_	_
14	proportion	proportion	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	patients	patient	B-NP	NNS	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	involvement	involvement	B-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	liver	liver	B-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
21	leading	lead	B-VP	VBG	0	_	_	_	_
22	to	to	B-PP	TO	0	_	_	_	_
23	acute	acute	B-NP	JJ	UMLS:C0267797:T047:DISO	_	_	_	_
24	hepatitis	hepatitis	I-NP	NN	UMLS:C0267797:T047:DISO	_	_	_	_
25	or	or	I-NP	CC	0	_	_	_	_
26	liver	liver	I-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
27	cell	cell	I-NP	NN	0	_	_	_	_
28	necrosis	necrosis	I-NP	NN	0	_	_	_	_
29	is	be	B-VP	VBZ	0	_	_	_	_
30	a	a	B-NP	DT	0	_	_	_	_
31	relatively	relatively	I-NP	RB	0	_	_	_	_
32	uncommon	uncommon	I-NP	JJ	0	_	_	_	_
33	complication	complication	I-NP	NN	0	_	_	_	_
34	in	in	B-PP	IN	0	_	_	_	_
35	P	P	B-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_
37	falciparum	falciparum	B-NP	NN	UMLS:C0024535:T047:DISO	_	_	_	_
38	malaria	malaria	I-NP	NN	UMLS:C0024535:T047:DISO	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	For	For	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	first	first	I-NP	JJ	0	_	_	_	_
4	group	group	I-NP	NN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	maximal	maximal	I-NP	JJ	0	_	_	_	_
8	decrease	decrease	I-NP	NN	0	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	plasma	plasma	B-NP	NN	0	_	_	_	_
11	potassium	potassium	I-NP	NN	0	_	_	_	_
12	elicited	elicit	B-VP	VBN	0	_	_	_	_
13	by	by	B-PP	IN	0	_	_	_	_
14	salbutamol	salbutamol	B-NP	NN	0	_	_	_	_
15	was	be	B-VP	VBD	0	_	_	_	_
16	0	0	B-NP	CD	0	_	_	_	_
17	.	.	I-NP	SYM	0	_	_	_	_
18	80	80	I-NP	CD	0	_	_	_	_
19	+	+	O	SYM	0	_	_	_	_
20	/	/	O	SYM	0	_	_	_	_
21	-	-	B-NP	SYM	0	_	_	_	_
22	0	0	B-NP	CD	0	_	_	_	_
23	.	.	I-NP	SYM	0	_	_	_	_
24	19	19	I-NP	CD	0	_	_	_	_
25	,	,	I-NP	,	0	_	_	_	_
26	0	0	I-NP	CD	0	_	_	_	_
27	.	.	I-NP	.	0	_	_	_	_
28	48	48	I-NP	CD	0	_	_	_	_
29	+	+	O	SYM	0	_	_	_	_
30	/	/	O	SYM	0	_	_	_	_
31	-	-	B-NP	SYM	0	_	_	_	_
32	0	0	B-NP	CD	0	_	_	_	_
33	.	.	I-NP	SYM	0	_	_	_	_
34	22	22	I-NP	CD	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	and	and	O	CC	0	_	_	_	_
37	0	0	B-NP	CD	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_
39	78	78	B-NP	CD	0	_	_	_	_
40	+	+	O	SYM	0	_	_	_	_
41	/	/	O	SYM	0	_	_	_	_
42	-	-	B-NP	SYM	0	_	_	_	_
43	0	0	B-NP	CD	0	_	_	_	_
44	.	.	I-NP	SYM	0	_	_	_	_
45	46	46	I-NP	CD	0	_	_	_	_
46	mmol	mmol	I-NP	NN	0	_	_	_	_
47	/	/	B-NP	SYM	0	_	_	_	_
48	l	l	I-NP	NN	0	_	_	_	_
49	,	,	O	,	0	_	_	_	_
50	and	and	O	CC	0	_	_	_	_
51	for	for	B-PP	IN	0	_	_	_	_
52	the	the	B-NP	DT	0	_	_	_	_
53	second	second	I-NP	JJ	0	_	_	_	_
54	group	group	I-NP	NN	0	_	_	_	_
55	,	,	O	,	0	_	_	_	_
56	maximal	maximal	B-NP	JJ	0	_	_	_	_
57	decrement	decrement	I-NP	NN	0	_	_	_	_
58	was	be	B-VP	VBD	0	_	_	_	_
59	1	1	B-NP	CD	0	_	_	_	_
60	.	.	I-NP	.	0	_	_	_	_
61	31	31	I-NP	CD	0	_	_	_	_
62	+	+	O	SYM	0	_	_	_	_
63	/	/	O	SYM	0	_	_	_	_
64	-	-	B-NP	SYM	0	_	_	_	_
65	0	0	B-NP	CD	0	_	_	_	_
66	.	.	I-NP	SYM	0	_	_	_	_
67	37	37	I-NP	CD	0	_	_	_	_
68	,	,	I-NP	,	0	_	_	_	_
69	0	0	I-NP	CD	0	_	_	_	_
70	.	.	I-NP	.	0	_	_	_	_
71	70	70	I-NP	CD	0	_	_	_	_
72	+	+	O	SYM	0	_	_	_	_
73	/	/	O	SYM	0	_	_	_	_
74	-	-	B-NP	SYM	0	_	_	_	_
75	0	0	B-NP	CD	0	_	_	_	_
76	.	.	I-NP	SYM	0	_	_	_	_
77	24	24	I-NP	CD	0	_	_	_	_
78	,	,	O	,	0	_	_	_	_
79	and	and	O	CC	0	_	_	_	_
80	0	0	B-NP	CD	0	_	_	_	_
81	.	.	O	.	0	_	_	_	_
82	84	84	B-NP	CD	0	_	_	_	_
83	+	+	O	SYM	0	_	_	_	_
84	/	/	O	SYM	0	_	_	_	_
85	-	-	B-NP	SYM	0	_	_	_	_
86	0	0	B-NP	CD	0	_	_	_	_
87	.	.	I-NP	SYM	0	_	_	_	_
88	17	17	I-NP	CD	0	_	_	_	_
89	mmol	mmol	I-NP	NN	0	_	_	_	_
90	/	/	B-NP	SYM	0	_	_	_	_
91	l	l	I-NP	NN	0	_	_	_	_
92	for	for	B-PP	IN	0	_	_	_	_
93	the	the	B-NP	DT	0	_	_	_	_
94	iv	iv	I-NP	NN	0	_	_	_	_
95	,	,	O	,	0	_	_	_	_
96	po	po	B-NP	NN	0	_	_	_	_
97	,	,	O	,	0	_	_	_	_
98	and	and	O	CC	0	_	_	_	_
99	it	it	B-NP	PRP	0	_	_	_	_
100	routes	rout	B-VP	VBZ	0	_	_	_	_
101	,	,	O	,	0	_	_	_	_
102	respectively	respectively	B-ADVP	RB	0	_	_	_	_
103	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	two	two	I-NP	CD	0	_	_	_	_
3	drugs	drug	I-NP	NNS	0	_	_	_	_
4	increase	increase	B-VP	VBP	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	rate	rate	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	early	early	B-NP	JJ	0	_	_	_	_
9	diastolic	diastolic	I-NP	JJ	0	_	_	_	_
10	filling	filling	I-NP	NN	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	statistically	statistically	I-NP	RB	0	_	_	_	_
3	significant	significant	I-NP	JJ	0	_	_	_	_
4	improvement	improvement	I-NP	NN	0	_	_	_	_
5	due	due	B-PP	JJ	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	administration	administration	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	Bromergon	Bromergon	B-NP	NNP	0	_	_	_	_
11	was	be	B-VP	VBD	0	_	_	_	_
12	observed	observe	I-VP	VBN	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	symptoms	symptom	B-NP	NNS	0	_	_	_	_
15	associated	associate	B-VP	VBN	0	_	_	_	_
16	with	with	B-PP	IN	0	_	_	_	_
17	overreactiveness	overreactiveness	B-NP	NN	0	_	_	_	_
18	to	to	B-PP	TO	0	_	_	_	_
19	normal	normal	B-NP	JJ	0	_	_	_	_
20	prolactin	prolactin	I-NP	NN	:::NOCLASS	_	_	_	_
21	levels	level	I-NP	NNS	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	i	i	B-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_
25	e	e	B-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_
27	abdominal	abdominal	B-NP	JJ	0	_	_	_	_
28	tension	tension	I-NP	NN	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	edema	edema	B-NP	NN	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	weight	weight	B-NP	NN	0	_	_	_	_
33	gain	gain	I-NP	NN	0	_	_	_	_
34	and	and	O	CC	0	_	_	_	_
35	breast	breast	B-NP	NN	UMLS:C0006141:T023:ANAT	_	_	_	_
36	tenderness	tenderness	I-NP	NN	0	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	magnitude	magnitude	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	early	early	I-NP	JJ	0	_	_	_	_
6	response	response	I-NP	NN	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	241	241	B-NP	CD	0	_	_	_	_
9	+	+	O	SYM	0	_	_	_	_
10	/	/	O	SYM	0	_	_	_	_
11	-	-	O	SYM	0	_	_	_	_
12	51	51	B-NP	CD	0	_	_	_	_
13	%	%	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	A	A	B-NP	NN	0	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	%	%	B-NP	NN	0	_	_	_	_
18	baseline	baseline	I-NP	NN	0	_	_	_	_
19	RL	RL	I-NP	NN	0	_	_	_	_
20	;	;	O	:	0	_	_	_	_
21	mean	mean	B-NP	NN	0	_	_	_	_
22	+	+	O	SYM	0	_	_	_	_
23	/	/	O	SYM	0	_	_	_	_
24	-	-	O	HYPH	0	_	_	_	_
25	SE	SE	B-NP	NN	0	_	_	_	_
26	)	)	O	)	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	and	and	O	CC	0	_	_	_	_
29	significantly	significantly	B-ADJP	RB	0	_	_	_	_
30	less	less	I-ADJP	JJR	0	_	_	_	_
31	in	in	B-PP	IN	0	_	_	_	_
32	B	B	B-NP	NN	0	_	_	_	_
33	(	(	O	(	0	_	_	_	_
34	119	119	B-NP	CD	0	_	_	_	_
35	+	+	O	SYM	0	_	_	_	_
36	/	/	O	SYM	0	_	_	_	_
37	-	-	O	SYM	0	_	_	_	_
38	7	7	B-NP	CD	0	_	_	_	_
39	%	%	I-NP	NN	0	_	_	_	_
40	)	)	O	)	0	_	_	_	_
41	and	and	O	CC	0	_	_	_	_
42	C	C	B-NP	NN	0	_	_	_	_
43	(	(	O	(	0	_	_	_	_
44	131	131	B-NP	CD	0	_	_	_	_
45	+	+	O	SYM	0	_	_	_	_
46	/	/	O	SYM	0	_	_	_	_
47	-	-	O	SYM	0	_	_	_	_
48	16	16	B-NP	CD	0	_	_	_	_
49	%	%	I-NP	NN	0	_	_	_	_
50	)	)	O	)	0	_	_	_	_
51	(	(	O	(	0	_	_	_	_
52	p	p	B-NP	NN	0	_	_	_	_
53	<	<	B-ADJP	SYM	0	_	_	_	_
54	0	0	B-NP	CD	0	_	_	_	_
55	.	.	I-NP	.	0	_	_	_	_
56	01	01	I-NP	CD	0	_	_	_	_
57	)	)	O	)	0	_	_	_	_
58	.	.	O	.	0	_	_	_	_

1	Most	Most	B-NP	JJS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	patients	patient	I-NP	NNS	0	_	_	_	_
5	presented	present	B-VP	VBD	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	Transient	Transient	B-NP	JJ	UMLS:C0007787:T047:DISO	_	_	_	_
8	Ischemic	Ischemic	I-NP	JJ	UMLS:C0007787:T047:DISO	_	_	_	_
9	Attacks	Attack	I-NP	NNS	UMLS:C0007787:T047:DISO	_	_	_	_
10	(	(	O	(	0	_	_	_	_
11	64	64	B-NP	CD	0	_	_	_	_
12	%	%	I-NP	NN	0	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	or	or	O	CC	0	_	_	_	_
15	Reversible	Reversible	B-NP	JJ	0	_	_	_	_
16	Ischemic	Ischemic	I-NP	JJ	0	_	_	_	_
17	Neurologic	Neurologic	I-NP	JJ	0	_	_	_	_
18	Deficits	Deficit	I-NP	NNS	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	19	19	B-NP	CD	0	_	_	_	_
21	%	%	I-NP	NN	0	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	cloned	clone	B-VP	VBD	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	third	third	I-NP	JJ	0	_	_	_	_
5	human	human	I-NP	JJ	0	_	_	_	_
6	gene	gene	I-NP	NN	0	_	_	_	_
7	for	for	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	LD78	LD78	I-NP	NNP	:::NOCLASS	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	termed	term	B-NP	VBN	0	_	_	_	_
12	LD78	LD78	I-NP	NN	:::NOCLASS	_	_	_	_
13	gamma	gamma	I-NP	NN	:::NOCLASS	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	sequence	sequence	I-NP	NN	0	_	_	_	_
17	analysis	analysis	I-NP	NN	0	_	_	_	_
18	showed	show	B-VP	VBD	0	_	_	_	_
19	that	that	B-SBAR	IN	0	_	_	_	_
20	it	it	B-NP	PRP	0	_	_	_	_
21	is	be	B-VP	VBZ	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	5	5	I-NP	CD	0	_	_	_	_
24	'	'	I-NP	SYM	0	_	_	_	_
25	-	-	I-NP	HYPH	0	_	_	_	_
26	truncated	truncate	I-NP	VBN	0	_	_	_	_
27	pseudogene	pseudogene	I-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	analysis	analysis	I-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	together	together	B-ADVP	RB	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	consideration	consideration	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	SCBs	SCB	I-NP	NNS	0	_	_	_	_
11	found	find	B-VP	VBN	0	_	_	_	_
12	upstream	upstream	B-ADVP	RB	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	known	known	B-NP	JJ	0	_	_	_	_
15	SWI4	SWI4	I-NP	NN	:::NOCLASS	_	_	_	_
16	,	,	O	,	:::NOCLASS	_	_	_	_
17	6	6	B-NP	CD	:::NOCLASS	_	_	_	_
18	-	-	I-NP	HYPH	0	_	_	_	_
19	dependent	dependent	I-NP	JJ	0	_	_	_	_
20	genes	gene	I-NP	NNS	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	leads	lead	B-VP	VBZ	0	_	_	_	_
23	to	to	B-PP	TO	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	proposal	proposal	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	a	a	B-NP	DT	0	_	_	_	_
28	revised	revise	I-NP	VBN	0	_	_	_	_
29	consensus	consensus	I-NP	NN	0	_	_	_	_
30	sequence	sequence	I-NP	NN	0	_	_	_	_
31	for	for	B-PP	IN	0	_	_	_	_
32	this	this	B-NP	DT	0	_	_	_	_
33	important	important	I-NP	JJ	0	_	_	_	_
34	regulatory	regulatory	I-NP	JJ	0	_	_	_	_
35	element	element	I-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	Mutational	Mutational	B-NP	JJ	0	_	_	_	_
2	analysis	analysis	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	DNA	DNA	I-NP	NN	0	_	_	_	_
6	sequence	sequence	I-NP	NN	0	_	_	_	_
7	involved	involve	B-VP	VBN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	linking	link	B-VP	VBG	0	_	_	_	_
10	gene	gene	B-NP	NN	0	_	_	_	_
11	expression	expression	I-NP	NN	0	_	_	_	_
12	to	to	B-PP	TO	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	cell	cell	I-NP	NN	0	_	_	_	_
15	cycle	cycle	I-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	natural	natural	I-NP	JJ	0	_	_	_	_
3	history	history	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	these	these	B-NP	DT	0	_	_	_	_
6	lesions	lesion	I-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	locoregional	locoregional	B-NP	JJ	0	_	_	_	_
9	efficiency	efficiency	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	different	different	I-NP	JJ	0	_	_	_	_
13	treatments	treatment	I-NP	NNS	0	_	_	_	_
14	used	use	B-VP	VBN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	part	part	I-NP	NN	0	_	_	_	_
18	played	play	B-VP	VBN	0	_	_	_	_
19	by	by	B-PP	IN	0	_	_	_	_
20	chemotherapy	chemotherapy	B-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	survival	survival	B-NP	NN	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	causes	cause	B-VP	VBZ	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	death	death	B-NP	NN	0	_	_	_	_
27	and	and	O	CC	0	_	_	_	_
28	therapeutic	therapeutic	B-NP	JJ	0	_	_	_	_
29	modalities	modality	I-NP	NNS	0	_	_	_	_
30	used	use	B-VP	VBN	0	_	_	_	_
31	as	as	B-PP	IN	0	_	_	_	_
32	a	a	B-NP	DT	0	_	_	_	_
33	last	last	I-NP	JJ	0	_	_	_	_
34	measure	measure	I-NP	NN	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	have	have	B-VP	VBP	0	_	_	_	_
37	been	be	I-VP	VBN	0	_	_	_	_
38	analysed	analyse	I-VP	VBN	0	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	method	method	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	adapted	adapt	I-VP	VBN	0	_	_	_	_
5	for	for	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	determination	determination	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	nadolol	nadolol	B-NP	NN	0	_	_	_	_
10	racemate	racemate	I-NP	NN	0	_	_	_	_
11	A	A	I-NP	NN	0	_	_	_	_
12	by	by	B-PP	IN	0	_	_	_	_
13	a	a	B-NP	DT	0	_	_	_	_
14	change	change	I-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	mobile	mobile	B-NP	JJ	0	_	_	_	_
17	phase	phase	I-NP	NN	0	_	_	_	_
18	composition	composition	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	general	general	B-ADJP	JJ	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	however	however	B-ADVP	RB	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	this	this	B-NP	DT	0	_	_	_	_
7	study	study	I-NP	NN	0	_	_	_	_
8	provided	provide	B-VP	VBD	0	_	_	_	_
9	little	little	B-NP	JJ	0	_	_	_	_
10	evidence	evidence	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	any	any	B-NP	DT	0	_	_	_	_
13	effect	effect	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	supplementation	supplementation	B-NP	NN	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	athletic	athletic	B-NP	JJ	0	_	_	_	_
18	performance	performance	I-NP	NN	0	_	_	_	_
19	for	for	B-PP	IN	0	_	_	_	_
20	athletes	athlete	B-NP	NNS	0	_	_	_	_
21	consuming	consume	B-VP	VBG	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	dietary	dietary	I-NP	JJ	0	_	_	_	_
24	RDIs	RDI	I-NP	NNS	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	absence	absence	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	histological	histological	B-NP	JJ	0	_	_	_	_
6	criteria	criterion	I-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	which	which	B-NP	WDT	0	_	_	_	_
9	it	it	B-NP	PRP	0	_	_	_	_
10	is	be	B-VP	VBZ	0	_	_	_	_
11	difficult	difficult	B-ADJP	JJ	0	_	_	_	_
12	to	to	B-VP	TO	0	_	_	_	_
13	demand	demand	I-VP	VB	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	view	view	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	variability	variability	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	results	result	B-NP	NNS	0	_	_	_	_
21	and	and	O	CC	0	_	_	_	_
22	potential	potential	B-NP	JJ	0	_	_	_	_
23	dangers	danger	I-NP	NNS	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	endomyocardial	endomyocardial	B-NP	JJ	0	_	_	_	_
26	biopsy	biopsy	I-NP	NN	0	_	_	_	_
27	involving	involve	B-VP	VBG	0	_	_	_	_
28	such	such	B-NP	JJ	0	_	_	_	_
29	thin	thin	I-NP	JJ	0	_	_	_	_
30	and	and	I-NP	CC	0	_	_	_	_
31	fragile	fragile	I-NP	JJ	0	_	_	_	_
32	ventricular	ventricular	I-NP	JJ	UMLS:C0018827:T023:ANAT	_	_	_	_
33	walls	wall	I-NP	NNS	0	_	_	_	_
34	,	,	O	,	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
37	of	of	B-PP	IN	0	_	_	_	_
38	ACRV	ACRV	B-NP	NN	0	_	_	_	_
39	is	be	B-VP	VBZ	0	_	_	_	_
40	based	base	I-VP	VBN	0	_	_	_	_
41	upon	upon	B-PP	IN	0	_	_	_	_
42	the	the	B-NP	DT	0	_	_	_	_
43	concomitant	concomitant	I-NP	JJ	0	_	_	_	_
44	existence	existence	I-NP	NN	0	_	_	_	_
45	of	of	B-PP	IN	0	_	_	_	_
46	:	:	O	:	0	_	_	_	_
47	(	(	B-LST	(	0	_	_	_	_
48	1	1	I-LST	LS	0	_	_	_	_
49	)	)	O	)	0	_	_	_	_
50	electrophysiological	electrophysiological	B-NP	JJ	0	_	_	_	_
51	criteria	criterion	I-NP	NNS	0	_	_	_	_
52	:	:	O	:	0	_	_	_	_
53	ventricular	ventricular	B-NP	JJ	UMLS:C0018827:T023:ANAT	_	_	_	_
54	arrhythmias	arrhythmia	I-NP	NNS	0	_	_	_	_
55	,	,	O	,	0	_	_	_	_
56	in	in	B-PP	IN	0	_	_	_	_
57	particular	particular	B-NP	JJ	0	_	_	_	_
58	sustained	sustained	I-NP	JJ	0	_	_	_	_
59	monomorphous	monomorphous	I-NP	JJ	0	_	_	_	_
60	VT	VT	I-NP	NN	0	_	_	_	_
61	,	,	O	,	0	_	_	_	_
62	with	with	B-PP	IN	0	_	_	_	_
63	the	the	B-NP	DT	0	_	_	_	_
64	particular	particular	I-NP	JJ	0	_	_	_	_
65	feature	feature	I-NP	NN	0	_	_	_	_
66	of	of	B-PP	IN	0	_	_	_	_
67	a	a	B-NP	DT	0	_	_	_	_
68	very	very	I-NP	RB	0	_	_	_	_
69	high	high	I-NP	JJ	0	_	_	_	_
70	degree	degree	I-NP	NN	0	_	_	_	_
71	of	of	B-PP	IN	0	_	_	_	_
72	sensitivity	sensitivity	B-NP	NN	0	_	_	_	_
73	to	to	B-PP	TO	0	_	_	_	_
74	adrenergic	adrenergic	B-NP	JJ	0	_	_	_	_
75	stimulation	stimulation	I-NP	NN	0	_	_	_	_
76	(	(	O	(	0	_	_	_	_
77	exercise	exercise	B-NP	NN	0	_	_	_	_
78	)	)	O	)	0	_	_	_	_
79	,	,	O	,	0	_	_	_	_
80	the	the	B-NP	DT	0	_	_	_	_
81	existence	existence	I-NP	NN	0	_	_	_	_
82	of	of	B-PP	IN	0	_	_	_	_
83	late	late	B-NP	JJ	0	_	_	_	_
84	potentials	potential	I-NP	NNS	0	_	_	_	_
85	on	on	B-PP	IN	0	_	_	_	_
86	the	the	B-NP	DT	0	_	_	_	_
87	high	high	I-NP	JJ	0	_	_	_	_
88	amplification	amplification	I-NP	NN	0	_	_	_	_
89	ECG	ECG	I-NP	NN	0	_	_	_	_
90	,	,	O	,	0	_	_	_	_
91	a	a	B-NP	DT	0	_	_	_	_
92	highly	highly	I-NP	RB	0	_	_	_	_
93	specific	specific	I-NP	JJ	0	_	_	_	_
94	sign	sign	I-NP	NN	0	_	_	_	_
95	,	,	O	,	0	_	_	_	_
96	though	though	O	RB	0	_	_	_	_
97	unfortunately	unfortunately	B-ADVP	RB	0	_	_	_	_
98	of	of	B-PP	IN	0	_	_	_	_
99	poor	poor	B-NP	JJ	0	_	_	_	_
100	sensitivity	sensitivity	I-NP	NN	0	_	_	_	_
101	in	in	B-PP	IN	0	_	_	_	_
102	localized	localize	B-NP	VBN	0	_	_	_	_
103	froms	from	I-NP	NNS	0	_	_	_	_
104	,	,	O	,	0	_	_	_	_
105	those	those	B-NP	DT	0	_	_	_	_
106	which	which	B-NP	WDT	0	_	_	_	_
107	are	be	B-VP	VBP	0	_	_	_	_
108	most	most	B-ADJP	RBS	0	_	_	_	_
109	difficult	difficult	I-ADJP	JJ	0	_	_	_	_
110	to	to	B-VP	TO	0	_	_	_	_
111	identify	identify	I-VP	VB	0	_	_	_	_
112	(	(	O	(	0	_	_	_	_
113	2	2	B-NP	CD	0	_	_	_	_
114	)	)	O	)	0	_	_	_	_
115	;	;	O	:	0	_	_	_	_
116	segmentary	segmentary	B-NP	JJ	0	_	_	_	_
117	morphological	morphological	I-NP	JJ	0	_	_	_	_
118	and	and	I-NP	CC	0	_	_	_	_
119	kinetic	kinetic	I-NP	JJ	0	_	_	_	_
120	RV	RV	I-NP	NN	0	_	_	_	_
121	abnormalities	abnormality	I-NP	NNS	0	_	_	_	_
122	,	,	O	,	0	_	_	_	_
123	most	most	B-ADVP	RBS	0	_	_	_	_
124	often	often	I-ADVP	RB	0	_	_	_	_
125	resulting	result	B-VP	VBG	0	_	_	_	_
126	in	in	B-PP	IN	0	_	_	_	_
127	localized	localize	B-NP	VBN	0	_	_	_	_
128	akinetic	akinetic	I-NP	JJ	0	_	_	_	_
129	or	or	I-NP	CC	0	_	_	_	_
130	dyskinetic	dyskinetic	I-NP	JJ	0	_	_	_	_
131	parietal	parietal	I-NP	JJ	0	_	_	_	_
132	vaulting	vaulting	I-NP	NN	0	_	_	_	_
133	,	,	O	,	0	_	_	_	_
134	with	with	B-PP	IN	0	_	_	_	_
135	stasis	stasis	B-NP	NN	0	_	_	_	_
136	"	"	O	''	0	_	_	_	_
137	in	in	B-ADVP	FW	0	_	_	_	_
138	situ	situ	I-ADVP	FW	0	_	_	_	_
139	"	"	O	``	0	_	_	_	_
140	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	7	7	B-NP	CD	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	9	9	B-NP	CD	0	_	_	_	_
5	cases	case	I-NP	NNS	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	enhancer	enhancer	I-NP	NN	0	_	_	_	_
9	is	be	B-VP	VBZ	0	_	_	_	_
10	fused	fuse	I-VP	VBN	0	_	_	_	_
11	to	to	B-PP	TO	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	c	c	I-NP	NN	:::NOCLASS	_	_	_	_
14	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
15	myc	myc	I-NP	NN	:::NOCLASS	_	_	_	_
16	bearing	bear	B-VP	VBG	:::NOCLASS	_	_	_	_
17	sequences	sequence	B-NP	NNS	:::NOCLASS	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	chromosome	chromosome	B-NP	NN	0	_	_	_	_
20	8	8	I-NP	CD	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	components	component	I-NP	NNS	0	_	_	_	_
3	both	both	O	DT	0	_	_	_	_
4	had	have	B-VP	VBD	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	median	median	I-NP	JJ	0	_	_	_	_
7	R2	R2	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	0	0	B-NP	CD	0	_	_	_	_
10	.	.	I-NP	.	0	_	_	_	_
11	84	84	I-NP	CD	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	compared	compare	B-PP	VBN	0	_	_	_	_
14	to	to	B-PP	TO	0	_	_	_	_
15	median	median	B-NP	JJ	0	_	_	_	_
16	R2s	R2	I-NP	NNS	0	_	_	_	_
17	ranging	range	B-VP	VBG	0	_	_	_	_
18	from	from	B-PP	IN	0	_	_	_	_
19	0	0	B-NP	CD	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_
21	37	37	B-NP	CD	0	_	_	_	_
22	to	to	B-PP	TO	0	_	_	_	_
23	0	0	B-NP	CD	0	_	_	_	_
24	.	.	I-NP	.	0	_	_	_	_
25	83	83	I-NP	CD	0	_	_	_	_
26	for	for	B-PP	IN	0	_	_	_	_
27	five	five	B-NP	CD	0	_	_	_	_
28	commonly	commonly	I-NP	RB	0	_	_	_	_
29	used	use	I-NP	VBN	0	_	_	_	_
30	ad	ad	I-NP	NN	UMLS:C0002395:T047:DISO|UMLS:C0228318:T023:ANAT	_	_	_	_
31	hoc	hoc	I-NP	NN	0	_	_	_	_
32	EEG	EEG	I-NP	NN	0	_	_	_	_
33	components	component	I-NP	NNS	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	obtained	obtain	I-NP	VBN	0	_	_	_	_
3	results	result	I-NP	NNS	0	_	_	_	_
4	were	be	B-VP	VBD	0	_	_	_	_
5	compared	compare	I-VP	VBN	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	control	control	B-NP	NN	0	_	_	_	_
8	group	group	I-NP	NN	0	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	10	10	B-NP	CD	0	_	_	_	_
11	female	female	I-NP	JJ	0	_	_	_	_
12	volunteers	volunteer	I-NP	NNS	0	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	100	100	B-NP	CD	0	_	_	_	_
2	years	year	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	dentistry	dentistry	B-NP	NN	0	_	_	_	_
5	at	at	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	Friedrich	Friedrich	I-NP	NNP	0	_	_	_	_
8	Schiller	Schiller	I-NP	NNP	0	_	_	_	_
9	University	University	I-NP	NNP	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	Jena	Jena	B-NP	NNP	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	target	target	I-NP	NN	0	_	_	_	_
3	contained	contain	B-VP	VBN	0	_	_	_	_
4	between	between	B-PP	IN	0	_	_	_	_
5	positions	position	B-NP	NNS	0	_	_	_	_
6	-	-	O	SYM	0	_	_	_	_
7	403	403	B-NP	CD	0	_	_	_	_
8	and	and	O	CC	0	_	_	_	_
9	-	-	B-NP	SYM	0	_	_	_	_
10	125	125	B-NP	CD	0	_	_	_	_
11	acts	act	B-VP	VBZ	0	_	_	_	_
12	independently	independently	B-ADVP	RB	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	orientation	orientation	B-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	different	different	B-NP	JJ	0	_	_	_	_
18	cell	cell	I-NP	NN	0	_	_	_	_
19	types	type	I-NP	NNS	0	_	_	_	_
20	and	and	I-NP	CC	0	_	_	_	_
21	species	specie	I-NP	NNS	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	and	and	O	CC	0	_	_	_	_
24	in	in	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	context	context	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	a	a	B-NP	DT	0	_	_	_	_
29	heterologous	heterologous	I-NP	JJ	0	_	_	_	_
30	promoter	promoter	I-NP	NN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	66	66	B-NP	CD	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	469	469	B-NP	CD	0	_	_	_	_
4	-	-	I-NP	HYPH	0	_	_	_	_
5	479	479	I-NP	CD	0	_	_	_	_
6	,	,	I-NP	,	0	_	_	_	_
7	1992	1992	I-NP	CD	0	_	_	_	_
8	)	)	O	)	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	Synergistic	Synergistic	B-NP	JJ	0	_	_	_	_
2	transactivation	transactivation	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	BMRF1	BMRF1	I-NP	NN	:::NOCLASS	_	_	_	_
6	promoter	promoter	I-NP	NN	:::NOCLASS	_	_	_	_
7	by	by	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	Z	Z	I-NP	NN	:::NOCLASS	_	_	_	_
10	/	/	B-NP	SYM	0	_	_	_	_
11	c	c	I-NP	NN	:::NOCLASS	_	_	_	_
12	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
13	myb	myb	I-NP	NN	:::NOCLASS	_	_	_	_
14	combination	combination	I-NP	NN	0	_	_	_	_
15	appears	appear	B-VP	VBZ	0	_	_	_	_
16	to	to	I-VP	TO	0	_	_	_	_
17	involve	involve	I-VP	VB	0	_	_	_	_
18	direct	direct	B-NP	JJ	0	_	_	_	_
19	binding	binding	I-NP	NN	0	_	_	_	_
20	by	by	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	Z	Z	I-NP	NN	:::NOCLASS	_	_	_	_
23	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
24	but	but	B-CONJP	CC	0	_	_	_	_
25	not	not	I-CONJP	RB	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	c	c	I-NP	NN	:::NOCLASS	_	_	_	_
28	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
29	myb	myb	I-NP	NN	:::NOCLASS	_	_	_	_
30	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	UCR	UCR	I-NP	NN	0	_	_	_	_
3	core	core	I-NP	NN	0	_	_	_	_
4	sequence	sequence	I-NP	NN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	CGCCATTTT	CGCCATTTT	B-NP	NN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	binds	bind	B-VP	VBZ	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	ubiquitous	ubiquitous	I-NP	JJ	0	_	_	_	_
11	nuclear	nuclear	I-NP	JJ	0	_	_	_	_
12	factor	factor	I-NP	NN	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	mediates	mediate	B-VP	VBZ	0	_	_	_	_
15	negative	negative	B-NP	JJ	0	_	_	_	_
16	regulation	regulation	I-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	MuLV	MuLV	B-NP	NN	0	_	_	_	_
19	promoter	promoter	I-NP	NN	0	_	_	_	_
20	activity	activity	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	show	show	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	UCRBP	UCRBP	B-NP	NN	:::NOCLASS	_	_	_	_
6	binds	bind	B-VP	VBZ	0	_	_	_	_
7	to	to	B-PP	TO	0	_	_	_	_
8	various	various	B-NP	JJ	0	_	_	_	_
9	target	target	I-NP	NN	0	_	_	_	_
10	motifs	motif	I-NP	NNS	0	_	_	_	_
11	that	that	B-NP	WDT	0	_	_	_	_
12	are	be	B-VP	VBP	0	_	_	_	_
13	distinct	distinct	B-ADJP	JJ	0	_	_	_	_
14	from	from	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	UCR	UCR	I-NP	NN	0	_	_	_	_
17	motif	motif	I-NP	NN	0	_	_	_	_
18	:	:	O	:	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	adeno	adeno	I-NP	AFX	:::NOCLASS	_	_	_	_
21	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
22	associated	associate	I-NP	VBN	:::NOCLASS	_	_	_	_
23	virus	virus	I-NP	NN	:::NOCLASS	_	_	_	_
24	P5	P5	I-NP	NN	:::NOCLASS	_	_	_	_
25	promoter	promoter	I-NP	NN	:::NOCLASS	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	elements	element	B-NP	NNS	0	_	_	_	_
28	in	in	B-PP	IN	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	immunoglobulin	immunoglobulin	I-NP	NN	:::NOCLASS	_	_	_	_
31	light	light	I-NP	NN	:::NOCLASS	_	_	_	_
32	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
33	and	and	I-NP	CC	:::NOCLASS	_	_	_	_
34	heavy	heavy	I-NP	JJ	:::NOCLASS	_	_	_	_
35	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
36	chain	chain	I-NP	NN	:::NOCLASS	_	_	_	_
37	genes	gene	I-NP	NNS	0	_	_	_	_
38	,	,	O	,	0	_	_	_	_
39	as	as	B-CONJP	RB	0	_	_	_	_
40	well	well	I-CONJP	RB	0	_	_	_	_
41	as	as	I-CONJP	IN	0	_	_	_	_
42	elements	element	B-NP	NNS	0	_	_	_	_
43	in	in	B-PP	IN	0	_	_	_	_
44	ribosomal	ribosomal	B-NP	JJ	:::NOCLASS	_	_	_	_
45	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
46	genes	gene	I-NP	NNS	:::NOCLASS	_	_	_	_
47	.	.	O	.	0	_	_	_	_

1	Possibly	Possibly	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	scr1	scr1	I-NP	NN	:::NOCLASS	_	_	_	_
5	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
6	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
7	mutation	mutation	I-NP	NN	:::NOCLASS	_	_	_	_
8	does	do	B-VP	VBZ	0	_	_	_	_
9	not	not	I-VP	RB	0	_	_	_	_
10	affect	affect	I-VP	VB	0	_	_	_	_
11	signal	signal	B-NP	NN	0	_	_	_	_
12	recognition	recognition	I-NP	NN	0	_	_	_	_
13	or	or	O	CC	0	_	_	_	_
14	translational	translational	B-NP	JJ	0	_	_	_	_
15	arrest	arrest	I-NP	NN	0	_	_	_	_
16	but	but	O	CC	0	_	_	_	_
17	instead	instead	B-VP	RB	0	_	_	_	_
18	results	result	I-VP	VBZ	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	maintenance	maintenance	B-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	translational	translational	B-NP	JJ	0	_	_	_	_
23	arrest	arrest	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	AEP	AEP	B-NP	NN	:::NOCLASS	_	_	_	_
26	synthesis	synthesis	I-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	cellular	cellular	I-NP	JJ	0	_	_	_	_
3	sequences	sequence	I-NP	NNS	0	_	_	_	_
4	5	5	B-NP	CD	0	_	_	_	_
5	'	'	B-NP	SYM	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	viral	viral	I-NP	JJ	0	_	_	_	_
9	integration	integration	I-NP	NN	0	_	_	_	_
10	site	site	I-NP	NN	0	_	_	_	_
11	exhibited	exhibit	B-VP	VBD	0	_	_	_	_
12	85	85	B-NP	CD	0	_	_	_	_
13	to	to	B-PP	TO	0	_	_	_	_
14	97	97	B-NP	CD	0	_	_	_	_
15	%	%	I-NP	NN	0	_	_	_	_
16	identity	identity	I-NP	NN	0	_	_	_	_
17	to	to	B-PP	TO	0	_	_	_	_
18	several	several	B-NP	JJ	0	_	_	_	_
19	sequences	sequence	I-NP	NNS	0	_	_	_	_
20	belonging	belong	B-VP	VBG	0	_	_	_	_
21	to	to	B-PP	TO	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	mouse	mouse	I-NP	NN	:::NOCLASS	_	_	_	_
24	L1	L1	I-NP	NN	:::NOCLASS	_	_	_	_
25	family	family	I-NP	NN	:::NOCLASS	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	long	long	B-NP	JJ	0	_	_	_	_
28	interspersed	interspersed	I-NP	JJ	0	_	_	_	_
29	repetitive	repetitive	I-NP	JJ	0	_	_	_	_
30	sequences	sequence	I-NP	NNS	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Both	Both	O	CC	0	_	_	_	_
2	Rep78	Rep78	B-NP	NN	:::NOCLASS	_	_	_	_
3	and	and	I-NP	CC	0	_	_	_	_
4	Rep68	Rep68	I-NP	NN	:::NOCLASS	_	_	_	_
5	cut	cut	B-VP	VBD	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	terminal	terminal	I-NP	JJ	0	_	_	_	_
8	AAV	AAV	I-NP	NN	0	_	_	_	_
9	sequence	sequence	I-NP	NN	0	_	_	_	_
10	at	at	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	same	same	I-NP	JJ	0	_	_	_	_
13	site	site	I-NP	NN	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	nucleotide	nucleotide	B-NP	NN	0	_	_	_	_
16	124	124	I-NP	CD	0	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Nucleotide	Nucleotide	B-NP	NN	0	_	_	_	_
2	sequence	sequence	I-NP	NN	0	_	_	_	_
3	analysis	analysis	I-NP	NN	0	_	_	_	_
4	revealed	reveal	B-VP	VBD	0	_	_	_	_
5	that	that	B-SBAR	IN	0	_	_	_	_
6	TAR	TAR	B-NP	NN	:::NOCLASS	_	_	_	_
7	-	-	B-PP	HYPH	:::NOCLASS	_	_	_	_
8	binding	bind	B-NP	VBG	:::NOCLASS	_	_	_	_
9	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
10	is	be	B-VP	VBZ	0	_	_	_	_
11	very	very	B-ADJP	RB	0	_	_	_	_
12	similar	similar	I-ADJP	JJ	0	_	_	_	_
13	to	to	B-PP	TO	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	CREB2	CREB2	I-NP	NN	:::NOCLASS	_	_	_	_
16	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	indicate	indicate	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	both	both	O	CC	0	_	_	_	_
6	N	N	B-NP	NN	0	_	_	_	_
7	-	-	B-NP	HYPH	0	_	_	_	_
8	and	and	I-NP	CC	0	_	_	_	_
9	C	C	I-NP	NN	0	_	_	_	_
10	-	-	O	HYPH	0	_	_	_	_
11	terminal	terminal	B-NP	JJ	0	_	_	_	_
12	mutations	mutation	I-NP	NNS	0	_	_	_	_
13	are	be	B-VP	VBP	0	_	_	_	_
14	required	require	I-VP	VBN	0	_	_	_	_
15	to	to	I-VP	TO	0	_	_	_	_
16	inhibit	inhibit	I-VP	VB	0	_	_	_	_
17	transrepression	transrepression	B-NP	NN	0	_	_	_	_
18	by	by	B-PP	IN	0	_	_	_	_
19	FBR	FBR	B-NP	NN	:::NOCLASS	_	_	_	_
20	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
21	and	and	O	CC	0	_	_	_	_
22	that	that	B-SBAR	IN	0	_	_	_	_
23	multiple	multiple	B-NP	JJ	0	_	_	_	_
24	structural	structural	I-NP	JJ	0	_	_	_	_
25	mutations	mutation	I-NP	NNS	0	_	_	_	_
26	accompanied	accompany	B-VP	VBN	0	_	_	_	_
27	by	by	B-PP	IN	0	_	_	_	_
28	posttranslational	posttranslational	B-NP	JJ	0	_	_	_	_
29	protein	protein	I-NP	NN	0	_	_	_	_
30	modification	modification	I-NP	NN	0	_	_	_	_
31	alter	alter	B-VP	VBP	0	_	_	_	_
32	gene	gene	B-NP	NN	0	_	_	_	_
33	regulation	regulation	I-NP	NN	0	_	_	_	_
34	by	by	B-PP	IN	0	_	_	_	_
35	FBR	FBR	B-NP	NN	:::NOCLASS	_	_	_	_
36	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	JS78	JS78	I-NP	NNP	0	_	_	_	_
3	mutation	mutation	I-NP	NN	0	_	_	_	_
4	changes	change	B-VP	VBZ	0	_	_	_	_
5	Gln243	Gln243	B-NP	NN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	gp0	gp0	B-NP	NN	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_
9	7	7	B-NP	CD	0	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	an	an	B-NP	DT	0	_	_	_	_
12	amber	amber	I-NP	NN	0	_	_	_	_
13	codon	codon	I-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	which	which	B-NP	WDT	0	_	_	_	_
16	explains	explain	B-VP	VBZ	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	production	production	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	truncated	truncate	I-NP	VBN	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	30	30	B-NP	CD	:::NOCLASS	_	_	_	_
24	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
25	kDa	kDa	I-NP	NN	:::NOCLASS	_	_	_	_
26	gp0	gp0	I-NP	NN	:::NOCLASS	_	_	_	_
27	.	.	B-NP	.	:::NOCLASS	_	_	_	_
28	7	7	I-NP	CD	:::NOCLASS	_	_	_	_
29	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
30	related	relate	I-NP	VBN	:::NOCLASS	_	_	_	_
31	polypeptide	polypeptide	I-NP	NN	:::NOCLASS	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	and	and	O	CC	0	_	_	_	_
34	implicates	implicate	B-VP	VBZ	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	11	11	I-NP	CD	0	_	_	_	_
37	-	-	I-NP	HYPH	0	_	_	_	_
38	kDa	kDa	I-NP	NN	0	_	_	_	_
39	C	C	I-NP	NN	0	_	_	_	_
40	-	-	B-NP	HYPH	0	_	_	_	_
41	terminal	terminal	I-NP	JJ	0	_	_	_	_
42	domain	domain	I-NP	NN	0	_	_	_	_
43	in	in	B-PP	IN	0	_	_	_	_
44	host	host	B-NP	NN	0	_	_	_	_
45	transcription	transcription	I-NP	NN	0	_	_	_	_
46	shut	shut	I-NP	NN	0	_	_	_	_
47	-	-	B-VP	HYPH	0	_	_	_	_
48	off	off	B-PRT	RP	0	_	_	_	_
49	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	patient	patient	I-NP	NN	0	_	_	_	_
3	suffering	suffer	B-VP	VBG	0	_	_	_	_
4	from	from	B-PP	IN	0	_	_	_	_
5	heparin	heparin	B-NP	NN	0	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	associated	associate	I-NP	VBN	0	_	_	_	_
8	thrombocytopenia	thrombocytopenia	I-NP	NN	UMLS:C0040034:T047:DISO	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	HAT	HAT	B-NP	NN	0	_	_	_	_
11	)	)	O	)	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	recurrent	recurrent	B-NP	JJ	0	_	_	_	_
14	arteriothromboses	arteriothrombos	I-NP	NNS	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	and	and	O	CC	0	_	_	_	_
17	acute	acute	B-NP	JJ	UMLS:C0022660:T047:DISO	_	_	_	_
18	renal	renal	I-NP	JJ	UMLS:C0022660:T047:DISO|UMLS:C0022646:T023:ANAT	_	_	_	_
19	failure	failure	I-NP	NN	UMLS:C0022660:T047:DISO	_	_	_	_
20	after	after	B-PP	IN	0	_	_	_	_
21	treatment	treatment	B-NP	NN	0	_	_	_	_
22	with	with	B-PP	IN	0	_	_	_	_
23	standard	standard	B-NP	JJ	0	_	_	_	_
24	heparin	heparin	I-NP	NN	0	_	_	_	_
25	is	be	B-VP	VBZ	0	_	_	_	_
26	described	describe	I-VP	VBN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	predicted	predict	I-NP	VBN	0	_	_	_	_
3	receptor	receptor	I-NP	NN	0	_	_	_	_
4	structure	structure	I-NP	NN	0	_	_	_	_
5	includes	include	B-VP	VBZ	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	cysteine	cysteine	I-NP	NN	0	_	_	_	_
8	-	-	B-NP	HYPH	0	_	_	_	_
9	rich	rich	I-NP	JJ	0	_	_	_	_
10	extracellular	extracellular	I-NP	JJ	0	_	_	_	_
11	domain	domain	I-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	a	a	B-NP	DT	0	_	_	_	_
14	single	single	I-NP	JJ	0	_	_	_	_
15	hydrophobic	hydrophobic	I-NP	JJ	0	_	_	_	_
16	transmembrane	transmembrane	I-NP	JJ	0	_	_	_	_
17	domain	domain	I-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	a	a	B-NP	DT	0	_	_	_	_
21	predicted	predict	I-NP	VBN	0	_	_	_	_
22	cytoplasmic	cytoplasmic	I-NP	JJ	:::NOCLASS	_	_	_	_
23	serine	serine	I-NP	NN	:::NOCLASS	_	_	_	_
24	/	/	B-NP	SYM	:::NOCLASS	_	_	_	_
25	threonine	threonine	I-NP	NN	:::NOCLASS	_	_	_	_
26	kinase	kinase	I-NP	NN	:::NOCLASS	_	_	_	_
27	domain	domain	I-NP	NN	:::NOCLASS	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	Drosophila	Drosophila	B-NP	FW	:::NOCLASS	_	_	_	_
2	UbcD1	UbcD1	I-NP	NN	:::NOCLASS	_	_	_	_
3	encodes	encode	B-VP	VBZ	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	highly	highly	I-NP	RB	0	_	_	_	_
6	conserved	conserve	I-NP	VBN	0	_	_	_	_
7	ubiquitin	ubiquitin	I-NP	NN	:::NOCLASS	_	_	_	_
8	-	-	O	HYPH	0	_	_	_	_
9	conjugating	conjugate	B-VP	VBG	0	_	_	_	_
10	enzyme	enzyme	B-NP	NN	0	_	_	_	_
11	involved	involve	B-VP	VBN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	selective	selective	B-NP	JJ	0	_	_	_	_
14	protein	protein	I-NP	NN	0	_	_	_	_
15	degradation	degradation	I-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Analysis	Analysis	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	entire	entire	I-NP	JJ	0	_	_	_	_
5	16	16	I-NP	CD	0	_	_	_	_
6	.	.	I-NP	.	0	_	_	_	_
7	7	7	I-NP	CD	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	kb	kb	I-NP	NN	0	_	_	_	_
10	mt	mt	I-NP	NN	0	_	_	_	_
11	genome	genome	I-NP	NN	0	_	_	_	_
12	determined	determine	B-VP	VBD	0	_	_	_	_
13	that	that	B-SBAR	IN	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	MDP1	MDP1	I-NP	NN	:::NOCLASS	_	_	_	_
16	mediates	mediate	B-VP	VBZ	0	_	_	_	_
17	cleavage	cleavage	B-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	chick	chick	B-NP	NN	0	_	_	_	_
20	mtDNA	mtDNA	I-NP	NN	0	_	_	_	_
21	in	in	B-ADVP	FW	0	_	_	_	_
22	vitro	vitro	I-ADVP	FW	0	_	_	_	_
23	at	at	B-PP	IN	0	_	_	_	_
24	three	three	B-NP	CD	0	_	_	_	_
25	H	H	I-NP	NN	0	_	_	_	_
26	-	-	B-ADJP	HYPH	0	_	_	_	_
27	and	and	O	CC	0	_	_	_	_
28	two	two	B-NP	CD	0	_	_	_	_
29	L	L	I-NP	NN	0	_	_	_	_
30	-	-	B-NP	HYPH	0	_	_	_	_
31	strand	strand	I-NP	NN	0	_	_	_	_
32	sequence	sequence	I-NP	NN	0	_	_	_	_
33	-	-	B-NP	HYPH	0	_	_	_	_
34	specific	specific	I-NP	JJ	0	_	_	_	_
35	target	target	I-NP	NN	0	_	_	_	_
36	sites	site	I-NP	NNS	0	_	_	_	_
37	located	located	B-ADJP	JJ	0	_	_	_	_
38	within	within	B-PP	IN	0	_	_	_	_
39	a	a	B-NP	DT	0	_	_	_	_
40	90	90	I-NP	CD	0	_	_	_	_
41	-	-	I-NP	HYPH	0	_	_	_	_
42	bp	bp	I-NP	NN	0	_	_	_	_
43	A	A	I-NP	NN	0	_	_	_	_
44	+	+	I-NP	SYM	0	_	_	_	_
45	T	T	I-NP	NN	0	_	_	_	_
46	-	-	I-NP	HYPH	0	_	_	_	_
47	rich	rich	I-NP	JJ	0	_	_	_	_
48	genomic	genomic	I-NP	JJ	0	_	_	_	_
49	tract	tract	I-NP	NN	UMLS:C1185740:T023:ANAT	_	_	_	_
50	,	,	O	,	0	_	_	_	_
51	theoretically	theoretically	B-ADJP	RB	0	_	_	_	_
52	capable	capable	I-ADJP	JJ	0	_	_	_	_
53	of	of	B-PP	IN	0	_	_	_	_
54	forming	form	B-VP	VBG	0	_	_	_	_
55	stable	stable	B-NP	JJ	0	_	_	_	_
56	secondary	secondary	I-NP	JJ	0	_	_	_	_
57	structures	structure	I-NP	NNS	0	_	_	_	_
58	,	,	O	,	0	_	_	_	_
59	approximately	approximately	B-NP	RB	0	_	_	_	_
60	200	200	I-NP	CD	0	_	_	_	_
61	bases	base	I-NP	NNS	0	_	_	_	_
62	upstream	upstream	B-ADVP	RB	0	_	_	_	_
63	from	from	B-PP	IN	0	_	_	_	_
64	the	the	B-NP	DT	0	_	_	_	_
65	H	H	I-NP	NN	0	_	_	_	_
66	-	-	O	HYPH	0	_	_	_	_
67	strand	strand	B-NP	NN	0	_	_	_	_
68	origin	origin	I-NP	NN	0	_	_	_	_
69	(	(	O	(	0	_	_	_	_
70	OH	OH	B-NP	NN	0	_	_	_	_
71	)	)	O	)	0	_	_	_	_
72	of	of	B-PP	IN	0	_	_	_	_
73	replication	replication	B-NP	NN	0	_	_	_	_
74	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	goal	goal	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	present	present	I-NP	JJ	0	_	_	_	_
6	study	study	I-NP	NN	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	to	to	B-VP	TO	0	_	_	_	_
9	determine	determine	I-VP	VB	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	feasibility	feasibility	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	retrovirus	retrovirus	B-NP	NN	0	_	_	_	_
14	mediated	mediate	B-VP	VBN	0	_	_	_	_
15	expression	expression	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	rp47phox	rp47phox	B-NP	NN	:::NOCLASS	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	HL60	HL60	I-NP	NN	0	_	_	_	_
21	and	and	I-NP	CC	0	_	_	_	_
22	U937	U937	I-NP	NN	0	_	_	_	_
23	human	human	I-NP	JJ	0	_	_	_	_
24	hematopoietic	hematopoietic	I-NP	JJ	0	_	_	_	_
25	cell	cell	I-NP	NN	0	_	_	_	_
26	lines	line	I-NP	NNS	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	and	and	O	CC	0	_	_	_	_
29	in	in	B-PP	IN	0	_	_	_	_
30	an	an	B-NP	DT	0	_	_	_	_
31	Epstein	Epstein	I-NP	NNP	UMLS:C1396851:T047:DISO	_	_	_	_
32	-	-	I-NP	HYPH	0	_	_	_	_
33	Barr	Barr	I-NP	NNP	0	_	_	_	_
34	virus	virus	I-NP	NN	0	_	_	_	_
35	transformed	transform	B-VP	VBD	0	_	_	_	_
36	B	B	B-NP	NN	0	_	_	_	_
37	-	-	B-NP	HYPH	0	_	_	_	_
38	lymphocyte	lymphocyte	I-NP	NN	0	_	_	_	_
39	cell	cell	I-NP	NN	0	_	_	_	_
40	line	line	I-NP	NN	0	_	_	_	_
41	(	(	O	(	0	_	_	_	_
42	EBV	EBV	B-NP	NN	0	_	_	_	_
43	-	-	B-NP	HYPH	0	_	_	_	_
44	BCL	BCL	I-NP	NN	0	_	_	_	_
45	)	)	O	)	0	_	_	_	_
46	derived	derive	B-VP	VBN	0	_	_	_	_
47	from	from	B-PP	IN	0	_	_	_	_
48	a	a	B-NP	DT	0	_	_	_	_
49	p47phox	p47phox	I-NP	NN	:::NOCLASS	_	_	_	_
50	-	-	I-NP	HYPH	0	_	_	_	_
51	deficient	deficient	I-NP	JJ	0	_	_	_	_
52	CGD	CGD	I-NP	NN	UMLS:C1844376:T047:DISO|UMLS:C0018203:T047:DISO	_	_	_	_
53	patient	patient	I-NP	NN	0	_	_	_	_
54	.	.	O	.	0	_	_	_	_

1	Comparison	Comparison	B-NP	NN	0	_	_	_	_
2	with	with	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	sequence	sequence	I-NP	NN	0	_	_	_	_
5	databanks	databank	I-NP	NNS	0	_	_	_	_
6	show	show	B-VP	VBP	0	_	_	_	_
7	that	that	B-SBAR	IN	0	_	_	_	_
8	Tactile	Tactile	B-NP	NN	:::NOCLASS	_	_	_	_
9	is	be	B-VP	VBZ	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	member	member	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	immunoglobulin	immunoglobulin	I-NP	NN	:::NOCLASS	_	_	_	_
15	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
16	superfamily	superfamily	I-NP	NN	:::NOCLASS	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	with	with	B-PP	IN	0	_	_	_	_
19	similarity	similarity	B-NP	NN	0	_	_	_	_
20	to	to	B-PP	TO	0	_	_	_	_
21	Drosophila	Drosophila	B-NP	FW	:::NOCLASS	_	_	_	_
22	amalgam	amalgam	I-NP	NN	:::NOCLASS	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	melanoma	melanoma	I-NP	NN	:::NOCLASS	_	_	_	_
26	Ag	Ag	I-NP	NN	:::NOCLASS	_	_	_	_
27	MUC	MUC	I-NP	NN	:::NOCLASS	_	_	_	_
28	-	-	O	HYPH	:::NOCLASS	_	_	_	_
29	18	18	B-NP	CD	:::NOCLASS	_	_	_	_
30	,	,	O	,	0	_	_	_	_
31	members	member	B-NP	NNS	0	_	_	_	_
32	of	of	B-PP	IN	0	_	_	_	_
33	the	the	B-NP	DT	0	_	_	_	_
34	carcinoembryonic	carcinoembryonic	I-NP	JJ	:::NOCLASS	_	_	_	_
35	Ag	Ag	I-NP	NN	:::NOCLASS	_	_	_	_
36	family	family	I-NP	NN	:::NOCLASS	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	the	the	B-NP	DT	0	_	_	_	_
39	poliovirus	poliovirus	I-NP	NN	:::NOCLASS	_	_	_	_
40	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
41	,	,	O	,	0	_	_	_	_
42	and	and	O	CC	0	_	_	_	_
43	the	the	B-NP	DT	0	_	_	_	_
44	neural	neural	I-NP	JJ	:::NOCLASS	_	_	_	_
45	cell	cell	I-NP	NN	:::NOCLASS	_	_	_	_
46	adhesion	adhesion	I-NP	NN	:::NOCLASS	_	_	_	_
47	molecule	molecule	I-NP	NN	:::NOCLASS	_	_	_	_
48	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	rather	rather	I-NP	RB	0	_	_	_	_
3	similar	similar	I-NP	JJ	0	_	_	_	_
4	pattern	pattern	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	results	result	B-NP	NNS	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	obtained	obtain	I-VP	VBN	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	respect	respect	B-NP	NN	0	_	_	_	_
11	to	to	B-PP	TO	0	_	_	_	_
12	LMP2B	LMP2B	B-NP	NN	:::NOCLASS	_	_	_	_
13	mRNA	mRNA	I-NP	NN	:::NOCLASS	_	_	_	_
14	expression	expression	I-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	such	such	B-NP	JJ	0	_	_	_	_
17	transcripts	transcript	I-NP	NNS	0	_	_	_	_
18	being	be	B-VP	VBG	0	_	_	_	_
19	detectable	detectable	B-ADJP	JJ	0	_	_	_	_
20	only	only	B-PP	RB	0	_	_	_	_
21	in	in	I-PP	IN	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	subset	subset	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	tumors	tumor	B-NP	NNS	0	_	_	_	_
26	,	,	O	,	0	_	_	_	_
27	and	and	O	CC	0	_	_	_	_
28	then	then	B-ADVP	RB	0	_	_	_	_
29	at	at	B-PP	IN	0	_	_	_	_
30	apparently	apparently	B-NP	RB	0	_	_	_	_
31	low	low	I-NP	JJ	0	_	_	_	_
32	levels	level	I-NP	NNS	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	phenotypes	phenotype	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	ICP0	ICP0	I-NP	NN	:::NOCLASS	_	_	_	_
6	nonsense	nonsense	I-NP	JJ	0	_	_	_	_
7	mutants	mutant	I-NP	NNS	0	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	intermediate	intermediate	B-ADJP	JJ	0	_	_	_	_
10	between	between	B-PP	IN	0	_	_	_	_
11	those	those	B-NP	DT	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	wild	wild	I-NP	JJ	0	_	_	_	_
15	-	-	I-NP	HYPH	0	_	_	_	_
16	type	type	I-NP	NN	0	_	_	_	_
17	virus	virus	I-NP	NN	0	_	_	_	_
18	and	and	O	CC	0	_	_	_	_
19	7134	7134	B-NP	CD	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	that	that	B-SBAR	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	more	more	I-NP	JJR	0	_	_	_	_
24	ICP0	ICP0	I-NP	NN	:::NOCLASS	_	_	_	_
25	-	-	O	HYPH	:::NOCLASS	_	_	_	_
26	coding	cod	B-VP	VBG	:::NOCLASS	_	_	_	_
27	sequence	sequence	B-NP	NN	:::NOCLASS	_	_	_	_
28	expressed	express	B-VP	VBN	0	_	_	_	_
29	by	by	B-PP	IN	0	_	_	_	_
30	a	a	B-NP	DT	0	_	_	_	_
31	given	give	I-NP	VBN	0	_	_	_	_
32	nonsense	nonsense	I-NP	NN	0	_	_	_	_
33	mutant	mutant	I-NP	NN	0	_	_	_	_
34	,	,	O	,	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	more	more	I-NP	RBR	0	_	_	_	_
37	wild	wild	I-NP	JJ	0	_	_	_	_
38	type	type	I-NP	NN	0	_	_	_	_
39	-	-	B-NP	HYPH	0	_	_	_	_
40	like	like	I-NP	JJ	0	_	_	_	_
41	was	be	B-VP	VBD	0	_	_	_	_
42	its	its	B-NP	PRP$	0	_	_	_	_
43	phenotype	phenotype	I-NP	NN	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	Analysis	Analysis	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	nucleotide	nucleotide	B-NP	NN	0	_	_	_	_
4	sequence	sequence	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	rightmost	rightmost	I-NP	JJ	0	_	_	_	_
8	43	43	I-NP	CD	0	_	_	_	_
9	kbp	kbp	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	herpesvirus	herpesvirus	B-NP	NN	0	_	_	_	_
12	saimiri	saimiri	I-NP	NN	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	HVS	HVS	B-NP	NN	0	_	_	_	_
15	)	)	O	)	0	_	_	_	_
16	L	L	B-NP	NN	0	_	_	_	_
17	-	-	B-NP	HYPH	0	_	_	_	_
18	DNA	DNA	I-NP	NN	0	_	_	_	_
19	:	:	O	:	0	_	_	_	_
20	general	general	B-NP	JJ	0	_	_	_	_
21	conservation	conservation	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	genetic	genetic	B-NP	JJ	0	_	_	_	_
24	organization	organization	I-NP	NN	0	_	_	_	_
25	between	between	B-PP	IN	0	_	_	_	_
26	HVS	HVS	B-NP	NNP	0	_	_	_	_
27	and	and	I-NP	CC	0	_	_	_	_
28	Epstein	Epstein	I-NP	NNP	UMLS:C1396851:T047:DISO	_	_	_	_
29	-	-	B-NP	HYPH	0	_	_	_	_
30	Barr	Barr	I-NP	NNP	0	_	_	_	_
31	virus	virus	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Treatment	Treatment	B-NP	NN	0	_	_	_	_
2	with	with	B-PP	IN	0	_	_	_	_
3	MK	MK	B-NP	NN	UMLS:C0022716:T047:DISO	_	_	_	_
4	-	-	B-NP	HYPH	0	_	_	_	_
5	801	801	I-NP	CD	0	_	_	_	_
6	induced	induce	B-VP	VBD	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	burst	burst	I-NP	JJ	0	_	_	_	_
9	suppression	suppression	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	EEG	EEG	I-NP	NN	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	transient	transient	I-NP	JJ	0	_	_	_	_
16	drop	drop	I-NP	NN	0	_	_	_	_
17	(	(	O	(	0	_	_	_	_
18	11	11	B-NP	CD	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_
20	4	4	B-NP	CD	0	_	_	_	_
21	+	+	O	SYM	0	_	_	_	_
22	/	/	O	SYM	0	_	_	_	_
23	-	-	B-NP	SYM	0	_	_	_	_
24	6	6	B-NP	CD	0	_	_	_	_
25	.	.	I-NP	SYM	0	_	_	_	_
26	5	5	I-NP	CD	0	_	_	_	_
27	mm	mm	I-NP	NN	0	_	_	_	_
28	Hg	Hg	I-NP	NN	0	_	_	_	_
29	)	)	O	)	0	_	_	_	_
30	in	in	B-PP	IN	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	mean	mean	I-NP	JJ	0	_	_	_	_
33	arterial	arterial	I-NP	JJ	UMLS:C0003842:T023:ANAT	_	_	_	_
34	pressure	pressure	I-NP	NN	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	contrast	contrast	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	gel	gel	B-NP	NN	0	_	_	_	_
5	mobility	mobility	I-NP	NN	0	_	_	_	_
6	shift	shift	I-NP	NN	0	_	_	_	_
7	experiments	experiment	I-NP	NNS	0	_	_	_	_
8	have	have	B-VP	VBP	0	_	_	_	_
9	failed	fail	I-VP	VBN	0	_	_	_	_
10	to	to	I-VP	TO	0	_	_	_	_
11	reveal	reveal	I-VP	VB	0	_	_	_	_
12	that	that	B-NP	DT	0	_	_	_	_
13	HAP2	HAP2	I-NP	NN	:::NOCLASS	_	_	_	_
14	or	or	I-NP	CC	0	_	_	_	_
15	HAP3	HAP3	I-NP	NN	:::NOCLASS	_	_	_	_
16	binds	bind	B-VP	VBZ	0	_	_	_	_
17	to	to	B-PP	TO	0	_	_	_	_
18	domain	domain	B-NP	NN	0	_	_	_	_
19	1	1	I-NP	CD	0	_	_	_	_
20	or	or	O	CC	0	_	_	_	_
21	that	that	B-SBAR	IN	0	_	_	_	_
22	hap3	hap3	B-NP	NN	:::NOCLASS	_	_	_	_
23	mutations	mutation	I-NP	NNS	0	_	_	_	_
24	affect	affect	B-VP	VBP	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	complexes	complex	I-NP	NNS	0	_	_	_	_
27	bound	bind	B-VP	VBD	0	_	_	_	_
28	to	to	B-PP	TO	0	_	_	_	_
29	it	it	B-NP	PRP	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Myogenic	Myogenic	B-NP	JJ	0	_	_	_	_
2	differentiation	differentiation	I-NP	NN	0	_	_	_	_
3	can	can	B-VP	MD	0	_	_	_	_
4	be	be	I-VP	VB	0	_	_	_	_
5	inhibited	inhibit	I-VP	VBN	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	adenovirus	adenovirus	I-NP	NN	UMLS:C0001486:T047:DISO	_	_	_	_
9	E1a	E1a	I-NP	NN	:::NOCLASS	_	_	_	_
10	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	rat	rat	I-NP	NN	0	_	_	_	_
14	L6	L6	I-NP	NN	0	_	_	_	_
15	muscle	muscle	I-NP	NN	0	_	_	_	_
16	cell	cell	I-NP	NN	0	_	_	_	_
17	line	line	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	experiment	experiment	I-NP	NN	0	_	_	_	_
3	results	result	I-NP	NNS	0	_	_	_	_
4	showed	show	B-VP	VBD	0	_	_	_	_
5	:	:	O	:	0	_	_	_	_
6	(	(	B-LST	(	0	_	_	_	_
7	i	i	I-LST	LS	0	_	_	_	_
8	)	)	O	)	0	_	_	_	_
9	not	not	B-CONJP	RB	0	_	_	_	_
10	only	only	I-CONJP	RB	0	_	_	_	_
11	1O2	1O2	B-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	but	but	B-CONJP	CC	0	_	_	_	_
14	also	also	I-CONJP	RB	0	_	_	_	_
15	free	free	B-ADVP	JJ	0	_	_	_	_
16	radicals	radical	B-NP	NNS	0	_	_	_	_
17	(	(	O	(	0	_	_	_	_
18	O2	O2	B-NP	NN	0	_	_	_	_
19	-	-	B-ADJP	HYPH	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_
22	OH	OH	B-NP	NN	0	_	_	_	_
23	and	and	I-NP	CC	0	_	_	_	_
24	YHPD	YHPD	I-NP	NN	0	_	_	_	_
25	-	-	O	HYPH	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_
27	)	)	O	)	0	_	_	_	_
28	can	can	B-VP	MD	0	_	_	_	_
29	be	be	I-VP	VB	0	_	_	_	_
30	formed	form	I-VP	VBN	0	_	_	_	_
31	by	by	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	aid	aid	I-NP	NN	0	_	_	_	_
34	of	of	B-PP	IN	0	_	_	_	_
35	YHPD	YHPD	B-NP	NN	0	_	_	_	_
36	;	;	O	:	0	_	_	_	_
37	and	and	O	CC	0	_	_	_	_
38	(	(	B-LST	(	0	_	_	_	_
39	ii	ii	I-LST	LS	0	_	_	_	_
40	)	)	O	)	0	_	_	_	_
41	as	as	B-PP	IN	0	_	_	_	_
42	to	to	B-PP	TO	0	_	_	_	_
43	the	the	B-NP	DT	0	_	_	_	_
44	ability	ability	I-NP	NN	0	_	_	_	_
45	of	of	B-PP	IN	0	_	_	_	_
46	producing	produce	B-VP	VBG	0	_	_	_	_
47	1O2	1O2	B-NP	NN	0	_	_	_	_
48	,	,	O	,	0	_	_	_	_
49	YHPD	YHPD	B-NP	NN	0	_	_	_	_
50	less	less	B-ADJP	JJR	0	_	_	_	_
51	than	than	B-PP	IN	0	_	_	_	_
52	BHPD	BHPD	B-NP	NN	0	_	_	_	_
53	,	,	O	,	0	_	_	_	_
54	while	while	B-SBAR	IN	0	_	_	_	_
55	for	for	B-PP	IN	0	_	_	_	_
56	generating	generate	B-VP	VBG	0	_	_	_	_
57	O2	O2	B-NP	NN	0	_	_	_	_
58	-	-	B-ADJP	HYPH	0	_	_	_	_
59	.	.	O	.	0	_	_	_	_
60	and	and	O	CC	0	_	_	_	_
61	.	.	O	.	0	_	_	_	_
62	OH	OH	B-NP	NN	0	_	_	_	_
63	,	,	O	,	0	_	_	_	_
64	YHPD	YHPD	B-NP	NN	0	_	_	_	_
65	greater	great	B-ADJP	JJR	0	_	_	_	_
66	than	than	B-PP	IN	0	_	_	_	_
67	BHPD	BHPD	B-NP	NN	0	_	_	_	_
68	.	.	O	.	0	_	_	_	_

1	Two	Two	B-NP	CD	0	_	_	_	_
2	points	point	I-NP	NNS	0	_	_	_	_
3	are	be	B-VP	VBP	0	_	_	_	_
4	indicated	indicate	I-VP	VBN	0	_	_	_	_
5	:	:	O	:	0	_	_	_	_
6	first	first	B-ADVP	JJ	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	photosensitized	photosensitize	I-NP	VBN	0	_	_	_	_
10	damage	damage	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	YHPD	YHPD	B-NP	NN	0	_	_	_	_
13	is	be	B-VP	VBZ	0	_	_	_	_
14	interrelated	interrelate	I-VP	VBN	0	_	_	_	_
15	to	to	B-PP	TO	0	_	_	_	_
16	not	not	B-CONJP	RB	0	_	_	_	_
17	only	only	I-CONJP	RB	0	_	_	_	_
18	1O2	1O2	B-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	but	but	B-CONJP	CC	0	_	_	_	_
21	also	also	I-CONJP	RB	0	_	_	_	_
22	free	free	B-ADVP	JJ	0	_	_	_	_
23	radicals	radical	B-NP	NNS	0	_	_	_	_
24	(	(	O	(	0	_	_	_	_
25	O2	O2	B-NP	NN	0	_	_	_	_
26	-	-	B-ADJP	HYPH	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_
29	OH	OH	B-NP	NN	0	_	_	_	_
30	and	and	I-NP	CC	0	_	_	_	_
31	YHPD	YHPD	I-NP	NN	0	_	_	_	_
32	-	-	O	HYPH	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_
34	)	)	O	)	0	_	_	_	_
35	;	;	O	:	0	_	_	_	_
36	second	second	B-NP	JJ	0	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	although	although	B-SBAR	IN	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	photosensitized	photosensitize	I-NP	VBN	0	_	_	_	_
41	damage	damage	I-NP	NN	0	_	_	_	_
42	of	of	B-PP	IN	0	_	_	_	_
43	YHPD	YHPD	B-NP	NN	0	_	_	_	_
44	is	be	B-VP	VBZ	0	_	_	_	_
45	stronger	strong	B-ADJP	JJR	0	_	_	_	_
46	than	than	B-PP	IN	0	_	_	_	_
47	that	that	B-NP	DT	0	_	_	_	_
48	of	of	B-PP	IN	0	_	_	_	_
49	BHPD	BHPD	B-NP	NN	0	_	_	_	_
50	,	,	O	,	0	_	_	_	_
51	yet	yet	O	CC	0	_	_	_	_
52	the	the	B-NP	DT	0	_	_	_	_
53	photosensitized	photosensitize	I-NP	VBN	0	_	_	_	_
54	damage	damage	I-NP	NN	0	_	_	_	_
55	is	be	B-VP	VBZ	0	_	_	_	_
56	negatively	negatively	I-VP	RB	0	_	_	_	_
57	correlated	correlate	I-VP	VBN	0	_	_	_	_
58	to	to	B-PP	TO	0	_	_	_	_
59	the	the	B-NP	DT	0	_	_	_	_
60	yield	yield	I-NP	NN	0	_	_	_	_
61	of	of	B-PP	IN	0	_	_	_	_
62	1O2	1O2	B-NP	NN	0	_	_	_	_
63	but	but	O	CC	0	_	_	_	_
64	positively	positively	B-VP	RB	0	_	_	_	_
65	correlated	correlate	I-VP	VBD	0	_	_	_	_
66	to	to	B-PP	TO	0	_	_	_	_
67	those	those	B-NP	DT	0	_	_	_	_
68	of	of	B-PP	IN	0	_	_	_	_
69	O2	O2	B-NP	NN	0	_	_	_	_
70	-	-	B-NP	HYPH	0	_	_	_	_
71	.	.	O	.	0	_	_	_	_
72	and	and	O	CC	0	_	_	_	_
73	OH	OH	B-NP	NN	0	_	_	_	_
74	.	.	O	.	0	_	_	_	_

1	Acad	Acad	B-NP	NN	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	Both	Both	B-NP	DT	0	_	_	_	_
2	in	in	B-NP	FW	0	_	_	_	_
3	vitro	vitro	I-NP	FW	0	_	_	_	_
4	-	-	B-NP	HYPH	0	_	_	_	_
5	synthesized	synthesize	I-NP	VBN	0	_	_	_	_
6	S2	S2	I-NP	NN	:::NOCLASS	_	_	_	_
7	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
8	and	and	O	CC	0	_	_	_	_
9	synthetic	synthetic	B-NP	JJ	0	_	_	_	_
10	peptides	peptide	I-NP	NNS	0	_	_	_	_
11	corresponding	correspond	B-VP	VBG	0	_	_	_	_
12	to	to	B-PP	TO	0	_	_	_	_
13	S2	S2	B-NP	NN	:::NOCLASS	_	_	_	_
14	are	be	B-VP	VBP	0	_	_	_	_
15	shown	show	I-VP	VBN	0	_	_	_	_
16	to	to	I-VP	TO	0	_	_	_	_
17	react	react	I-VP	VB	0	_	_	_	_
18	positively	positively	B-ADVP	RB	0	_	_	_	_
19	with	with	B-PP	IN	0	_	_	_	_
20	sera	serum	B-NP	NNS	0	_	_	_	_
21	obtained	obtain	B-VP	VBN	0	_	_	_	_
22	from	from	B-PP	IN	0	_	_	_	_
23	EIAV	EIAV	B-NP	NN	0	_	_	_	_
24	-	-	B-NP	HYPH	0	_	_	_	_
25	infected	infect	I-NP	VBN	0	_	_	_	_
26	horses	horse	I-NP	NNS	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	providing	provide	B-VP	VBG	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	first	first	I-NP	JJ	0	_	_	_	_
31	direct	direct	I-NP	JJ	0	_	_	_	_
32	evidence	evidence	I-NP	NN	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	expression	expression	B-NP	NN	0	_	_	_	_
35	of	of	B-PP	IN	0	_	_	_	_
36	this	this	B-NP	DT	0	_	_	_	_
37	protein	protein	I-NP	NN	0	_	_	_	_
38	in	in	B-PP	IN	0	_	_	_	_
39	infected	infected	B-NP	JJ	0	_	_	_	_
40	animals	animal	I-NP	NNS	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	Many	Many	B-NP	JJ	0	_	_	_	_
2	canonical	canonical	I-NP	JJ	0	_	_	_	_
3	TATA	TATA	I-NP	NN	0	_	_	_	_
4	sequences	sequence	I-NP	NNS	0	_	_	_	_
5	are	be	B-VP	VBP	0	_	_	_	_
6	present	present	B-ADJP	JJ	0	_	_	_	_
7	upstream	upstream	B-ADVP	RB	0	_	_	_	_
8	from	from	B-PP	IN	0	_	_	_	_
9	these	these	B-NP	DT	0	_	_	_	_
10	VZV	VZV	I-NP	NN	0	_	_	_	_
11	transcriptional	transcriptional	I-NP	JJ	0	_	_	_	_
12	start	start	I-NP	NN	0	_	_	_	_
13	sites	site	I-NP	NNS	0	_	_	_	_
14	but	but	O	CC	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	apparently	apparently	B-ADVP	RB	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	are	be	B-VP	VBP	0	_	_	_	_
19	not	not	I-VP	RB	0	_	_	_	_
20	used	use	I-VP	VBN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	ORF	ORF	I-NP	NN	UMLS:C0013570:T047:DISO	_	_	_	_
3	4	4	I-NP	CD	0	_	_	_	_
4	gene	gene	I-NP	NN	0	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	minimally	minimally	B-ADJP	RB	0	_	_	_	_
7	active	active	I-ADJP	JJ	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	whereas	whereas	O	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	ORF	ORF	I-NP	NN	UMLS:C0013570:T047:DISO	_	_	_	_
12	62	62	I-NP	CD	0	_	_	_	_
13	gene	gene	I-NP	NN	0	_	_	_	_
14	gave	give	B-VP	VBD	0	_	_	_	_
15	twofold	twofold	B-NP	JJ	0	_	_	_	_
16	induction	induction	I-NP	NN	0	_	_	_	_
17	;	;	O	:	0	_	_	_	_
18	both	both	B-NP	DT	0	_	_	_	_
19	genes	gene	I-NP	NNS	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	acting	act	B-VP	VBG	0	_	_	_	_
22	together	together	B-ADVP	RB	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	gave	give	B-VP	VBD	0	_	_	_	_
25	fivefold	fivefold	B-NP	JJ	0	_	_	_	_
26	induction	induction	I-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Interestingly	Interestingly	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	IR5	IR5	I-NP	NN	:::NOCLASS	_	_	_	_
5	ORF	ORF	I-NP	NN	:::NOCLASS|UMLS:C0013570:T047:DISO	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	EHV	EHV	B-NP	NN	0	_	_	_	_
8	-	-	B-NP	HYPH	0	_	_	_	_
9	1	1	I-NP	CD	0	_	_	_	_
10	possesses	possess	I-NP	NNS	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	sequence	sequence	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	13	13	B-NP	CD	0	_	_	_	_
15	amino	amino	I-NP	NN	0	_	_	_	_
16	acids	acid	I-NP	NNS	0	_	_	_	_
17	(	(	O	(	0	_	_	_	_
18	CAYWCCLGHAFAC	CAYWCCLGHAFAC	B-NP	NN	0	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	that	that	B-NP	WDT	0	_	_	_	_
21	is	be	B-VP	VBZ	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	perfect	perfect	I-NP	JJ	0	_	_	_	_
24	match	match	I-NP	NN	0	_	_	_	_
25	to	to	B-PP	TO	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	consensus	consensus	I-NP	NN	0	_	_	_	_
28	zinc	zinc	I-NP	NN	0	_	_	_	_
29	finger	finger	I-NP	NN	0	_	_	_	_
30	motif	motif	I-NP	NN	0	_	_	_	_
31	(	(	O	(	0	_	_	_	_
32	C	C	B-NP	NN	0	_	_	_	_
33	-	-	B-NP	HYPH	0	_	_	_	_
34	X2	X2	I-NP	NN	0	_	_	_	_
35	-	-	B-NP	HYPH	0	_	_	_	_
36	4	4	I-NP	CD	0	_	_	_	_
37	-	-	I-NP	HYPH	0	_	_	_	_
38	C	C	I-NP	NN	0	_	_	_	_
39	-	-	B-NP	HYPH	0	_	_	_	_
40	X2	X2	I-NP	NN	0	_	_	_	_
41	-	-	B-NP	HYPH	0	_	_	_	_
42	15	15	I-NP	CD	0	_	_	_	_
43	-	-	I-NP	HYPH	0	_	_	_	_
44	C	C	I-NP	NN	0	_	_	_	_
45	/	/	B-NP	SYM	0	_	_	_	_
46	H	H	I-NP	NN	0	_	_	_	_
47	-	-	B-NP	HYPH	0	_	_	_	_
48	X2	X2	I-NP	NN	0	_	_	_	_
49	-	-	B-NP	HYPH	0	_	_	_	_
50	4	4	I-NP	CD	0	_	_	_	_
51	-	-	I-NP	HYPH	0	_	_	_	_
52	C	C	I-NP	NN	0	_	_	_	_
53	/	/	B-NP	SYM	0	_	_	_	_
54	H	H	I-NP	NN	0	_	_	_	_
55	)	)	O	)	0	_	_	_	_
56	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	DNA	DNA	I-NP	NN	0	_	_	_	_
3	sequence	sequence	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	sulfate	sulfate	I-NP	NN	:::NOCLASS	_	_	_	_
7	activation	activation	I-NP	NN	:::NOCLASS	_	_	_	_
8	locus	locus	I-NP	NN	:::NOCLASS	_	_	_	_
9	from	from	B-PP	IN	0	_	_	_	_
10	Escherichia	Escherichia	B-NP	FW	0	_	_	_	_
11	coli	coli	I-NP	FW	0	_	_	_	_
12	K	K	I-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	12	12	I-NP	CD	0	_	_	_	_
15	has	have	B-VP	VBZ	0	_	_	_	_
16	been	be	I-VP	VBN	0	_	_	_	_
17	determined	determine	I-VP	VBN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	unphosphorylated	unphosphorylated	I-NP	JJ	0	_	_	_	_
3	form	form	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	RNA	RNA	B-NP	NN	:::NOCLASS	_	_	_	_
6	polymerase	polymerase	I-NP	NN	:::NOCLASS	_	_	_	_
7	II	II	I-NP	CD	:::NOCLASS	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	designated	designate	I-VP	VBN	0	_	_	_	_
10	IIA	IIA	B-NP	NNP	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	whereas	whereas	O	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	phosphorylated	phosphorylated	I-NP	JJ	0	_	_	_	_
15	form	form	I-NP	NN	0	_	_	_	_
16	is	be	B-VP	VBZ	0	_	_	_	_
17	designated	designate	I-VP	VBN	0	_	_	_	_
18	IIO	IIO	B-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	RNA	RNA	B-NP	NN	:::NOCLASS	_	_	_	_
2	polymerase	polymerase	I-NP	NN	:::NOCLASS	_	_	_	_
3	IIA	IIA	I-NP	NN	:::NOCLASS	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	recovered	recover	I-VP	VBN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	transcriptionally	transcriptionally	B-NP	RB	0	_	_	_	_
8	active	active	I-NP	JJ	0	_	_	_	_
9	complexes	complex	I-NP	NNS	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	reactions	reaction	B-NP	NNS	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	which	which	B-NP	WDT	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	input	input	I-NP	NN	0	_	_	_	_
16	enzyme	enzyme	I-NP	NN	0	_	_	_	_
17	was	be	B-VP	VBD	0	_	_	_	_
18	RNA	RNA	B-NP	NN	:::NOCLASS	_	_	_	_
19	polymerase	polymerase	I-NP	NN	:::NOCLASS	_	_	_	_
20	IIA	IIA	I-NP	NN	:::NOCLASS	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Fructokinase	Fructokinase	B-NP	NN	:::NOCLASS	_	_	_	_
2	activity	activity	I-NP	NN	0	_	_	_	_
3	is	be	B-VP	VBZ	0	_	_	_	_
4	elevated	elevate	I-VP	VBN	0	_	_	_	_
5	up	up	B-PRT	RP	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	twofold	twofold	B-NP	RB	0	_	_	_	_
8	when	when	B-ADVP	WRB	0	_	_	_	_
9	Z	Z	B-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_
11	mobilis	mobilis	O	''	0	_	_	_	_
12	was	be	B-VP	VBD	0	_	_	_	_
13	grown	grow	I-VP	VBN	0	_	_	_	_
14	on	on	B-PP	IN	0	_	_	_	_
15	fructose	fructose	B-NP	NN	0	_	_	_	_
16	instead	instead	B-PP	RB	0	_	_	_	_
17	of	of	I-PP	IN	0	_	_	_	_
18	glucose	glucose	B-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	there	there	B-NP	EX	0	_	_	_	_
22	was	be	B-VP	VBD	0	_	_	_	_
23	a	a	B-NP	DT	0	_	_	_	_
24	parallel	parallel	I-NP	JJ	0	_	_	_	_
25	increase	increase	I-NP	NN	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	frk	frk	B-NP	NN	:::NOCLASS	_	_	_	_
28	mRNA	mRNA	I-NP	NN	:::NOCLASS	_	_	_	_
29	levels	level	I-NP	NNS	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Plasma	Plasma	B-NP	NN	0	_	_	_	_
2	membranes	membrane	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	cultured	culture	B-NP	VBN	0	_	_	_	_
5	cells	cell	I-NP	NNS	0	_	_	_	_
6	contain	contain	B-VP	VBP	0	_	_	_	_
7	high	high	B-NP	JJ	:::NOCLASS	_	_	_	_
8	affinity	affinity	I-NP	NN	0	_	_	_	_
9	receptors	receptor	I-NP	NNS	0	_	_	_	_
10	for	for	B-PP	IN	0	_	_	_	_
11	high	high	B-NP	JJ	:::NOCLASS	_	_	_	_
12	density	density	I-NP	NN	:::NOCLASS	_	_	_	_
13	lipoprotein	lipoprotein	I-NP	NN	:::NOCLASS	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	HDL	HDL	B-NP	NN	:::NOCLASS	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	that	that	B-NP	WDT	0	_	_	_	_
18	appear	appear	B-VP	VBP	0	_	_	_	_
19	to	to	I-VP	TO	0	_	_	_	_
20	mediate	mediate	I-VP	VB	0	_	_	_	_
21	removal	removal	B-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	excess	excess	B-NP	JJ	0	_	_	_	_
24	intracellular	intracellular	I-NP	JJ	0	_	_	_	_
25	cholesterol	cholesterol	I-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	After	After	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	first	first	I-NP	JJ	0	_	_	_	_
4	28	28	I-NP	CD	0	_	_	_	_
5	patients	patient	I-NP	NNS	0	_	_	_	_
6	vincristine	vincristine	I-NP	NN	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	replaced	replace	I-VP	VBN	0	_	_	_	_
9	by	by	B-PP	IN	0	_	_	_	_
10	teniposide	teniposide	B-NP	NN	0	_	_	_	_
11	(	(	O	(	0	_	_	_	_
12	VM	VM	B-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	26	26	I-NP	CD	0	_	_	_	_
15	)	)	O	)	0	_	_	_	_
16	due	due	B-PP	IN	0	_	_	_	_
17	to	to	B-PP	TO	0	_	_	_	_
18	neurotoxicity	neurotoxicity	B-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	indicate	indicate	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	an	an	B-NP	DT	0	_	_	_	_
6	internal	internal	I-NP	JJ	0	_	_	_	_
7	short	short	I-NP	JJ	0	_	_	_	_
8	element	element	I-NP	NN	0	_	_	_	_
9	located	located	B-ADJP	JJ	0	_	_	_	_
10	at	at	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	very	very	I-NP	RB	0	_	_	_	_
13	5	5	I-NP	CD	0	_	_	_	_
14	'	'	I-NP	SYM	0	_	_	_	_
15	terminal	terminal	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	L1	L1	B-NP	NN	:::NOCLASS	_	_	_	_
18	sequence	sequence	I-NP	NN	:::NOCLASS	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	nuclear	nuclear	I-NP	JJ	0	_	_	_	_
22	factor	factor	I-NP	NN	0	_	_	_	_
23	binding	bind	B-VP	VBG	0	_	_	_	_
24	to	to	B-PP	TO	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	element	element	I-NP	NN	0	_	_	_	_
27	play	play	B-VP	VBP	0	_	_	_	_
28	a	a	B-NP	DT	0	_	_	_	_
29	crucial	crucial	I-NP	JJ	0	_	_	_	_
30	role	role	I-NP	NN	0	_	_	_	_
31	in	in	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	transcription	transcription	I-NP	NN	0	_	_	_	_
34	of	of	B-PP	IN	0	_	_	_	_
35	human	human	B-NP	JJ	:::NOCLASS	_	_	_	_
36	L1	L1	I-NP	NN	:::NOCLASS	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	Tumor	Tumor	B-NP	NN	0	_	_	_	_
2	cells	cell	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	focally	focally	B-ADJP	RB	0	_	_	_	_
5	immunoreactive	immunoreactive	I-ADJP	JJ	0	_	_	_	_
6	for	for	B-PP	IN	0	_	_	_	_
7	neuron	neuron	B-NP	NN	:::NOCLASS	_	_	_	_
8	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
9	specific	specific	I-NP	JJ	:::NOCLASS	_	_	_	_
10	enolase	enolase	I-NP	NN	:::NOCLASS	_	_	_	_
11	,	,	I-NP	,	0	_	_	_	_
12	insulin	insulin	I-NP	NN	:::NOCLASS	_	_	_	_
13	,	,	I-NP	,	0	_	_	_	_
14	glucagon	glucagon	I-NP	NN	:::NOCLASS	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	VIP	VIP	I-NP	NN	:::NOCLASS	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	recombinant	recombinant	I-NP	JJ	0	_	_	_	_
3	with	with	B-PP	IN	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	5	5	I-NP	CD	0	_	_	_	_
6	'	'	I-NP	SYM	0	_	_	_	_
7	end	end	I-NP	NN	0	_	_	_	_
8	from	from	B-PP	IN	0	_	_	_	_
9	src	src	B-NP	NN	:::NOCLASS	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	3	3	I-NP	CD	0	_	_	_	_
13	'	'	I-NP	SYM	0	_	_	_	_
14	end	end	I-NP	NN	0	_	_	_	_
15	from	from	B-PP	IN	0	_	_	_	_
16	ros	ro	B-NP	NNS	:::NOCLASS	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	called	call	B-VP	VBD	0	_	_	_	_
19	SRC	SRC	B-NP	NNP	:::NOCLASS	_	_	_	_
20	x	x	I-NP	NNP	0	_	_	_	_
21	ROS	ROS	I-NP	NNP	:::NOCLASS	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	transformed	transform	B-NP	VBN	0	_	_	_	_
24	chicken	chicken	I-NP	NN	0	_	_	_	_
25	embryo	embryo	I-NP	NN	0	_	_	_	_
26	fibroblasts	fibroblast	I-NP	NNS	0	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	CEF	CEF	B-NP	NN	0	_	_	_	_
29	)	)	O	)	0	_	_	_	_
30	to	to	B-PP	TO	0	_	_	_	_
31	a	a	B-NP	DT	0	_	_	_	_
32	spindle	spindle	I-NP	NN	0	_	_	_	_
33	shape	shape	I-NP	NN	0	_	_	_	_
34	morphology	morphology	I-NP	NN	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	mimicking	mimic	B-VP	VBG	0	_	_	_	_
37	that	that	B-NP	DT	0	_	_	_	_
38	of	of	B-PP	IN	0	_	_	_	_
39	UR2	UR2	B-NP	NN	:::NOCLASS	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	ROS	ROS	B-NP	NN	:::NOCLASS	_	_	_	_
2	x	x	O	SYM	0	_	_	_	_
3	SRC	SRC	B-NP	NN	:::NOCLASS	_	_	_	_
4	(	(	O	(	0	_	_	_	_
5	R	R	B-NP	NN	:::NOCLASS	_	_	_	_
6	)	)	O	)	0	_	_	_	_
7	contains	contain	B-VP	VBZ	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	16	16	I-NP	CD	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	amino	amino	I-NP	JJ	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	acid	acid	I-NP	NN	0	_	_	_	_
14	deletion	deletion	I-NP	NN	0	_	_	_	_
15	that	that	B-NP	WDT	0	_	_	_	_
16	includes	include	B-VP	VBZ	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	3	3	I-NP	CD	0	_	_	_	_
19	'	'	I-NP	SYM	0	_	_	_	_
20	half	half	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	transmembrane	transmembrane	I-NP	JJ	0	_	_	_	_
24	domain	domain	I-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	ros	ro	B-NP	NNS	:::NOCLASS	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	To	To	B-VP	TO	0	_	_	_	_
2	define	define	I-VP	VB	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	number	number	I-NP	NN	0	_	_	_	_
5	and	and	I-NP	CC	0	_	_	_	_
6	nature	nature	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	E6	E6	I-NP	NN	:::NOCLASS	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	E7	E7	I-NP	NN	:::NOCLASS	_	_	_	_
12	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
13	products	product	I-NP	NNS	0	_	_	_	_
14	expressed	express	B-VP	VBN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	BPV	BPV	B-NP	NN	0	_	_	_	_
17	-	-	B-NP	HYPH	0	_	_	_	_
18	1	1	I-NP	CD	0	_	_	_	_
19	-	-	I-NP	HYPH	0	_	_	_	_
20	transformed	transform	I-NP	VBN	0	_	_	_	_
21	cells	cell	I-NP	NNS	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	we	we	B-NP	PRP	0	_	_	_	_
24	performed	perform	B-VP	VBD	0	_	_	_	_
25	immunoprecipitation	immunoprecipitation	B-NP	NN	0	_	_	_	_
26	experiments	experiment	I-NP	NNS	0	_	_	_	_
27	with	with	B-PP	IN	0	_	_	_	_
28	antisera	antiserum	B-NP	NNS	0	_	_	_	_
29	raised	raise	B-VP	VBN	0	_	_	_	_
30	to	to	B-PP	TO	0	_	_	_	_
31	bacterially	bacterially	B-NP	RB	0	_	_	_	_
32	expressed	express	I-NP	VBN	0	_	_	_	_
33	BPV	BPV	I-NP	NN	:::NOCLASS	_	_	_	_
34	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
35	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
36	E6	E6	I-NP	NN	:::NOCLASS	_	_	_	_
37	and	and	I-NP	CC	0	_	_	_	_
38	E7	E7	I-NP	NN	:::NOCLASS	_	_	_	_
39	fusion	fusion	I-NP	NN	:::NOCLASS	_	_	_	_
40	proteins	protein	I-NP	NNS	:::NOCLASS	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	Transient	Transient	B-NP	JJ	0	_	_	_	_
2	transfection	transfection	I-NP	NN	0	_	_	_	_
3	assays	assay	I-NP	NNS	0	_	_	_	_
4	showed	show	B-VP	VBD	0	_	_	_	_
5	that	that	B-SBAR	IN	0	_	_	_	_
6	site	site	B-NP	NN	0	_	_	_	_
7	A	A	I-NP	NN	0	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	necessary	necessary	B-ADJP	JJ	0	_	_	_	_
10	and	and	I-ADJP	CC	0	_	_	_	_
11	sufficient	sufficient	I-ADJP	JJ	0	_	_	_	_
12	for	for	B-PP	IN	0	_	_	_	_
13	RXR	RXR	B-NP	NN	:::NOCLASS	_	_	_	_
14	alpha	alpha	B-NP	SYM	:::NOCLASS	_	_	_	_
15	-	-	B-VP	HYPH	0	_	_	_	_
16	mediated	mediate	B-NP	VBN	0	_	_	_	_
17	transactivation	transactivation	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	apoAI	apoAI	I-NP	NN	:::NOCLASS	_	_	_	_
21	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
22	basal	basal	I-NP	JJ	:::NOCLASS	_	_	_	_
23	promoter	promoter	I-NP	NN	:::NOCLASS	_	_	_	_
24	in	in	B-PP	IN	0	_	_	_	_
25	human	human	B-NP	JJ	0	_	_	_	_
26	hepatoma	hepatoma	I-NP	NN	0	_	_	_	_
27	HepG2	HepG2	I-NP	NN	0	_	_	_	_
28	cells	cell	I-NP	NNS	0	_	_	_	_
29	in	in	B-PP	IN	0	_	_	_	_
30	the	the	I-PP	DT	0	_	_	_	_
31	presence	presence	I-PP	NN	0	_	_	_	_
32	of	of	I-PP	IN	0	_	_	_	_
33	RA	RA	B-NP	NN	UMLS:C0002893:T047:DISO|UMLS:C0003873:T047:DISO	_	_	_	_
34	and	and	O	CC	0	_	_	_	_
35	that	that	B-SBAR	IN	0	_	_	_	_
36	this	this	B-NP	DT	0	_	_	_	_
37	transactivation	transactivation	I-NP	NN	0	_	_	_	_
38	is	be	B-VP	VBZ	0	_	_	_	_
39	abolished	abolish	I-VP	VBN	0	_	_	_	_
40	by	by	B-PP	IN	0	_	_	_	_
41	increasing	increase	B-VP	VBG	0	_	_	_	_
42	amounts	amount	B-NP	NNS	0	_	_	_	_
43	of	of	B-PP	IN	0	_	_	_	_
44	cotransfected	cotransfecte	B-NP	VBN	0	_	_	_	_
45	ARP	ARP	I-NP	NN	:::NOCLASS	_	_	_	_
46	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
47	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
48	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	enhancer	enhancer	I-NP	NN	0	_	_	_	_
3	region	region	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	Akv	Akv	B-NP	NN	UMLS:C0265971:T047:DISO	_	_	_	_
6	murine	murine	I-NP	JJ	0	_	_	_	_
7	leukemia	leukemia	I-NP	NN	0	_	_	_	_
8	virus	virus	I-NP	NN	0	_	_	_	_
9	contains	contain	B-VP	VBZ	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	sequence	sequence	I-NP	NN	0	_	_	_	_
12	motif	motif	I-NP	NN	0	_	_	_	_
13	ACAGATGG	ACAGATGG	I-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Two	Two	B-NP	CD	0	_	_	_	_
2	splice	splice	I-NP	NN	0	_	_	_	_
3	variants	variant	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	ALF1	ALF1	B-NP	NN	:::NOCLASS	_	_	_	_
6	cDNA	cDNA	I-NP	NN	:::NOCLASS	_	_	_	_
7	have	have	B-VP	VBP	0	_	_	_	_
8	been	be	I-VP	VBN	0	_	_	_	_
9	found	find	I-VP	VBN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	differing	differ	B-VP	VBG	0	_	_	_	_
12	by	by	B-PP	IN	0	_	_	_	_
13	a	a	B-NP	DT	0	_	_	_	_
14	72	72	I-NP	CD	0	_	_	_	_
15	-	-	I-NP	HYPH	0	_	_	_	_
16	bp	bp	I-NP	NN	0	_	_	_	_
17	insertion	insertion	I-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	coding	cod	B-VP	VBG	0	_	_	_	_
20	for	for	B-PP	IN	0	_	_	_	_
21	putative	putative	B-NP	JJ	0	_	_	_	_
22	proteins	protein	I-NP	NNS	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	682	682	B-NP	CD	0	_	_	_	_
25	and	and	I-NP	CC	0	_	_	_	_
26	706	706	I-NP	CD	0	_	_	_	_
27	amino	amino	I-NP	JJ	0	_	_	_	_
28	acids	acid	I-NP	NNS	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	third	third	I-NP	JJ	0	_	_	_	_
3	prominent	prominent	I-NP	JJ	0	_	_	_	_
4	component	component	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	apparent	apparent	B-NP	JJ	0	_	_	_	_
7	molecular	molecular	I-NP	JJ	0	_	_	_	_
8	mass	mass	I-NP	NN	0	_	_	_	_
9	16	16	I-NP	CD	0	_	_	_	_
10	kDa	kDa	I-NP	NN	0	_	_	_	_
11	displayed	display	B-VP	VBD	0	_	_	_	_
12	several	several	B-NP	JJ	0	_	_	_	_
13	properties	property	I-NP	NNS	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	including	include	B-PP	VBG	0	_	_	_	_
16	ability	ability	B-NP	NN	0	_	_	_	_
17	to	to	B-VP	TO	0	_	_	_	_
18	bind	bind	I-VP	VB	0	_	_	_	_
19	45Ca2+	45Ca2+	B-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	that	that	B-NP	WDT	0	_	_	_	_
22	are	be	B-VP	VBP	0	_	_	_	_
23	characteristic	characteristic	B-ADJP	JJ	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	regulatory	regulatory	I-NP	JJ	0	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	B	B	B-NP	NN	0	_	_	_	_
29	)	)	O	)	0	_	_	_	_
30	subunit	subunit	B-NP	NN	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	mammalian	mammalian	B-NP	JJ	:::NOCLASS	_	_	_	_
33	calcineurin	calcineurin	I-NP	NN	:::NOCLASS	_	_	_	_
34	and	and	O	CC	0	_	_	_	_
35	was	be	B-VP	VBD	0	_	_	_	_
36	recognized	recognize	I-VP	VBN	0	_	_	_	_
37	by	by	B-PP	IN	0	_	_	_	_
38	an	an	B-NP	DT	0	_	_	_	_
39	antiserum	antiserum	I-NP	NN	0	_	_	_	_
40	raised	raise	B-VP	VBN	0	_	_	_	_
41	against	against	B-PP	IN	0	_	_	_	_
42	bovine	bovine	B-NP	JJ	:::NOCLASS	_	_	_	_
43	calcineurin	calcineurin	I-NP	NN	:::NOCLASS	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	As	As	B-SBAR	IN	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	observed	observe	I-VP	VBN	0	_	_	_	_
4	previously	previously	B-ADVP	RB	0	_	_	_	_
5	for	for	B-PP	IN	0	_	_	_	_
6	MATa	MATa	B-NP	NN	:::NOCLASS	_	_	_	_
7	cna1	cna1	I-NP	NN	UMLS:C1852557:T047:DISO|:::NOCLASS	_	_	_	_
8	cna2	cna2	I-NP	NN	UMLS:C1857574:T047:DISO|:::NOCLASS	_	_	_	_
9	double	double	I-NP	JJ	0	_	_	_	_
10	mutants	mutant	I-NP	NNS	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	MATa	MATa	B-NP	NNP	:::NOCLASS	_	_	_	_
13	cnb1	cnb1	I-NP	NN	:::NOCLASS	_	_	_	_
14	mutants	mutant	I-NP	NNS	:::NOCLASS	_	_	_	_
15	were	be	B-VP	VBD	0	_	_	_	_
16	defective	defective	B-ADJP	JJ	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	their	their	B-NP	PRP$	0	_	_	_	_
19	ability	ability	I-NP	NN	0	_	_	_	_
20	to	to	B-VP	TO	0	_	_	_	_
21	recover	recover	I-VP	VB	0	_	_	_	_
22	from	from	B-PP	IN	0	_	_	_	_
23	alpha	alpha	B-NP	SYM	:::NOCLASS	_	_	_	_
24	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
25	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
26	-	-	B-NP	HYPH	0	_	_	_	_
27	induced	induce	I-NP	VBN	0	_	_	_	_
28	growth	growth	I-NP	NN	0	_	_	_	_
29	arrest	arrest	I-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Antibodies	Antibody	B-NP	NNS	0	_	_	_	_
2	against	against	B-PP	IN	0	_	_	_	_
3	this	this	B-NP	DT	0	_	_	_	_
4	purified	purify	I-NP	VBN	0	_	_	_	_
5	protein	protein	I-NP	NN	0	_	_	_	_
6	localize	localize	B-VP	VBP	0	_	_	_	_
7	RIM1	RIM1	B-NP	NN	:::NOCLASS	_	_	_	_
8	to	to	B-PP	TO	0	_	_	_	_
9	mitochondria	mitochondrion	B-NP	NNS	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	METHODS	METHODS	B-NP	NNS	0	_	_	_	_
2	:	:	O	:	0	_	_	_	_
3	IgG	IgG	B-NP	NN	:::NOCLASS	_	_	_	_
4	antibodies	antibody	I-NP	NNS	:::NOCLASS	_	_	_	_
5	vs	vs	B-PP	IN	0	_	_	_	_
6	HHV	HHV	B-NP	NN	0	_	_	_	_
7	-	-	B-NP	HYPH	0	_	_	_	_
8	6	6	I-NP	CD	0	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	anti	anti	B-NP	AFX	:::NOCLASS	_	_	_	_
11	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
12	HHV	HHV	I-NP	NN	:::NOCLASS	_	_	_	_
13	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
14	6	6	I-NP	CD	:::NOCLASS	_	_	_	_
15	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
16	IgG	IgG	I-NP	NN	:::NOCLASS	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	were	be	B-VP	VBD	0	_	_	_	_
19	determined	determine	I-VP	VBN	0	_	_	_	_
20	by	by	B-PP	IN	0	_	_	_	_
21	indirect	indirect	B-NP	JJ	0	_	_	_	_
22	immunofluorescence	immunofluorescence	I-NP	NN	0	_	_	_	_
23	in	in	B-PP	IN	0	_	_	_	_
24	100	100	B-NP	CD	0	_	_	_	_
25	IVDA	IVDA	I-NP	NN	0	_	_	_	_
26	(	(	O	(	0	_	_	_	_
27	29	29	B-NP	CD	0	_	_	_	_
28	seronegative	seronegative	I-NP	JJ	0	_	_	_	_
29	and	and	O	CC	0	_	_	_	_
30	71	71	B-NP	CD	0	_	_	_	_
31	seropositive	seropositive	I-NP	JJ	0	_	_	_	_
32	for	for	B-PP	IN	0	_	_	_	_
33	HIV	HIV	B-NP	NN	UMLS:C0019693:T047:DISO	_	_	_	_
34	-	-	B-NP	HYPH	0	_	_	_	_
35	1	1	I-NP	CD	0	_	_	_	_
36	of	of	B-PP	IN	0	_	_	_	_
37	which	which	B-NP	WDT	0	_	_	_	_
38	45	45	B-NP	CD	0	_	_	_	_
39	were	be	B-VP	VBD	0	_	_	_	_
40	in	in	B-PP	IN	0	_	_	_	_
41	stage	stage	B-NP	NN	0	_	_	_	_
42	II	II	I-NP	CD	0	_	_	_	_
43	and	and	I-NP	CC	0	_	_	_	_
44	26	26	I-NP	CD	0	_	_	_	_
45	in	in	B-PP	IN	0	_	_	_	_
46	IV	IV	B-NP	CD	0	_	_	_	_
47	-	-	I-NP	HYPH	0	_	_	_	_
48	C1	C1	I-NP	NN	0	_	_	_	_
49	of	of	B-PP	IN	0	_	_	_	_
50	CDC	CDC	B-NP	NN	0	_	_	_	_
51	)	)	O	)	0	_	_	_	_
52	as	as	B-CONJP	RB	0	_	_	_	_
53	well	well	I-CONJP	RB	0	_	_	_	_
54	as	as	I-CONJP	IN	0	_	_	_	_
55	in	in	B-PP	IN	0	_	_	_	_
56	100	100	B-NP	CD	0	_	_	_	_
57	healthy	healthy	I-NP	JJ	0	_	_	_	_
58	subjects	subject	I-NP	NNS	0	_	_	_	_
59	of	of	B-PP	IN	0	_	_	_	_
60	a	a	B-NP	DT	0	_	_	_	_
61	similar	similar	I-NP	JJ	0	_	_	_	_
62	age	age	I-NP	NN	0	_	_	_	_
63	(	(	O	(	0	_	_	_	_
64	control	control	B-NP	NN	0	_	_	_	_
65	group	group	I-NP	NN	0	_	_	_	_
66	)	)	O	)	0	_	_	_	_
67	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	position	position	I-NP	NN	0	_	_	_	_
3	-	-	B-NP	HYPH	0	_	_	_	_
4	independent	independent	I-NP	JJ	0	_	_	_	_
5	activation	activation	I-NP	NN	0	_	_	_	_
6	domain	domain	I-NP	NN	0	_	_	_	_
7	which	which	B-NP	WDT	0	_	_	_	_
8	contained	contain	B-VP	VBD	0	_	_	_	_
9	conserved	conserve	B-NP	VBN	0	_	_	_	_
10	regions	region	I-NP	NNS	0	_	_	_	_
11	II	II	I-NP	CD	0	_	_	_	_
12	and	and	I-NP	CC	0	_	_	_	_
13	III	III	I-NP	CD	0	_	_	_	_
14	was	be	B-VP	VBD	0	_	_	_	_
15	identified	identify	I-VP	VBN	0	_	_	_	_
16	at	at	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	carboxyl	carboxyl	I-NP	NN	0	_	_	_	_
19	terminus	terminus	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	HNF	HNF	I-NP	NN	:::NOCLASS	_	_	_	_
23	-	-	O	HYPH	:::NOCLASS	_	_	_	_
24	3	3	B-NP	CD	:::NOCLASS	_	_	_	_
25	beta	beta	I-NP	SYM	:::NOCLASS	_	_	_	_
26	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	amino	amino	B-NP	NN	0	_	_	_	_
29	acids	acid	I-NP	NNS	0	_	_	_	_
30	361	361	B-NP	CD	0	_	_	_	_
31	to	to	B-PP	TO	0	_	_	_	_
32	458	458	B-NP	CD	0	_	_	_	_
33	)	)	O	)	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	HNF	HNF	B-NP	NN	:::NOCLASS	_	_	_	_
2	-	-	O	HYPH	:::NOCLASS	_	_	_	_
3	3	3	B-NP	CD	:::NOCLASS	_	_	_	_
4	beta	beta	I-NP	SYM	:::NOCLASS	_	_	_	_
5	amino	amino	I-NP	JJ	:::NOCLASS	_	_	_	_
6	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
7	terminal	terminal	I-NP	JJ	:::NOCLASS	_	_	_	_
8	sequences	sequence	I-NP	NNS	:::NOCLASS	_	_	_	_
9	defined	define	B-VP	VBN	0	_	_	_	_
10	by	by	B-PP	IN	0	_	_	_	_
11	conserved	conserve	B-NP	VBN	0	_	_	_	_
12	region	region	I-NP	NN	0	_	_	_	_
13	IV	IV	I-NP	CD	0	_	_	_	_
14	also	also	B-ADVP	RB	0	_	_	_	_
15	contributed	contribute	B-VP	VBD	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	transactivation	transactivation	B-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	but	but	O	CC	0	_	_	_	_
20	region	region	B-NP	NN	0	_	_	_	_
21	IV	IV	I-NP	CD	0	_	_	_	_
22	activity	activity	I-NP	NN	0	_	_	_	_
23	required	require	B-VP	VBD	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	participation	participation	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	region	region	I-NP	NN	0	_	_	_	_
29	II	II	I-NP	CD	0	_	_	_	_
30	-	-	I-NP	HYPH	0	_	_	_	_
31	III	III	I-NP	CD	0	_	_	_	_
32	domain	domain	I-NP	NN	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Possible	Possible	B-NP	JJ	0	_	_	_	_
2	roles	role	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	RAD5	RAD5	B-NP	NN	:::NOCLASS	_	_	_	_
5	putative	putative	I-NP	JJ	0	_	_	_	_
6	ATPase	ATPase	I-NP	NN	:::NOCLASS	_	_	_	_
7	/	/	B-NP	SYM	0	_	_	_	_
8	DNA	DNA	I-NP	NN	:::NOCLASS	_	_	_	_
9	helicase	helicase	I-NP	NN	:::NOCLASS	_	_	_	_
10	activity	activity	I-NP	NN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	DNA	DNA	B-NP	NN	0	_	_	_	_
13	repair	repair	I-NP	NN	0	_	_	_	_
14	and	and	B-PP	CC	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	maintenance	maintenance	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	wild	wild	B-NP	JJ	0	_	_	_	_
20	-	-	I-NP	HYPH	0	_	_	_	_
21	type	type	I-NP	NN	0	_	_	_	_
22	rates	rate	I-NP	NNS	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	instability	instability	B-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	simple	simple	B-NP	JJ	0	_	_	_	_
27	repetitive	repetitive	I-NP	JJ	0	_	_	_	_
28	sequences	sequence	I-NP	NNS	0	_	_	_	_
29	are	be	B-VP	VBP	0	_	_	_	_
30	discussed	discuss	I-VP	VBN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Susceptibilities	Susceptibility	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	540	540	B-NP	CD	0	_	_	_	_
4	anaerobic	anaerobic	I-NP	JJ	0	_	_	_	_
5	gram	gram	I-NP	NN	0	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	negative	negative	I-NP	JJ	0	_	_	_	_
8	bacilli	bacilli	I-NP	NNS	0	_	_	_	_
9	to	to	B-PP	TO	0	_	_	_	_
10	amoxicillin	amoxicillin	B-NP	NN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	amoxicillin	amoxicillin	B-NP	NN	0	_	_	_	_
13	-	-	O	HYPH	0	_	_	_	_
14	BRL	BRL	B-NP	NN	0	_	_	_	_
15	42715	42715	I-NP	CD	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	amoxicillin	amoxicillin	B-NP	NN	0	_	_	_	_
18	-	-	O	HYPH	0	_	_	_	_
19	clavulanate	clavulanate	B-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	temafloxacin	temafloxacin	B-NP	NN	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	and	and	O	CC	0	_	_	_	_
24	clindamycin	clindamycin	B-NP	NN	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Nocodazole	Nocodazole	B-NP	NN	0	_	_	_	_
2	arrest	arrest	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	DU249	DU249	B-NP	NN	0	_	_	_	_
5	cells	cell	I-NP	NNS	0	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	exploited	exploit	I-VP	VBN	0	_	_	_	_
8	for	for	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	detection	detection	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	an	an	B-NP	DT	0	_	_	_	_
13	M	M	I-NP	NN	0	_	_	_	_
14	-	-	B-NP	HYPH	0	_	_	_	_
15	phase	phase	I-NP	NN	0	_	_	_	_
16	-	-	O	HYPH	0	_	_	_	_
17	activated	activate	B-NP	VBN	0	_	_	_	_
18	MBP	MBP	I-NP	NN	:::NOCLASS	_	_	_	_
19	kinase	kinase	I-NP	NN	:::NOCLASS	_	_	_	_
20	that	that	B-NP	WDT	0	_	_	_	_
21	was	be	B-VP	VBD	0	_	_	_	_
22	resolved	resolve	I-VP	VBN	0	_	_	_	_
23	from	from	B-PP	IN	0	_	_	_	_
24	p41	p41	B-NP	NN	:::NOCLASS	_	_	_	_
25	MAP	MAP	I-NP	NN	:::NOCLASS	_	_	_	_
26	kinase	kinase	I-NP	NN	:::NOCLASS	_	_	_	_
27	by	by	B-PP	IN	0	_	_	_	_
28	phenyl	phenyl	B-NP	NN	0	_	_	_	_
29	-	-	I-NP	HYPH	0	_	_	_	_
30	Superose	Superose	I-NP	NN	0	_	_	_	_
31	chromatography	chromatography	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	hit1	hit1	I-NP	NN	:::NOCLASS	_	_	_	_
3	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
4	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
5	mutation	mutation	I-NP	NN	0	_	_	_	_
6	caused	cause	B-VP	VBD	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	defect	defect	I-NP	NN	UMLS:C1861101:T047:DISO	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	synthesis	synthesis	B-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	74	74	I-NP	CD	:::NOCLASS	_	_	_	_
14	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
15	kD	kD	I-NP	NN	:::NOCLASS|UMLS:C1839259:T047:DISO|UMLS:C0026691:T047:DISO	_	_	_	_
16	heat	heat	I-NP	NN	:::NOCLASS	_	_	_	_
17	shock	shock	I-NP	NN	:::NOCLASS	_	_	_	_
18	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	319	319	I-NP	CD	0	_	_	_	_
3	base	base	I-NP	NN	0	_	_	_	_
4	pair	pair	I-NP	NN	0	_	_	_	_
5	region	region	I-NP	NN	0	_	_	_	_
6	immediately	immediately	B-ADVP	RB	0	_	_	_	_
7	upstream	upstream	I-ADVP	RB	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	CAP	CAP	I-NP	NN	UMLS:C1855179:T047:DISO	_	_	_	_
11	site	site	I-NP	NN	0	_	_	_	_
12	is	be	B-VP	VBZ	0	_	_	_	_
13	characterized	characterize	I-VP	VBN	0	_	_	_	_
14	by	by	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	lack	lack	I-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	a	a	B-NP	DT	0	_	_	_	_
19	proximal	proximal	I-NP	JJ	0	_	_	_	_
20	TATA	TATA	I-NP	NN	0	_	_	_	_
21	box	box	I-NP	NN	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	presence	presence	I-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	sequences	sequence	B-NP	NNS	0	_	_	_	_
27	similar	similar	B-ADJP	JJ	0	_	_	_	_
28	to	to	B-PP	TO	0	_	_	_	_
29	GC	GC	B-NP	NN	0	_	_	_	_
30	boxes	box	I-NP	NNS	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	CACCC	CACCC	B-NP	NN	0	_	_	_	_
33	boxes	box	I-NP	NNS	0	_	_	_	_
34	,	,	O	,	0	_	_	_	_
35	CCAAT	CCAAT	B-NP	NN	0	_	_	_	_
36	boxes	box	I-NP	NNS	0	_	_	_	_
37	,	,	O	,	0	_	_	_	_
38	activator	activator	B-NP	NN	:::NOCLASS	_	_	_	_
39	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
40	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
41	(	(	O	(	0	_	_	_	_
42	Ap	Ap	B-NP	NN	:::NOCLASS	_	_	_	_
43	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
44	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
45	)	)	O	)	0	_	_	_	_
46	sites	site	B-NP	NNS	0	_	_	_	_
47	,	,	O	,	0	_	_	_	_
48	partial	partial	B-NP	JJ	0	_	_	_	_
49	glucocorticoid	glucocorticoid	I-NP	NN	0	_	_	_	_
50	response	response	I-NP	NN	0	_	_	_	_
51	elements	element	I-NP	NNS	0	_	_	_	_
52	(	(	O	(	0	_	_	_	_
53	GREs	GRE	B-NP	NNS	0	_	_	_	_
54	)	)	O	)	0	_	_	_	_
55	,	,	O	,	0	_	_	_	_
56	and	and	O	CC	0	_	_	_	_
57	partial	partial	B-NP	JJ	0	_	_	_	_
58	cyclic	cyclic	I-NP	JJ	0	_	_	_	_
59	AMP	AMP	I-NP	NN	0	_	_	_	_
60	response	response	I-NP	NN	0	_	_	_	_
61	elements	element	I-NP	NNS	0	_	_	_	_
62	(	(	O	(	0	_	_	_	_
63	CREs	CRE	B-NP	NNS	0	_	_	_	_
64	)	)	O	)	0	_	_	_	_
65	.	.	O	.	0	_	_	_	_

1	Cloning	Cloning	B-NP	NN	0	_	_	_	_
2	and	and	O	CC	0	_	_	_	_
3	primary	primary	B-NP	JJ	0	_	_	_	_
4	structure	structure	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	neurocan	neurocan	B-NP	NN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	developmentally	developmentally	I-NP	RB	0	_	_	_	_
10	regulated	regulate	I-NP	VBN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	aggregating	aggregate	B-VP	VBG	0	_	_	_	_
13	chondroitin	chondroitin	B-NP	NN	0	_	_	_	_
14	sulfate	sulfate	I-NP	NN	0	_	_	_	_
15	proteoglycan	proteoglycan	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	brain	brain	B-NP	NN	UMLS:C0006104:T023:ANAT	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	rats	rat	B-NP	NNS	0	_	_	_	_
3	anaesthetized	anaesthetize	B-VP	VBN	0	_	_	_	_
4	with	with	B-PP	IN	0	_	_	_	_
5	+	+	O	SYM	0	_	_	_	_
6	-	-	O	HYPH	0	_	_	_	_
7	chloralose	chloralose	B-NP	NN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	changes	change	I-NP	NNS	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	extracellular	extracellular	B-NP	JJ	0	_	_	_	_
12	pH	pH	I-NP	NN	0	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	K+	K+	I-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	spinal	spinal	B-NP	JJ	UMLS:C0037925:T023:ANAT	_	_	_	_
17	cord	cord	I-NP	NN	UMLS:C0037925:T023:ANAT|UMLS:C0035334:T047:DISO	_	_	_	_
18	dorsal	dorsal	I-NP	JJ	UMLS:C0228575:T023:ANAT	_	_	_	_
19	horn	horn	I-NP	NN	UMLS:C0228575:T023:ANAT	_	_	_	_
20	were	be	B-VP	VBD	0	_	_	_	_
21	studied	study	I-VP	VBN	0	_	_	_	_
22	using	use	B-VP	VBG	0	_	_	_	_
23	pH	pH	B-NP	NN	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	K+	K+	B-NP	NN	0	_	_	_	_
26	ion	ion	I-NP	NN	0	_	_	_	_
27	-	-	B-NP	HYPH	0	_	_	_	_
28	selective	selective	I-NP	JJ	0	_	_	_	_
29	electrodes	electrode	I-NP	NNS	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Replication	Replication	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	bovine	bovine	B-NP	JJ	0	_	_	_	_
4	papillomavirus	papillomavirus	I-NP	NN	0	_	_	_	_
5	-	-	B-NP	HYPH	0	_	_	_	_
6	1	1	I-NP	CD	0	_	_	_	_
7	(	(	O	(	0	_	_	_	_
8	BPV	BPV	O	NN	0	_	_	_	_
9	-	-	O	HYPH	0	_	_	_	_
10	1	1	O	CD	0	_	_	_	_
11	)	)	O	)	0	_	_	_	_
12	DNA	DNA	B-NP	NN	0	_	_	_	_
13	requires	require	B-VP	VBZ	0	_	_	_	_
14	two	two	B-NP	CD	0	_	_	_	_
15	viral	viral	I-NP	JJ	0	_	_	_	_
16	gene	gene	I-NP	NN	0	_	_	_	_
17	products	product	I-NP	NNS	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	E1	E1	I-NP	NN	:::NOCLASS	_	_	_	_
21	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	full	full	I-NP	JJ	:::NOCLASS	_	_	_	_
25	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
26	length	length	I-NP	NN	:::NOCLASS	_	_	_	_
27	E2	E2	I-NP	NN	:::NOCLASS	_	_	_	_
28	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	Insertional	Insertional	B-NP	JJ	0	_	_	_	_
2	inactivation	inactivation	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	sms	sm	B-NP	NNS	UMLS:C0795864:T047:DISO|:::NOCLASS	_	_	_	_
5	led	lead	B-VP	VBD	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	increased	increase	B-NP	VBN	0	_	_	_	_
8	sensitivity	sensitivity	I-NP	NN	0	_	_	_	_
9	to	to	B-PP	TO	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	alkylating	alkylate	I-NP	VBG	0	_	_	_	_
12	agent	agent	I-NP	NN	0	_	_	_	_
13	methylmethane	methylmethane	I-NP	NN	0	_	_	_	_
14	sulfonate	sulfonate	I-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	but	but	O	CC	0	_	_	_	_
17	not	not	O	RB	0	_	_	_	_
18	to	to	B-PP	TO	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	requirement	requirement	I-NP	NN	0	_	_	_	_
21	for	for	B-PP	IN	0	_	_	_	_
22	serine	serine	B-NP	NN	0	_	_	_	_
23	or	or	O	CC	0	_	_	_	_
24	other	other	B-NP	JJ	0	_	_	_	_
25	metabolites	metabolite	I-NP	NNS	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	findings	finding	I-NP	NNS	0	_	_	_	_
3	suggest	suggest	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	MAP	MAP	I-NP	NN	:::NOCLASS	_	_	_	_
7	kinase	kinase	I-NP	NN	:::NOCLASS	_	_	_	_
8	activator	activator	I-NP	NN	:::NOCLASS	_	_	_	_
9	/	/	B-NP	SYM	0	_	_	_	_
10	MAP	MAP	I-NP	NN	:::NOCLASS	_	_	_	_
11	kinase	kinase	I-NP	NN	:::NOCLASS	_	_	_	_
12	system	system	I-NP	NN	0	_	_	_	_
13	may	may	B-VP	MD	0	_	_	_	_
14	be	be	I-VP	VB	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	downstream	downstream	I-NP	JJ	0	_	_	_	_
17	components	component	I-NP	NNS	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	ras	ras	B-NP	NN	:::NOCLASS	_	_	_	_
20	signal	signal	I-NP	NN	0	_	_	_	_
21	transduction	transduction	I-NP	NN	0	_	_	_	_
22	pathways	pathway	I-NP	NNS	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	NSCL	NSCL	B-NP	NN	:::NOCLASS	_	_	_	_
2	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
3	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
4	is	be	B-VP	VBZ	0	_	_	_	_
5	expressed	express	I-VP	VBN	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	larger	large	I-NP	JJR	0	_	_	_	_
9	number	number	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	these	these	B-NP	DT	0	_	_	_	_
12	cell	cell	I-NP	NN	0	_	_	_	_
13	lines	line	I-NP	NNS	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Labile	Labile	B-NP	JJ	0	_	_	_	_
2	LTR	LTR	I-NP	NN	:::NOCLASS	_	_	_	_
3	-	-	B-VP	HYPH	:::NOCLASS	_	_	_	_
4	binding	bind	B-NP	VBG	:::NOCLASS	_	_	_	_
5	proteins	protein	I-NP	NNS	:::NOCLASS	_	_	_	_
6	appear	appear	B-VP	VBP	0	_	_	_	_
7	to	to	I-VP	TO	0	_	_	_	_
8	be	be	I-VP	VB	0	_	_	_	_
9	essential	essential	B-ADJP	JJ	0	_	_	_	_
10	for	for	B-PP	IN	0	_	_	_	_
11	c	c	B-NP	NN	:::NOCLASS	_	_	_	_
12	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
13	myc	myc	I-NP	NN	:::NOCLASS	_	_	_	_
14	hyperexpression	hyperexpression	I-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	since	since	B-SBAR	IN	0	_	_	_	_
17	both	both	O	CC	0	_	_	_	_
18	LTR	LTR	B-NP	NN	0	_	_	_	_
19	-	-	O	HYPH	0	_	_	_	_
20	enhanced	enhance	B-VP	VBN	0	_	_	_	_
21	transcription	transcription	B-NP	NN	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	activities	activity	I-NP	NNS	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	LTR	LTR	B-NP	NN	:::NOCLASS	_	_	_	_
27	-	-	O	HYPH	:::NOCLASS	_	_	_	_
28	binding	bind	B-NP	VBG	:::NOCLASS	_	_	_	_
29	proteins	protein	I-NP	NNS	:::NOCLASS	_	_	_	_
30	are	be	B-VP	VBP	0	_	_	_	_
31	specifically	specifically	I-VP	RB	0	_	_	_	_
32	decreased	decrease	I-VP	VBN	0	_	_	_	_
33	after	after	B-PP	IN	0	_	_	_	_
34	inhibition	inhibition	B-NP	NN	0	_	_	_	_
35	of	of	B-PP	IN	0	_	_	_	_
36	protein	protein	B-NP	NN	0	_	_	_	_
37	synthesis	synthesis	I-NP	NN	0	_	_	_	_
38	(	(	O	(	0	_	_	_	_
39	A	A	B-NP	NN	0	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	Ruddell	Ruddell	B-NP	NNP	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	M	M	B-NP	NNP	0	_	_	_	_
4	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	single	single	I-NP	JJ	0	_	_	_	_
3	MEF	MEF	I-NP	NN	:::NOCLASS	_	_	_	_
4	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
5	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
6	site	site	I-NP	NN	:::NOCLASS	_	_	_	_
7	is	be	B-VP	VBZ	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	major	major	I-NP	JJ	0	_	_	_	_
10	positive	positive	I-NP	JJ	0	_	_	_	_
11	regulatory	regulatory	I-NP	JJ	0	_	_	_	_
12	element	element	I-NP	NN	0	_	_	_	_
13	required	require	B-VP	VBN	0	_	_	_	_
14	for	for	B-PP	IN	0	_	_	_	_
15	transcription	transcription	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	muscle	muscle	I-NP	NN	0	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	specific	specific	I-NP	JJ	0	_	_	_	_
21	subunit	subunit	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	human	human	I-NP	JJ	:::NOCLASS	_	_	_	_
25	phosphoglycerate	phosphoglycerate	I-NP	JJ	:::NOCLASS	_	_	_	_
26	mutase	mutase	I-NP	NN	:::NOCLASS	_	_	_	_
27	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
28	in	in	B-PP	IN	0	_	_	_	_
29	skeletal	skeletal	B-NP	JJ	0	_	_	_	_
30	and	and	I-NP	CC	0	_	_	_	_
31	cardiac	cardiac	I-NP	JJ	UMLS:C0018787:T023:ANAT	_	_	_	_
32	muscle	muscle	I-NP	NN	0	_	_	_	_
33	cells	cell	I-NP	NNS	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Truncation	Truncation	B-NP	NN	0	_	_	_	_
2	variants	variant	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	peptides	peptide	B-NP	NNS	0	_	_	_	_
5	isolated	isolate	B-VP	VBN	0	_	_	_	_
6	from	from	B-PP	IN	0	_	_	_	_
7	MHC	MHC	B-NP	NN	:::NOCLASS	_	_	_	_
8	class	class	I-NP	NN	:::NOCLASS	_	_	_	_
9	II	II	B-NP	CD	:::NOCLASS	_	_	_	_
10	molecules	molecule	I-NP	NNS	:::NOCLASS	_	_	_	_
11	suggest	suggest	B-VP	VBP	0	_	_	_	_
12	sequence	sequence	B-NP	NN	0	_	_	_	_
13	motifs	motif	I-NP	NNS	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Although	Although	B-SBAR	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	E	E	I-NP	NN	0	_	_	_	_
4	-	-	B-NP	HYPH	0	_	_	_	_
5	box	box	I-NP	NN	0	_	_	_	_
6	consensus	consensus	I-NP	NN	0	_	_	_	_
7	is	be	B-VP	VBZ	0	_	_	_	_
8	minimally	minimally	I-VP	RB	0	_	_	_	_
9	defined	define	I-VP	VBN	0	_	_	_	_
10	as	as	B-PP	IN	0	_	_	_	_
11	CANNTG	CANNTG	B-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	adjacent	adjacent	I-NP	JJ	0	_	_	_	_
15	nucleotides	nucleotide	I-NP	NNS	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	functional	functional	B-NP	JJ	0	_	_	_	_
18	E	E	I-NP	NN	0	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	boxes	box	I-NP	NNS	0	_	_	_	_
21	are	be	B-VP	VBP	0	_	_	_	_
22	variable	variable	B-ADJP	JJ	0	_	_	_	_
23	for	for	B-PP	IN	0	_	_	_	_
24	genes	gene	B-NP	NNS	0	_	_	_	_
25	regulated	regulate	B-VP	VBN	0	_	_	_	_
26	by	by	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	bHLH	bHLH	I-NP	JJ	:::NOCLASS	_	_	_	_
29	proteins	protein	I-NP	NNS	:::NOCLASS	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Intermediate	Intermediate	B-NP	JJ	0	_	_	_	_
2	levels	level	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	gene	gene	B-NP	NN	0	_	_	_	_
5	activity	activity	I-NP	NN	0	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	observed	observe	I-VP	VBN	0	_	_	_	_
8	for	for	B-PP	IN	0	_	_	_	_
9	TnI	TnI	B-NP	NN	:::NOCLASS	_	_	_	_
10	enhancers	enhancer	I-NP	NNS	:::NOCLASS	_	_	_	_
11	containing	contain	B-VP	VBG	0	_	_	_	_
12	E	E	B-NP	NN	0	_	_	_	_
13	-	-	O	HYPH	0	_	_	_	_
14	boxes	box	B-NP	NNS	0	_	_	_	_
15	derived	derive	B-VP	VBN	0	_	_	_	_
16	from	from	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	MCK	MCK	I-NP	NN	:::NOCLASS	_	_	_	_
19	left	leave	B-VP	VBD	:::NOCLASS	_	_	_	_
20	E	E	B-NP	NN	:::NOCLASS	_	_	_	_
21	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
22	box	box	I-NP	NN	:::NOCLASS	_	_	_	_
23	site	site	I-NP	NN	:::NOCLASS	_	_	_	_
24	or	or	B-PP	CC	0	_	_	_	_
25	from	from	B-PP	IN	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	Ig	Ig	I-NP	NN	:::NOCLASS	_	_	_	_
28	kappa	kappa	I-NP	NN	:::NOCLASS	_	_	_	_
29	E2	E2	I-NP	NN	:::NOCLASS	_	_	_	_
30	E	E	I-NP	NN	:::NOCLASS	_	_	_	_
31	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
32	box	box	I-NP	NN	:::NOCLASS	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	T	T	B-NP	NN	:::NOCLASS	_	_	_	_
2	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
3	cell	cell	I-NP	NN	:::NOCLASS	_	_	_	_
4	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
5	beta	beta	I-NP	NN	:::NOCLASS	_	_	_	_
6	(	(	O	(	0	_	_	_	_
7	TCR	TCR	B-NP	NN	:::NOCLASS	_	_	_	_
8	beta	beta	I-NP	NN	:::NOCLASS	_	_	_	_
9	)	)	O	)	0	_	_	_	_
10	gene	gene	B-NP	NN	0	_	_	_	_
11	rearrangements	rearrangement	I-NP	NNS	0	_	_	_	_
12	occur	occur	B-VP	VBP	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	third	third	I-NP	JJ	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	early	early	B-NP	JJ	0	_	_	_	_
18	B	B	I-NP	NN	0	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	cell	cell	I-NP	NN	0	_	_	_	_
21	acute	acute	I-NP	JJ	0	_	_	_	_
22	lymphoblastic	lymphoblastic	I-NP	JJ	0	_	_	_	_
23	leukemias	leukemia	I-NP	NNS	0	_	_	_	_
24	(	(	O	(	0	_	_	_	_
25	ALLs	ALL	B-NP	NNS	0	_	_	_	_
26	)	)	O	)	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	CANNTG	CANNTG	I-NP	NN	0	_	_	_	_
3	motifs	motif	I-NP	NNS	0	_	_	_	_
4	were	be	B-VP	VBD	0	_	_	_	_
5	found	find	I-VP	VBN	0	_	_	_	_
6	to	to	I-VP	TO	0	_	_	_	_
7	bind	bind	I-VP	VB	0	_	_	_	_
8	MyoD	MyoD	B-NP	NN	:::NOCLASS	_	_	_	_
9	and	and	I-NP	CC	0	_	_	_	_
10	myogenin	myogenin	I-NP	NN	:::NOCLASS	_	_	_	_
11	fusion	fusion	I-NP	NN	:::NOCLASS	_	_	_	_
12	proteins	protein	I-NP	NNS	:::NOCLASS	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	to	to	B-VP	TO	0	_	_	_	_
15	interact	interact	I-VP	VB	0	_	_	_	_
16	with	with	B-PP	IN	0	_	_	_	_
17	proteins	protein	B-NP	NNS	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	nuclear	nuclear	B-NP	JJ	0	_	_	_	_
20	extracts	extract	I-NP	NNS	0	_	_	_	_
21	from	from	B-PP	IN	0	_	_	_	_
22	cultured	culture	B-NP	VBN	0	_	_	_	_
23	myotubes	myotube	I-NP	NNS	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Peripheral	Peripheral	B-NP	JJ	0	_	_	_	_
2	polyneuropathy	polyneuropathy	I-NP	NN	UMLS:C0152025:T047:DISO	_	_	_	_
3	associated	associate	B-VP	VBN	0	_	_	_	_
4	with	with	B-PP	IN	0	_	_	_	_
5	multiple	multiple	B-NP	JJ	0	_	_	_	_
6	myeloma	myeloma	I-NP	NN	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	have	have	B-VP	VBP	0	_	_	_	_
3	cloned	clone	I-VP	VBN	0	_	_	_	_
4	and	and	I-VP	CC	0	_	_	_	_
5	sequenced	sequence	I-VP	VBN	0	_	_	_	_
6	COX12	COX12	B-NP	NN	:::NOCLASS	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	nuclear	nuclear	I-NP	JJ	0	_	_	_	_
10	gene	gene	I-NP	NN	0	_	_	_	_
11	for	for	B-PP	IN	0	_	_	_	_
12	subunit	subunit	B-NP	NN	:::NOCLASS	_	_	_	_
13	VIb	VIb	I-NP	NN	:::NOCLASS	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	Saccharomyces	Saccharomyces	B-NP	NNP	:::NOCLASS	_	_	_	_
16	cerevisiae	cerevisiae	I-NP	NNP	:::NOCLASS	_	_	_	_
17	cytochrome	cytochrome	I-NP	NN	:::NOCLASS	_	_	_	_
18	c	c	I-NP	NN	:::NOCLASS	_	_	_	_
19	oxidase	oxidase	I-NP	NN	:::NOCLASS	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	structure	structure	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	calcineurin	calcineurin	I-NP	NN	:::NOCLASS	_	_	_	_
6	A	A	I-NP	NN	:::NOCLASS	_	_	_	_
7	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
8	was	be	B-VP	VBD	0	_	_	_	_
9	determined	determine	I-VP	VBN	0	_	_	_	_
10	by	by	B-PP	IN	0	_	_	_	_
11	comparison	comparison	B-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	genomic	genomic	I-NP	JJ	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	cDNA	cDNA	I-NP	NN	0	_	_	_	_
17	sequences	sequence	I-NP	NNS	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	basal	basal	I-NP	JJ	0	_	_	_	_
3	promoter	promoter	I-NP	NN	0	_	_	_	_
4	elements	element	I-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	murine	murine	B-NP	JJ	:::NOCLASS	_	_	_	_
7	cytochrome	cytochrome	I-NP	NN	:::NOCLASS	_	_	_	_
8	c	c	I-NP	NN	:::NOCLASS	_	_	_	_
9	oxidase	oxidase	I-NP	NN	:::NOCLASS	_	_	_	_
10	subunit	subunit	I-NP	NN	:::NOCLASS	_	_	_	_
11	IV	IV	I-NP	CD	:::NOCLASS	_	_	_	_
12	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
13	consist	consist	B-VP	VBP	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	tandemly	tandemly	B-NP	RB	0	_	_	_	_
16	duplicated	duplicate	I-NP	VBN	0	_	_	_	_
17	ets	ets	I-NP	NN	:::NOCLASS	_	_	_	_
18	motifs	motif	I-NP	NNS	0	_	_	_	_
19	that	that	B-NP	WDT	0	_	_	_	_
20	bind	bind	B-VP	VBP	0	_	_	_	_
21	to	to	B-PP	TO	0	_	_	_	_
22	GABP	GABP	B-NP	NN	:::NOCLASS	_	_	_	_
23	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
24	related	relate	B-NP	VBN	:::NOCLASS	_	_	_	_
25	transcription	transcription	I-NP	NN	:::NOCLASS	_	_	_	_
26	factors	factor	I-NP	NNS	:::NOCLASS	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Lastly	Lastly	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	there	there	B-NP	EX	0	_	_	_	_
4	are	be	B-VP	VBP	0	_	_	_	_
5	multiple	multiple	B-NP	JJ	0	_	_	_	_
6	instances	instance	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	which	which	B-NP	WDT	0	_	_	_	_
9	short	short	B-NP	JJ	0	_	_	_	_
10	oligonucleotide	oligonucleotide	I-NP	NN	0	_	_	_	_
11	direct	direct	I-NP	JJ	0	_	_	_	_
12	repeats	repeat	I-NP	NNS	0	_	_	_	_
13	flank	flank	B-VP	VBP	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	region	region	I-NP	NN	0	_	_	_	_
16	absent	absent	B-ADJP	JJ	0	_	_	_	_
17	from	from	B-PP	IN	0	_	_	_	_
18	either	either	O	CC	0	_	_	_	_
19	variola	variola	B-NP	NN	UMLS:C0037354:T047:DISO	_	_	_	_
20	or	or	O	CC	0	_	_	_	_
21	vaccinia	vaccinia	B-NP	NN	UMLS:C0042214:T047:DISO	_	_	_	_
22	virus	virus	I-NP	NN	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	Here	Here	B-ADVP	RB	0	_	_	_	_
2	we	we	B-NP	PRP	0	_	_	_	_
3	show	show	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	short	short	B-NP	JJ	0	_	_	_	_
6	synthetic	synthetic	I-NP	JJ	0	_	_	_	_
7	peptides	peptide	I-NP	NNS	0	_	_	_	_
8	containing	contain	B-VP	VBG	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	pRB	pRB	I-NP	NN	:::NOCLASS	_	_	_	_
11	-	-	O	HYPH	:::NOCLASS	_	_	_	_
12	binding	bind	B-VP	VBG	:::NOCLASS	_	_	_	_
13	sequences	sequence	B-NP	NNS	:::NOCLASS	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	E1A	E1A	B-NP	NN	:::NOCLASS	_	_	_	_
16	are	be	B-VP	VBP	0	_	_	_	_
17	sufficient	sufficient	B-ADJP	JJ	0	_	_	_	_
18	for	for	B-PP	IN	0	_	_	_	_
19	interaction	interaction	B-NP	NN	0	_	_	_	_
20	with	with	B-PP	IN	0	_	_	_	_
21	p107	p107	B-NP	NN	:::NOCLASS	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	cyclin	cyclin	B-NP	NN	:::NOCLASS	_	_	_	_
24	A	A	I-NP	NN	:::NOCLASS	_	_	_	_
25	,	,	O	,	0	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	p130	p130	B-NP	NN	:::NOCLASS	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	mutants	mutant	I-NP	NNS	0	_	_	_	_
3	grow	grow	B-VP	VBP	0	_	_	_	_
4	normally	normally	B-ADVP	RB	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	3T6	3T6	B-NP	NN	0	_	_	_	_
7	mouse	mouse	I-NP	NN	0	_	_	_	_
8	fibroblast	fibroblast	I-NP	NN	0	_	_	_	_
9	cells	cell	I-NP	NNS	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	they	they	B-NP	PRP	0	_	_	_	_
13	do	do	B-VP	VBP	0	_	_	_	_
14	not	not	I-VP	RB	0	_	_	_	_
15	complement	complement	I-VP	VB	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	wild	wild	I-NP	JJ	0	_	_	_	_
18	-	-	I-NP	HYPH	0	_	_	_	_
19	type	type	I-NP	NN	0	_	_	_	_
20	virus	virus	I-NP	NN	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	coinfection	coinfection	B-NP	NN	UMLS:C0275524:T047:DISO	_	_	_	_
23	experiments	experiment	I-NP	NNS	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	C2	C2	B-NP	NN	0	_	_	_	_
26	myoblasts	myoblast	I-NP	NNS	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	MICs	MIC	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	this	this	B-NP	DT	0	_	_	_	_
5	compound	compound	I-NP	NN	0	_	_	_	_
6	against	against	B-PP	IN	0	_	_	_	_
7	90	90	B-NP	CD	0	_	_	_	_
8	%	%	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	these	these	B-NP	DT	0	_	_	_	_
11	organisms	organism	I-NP	NNS	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	except	except	B-PP	IN	0	_	_	_	_
14	for	for	B-PP	IN	0	_	_	_	_
15	methicillin	methicillin	B-NP	NN	0	_	_	_	_
16	-	-	B-NP	HYPH	0	_	_	_	_
17	resistant	resistant	I-NP	JJ	0	_	_	_	_
18	S	S	I-NP	NN	0	_	_	_	_
19	.	.	I-NP	.	0	_	_	_	_
20	aureus	aureus	I-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	ranged	range	B-VP	VBD	0	_	_	_	_
23	from	from	B-PP	IN	0	_	_	_	_
24	less	less	B-NP	JJR	0	_	_	_	_
25	than	than	B-PP	IN	0	_	_	_	_
26	or	or	O	CC	0	_	_	_	_
27	equal	equal	B-ADJP	JJ	0	_	_	_	_
28	to	to	B-PP	TO	0	_	_	_	_
29	0	0	B-NP	CD	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_
31	006	006	B-NP	CD	0	_	_	_	_
32	to	to	B-PP	TO	0	_	_	_	_
33	3	3	B-NP	CD	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_
35	13	13	B-NP	CD	0	_	_	_	_
36	micrograms	microgram	I-NP	NNS	0	_	_	_	_
37	/	/	B-NP	SYM	0	_	_	_	_
38	ml	ml	I-NP	NN	0	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	minimal	minimal	I-NP	JJ	0	_	_	_	_
3	promoter	promoter	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	RII	RII	I-NP	NN	:::NOCLASS	_	_	_	_
7	beta	beta	I-NP	NN	:::NOCLASS	_	_	_	_
8	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	composed	compose	I-VP	VBN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	two	two	B-NP	CD	0	_	_	_	_
13	adjacent	adjacent	I-NP	JJ	0	_	_	_	_
14	functional	functional	I-NP	JJ	0	_	_	_	_
15	elements	element	I-NP	NNS	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Mapping	Map	B-VP	VBG	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	cAMP	cAMP	I-NP	NN	:::NOCLASS	_	_	_	_
4	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
5	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
6	contact	contact	I-NP	NN	:::NOCLASS	_	_	_	_
7	site	site	I-NP	NN	:::NOCLASS	_	_	_	_
8	on	on	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	alpha	alpha	I-NP	NN	0	_	_	_	_
11	subunit	subunit	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	Escherichia	Escherichia	B-NP	FW	:::NOCLASS	_	_	_	_
14	coli	coli	I-NP	FW	:::NOCLASS	_	_	_	_
15	RNA	RNA	I-NP	NN	:::NOCLASS	_	_	_	_
16	polymerase	polymerase	I-NP	NN	:::NOCLASS	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Here	Here	B-ADVP	RB	0	_	_	_	_
2	we	we	B-NP	PRP	0	_	_	_	_
3	show	show	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	epidermal	epidermal	B-NP	JJ	:::NOCLASS	_	_	_	_
6	growth	growth	I-NP	NN	:::NOCLASS	_	_	_	_
7	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
8	or	or	I-NP	CC	0	_	_	_	_
9	platelet	platelet	I-NP	NN	:::NOCLASS	_	_	_	_
10	-	-	O	HYPH	:::NOCLASS	_	_	_	_
11	derived	derive	B-NP	VBN	:::NOCLASS	_	_	_	_
12	growth	growth	I-NP	NN	:::NOCLASS	_	_	_	_
13	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
14	stimulation	stimulation	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	intact	intact	B-NP	JJ	0	_	_	_	_
17	human	human	I-NP	JJ	0	_	_	_	_
18	or	or	I-NP	CC	0	_	_	_	_
19	murine	murine	I-NP	JJ	0	_	_	_	_
20	cells	cell	I-NP	NNS	0	_	_	_	_
21	leads	lead	B-VP	VBZ	0	_	_	_	_
22	to	to	B-PP	TO	0	_	_	_	_
23	phosphorylation	phosphorylation	B-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	Nck	Nck	B-NP	NN	:::NOCLASS	_	_	_	_
26	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
27	on	on	B-PP	IN	0	_	_	_	_
28	tyrosine	tyrosine	B-NP	NN	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	serine	serine	B-NP	NN	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	and	and	O	CC	0	_	_	_	_
33	threonine	threonine	B-NP	NN	0	_	_	_	_
34	residues	residue	I-NP	NNS	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	major	major	I-NP	JJ	0	_	_	_	_
3	mechanism	mechanism	I-NP	NN	0	_	_	_	_
4	whereby	whereby	B-ADVP	WRB	0	_	_	_	_
5	steroid	steroid	B-NP	NN	:::NOCLASS	_	_	_	_
6	hydroxylase	hydroxylase	I-NP	NN	:::NOCLASS	_	_	_	_
7	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
8	transcription	transcription	I-NP	NN	0	_	_	_	_
9	is	be	B-VP	VBZ	0	_	_	_	_
10	regulated	regulate	I-VP	VBN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	adrenal	adrenal	I-NP	JJ	UMLS:C0001613:T023:ANAT	_	_	_	_
14	cortex	cortex	I-NP	NN	UMLS:C0001613:T023:ANAT	_	_	_	_
15	requires	require	B-VP	VBZ	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	pituitary	pituitary	I-NP	JJ	UMLS:C0032005:T023:ANAT	_	_	_	_
18	peptide	peptide	I-NP	NN	0	_	_	_	_
19	hormone	hormone	I-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	ACTH	ACTH	B-NP	NN	:::NOCLASS	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	which	which	B-NP	WDT	0	_	_	_	_
24	acts	act	B-VP	VBZ	0	_	_	_	_
25	via	via	B-PP	IN	0	_	_	_	_
26	cAMP	cAMP	B-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	combination	combination	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	comparative	comparative	B-NP	JJ	0	_	_	_	_
5	sequence	sequence	I-NP	NN	0	_	_	_	_
6	analysis	analysis	I-NP	NN	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	thermodynamic	thermodynamic	B-NP	JJ	0	_	_	_	_
9	methods	method	I-NP	NNS	0	_	_	_	_
10	reveals	reveal	B-VP	VBZ	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	conservation	conservation	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	tertiary	tertiary	B-NP	JJ	0	_	_	_	_
15	structure	structure	I-NP	NN	0	_	_	_	_
16	elements	element	I-NP	NNS	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	5	5	I-NP	CD	0	_	_	_	_
20	'	'	I-NP	SYM	0	_	_	_	_
21	untranslated	untranslated	I-NP	JJ	0	_	_	_	_
22	region	region	I-NP	NN	0	_	_	_	_
23	(	(	O	(	0	_	_	_	_
24	UTR	UTR	B-NP	NN	0	_	_	_	_
25	)	)	O	)	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	human	human	B-NP	JJ	0	_	_	_	_
28	enteroviruses	enterovirus	I-NP	NNS	0	_	_	_	_
29	and	and	I-NP	CC	0	_	_	_	_
30	rhinoviruses	rhinovirus	I-NP	NNS	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	-	-	I-NP	SYM	0	_	_	_	_
3	64	64	I-NP	CD	0	_	_	_	_
4	/	/	I-NP	SYM	0	_	_	_	_
5	-	-	I-NP	SYM	0	_	_	_	_
6	37	37	B-NP	CD	0	_	_	_	_
7	region	region	I-NP	NN	0	_	_	_	_
8	interacted	interact	B-VP	VBD	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	purified	purify	B-NP	VBN	0	_	_	_	_
11	Sp1	Sp1	I-NP	NN	:::NOCLASS	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	an	an	B-NP	DT	0	_	_	_	_
14	unidentified	unidentified	I-NP	JJ	0	_	_	_	_
15	protein	protein	I-NP	NN	0	_	_	_	_
16	(	(	I-NP	(	0	_	_	_	_
17	s	s	I-NP	NNS	0	_	_	_	_
18	)	)	O	)	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	proximal	proximal	B-NP	JJ	:::NOCLASS	_	_	_	_
21	regulatory	regulatory	I-NP	JJ	:::NOCLASS	_	_	_	_
22	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
23	(	(	I-NP	(	:::NOCLASS	_	_	_	_
24	s	s	I-NP	NNS	:::NOCLASS	_	_	_	_
25	)	)	O	)	:::NOCLASS	_	_	_	_
26	I	I	B-NP	NN	:::NOCLASS	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	PRF	PRF	B-NP	NN	:::NOCLASS	_	_	_	_
29	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
30	I	I	I-NP	NN	:::NOCLASS	_	_	_	_
31	)	)	O	)	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Km	Km	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	Vmax	Vmax	I-NP	NN	0	_	_	_	_
4	for	for	B-PP	IN	0	_	_	_	_
5	two	two	B-NP	CD	0	_	_	_	_
6	substrates	substrate	I-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	src	src	B-NP	NN	:::NOCLASS	_	_	_	_
9	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
10	related	relate	I-NP	VBN	:::NOCLASS	_	_	_	_
11	peptide	peptide	I-NP	NN	:::NOCLASS	_	_	_	_
12	and	and	I-NP	CC	0	_	_	_	_
13	poly	poly	I-NP	NN	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	Glu	Glu	B-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	Tyr	Tyr	B-NP	NN	0	_	_	_	_
18	)	)	O	)	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	4	4	B-NP	CD	0	_	_	_	_
21	:	:	O	:	0	_	_	_	_
22	1	1	B-NP	CD	0	_	_	_	_
23	)	)	O	)	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	were	be	B-VP	VBD	0	_	_	_	_
26	2	2	B-NP	CD	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_
28	4	4	B-NP	CD	0	_	_	_	_
29	mM	mM	I-NP	NN	0	_	_	_	_
30	and	and	O	CC	0	_	_	_	_
31	2	2	B-NP	CD	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_
33	5	5	B-NP	CD	0	_	_	_	_
34	mumol	mumol	I-NP	NN	0	_	_	_	_
35	min	min	I-NP	NN	0	_	_	_	_
36	-	-	O	HYPH	0	_	_	_	_
37	1	1	B-NP	CD	0	_	_	_	_
38	mg	mg	I-NP	NN	0	_	_	_	_
39	-	-	B-NP	HYPH	0	_	_	_	_
40	1	1	I-NP	CD	0	_	_	_	_
41	and	and	I-NP	CC	0	_	_	_	_
42	0	0	I-NP	CD	0	_	_	_	_
43	.	.	O	.	0	_	_	_	_
44	26	26	B-NP	CD	0	_	_	_	_
45	mM	mM	I-NP	NN	0	_	_	_	_
46	and	and	O	CC	0	_	_	_	_
47	1	1	B-NP	CD	0	_	_	_	_
48	.	.	O	.	0	_	_	_	_
49	2	2	B-NP	CD	0	_	_	_	_
50	mumol	mumol	I-NP	NN	0	_	_	_	_
51	min	min	I-NP	NN	0	_	_	_	_
52	-	-	O	HYPH	0	_	_	_	_
53	1	1	B-NP	CD	0	_	_	_	_
54	mg	mg	I-NP	NN	0	_	_	_	_
55	-	-	B-NP	HYPH	0	_	_	_	_
56	1	1	I-NP	CD	0	_	_	_	_
57	,	,	O	,	0	_	_	_	_
58	respectively	respectively	B-ADVP	RB	0	_	_	_	_
59	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	soluble	soluble	I-NP	JJ	:::NOCLASS	_	_	_	_
3	form	form	I-NP	NN	:::NOCLASS	_	_	_	_
4	of	of	B-PP	IN	:::NOCLASS	_	_	_	_
5	the	the	B-NP	DT	:::NOCLASS	_	_	_	_
6	HGFr	HGFr	I-NP	NN	:::NOCLASS	_	_	_	_
7	(	(	O	(	0	_	_	_	_
8	sHGFr	sHGFr	B-NP	NN	:::NOCLASS	_	_	_	_
9	)	)	O	)	0	_	_	_	_
10	bound	bind	B-VP	VBD	0	_	_	_	_
11	HGF	HGF	B-NP	NN	UMLS:C0399440:T047:DISO|:::NOCLASS	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	an	an	B-NP	DT	0	_	_	_	_
14	affinity	affinity	I-NP	NN	0	_	_	_	_
15	similar	similar	B-ADJP	JJ	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	that	that	B-NP	DT	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	authentic	authentic	I-NP	JJ	0	_	_	_	_
21	,	,	I-NP	,	0	_	_	_	_
22	membrane	membrane	I-NP	NN	0	_	_	_	_
23	-	-	I-NP	HYPH	0	_	_	_	_
24	associated	associate	I-NP	VBN	0	_	_	_	_
25	receptor	receptor	I-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	Strategies	Strategy	B-NP	NNS	0	_	_	_	_
2	for	for	B-PP	IN	0	_	_	_	_
3	blood	blood	B-NP	NN	0	_	_	_	_
4	screening	screening	I-NP	NN	0	_	_	_	_
5	for	for	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	hepatitis	hepatitis	I-NP	NN	UMLS:C0019196:T047:DISO	_	_	_	_
8	C	C	I-NP	NN	UMLS:C0019196:T047:DISO	_	_	_	_
9	virus	virus	I-NP	NN	0	_	_	_	_
10	and	and	B-PP	CC	0	_	_	_	_
11	for	for	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	human	human	I-NP	JJ	UMLS:C0019693:T047:DISO	_	_	_	_
14	immunodeficiency	immunodeficiency	I-NP	NN	UMLS:C0019693:T047:DISO	_	_	_	_
15	virus	virus	I-NP	NN	UMLS:C0019693:T047:DISO	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	high	high	B-NP	JJ	0	_	_	_	_
18	risk	risk	I-NP	NN	0	_	_	_	_
19	groups	group	I-NP	NNS	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Also	Also	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	human	human	I-NP	JJ	:::NOCLASS	_	_	_	_
5	glycoprotein	glycoprotein	I-NP	NN	:::NOCLASS	_	_	_	_
6	alpha	alpha	B-NP	SYM	:::NOCLASS	_	_	_	_
7	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
8	subunit	subunit	I-NP	NN	:::NOCLASS	_	_	_	_
9	promoter	promoter	I-NP	NN	:::NOCLASS	_	_	_	_
10	was	be	B-VP	VBD	0	_	_	_	_
11	induced	induce	I-VP	VBN	0	_	_	_	_
12	10	10	B-NP	CD	0	_	_	_	_
13	-	-	O	HYPH	0	_	_	_	_
14	fold	fold	B-ADVP	RB	0	_	_	_	_
15	by	by	B-PP	IN	0	_	_	_	_
16	FSK	FSK	B-NP	NN	:::NOCLASS	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	GH4	GH4	B-NP	NN	0	_	_	_	_
19	rat	rat	I-NP	NN	UMLS:C1882827:T023:ANAT	_	_	_	_
20	pituitary	pituitary	I-NP	JJ	UMLS:C1882827:T023:ANAT	_	_	_	_
21	cells	cell	I-NP	NNS	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_
23	(	(	O	(	0	_	_	_	_
24	ABSTRACT	ABSTRACT	B-NP	NN	0	_	_	_	_
25	TRUNCATED	TRUNCATED	B-VP	VBN	0	_	_	_	_
26	AT	AT	B-PP	IN	0	_	_	_	_
27	400	400	B-NP	CD	0	_	_	_	_
28	WORDS	WORDS	I-NP	NNS	0	_	_	_	_
29	)	)	O	)	0	_	_	_	_

1	Comparison	Comparison	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	data	datum	B-NP	NNS	0	_	_	_	_
4	obtained	obtain	B-VP	VBN	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	results	result	I-NP	NNS	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	chronic	chronic	B-NP	JJ	0	_	_	_	_
10	treatment	treatment	I-NP	NN	0	_	_	_	_
11	with	with	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	opioid	opioid	I-NP	JJ	0	_	_	_	_
14	antagonist	antagonist	I-NP	NN	0	_	_	_	_
15	permits	permit	B-VP	VBZ	0	_	_	_	_
16	to	to	I-VP	TO	0	_	_	_	_
17	conclude	conclude	I-VP	VB	0	_	_	_	_
18	that	that	B-SBAR	IN	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	chronic	chronic	I-NP	JJ	0	_	_	_	_
21	blockade	blockade	I-NP	NN	0	_	_	_	_
22	increases	increase	B-VP	VBZ	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	fatiguability	fatiguability	I-NP	NN	0	_	_	_	_
25	to	to	B-PP	TO	0	_	_	_	_
26	a	a	B-NP	DT	0	_	_	_	_
27	great	great	I-NP	JJ	0	_	_	_	_
28	extent	extent	I-NP	NN	0	_	_	_	_
29	than	than	B-PP	IN	0	_	_	_	_
30	chronic	chronic	B-NP	JJ	0	_	_	_	_
31	activation	activation	I-NP	NN	0	_	_	_	_
32	of	of	B-PP	IN	0	_	_	_	_
33	opioid	opioid	B-NP	JJ	0	_	_	_	_
34	system	system	I-NP	NN	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	Laboratory	Laboratory	B-NP	NN	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	using	use	B-VP	VBG	0	_	_	_	_
4	Ca45	Ca45	B-NP	NN	0	_	_	_	_
5	labeled	label	I-NP	VBN	0	_	_	_	_
6	teeth	tooth	I-NP	NNS	UMLS:C0040426:T023:ANAT	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	biologically	biologically	B-NP	RB	0	_	_	_	_
9	stained	stain	I-NP	VBN	0	_	_	_	_
10	teeth	tooth	I-NP	NNS	UMLS:C0040426:T023:ANAT	_	_	_	_
11	confirmed	confirm	B-VP	VBD	0	_	_	_	_
12	that	that	B-SBAR	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	dentifrice	dentifrice	I-NP	NN	0	_	_	_	_
15	did	do	B-VP	VBD	0	_	_	_	_
16	not	not	I-VP	RB	0	_	_	_	_
17	decalcify	decalcify	I-VP	VB	0	_	_	_	_
18	enamel	enamel	B-NP	NN	0	_	_	_	_
19	or	or	O	CC	0	_	_	_	_
20	bleach	bleach	B-NP	JJ	0	_	_	_	_
21	teeth	tooth	I-NP	NNS	UMLS:C0040426:T023:ANAT	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Structure	Structure	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	expression	expression	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	gene	gene	I-NP	NN	0	_	_	_	_
7	from	from	B-PP	IN	0	_	_	_	_
8	Arabidopsis	Arabidopsis	B-NP	NNP	0	_	_	_	_
9	thaliana	thaliana	B-ADVP	IN	0	_	_	_	_
10	encoding	encode	B-VP	VBG	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	protein	protein	I-NP	NN	0	_	_	_	_
13	related	relate	B-VP	VBN	0	_	_	_	_
14	to	to	B-PP	TO	0	_	_	_	_
15	SNF1	SNF1	B-NP	NN	:::NOCLASS	_	_	_	_
16	protein	protein	I-NP	NN	0	_	_	_	_
17	kinase	kinase	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	have	have	B-VP	VBP	0	_	_	_	_
3	cloned	clone	I-VP	VBN	0	_	_	_	_
4	and	and	I-VP	CC	0	_	_	_	_
5	characterized	characterize	I-VP	VBN	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	55	55	I-NP	CD	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	kb	kb	I-NP	NN	0	_	_	_	_
10	region	region	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	DNA	DNA	B-NP	NN	0	_	_	_	_
13	surrounding	surround	B-VP	VBG	0	_	_	_	_
14	HRAS1	HRAS1	B-NP	NN	:::NOCLASS	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	ORF1	ORF1	I-NP	NN	0	_	_	_	_
3	protein	protein	I-NP	NN	0	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	found	find	I-VP	VBN	0	_	_	_	_
6	to	to	I-VP	TO	0	_	_	_	_
7	be	be	I-VP	VB	0	_	_	_	_
8	highly	highly	B-ADJP	RB	0	_	_	_	_
9	homologous	homologous	I-ADJP	JJ	0	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	putative	putative	I-NP	JJ	0	_	_	_	_
13	potexvirus	potexvirus	I-NP	NN	:::NOCLASS	_	_	_	_
14	RNA	RNA	I-NP	NN	:::NOCLASS	_	_	_	_
15	replicases	replicas	I-NP	NNS	:::NOCLASS	_	_	_	_
16	;	;	O	:	0	_	_	_	_
17	ORF2	ORF2	B-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	3	3	I-NP	CD	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	-	-	B-NP	HYPH	0	_	_	_	_
23	5	5	I-NP	CD	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	-	-	B-NP	HYPH	0	_	_	_	_
26	6	6	I-NP	CD	0	_	_	_	_
27	proteins	protein	I-NP	NNS	0	_	_	_	_
28	also	also	B-ADVP	RB	0	_	_	_	_
29	have	have	B-VP	VBP	0	_	_	_	_
30	analogues	analogue	B-NP	NNS	0	_	_	_	_
31	among	among	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	potex	potex	I-NP	NN	0	_	_	_	_
34	-	-	B-ADJP	HYPH	0	_	_	_	_
35	and	and	O	CC	0	_	_	_	_
36	/	/	B-NP	SYM	0	_	_	_	_
37	or	or	O	CC	0	_	_	_	_
38	carlavirus	carlavirus	B-NP	NN	0	_	_	_	_
39	-	-	B-NP	HYPH	0	_	_	_	_
40	encoded	encode	I-NP	VBN	0	_	_	_	_
41	proteins	protein	I-NP	NNS	0	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	total	total	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	281	281	B-NP	CD	0	_	_	_	_
5	patients	patient	I-NP	NNS	0	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	divided	divide	I-VP	VBN	0	_	_	_	_
8	into	into	B-PP	IN	0	_	_	_	_
9	groups	group	B-NP	NNS	0	_	_	_	_
10	according	accord	B-PP	VBG	0	_	_	_	_
11	to	to	B-PP	TO	0	_	_	_	_
12	their	their	B-NP	PRP$	0	_	_	_	_
13	clinical	clinical	I-NP	JJ	0	_	_	_	_
14	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	were	be	B-VP	VBD	0	_	_	_	_
17	examined	examine	I-VP	VBN	0	_	_	_	_
18	using	use	B-VP	VBG	0	_	_	_	_
19	capnography	capnography	B-NP	NN	0	_	_	_	_
20	,	,	I-NP	,	0	_	_	_	_
21	spirometry	spirometry	I-NP	NN	0	_	_	_	_
22	and	and	I-NP	CC	0	_	_	_	_
23	blood	blood	I-NP	NN	0	_	_	_	_
24	-	-	I-NP	HYPH	0	_	_	_	_
25	gas	gas	I-NP	NN	0	_	_	_	_
26	analysis	analysis	I-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	relationships	relationship	I-NP	NNS	0	_	_	_	_
3	between	between	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	partial	partial	I-NP	JJ	0	_	_	_	_
6	pressures	pressure	I-NP	NNS	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	O2	O2	B-NP	NN	0	_	_	_	_
9	and	and	I-NP	CC	0	_	_	_	_
10	CO2	CO2	I-NP	NN	0	_	_	_	_
11	as	as	B-CONJP	RB	0	_	_	_	_
12	well	well	I-CONJP	RB	0	_	_	_	_
13	as	as	I-CONJP	IN	0	_	_	_	_
14	between	between	B-PP	IN	0	_	_	_	_
15	their	their	B-NP	PRP$	0	_	_	_	_
16	gradients	gradient	I-NP	NNS	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	become	become	B-VP	VBP	0	_	_	_	_
19	stronger	strong	B-ADJP	JJR	0	_	_	_	_
20	with	with	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	increase	increase	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	ventilation	ventilation	I-NP	NN	0	_	_	_	_
26	-	-	B-NP	HYPH	0	_	_	_	_
27	perfusion	perfusion	I-NP	NN	0	_	_	_	_
28	ratio	ratio	I-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	No	No	B-NP	DT	0	_	_	_	_
2	significant	significant	I-NP	JJ	0	_	_	_	_
3	correlations	correlation	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	peak	peak	B-NP	NN	0	_	_	_	_
6	VO2	VO2	I-NP	NN	0	_	_	_	_
7	were	be	B-VP	VBD	0	_	_	_	_
8	observed	observe	I-VP	VBN	0	_	_	_	_
9	between	between	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	3	3	I-NP	CD	0	_	_	_	_
12	tests	test	I-NP	NNS	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	An	An	B-NP	DT	0	_	_	_	_
2	RNA	RNA	I-NP	NN	:::NOCLASS	_	_	_	_
3	-	-	O	HYPH	:::NOCLASS	_	_	_	_
4	binding	bind	B-VP	VBG	:::NOCLASS	_	_	_	_
5	protein	protein	B-NP	NN	:::NOCLASS	_	_	_	_
6	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
7	(	(	O	(	0	_	_	_	_
8	rbp1	rbp1	B-NP	NN	:::NOCLASS	_	_	_	_
9	)	)	O	)	0	_	_	_	_
10	from	from	B-PP	IN	0	_	_	_	_
11	Drosophila	Drosophila	B-NP	FW	0	_	_	_	_
12	melanogaster	melanogaster	I-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	encoding	encode	B-VP	VBG	0	_	_	_	_
15	an	an	B-NP	DT	0	_	_	_	_
16	RNA	RNA	I-NP	NN	0	_	_	_	_
17	recognition	recognition	I-NP	NN	0	_	_	_	_
18	motif	motif	I-NP	NN	0	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	an	an	B-NP	DT	0	_	_	_	_
21	Arg	Arg	I-NP	NN	0	_	_	_	_
22	-	-	B-NP	HYPH	0	_	_	_	_
23	Ser	Ser	I-NP	NN	0	_	_	_	_
24	rich	rich	B-ADJP	JJ	0	_	_	_	_
25	(	(	O	(	0	_	_	_	_
26	RS	RS	B-NP	NN	0	_	_	_	_
27	)	)	O	)	0	_	_	_	_
28	domain	domain	B-NP	NN	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	has	have	B-VP	VBZ	0	_	_	_	_
31	been	be	I-VP	VBN	0	_	_	_	_
32	characterized	characterize	I-VP	VBN	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Some	Some	B-NP	DT	0	_	_	_	_
2	research	research	I-NP	NN	0	_	_	_	_
3	studies	study	I-NP	NNS	0	_	_	_	_
4	have	have	B-VP	VBP	0	_	_	_	_
5	related	relate	I-VP	VBN	0	_	_	_	_
6	this	this	B-NP	DT	0	_	_	_	_
7	kind	kind	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	tumors	tumor	B-NP	NNS	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	prolonged	prolonged	B-NP	JJ	0	_	_	_	_
12	ingestion	ingestion	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	H2	H2	B-NP	NN	0	_	_	_	_
15	inhibitors	inhibitor	I-NP	NNS	0	_	_	_	_
16	and	and	I-NP	CC	0	_	_	_	_
17	others	other	I-NP	NNS	0	_	_	_	_
18	antacid	antacid	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	comparative	comparative	I-NP	JJ	0	_	_	_	_
3	study	study	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	total	total	I-NP	JJ	0	_	_	_	_
7	protein	protein	I-NP	NN	0	_	_	_	_
8	profiles	profile	I-NP	NNS	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	wild	wild	B-NP	JJ	0	_	_	_	_
11	-	-	I-NP	HYPH	0	_	_	_	_
12	type	type	I-NP	NN	0	_	_	_	_
13	S	S	I-NP	NN	0	_	_	_	_
14	.	.	I-NP	.	0	_	_	_	_
15	entomophila	entomophila	I-NP	NN	0	_	_	_	_
16	UC9	UC9	I-NP	NN	0	_	_	_	_
17	and	and	I-NP	CC	0	_	_	_	_
18	mutant	mutant	I-NP	JJ	0	_	_	_	_
19	UC21	UC21	I-NP	NN	0	_	_	_	_
20	revealed	reveal	B-VP	VBD	0	_	_	_	_
21	that	that	B-SBAR	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	mutant	mutant	I-NP	NN	0	_	_	_	_
24	lacked	lack	B-VP	VBD	0	_	_	_	_
25	an	an	B-NP	DT	0	_	_	_	_
26	approximately	approximately	I-NP	RB	0	_	_	_	_
27	44	44	I-NP	CD	0	_	_	_	_
28	-	-	I-NP	HYPH	0	_	_	_	_
29	kDa	kDa	I-NP	NN	0	_	_	_	_
30	protein	protein	I-NP	NN	0	_	_	_	_
31	and	and	O	CC	0	_	_	_	_
32	overexpressed	overexpresse	B-VP	VBD	0	_	_	_	_
33	an	an	B-NP	DT	0	_	_	_	_
34	approximately	approximately	I-NP	RB	0	_	_	_	_
35	20	20	I-NP	CD	0	_	_	_	_
36	-	-	I-NP	HYPH	0	_	_	_	_
37	kDa	kDa	I-NP	NN	0	_	_	_	_
38	protein	protein	I-NP	NN	0	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	Characterization	Characterization	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	regulon	regulon	I-NP	NN	0	_	_	_	_
5	controlled	control	B-VP	VBN	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	leucine	leucine	I-NP	NN	:::NOCLASS	_	_	_	_
9	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
10	responsive	responsive	I-NP	JJ	:::NOCLASS	_	_	_	_
11	regulatory	regulatory	I-NP	JJ	:::NOCLASS	_	_	_	_
12	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	Escherichia	Escherichia	B-NP	NNP	0	_	_	_	_
15	coli	coli	I-NP	NNP	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Mapping	Mapping	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	mouse	mouse	I-NP	NN	:::NOCLASS	_	_	_	_
5	ornithine	ornithine	I-NP	NN	:::NOCLASS	_	_	_	_
6	decarboxylase	decarboxylase	I-NP	NN	:::NOCLASS	_	_	_	_
7	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
8	related	relate	I-NP	VBN	:::NOCLASS	_	_	_	_
9	sequence	sequence	I-NP	NN	:::NOCLASS	_	_	_	_
10	family	family	I-NP	NN	:::NOCLASS	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	mutation	mutation	I-NP	NN	0	_	_	_	_
3	also	also	B-ADVP	RB	0	_	_	_	_
4	results	result	B-VP	VBZ	0	_	_	_	_
5	in	in	B-PP	IN	0	_	_	_	_
6	markedly	markedly	B-NP	RB	0	_	_	_	_
7	decreased	decrease	I-NP	VBN	0	_	_	_	_
8	levels	level	I-NP	NNS	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	CAD	CAD	B-NP	NN	:::NOCLASS|UMLS:C0010068:T047:DISO|UMLS:C0010054:T047:DISO	_	_	_	_
11	mRNA	mRNA	I-NP	NN	:::NOCLASS	_	_	_	_
12	and	and	I-NP	CC	0	_	_	_	_
13	protein	protein	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	mutant	mutant	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	rationale	rationale	I-NP	NN	0	_	_	_	_
3	for	for	B-PP	IN	0	_	_	_	_
4	continuous	continuous	B-NP	JJ	0	_	_	_	_
5	dopaminergic	dopaminergic	I-NP	JJ	0	_	_	_	_
6	stimulation	stimulation	I-NP	NN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	patients	patient	B-NP	NNS	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	Parkinson	Parkinson	B-NP	NNP	UMLS:C0030567:T047:DISO	_	_	_	_
11	's	's	B-NP	POS	UMLS:C0030567:T047:DISO	_	_	_	_
12	disease	disease	I-NP	NN	UMLS:C0030567:T047:DISO	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	Mutational	Mutational	B-NP	JJ	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	revealed	reveal	B-VP	VBD	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	it	it	B-NP	PRP	0	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	homeodomain	homeodomain	I-NP	NN	:::NOCLASS	_	_	_	_
9	binding	binding	I-NP	NN	:::NOCLASS	_	_	_	_
10	site	site	I-NP	NN	:::NOCLASS	_	_	_	_
11	II	II	I-NP	CD	:::NOCLASS	_	_	_	_
12	sequence	sequence	I-NP	NN	:::NOCLASS	_	_	_	_
13	that	that	B-NP	WDT	0	_	_	_	_
14	was	be	B-VP	VBD	0	_	_	_	_
15	required	require	I-VP	VBN	0	_	_	_	_
16	for	for	B-PP	IN	0	_	_	_	_
17	this	this	B-NP	DT	0	_	_	_	_
18	regulation	regulation	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Thus	Thus	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	pol	pol	I-NP	NN	:::NOCLASS	_	_	_	_
5	alpha	alpha	B-VP	SYM	:::NOCLASS	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	primase	primase	I-NP	NN	:::NOCLASS	_	_	_	_
8	complex	complex	I-NP	NN	0	_	_	_	_
9	appears	appear	B-VP	VBZ	0	_	_	_	_
10	to	to	I-VP	TO	0	_	_	_	_
11	act	act	I-VP	VB	0	_	_	_	_
12	processively	processively	B-ADVP	RB	0	_	_	_	_
13	for	for	B-PP	IN	0	_	_	_	_
14	only	only	B-NP	RB	0	_	_	_	_
15	a	a	I-NP	DT	0	_	_	_	_
16	short	short	I-NP	JJ	0	_	_	_	_
17	distance	distance	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Interestingly	Interestingly	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	positions	position	I-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	these	these	B-NP	DT	0	_	_	_	_
7	introns	intron	I-NP	NNS	0	_	_	_	_
8	have	have	B-VP	VBP	0	_	_	_	_
9	been	be	I-VP	VBN	0	_	_	_	_
10	conserved	conserve	I-VP	VBN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	comparison	comparison	B-NP	NN	0	_	_	_	_
13	with	with	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	genes	gene	I-NP	NNS	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	two	two	B-NP	CD	0	_	_	_	_
18	other	other	I-NP	JJ	0	_	_	_	_
19	transglutaminase	transglutaminase	I-NP	NN	0	_	_	_	_
20	-	-	B-VP	HYPH	0	_	_	_	_
21	like	like	B-NP	JJ	0	_	_	_	_
22	activities	activity	I-NP	NNS	0	_	_	_	_
23	described	describe	B-VP	VBN	0	_	_	_	_
24	in	in	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	literature	literature	I-NP	NN	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	but	but	O	CC	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	TGM1	TGM1	I-NP	NN	:::NOCLASS	_	_	_	_
31	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
32	is	be	B-VP	VBZ	0	_	_	_	_
33	by	by	B-PP	IN	0	_	_	_	_
34	far	far	B-ADVP	RB	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	smallest	small	I-NP	JJS	0	_	_	_	_
37	characterized	characterize	B-VP	VBN	0	_	_	_	_
38	to	to	B-PP	TO	0	_	_	_	_
39	date	date	B-NP	NN	0	_	_	_	_
40	because	because	B-SBAR	IN	0	_	_	_	_
41	its	its	B-NP	PRP$	0	_	_	_	_
42	introns	intron	I-NP	NNS	0	_	_	_	_
43	are	be	B-VP	VBP	0	_	_	_	_
44	relatively	relatively	B-ADJP	RB	0	_	_	_	_
45	smaller	small	I-ADJP	JJR	0	_	_	_	_
46	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	a	a	B-NP	DT	0	_	_	_	_
3	retrospective	retrospective	I-NP	JJ	0	_	_	_	_
4	analysis	analysis	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	data	datum	B-NP	NNS	0	_	_	_	_
7	from	from	B-PP	IN	0	_	_	_	_
8	35	35	B-NP	CD	0	_	_	_	_
9	cases	case	I-NP	NNS	0	_	_	_	_
10	with	with	B-PP	IN	0	_	_	_	_
11	malignant	malignant	B-NP	JJ	0	_	_	_	_
12	lymphoma	lymphoma	I-NP	NN	0	_	_	_	_
13	from	from	B-PP	IN	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	cohort	cohort	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	2017	2017	B-NP	CD	0	_	_	_	_
18	HIV	HIV	I-NP	NN	UMLS:C0019693:T047:DISO	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	infected	infect	I-NP	VBN	0	_	_	_	_
21	patients	patient	I-NP	NNS	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	stage	stage	I-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	HIV	HIV	B-NP	NN	UMLS:C0019693:T047:DISO	_	_	_	_
27	-	-	B-NP	HYPH	0	_	_	_	_
28	disease	disease	I-NP	NN	0	_	_	_	_
29	,	,	O	,	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	CD4	CD4	I-NP	NN	:::NOCLASS	_	_	_	_
32	counts	count	B-VP	VBZ	0	_	_	_	_
33	at	at	B-PP	IN	0	_	_	_	_
34	the	the	B-NP	DT	0	_	_	_	_
35	time	time	I-NP	NN	0	_	_	_	_
36	of	of	B-PP	IN	0	_	_	_	_
37	diagnosis	diagnosis	B-NP	NN	0	_	_	_	_
38	,	,	O	,	0	_	_	_	_
39	and	and	O	CC	0	_	_	_	_
40	the	the	B-NP	DT	0	_	_	_	_
41	use	use	I-NP	NN	0	_	_	_	_
42	of	of	B-PP	IN	0	_	_	_	_
43	antineoplastic	antineoplastic	B-NP	JJ	0	_	_	_	_
44	agents	agent	I-NP	NNS	0	_	_	_	_
45	or	or	O	CC	0	_	_	_	_
46	radiotherapy	radiotherapy	B-NP	NN	0	_	_	_	_
47	were	be	B-VP	VBD	0	_	_	_	_
48	correlated	correlate	I-VP	VBN	0	_	_	_	_
49	with	with	B-PP	IN	0	_	_	_	_
50	outcome	outcome	B-NP	NN	0	_	_	_	_
51	.	.	O	.	0	_	_	_	_

1	1	1	B-LST	LS	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	Effects	Effect	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	dioxins	dioxin	B-NP	NNS	0	_	_	_	_
4	on	on	B-PP	IN	0	_	_	_	_
5	thyroid	thyroid	B-NP	NN	UMLS:C0040132:T023:ANAT	_	_	_	_
6	function	function	I-NP	NN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	newborn	newborn	B-NP	JJ	0	_	_	_	_
9	babies	baby	I-NP	NNS	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	cDNA	cDNA	B-NP	NN	0	_	_	_	_
2	clones	clone	I-NP	NNS	0	_	_	_	_
3	encoding	encode	B-VP	VBG	0	_	_	_	_
4	Arabidopsis	Arabidopsis	B-NP	NNP	0	_	_	_	_
5	thaliana	thaliana	I-NP	NNP	0	_	_	_	_
6	and	and	O	CC	0	_	_	_	_
7	Zea	Zea	B-NP	NNP	:::NOCLASS	_	_	_	_
8	mays	may	B-VP	VBZ	:::NOCLASS	_	_	_	_
9	mitochondrial	mitochondrial	B-NP	JJ	:::NOCLASS	_	_	_	_
10	chaperonin	chaperonin	I-NP	NN	:::NOCLASS	_	_	_	_
11	HSP60	HSP60	I-NP	NN	:::NOCLASS	_	_	_	_
12	and	and	I-NP	CC	0	_	_	_	_
13	gene	gene	I-NP	NN	0	_	_	_	_
14	expression	expression	I-NP	NN	0	_	_	_	_
15	during	during	B-PP	IN	0	_	_	_	_
16	seed	seed	B-NP	NN	0	_	_	_	_
17	germination	germination	I-NP	NN	0	_	_	_	_
18	and	and	O	CC	0	_	_	_	_
19	heat	heat	B-NP	NN	0	_	_	_	_
20	shock	shock	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Amino	Amino	B-NP	NN	0	_	_	_	_
2	acid	acid	I-NP	NN	0	_	_	_	_
3	sequence	sequence	I-NP	NN	0	_	_	_	_
4	comparison	comparison	I-NP	NN	0	_	_	_	_
5	revealed	reveal	B-VP	VBD	0	_	_	_	_
6	significant	significant	B-NP	JJ	0	_	_	_	_
7	homology	homology	I-NP	NN	0	_	_	_	_
8	between	between	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	yeast	yeast	I-NP	NN	:::NOCLASS	_	_	_	_
11	and	and	O	CC	:::NOCLASS	_	_	_	_
12	Escherichia	Escherichia	B-NP	FW	:::NOCLASS	_	_	_	_
13	coli	coli	I-NP	FW	:::NOCLASS	_	_	_	_
14	gamma	gamma	B-NP	SYM	:::NOCLASS	_	_	_	_
15	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
16	glutamyl	glutamyl	I-NP	NN	:::NOCLASS	_	_	_	_
17	kinases	kinase	I-NP	NNS	:::NOCLASS	_	_	_	_
18	throughout	throughout	B-PP	IN	0	_	_	_	_
19	their	their	B-NP	PRP$	0	_	_	_	_
20	lengths	length	I-NP	NNS	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	single	single	I-NP	JJ	0	_	_	_	_
3	site	site	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	glycosylation	glycosylation	B-NP	NN	0	_	_	_	_
6	is	be	B-VP	VBZ	0	_	_	_	_
7	located	located	B-ADJP	JJ	0	_	_	_	_
8	near	near	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	C	C	I-NP	NN	0	_	_	_	_
11	-	-	B-NP	HYPH	0	_	_	_	_
12	terminus	terminus	I-NP	NN	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	N	N	I-NP	NN	0	_	_	_	_
16	-	-	O	HYPH	0	_	_	_	_
17	glycosylation	glycosylation	B-NP	NN	0	_	_	_	_
18	sequon	sequon	I-NP	NN	0	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	Asn	Asn	I-NP	NN	0	_	_	_	_
21	-	-	B-NP	HYPH	0	_	_	_	_
22	Cys	Cys	I-NP	NN	0	_	_	_	_
23	-	-	B-NP	HYPH	0	_	_	_	_
24	Ser	Ser	I-NP	NN	0	_	_	_	_
25	-	-	B-ADJP	HYPH	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	which	which	B-NP	WDT	0	_	_	_	_
28	Cys	Cys	B-NP	NN	0	_	_	_	_
29	forms	form	B-VP	VBZ	0	_	_	_	_
30	part	part	B-NP	NN	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	a	a	B-NP	DT	0	_	_	_	_
33	disulphide	disulphide	I-NP	NN	0	_	_	_	_
34	bridge	bridge	I-NP	NN	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	pulmonary	pulmonary	I-NP	JJ	UMLS:C0024109:T023:ANAT	_	_	_	_
3	toxic	toxic	I-NP	JJ	0	_	_	_	_
4	events	event	I-NP	NNS	0	_	_	_	_
5	induced	induce	B-VP	VBN	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	acute	acute	B-NP	JJ	0	_	_	_	_
8	nitrogen	nitrogen	I-NP	NN	0	_	_	_	_
9	dioxide	dioxide	I-NP	NN	0	_	_	_	_
10	(	(	O	(	0	_	_	_	_
11	NO	NO	B-NP	NN	0	_	_	_	_
12	)	)	O	)	0	_	_	_	_
13	2	2	B-NP	CD	0	_	_	_	_
14	exposure	exposure	I-NP	NN	0	_	_	_	_
15	were	be	B-VP	VBD	0	_	_	_	_
16	studied	study	I-VP	VBN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	rat	rat	I-NP	NN	0	_	_	_	_
20	to	to	B-VP	TO	0	_	_	_	_
21	develop	develop	I-VP	VB	0	_	_	_	_
22	an	an	B-NP	DT	0	_	_	_	_
23	inhalation	inhalation	I-NP	NN	0	_	_	_	_
24	model	model	I-NP	NN	0	_	_	_	_
25	to	to	B-VP	TO	0	_	_	_	_
26	investigate	investigate	I-VP	VB	0	_	_	_	_
27	therapeutic	therapeutic	B-NP	JJ	0	_	_	_	_
28	measures	measure	I-NP	NNS	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	pulmonary	pulmonary	I-NP	JJ	UMLS:C0024109:T023:ANAT	_	_	_	_
3	effects	effect	I-NP	NNS	0	_	_	_	_
4	observed	observe	B-VP	VBN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	became	become	B-VP	VBD	0	_	_	_	_
7	more	more	B-ADJP	RBR	0	_	_	_	_
8	pronounced	pronounced	I-ADJP	JJ	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	increasing	increase	B-NP	VBG	0	_	_	_	_
11	NO2	NO2	I-NP	NN	0	_	_	_	_
12	concentrations	concentration	I-NP	NNS	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	0	0	B-NP	CD	0	_	_	_	_
15	,	,	I-NP	,	0	_	_	_	_
16	25	25	I-NP	CD	0	_	_	_	_
17	,	,	I-NP	,	0	_	_	_	_
18	75	75	I-NP	CD	0	_	_	_	_
19	,	,	I-NP	,	0	_	_	_	_
20	125	125	I-NP	CD	0	_	_	_	_
21	,	,	I-NP	,	0	_	_	_	_
22	175	175	I-NP	CD	0	_	_	_	_
23	or	or	I-NP	CC	0	_	_	_	_
24	200	200	I-NP	CD	0	_	_	_	_
25	ppm	ppm	I-NP	NN	0	_	_	_	_
26	,	,	O	,	0	_	_	_	_
27	1	1	B-NP	CD	0	_	_	_	_
28	ppm	ppm	I-NP	NN	0	_	_	_	_
29	NO2	NO2	I-NP	NN	0	_	_	_	_
30	=	=	B-VP	SYM	0	_	_	_	_
31	1	1	B-NP	CD	0	_	_	_	_
32	.	.	I-NP	SYM	0	_	_	_	_
33	88	88	I-NP	CD	0	_	_	_	_
34	mg	mg	I-NP	NN	0	_	_	_	_
35	m	m	I-NP	NN	0	_	_	_	_
36	-	-	B-NP	HYPH	0	_	_	_	_
37	3	3	I-NP	CD	0	_	_	_	_
38	NO2	NO2	I-NP	NN	0	_	_	_	_
39	)	)	O	)	0	_	_	_	_
40	and	and	O	CC	0	_	_	_	_
41	exposure	exposure	B-NP	NN	0	_	_	_	_
42	times	time	I-NP	NNS	0	_	_	_	_
43	(	(	O	(	0	_	_	_	_
44	5	5	B-NP	CD	0	_	_	_	_
45	,	,	I-NP	,	0	_	_	_	_
46	10	10	I-NP	CD	0	_	_	_	_
47	,	,	I-NP	,	0	_	_	_	_
48	20	20	I-NP	CD	0	_	_	_	_
49	or	or	I-NP	CC	0	_	_	_	_
50	30	30	I-NP	CD	0	_	_	_	_
51	min	min	I-NP	NN	0	_	_	_	_
52	)	)	O	)	0	_	_	_	_
53	.	.	O	.	0	_	_	_	_

1	Interaction	Interaction	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	H	H	B-NP	NN	:::NOCLASS	_	_	_	_
4	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
5	2Eb	2Eb	I-NP	NN	:::NOCLASS	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	an	an	B-NP	DT	0	_	_	_	_
8	IAP	IAP	I-NP	NN	:::NOCLASS	_	_	_	_
9	retrotransposon	retrotransposon	I-NP	NN	:::NOCLASS	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	A20	A20	I-NP	NN	0	_	_	_	_
13	/	/	B-NP	SYM	0	_	_	_	_
14	2J	2J	I-NP	NN	0	_	_	_	_
15	B	B	I-NP	NN	0	_	_	_	_
16	cell	cell	I-NP	NN	0	_	_	_	_
17	lymphoma	lymphoma	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Gestational	Gestational	B-NP	JJ	UMLS:C2931618:T047:DISO	_	_	_	_
2	trophoblastic	trophoblastic	I-NP	JJ	UMLS:C2931618:T047:DISO	_	_	_	_
3	diseases	disease	I-NP	NNS	UMLS:C2931618:T047:DISO	_	_	_	_
4	:	:	O	:	0	_	_	_	_
5	recent	recent	B-NP	JJ	0	_	_	_	_
6	advances	advance	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	understanding	understanding	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	cytogenetics	cytogenetic	B-NP	NNS	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	histopathology	histopathology	B-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	natural	natural	B-NP	JJ	0	_	_	_	_
17	history	history	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	With	With	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	exception	exception	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	mutants	mutant	B-NP	NNS	0	_	_	_	_
6	that	that	B-NP	WDT	0	_	_	_	_
7	remove	remove	B-VP	VBP	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	membrane	membrane	I-NP	NN	0	_	_	_	_
10	anchor	anchor	I-NP	NN	0	_	_	_	_
11	domain	domain	I-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	all	all	B-NP	DT	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	mutant	mutant	I-NP	JJ	0	_	_	_	_
17	glycoproteins	glycoprotein	I-NP	NNS	0	_	_	_	_
18	retained	retain	B-VP	VBD	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	ability	ability	I-NP	NN	0	_	_	_	_
21	to	to	B-VP	TO	0	_	_	_	_
22	cause	cause	I-VP	VB	0	_	_	_	_
23	fusion	fusion	B-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	CD4	CD4	B-NP	NN	:::NOCLASS	_	_	_	_
26	-	-	O	HYPH	0	_	_	_	_
27	bearing	bear	B-VP	VBG	0	_	_	_	_
28	cells	cell	B-NP	NNS	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	subunit	subunit	I-NP	NN	0	_	_	_	_
3	protein	protein	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	curli	curli	B-NP	NN	:::NOCLASS	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	highly	highly	B-ADJP	RB	0	_	_	_	_
8	homologous	homologous	I-ADJP	JJ	0	_	_	_	_
9	at	at	B-PP	IN	0	_	_	_	_
10	its	its	B-NP	PRP$	0	_	_	_	_
11	amino	amino	I-NP	JJ	0	_	_	_	_
12	terminus	terminus	I-NP	NN	0	_	_	_	_
13	to	to	B-PP	TO	0	_	_	_	_
14	SEF	SEF	B-NP	NN	:::NOCLASS	_	_	_	_
15	-	-	O	HYPH	:::NOCLASS	_	_	_	_
16	17	17	B-NP	CD	:::NOCLASS	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	subunit	subunit	I-NP	NN	0	_	_	_	_
20	protein	protein	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	thin	thin	B-NP	JJ	0	_	_	_	_
23	,	,	I-NP	,	0	_	_	_	_
24	aggregative	aggregative	I-NP	JJ	0	_	_	_	_
25	fimbriae	fimbria	I-NP	NNS	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	Salmonella	Salmonella	B-NP	NNP	UMLS:C0036117:T047:DISO	_	_	_	_
28	enteritidis	enteritidi	B-VP	VBZ	0	_	_	_	_
29	27655	27655	B-NP	CD	0	_	_	_	_
30	strain	strain	I-NP	NN	0	_	_	_	_
31	3b	3b	I-NP	NN	0	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	suggesting	suggest	B-VP	VBG	0	_	_	_	_
34	that	that	B-SBAR	IN	0	_	_	_	_
35	these	these	B-NP	DT	0	_	_	_	_
36	fibres	fibre	I-NP	NNS	0	_	_	_	_
37	form	form	B-VP	VBP	0	_	_	_	_
38	a	a	B-NP	DT	0	_	_	_	_
39	novel	novel	I-NP	JJ	0	_	_	_	_
40	class	class	I-NP	NN	0	_	_	_	_
41	of	of	B-PP	IN	0	_	_	_	_
42	surface	surface	B-NP	NN	0	_	_	_	_
43	organelles	organelle	I-NP	NNS	0	_	_	_	_
44	on	on	B-PP	IN	0	_	_	_	_
45	enterobacteria	enterobacteria	B-NP	NNS	0	_	_	_	_
46	.	.	O	.	0	_	_	_	_

1	Substitution	Substitution	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	DR1	DR1	I-NP	NN	:::NOCLASS	_	_	_	_
5	beta	beta	I-NP	NN	:::NOCLASS	_	_	_	_
6	chain	chain	I-NP	NN	:::NOCLASS	_	_	_	_
7	with	with	B-PP	IN	0	_	_	_	_
8	H	H	B-NP	NN	:::NOCLASS	_	_	_	_
9	-	-	O	HYPH	:::NOCLASS	_	_	_	_
10	2E	2E	B-NP	NN	:::NOCLASS	_	_	_	_
11	beta	beta	I-NP	NN	:::NOCLASS	_	_	_	_
12	k	k	I-NP	NN	:::NOCLASS	_	_	_	_
13	led	lead	B-VP	VBD	0	_	_	_	_
14	to	to	B-PP	TO	0	_	_	_	_
15	a	a	B-NP	DT	0	_	_	_	_
16	dramatic	dramatic	I-NP	JJ	0	_	_	_	_
17	loss	loss	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	recognition	recognition	B-NP	NN	0	_	_	_	_
20	;	;	O	:	0	_	_	_	_
21	alpha	alpha	B-NP	SYM	0	_	_	_	_
22	chain	chain	I-NP	NN	0	_	_	_	_
23	substitution	substitution	I-NP	NN	0	_	_	_	_
24	had	have	B-VP	VBD	0	_	_	_	_
25	a	a	B-NP	DT	0	_	_	_	_
26	less	less	I-NP	RBR	0	_	_	_	_
27	marked	marked	I-NP	JJ	0	_	_	_	_
28	effect	effect	I-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	negative	negative	I-NP	JJ	0	_	_	_	_
3	regulatory	regulatory	I-NP	JJ	0	_	_	_	_
4	pathway	pathway	I-NP	NN	0	_	_	_	_
5	may	may	B-VP	MD	0	_	_	_	_
6	be	be	I-VP	VB	0	_	_	_	_
7	important	important	B-ADJP	JJ	0	_	_	_	_
8	for	for	B-PP	IN	0	_	_	_	_
9	determining	determine	B-VP	VBG	0	_	_	_	_
10	cell	cell	B-NP	NN	0	_	_	_	_
11	fate	fate	I-NP	NN	0	_	_	_	_
12	or	or	O	CC	0	_	_	_	_
13	maintaining	maintain	B-VP	VBG	0	_	_	_	_
14	an	an	B-NP	DT	0	_	_	_	_
15	inducible	inducible	I-NP	JJ	0	_	_	_	_
16	state	state	I-NP	NN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	ventroposterior	ventroposterior	I-NP	JJ	0	_	_	_	_
20	region	region	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	embryo	embryo	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	distal	distal	I-NP	JJ	0	_	_	_	_
3	portion	portion	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	rat	rat	I-NP	NN	:::NOCLASS	_	_	_	_
7	insulin	insulin	I-NP	NN	:::NOCLASS	_	_	_	_
8	I	I	I-NP	CD	:::NOCLASS	_	_	_	_
9	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
10	5	5	B-NP	CD	:::NOCLASS	_	_	_	_
11	'	'	I-NP	SYM	:::NOCLASS	_	_	_	_
12	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
13	flanking	flank	B-NP	VBG	:::NOCLASS	_	_	_	_
14	DNA	DNA	I-NP	NN	:::NOCLASS	_	_	_	_
15	contains	contain	B-VP	VBZ	0	_	_	_	_
16	two	two	B-NP	CD	0	_	_	_	_
17	sequence	sequence	I-NP	NN	0	_	_	_	_
18	elements	element	I-NP	NNS	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	Far	Far	I-NP	NN	0	_	_	_	_
22	and	and	I-NP	CC	0	_	_	_	_
23	FLAT	FLAT	I-NP	NN	0	_	_	_	_
24	elements	element	I-NP	NNS	0	_	_	_	_
25	,	,	O	,	0	_	_	_	_
26	that	that	B-NP	WDT	0	_	_	_	_
27	can	can	B-VP	MD	0	_	_	_	_
28	function	function	I-VP	VB	0	_	_	_	_
29	in	in	B-PP	IN	0	_	_	_	_
30	combination	combination	B-NP	NN	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	but	but	O	CC	0	_	_	_	_
33	not	not	O	RB	0	_	_	_	_
34	separately	separately	B-ADVP	RB	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	as	as	B-PP	IN	0	_	_	_	_
37	a	a	B-NP	DT	0	_	_	_	_
38	beta	beta	I-NP	SYM	0	_	_	_	_
39	-	-	I-NP	HYPH	0	_	_	_	_
40	cell	cell	I-NP	NN	0	_	_	_	_
41	-	-	I-NP	HYPH	0	_	_	_	_
42	specific	specific	I-NP	JJ	0	_	_	_	_
43	transcriptional	transcriptional	I-NP	JJ	0	_	_	_	_
44	enhancer	enhancer	I-NP	NN	0	_	_	_	_
45	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	deduced	deduce	I-NP	VBN	0	_	_	_	_
3	amino	amino	I-NP	JJ	0	_	_	_	_
4	acid	acid	I-NP	NN	0	_	_	_	_
5	sequence	sequence	I-NP	NN	0	_	_	_	_
6	exhibited	exhibit	B-VP	VBD	0	_	_	_	_
7	98	98	B-NP	CD	0	_	_	_	_
8	%	%	I-NP	NN	0	_	_	_	_
9	identity	identity	I-NP	NN	0	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	human	human	I-NP	JJ	0	_	_	_	_
13	cellular	cellular	I-NP	JJ	0	_	_	_	_
14	transglutaminase	transglutaminase	I-NP	NN	0	_	_	_	_
15	sequence	sequence	I-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	computation	computation	I-NP	NN	0	_	_	_	_
3	is	be	B-VP	VBZ	0	_	_	_	_
4	performed	perform	I-VP	VBN	0	_	_	_	_
5	by	by	B-PP	IN	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	parallel	parallel	I-NP	JJ	0	_	_	_	_
8	network	network	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	locally	locally	B-NP	RB	0	_	_	_	_
11	connected	connect	I-NP	VBN	0	_	_	_	_
12	neuron	neuron	I-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	like	like	I-NP	JJ	0	_	_	_	_
15	elements	element	I-NP	NNS	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Repeated	Repeat	B-NP	VBN	0	_	_	_	_
2	efforts	effort	I-NP	NNS	0	_	_	_	_
3	to	to	B-VP	TO	0	_	_	_	_
4	isolate	isolate	I-VP	VB	0	_	_	_	_
5	recombinant	recombinant	B-NP	JJ	0	_	_	_	_
6	baculoviruses	baculovirus	I-NP	NNS	0	_	_	_	_
7	containing	contain	B-VP	VBG	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	wild	wild	I-NP	JJ	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	type	type	I-NP	NN	0	_	_	_	_
12	kinase	kinase	I-NP	NN	0	_	_	_	_
13	failed	fail	B-VP	VBD	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	whereas	whereas	O	IN	0	_	_	_	_
16	recombinants	recombinant	B-NP	NNS	0	_	_	_	_
17	expressing	express	B-VP	VBG	0	_	_	_	_
18	a	a	B-NP	DT	0	_	_	_	_
19	nonfunctional	nonfunctional	I-NP	JJ	0	_	_	_	_
20	kinase	kinase	I-NP	NN	0	_	_	_	_
21	with	with	B-PP	IN	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	catalytic	catalytic	I-NP	JJ	0	_	_	_	_
24	domain	domain	I-NP	NN	0	_	_	_	_
25	II	II	I-NP	CD	0	_	_	_	_
26	mutation	mutation	I-NP	NN	0	_	_	_	_
27	were	be	B-VP	VBD	0	_	_	_	_
28	readily	readily	I-VP	RB	0	_	_	_	_
29	isolated	isolate	I-VP	VBN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Finally	Finally	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	we	we	B-NP	PRP	0	_	_	_	_
4	determined	determine	B-VP	VBD	0	_	_	_	_
5	that	that	B-SBAR	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	P68	P68	I-NP	NN	:::NOCLASS	_	_	_	_
8	amino	amino	I-NP	JJ	0	_	_	_	_
9	terminus	terminus	I-NP	NN	0	_	_	_	_
10	was	be	B-VP	VBD	0	_	_	_	_
11	both	both	O	CC	0	_	_	_	_
12	necessary	necessary	B-ADJP	JJ	0	_	_	_	_
13	and	and	I-ADJP	CC	0	_	_	_	_
14	sufficient	sufficient	I-ADJP	JJ	0	_	_	_	_
15	for	for	B-PP	IN	0	_	_	_	_
16	binding	bind	B-NP	VBG	0	_	_	_	_
17	dsRNA	dsRNA	I-NP	NN	0	_	_	_	_
18	as	as	B-SBAR	IN	0	_	_	_	_
19	we	we	B-NP	PRP	0	_	_	_	_
20	were	be	B-VP	VBD	0	_	_	_	_
21	able	able	B-ADJP	JJ	0	_	_	_	_
22	to	to	B-VP	TO	0	_	_	_	_
23	transfer	transfer	I-VP	VB	0	_	_	_	_
24	dsRNA	dsRNA	B-NP	NN	0	_	_	_	_
25	-	-	O	HYPH	0	_	_	_	_
26	binding	bind	B-VP	VBG	0	_	_	_	_
27	properties	property	B-NP	NNS	0	_	_	_	_
28	to	to	B-PP	TO	0	_	_	_	_
29	a	a	B-NP	DT	0	_	_	_	_
30	reporter	reporter	I-NP	NN	0	_	_	_	_
31	gene	gene	I-NP	NN	0	_	_	_	_
32	product	product	I-NP	NN	0	_	_	_	_
33	previously	previously	B-ADJP	RB	0	_	_	_	_
34	unable	unable	I-ADJP	JJ	0	_	_	_	_
35	to	to	B-VP	TO	0	_	_	_	_
36	bind	bind	I-VP	VB	0	_	_	_	_
37	RNA	RNA	B-NP	NN	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_

1	From	From	B-PP	IN	0	_	_	_	_
2	August	August	B-NP	NNP	0	_	_	_	_
3	1989	1989	I-NP	CD	0	_	_	_	_
4	to	to	B-PP	TO	0	_	_	_	_
5	October	October	B-NP	NNP	0	_	_	_	_
6	1990	1990	I-NP	CD	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	83	83	B-NP	CD	0	_	_	_	_
9	pregnant	pregnant	I-NP	JJ	0	_	_	_	_
10	Chinese	Chinese	I-NP	JJ	0	_	_	_	_
11	women	woman	I-NP	NNS	0	_	_	_	_
12	were	be	B-VP	VBD	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	subjects	subject	I-NP	NNS	0	_	_	_	_
15	for	for	B-PP	IN	0	_	_	_	_
16	measuring	measure	B-VP	VBG	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	levels	level	I-NP	NNS	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	plasma	plasma	B-NP	NN	0	_	_	_	_
21	functional	functional	I-NP	JJ	0	_	_	_	_
22	antithrombin	antithrombin	I-NP	NN	:::NOCLASS	_	_	_	_
23	III	III	I-NP	CD	:::NOCLASS	_	_	_	_
24	(	(	O	(	0	_	_	_	_
25	AT	AT	O	NN	:::NOCLASS	_	_	_	_
26	III	III	O	CD	:::NOCLASS	_	_	_	_
27	)	)	O	)	0	_	_	_	_
28	activity	activity	B-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	Visual	Visual	B-NP	JJ	0	_	_	_	_
2	acuity	acuity	I-NP	NN	0	_	_	_	_
3	may	may	B-VP	MD	0	_	_	_	_
4	be	be	I-VP	VB	0	_	_	_	_
5	decreased	decrease	I-VP	VBN	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	transient	transient	B-NP	JJ	0	_	_	_	_
8	changes	change	I-NP	NNS	0	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	refractive	refractive	B-NP	JJ	UMLS:C0034951:T047:DISO	_	_	_	_
11	error	error	I-NP	NN	UMLS:C0034951:T047:DISO	_	_	_	_
12	caused	cause	B-VP	VBN	0	_	_	_	_
13	by	by	B-PP	IN	0	_	_	_	_
14	sulfonamides	sulfonamide	B-NP	NNS	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	antifungal	antifungal	I-NP	JJ	0	_	_	_	_
18	agent	agent	I-NP	NN	0	_	_	_	_
19	metronidazole	metronidazole	I-NP	NN	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	thiazide	thiazide	B-NP	NN	0	_	_	_	_
22	diuretics	diuretic	I-NP	NNS	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	carbonic	carbonic	B-NP	JJ	:::NOCLASS	_	_	_	_
26	anhydrase	anhydrase	I-NP	NN	:::NOCLASS	_	_	_	_
27	inhibitors	inhibitor	I-NP	NNS	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	Currents	Current	B-NP	NNS	0	_	_	_	_
2	aspects	aspect	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	H2	H2	B-NP	NN	:::NOCLASS	_	_	_	_
5	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
6	antagonists	antagonist	I-NP	NNS	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	treatment	treatment	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	ulcers	ulcer	B-NP	NNS	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	addition	addition	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	21	21	I-NP	CD	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	mer	mer	I-NP	NN	0	_	_	_	_
8	subrepeat	subrepeat	I-NP	NN	0	_	_	_	_
9	structure	structure	I-NP	NN	0	_	_	_	_
10	is	be	B-VP	VBZ	0	_	_	_	_
11	also	also	B-ADVP	RB	0	_	_	_	_
12	present	present	B-ADJP	JJ	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	each	each	B-NP	DT	0	_	_	_	_
15	unit	unit	I-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Sequencing	Sequencing	B-NP	NN	0	_	_	_	_
2	revealed	reveal	B-VP	VBD	0	_	_	_	_
3	one	one	B-NP	CD	0	_	_	_	_
4	large	large	I-NP	JJ	0	_	_	_	_
5	open	open	I-NP	JJ	0	_	_	_	_
6	reading	reading	I-NP	NN	0	_	_	_	_
7	frame	frame	I-NP	NN	0	_	_	_	_
8	encoding	encode	B-VP	VBG	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	39	39	I-NP	CD	0	_	_	_	_
11	-	-	I-NP	HYPH	0	_	_	_	_
12	kDa	kDa	I-NP	NN	0	_	_	_	_
13	protein	protein	I-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	sites	site	I-NP	NNS	0	_	_	_	_
3	are	be	B-VP	VBP	0	_	_	_	_
4	also	also	B-ADVP	RB	0	_	_	_	_
5	potential	potential	B-NP	JJ	0	_	_	_	_
6	keratan	keratan	I-NP	NN	0	_	_	_	_
7	sulfate	sulfate	I-NP	NN	0	_	_	_	_
8	attachment	attachment	I-NP	NN	0	_	_	_	_
9	sites	site	I-NP	NNS	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	propose	propose	B-VP	VBP	0	_	_	_	_
3	that	that	B-SBAR	IN	0	_	_	_	_
4	plasmids	plasmid	B-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	pLS1	pLS1	I-NP	NN	0	_	_	_	_
8	family	family	I-NP	NN	0	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	pE194	pE194	B-NP	NN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	pADB201	pADB201	B-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	pLB4	pLB4	B-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	share	share	B-VP	VBP	0	_	_	_	_
18	functional	functional	B-NP	JJ	0	_	_	_	_
19	and	and	I-NP	CC	0	_	_	_	_
20	structural	structural	I-NP	JJ	0	_	_	_	_
21	characteristics	characteristic	I-NP	NNS	0	_	_	_	_
22	for	for	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	regulation	regulation	I-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	their	their	B-NP	PRP$	0	_	_	_	_
27	copy	copy	I-NP	NN	0	_	_	_	_
28	numbers	number	I-NP	NNS	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	Perturbation	Perturbation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	dNTP	dNTP	B-NP	NN	0	_	_	_	_
4	pools	pool	I-NP	NNS	0	_	_	_	_
5	also	also	B-ADVP	RB	0	_	_	_	_
6	affected	affect	B-VP	VBD	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	frameshift	frameshift	I-NP	NN	0	_	_	_	_
9	fidelity	fidelity	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	replicative	replicative	I-NP	JJ	0	_	_	_	_
13	yeast	yeast	I-NP	NN	:::NOCLASS	_	_	_	_
14	DNA	DNA	I-NP	NN	:::NOCLASS	_	_	_	_
15	polymerase	polymerase	I-NP	NN	:::NOCLASS	_	_	_	_
16	alpha	alpha	I-NP	NN	:::NOCLASS	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Differential	Differential	B-NP	JJ	0	_	_	_	_
2	expression	expression	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	"	"	I-NP	``	0	_	_	_	_
6	B	B	I-NP	NN	0	_	_	_	_
7	"	"	I-NP	''	0	_	_	_	_
8	subunit	subunit	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	vacuolar	vacuolar	I-NP	JJ	:::NOCLASS	_	_	_	_
12	H	H	I-NP	NN	:::NOCLASS	_	_	_	_
13	(	(	O	(	:::NOCLASS	_	_	_	_
14	+	+	B-NP	SYM	:::NOCLASS	_	_	_	_
15	)	)	O	)	:::NOCLASS	_	_	_	_
16	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
17	ATPase	ATPase	I-NP	NN	:::NOCLASS	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	bovine	bovine	B-NP	JJ	0	_	_	_	_
20	tissues	tissue	I-NP	NNS	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	addition	addition	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	hGCSFR	hGCSFR	I-NP	NN	:::NOCLASS	_	_	_	_
6	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	chromosomally	chromosomally	I-VP	RB	0	_	_	_	_
9	localized	localize	I-VP	VBN	0	_	_	_	_
10	by	by	B-PP	IN	0	_	_	_	_
11	Southern	Southern	B-NP	JJ	0	_	_	_	_
12	blot	blot	I-NP	NN	0	_	_	_	_
13	analysis	analysis	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	its	its	B-NP	PRP$	0	_	_	_	_
16	segregation	segregation	I-NP	NN	0	_	_	_	_
17	pattern	pattern	I-NP	NN	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	panel	panel	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	rodent	rodent	B-NP	NN	0	_	_	_	_
23	-	-	B-NP	HYPH	0	_	_	_	_
24	human	human	I-NP	JJ	0	_	_	_	_
25	hybrid	hybrid	I-NP	NN	0	_	_	_	_
26	DNAs	DNA	I-NP	NNS	0	_	_	_	_
27	using	use	B-VP	VBG	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	radiolabeled	radiolabele	I-NP	VBN	0	_	_	_	_
30	cDNA	cDNA	I-NP	NN	0	_	_	_	_
31	probe	probe	I-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	have	have	B-VP	VBP	0	_	_	_	_
3	isolated	isolate	I-VP	VBN	0	_	_	_	_
4	and	and	I-VP	CC	0	_	_	_	_
5	characterised	characterise	I-VP	VBN	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	differentially	differentially	I-NP	RB	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	regulated	regulate	I-NP	VBN	0	_	_	_	_
10	gene	gene	I-NP	NN	0	_	_	_	_
11	family	family	I-NP	NN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	protozoan	protozoan	I-NP	NN	0	_	_	_	_
15	parasite	parasite	I-NP	NN	0	_	_	_	_
16	Leishmania	Leishmania	I-NP	NNP	0	_	_	_	_
17	major	major	I-NP	JJ	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	At	At	B-PP	IN	0	_	_	_	_
2	some	some	B-NP	DT	0	_	_	_	_
3	sites	site	I-NP	NNS	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	%	%	B-NP	NN	0	_	_	_	_
6	T	T	I-NP	NN	0	_	_	_	_
7	is	be	B-VP	VBZ	0	_	_	_	_
8	greatly	greatly	I-VP	RB	0	_	_	_	_
9	increased	increase	I-VP	VBN	0	_	_	_	_
10	by	by	B-PP	IN	0	_	_	_	_
11	Cl	Cl	B-NP	NN	0	_	_	_	_
12	-	-	O	HYPH	0	_	_	_	_
13	concentrations	concentration	B-NP	NNS	0	_	_	_	_
14	up	up	B-NP	IN	0	_	_	_	_
15	to	to	I-NP	TO	0	_	_	_	_
16	1	1	I-NP	CD	0	_	_	_	_
17	M	M	I-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	while	while	B-SBAR	IN	0	_	_	_	_
20	at	at	B-PP	IN	0	_	_	_	_
21	other	other	B-NP	JJ	0	_	_	_	_
22	sites	site	I-NP	NNS	0	_	_	_	_
23	%	%	I-NP	NN	0	_	_	_	_
24	T	T	I-NP	NN	0	_	_	_	_
25	is	be	B-VP	VBZ	0	_	_	_	_
26	reduced	reduce	I-VP	VBN	0	_	_	_	_
27	or	or	O	CC	0	_	_	_	_
28	unaffected	unaffected	B-ADJP	JJ	0	_	_	_	_
29	by	by	B-PP	IN	0	_	_	_	_
30	these	these	B-NP	DT	0	_	_	_	_
31	conditions	condition	I-NP	NNS	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Necrosis	Necrosis	B-NP	NN	0	_	_	_	_
2	appears	appear	B-VP	VBZ	0	_	_	_	_
3	6	6	B-NP	CD	0	_	_	_	_
4	h	h	I-NP	NN	0	_	_	_	_
5	after	after	B-PP	IN	0	_	_	_	_
6	TA	TA	B-NP	NN	0	_	_	_	_
7	infusion	infusion	I-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	being	be	B-VP	VBG	0	_	_	_	_
10	5	5	B-NP	CD	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_
12	77	77	B-NP	CD	0	_	_	_	_
13	%	%	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	extent	extent	B-NP	NN	0	_	_	_	_
16	after	after	B-PP	IN	0	_	_	_	_
17	12	12	B-NP	CD	0	_	_	_	_
18	h	h	I-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	14	14	B-NP	CD	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_
22	9	9	B-NP	CD	0	_	_	_	_
23	%	%	I-NP	NN	0	_	_	_	_
24	after	after	B-PP	IN	0	_	_	_	_
25	24	24	B-NP	CD	0	_	_	_	_
26	h	h	I-NP	NN	0	_	_	_	_
27	and	and	I-NP	CC	0	_	_	_	_
28	animals	animal	I-NP	NNS	0	_	_	_	_
29	die	die	B-VP	VBP	0	_	_	_	_
30	with	with	B-PP	IN	0	_	_	_	_
31	an	an	B-NP	DT	0	_	_	_	_
32	area	area	I-NP	NN	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	29	29	B-NP	CD	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_
36	5	5	B-NP	CD	0	_	_	_	_
37	%	%	I-NP	NN	0	_	_	_	_
38	necrosis	necrosis	I-NP	NN	0	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	summary	summary	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	segments	segment	I-NP	NNS	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	C3	C3	B-NP	NN	:::NOCLASS	_	_	_	_
8	represented	represent	B-VP	VBN	0	_	_	_	_
9	by	by	B-PP	IN	0	_	_	_	_
10	amino	amino	B-NP	JJ	0	_	_	_	_
11	acid	acid	I-NP	NN	0	_	_	_	_
12	residues	residue	I-NP	NNS	0	_	_	_	_
13	1082	1082	B-NP	CD	0	_	_	_	_
14	-	-	I-NP	HYPH	0	_	_	_	_
15	1118	1118	I-NP	CD	0	_	_	_	_
16	,	,	I-NP	,	0	_	_	_	_
17	1117	1117	I-NP	CD	0	_	_	_	_
18	-	-	I-NP	HYPH	0	_	_	_	_
19	1155	1155	I-NP	CD	0	_	_	_	_
20	,	,	I-NP	,	0	_	_	_	_
21	1234	1234	I-NP	CD	0	_	_	_	_
22	-	-	I-NP	HYPH	0	_	_	_	_
23	1294	1294	I-NP	CD	0	_	_	_	_
24	and	and	I-NP	CC	0	_	_	_	_
25	1312	1312	I-NP	CD	0	_	_	_	_
26	-	-	I-NP	HYPH	0	_	_	_	_
27	1404	1404	I-NP	CD	0	_	_	_	_
28	accommodate	accommodate	I-NP	NN	0	_	_	_	_
29	C3	C3	I-NP	NN	:::NOCLASS	_	_	_	_
30	(	(	O	(	:::NOCLASS	_	_	_	_
31	D	D	B-NP	NN	:::NOCLASS	_	_	_	_
32	)	)	O	)	:::NOCLASS	_	_	_	_
33	epitopes	epitope	B-NP	NNS	:::NOCLASS	_	_	_	_
34	that	that	B-NP	WDT	0	_	_	_	_
35	are	be	B-VP	VBP	0	_	_	_	_
36	expressed	express	I-VP	VBN	0	_	_	_	_
37	by	by	B-PP	IN	0	_	_	_	_
38	erythrocyte	erythrocyte	B-NP	NN	0	_	_	_	_
39	-	-	O	HYPH	0	_	_	_	_
40	bound	bind	B-NP	VBN	0	_	_	_	_
41	C3	C3	I-NP	NN	:::NOCLASS	_	_	_	_
42	fragments	fragment	I-NP	NNS	:::NOCLASS	_	_	_	_
43	,	,	B-PP	,	0	_	_	_	_
44	but	but	I-PP	CC	0	_	_	_	_
45	not	not	I-PP	RB	0	_	_	_	_
46	by	by	B-PP	IN	0	_	_	_	_
47	the	the	B-NP	DT	0	_	_	_	_
48	corresponding	correspond	I-NP	VBG	0	_	_	_	_
49	fluid	fluid	I-NP	NN	0	_	_	_	_
50	-	-	B-NP	HYPH	0	_	_	_	_
51	phase	phase	I-NP	NN	0	_	_	_	_
52	fragment	fragment	I-NP	NN	0	_	_	_	_
53	,	,	O	,	0	_	_	_	_
54	whereas	whereas	O	IN	0	_	_	_	_
55	the	the	B-NP	DT	0	_	_	_	_
56	segments	segment	I-NP	NNS	0	_	_	_	_
57	spanning	span	B-VP	VBG	0	_	_	_	_
58	residues	residue	B-NP	NNS	0	_	_	_	_
59	973	973	B-NP	CD	0	_	_	_	_
60	-	-	I-NP	HYPH	0	_	_	_	_
61	1026	1026	I-NP	CD	0	_	_	_	_
62	and	and	I-NP	CC	0	_	_	_	_
63	1477	1477	I-NP	CD	0	_	_	_	_
64	-	-	I-NP	HYPH	0	_	_	_	_
65	1510	1510	I-NP	CD	0	_	_	_	_
66	contain	contain	B-VP	VBP	0	_	_	_	_
67	C3	C3	B-NP	NN	:::NOCLASS	_	_	_	_
68	(	(	O	(	:::NOCLASS	_	_	_	_
69	D	D	B-NP	NN	:::NOCLASS	_	_	_	_
70	)	)	O	)	:::NOCLASS	_	_	_	_
71	epitopes	epitope	B-NP	NNS	:::NOCLASS	_	_	_	_
72	that	that	B-NP	WDT	0	_	_	_	_
73	are	be	B-VP	VBP	0	_	_	_	_
74	exposed	expose	I-VP	VBN	0	_	_	_	_
75	exclusively	exclusively	B-ADVP	RB	0	_	_	_	_
76	in	in	B-PP	IN	0	_	_	_	_
77	denatured	denature	B-NP	VBN	0	_	_	_	_
78	C3	C3	I-NP	NN	:::NOCLASS	_	_	_	_
79	and	and	O	CC	0	_	_	_	_
80	therefore	therefore	B-ADVP	RB	0	_	_	_	_
81	hidden	hide	B-VP	VBN	0	_	_	_	_
82	in	in	B-PP	IN	0	_	_	_	_
83	physiological	physiological	B-NP	JJ	0	_	_	_	_
84	fragments	fragment	I-NP	NNS	0	_	_	_	_
85	of	of	B-PP	IN	0	_	_	_	_
86	the	the	B-NP	DT	0	_	_	_	_
87	protein	protein	I-NP	NN	0	_	_	_	_
88	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	exons	exon	I-NP	NNS	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	further	further	B-VP	RB	0	_	_	_	_
5	identified	identify	I-VP	VBN	0	_	_	_	_
6	as	as	B-PP	IN	0	_	_	_	_
7	exons	exon	B-NP	NNS	0	_	_	_	_
8	9	9	I-NP	CD	0	_	_	_	_
9	,	,	I-NP	,	0	_	_	_	_
10	10	10	I-NP	CD	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	11	11	B-NP	CD	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	together	together	B-ADVP	RB	0	_	_	_	_
16	encode	encode	B-VP	VBP	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	37	37	I-NP	CD	0	_	_	_	_
19	amino	amino	I-NP	NN	0	_	_	_	_
20	acid	acid	I-NP	NN	0	_	_	_	_
21	residues	residue	I-NP	NNS	0	_	_	_	_
22	present	present	B-ADJP	JJ	0	_	_	_	_
23	in	in	B-PP	IN	0	_	_	_	_
24	alpha	alpha	B-NP	SYM	:::NOCLASS	_	_	_	_
25	s1	s1	I-NP	NN	:::NOCLASS	_	_	_	_
26	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
27	casein	casein	I-NP	NN	:::NOCLASS	_	_	_	_
28	variant	variant	I-NP	JJ	:::NOCLASS	_	_	_	_
29	A	A	I-NP	NN	:::NOCLASS	_	_	_	_
30	but	but	O	CC	0	_	_	_	_
31	missing	miss	B-VP	VBG	0	_	_	_	_
32	in	in	B-PP	IN	0	_	_	_	_
33	variant	variant	B-NP	JJ	0	_	_	_	_
34	F	F	I-NP	NN	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	also	also	B-ADVP	RB	0	_	_	_	_
3	report	report	B-VP	VBP	0	_	_	_	_
4	here	here	B-ADVP	RB	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	complete	complete	I-NP	JJ	0	_	_	_	_
7	structural	structural	I-NP	JJ	0	_	_	_	_
8	organization	organization	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	goat	goat	I-NP	NN	:::NOCLASS	_	_	_	_
12	alpha	alpha	I-NP	NN	:::NOCLASS	_	_	_	_
13	s1	s1	I-NP	NN	:::NOCLASS	_	_	_	_
14	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
15	casein	casein	I-NP	NN	:::NOCLASS	_	_	_	_
16	transcription	transcription	I-NP	NN	:::NOCLASS	_	_	_	_
17	unit	unit	I-NP	NN	:::NOCLASS	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	deduced	deduce	B-VP	VBN	0	_	_	_	_
20	from	from	B-PP	IN	0	_	_	_	_
21	polymerase	polymerase	B-NP	NN	0	_	_	_	_
22	chain	chain	I-NP	NN	0	_	_	_	_
23	reaction	reaction	I-NP	NN	0	_	_	_	_
24	experiments	experiment	I-NP	NNS	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Homodimers	Homodimer	B-NP	NNS	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	three	three	I-NP	CD	0	_	_	_	_
5	proteins	protein	I-NP	NNS	0	_	_	_	_
6	specifically	specifically	B-ADVP	RB	0	_	_	_	_
7	recognize	recognize	B-VP	VBP	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	G	G	I-NP	NN	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	box	box	I-NP	NN	0	_	_	_	_
12	motif	motif	I-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	GBF1	GBF1	B-NP	NN	:::NOCLASS	_	_	_	_
16	and	and	I-NP	CC	0	_	_	_	_
17	GBF3	GBF3	I-NP	NN	:::NOCLASS	_	_	_	_
18	binding	binding	I-NP	NN	0	_	_	_	_
19	symmetrically	symmetrically	B-ADVP	RB	0	_	_	_	_
20	to	to	B-PP	TO	0	_	_	_	_
21	this	this	B-NP	DT	0	_	_	_	_
22	palindromic	palindromic	I-NP	JJ	0	_	_	_	_
23	sequence	sequence	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Neither	Neither	B-NP	DT	0	_	_	_	_
2	gene	gene	I-NP	NN	0	_	_	_	_
3	possesses	possess	B-VP	VBZ	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	distinct	distinct	I-NP	JJ	0	_	_	_	_
6	transcriptional	transcriptional	I-NP	JJ	0	_	_	_	_
7	start	start	I-NP	NN	0	_	_	_	_
8	site	site	I-NP	NN	0	_	_	_	_
9	as	as	B-SBAR	IN	0	_	_	_	_
10	shown	show	B-VP	VBN	0	_	_	_	_
11	by	by	B-PP	IN	0	_	_	_	_
12	nuclease	nuclease	B-NP	NN	:::NOCLASS	_	_	_	_
13	S1	S1	I-NP	NN	:::NOCLASS	_	_	_	_
14	analysis	analysis	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	hydrophobicity	hydrophobicity	I-NP	NN	0	_	_	_	_
3	plot	plot	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	NHE	NHE	B-NP	NN	:::NOCLASS	_	_	_	_
6	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
7	3	3	I-NP	CD	:::NOCLASS	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	very	very	B-ADJP	RB	0	_	_	_	_
10	similar	similar	I-ADJP	JJ	0	_	_	_	_
11	to	to	B-PP	TO	0	_	_	_	_
12	that	that	B-NP	DT	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	NHE	NHE	B-NP	NN	:::NOCLASS	_	_	_	_
15	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
16	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
17	and	and	I-NP	CC	0	_	_	_	_
18	NHE	NHE	I-NP	NN	:::NOCLASS	_	_	_	_
19	-	-	O	HYPH	:::NOCLASS	_	_	_	_
20	2	2	B-NP	CD	:::NOCLASS	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	initial	initial	I-NP	JJ	0	_	_	_	_
3	translation	translation	I-NP	NN	0	_	_	_	_
4	protein	protein	I-NP	NN	0	_	_	_	_
5	encoded	encode	B-VP	VBN	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	cDNA	cDNA	I-NP	NN	0	_	_	_	_
9	is	be	B-VP	VBZ	0	_	_	_	_
10	53	53	B-NP	CD	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	932	932	B-NP	CD	0	_	_	_	_
13	kDa	kDa	I-NP	NN	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	possesses	possess	B-VP	VBZ	0	_	_	_	_
16	a	a	B-NP	DT	0	_	_	_	_
17	hydrophilic	hydrophilic	I-NP	JJ	0	_	_	_	_
18	amino	amino	I-NP	NN	0	_	_	_	_
19	acid	acid	I-NP	NN	0	_	_	_	_
20	composition	composition	I-NP	NN	0	_	_	_	_
21	with	with	B-PP	IN	0	_	_	_	_
22	glutamic	glutamic	B-NP	JJ	0	_	_	_	_
23	acid	acid	I-NP	NN	0	_	_	_	_
24	comprising	comprise	B-VP	VBG	0	_	_	_	_
25	22	22	B-NP	CD	0	_	_	_	_
26	%	%	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	total	total	I-NP	JJ	0	_	_	_	_
30	amino	amino	I-NP	JJ	0	_	_	_	_
31	acid	acid	I-NP	NN	0	_	_	_	_
32	residues	residue	I-NP	NNS	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Each	Each	B-NP	DT	0	_	_	_	_
2	group	group	I-NP	NN	0	_	_	_	_
3	received	receive	B-VP	VBD	0	_	_	_	_
4	15	15	B-NP	CD	0	_	_	_	_
5	ml	ml	I-NP	NN	0	_	_	_	_
6	/	/	O	SYM	0	_	_	_	_
7	kg	kg	B-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	either	either	B-NP	CC	0	_	_	_	_
10	6	6	I-NP	CD	0	_	_	_	_
11	%	%	I-NP	NN	0	_	_	_	_
12	pentafraction	pentafraction	I-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	6	6	B-NP	CD	0	_	_	_	_
15	%	%	I-NP	NN	0	_	_	_	_
16	pentastarch	pentastarch	I-NP	NN	0	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	or	or	O	CC	0	_	_	_	_
19	plasma	plasma	B-NP	NN	0	_	_	_	_
20	followed	follow	B-VP	VBD	0	_	_	_	_
21	two	two	B-NP	CD	0	_	_	_	_
22	hours	hour	I-NP	NNS	0	_	_	_	_
23	later	later	B-ADVP	RB	0	_	_	_	_
24	by	by	B-PP	IN	0	_	_	_	_
25	1	1	B-NP	CD	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_
27	5	5	B-NP	CD	0	_	_	_	_
28	micrograms	microgram	I-NP	NNS	0	_	_	_	_
29	/	/	B-NP	SYM	0	_	_	_	_
30	kg	kg	I-NP	NN	0	_	_	_	_
31	/	/	B-NP	SYM	0	_	_	_	_
32	0	0	I-NP	CD	0	_	_	_	_
33	.	.	I-NP	SYM	0	_	_	_	_
34	5	5	I-NP	CD	0	_	_	_	_
35	hr	hr	I-NP	NN	0	_	_	_	_
36	E	E	I-NP	NN	0	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	Genetic	Genetic	B-NP	JJ	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	biochemical	biochemical	I-NP	JJ	0	_	_	_	_
4	evidence	evidence	I-NP	NN	0	_	_	_	_
5	suggests	suggest	B-VP	VBZ	0	_	_	_	_
6	that	that	B-SBAR	IN	0	_	_	_	_
7	v	v	B-NP	NN	:::NOCLASS	_	_	_	_
8	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
9	Crk	Crk	I-NP	NN	:::NOCLASS	_	_	_	_
10	can	can	B-VP	MD	0	_	_	_	_
11	induce	induce	I-VP	VB	0	_	_	_	_
12	transformation	transformation	B-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	chicken	chicken	B-NP	NN	0	_	_	_	_
15	embryo	embryo	I-NP	NN	0	_	_	_	_
16	fibroblasts	fibroblast	I-NP	NNS	0	_	_	_	_
17	by	by	B-PP	IN	0	_	_	_	_
18	influencing	influence	B-VP	VBG	0	_	_	_	_
19	the	the	B-NP	DT	0	_	_	_	_
20	activity	activity	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	cellular	cellular	B-NP	JJ	0	_	_	_	_
23	proteins	protein	I-NP	NNS	0	_	_	_	_
24	involved	involve	B-VP	VBN	0	_	_	_	_
25	in	in	B-PP	IN	0	_	_	_	_
26	growth	growth	B-NP	NN	0	_	_	_	_
27	regulation	regulation	I-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	have	have	B-VP	VBP	0	_	_	_	_
3	constructed	construct	I-VP	VBN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	using	use	B-VP	VBG	0	_	_	_	_
6	synthetic	synthetic	B-NP	JJ	0	_	_	_	_
7	DNA	DNA	I-NP	NN	0	_	_	_	_
8	oligonucleotides	oligonucleotide	I-NP	NNS	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	U14	U14	I-NP	NN	:::NOCLASS	_	_	_	_
12	snRNA	snRNA	I-NP	NN	:::NOCLASS	_	_	_	_
13	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
14	which	which	B-NP	WDT	0	_	_	_	_
15	has	have	B-VP	VBZ	0	_	_	_	_
16	been	be	I-VP	VBN	0	_	_	_	_
17	positioned	position	I-VP	VBN	0	_	_	_	_
18	behind	behind	B-PP	IN	0	_	_	_	_
19	a	a	B-NP	DT	0	_	_	_	_
20	T7	T7	I-NP	NN	:::NOCLASS	_	_	_	_
21	RNA	RNA	I-NP	NN	:::NOCLASS	_	_	_	_
22	polymerase	polymerase	I-NP	NN	:::NOCLASS	_	_	_	_
23	promoter	promoter	I-NP	NN	:::NOCLASS	_	_	_	_
24	site	site	I-NP	NN	:::NOCLASS	_	_	_	_
25	and	and	O	CC	0	_	_	_	_
26	then	then	B-VP	RB	0	_	_	_	_
27	inserted	insert	I-VP	VBN	0	_	_	_	_
28	into	into	B-PP	IN	0	_	_	_	_
29	a	a	B-NP	DT	0	_	_	_	_
30	plasmid	plasmid	I-NP	NN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Gene	Gene	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	pseudogene	pseudogene	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	mouse	mouse	I-NP	NN	0	_	_	_	_
7	cation	cation	I-NP	NN	0	_	_	_	_
8	-	-	B-NP	HYPH	0	_	_	_	_
9	dependent	dependent	I-NP	JJ	0	_	_	_	_
10	mannose	mannose	I-NP	NN	:::NOCLASS	_	_	_	_
11	6	6	I-NP	CD	:::NOCLASS	_	_	_	_
12	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
13	phosphate	phosphate	I-NP	NN	:::NOCLASS	_	_	_	_
14	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	chick	chick	I-NP	NN	0	_	_	_	_
3	axon	axon	I-NP	NN	0	_	_	_	_
4	-	-	B-VP	HYPH	0	_	_	_	_
5	associated	associate	B-NP	VBN	0	_	_	_	_
6	surface	surface	I-NP	NN	0	_	_	_	_
7	glycoprotein	glycoprotein	I-NP	NN	0	_	_	_	_
8	neurofascin	neurofascin	I-NP	NN	:::NOCLASS	_	_	_	_
9	is	be	B-VP	VBZ	0	_	_	_	_
10	implicated	implicate	I-VP	VBN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	axonal	axonal	B-NP	JJ	0	_	_	_	_
13	growth	growth	I-NP	NN	0	_	_	_	_
14	and	and	I-NP	CC	0	_	_	_	_
15	fasciculation	fasciculation	I-NP	NN	0	_	_	_	_
16	as	as	B-SBAR	IN	0	_	_	_	_
17	revealed	reveal	B-VP	VBN	0	_	_	_	_
18	by	by	B-PP	IN	0	_	_	_	_
19	antibody	antibody	B-NP	NN	0	_	_	_	_
20	perturbation	perturbation	I-NP	NN	0	_	_	_	_
21	experiments	experiment	I-NP	NNS	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	carcinoma	carcinoma	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	restricted	restricted	B-ADJP	JJ	0	_	_	_	_
5	within	within	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	epithelium	epithelium	I-NP	NN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	one	one	B-NP	CD	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	mucosal	mucosal	I-NP	JJ	0	_	_	_	_
13	layer	layer	I-NP	NN	UMLS:C0934502:T023:ANAT	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	five	five	B-NP	CD	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	submucosal	submucosal	I-NP	JJ	0	_	_	_	_
20	layer	layer	I-NP	NN	UMLS:C0934502:T023:ANAT	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	two	two	B-NP	CD	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	addition	addition	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	C	C	B-NP	NN	:::NOCLASS	_	_	_	_
5	/	/	I-NP	SYM	:::NOCLASS	_	_	_	_
6	EBP	EBP	I-NP	NN	:::NOCLASS	_	_	_	_
7	beta	beta	B-NP	SYM	:::NOCLASS	_	_	_	_
8	and	and	O	CC	0	_	_	_	_
9	C	C	B-NP	NN	:::NOCLASS	_	_	_	_
10	/	/	I-NP	SYM	:::NOCLASS	_	_	_	_
11	EBP	EBP	I-NP	NN	:::NOCLASS	_	_	_	_
12	gamma	gamma	B-VP	SYM	:::NOCLASS	_	_	_	_
13	readily	readily	I-VP	RB	0	_	_	_	_
14	heterodimerize	heterodimerize	I-VP	VB	0	_	_	_	_
15	with	with	B-PP	IN	0	_	_	_	_
16	each	each	B-NP	DT	0	_	_	_	_
17	other	other	I-NP	JJ	0	_	_	_	_
18	as	as	B-CONJP	RB	0	_	_	_	_
19	well	well	I-CONJP	RB	0	_	_	_	_
20	as	as	I-CONJP	IN	0	_	_	_	_
21	with	with	B-PP	IN	0	_	_	_	_
22	C	C	B-NP	NN	:::NOCLASS	_	_	_	_
23	/	/	B-NP	SYM	:::NOCLASS	_	_	_	_
24	EBP	EBP	I-NP	NN	:::NOCLASS	_	_	_	_
25	alpha	alpha	B-NP	SYM	:::NOCLASS	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	contrast	contrast	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	tobacco	tobacco	B-NP	NN	:::NOCLASS	_	_	_	_
5	GS	GS	I-NP	NN	:::NOCLASS|UMLS:C0017097:T047:DISO	_	_	_	_
6	-	-	O	HYPH	:::NOCLASS	_	_	_	_
7	2	2	B-NP	CD	:::NOCLASS	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	composed	compose	I-VP	VBN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	subunits	subunit	B-NP	NNS	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	identical	identical	B-NP	JJ	0	_	_	_	_
14	size	size	I-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	all	all	B-NP	DT	0	_	_	_	_
17	organs	organ	I-NP	NNS	UMLS:C0178784:T023:ANAT	_	_	_	_
18	examined	examine	B-VP	VBN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	Between	Between	B-PP	IN	0	_	_	_	_
2	acoR	acoR	B-NP	NN	:::NOCLASS	_	_	_	_
3	and	and	I-NP	CC	0	_	_	_	_
4	acoXABC	acoXABC	I-NP	NN	:::NOCLASS	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	two	two	B-NP	CD	0	_	_	_	_
7	different	different	I-NP	JJ	0	_	_	_	_
8	types	type	I-NP	NNS	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	sequences	sequence	B-NP	NNS	0	_	_	_	_
11	with	with	B-PP	IN	0	_	_	_	_
12	dual	dual	B-NP	JJ	0	_	_	_	_
13	rotational	rotational	I-NP	JJ	0	_	_	_	_
14	symmetry	symmetry	I-NP	NN	0	_	_	_	_
15	[	[	O	(	0	_	_	_	_
16	CAC	CAC	B-NP	NN	0	_	_	_	_
17	-	-	O	HYPH	0	_	_	_	_
18	(	(	O	(	0	_	_	_	_
19	N11	N11	B-NP	NN	0	_	_	_	_
20	to	to	B-PP	TO	0	_	_	_	_
21	N18	N18	B-NP	NN	0	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	-	-	B-NP	HYPH	0	_	_	_	_
24	GTG	GTG	I-NP	NN	0	_	_	_	_
25	and	and	I-NP	CC	0	_	_	_	_
26	TGT	TGT	I-NP	NN	0	_	_	_	_
27	-	-	O	HYPH	0	_	_	_	_
28	(	(	O	(	0	_	_	_	_
29	N10	N10	B-NP	NN	0	_	_	_	_
30	to	to	B-PP	TO	0	_	_	_	_
31	N14	N14	B-NP	NN	0	_	_	_	_
32	)	)	O	)	0	_	_	_	_
33	-	-	B-NP	HYPH	0	_	_	_	_
34	ACA	ACA	I-NP	NN	UMLS:C0149561:T023:ANAT	_	_	_	_
35	]	]	O	)	0	_	_	_	_
36	were	be	B-VP	VBD	0	_	_	_	_
37	found	find	I-VP	VBN	0	_	_	_	_
38	;	;	O	:	0	_	_	_	_
39	these	these	B-NP	DT	0	_	_	_	_
40	sequences	sequence	I-NP	NNS	0	_	_	_	_
41	are	be	B-VP	VBP	0	_	_	_	_
42	similar	similar	B-ADJP	JJ	0	_	_	_	_
43	to	to	B-PP	TO	0	_	_	_	_
44	NtrC	NtrC	B-NP	NN	:::NOCLASS	_	_	_	_
45	and	and	I-NP	CC	0	_	_	_	_
46	NifA	NifA	I-NP	NN	:::NOCLASS	_	_	_	_
47	upstream	upstream	I-NP	JJ	:::NOCLASS	_	_	_	_
48	activator	activator	I-NP	NN	:::NOCLASS	_	_	_	_
49	sequences	sequence	I-NP	NNS	:::NOCLASS	_	_	_	_
50	,	,	O	,	0	_	_	_	_
51	respectively	respectively	B-ADVP	RB	0	_	_	_	_
52	.	.	O	.	0	_	_	_	_

1	Although	Although	B-SBAR	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	effects	effect	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	calcium	calcium	I-NP	NN	0	_	_	_	_
7	supplement	supplement	I-NP	NN	0	_	_	_	_
8	or	or	O	CC	0	_	_	_	_
9	calcium	calcium	B-NP	NN	0	_	_	_	_
10	antagonist	antagonist	I-NP	NN	0	_	_	_	_
11	alone	alone	B-ADVP	RB	0	_	_	_	_
12	were	be	B-VP	VBD	0	_	_	_	_
13	significant	significant	B-ADJP	JJ	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	such	such	B-NP	JJ	0	_	_	_	_
16	hypotensive	hypotensive	I-NP	JJ	0	_	_	_	_
17	responses	response	I-NP	NNS	0	_	_	_	_
18	were	be	B-VP	VBD	0	_	_	_	_
19	not	not	O	RB	0	_	_	_	_
20	optimal	optimal	B-ADJP	JJ	0	_	_	_	_
21	or	or	I-ADJP	CC	0	_	_	_	_
22	predictable	predictable	I-ADJP	JJ	0	_	_	_	_
23	or	or	O	CC	0	_	_	_	_
24	clearly	clearly	B-ADVP	RB	0	_	_	_	_
25	dose	dose	B-NP	NN	0	_	_	_	_
26	-	-	B-VP	HYPH	0	_	_	_	_
27	dependent	dependent	B-ADJP	JJ	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	C	C	B-NP	NN	0	_	_	_	_
2	.	.	I-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	Sun	Sun	B-NP	NNP	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	J	J	B-NP	NNP	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	Hsu	Hsu	B-NP	NNP	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	M	M	B-NP	NNP	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	Y	Y	I-NP	NN	0	_	_	_	_
15	.	.	I-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	Vallejo	Vallejo	B-NP	NNP	0	_	_	_	_
18	-	-	I-NP	HYPH	0	_	_	_	_
19	Ramirez	Ramirez	I-NP	NNP	0	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	J	J	B-NP	NNP	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	Inouye	Inouye	B-NP	NNP	0	_	_	_	_
25	,	,	O	,	0	_	_	_	_
26	S	S	B-NP	NNP	0	_	_	_	_
27	.	.	I-NP	NN	0	_	_	_	_
28	,	,	O	,	0	_	_	_	_
29	and	and	O	CC	0	_	_	_	_
30	Inouye	Inouye	B-NP	NNP	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	M	M	B-NP	NNP	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Surprisingly	Surprisingly	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	full	full	I-NP	JJ	0	_	_	_	_
5	-	-	I-NP	HYPH	0	_	_	_	_
6	deletion	deletion	I-NP	NN	0	_	_	_	_
7	mutant	mutant	I-NP	NN	0	_	_	_	_
8	showed	show	B-VP	VBD	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	strong	strong	I-NP	JJ	0	_	_	_	_
11	block	block	I-NP	NN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	virus	virus	B-NP	NN	0	_	_	_	_
14	release	release	I-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	suggesting	suggest	B-VP	VBG	0	_	_	_	_
17	that	that	B-SBAR	IN	0	_	_	_	_
18	NC	NC	B-NP	NN	:::NOCLASS	_	_	_	_
19	is	be	B-VP	VBZ	0	_	_	_	_
20	involved	involve	I-VP	VBN	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	virus	virus	B-NP	NN	0	_	_	_	_
23	assembly	assembly	I-NP	NN	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Furthermore	Furthermore	B-ADVP	RB	0	_	_	_	_
2	it	it	B-NP	PRP	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	suggested	suggest	I-VP	VBN	0	_	_	_	_
5	that	that	B-SBAR	IN	0	_	_	_	_
6	FK506	FK506	B-NP	NN	0	_	_	_	_
7	plasma	plasma	I-NP	NN	0	_	_	_	_
8	levels	level	I-NP	NNS	0	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	concerned	concern	I-VP	VBN	0	_	_	_	_
11	with	with	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	appearance	appearance	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	side	side	B-NP	NN	0	_	_	_	_
16	effect	effect	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Thirty	Thirty	B-NP	CD	0	_	_	_	_
2	percent	percent	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	patients	patient	B-NP	NNS	0	_	_	_	_
5	were	be	B-VP	VBD	0	_	_	_	_
6	tapered	taper	I-VP	VBN	0	_	_	_	_
7	off	off	B-PRT	RP	0	_	_	_	_
8	all	all	B-NP	DT	0	_	_	_	_
9	steroids	steroid	I-NP	NNS	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	average	average	I-NP	JJ	0	_	_	_	_
14	steroid	steroid	I-NP	NN	0	_	_	_	_
15	dose	dose	I-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	group	group	I-NP	NN	0	_	_	_	_
19	who	who	B-NP	WP	0	_	_	_	_
20	received	receive	B-VP	VBD	0	_	_	_	_
21	steroids	steroid	B-NP	NNS	0	_	_	_	_
22	was	be	B-VP	VBD	0	_	_	_	_
23	8	8	B-NP	CD	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_
25	6	6	B-NP	CD	0	_	_	_	_
26	mg	mg	I-NP	NN	0	_	_	_	_
27	of	of	B-PP	IN	0	_	_	_	_
28	prednisone	prednisone	B-NP	NN	0	_	_	_	_
29	per	per	B-PP	IN	0	_	_	_	_
30	day	day	B-NP	NN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Thus	Thus	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	cibenzoline	cibenzoline	B-NP	NN	0	_	_	_	_
4	is	be	B-VP	VBZ	0	_	_	_	_
5	an	an	B-NP	DT	0	_	_	_	_
6	effective	effective	I-NP	JJ	0	_	_	_	_
7	antiarrhythmic	antiarrhythmic	I-NP	JJ	0	_	_	_	_
8	agent	agent	I-NP	NN	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	favourable	favourable	I-NP	JJ	0	_	_	_	_
12	pharmacokinetic	pharmacokinetic	I-NP	JJ	0	_	_	_	_
13	profile	profile	I-NP	NN	0	_	_	_	_
14	that	that	B-NP	WDT	0	_	_	_	_
15	may	may	B-VP	MD	0	_	_	_	_
16	be	be	I-VP	VB	0	_	_	_	_
17	considered	consider	I-VP	VBN	0	_	_	_	_
18	with	with	B-PP	IN	0	_	_	_	_
19	other	other	B-NP	JJ	0	_	_	_	_
20	class	class	I-NP	NN	0	_	_	_	_
21	I	I	B-NP	CD	0	_	_	_	_
22	drugs	drug	I-NP	NNS	0	_	_	_	_
23	in	in	B-PP	IN	0	_	_	_	_
24	patients	patient	B-NP	NNS	0	_	_	_	_
25	requiring	require	B-VP	VBG	0	_	_	_	_
26	therapy	therapy	B-NP	NN	0	_	_	_	_
27	for	for	B-PP	IN	0	_	_	_	_
28	high	high	B-NP	JJ	0	_	_	_	_
29	risk	risk	I-NP	NN	0	_	_	_	_
30	arrhythmias	arrhythmia	I-NP	NNS	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	T	T	B-NP	NN	:::NOCLASS	_	_	_	_
2	antigen	antigen	I-NP	NN	:::NOCLASS	_	_	_	_
3	contains	contain	B-VP	VBZ	0	_	_	_	_
4	four	four	B-NP	CD	0	_	_	_	_
5	H	H	I-NP	NN	0	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	2Db	2Db	I-NP	NN	0	_	_	_	_
8	-	-	B-VP	HYPH	0	_	_	_	_
9	restricted	restrict	B-NP	VBN	0	_	_	_	_
10	cytotoxic	cytotoxic	I-NP	JJ	0	_	_	_	_
11	T	T	I-NP	NN	0	_	_	_	_
12	lymphocyte	lymphocyte	I-NP	NN	0	_	_	_	_
13	(	(	O	(	0	_	_	_	_
14	CTL	CTL	B-NP	NN	0	_	_	_	_
15	)	)	O	)	0	_	_	_	_
16	recognition	recognition	B-NP	NN	0	_	_	_	_
17	epitopes	epitope	I-NP	NNS	0	_	_	_	_
18	that	that	B-NP	WDT	0	_	_	_	_
19	are	be	B-VP	VBP	0	_	_	_	_
20	targets	target	B-NP	NNS	0	_	_	_	_
21	for	for	B-PP	IN	0	_	_	_	_
22	CTL	CTL	B-NP	NN	0	_	_	_	_
23	clones	clone	I-NP	NNS	0	_	_	_	_
24	Y	Y	I-NP	NN	0	_	_	_	_
25	-	-	B-NP	HYPH	0	_	_	_	_
26	1	1	I-NP	CD	0	_	_	_	_
27	,	,	O	,	0	_	_	_	_
28	Y	Y	B-NP	NN	0	_	_	_	_
29	-	-	O	HYPH	0	_	_	_	_
30	2	2	B-NP	CD	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	Y	Y	B-NP	NN	0	_	_	_	_
33	-	-	B-NP	HYPH	0	_	_	_	_
34	3	3	I-NP	CD	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	and	and	O	CC	0	_	_	_	_
37	Y	Y	B-NP	NN	0	_	_	_	_
38	-	-	O	HYPH	0	_	_	_	_
39	5	5	B-NP	CD	0	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	method	method	I-NP	NN	0	_	_	_	_
3	requires	require	B-VP	VBZ	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	reversed	reverse	I-NP	VBN	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	phase	phase	I-NP	NN	0	_	_	_	_
8	column	column	I-NP	NN	UMLS:C1185738:T023:ANAT	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	paired	paired	I-NP	JJ	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	ion	ion	I-NP	NN	0	_	_	_	_
14	technique	technique	I-NP	NN	0	_	_	_	_
15	to	to	B-PP	TO	0	_	_	_	_
16	separate	separate	B-NP	JJ	0	_	_	_	_
17	docusate	docusate	I-NP	NN	0	_	_	_	_
18	sodium	sodium	I-NP	NN	0	_	_	_	_
19	from	from	B-PP	IN	0	_	_	_	_
20	other	other	B-NP	JJ	0	_	_	_	_
21	components	component	I-NP	NNS	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Here	Here	B-ADVP	RB	0	_	_	_	_
2	we	we	B-NP	PRP	0	_	_	_	_
3	demonstrate	demonstrate	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	protein	protein	I-NP	NN	0	_	_	_	_
7	product	product	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	ref	ref	I-NP	NN	:::NOCLASS	_	_	_	_
11	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
12	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
13	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
14	stimulates	stimulate	B-VP	VBZ	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	DNA	DNA	I-NP	NN	0	_	_	_	_
17	binding	binding	I-NP	NN	0	_	_	_	_
18	activity	activity	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	Fos	Fos	B-NP	NN	:::NOCLASS	_	_	_	_
21	-	-	B-NP	HYPH	0	_	_	_	_
22	Jun	Jun	I-NP	NN	:::NOCLASS	_	_	_	_
23	heterodimers	heterodimer	I-NP	NNS	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	Jun	Jun	B-NP	NN	:::NOCLASS	_	_	_	_
26	-	-	I-NP	HYPH	0	_	_	_	_
27	Jun	Jun	I-NP	NN	:::NOCLASS	_	_	_	_
28	homodimers	homodimer	I-NP	NNS	0	_	_	_	_
29	and	and	O	CC	0	_	_	_	_
30	Hela	Hela	B-NP	NN	0	_	_	_	_
31	cell	cell	I-NP	NN	0	_	_	_	_
32	AP	AP	I-NP	NN	:::NOCLASS	_	_	_	_
33	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
34	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
35	proteins	protein	I-NP	NNS	:::NOCLASS	_	_	_	_
36	as	as	B-CONJP	RB	0	_	_	_	_
37	well	well	I-CONJP	RB	0	_	_	_	_
38	as	as	I-CONJP	IN	0	_	_	_	_
39	that	that	B-NP	DT	0	_	_	_	_
40	of	of	B-PP	IN	0	_	_	_	_
41	several	several	B-NP	JJ	0	_	_	_	_
42	other	other	I-NP	JJ	0	_	_	_	_
43	transcription	transcription	I-NP	NN	0	_	_	_	_
44	factors	factor	I-NP	NNS	0	_	_	_	_
45	including	include	B-PP	VBG	0	_	_	_	_
46	NF	NF	B-NP	NN	:::NOCLASS	_	_	_	_
47	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
48	kappa	kappa	I-NP	NN	:::NOCLASS	_	_	_	_
49	B	B	I-NP	NN	:::NOCLASS	_	_	_	_
50	,	,	O	,	0	_	_	_	_
51	Myb	Myb	B-NP	NN	:::NOCLASS	_	_	_	_
52	and	and	O	CC	0	_	_	_	_
53	members	member	B-NP	NNS	0	_	_	_	_
54	of	of	B-PP	IN	0	_	_	_	_
55	the	the	B-NP	DT	0	_	_	_	_
56	ATF	ATF	I-NP	NN	:::NOCLASS	_	_	_	_
57	/	/	B-NP	SYM	0	_	_	_	_
58	CREB	CREB	I-NP	NN	:::NOCLASS	_	_	_	_
59	family	family	I-NP	NN	0	_	_	_	_
60	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	pulpal	pulpal	I-NP	JJ	0	_	_	_	_
3	tissues	tissue	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	permanent	permanent	I-NP	JJ	0	_	_	_	_
7	mandibular	mandibular	I-NP	JJ	UMLS:C0024687:T023:ANAT	_	_	_	_
8	molars	molar	I-NP	NNS	UMLS:C0026367:T023:ANAT	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	amputated	amputate	I-VP	VBN	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	then	then	B-VP	RB	0	_	_	_	_
13	dressed	dress	I-VP	VBN	0	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	calcium	calcium	B-NP	NN	0	_	_	_	_
16	hydrate	hydrate	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Northern	Northern	B-NP	NN	0	_	_	_	_
2	blot	blot	I-NP	NN	0	_	_	_	_
3	analyses	analysis	I-NP	NNS	0	_	_	_	_
4	demonstrate	demonstrate	B-VP	VBP	0	_	_	_	_
5	that	that	B-SBAR	IN	0	_	_	_	_
6	3	3	B-NP	CD	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_
8	9	9	B-NP	CD	0	_	_	_	_
9	-	-	B-NP	HYPH	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	5	5	I-NP	CD	0	_	_	_	_
12	-	-	I-NP	HYPH	0	_	_	_	_
13	kilobase	kilobase	I-NP	NN	0	_	_	_	_
14	mRNAs	mRNA	I-NP	NNS	0	_	_	_	_
15	corresponding	correspond	B-VP	VBG	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	cDNA	cDNA	I-NP	NN	0	_	_	_	_
19	were	be	B-VP	VBD	0	_	_	_	_
20	present	present	B-ADJP	JJ	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	all	all	B-NP	DT	0	_	_	_	_
23	tissues	tissue	I-NP	NNS	0	_	_	_	_
24	examined	examine	B-VP	VBN	0	_	_	_	_
25	,	,	O	,	0	_	_	_	_
26	suggesting	suggest	B-VP	VBG	0	_	_	_	_
27	that	that	B-SBAR	IN	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	protein	protein	I-NP	NN	0	_	_	_	_
30	it	it	B-NP	PRP	0	_	_	_	_
31	encodes	encode	B-VP	VBZ	0	_	_	_	_
32	performs	perform	B-VP	VBZ	0	_	_	_	_
33	a	a	B-NP	DT	0	_	_	_	_
34	housekeeping	housekeeping	I-NP	JJ	0	_	_	_	_
35	function	function	I-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	ARG	ARG	I-NP	NN	:::NOCLASS	_	_	_	_
3	SH2	SH2	I-NP	NN	:::NOCLASS	_	_	_	_
4	domain	domain	I-NP	NN	:::NOCLASS	_	_	_	_
5	exhibited	exhibit	B-VP	VBD	0	_	_	_	_
6	relatively	relatively	B-NP	RB	0	_	_	_	_
7	weak	weak	I-NP	JJ	0	_	_	_	_
8	affinity	affinity	I-NP	NN	0	_	_	_	_
9	for	for	B-PP	IN	0	_	_	_	_
10	BCR	BCR	B-NP	NN	:::NOCLASS	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	was	be	B-VP	VBD	0	_	_	_	_
13	determined	determine	I-VP	VBN	0	_	_	_	_
14	to	to	I-VP	TO	0	_	_	_	_
15	bind	bind	I-VP	VB	0	_	_	_	_
16	about	about	B-NP	RB	0	_	_	_	_
17	10	10	I-NP	CD	0	_	_	_	_
18	-	-	I-NP	HYPH	0	_	_	_	_
19	fold	fold	I-NP	RB	0	_	_	_	_
20	less	less	I-NP	RBR	0	_	_	_	_
21	strongly	strongly	I-NP	RB	0	_	_	_	_
22	than	than	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	ABL	ABL	I-NP	NN	UMLS:C0000744:T047:DISO|:::NOCLASS	_	_	_	_
25	SH2	SH2	I-NP	NN	:::NOCLASS	_	_	_	_
26	domain	domain	I-NP	NN	:::NOCLASS	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	analyzed	analyze	B-VP	VBD	0	_	_	_	_
3	an	an	B-NP	DT	0	_	_	_	_
4	EBV	EBV	I-NP	NN	0	_	_	_	_
5	B	B	I-NP	NN	0	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	cell	cell	I-NP	NN	0	_	_	_	_
8	clone	clone	I-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	E29	E29	B-NP	NN	0	_	_	_	_
11	.	.	I-NP	.	0	_	_	_	_
12	1	1	I-NP	CD	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	derived	derive	B-VP	VBN	0	_	_	_	_
15	from	from	B-PP	IN	0	_	_	_	_
16	an	an	B-NP	DT	0	_	_	_	_
17	11	11	I-NP	CD	0	_	_	_	_
18	week	week	I-NP	NN	0	_	_	_	_
19	-	-	B-NP	HYPH	0	_	_	_	_
20	old	old	I-NP	JJ	0	_	_	_	_
21	embryo	embryo	I-NP	NN	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	and	and	O	CC	0	_	_	_	_
24	secreting	secrete	B-VP	VBG	0	_	_	_	_
25	both	both	O	CC	0	_	_	_	_
26	IgM	IgM	B-NP	NN	:::NOCLASS	_	_	_	_
27	kappa	kappa	I-NP	NN	:::NOCLASS	_	_	_	_
28	and	and	O	CC	0	_	_	_	_
29	IgM	IgM	B-NP	NN	:::NOCLASS	_	_	_	_
30	lambda	lambda	I-NP	NN	:::NOCLASS	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Interestingly	Interestingly	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	this	this	B-NP	DT	0	_	_	_	_
4	activation	activation	I-NP	NN	0	_	_	_	_
5	occurred	occur	B-VP	VBD	0	_	_	_	_
6	only	only	B-ADVP	RB	0	_	_	_	_
7	when	when	B-ADVP	WRB	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	regions	region	I-NP	NNS	0	_	_	_	_
10	were	be	B-VP	VBD	0	_	_	_	_
11	cloned	clone	I-VP	VBN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	same	same	I-NP	JJ	0	_	_	_	_
15	relative	relative	I-NP	JJ	0	_	_	_	_
16	orientation	orientation	I-NP	NN	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	which	which	B-NP	WDT	0	_	_	_	_
19	they	they	B-NP	PRP	0	_	_	_	_
20	exist	exist	B-VP	VBP	0	_	_	_	_
21	on	on	B-PP	IN	0	_	_	_	_
22	wild	wild	B-NP	JJ	0	_	_	_	_
23	-	-	I-NP	HYPH	0	_	_	_	_
24	type	type	I-NP	NN	0	_	_	_	_
25	pCF10	pCF10	I-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	rats	rat	B-NP	NNS	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	we	we	B-NP	PRP	0	_	_	_	_
5	examined	examine	B-VP	VBD	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	effect	effect	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	an	an	B-NP	DT	0	_	_	_	_
10	omentum	omentum	I-NP	NN	UMLS:C0028977:T023:ANAT	_	_	_	_
11	wrapping	wrap	B-VP	VBG	0	_	_	_	_
12	on	on	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	vascularization	vascularization	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	trachea	trachea	I-NP	NN	UMLS:C0040578:T023:ANAT	_	_	_	_
18	and	and	B-PP	CC	0	_	_	_	_
19	on	on	B-PP	IN	0	_	_	_	_
20	regeneration	regeneration	B-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	mucosal	mucosal	I-NP	JJ	0	_	_	_	_
24	epithelium	epithelium	I-NP	NN	0	_	_	_	_
25	in	in	B-PP	IN	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	very	very	I-NP	RB	0	_	_	_	_
28	early	early	I-NP	JJ	0	_	_	_	_
29	stage	stage	I-NP	NN	0	_	_	_	_
30	after	after	B-PP	IN	0	_	_	_	_
31	free	free	B-NP	JJ	0	_	_	_	_
32	tracheal	tracheal	I-NP	JJ	0	_	_	_	_
33	grafting	grafting	I-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	To	To	B-VP	TO	0	_	_	_	_
2	study	study	I-VP	VB	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	possible	possible	I-NP	JJ	0	_	_	_	_
5	functional	functional	I-NP	JJ	0	_	_	_	_
6	role	role	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	this	this	B-NP	DT	0	_	_	_	_
9	putative	putative	I-NP	JJ	0	_	_	_	_
10	chicken	chicken	I-NP	NN	0	_	_	_	_
11	ICS	ICS	I-NP	NN	UMLS:C0022521:T047:DISO|:::NOCLASS	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	an	an	B-NP	DT	0	_	_	_	_
14	oligonucleotide	oligonucleotide	I-NP	NN	0	_	_	_	_
15	spanning	span	B-VP	VBG	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	upstream	upstream	I-NP	JJ	0	_	_	_	_
18	sequences	sequence	I-NP	NNS	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	BF	BF	I-NP	NN	:::NOCLASS	_	_	_	_
22	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
23	IV	IV	I-NP	CD	:::NOCLASS	_	_	_	_
24	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
25	(	(	O	(	0	_	_	_	_
26	-	-	B-NP	SYM	0	_	_	_	_
27	174	174	B-NP	CD	0	_	_	_	_
28	/	/	I-NP	SYM	0	_	_	_	_
29	-	-	I-NP	SYM	0	_	_	_	_
30	194	194	I-NP	CD	0	_	_	_	_
31	)	)	O	)	0	_	_	_	_
32	was	be	B-VP	VBD	0	_	_	_	_
33	cloned	clone	I-VP	VBN	0	_	_	_	_
34	singly	singly	B-ADVP	RB	0	_	_	_	_
35	or	or	O	CC	0	_	_	_	_
36	in	in	B-PP	IN	0	_	_	_	_
37	multiple	multiple	B-NP	JJ	0	_	_	_	_
38	copies	copy	I-NP	NNS	0	_	_	_	_
39	before	before	B-PP	IN	0	_	_	_	_
40	the	the	B-NP	DT	0	_	_	_	_
41	herpes	herpes	I-NP	NN	UMLS:C0019340:T047:DISO	_	_	_	_
42	TK	TK	I-NP	NN	:::NOCLASS	_	_	_	_
43	promoter	promoter	I-NP	NN	:::NOCLASS	_	_	_	_
44	controlling	control	B-VP	VBG	0	_	_	_	_
45	the	the	B-NP	DT	0	_	_	_	_
46	chloramphenicol	chloramphenicol	I-NP	NN	:::NOCLASS	_	_	_	_
47	acetyl	acetyl	I-NP	NN	:::NOCLASS	_	_	_	_
48	transferase	transferase	I-NP	NN	:::NOCLASS	_	_	_	_
49	(	(	O	(	0	_	_	_	_
50	CAT	CAT	B-NP	NN	:::NOCLASS	_	_	_	_
51	)	)	O	)	0	_	_	_	_
52	gene	gene	B-NP	NN	0	_	_	_	_
53	(	(	O	(	0	_	_	_	_
54	pBLCAT2	pBLCAT2	B-NP	NN	:::NOCLASS	_	_	_	_
55	)	)	O	)	0	_	_	_	_
56	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	general	general	B-ADJP	JJ	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	two	two	B-NP	CD	0	_	_	_	_
5	separate	separate	I-NP	JJ	0	_	_	_	_
6	high	high	I-NP	JJ	0	_	_	_	_
7	-	-	I-NP	HYPH	0	_	_	_	_
8	performance	performance	I-NP	NN	0	_	_	_	_
9	liquid	liquid	I-NP	JJ	0	_	_	_	_
10	chromatographic	chromatographic	I-NP	JJ	0	_	_	_	_
11	runs	run	I-NP	NNS	0	_	_	_	_
12	were	be	B-VP	VBD	0	_	_	_	_
13	performed	perform	I-VP	VBN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	one	one	B-NP	CD	0	_	_	_	_
16	for	for	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	gamma	gamma	I-NP	SYM	0	_	_	_	_
19	-	-	I-NP	HYPH	0	_	_	_	_
20	aminobutyric	aminobutyric	I-NP	JJ	0	_	_	_	_
21	acid	acid	I-NP	NN	0	_	_	_	_
22	determination	determination	I-NP	NN	0	_	_	_	_
23	and	and	O	CC	0	_	_	_	_
24	one	one	B-NP	CD	0	_	_	_	_
25	for	for	B-PP	IN	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	determination	determination	I-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	the	the	B-NP	DT	0	_	_	_	_
30	monoamines	monoamine	I-NP	NNS	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	report	report	B-VP	VBP	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	successful	successful	I-NP	JJ	0	_	_	_	_
5	use	use	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	electroconvulsive	electroconvulsive	B-NP	JJ	0	_	_	_	_
8	therapy	therapy	I-NP	NN	0	_	_	_	_
9	for	for	B-PP	IN	0	_	_	_	_
10	treatment	treatment	B-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	severe	severe	B-NP	JJ	0	_	_	_	_
13	depression	depression	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	a	a	B-NP	DT	0	_	_	_	_
16	young	young	I-NP	JJ	0	_	_	_	_
17	man	man	I-NP	NN	0	_	_	_	_
18	with	with	B-PP	IN	0	_	_	_	_
19	adult	adult	B-NP	JJ	0	_	_	_	_
20	GM2	GM2	I-NP	NN	UMLS:C0268274:T047:DISO	_	_	_	_
21	gangliosidosis	gangliosidosis	I-NP	NN	UMLS:C0268274:T047:DISO	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Entry	Entry	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	yeast	yeast	B-NP	NN	0	_	_	_	_
4	cells	cell	I-NP	NNS	0	_	_	_	_
5	into	into	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	mitotic	mitotic	I-NP	JJ	0	_	_	_	_
8	cell	cell	I-NP	NN	0	_	_	_	_
9	cycle	cycle	I-NP	NN	0	_	_	_	_
10	(	(	O	(	0	_	_	_	_
11	Start	Start	B-NP	NN	0	_	_	_	_
12	)	)	O	)	0	_	_	_	_
13	involves	involve	B-VP	VBZ	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	form	form	I-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	CDC28	CDC28	I-NP	NN	:::NOCLASS	_	_	_	_
19	kinase	kinase	I-NP	NN	:::NOCLASS	_	_	_	_
20	that	that	B-NP	WDT	0	_	_	_	_
21	associates	associate	B-VP	VBZ	0	_	_	_	_
22	with	with	B-PP	IN	0	_	_	_	_
23	G1	G1	B-NP	NN	0	_	_	_	_
24	-	-	B-NP	HYPH	0	_	_	_	_
25	specific	specific	I-NP	JJ	0	_	_	_	_
26	cyclins	cyclin	I-NP	NNS	:::NOCLASS	_	_	_	_
27	encoded	encode	B-VP	VBN	0	_	_	_	_
28	by	by	B-PP	IN	0	_	_	_	_
29	CLN1	CLN1	B-NP	NN	UMLS:C1850451:T047:DISO|:::NOCLASS	_	_	_	_
30	and	and	O	CC	0	_	_	_	_
31	CLN2	CLN2	B-NP	NN	UMLS:C1876161:T047:DISO|:::NOCLASS	_	_	_	_
32	(	(	O	(	0	_	_	_	_
33	ref	ref	B-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Through	Through	B-PP	IN	0	_	_	_	_
2	Southern	Southern	B-NP	JJ	0	_	_	_	_
3	blot	blot	I-NP	NN	0	_	_	_	_
4	analyses	analysis	I-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	DNA	DNA	B-NP	NN	0	_	_	_	_
7	from	from	B-PP	IN	0	_	_	_	_
8	backcross	backcross	B-NP	NN	0	_	_	_	_
9	and	and	O	CC	0	_	_	_	_
10	cogenic	cogenic	B-NP	JJ	0	_	_	_	_
11	mice	mouse	I-NP	NNS	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	recombinant	recombinant	B-NP	JJ	0	_	_	_	_
14	inbred	inbred	I-NP	JJ	0	_	_	_	_
15	strains	strain	I-NP	NNS	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	somatic	somatic	B-NP	JJ	0	_	_	_	_
19	cell	cell	I-NP	NN	0	_	_	_	_
20	hybrids	hybrid	I-NP	NNS	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	genetic	genetic	I-NP	JJ	0	_	_	_	_
24	loci	locus	I-NP	NNS	0	_	_	_	_
25	that	that	B-NP	WDT	0	_	_	_	_
26	produce	produce	B-VP	VBP	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	cyclin	cyclin	I-NP	NN	:::NOCLASS	_	_	_	_
29	B1	B1	I-NP	NN	:::NOCLASS|UMLS:C0507112:T023:ANAT	_	_	_	_
30	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
31	related	relate	I-NP	VBN	:::NOCLASS	_	_	_	_
32	sequences	sequence	I-NP	NNS	:::NOCLASS	_	_	_	_
33	(	(	O	(	0	_	_	_	_
34	designated	designate	B-NP	VBN	0	_	_	_	_
35	loci	locus	I-NP	NNS	:::NOCLASS	_	_	_	_
36	Cycb1	Cycb1	I-NP	NN	:::NOCLASS	_	_	_	_
37	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
38	rs1	rs1	I-NP	NN	:::NOCLASS	_	_	_	_
39	to	to	B-PP	TO	0	_	_	_	_
40	Cycb1	Cycb1	B-NP	NN	:::NOCLASS	_	_	_	_
41	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
42	rs9	rs9	I-NP	NN	:::NOCLASS	_	_	_	_
43	)	)	O	)	0	_	_	_	_
44	were	be	B-VP	VBD	0	_	_	_	_
45	mapped	map	I-VP	VBN	0	_	_	_	_
46	on	on	B-PP	IN	0	_	_	_	_
47	mouse	mouse	B-NP	NN	0	_	_	_	_
48	chromosomes	chromosome	I-NP	NNS	0	_	_	_	_
49	5	5	B-NP	CD	0	_	_	_	_
50	,	,	I-NP	,	0	_	_	_	_
51	1	1	I-NP	CD	0	_	_	_	_
52	,	,	I-NP	,	0	_	_	_	_
53	17	17	I-NP	CD	0	_	_	_	_
54	,	,	I-NP	,	0	_	_	_	_
55	4	4	I-NP	CD	0	_	_	_	_
56	,	,	I-NP	,	0	_	_	_	_
57	14	14	I-NP	CD	0	_	_	_	_
58	,	,	I-NP	,	0	_	_	_	_
59	13	13	I-NP	CD	0	_	_	_	_
60	,	,	I-NP	,	0	_	_	_	_
61	7	7	I-NP	CD	0	_	_	_	_
62	,	,	O	,	0	_	_	_	_
63	X	X	B-NP	NN	0	_	_	_	_
64	,	,	O	,	0	_	_	_	_
65	and	and	O	CC	0	_	_	_	_
66	8	8	B-NP	CD	0	_	_	_	_
67	,	,	O	,	0	_	_	_	_
68	respectively	respectively	B-ADVP	RB	0	_	_	_	_
69	.	.	O	.	0	_	_	_	_

1	Again	Again	B-NP	NN	0	_	_	_	_
2	residue	residue	I-NP	NN	0	_	_	_	_
3	Glu	Glu	I-NP	NN	0	_	_	_	_
4	-	-	O	HYPH	0	_	_	_	_
5	381	381	B-NP	CD	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	beta	beta	B-NP	NN	0	_	_	_	_
8	was	be	B-VP	VBD	0	_	_	_	_
9	notably	notably	I-VP	RB	0	_	_	_	_
10	reduced	reduce	I-VP	VBN	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	no	no	B-NP	DT	0	_	_	_	_
13	missing	missing	I-NP	JJ	0	_	_	_	_
14	residue	residue	I-NP	NN	0	_	_	_	_
15	from	from	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	epsilon	epsilon	I-NP	NN	0	_	_	_	_
18	peptide	peptide	I-NP	NN	0	_	_	_	_
19	could	could	B-VP	MD	0	_	_	_	_
20	be	be	I-VP	VB	0	_	_	_	_
21	identified	identify	I-VP	VBN	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	but	but	O	CC	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	peptide	peptide	I-NP	NN	0	_	_	_	_
26	sequence	sequence	I-NP	NN	0	_	_	_	_
27	limited	limit	B-VP	VBD	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	possible	possible	I-NP	JJ	0	_	_	_	_
30	choices	choice	I-NP	NNS	0	_	_	_	_
31	to	to	B-PP	TO	0	_	_	_	_
32	Ser	Ser	B-NP	NN	0	_	_	_	_
33	-	-	O	HYPH	0	_	_	_	_
34	106	106	B-NP	CD	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	Ser	Ser	B-NP	NN	0	_	_	_	_
37	-	-	O	HYPH	0	_	_	_	_
38	107	107	B-NP	CD	0	_	_	_	_
39	,	,	O	,	0	_	_	_	_
40	or	or	O	CC	0	_	_	_	_
41	Ser	Ser	B-NP	NN	0	_	_	_	_
42	-	-	B-NP	SYM	0	_	_	_	_
43	108	108	B-NP	CD	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	Porcelain	Porcelain	B-NP	NN	0	_	_	_	_
2	to	to	B-VP	TO	0	_	_	_	_
3	dentin	dentin	I-VP	VB	UMLS:C0011429:T023:ANAT	_	_	_	_
4	bond	bond	B-NP	NN	0	_	_	_	_
5	strength	strength	I-NP	NN	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	dentin	dentin	I-NP	NN	UMLS:C0011429:T023:ANAT	_	_	_	_
9	adhesive	adhesive	B-ADJP	JJ	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	TBPf	TBPf	B-NP	NN	0	_	_	_	_
2	is	be	B-VP	VBZ	0	_	_	_	_
3	defined	define	I-VP	VBN	0	_	_	_	_
4	as	as	B-PP	IN	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	quotient	quotient	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	difference	difference	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	first	first	I-NP	JJ	0	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	second	second	I-NP	JJ	0	_	_	_	_
16	measurement	measurement	I-NP	NN	0	_	_	_	_
17	:	:	O	:	0	_	_	_	_
18	TBPf	TBPf	B-NP	NN	0	_	_	_	_
19	=	=	B-NP	SYM	0	_	_	_	_
20	(	(	O	(	0	_	_	_	_
21	P1	P1	B-NP	NN	0	_	_	_	_
22	-	-	B-NP	HYPH	0	_	_	_	_
23	P2	P2	I-NP	NN	0	_	_	_	_
24	)	)	O	)	0	_	_	_	_
25	/	/	O	SYM	0	_	_	_	_
26	(	(	O	(	0	_	_	_	_
27	A1	A1	B-NP	NN	UMLS:C0933653:T023:ANAT	_	_	_	_
28	-	-	B-NP	HYPH	0	_	_	_	_
29	A2	A2	I-NP	NN	UMLS:C0935080:T023:ANAT	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	concluded	conclude	I-VP	VBN	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	Scotchbond	Scotchbond	B-NP	NN	0	_	_	_	_
6	2	2	I-NP	CD	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	Prisma	Prisma	B-NP	NNP	0	_	_	_	_
9	Universal	Universal	I-NP	NNP	0	_	_	_	_
10	Bond	Bond	I-NP	NNP	0	_	_	_	_
11	2	2	I-NP	CD	0	_	_	_	_
12	are	be	B-VP	VBP	0	_	_	_	_
13	effective	effective	B-ADJP	JJ	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	are	be	B-VP	VBP	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	dentine	dentine	I-NP	JJ	UMLS:C0011429:T023:ANAT	_	_	_	_
18	bonding	bonding	I-NP	NN	0	_	_	_	_
19	agents	agent	I-NP	NNS	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	choice	choice	B-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	From	From	B-PP	IN	0	_	_	_	_
2	all	all	B-NP	DT	0	_	_	_	_
3	clinically	clinically	I-NP	RB	0	_	_	_	_
4	important	important	I-NP	JJ	0	_	_	_	_
5	yeasts	yeast	I-NP	NNS	0	_	_	_	_
6	species	specie	I-NP	NNS	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	total	total	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	96	96	B-NP	CD	0	_	_	_	_
12	%	%	I-NP	NN	0	_	_	_	_
13	were	be	B-VP	VBD	0	_	_	_	_
14	identified	identify	I-VP	VBN	0	_	_	_	_
15	by	by	B-PP	IN	0	_	_	_	_
16	ATB	ATB	B-NP	NN	0	_	_	_	_
17	method	method	I-NP	NN	0	_	_	_	_
18	according	accord	B-PP	VBG	0	_	_	_	_
19	to	to	B-PP	TO	0	_	_	_	_
20	conventional	conventional	B-NP	JJ	0	_	_	_	_
21	methods	method	I-NP	NNS	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	neurohypophysial	neurohypophysial	I-NP	JJ	0	_	_	_	_
3	vasopressin	vasopressin	I-NP	NN	:::NOCLASS	_	_	_	_
4	and	and	I-NP	CC	0	_	_	_	_
5	oxytocin	oxytocin	I-NP	NN	:::NOCLASS	_	_	_	_
6	content	content	I-NP	NN	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	bioassayed	bioassay	I-VP	VBN	0	_	_	_	_
9	by	by	B-PP	IN	0	_	_	_	_
10	pressor	pressor	B-NP	NN	0	_	_	_	_
11	effect	effect	I-NP	NN	0	_	_	_	_
12	following	follow	B-PP	VBG	0	_	_	_	_
13	Dekanski	Dekanski	B-NP	NNP	0	_	_	_	_
14	or	or	O	CC	0	_	_	_	_
15	milk	milk	B-NP	NN	0	_	_	_	_
16	-	-	O	HYPH	0	_	_	_	_
17	ejection	ejection	B-NP	NN	0	_	_	_	_
18	activity	activity	I-NP	NN	0	_	_	_	_
19	in	in	B-ADVP	FW	0	_	_	_	_
20	vitro	vitro	I-ADVP	FW	0	_	_	_	_
21	following	follow	B-PP	VBG	0	_	_	_	_
22	van	van	B-NP	NNP	0	_	_	_	_
23	Dongen	Dongen	I-NP	NNP	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	Hays	Hays	B-NP	NNP	0	_	_	_	_
26	,	,	O	,	0	_	_	_	_
27	respectively	respectively	B-ADVP	RB	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	Comments	Comment	B-NP	NNS	0	_	_	_	_
2	are	be	B-VP	VBP	0	_	_	_	_
3	given	give	I-VP	VBN	0	_	_	_	_
4	on	on	B-PP	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	present	present	I-NP	JJ	0	_	_	_	_
7	status	status	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	regulations	regulation	B-NP	NNS	0	_	_	_	_
10	concerning	concern	B-VP	VBG	0	_	_	_	_
11	water	water	B-NP	NN	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	swimming	swimming	B-NP	NN	0	_	_	_	_
14	pools	pool	I-NP	NNS	0	_	_	_	_
15	and	and	I-NP	CC	0	_	_	_	_
16	baths	bath	I-NP	NNS	0	_	_	_	_
17	-	-	B-NP	SYM	0	_	_	_	_
18	-	-	B-NP	SYM	0	_	_	_	_
19	1991	1991	I-NP	CD	0	_	_	_	_
20	-	-	O	HYPH	0	_	_	_	_
21	-	-	O	HYPH	0	_	_	_	_
22	(	(	O	(	0	_	_	_	_
23	in	in	B-PP	IN	0	_	_	_	_
24	connection	connection	B-NP	NN	0	_	_	_	_
25	with	with	B-PP	IN	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	KOK	KOK	I-NP	NN	0	_	_	_	_
28	regulations	regulation	I-NP	NNS	0	_	_	_	_
29	-	-	B-NP	SYM	0	_	_	_	_
30	-	-	B-NP	SYM	0	_	_	_	_
31	1972	1972	I-NP	CD	0	_	_	_	_
32	-	-	O	HYPH	0	_	_	_	_
33	-	-	O	HYPH	0	_	_	_	_
34	and	and	O	CC	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	Federal	Federal	I-NP	JJ	0	_	_	_	_
37	German	German	I-NP	JJ	0	_	_	_	_
38	standard	standard	I-NP	NN	0	_	_	_	_
39	[	[	O	(	0	_	_	_	_
40	DIN	DIN	B-NP	NN	0	_	_	_	_
41	]	]	O	)	0	_	_	_	_
42	No	No	B-NP	NNP	0	_	_	_	_
43	.	.	O	.	0	_	_	_	_

1	If	If	B-SBAR	IN	0	_	_	_	_
2	no	no	B-NP	DT	0	_	_	_	_
3	reply	reply	I-NP	NN	0	_	_	_	_
4	was	be	B-VP	VBD	0	_	_	_	_
5	received	receive	I-VP	VBN	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	telephone	telephone	B-NP	NN	0	_	_	_	_
8	contact	contact	I-NP	NN	0	_	_	_	_
9	or	or	I-NP	CC	0	_	_	_	_
10	home	home	I-NP	NN	0	_	_	_	_
11	visits	visit	I-NP	NNS	0	_	_	_	_
12	were	be	B-VP	VBD	0	_	_	_	_
13	made	make	I-VP	VBN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	treatment	treatment	I-NP	NN	0	_	_	_	_
3	group	group	I-NP	NN	0	_	_	_	_
4	also	also	B-ADVP	RB	0	_	_	_	_
5	showed	show	B-VP	VBD	0	_	_	_	_
6	in	in	B-NP	FW	0	_	_	_	_
7	vivo	vivo	I-NP	FW	0	_	_	_	_
8	T	T	I-NP	NN	0	_	_	_	_
9	-	-	B-NP	HYPH	0	_	_	_	_
10	cell	cell	I-NP	NN	0	_	_	_	_
11	activation	activation	I-NP	NN	0	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	an	an	B-NP	DT	0	_	_	_	_
14	initial	initial	I-NP	JJ	0	_	_	_	_
15	lymphopenia	lymphopenia	I-NP	NN	UMLS:C0024312:T047:DISO	_	_	_	_
16	followed	follow	B-VP	VBN	0	_	_	_	_
17	by	by	B-PP	IN	0	_	_	_	_
18	a	a	B-NP	DT	0	_	_	_	_
19	rebound	rebound	I-NP	NN	0	_	_	_	_
20	lymphocytosis	lymphocytosis	I-NP	NN	UMLS:C0024282:T047:DISO	_	_	_	_
21	and	and	I-NP	CC	0	_	_	_	_
22	upregulation	upregulation	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	subset	subset	I-NP	NN	0	_	_	_	_
26	markers	marker	I-NP	NNS	0	_	_	_	_
27	CD25	CD25	I-NP	NN	:::NOCLASS	_	_	_	_
28	(	(	O	(	0	_	_	_	_
29	interleukin	interleukin	B-NP	NN	:::NOCLASS	_	_	_	_
30	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
31	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
32	)	)	O	)	0	_	_	_	_
33	and	and	O	CC	0	_	_	_	_
34	CD45RO	CD45RO	B-NP	NN	:::NOCLASS	_	_	_	_
35	(	(	O	(	0	_	_	_	_
36	T	T	B-NP	NN	0	_	_	_	_
37	-	-	I-NP	HYPH	0	_	_	_	_
38	memory	memory	I-NP	NN	0	_	_	_	_
39	cells	cell	I-NP	NNS	0	_	_	_	_
40	)	)	O	)	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	Urease	Urease	B-NP	NN	:::NOCLASS	_	_	_	_
2	activity	activity	I-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	judged	judge	B-VP	VBN	0	_	_	_	_
5	as	as	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	amount	amount	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	ammonia	ammonia	B-NP	NN	0	_	_	_	_
10	production	production	I-NP	NN	0	_	_	_	_
11	from	from	B-PP	IN	0	_	_	_	_
12	urea	urea	B-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	could	could	B-VP	MD	0	_	_	_	_
15	be	be	I-VP	VB	0	_	_	_	_
16	measured	measure	I-VP	VBN	0	_	_	_	_
17	at	at	B-PP	IN	0	_	_	_	_
18	25	25	B-NP	CD	0	_	_	_	_
19	ng	ng	I-NP	NN	0	_	_	_	_
20	per	per	B-PP	IN	0	_	_	_	_
21	tube	tube	B-NP	NN	0	_	_	_	_
22	(	(	O	(	0	_	_	_	_
23	S	S	B-NP	NN	0	_	_	_	_
24	/	/	O	SYM	0	_	_	_	_
25	N	N	B-NP	NN	0	_	_	_	_
26	=	=	B-VP	SYM	0	_	_	_	_
27	1	1	B-NP	CD	0	_	_	_	_
28	.	.	I-NP	SYM	0	_	_	_	_
29	5	5	I-NP	CD	0	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	with	with	B-PP	IN	0	_	_	_	_
32	Jack	Jack	B-NP	NNP	:::NOCLASS	_	_	_	_
33	bean	bean	I-NP	NN	:::NOCLASS	_	_	_	_
34	meal	meal	I-NP	JJ	:::NOCLASS	_	_	_	_
35	urease	urease	I-NP	NN	:::NOCLASS	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	Consequently	Consequently	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	significant	significant	B-NP	JJ	0	_	_	_	_
4	differences	difference	I-NP	NNS	0	_	_	_	_
5	between	between	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	measured	measure	I-NP	VBN	0	_	_	_	_
8	and	and	I-NP	CC	0	_	_	_	_
9	calculated	calculate	I-NP	VBN	0	_	_	_	_
10	methods	method	I-NP	NNS	0	_	_	_	_
11	were	be	B-VP	VBD	0	_	_	_	_
12	noted	note	I-VP	VBN	0	_	_	_	_
13	in	in	B-PP	IN	0	_	_	_	_
14	oxygen	oxygen	B-NP	NN	0	_	_	_	_
15	uptake	uptake	I-NP	NN	0	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	213	213	B-NP	CD	0	_	_	_	_
18	+	+	O	SYM	0	_	_	_	_
19	/	/	O	SYM	0	_	_	_	_
20	-	-	O	SYM	0	_	_	_	_
21	41	41	B-NP	CD	0	_	_	_	_
22	ml	ml	I-NP	NN	0	_	_	_	_
23	/	/	B-NP	SYM	0	_	_	_	_
24	min	min	I-NP	NN	0	_	_	_	_
25	vs	vs	B-PP	IN	0	_	_	_	_
26	193	193	B-NP	CD	0	_	_	_	_
27	+	+	O	SYM	0	_	_	_	_
28	/	/	O	SYM	0	_	_	_	_
29	-	-	O	SYM	0	_	_	_	_
30	25	25	B-NP	CD	0	_	_	_	_
31	ml	ml	I-NP	NN	0	_	_	_	_
32	/	/	O	SYM	0	_	_	_	_
33	min	min	B-NP	NN	0	_	_	_	_
34	,	,	O	,	0	_	_	_	_
35	p	p	B-NP	NN	0	_	_	_	_
36	<	<	B-VP	SYM	0	_	_	_	_
37	0	0	B-NP	CD	0	_	_	_	_
38	.	.	I-NP	.	0	_	_	_	_
39	001	001	I-NP	CD	0	_	_	_	_
40	)	)	O	)	0	_	_	_	_
41	,	,	O	,	0	_	_	_	_
42	oxygen	oxygen	B-NP	NN	0	_	_	_	_
43	delivery	delivery	I-NP	NN	0	_	_	_	_
44	(	(	O	(	0	_	_	_	_
45	780	780	B-NP	CD	0	_	_	_	_
46	+	+	O	SYM	0	_	_	_	_
47	/	/	O	SYM	0	_	_	_	_
48	-	-	O	SYM	0	_	_	_	_
49	297	297	B-NP	CD	0	_	_	_	_
50	ml	ml	I-NP	NN	0	_	_	_	_
51	/	/	B-NP	SYM	0	_	_	_	_
52	min	min	I-NP	NN	0	_	_	_	_
53	vs	vs	B-PP	IN	0	_	_	_	_
54	716	716	B-NP	CD	0	_	_	_	_
55	+	+	O	SYM	0	_	_	_	_
56	/	/	O	SYM	0	_	_	_	_
57	-	-	O	SYM	0	_	_	_	_
58	296	296	B-NP	CD	0	_	_	_	_
59	ml	ml	I-NP	NN	0	_	_	_	_
60	/	/	O	SYM	0	_	_	_	_
61	min	min	B-NP	NN	0	_	_	_	_
62	,	,	O	,	0	_	_	_	_
63	p	p	B-NP	NN	0	_	_	_	_
64	<	<	B-VP	SYM	0	_	_	_	_
65	0	0	B-NP	CD	0	_	_	_	_
66	.	.	I-NP	.	0	_	_	_	_
67	001	001	I-NP	CD	0	_	_	_	_
68	)	)	O	)	0	_	_	_	_
69	,	,	O	,	0	_	_	_	_
70	and	and	O	CC	0	_	_	_	_
71	cardiac	cardiac	B-NP	JJ	UMLS:C0018787:T023:ANAT	_	_	_	_
72	output	output	I-NP	NN	0	_	_	_	_
73	(	(	O	(	0	_	_	_	_
74	5	5	B-NP	CD	0	_	_	_	_
75	.	.	O	.	0	_	_	_	_
76	8	8	B-NP	CD	0	_	_	_	_
77	+	+	O	SYM	0	_	_	_	_
78	/	/	O	SYM	0	_	_	_	_
79	-	-	B-NP	SYM	0	_	_	_	_
80	2	2	B-NP	CD	0	_	_	_	_
81	.	.	I-NP	SYM	0	_	_	_	_
82	2	2	I-NP	CD	0	_	_	_	_
83	L	L	I-NP	NN	0	_	_	_	_
84	/	/	B-NP	SYM	0	_	_	_	_
85	min	min	B-NP	NN	0	_	_	_	_
86	vs	vs	B-PP	IN	0	_	_	_	_
87	5	5	B-NP	CD	0	_	_	_	_
88	.	.	I-NP	.	0	_	_	_	_
89	3	3	I-NP	CD	0	_	_	_	_
90	+	+	B-NP	SYM	0	_	_	_	_
91	/	/	B-VP	SYM	0	_	_	_	_
92	-	-	B-NP	SYM	0	_	_	_	_
93	1	1	I-NP	CD	0	_	_	_	_
94	.	.	I-NP	SYM	0	_	_	_	_
95	8	8	I-NP	CD	0	_	_	_	_
96	L	L	I-NP	NN	0	_	_	_	_
97	/	/	O	SYM	0	_	_	_	_
98	min	min	B-NP	NN	0	_	_	_	_
99	,	,	O	,	0	_	_	_	_
100	p	p	B-NP	NN	0	_	_	_	_
101	<	<	B-VP	SYM	0	_	_	_	_
102	0	0	B-NP	CD	0	_	_	_	_
103	.	.	I-NP	.	0	_	_	_	_
104	001	001	I-NP	CD	0	_	_	_	_
105	)	)	O	)	0	_	_	_	_
106	.	.	O	.	0	_	_	_	_

1	Although	Although	B-SBAR	IN	0	_	_	_	_
2	a	a	B-NP	DT	0	_	_	_	_
3	wide	wide	I-NP	JJ	0	_	_	_	_
4	range	range	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	cognitive	cognitive	B-NP	JJ	0	_	_	_	_
7	functions	function	I-NP	NNS	0	_	_	_	_
8	had	have	B-VP	VBD	0	_	_	_	_
9	been	be	I-VP	VBN	0	_	_	_	_
10	tested	test	I-VP	VBN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	all	all	O	DT	0	_	_	_	_
13	but	but	B-PP	IN	0	_	_	_	_
14	one	one	B-NP	CD	0	_	_	_	_
15	seizure	seizure	I-NP	NN	0	_	_	_	_
16	occurred	occur	B-VP	VBD	0	_	_	_	_
17	during	during	B-PP	IN	0	_	_	_	_
18	assessment	assessment	B-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	memory	memory	B-NP	NN	0	_	_	_	_
21	performance	performance	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	experiments	experiment	I-NP	NNS	0	_	_	_	_
3	show	show	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	it	it	B-NP	PRP	0	_	_	_	_
6	is	be	B-VP	VBZ	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	micromilieu	micromilieu	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	alveoli	alveolus	I-NP	NNS	UMLS:C1515933:T023:ANAT	_	_	_	_
12	and	and	O	CC	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	condition	condition	I-NP	NN	UMLS:C0012634:T047:DISO	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	AM	AM	I-NP	NN	0	_	_	_	_
18	(	(	O	(	0	_	_	_	_
19	certain	certain	B-NP	JJ	0	_	_	_	_
20	physiological	physiological	I-NP	JJ	0	_	_	_	_
21	activation	activation	I-NP	NN	0	_	_	_	_
22	states	state	I-NP	NNS	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	such	such	B-PP	JJ	0	_	_	_	_
25	as	as	I-PP	IN	0	_	_	_	_
26	phagocytic	phagocytic	B-NP	JJ	0	_	_	_	_
27	activity	activity	I-NP	NN	0	_	_	_	_
28	)	)	O	)	0	_	_	_	_
29	that	that	B-NP	WDT	0	_	_	_	_
30	essentially	essentially	B-ADVP	RB	0	_	_	_	_
31	determine	determine	B-VP	VBP	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	degree	degree	I-NP	NN	0	_	_	_	_
34	of	of	B-PP	IN	0	_	_	_	_
35	recovery	recovery	B-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	Negatively	Negatively	B-NP	RB	0	_	_	_	_
2	supercoiled	supercoile	I-NP	VBN	0	_	_	_	_
3	plasmid	plasmid	I-NP	NN	0	_	_	_	_
4	pUC19	pUC19	I-NP	NN	0	_	_	_	_
5	did	do	B-VP	VBD	0	_	_	_	_
6	not	not	I-VP	RB	0	_	_	_	_
7	compete	compete	I-VP	VB	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	whereas	whereas	O	IN	0	_	_	_	_
10	an	an	B-NP	DT	0	_	_	_	_
11	otherwise	otherwise	I-NP	RB	0	_	_	_	_
12	identical	identical	I-NP	JJ	0	_	_	_	_
13	plasmid	plasmid	I-NP	NN	0	_	_	_	_
14	pUC19	pUC19	I-NP	NN	0	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	CG	CG	B-NP	NN	0	_	_	_	_
17	)	)	O	)	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	which	which	B-NP	WDT	0	_	_	_	_
20	contained	contain	B-VP	VBD	0	_	_	_	_
21	a	a	O	DT	0	_	_	_	_
22	(	(	O	(	0	_	_	_	_
23	dG	dG	B-NP	NN	0	_	_	_	_
24	-	-	B-NP	HYPH	0	_	_	_	_
25	dC	dC	I-NP	NN	0	_	_	_	_
26	)	)	O	)	0	_	_	_	_
27	7	7	B-NP	CD	0	_	_	_	_
28	segment	segment	I-NP	NN	0	_	_	_	_
29	in	in	B-PP	IN	0	_	_	_	_
30	the	the	B-NP	DT	0	_	_	_	_
31	Z	Z	I-NP	NN	0	_	_	_	_
32	-	-	B-NP	HYPH	0	_	_	_	_
33	form	form	I-NP	NN	0	_	_	_	_
34	was	be	B-VP	VBD	0	_	_	_	_
35	an	an	B-NP	DT	0	_	_	_	_
36	excellent	excellent	I-NP	JJ	0	_	_	_	_
37	competitor	competitor	I-NP	NN	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	cDNA	cDNA	I-NP	NN	0	_	_	_	_
3	library	library	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	tumour	tumour	B-NP	NN	0	_	_	_	_
6	cells	cell	I-NP	NNS	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	screened	screen	I-VP	VBN	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	an	an	B-NP	DT	0	_	_	_	_
11	interleukin	interleukin	I-NP	NN	:::NOCLASS	_	_	_	_
12	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
13	gene	gene	I-NP	NN	0	_	_	_	_
14	-	-	B-NP	HYPH	0	_	_	_	_
15	specific	specific	I-NP	JJ	0	_	_	_	_
16	probe	probe	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Our	Our	B-NP	PRP$	0	_	_	_	_
2	experiments	experiment	I-NP	NNS	0	_	_	_	_
3	suggest	suggest	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	SCL	SCL	I-NP	NN	:::NOCLASS	_	_	_	_
7	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
8	can	can	B-VP	MD	0	_	_	_	_
9	be	be	I-VP	VB	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	target	target	I-NP	NN	0	_	_	_	_
12	for	for	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	erythroid	erythroid	I-NP	JJ	:::NOCLASS	_	_	_	_
15	transcription	transcription	I-NP	NN	:::NOCLASS	_	_	_	_
16	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
17	GATA	GATA	I-NP	NN	:::NOCLASS	_	_	_	_
18	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
19	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	that	that	B-SBAR	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	SCL	SCL	I-NP	NN	:::NOCLASS	_	_	_	_
24	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
25	product	product	I-NP	NN	:::NOCLASS	_	_	_	_
26	serves	serve	B-VP	VBZ	0	_	_	_	_
27	as	as	B-PP	IN	0	_	_	_	_
28	a	a	B-NP	DT	0	_	_	_	_
29	positive	positive	I-NP	JJ	0	_	_	_	_
30	regulator	regulator	I-NP	NN	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	erythroid	erythroid	B-NP	JJ	0	_	_	_	_
33	differentiation	differentiation	I-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	contrast	contrast	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	lumenal	lumenal	I-NP	JJ	0	_	_	_	_
6	domains	domain	I-NP	NNS	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	Sec12p	Sec12p	B-NP	NN	:::NOCLASS	_	_	_	_
9	,	,	I-NP	,	0	_	_	_	_
10	Stl1p	Stl1p	I-NP	NN	:::NOCLASS	_	_	_	_
11	and	and	I-NP	CC	0	_	_	_	_
12	Stl2p	Stl2p	I-NP	NN	:::NOCLASS	_	_	_	_
13	are	be	B-VP	VBP	0	_	_	_	_
14	very	very	B-ADJP	RB	0	_	_	_	_
15	different	different	I-ADJP	JJ	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	size	size	B-NP	NN	0	_	_	_	_
18	and	and	O	CC	0	_	_	_	_
19	do	do	B-VP	VBP	0	_	_	_	_
20	not	not	I-VP	RB	0	_	_	_	_
21	show	show	I-VP	VB	0	_	_	_	_
22	any	any	B-NP	DT	0	_	_	_	_
23	appreciable	appreciable	I-NP	JJ	0	_	_	_	_
24	homology	homology	I-NP	NN	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Complexes	Complex	B-NP	NNS	0	_	_	_	_
2	containing	contain	B-VP	VBG	0	_	_	_	_
3	wild	wild	B-NP	JJ	0	_	_	_	_
4	-	-	I-NP	HYPH	0	_	_	_	_
5	type	type	I-NP	NN	0	_	_	_	_
6	and	and	O	CC	0	_	_	_	_
7	either	either	O	CC	0	_	_	_	_
8	his175	his175	B-NP	NN	:::NOCLASS	_	_	_	_
9	or	or	O	CC	:::NOCLASS	_	_	_	_
10	his273	his273	B-NP	NN	:::NOCLASS	_	_	_	_
11	mutant	mutant	I-NP	JJ	:::NOCLASS	_	_	_	_
12	p53	p53	I-NP	NN	:::NOCLASS	_	_	_	_
13	proteins	protein	I-NP	NNS	:::NOCLASS	_	_	_	_
14	are	be	B-VP	VBP	0	_	_	_	_
15	completely	completely	B-ADJP	RB	0	_	_	_	_
16	unable	unable	I-ADJP	JJ	0	_	_	_	_
17	to	to	B-VP	TO	0	_	_	_	_
18	bind	bind	I-VP	VB	0	_	_	_	_
19	to	to	B-PP	TO	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	RGC	RGC	I-NP	NN	:::NOCLASS	_	_	_	_
22	DNA	DNA	I-NP	NN	:::NOCLASS	_	_	_	_
23	sequence	sequence	I-NP	NN	:::NOCLASS	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	temperature	temperature	I-NP	NN	0	_	_	_	_
3	-	-	B-NP	HYPH	0	_	_	_	_
4	and	and	I-NP	CC	0	_	_	_	_
5	cold	cold	I-NP	JJ	UMLS:C0009443:T047:DISO|UMLS:C0024117:T047:DISO	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	sensitive	sensitive	I-NP	JJ	0	_	_	_	_
8	strains	strain	I-NP	NNS	0	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	used	use	I-VP	VBN	0	_	_	_	_
11	to	to	B-VP	TO	0	_	_	_	_
12	prepare	prepare	I-VP	VB	0	_	_	_	_
13	extracts	extract	B-NP	NNS	0	_	_	_	_
14	deficient	deficient	B-ADJP	JJ	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	BRF1	BRF1	B-NP	NN	:::NOCLASS	_	_	_	_
17	activity	activity	I-NP	NN	0	_	_	_	_
18	and	and	O	CC	0	_	_	_	_
19	were	be	B-VP	VBD	0	_	_	_	_
20	tested	test	I-VP	VBN	0	_	_	_	_
21	for	for	B-PP	IN	0	_	_	_	_
22	transcriptional	transcriptional	B-NP	JJ	0	_	_	_	_
23	activity	activity	I-NP	NN	0	_	_	_	_
24	by	by	B-PP	IN	0	_	_	_	_
25	RNA	RNA	B-NP	NN	:::NOCLASS	_	_	_	_
26	polymerases	polymeras	I-NP	NNS	:::NOCLASS	_	_	_	_
27	I	I	I-NP	CD	:::NOCLASS	_	_	_	_
28	,	,	I-NP	,	:::NOCLASS	_	_	_	_
29	II	II	I-NP	CD	:::NOCLASS	_	_	_	_
30	,	,	O	,	:::NOCLASS	_	_	_	_
31	and	and	O	CC	:::NOCLASS	_	_	_	_
32	III	III	B-NP	CD	:::NOCLASS	_	_	_	_
33	in	in	B-ADVP	FW	0	_	_	_	_
34	vitro	vitro	I-ADVP	FW	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	lead	lead	B-VP	VBP	0	_	_	_	_
4	us	us	B-NP	PRP	0	_	_	_	_
5	to	to	B-VP	TO	0	_	_	_	_
6	hypothesize	hypothesize	I-VP	VB	0	_	_	_	_
7	that	that	B-SBAR	IN	0	_	_	_	_
8	a	a	B-NP	DT	0	_	_	_	_
9	single	single	I-NP	JJ	0	_	_	_	_
10	multisubunit	multisubunit	I-NP	JJ	:::NOCLASS	_	_	_	_
11	TFIID	TFIID	I-NP	NN	:::NOCLASS	_	_	_	_
12	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
13	supports	support	B-VP	VBZ	0	_	_	_	_
14	transcriptional	transcriptional	B-NP	JJ	0	_	_	_	_
15	stimulation	stimulation	I-NP	NN	0	_	_	_	_
16	by	by	B-PP	IN	0	_	_	_	_
17	diverse	diverse	B-NP	JJ	0	_	_	_	_
18	activation	activation	I-NP	NN	0	_	_	_	_
19	domains	domain	I-NP	NNS	0	_	_	_	_
20	and	and	B-PP	CC	0	_	_	_	_
21	from	from	B-PP	IN	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	TATA	TATA	I-NP	NN	0	_	_	_	_
24	-	-	I-NP	HYPH	0	_	_	_	_
25	less	less	I-NP	JJ	0	_	_	_	_
26	promoter	promoter	I-NP	NN	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	gene	gene	I-NP	NN	0	_	_	_	_
3	sequence	sequence	I-NP	NN	0	_	_	_	_
4	also	also	B-ADVP	RB	0	_	_	_	_
5	identified	identify	B-VP	VBD	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	340	340	I-NP	CD	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	nucleotide	nucleotide	I-NP	NN	0	_	_	_	_
10	RNA	RNA	I-NP	NN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	total	total	B-NP	JJ	0	_	_	_	_
13	yeast	yeast	I-NP	NN	0	_	_	_	_
14	RNA	RNA	I-NP	NN	0	_	_	_	_
15	and	and	B-PP	CC	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	purified	purify	B-NP	VBN	0	_	_	_	_
18	RNase	RNase	I-NP	NN	:::NOCLASS	_	_	_	_
19	MRP	MRP	I-NP	NN	:::NOCLASS	_	_	_	_
20	enzyme	enzyme	I-NP	NN	:::NOCLASS	_	_	_	_
21	preparations	preparation	I-NP	NNS	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	RNase	RNase	I-NP	NN	:::NOCLASS	_	_	_	_
3	MRP	MRP	I-NP	NN	:::NOCLASS	_	_	_	_
4	RNA	RNA	I-NP	NN	:::NOCLASS	_	_	_	_
5	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
6	was	be	B-VP	VBD	0	_	_	_	_
7	deleted	delete	I-VP	VBN	0	_	_	_	_
8	by	by	B-PP	IN	0	_	_	_	_
9	insertional	insertional	B-NP	JJ	0	_	_	_	_
10	replacement	replacement	I-NP	NN	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	found	find	B-VP	VBN	0	_	_	_	_
13	to	to	I-VP	TO	0	_	_	_	_
14	be	be	I-VP	VB	0	_	_	_	_
15	essential	essential	B-ADJP	JJ	0	_	_	_	_
16	for	for	B-PP	IN	0	_	_	_	_
17	cellular	cellular	B-NP	JJ	0	_	_	_	_
18	viability	viability	I-NP	NN	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	indicating	indicate	B-VP	VBG	0	_	_	_	_
21	a	a	B-NP	DT	0	_	_	_	_
22	critical	critical	I-NP	JJ	0	_	_	_	_
23	nuclear	nuclear	I-NP	JJ	0	_	_	_	_
24	role	role	I-NP	NN	0	_	_	_	_
25	for	for	B-PP	IN	0	_	_	_	_
26	RNase	RNase	B-NP	NN	:::NOCLASS	_	_	_	_
27	MRP	MRP	I-NP	NN	:::NOCLASS	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	Clone	Clone	B-NP	NN	0	_	_	_	_
2	pSRc200	pSRc200	I-NP	NN	0	_	_	_	_
3	hybrid	hybrid	I-NP	NN	0	_	_	_	_
4	selected	select	B-VP	VBD	0	_	_	_	_
5	an	an	B-NP	DT	0	_	_	_	_
6	mRNA	mRNA	I-NP	NN	0	_	_	_	_
7	that	that	B-SBAR	IN	0	_	_	_	_
8	on	on	B-PP	IN	0	_	_	_	_
9	cell	cell	B-NP	NN	0	_	_	_	_
10	-	-	B-NP	HYPH	0	_	_	_	_
11	free	free	I-NP	JJ	0	_	_	_	_
12	translation	translation	I-NP	NN	0	_	_	_	_
13	produced	produce	B-VP	VBD	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	38	38	I-NP	CD	0	_	_	_	_
16	-	-	I-NP	HYPH	0	_	_	_	_
17	kDa	kDa	I-NP	NN	0	_	_	_	_
18	polypeptide	polypeptide	I-NP	NN	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_

1	From	From	B-PP	IN	0	_	_	_	_
2	these	these	B-NP	DT	0	_	_	_	_
3	results	result	I-NP	NNS	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	CBF	CBF	B-NP	NN	:::NOCLASS	_	_	_	_
6	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
7	A	A	I-NP	NN	:::NOCLASS	_	_	_	_
8	is	be	B-VP	VBZ	0	_	_	_	_
9	a	a	B-NP	DT	0	_	_	_	_
10	novel	novel	I-NP	JJ	0	_	_	_	_
11	CArG	CArG	I-NP	NN	0	_	_	_	_
12	box	box	I-NP	NN	0	_	_	_	_
13	-	-	B-ADJP	HYPH	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	ssDNA	ssDNA	B-NP	NN	:::NOCLASS	_	_	_	_
16	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
17	and	and	I-NP	CC	:::NOCLASS	_	_	_	_
18	RNA	RNA	I-NP	NN	:::NOCLASS	_	_	_	_
19	-	-	O	HYPH	:::NOCLASS	_	_	_	_
20	binding	bind	B-NP	VBG	:::NOCLASS	_	_	_	_
21	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	as	as	B-CONJP	RB	0	_	_	_	_
24	well	well	I-CONJP	RB	0	_	_	_	_
25	as	as	I-CONJP	IN	0	_	_	_	_
26	a	a	B-NP	DT	0	_	_	_	_
27	repressive	repressive	I-NP	JJ	0	_	_	_	_
28	transcriptional	transcriptional	I-NP	JJ	0	_	_	_	_
29	factor	factor	I-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Cleavage	Cleavage	B-NP	NN	0	_	_	_	_
2	by	by	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	intron	intron	I-NP	NN	0	_	_	_	_
5	-	-	B-VP	HYPH	0	_	_	_	_
6	encoded	encode	B-NP	VBN	0	_	_	_	_
7	enzyme	enzyme	I-NP	NN	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	I	I	B-NP	NN	:::NOCLASS	_	_	_	_
10	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
11	CreI	CreI	I-NP	NN	:::NOCLASS	_	_	_	_
12	)	)	O	)	0	_	_	_	_
13	occurs	occur	B-VP	VBZ	0	_	_	_	_
14	5	5	B-NP	CD	0	_	_	_	_
15	bp	bp	I-NP	NN	0	_	_	_	_
16	and	and	I-NP	CC	0	_	_	_	_
17	1	1	I-NP	CD	0	_	_	_	_
18	bp	bp	I-NP	NN	0	_	_	_	_
19	3	3	I-NP	CD	0	_	_	_	_
20	'	'	B-NP	SYM	0	_	_	_	_
21	to	to	B-PP	TO	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	intron	intron	I-NP	NN	0	_	_	_	_
24	insertion	insertion	I-NP	NN	0	_	_	_	_
25	site	site	I-NP	NN	0	_	_	_	_
26	(	(	O	(	0	_	_	_	_
27	in	in	B-PP	IN	0	_	_	_	_
28	the	the	B-NP	DT	0	_	_	_	_
29	3	3	I-NP	CD	0	_	_	_	_
30	'	'	I-NP	SYM	0	_	_	_	_
31	-	-	I-NP	HYPH	0	_	_	_	_
32	exon	exon	I-NP	NN	0	_	_	_	_
33	)	)	O	)	0	_	_	_	_
34	in	in	B-PP	IN	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	top	top	I-NP	JJ	0	_	_	_	_
37	(	(	O	(	0	_	_	_	_
38	/	/	O	SYM	0	_	_	_	_
39	)	)	O	)	0	_	_	_	_
40	and	and	O	CC	0	_	_	_	_
41	bottom	bottom	B-NP	NN	0	_	_	_	_
42	(	(	O	(	0	_	_	_	_
43	,	,	O	,	0	_	_	_	_
44	)	)	O	)	0	_	_	_	_
45	strands	strand	B-NP	NNS	0	_	_	_	_
46	,	,	O	,	0	_	_	_	_
47	respectively	respectively	B-ADVP	RB	0	_	_	_	_
48	,	,	O	,	0	_	_	_	_
49	resulting	result	B-VP	VBG	0	_	_	_	_
50	in	in	B-PP	IN	0	_	_	_	_
51	4	4	B-NP	CD	0	_	_	_	_
52	-	-	I-NP	HYPH	0	_	_	_	_
53	nt	nt	I-NP	NN	0	_	_	_	_
54	single	single	I-NP	JJ	0	_	_	_	_
55	-	-	I-NP	HYPH	0	_	_	_	_
56	stranded	stranded	I-NP	JJ	0	_	_	_	_
57	overhangs	overhang	I-NP	NNS	0	_	_	_	_
58	with	with	B-PP	IN	0	_	_	_	_
59	3	3	B-NP	CD	0	_	_	_	_
60	'	'	I-NP	SYM	0	_	_	_	_
61	-	-	I-NP	HYPH	0	_	_	_	_
62	OH	OH	I-NP	NN	0	_	_	_	_
63	termini	terminus	I-NP	NNS	0	_	_	_	_
64	.	.	O	.	0	_	_	_	_

1	Surprisingly	Surprisingly	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	Xenopus	Xenopus	I-NP	NN	:::NOCLASS	_	_	_	_
5	U7	U7	I-NP	NN	:::NOCLASS	_	_	_	_
6	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
7	contains	contain	B-VP	VBZ	0	_	_	_	_
8	two	two	B-NP	CD	0	_	_	_	_
9	adjacent	adjacent	I-NP	JJ	0	_	_	_	_
10	octamer	octamer	I-NP	NN	0	_	_	_	_
11	-	-	B-VP	HYPH	0	_	_	_	_
12	binding	bind	B-NP	VBG	0	_	_	_	_
13	motifs	motif	I-NP	NNS	0	_	_	_	_
14	located	locate	B-VP	VBN	0	_	_	_	_
15	only	only	B-NP	RB	0	_	_	_	_
16	12	12	I-NP	CD	0	_	_	_	_
17	and	and	I-NP	CC	0	_	_	_	_
18	24	24	I-NP	CD	0	_	_	_	_
19	bp	bp	I-NP	NN	0	_	_	_	_
20	upstream	upstream	B-ADVP	RB	0	_	_	_	_
21	from	from	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	PSE	PSE	I-NP	NN	:::NOCLASS	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	instead	instead	B-PP	RB	0	_	_	_	_
26	of	of	I-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	usual	usual	I-NP	JJ	0	_	_	_	_
29	location	location	I-NP	NN	0	_	_	_	_
30	around	around	B-NP	RB	0	_	_	_	_
31	150	150	I-NP	CD	0	_	_	_	_
32	-	-	I-NP	HYPH	0	_	_	_	_
33	200	200	I-NP	CD	0	_	_	_	_
34	bp	bp	I-NP	NN	0	_	_	_	_
35	upstream	upstream	B-ADVP	RB	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	support	support	B-VP	VBP	0	_	_	_	_
4	earlier	early	B-NP	JJR	0	_	_	_	_
5	reports	report	I-NP	NNS	0	_	_	_	_
6	that	that	B-SBAR	IN	0	_	_	_	_
7	collagenase	collagenase	B-NP	NN	:::NOCLASS	_	_	_	_
8	inhibitors	inhibitor	I-NP	NNS	0	_	_	_	_
9	are	be	B-VP	VBP	0	_	_	_	_
10	useful	useful	B-ADJP	JJ	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	controlling	control	B-VP	VBG	0	_	_	_	_
13	blister	blister	B-NP	NN	UMLS:C0344311:T047:DISO	_	_	_	_
14	formation	formation	I-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	recessive	recessive	B-NP	JJ	0	_	_	_	_
17	dystrophic	dystrophic	I-NP	JJ	UMLS:C0079294:T047:DISO	_	_	_	_
18	epidermolysis	epidermolysis	I-NP	NN	UMLS:C0079294:T047:DISO	_	_	_	_
19	bullosa	bullosa	I-NP	NN	UMLS:C0079294:T047:DISO	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Mutational	Mutational	B-NP	JJ	0	_	_	_	_
2	analysis	analysis	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	essential	essential	B-NP	JJ	0	_	_	_	_
5	IncP	IncP	I-NP	NN	0	_	_	_	_
6	alpha	alpha	I-NP	NN	0	_	_	_	_
7	plasmid	plasmid	I-NP	NN	0	_	_	_	_
8	transfer	transfer	I-NP	NN	0	_	_	_	_
9	genes	gene	I-NP	NNS	0	_	_	_	_
10	traF	traF	I-NP	NN	:::NOCLASS	_	_	_	_
11	and	and	I-NP	CC	0	_	_	_	_
12	traG	traG	I-NP	NN	:::NOCLASS	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	involvement	involvement	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	traF	traF	B-NP	NN	:::NOCLASS	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	phage	phage	B-NP	NN	0	_	_	_	_
19	sensitivity	sensitivity	I-NP	NN	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	promoter	promoter	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	stimulated	stimulate	I-VP	VBN	0	_	_	_	_
5	8	8	B-NP	CD	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	20	20	I-NP	CD	0	_	_	_	_
8	-	-	B-VP	HYPH	0	_	_	_	_
9	fold	fold	B-ADVP	RB	0	_	_	_	_
10	by	by	B-PP	IN	0	_	_	_	_
11	phorbol	phorbol	B-NP	NN	0	_	_	_	_
12	esters	ester	I-NP	NNS	0	_	_	_	_
13	accounting	account	B-VP	VBG	0	_	_	_	_
14	for	for	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	previously	previously	I-NP	RB	0	_	_	_	_
17	observed	observe	I-NP	VBN	0	_	_	_	_
18	transcriptional	transcriptional	I-NP	JJ	0	_	_	_	_
19	activation	activation	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	protein	protein	B-NP	NN	:::NOCLASS	_	_	_	_
22	kinase	kinase	I-NP	NN	:::NOCLASS	_	_	_	_
23	C	C	I-NP	NN	:::NOCLASS	_	_	_	_
24	beta	beta	I-NP	NN	:::NOCLASS	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	humans	human	B-NP	NNS	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	four	four	B-NP	CD	0	_	_	_	_
5	AMP	AMP	I-NP	NN	:::NOCLASS	_	_	_	_
6	deaminase	deaminase	I-NP	NN	:::NOCLASS	_	_	_	_
7	variants	variant	I-NP	NNS	:::NOCLASS	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	termed	term	B-VP	VBN	0	_	_	_	_
10	M	M	B-NP	NN	:::NOCLASS	_	_	_	_
11	(	(	O	(	0	_	_	_	_
12	muscle	muscle	B-NP	NN	0	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	L	L	B-NP	NN	:::NOCLASS	_	_	_	_
16	(	(	O	(	0	_	_	_	_
17	liver	liver	B-NP	NN	UMLS:C0023884:T023:ANAT	_	_	_	_
18	)	)	O	)	0	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	E1	E1	B-NP	NN	:::NOCLASS	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	E2	E2	B-NP	NN	:::NOCLASS	_	_	_	_
24	(	(	O	(	0	_	_	_	_
25	erythrocyte	erythrocyte	B-NP	NN	0	_	_	_	_
26	)	)	O	)	0	_	_	_	_
27	can	can	B-VP	MD	0	_	_	_	_
28	be	be	I-VP	VB	0	_	_	_	_
29	distinguished	distinguish	I-VP	VBN	0	_	_	_	_
30	by	by	B-PP	IN	0	_	_	_	_
31	a	a	B-NP	DT	0	_	_	_	_
32	variety	variety	I-NP	NN	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	biochemical	biochemical	B-NP	JJ	0	_	_	_	_
35	and	and	I-NP	CC	0	_	_	_	_
36	immunological	immunological	I-NP	JJ	0	_	_	_	_
37	criteria	criterion	I-NP	NNS	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_

1	Western	Western	B-NP	JJ	0	_	_	_	_
2	blot	blot	I-NP	NN	0	_	_	_	_
3	analyses	analysis	I-NP	NNS	0	_	_	_	_
4	detect	detect	B-VP	VBP	0	_	_	_	_
5	anti	anti	O	AFX	:::NOCLASS	_	_	_	_
6	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
7	E	E	I-NP	NN	:::NOCLASS	_	_	_	_
8	-	-	B-NP	HYPH	0	_	_	_	_
9	specific	specific	I-NP	JJ	0	_	_	_	_
10	immunoreactivity	immunoreactivity	I-NP	NN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	affinity	affinity	B-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	purified	purify	I-NP	VBN	0	_	_	_	_
15	extracts	extract	I-NP	NNS	0	_	_	_	_
16	derived	derive	B-VP	VBN	0	_	_	_	_
17	from	from	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	bacterial	bacterial	I-NP	JJ	0	_	_	_	_
20	expression	expression	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	truncated	truncate	I-NP	VBN	:::NOCLASS	_	_	_	_
24	AMPD3	AMPD3	I-NP	NN	:::NOCLASS	_	_	_	_
25	cDNA	cDNA	I-NP	NN	:::NOCLASS	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	demonstrate	demonstrate	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	endogenous	endogenous	B-NP	JJ	0	_	_	_	_
6	N	N	I-NP	NN	0	_	_	_	_
7	-	-	O	HYPH	0	_	_	_	_
8	methylation	methylation	B-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	salsolinol	salsolinol	B-NP	NN	0	_	_	_	_
11	into	into	B-PP	IN	0	_	_	_	_
12	N	N	B-NP	NN	0	_	_	_	_
13	-	-	B-NP	HYPH	0	_	_	_	_
14	methylsalsolinol	methylsalsolinol	I-NP	NN	0	_	_	_	_
15	occurs	occur	B-VP	VBZ	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	brain	brain	I-NP	NN	UMLS:C0006104:T023:ANAT	_	_	_	_
19	in	in	B-ADVP	FW	0	_	_	_	_
20	vivo	vivo	I-ADVP	FW	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	DR1	DR1	B-NP	NN	:::NOCLASS	_	_	_	_
2	molecules	molecule	I-NP	NNS	:::NOCLASS	_	_	_	_
3	purified	purify	B-VP	VBN	0	_	_	_	_
4	from	from	B-PP	IN	0	_	_	_	_
5	human	human	B-NP	JJ	0	_	_	_	_
6	lymphoblastoid	lymphoblastoid	I-NP	JJ	0	_	_	_	_
7	cell	cell	I-NP	NN	0	_	_	_	_
8	lines	line	I-NP	NNS	0	_	_	_	_
9	could	could	B-VP	MD	0	_	_	_	_
10	specifically	specifically	I-VP	RB	0	_	_	_	_
11	bind	bind	I-VP	VB	0	_	_	_	_
12	to	to	B-PP	TO	0	_	_	_	_
13	these	these	B-NP	DT	0	_	_	_	_
14	peptide	peptide	I-NP	NN	0	_	_	_	_
15	sequences	sequence	I-NP	NNS	0	_	_	_	_
16	expressed	express	B-VP	VBN	0	_	_	_	_
17	on	on	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	phage	phage	I-NP	NN	0	_	_	_	_
20	surface	surface	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	article	article	I-NP	NN	0	_	_	_	_
3	describes	describe	B-VP	VBZ	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	collaborative	collaborative	I-NP	JJ	0	_	_	_	_
6	care	care	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	woman	woman	I-NP	NN	0	_	_	_	_
10	participating	participate	B-VP	VBG	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	maternal	maternal	B-NP	JJ	0	_	_	_	_
13	blood	blood	I-NP	NN	0	_	_	_	_
14	donation	donation	I-NP	NN	0	_	_	_	_
15	for	for	B-PP	IN	0	_	_	_	_
16	intrauterine	intrauterine	B-NP	JJ	0	_	_	_	_
17	transfusion	transfusion	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Chronic	Chronic	B-NP	JJ	UMLS:C0524909:T047:DISO	_	_	_	_
2	hepatitis	hepatitis	I-NP	NN	UMLS:C0524909:T047:DISO	_	_	_	_
3	B	B	I-NP	NN	UMLS:C0524909:T047:DISO	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	adopted	adopt	B-NP	VBN	0	_	_	_	_
6	Romanian	Romanian	I-NP	JJ	0	_	_	_	_
7	children	child	I-NP	NNS	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Behind	Behind	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	ATPase	ATPase	I-NP	NN	:::NOCLASS	_	_	_	_
4	cluster	cluster	I-NP	NN	:::NOCLASS	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	two	two	B-NP	CD	0	_	_	_	_
7	open	open	I-NP	JJ	0	_	_	_	_
8	reading	reading	I-NP	NN	0	_	_	_	_
9	frames	frame	I-NP	NNS	0	_	_	_	_
10	were	be	B-VP	VBD	0	_	_	_	_
11	detected	detect	I-VP	VBN	0	_	_	_	_
12	that	that	B-NP	WDT	0	_	_	_	_
13	are	be	B-VP	VBP	0	_	_	_	_
14	not	not	O	RB	0	_	_	_	_
15	homologous	homologous	B-ADJP	JJ	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	any	any	B-NP	DT	0	_	_	_	_
18	known	know	I-NP	VBN	0	_	_	_	_
19	chloroplast	chloroplast	I-NP	NN	0	_	_	_	_
20	gene	gene	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	Therefore	Therefore	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	recombinant	recombinant	B-NP	JJ	0	_	_	_	_
4	human	human	I-NP	JJ	0	_	_	_	_
5	Ads	Ad	I-NP	NNS	0	_	_	_	_
6	that	that	B-NP	WDT	0	_	_	_	_
7	express	express	B-VP	VBP	0	_	_	_	_
8	noninfectious	noninfectious	B-NP	JJ	0	_	_	_	_
9	HIV	HIV	I-NP	NN	UMLS:C0019693:T047:DISO	_	_	_	_
10	or	or	O	CC	0	_	_	_	_
11	other	other	B-NP	JJ	0	_	_	_	_
12	microbial	microbial	I-NP	JJ	0	_	_	_	_
13	proteins	protein	I-NP	NNS	0	_	_	_	_
14	are	be	B-VP	VBP	0	_	_	_	_
15	attractive	attractive	B-NP	JJ	0	_	_	_	_
16	vaccine	vaccine	I-NP	NN	0	_	_	_	_
17	candidates	candidate	I-NP	NNS	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Alignment	Alignment	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	selected	select	I-NP	VBN	0	_	_	_	_
5	sequences	sequence	I-NP	NNS	0	_	_	_	_
6	allowed	allow	B-VP	VBD	0	_	_	_	_
7	us	us	B-NP	PRP	0	_	_	_	_
8	to	to	B-VP	TO	0	_	_	_	_
9	predict	predict	I-VP	VB	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	consensus	consensus	I-NP	NN	0	_	_	_	_
12	sequence	sequence	I-NP	NN	0	_	_	_	_
13	for	for	B-PP	IN	0	_	_	_	_
14	binding	binding	B-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	individual	individual	I-NP	JJ	0	_	_	_	_
18	homodimeric	homodimeric	I-NP	JJ	0	_	_	_	_
19	Rel	Rel	I-NP	NN	:::NOCLASS	_	_	_	_
20	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
21	related	relate	I-NP	VBN	:::NOCLASS	_	_	_	_
22	proteins	protein	I-NP	NNS	:::NOCLASS	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	DNA	DNA	B-NP	NN	0	_	_	_	_
26	-	-	B-NP	HYPH	0	_	_	_	_
27	protein	protein	I-NP	NN	0	_	_	_	_
28	binding	binding	I-NP	NN	0	_	_	_	_
29	analysis	analysis	I-NP	NN	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	the	the	B-NP	DT	0	_	_	_	_
32	selected	select	I-NP	VBN	0	_	_	_	_
33	DNA	DNA	I-NP	NN	0	_	_	_	_
34	sequences	sequence	I-NP	NNS	0	_	_	_	_
35	revealed	reveal	B-VP	VBD	0	_	_	_	_
36	sequence	sequence	B-NP	NN	0	_	_	_	_
37	specificity	specificity	I-NP	NN	0	_	_	_	_
38	of	of	B-PP	IN	0	_	_	_	_
39	the	the	B-NP	DT	0	_	_	_	_
40	proteins	protein	I-NP	NNS	0	_	_	_	_
41	.	.	O	.	0	_	_	_	_

1	Using	Use	B-VP	VBG	0	_	_	_	_
2	either	either	O	CC	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	p50	p50	I-NP	NN	:::NOCLASS	_	_	_	_
5	-	-	B-VP	HYPH	0	_	_	_	_
6	or	or	O	CC	0	_	_	_	_
7	p65	p65	B-NP	NN	:::NOCLASS	_	_	_	_
8	-	-	O	HYPH	:::NOCLASS	_	_	_	_
9	selected	select	B-NP	VBN	:::NOCLASS	_	_	_	_
10	kappa	kappa	I-NP	NN	:::NOCLASS	_	_	_	_
11	B	B	I-NP	NN	:::NOCLASS	_	_	_	_
12	motif	motif	I-NP	NN	:::NOCLASS	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	which	which	B-NP	WDT	0	_	_	_	_
15	displayed	display	B-VP	VBD	0	_	_	_	_
16	differential	differential	B-NP	JJ	0	_	_	_	_
17	binding	binding	I-NP	NN	0	_	_	_	_
18	with	with	B-PP	IN	0	_	_	_	_
19	respect	respect	B-NP	NN	0	_	_	_	_
20	to	to	B-PP	TO	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	other	other	I-NP	JJ	0	_	_	_	_
23	protein	protein	I-NP	NN	0	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	little	little	B-NP	JJ	0	_	_	_	_
26	to	to	B-PP	TO	0	_	_	_	_
27	no	no	B-NP	DT	0	_	_	_	_
28	binding	binding	I-NP	NN	0	_	_	_	_
29	was	be	B-VP	VBD	0	_	_	_	_
30	observed	observe	I-VP	VBN	0	_	_	_	_
31	with	with	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	heterodimeric	heterodimeric	I-NP	JJ	:::NOCLASS	_	_	_	_
34	NF	NF	I-NP	NN	:::NOCLASS	_	_	_	_
35	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
36	kappa	kappa	I-NP	NN	:::NOCLASS	_	_	_	_
37	B	B	I-NP	NN	:::NOCLASS	_	_	_	_
38	complex	complex	I-NP	NN	:::NOCLASS	_	_	_	_
39	.	.	O	.	0	_	_	_	_

1	However	However	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	cosmid	cosmid	I-NP	NN	0	_	_	_	_
5	clone	clone	I-NP	NN	0	_	_	_	_
6	containing	contain	B-VP	VBG	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	entire	entire	I-NP	JJ	0	_	_	_	_
9	mouse	mouse	I-NP	NN	:::NOCLASS	_	_	_	_
10	alpha	alpha	I-NP	NN	:::NOCLASS	_	_	_	_
11	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
12	(	(	O	(	:::NOCLASS	_	_	_	_
13	I	I	B-NP	NN	:::NOCLASS	_	_	_	_
14	)	)	O	)	:::NOCLASS	_	_	_	_
15	gene	gene	B-NP	NN	:::NOCLASS	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	including	include	B-PP	VBG	0	_	_	_	_
18	3	3	B-NP	CD	0	_	_	_	_
19	.	.	O	.	0	_	_	_	_
20	7	7	B-NP	CD	0	_	_	_	_
21	kb	kb	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	5	5	B-NP	CD	0	_	_	_	_
24	'	'	I-NP	SYM	0	_	_	_	_
25	-	-	I-NP	HYPH	0	_	_	_	_
26	and	and	O	CC	0	_	_	_	_
27	4	4	B-NP	CD	0	_	_	_	_
28	kb	kb	I-NP	NN	0	_	_	_	_
29	of	of	B-PP	IN	0	_	_	_	_
30	3	3	B-NP	CD	0	_	_	_	_
31	'	'	I-NP	SYM	0	_	_	_	_
32	-	-	I-NP	HYPH	0	_	_	_	_
33	flanking	flank	I-NP	VBG	0	_	_	_	_
34	DNA	DNA	I-NP	NN	0	_	_	_	_
35	,	,	O	,	0	_	_	_	_
36	was	be	B-VP	VBD	0	_	_	_	_
37	expressed	express	I-VP	VBN	0	_	_	_	_
38	at	at	B-PP	IN	0	_	_	_	_
39	reduced	reduce	B-NP	VBN	0	_	_	_	_
40	levels	level	I-NP	NNS	0	_	_	_	_
41	in	in	B-PP	IN	0	_	_	_	_
42	fibroblasts	fibroblast	B-NP	NNS	0	_	_	_	_
43	overexpressing	overexpresse	B-VP	VBG	0	_	_	_	_
44	oncogenic	oncogenic	B-NP	JJ	:::NOCLASS	_	_	_	_
45	ras	ras	I-NP	NN	:::NOCLASS	_	_	_	_
46	.	.	O	.	0	_	_	_	_

1	To	To	B-VP	TO	0	_	_	_	_
2	define	define	I-VP	VB	0	_	_	_	_
3	transcriptional	transcriptional	B-NP	JJ	0	_	_	_	_
4	control	control	I-NP	NN	0	_	_	_	_
5	elements	element	I-NP	NNS	0	_	_	_	_
6	responsible	responsible	B-ADJP	JJ	0	_	_	_	_
7	for	for	B-PP	IN	0	_	_	_	_
8	muscle	muscle	B-NP	NN	0	_	_	_	_
9	-	-	B-NP	HYPH	0	_	_	_	_
10	specific	specific	I-NP	JJ	0	_	_	_	_
11	expression	expression	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	human	human	I-NP	JJ	:::NOCLASS	_	_	_	_
15	myoglobin	myoglobin	I-NP	NN	:::NOCLASS	_	_	_	_
16	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
17	,	,	O	,	0	_	_	_	_
18	we	we	B-NP	PRP	0	_	_	_	_
19	performed	perform	B-VP	VBD	0	_	_	_	_
20	mutational	mutational	B-NP	JJ	0	_	_	_	_
21	analysis	analysis	I-NP	NN	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	upstream	upstream	B-NP	JJ	0	_	_	_	_
24	sequences	sequence	I-NP	NNS	0	_	_	_	_
25	(	(	O	(	0	_	_	_	_
26	nucleotide	nucleotide	B-NP	NN	0	_	_	_	_
27	positions	position	I-NP	NNS	0	_	_	_	_
28	-	-	O	SYM	0	_	_	_	_
29	373	373	B-NP	CD	0	_	_	_	_
30	to	to	B-PP	TO	0	_	_	_	_
31	+7	+7	B-NP	CD	0	_	_	_	_
32	relative	relative	B-ADVP	JJ	0	_	_	_	_
33	to	to	B-PP	TO	0	_	_	_	_
34	the	the	B-NP	DT	0	_	_	_	_
35	transcriptional	transcriptional	I-NP	JJ	0	_	_	_	_
36	start	start	I-NP	NN	0	_	_	_	_
37	site	site	I-NP	NN	0	_	_	_	_
38	)	)	O	)	0	_	_	_	_
39	linked	link	B-VP	VBN	0	_	_	_	_
40	to	to	B-PP	TO	0	_	_	_	_
41	a	a	B-NP	DT	0	_	_	_	_
42	firefly	firefly	I-NP	JJ	:::NOCLASS	_	_	_	_
43	luciferase	luciferase	I-NP	NN	:::NOCLASS	_	_	_	_
44	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
45	.	.	O	.	0	_	_	_	_

1	Sequencing	Sequencing	B-NP	NN	0	_	_	_	_
2	analysis	analysis	I-NP	NN	0	_	_	_	_
3	has	have	B-VP	VBZ	0	_	_	_	_
4	shown	show	I-VP	VBN	0	_	_	_	_
5	that	that	B-SBAR	IN	0	_	_	_	_
6	each	each	B-NP	DT	0	_	_	_	_
7	rap1t	rap1t	I-NP	NN	:::NOCLASS	_	_	_	_
8	allele	allele	I-NP	NN	:::NOCLASS	_	_	_	_
9	contains	contain	B-VP	VBZ	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	nonsense	nonsense	I-NP	JJ	0	_	_	_	_
12	mutation	mutation	I-NP	NN	0	_	_	_	_
13	within	within	B-PP	IN	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	discrete	discrete	I-NP	JJ	0	_	_	_	_
16	region	region	I-NP	NN	0	_	_	_	_
17	between	between	B-PP	IN	0	_	_	_	_
18	amino	amino	B-NP	NN	0	_	_	_	_
19	acids	acid	I-NP	NNS	0	_	_	_	_
20	663	663	B-NP	CD	0	_	_	_	_
21	and	and	I-NP	CC	0	_	_	_	_
22	684	684	I-NP	CD	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	By	By	B-PP	IN	0	_	_	_	_
2	screening	screen	B-VP	VBG	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	Y1	Y1	I-NP	NN	0	_	_	_	_
5	cell	cell	I-NP	NN	0	_	_	_	_
6	cDNA	cDNA	I-NP	NN	0	_	_	_	_
7	library	library	I-NP	NN	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	DNA	DNA	I-NP	NN	0	_	_	_	_
11	-	-	B-PP	HYPH	0	_	_	_	_
12	binding	bind	B-NP	VBG	0	_	_	_	_
13	region	region	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	H	H	I-NP	NN	:::NOCLASS	_	_	_	_
17	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
18	2RIIBP	2RIIBP	I-NP	NN	:::NOCLASS	_	_	_	_
19	nuclear	nuclear	I-NP	JJ	:::NOCLASS	_	_	_	_
20	hormone	hormone	I-NP	NN	:::NOCLASS	_	_	_	_
21	receptor	receptor	I-NP	NN	:::NOCLASS	_	_	_	_
22	cDNA	cDNA	I-NP	NN	:::NOCLASS	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	we	we	B-NP	PRP	0	_	_	_	_
25	isolated	isolate	B-VP	VBD	0	_	_	_	_
26	a	a	B-NP	DT	0	_	_	_	_
27	cDNA	cDNA	I-NP	NN	0	_	_	_	_
28	that	that	B-NP	WDT	0	_	_	_	_
29	is	be	B-VP	VBZ	0	_	_	_	_
30	selectively	selectively	I-VP	RB	0	_	_	_	_
31	expressed	express	I-VP	VBN	0	_	_	_	_
32	in	in	B-PP	IN	0	_	_	_	_
33	steroidogenic	steroidogenic	B-NP	JJ	0	_	_	_	_
34	cells	cell	I-NP	NNS	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	Autopsy	Autopsy	B-NP	NN	0	_	_	_	_
2	demonstrated	demonstrate	B-VP	VBD	0	_	_	_	_
3	good	good	B-NP	JJ	0	_	_	_	_
4	survival	survival	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	transplanted	transplant	I-NP	VBN	0	_	_	_	_
8	cells	cell	I-NP	NNS	0	_	_	_	_
9	with	with	B-PP	IN	0	_	_	_	_
10	good	good	B-NP	JJ	0	_	_	_	_
11	integration	integration	I-NP	NN	0	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	brain	brain	I-NP	NN	UMLS:C0006104:T023:ANAT	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	recipient	recipient	I-NP	NN	0	_	_	_	_
18	and	and	I-NP	CC	0	_	_	_	_
19	traces	trace	I-NP	NNS	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	positive	positive	B-NP	JJ	0	_	_	_	_
22	immunocytochemical	immunocytochemical	I-NP	JJ	0	_	_	_	_
23	reaction	reaction	I-NP	NN	0	_	_	_	_
24	for	for	B-PP	IN	0	_	_	_	_
25	tyrosine	tyrosine	B-NP	NN	:::NOCLASS	_	_	_	_
26	hydroxylase	hydroxylase	I-NP	NN	:::NOCLASS	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	technique	technique	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	TEE	TEE	I-NP	NN	0	_	_	_	_
6	visualization	visualization	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	proximal	proximal	I-NP	JJ	0	_	_	_	_
10	coronary	coronary	I-NP	JJ	UMLS:C0205042:T023:ANAT	_	_	_	_
11	arteries	artery	I-NP	NNS	UMLS:C0205042:T023:ANAT	_	_	_	_
12	is	be	B-VP	VBZ	0	_	_	_	_
13	described	describe	I-VP	VBN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	sequence	sequence	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	this	this	B-NP	DT	0	_	_	_	_
5	region	region	I-NP	NN	0	_	_	_	_
6	shows	show	B-VP	VBZ	0	_	_	_	_
7	high	high	B-NP	JJ	0	_	_	_	_
8	G+C	G+C	I-NP	NN	0	_	_	_	_
9	content	content	I-NP	NN	0	_	_	_	_
10	(	(	O	(	0	_	_	_	_
11	62	62	B-NP	CD	0	_	_	_	_
12	%	%	I-NP	NN	0	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	which	which	B-NP	WDT	0	_	_	_	_
16	is	be	B-VP	VBZ	0	_	_	_	_
17	particularly	particularly	I-VP	RB	0	_	_	_	_
18	emphasized	emphasize	I-VP	VBN	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	200	200	I-NP	CD	0	_	_	_	_
22	bp	bp	I-NP	NN	0	_	_	_	_
23	upstream	upstream	B-ADVP	RB	0	_	_	_	_
24	from	from	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	mRNA	mRNA	I-NP	NN	0	_	_	_	_
27	start	start	I-NP	NN	0	_	_	_	_
28	(	(	O	(	0	_	_	_	_
29	80	80	B-NP	CD	0	_	_	_	_
30	%	%	I-NP	NN	0	_	_	_	_
31	G+C	G+C	I-NP	NN	0	_	_	_	_
32	)	)	O	)	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	eight	eight	I-NP	CD	0	_	_	_	_
4	patients	patient	I-NP	NNS	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	persistent	persistent	B-NP	JJ	0	_	_	_	_
7	generalized	generalize	I-NP	VBN	0	_	_	_	_
8	lymph	lymph	I-NP	NN	0	_	_	_	_
9	-	-	O	HYPH	0	_	_	_	_
10	adenopathy	adenopathy	B-NP	NN	0	_	_	_	_
11	(	(	O	(	0	_	_	_	_
12	PGL	PGL	B-NP	NN	0	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	and	and	O	CC	0	_	_	_	_
15	nontender	nontender	B-NP	JJ	0	_	_	_	_
16	,	,	I-NP	,	0	_	_	_	_
17	nonenlarging	nonenlarging	I-NP	JJ	0	_	_	_	_
18	nodes	node	I-NP	NNS	UMLS:C0746922:T023:ANAT	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	pathologic	pathologic	B-NP	JJ	0	_	_	_	_
21	analysis	analysis	I-NP	NN	0	_	_	_	_
22	revealed	reveal	B-VP	VBD	0	_	_	_	_
23	lymphoid	lymphoid	B-NP	JJ	UMLS:C0333997:T047:DISO	_	_	_	_
24	hyperplasia	hyperplasia	I-NP	NN	UMLS:C0333997:T047:DISO	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	PaO2	PaO2	B-NP	NN	0	_	_	_	_
2	threshold	threshold	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	determined	determine	I-VP	VBN	0	_	_	_	_
5	through	through	B-PP	IN	0	_	_	_	_
6	an	an	B-NP	DT	0	_	_	_	_
7	indwelling	indwell	I-NP	VBG	0	_	_	_	_
8	O2	O2	I-NP	NN	0	_	_	_	_
9	sensor	sensor	I-NP	NN	0	_	_	_	_
10	catheter	catheter	I-NP	NN	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	found	find	B-VP	VBD	0	_	_	_	_
3	that	that	B-SBAR	IN	0	_	_	_	_
4	both	both	O	CC	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	E26	E26	I-NP	NN	0	_	_	_	_
7	virus	virus	I-NP	NN	0	_	_	_	_
8	-	-	B-VP	HYPH	0	_	_	_	_
9	encoded	encode	B-NP	VBN	0	_	_	_	_
10	v	v	I-NP	NN	:::NOCLASS	_	_	_	_
11	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
12	ets	ets	I-NP	NN	:::NOCLASS	_	_	_	_
13	and	and	O	CC	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	myeloid	myeloid	I-NP	JJ	:::NOCLASS	_	_	_	_
16	/	/	I-NP	SYM	:::NOCLASS	_	_	_	_
17	B	B	I-NP	NN	:::NOCLASS	_	_	_	_
18	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
19	cell	cell	I-NP	NN	:::NOCLASS	_	_	_	_
20	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
21	specific	specific	I-NP	JJ	:::NOCLASS	_	_	_	_
22	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
23	PU	PU	I-NP	NN	:::NOCLASS	_	_	_	_
24	.	.	O	.	:::NOCLASS	_	_	_	_
25	1	1	B-NP	CD	:::NOCLASS	_	_	_	_
26	bind	bind	B-VP	VBP	0	_	_	_	_
27	efficiently	efficiently	B-ADVP	RB	0	_	_	_	_
28	to	to	B-PP	TO	0	_	_	_	_
29	this	this	B-NP	DT	0	_	_	_	_
30	site	site	I-NP	NN	0	_	_	_	_
31	in	in	B-ADVP	FW	0	_	_	_	_
32	vitro	vitro	I-ADVP	FW	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	By	By	B-PP	IN	0	_	_	_	_
2	using	use	B-VP	VBG	0	_	_	_	_
3	lambda	lambda	B-NP	NN	0	_	_	_	_
4	gt11	gt11	I-NP	NN	0	_	_	_	_
5	expression	expression	I-NP	NN	0	_	_	_	_
6	cloning	clone	B-VP	VBG	0	_	_	_	_
7	with	with	B-PP	IN	0	_	_	_	_
8	oligonucleotides	oligonucleotide	B-NP	NNS	0	_	_	_	_
9	corresponding	correspond	B-VP	VBG	0	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	the	the	B-NP	DT	0	_	_	_	_
12	human	human	I-NP	JJ	UMLS:C0019693:T047:DISO	_	_	_	_
13	immunodeficiency	immunodeficiency	I-NP	NN	UMLS:C0019693:T047:DISO	_	_	_	_
14	virus	virus	I-NP	NN	UMLS:C0019693:T047:DISO	_	_	_	_
15	1	1	I-NP	CD	0	_	_	_	_
16	TATA	TATA	I-NP	NN	:::NOCLASS	_	_	_	_
17	element	element	I-NP	NN	:::NOCLASS	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	we	we	B-NP	PRP	0	_	_	_	_
20	report	report	B-VP	VBP	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	identification	identification	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	a	a	B-NP	DT	0	_	_	_	_
25	cellular	cellular	I-NP	JJ	0	_	_	_	_
26	protein	protein	I-NP	NN	0	_	_	_	_
27	with	with	B-PP	IN	0	_	_	_	_
28	a	a	B-NP	DT	0	_	_	_	_
29	calculated	calculate	I-NP	VBN	0	_	_	_	_
30	molecular	molecular	I-NP	JJ	0	_	_	_	_
31	mass	mass	I-NP	NN	0	_	_	_	_
32	of	of	B-PP	IN	0	_	_	_	_
33	123	123	B-NP	CD	0	_	_	_	_
34	kDa	kDa	I-NP	NN	0	_	_	_	_
35	that	that	B-NP	IN	0	_	_	_	_
36	we	we	B-NP	PRP	0	_	_	_	_
37	designate	designate	B-VP	VBP	0	_	_	_	_
38	TATA	TATA	B-NP	NN	:::NOCLASS	_	_	_	_
39	element	element	I-NP	NN	:::NOCLASS	_	_	_	_
40	modulatory	modulatory	I-NP	JJ	:::NOCLASS	_	_	_	_
41	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
42	(	(	O	(	0	_	_	_	_
43	TMF	TMF	B-NP	NN	:::NOCLASS	_	_	_	_
44	)	)	O	)	0	_	_	_	_
45	.	.	O	.	0	_	_	_	_

1	Blood	Blood	B-NP	NN	0	_	_	_	_
2	levels	level	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	melatonin	melatonin	B-NP	NN	0	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	serotonin	serotonin	B-NP	NN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	cortisol	cortisol	B-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	prolactin	prolactin	B-NP	NN	:::NOCLASS	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	relation	relation	B-NP	NN	0	_	_	_	_
14	to	to	B-PP	TO	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	circadian	circadian	I-NP	JJ	0	_	_	_	_
17	rhythm	rhythm	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	platelet	platelet	B-NP	NN	0	_	_	_	_
20	serotonin	serotonin	I-NP	NN	0	_	_	_	_
21	uptake	uptake	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	could	could	B-VP	MD	0	_	_	_	_
3	n't	n't	I-VP	RB	0	_	_	_	_
4	detect	detect	I-VP	VB	0	_	_	_	_
5	any	any	B-NP	DT	0	_	_	_	_
6	effect	effect	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	n	n	B-NP	NN	0	_	_	_	_
9	-	-	I-NP	HYPH	0	_	_	_	_
10	3	3	I-NP	CD	0	_	_	_	_
11	FA	FA	I-NP	NN	UMLS:C1856689:T047:DISO|UMLS:C0015625:T047:DISO	_	_	_	_
12	supplementation	supplementation	I-NP	NN	0	_	_	_	_
13	on	on	B-PP	IN	0	_	_	_	_
14	total	total	B-NP	JJ	0	_	_	_	_
15	cholesterol	cholesterol	I-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	HDL	HDL	B-NP	NN	:::NOCLASS	_	_	_	_
18	cholesterol	cholesterol	I-NP	NN	:::NOCLASS	_	_	_	_
19	,	,	O	,	0	_	_	_	_
20	LDL	LDL	B-NP	NN	:::NOCLASS	_	_	_	_
21	cholesterol	cholesterol	I-NP	NN	:::NOCLASS	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	apo	apo	B-NP	NN	:::NOCLASS	_	_	_	_
24	A1	A1	I-NP	NN	:::NOCLASS|UMLS:C0933653:T023:ANAT	_	_	_	_
25	,	,	O	,	0	_	_	_	_
26	Lp	Lp	B-NP	NN	:::NOCLASS|UMLS:C0228341:T023:ANAT	_	_	_	_
27	(	(	O	(	:::NOCLASS	_	_	_	_
28	a	a	O	DT	:::NOCLASS	_	_	_	_
29	)	)	O	)	:::NOCLASS	_	_	_	_
30	,	,	O	,	0	_	_	_	_
31	HbA1C	HbA1C	B-NP	NN	:::NOCLASS	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	glucose	glucose	B-NP	NN	0	_	_	_	_
34	,	,	O	,	0	_	_	_	_
35	fibrinogen	fibrinogen	B-NP	NN	:::NOCLASS	_	_	_	_
36	,	,	O	,	0	_	_	_	_
37	factor	factor	B-NP	NN	:::NOCLASS	_	_	_	_
38	VIII	VIII	I-NP	CD	:::NOCLASS	_	_	_	_
39	,	,	O	,	0	_	_	_	_
40	antithrombin	antithrombin	B-NP	NN	:::NOCLASS	_	_	_	_
41	III	III	I-NP	CD	:::NOCLASS	_	_	_	_
42	,	,	O	,	0	_	_	_	_
43	plasminogen	plasminogen	B-NP	NN	:::NOCLASS	_	_	_	_
44	activator	activator	I-NP	NN	:::NOCLASS	_	_	_	_
45	inhibitor	inhibitor	I-NP	NN	:::NOCLASS	_	_	_	_
46	,	,	O	,	0	_	_	_	_
47	tissue	tissue	B-NP	NN	:::NOCLASS	_	_	_	_
48	plasminogen	plasminogen	I-NP	NN	:::NOCLASS	_	_	_	_
49	activator	activator	I-NP	NN	:::NOCLASS	_	_	_	_
50	and	and	O	CC	0	_	_	_	_
51	von	von	B-NP	NN	:::NOCLASS|UMLS:C0042974:T047:DISO	_	_	_	_
52	Willebrand	Willebrand	I-NP	NN	:::NOCLASS|UMLS:C0042974:T047:DISO	_	_	_	_
53	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
54	concentration	concentration	I-NP	NN	0	_	_	_	_
55	,	,	O	,	0	_	_	_	_
56	on	on	B-PP	IN	0	_	_	_	_
57	bleeding	bleed	B-VP	VBG	0	_	_	_	_
58	time	time	B-NP	NN	0	_	_	_	_
59	or	or	B-PP	CC	0	_	_	_	_
60	on	on	B-PP	IN	0	_	_	_	_
61	systolic	systolic	B-NP	JJ	0	_	_	_	_
62	or	or	I-NP	CC	0	_	_	_	_
63	diastolic	diastolic	I-NP	JJ	0	_	_	_	_
64	blood	blood	I-NP	NN	0	_	_	_	_
65	pressure	pressure	I-NP	NN	0	_	_	_	_
66	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	8	8	B-NP	CD	0	_	_	_	_
3	healthy	healthy	I-NP	JJ	0	_	_	_	_
4	volunteers	volunteer	I-NP	NNS	0	_	_	_	_
5	there	there	B-NP	EX	0	_	_	_	_
6	were	be	B-VP	VBD	0	_	_	_	_
7	no	no	B-NP	DT	0	_	_	_	_
8	significant	significant	I-NP	JJ	0	_	_	_	_
9	differences	difference	I-NP	NNS	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	AUC	AUC	B-NP	NN	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	peak	peak	B-NP	JJ	0	_	_	_	_
14	plasma	plasma	I-NP	NN	0	_	_	_	_
15	concentrations	concentration	I-NP	NNS	0	_	_	_	_
16	or	or	O	CC	0	_	_	_	_
17	time	time	B-NP	NN	0	_	_	_	_
18	to	to	B-PP	TO	0	_	_	_	_
19	peak	peak	B-NP	JJ	0	_	_	_	_
20	concentration	concentration	I-NP	NN	0	_	_	_	_
21	when	when	B-ADVP	WRB	0	_	_	_	_
22	OXC	OXC	B-NP	NN	0	_	_	_	_
23	was	be	B-VP	VBD	0	_	_	_	_
24	administered	administer	I-VP	VBN	0	_	_	_	_
25	either	either	B-PP	CC	0	_	_	_	_
26	with	with	I-PP	IN	0	_	_	_	_
27	or	or	B-PP	CC	0	_	_	_	_
28	without	without	I-PP	IN	0	_	_	_	_
29	ERY	ERY	B-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	Using	Use	B-VP	VBG	0	_	_	_	_
2	5	5	B-NP	CD	0	_	_	_	_
3	ng	ng	I-NP	NN	0	_	_	_	_
4	/	/	B-NP	SYM	0	_	_	_	_
5	mL	mL	I-NP	NN	0	_	_	_	_
6	as	as	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	cutoff	cutoff	I-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	sensitivity	sensitivity	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	CEA	CEA	B-NP	NN	:::NOCLASS	_	_	_	_
14	was	be	B-VP	VBD	0	_	_	_	_
15	68	68	B-NP	CD	0	_	_	_	_
16	%	%	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Rolandic	Rolandic	B-NP	JJ	0	_	_	_	_
2	spikes	spike	I-NP	NNS	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	cognitive	cognitive	B-NP	JJ	0	_	_	_	_
5	function	function	I-NP	NN	0	_	_	_	_
6	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effect	effect	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	sodium	sodium	B-NP	NN	0	_	_	_	_
5	18	18	I-NP	CD	0	_	_	_	_
6	beta	beta	O	SYM	0	_	_	_	_
7	-	-	O	HYPH	0	_	_	_	_
8	glycyrrhetate	glycyrrhetate	B-NP	NN	0	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	SGA	SGA	B-NP	NN	0	_	_	_	_
11	)	)	O	)	0	_	_	_	_
12	on	on	B-PP	IN	0	_	_	_	_
13	experimental	experimental	B-NP	JJ	0	_	_	_	_
14	arrhythmia	arrhythmia	I-NP	NN	0	_	_	_	_
15	was	be	B-VP	VBD	0	_	_	_	_
16	investigated	investigate	I-VP	VBN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Thus	Thus	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	chronic	chronic	B-NP	JJ	0	_	_	_	_
4	hematocrit	hematocrit	I-NP	NN	0	_	_	_	_
5	decrease	decrease	I-NP	NN	0	_	_	_	_
6	induced	induce	B-VP	VBN	0	_	_	_	_
7	by	by	B-PP	IN	0	_	_	_	_
8	H	H	B-NP	NN	0	_	_	_	_
9	or	or	I-NP	CC	0	_	_	_	_
10	P	P	I-NP	NN	0	_	_	_	_
11	resulted	result	B-VP	VBD	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	a	a	B-NP	DT	0	_	_	_	_
14	significant	significant	I-NP	JJ	0	_	_	_	_
15	fall	fall	I-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	blood	blood	B-NP	NN	0	_	_	_	_
18	pressure	pressure	I-NP	NN	0	_	_	_	_
19	compared	compare	B-VP	VBN	0	_	_	_	_
20	to	to	B-PP	TO	0	_	_	_	_
21	control	control	B-NP	NN	0	_	_	_	_
22	(	(	O	(	0	_	_	_	_
23	201	201	B-NP	CD	0	_	_	_	_
24	+	+	O	SYM	0	_	_	_	_
25	/	/	O	SYM	0	_	_	_	_
26	-	-	O	SYM	0	_	_	_	_
27	3	3	B-NP	CD	0	_	_	_	_
28	v	v	I-NP	SYM	0	_	_	_	_
29	175	175	I-NP	CD	0	_	_	_	_
30	+	+	B-NP	SYM	0	_	_	_	_
31	/	/	I-NP	SYM	0	_	_	_	_
32	-	-	I-NP	SYM	0	_	_	_	_
33	4	4	I-NP	CD	0	_	_	_	_
34	,	,	I-NP	,	0	_	_	_	_
35	167	167	I-NP	CD	0	_	_	_	_
36	+	+	B-NP	SYM	0	_	_	_	_
37	/	/	I-NP	SYM	0	_	_	_	_
38	-	-	I-NP	SYM	0	_	_	_	_
39	4	4	I-NP	CD	0	_	_	_	_
40	mm	mm	I-NP	NN	0	_	_	_	_
41	Hg	Hg	I-NP	NN	0	_	_	_	_
42	,	,	O	,	0	_	_	_	_
43	respectively	respectively	B-ADVP	RB	0	_	_	_	_
44	;	;	O	:	0	_	_	_	_
45	P	P	B-NP	NN	0	_	_	_	_
46	<	<	B-NP	SYM	0	_	_	_	_
47	.	.	I-NP	.	0	_	_	_	_
48	05	05	I-NP	CD	0	_	_	_	_
49	)	)	O	)	0	_	_	_	_
50	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effects	effect	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	diltiazem	diltiazem	B-NP	NN	0	_	_	_	_
5	were	be	B-VP	VBD	0	_	_	_	_
6	stereoselective	stereoselective	B-ADJP	JJ	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	thus	thus	B-ADVP	RB	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	potentiation	potentiation	I-NP	NN	0	_	_	_	_
11	induced	induce	B-VP	VBN	0	_	_	_	_
12	by	by	B-PP	IN	0	_	_	_	_
13	d	d	B-NP	NN	0	_	_	_	_
14	-	-	I-NP	HYPH	0	_	_	_	_
15	cis	cis	I-NP	NN	0	_	_	_	_
16	diltiazem	diltiazem	I-NP	NN	0	_	_	_	_
17	was	be	B-VP	VBD	0	_	_	_	_
18	significantly	significantly	B-ADJP	RB	0	_	_	_	_
19	greater	great	I-ADJP	JJR	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	all	all	B-NP	DT	0	_	_	_	_
22	cases	case	I-NP	NNS	0	_	_	_	_
23	than	than	B-PP	IN	0	_	_	_	_
24	that	that	B-NP	DT	0	_	_	_	_
25	induced	induce	B-VP	VBN	0	_	_	_	_
26	by	by	B-PP	IN	0	_	_	_	_
27	l	l	B-NP	NN	0	_	_	_	_
28	-	-	I-NP	HYPH	0	_	_	_	_
29	cis	cis	I-NP	NN	0	_	_	_	_
30	diltiazem	diltiazem	I-NP	NN	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	which	which	B-NP	WDT	0	_	_	_	_
33	suggests	suggest	B-VP	VBZ	0	_	_	_	_
34	that	that	B-SBAR	IN	0	_	_	_	_
35	calcium	calcium	B-NP	NN	0	_	_	_	_
36	channel	channel	I-NP	NN	0	_	_	_	_
37	blockade	blockade	I-NP	NN	0	_	_	_	_
38	plays	play	B-VP	VBZ	0	_	_	_	_
39	a	a	B-NP	DT	0	_	_	_	_
40	role	role	I-NP	NN	0	_	_	_	_
41	in	in	B-PP	IN	0	_	_	_	_
42	these	these	B-NP	DT	0	_	_	_	_
43	interactions	interaction	I-NP	NNS	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	Localization	Localization	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	brachial	brachial	I-NP	JJ	UMLS:C0006090:T023:ANAT	_	_	_	_
5	plexus	plexus	I-NP	NN	UMLS:C0006090:T023:ANAT	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	nerve	nerve	I-NP	NN	0	_	_	_	_
9	stimulator	stimulator	I-NP	NN	0	_	_	_	_
10	is	be	B-VP	VBZ	0	_	_	_	_
11	equally	equally	B-ADJP	RB	0	_	_	_	_
12	effective	effective	I-ADJP	JJ	0	_	_	_	_
13	at	at	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	interscalene	interscalene	I-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	supraclavicular	supraclavicular	B-ADJP	JJ	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	and	and	O	CC	0	_	_	_	_
20	axillary	axillary	B-NP	JJ	0	_	_	_	_
21	sites	site	I-NP	NNS	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Substitution	Substitution	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	either	either	O	CC	0	_	_	_	_
4	Val33	Val33	B-NP	NN	0	_	_	_	_
5	(	(	O	(	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	Gly	Gly	B-NP	NN	0	_	_	_	_
8	)	)	O	)	0	_	_	_	_
9	or	or	O	CC	0	_	_	_	_
10	Gly28	Gly28	B-NP	NN	0	_	_	_	_
11	(	(	O	(	0	_	_	_	_
12	by	by	B-PP	IN	0	_	_	_	_
13	Ser	Ser	B-NP	NN	0	_	_	_	_
14	)	)	O	)	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	two	two	B-NP	CD	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	most	most	I-NP	RBS	0	_	_	_	_
20	conserved	conserve	I-NP	VBN	0	_	_	_	_
21	residues	residue	I-NP	NNS	0	_	_	_	_
22	in	in	B-PP	IN	0	_	_	_	_
23	all	all	B-NP	DT	0	_	_	_	_
24	protein	protein	I-NP	NN	0	_	_	_	_
25	kinases	kinase	I-NP	NNS	0	_	_	_	_
26	,	,	O	,	0	_	_	_	_
27	resulted	result	B-VP	VBD	0	_	_	_	_
28	in	in	B-PP	IN	0	_	_	_	_
29	enzyme	enzyme	B-NP	NN	0	_	_	_	_
30	with	with	B-PP	IN	0	_	_	_	_
31	marginally	marginally	B-NP	RB	0	_	_	_	_
32	detectable	detectable	I-NP	JJ	0	_	_	_	_
33	activity	activity	I-NP	NN	0	_	_	_	_
34	.	.	O	.	0	_	_	_	_

1	Significance	Significance	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	biopsy	biopsy	I-NP	NN	0	_	_	_	_
5	site	site	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	latissimus	latissimus	I-NP	JJ	UMLS:C0224362:T023:ANAT	_	_	_	_
9	dorsi	dorsi	I-NP	NN	UMLS:C0224362:T023:ANAT	_	_	_	_
10	muscle	muscle	I-NP	NN	UMLS:C0224362:T023:ANAT	_	_	_	_
11	for	for	B-PP	IN	0	_	_	_	_
12	fiber	fiber	B-NP	NN	0	_	_	_	_
13	typing	typing	I-NP	NN	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	TIMP	TIMP	I-NP	NN	:::NOCLASS	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	-	-	B-NP	SYM	0	_	_	_	_
5	59	59	B-NP	CD	0	_	_	_	_
6	/	/	I-NP	SYM	0	_	_	_	_
7	-	-	I-NP	SYM	0	_	_	_	_
8	53	53	I-NP	CD	0	_	_	_	_
9	)	)	O	)	0	_	_	_	_
10	AP1	AP1	B-NP	NN	:::NOCLASS	_	_	_	_
11	site	site	I-NP	NN	0	_	_	_	_
12	is	be	B-VP	VBZ	0	_	_	_	_
13	a	a	B-NP	DT	0	_	_	_	_
14	promiscuous	promiscuous	I-NP	JJ	0	_	_	_	_
15	motif	motif	I-NP	NN	0	_	_	_	_
16	that	that	B-NP	WDT	0	_	_	_	_
17	binds	bind	B-VP	VBZ	0	_	_	_	_
18	c	c	B-NP	NN	:::NOCLASS	_	_	_	_
19	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
20	Fos	Fos	I-NP	NN	:::NOCLASS	_	_	_	_
21	/	/	B-NP	SYM	0	_	_	_	_
22	c	c	I-NP	NN	:::NOCLASS	_	_	_	_
23	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
24	Jun	Jun	I-NP	NN	:::NOCLASS	_	_	_	_
25	AP1	AP1	I-NP	NN	:::NOCLASS	_	_	_	_
26	translated	translate	B-VP	VBN	0	_	_	_	_
27	in	in	B-ADVP	FW	0	_	_	_	_
28	vitro	vitro	I-ADVP	FW	0	_	_	_	_
29	and	and	O	CC	0	_	_	_	_
30	is	be	B-VP	VBZ	0	_	_	_	_
31	an	an	B-NP	DT	0	_	_	_	_
32	effective	effective	I-NP	JJ	0	_	_	_	_
33	competitor	competitor	I-NP	NN	0	_	_	_	_
34	for	for	B-PP	IN	0	_	_	_	_
35	binding	binding	B-NP	NN	0	_	_	_	_
36	of	of	B-PP	IN	0	_	_	_	_
37	nuclear	nuclear	B-NP	JJ	:::NOCLASS	_	_	_	_
38	AP1	AP1	I-NP	NN	:::NOCLASS	_	_	_	_
39	factors	factor	I-NP	NNS	:::NOCLASS	_	_	_	_
40	to	to	B-PP	TO	0	_	_	_	_
41	the	the	B-NP	DT	0	_	_	_	_
42	consensus	consensus	I-NP	NN	0	_	_	_	_
43	TRE	TRE	I-NP	NN	0	_	_	_	_
44	,	,	O	,	0	_	_	_	_
45	but	but	O	CC	0	_	_	_	_
46	in	in	B-PP	IN	0	_	_	_	_
47	addition	addition	B-NP	NN	0	_	_	_	_
48	it	it	B-NP	PRP	0	_	_	_	_
49	binds	bind	B-VP	VBZ	0	_	_	_	_
50	factors	factor	B-NP	NNS	0	_	_	_	_
51	that	that	B-NP	WDT	0	_	_	_	_
52	do	do	B-VP	VBP	0	_	_	_	_
53	not	not	I-VP	RB	0	_	_	_	_
54	associate	associate	I-VP	VB	0	_	_	_	_
55	with	with	B-PP	IN	0	_	_	_	_
56	the	the	B-NP	DT	0	_	_	_	_
57	consensus	consensus	I-NP	NN	0	_	_	_	_
58	TRE	TRE	I-NP	NN	0	_	_	_	_
59	.	.	O	.	0	_	_	_	_

1	Involvement	Involvement	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	AP1	AP1	B-NP	NN	:::NOCLASS	_	_	_	_
4	and	and	I-NP	CC	0	_	_	_	_
5	PEA3	PEA3	I-NP	NN	:::NOCLASS	_	_	_	_
6	binding	binding	I-NP	NN	:::NOCLASS	_	_	_	_
7	sites	site	I-NP	NNS	:::NOCLASS	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	regulation	regulation	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	murine	murine	B-NP	JJ	:::NOCLASS	_	_	_	_
13	tissue	tissue	I-NP	NN	:::NOCLASS	_	_	_	_
14	inhibitor	inhibitor	I-NP	NN	:::NOCLASS	_	_	_	_
15	of	of	B-PP	IN	:::NOCLASS	_	_	_	_
16	metalloproteinases	metalloproteinas	B-NP	NNS	:::NOCLASS	_	_	_	_
17	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
18	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	TIMP	TIMP	O	NN	:::NOCLASS	_	_	_	_
21	-	-	O	HYPH	:::NOCLASS	_	_	_	_
22	1	1	O	CD	:::NOCLASS	_	_	_	_
23	)	)	O	)	0	_	_	_	_
24	transcription	transcription	B-NP	NN	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	Of	Of	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	serum	serum	I-NP	NN	:::NOCLASS	_	_	_	_
4	neutralizing	neutralizing	I-NP	NN	:::NOCLASS	_	_	_	_
5	(	(	O	(	0	_	_	_	_
6	SN	SN	B-NP	NN	0	_	_	_	_
7	)	)	O	)	0	_	_	_	_
8	antibody	antibody	B-NP	NN	0	_	_	_	_
9	negative	negative	I-NP	JJ	0	_	_	_	_
10	calves	calf	I-NP	NNS	0	_	_	_	_
11	89	89	B-NP	CD	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_
13	7	7	B-NP	CD	0	_	_	_	_
14	%	%	I-NP	NN	0	_	_	_	_
15	(	(	O	(	0	_	_	_	_
16	26	26	B-NP	CD	0	_	_	_	_
17	/	/	B-NP	SYM	0	_	_	_	_
18	29	29	I-NP	CD	0	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	92	92	B-NP	CD	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_
23	8	8	B-NP	CD	0	_	_	_	_
24	%	%	I-NP	NN	0	_	_	_	_
25	(	(	O	(	0	_	_	_	_
26	90	90	B-NP	CD	0	_	_	_	_
27	/	/	O	SYM	0	_	_	_	_
28	97	97	B-NP	CD	0	_	_	_	_
29	)	)	O	)	0	_	_	_	_
30	developed	develop	B-VP	VBD	0	_	_	_	_
31	SN	SN	B-NP	NN	:::NOCLASS	_	_	_	_
32	antibody	antibody	I-NP	NN	:::NOCLASS	_	_	_	_
33	1	1	I-NP	CD	0	_	_	_	_
34	month	month	I-NP	NN	0	_	_	_	_
35	after	after	B-PP	IN	0	_	_	_	_
36	intranasal	intranasal	B-NP	JJ	0	_	_	_	_
37	and	and	I-NP	CC	0	_	_	_	_
38	intramuscular	intramuscular	I-NP	JJ	0	_	_	_	_
39	vaccination	vaccination	I-NP	NN	0	_	_	_	_
40	,	,	O	,	0	_	_	_	_
41	respectively	respectively	B-ADVP	RB	0	_	_	_	_
42	.	.	O	.	0	_	_	_	_

1	Fractionation	Fractionation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	crude	crude	B-NP	JJ	0	_	_	_	_
4	nuclear	nuclear	I-NP	JJ	0	_	_	_	_
5	extracts	extract	I-NP	NNS	0	_	_	_	_
6	by	by	B-PP	IN	0	_	_	_	_
7	heparin	heparin	B-NP	NN	0	_	_	_	_
8	-	-	B-NP	HYPH	0	_	_	_	_
9	agarose	agarose	I-NP	NN	0	_	_	_	_
10	chromatography	chromatography	I-NP	NN	0	_	_	_	_
11	indicates	indicate	B-VP	VBZ	0	_	_	_	_
12	that	that	B-SBAR	IN	0	_	_	_	_
13	PCAT	PCAT	B-NP	NN	:::NOCLASS	_	_	_	_
14	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
15	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
16	is	be	B-VP	VBZ	0	_	_	_	_
17	more	more	B-ADJP	RBR	0	_	_	_	_
18	prevalent	prevalent	I-ADJP	JJ	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	extracts	extract	B-NP	NNS	0	_	_	_	_
21	prepared	prepare	B-VP	VBN	0	_	_	_	_
22	from	from	B-PP	IN	0	_	_	_	_
23	salt	salt	B-NP	NN	0	_	_	_	_
24	-	-	B-NP	HYPH	0	_	_	_	_
25	stressed	stress	I-NP	VBN	0	_	_	_	_
26	leaf	leaf	I-NP	NN	0	_	_	_	_
27	tissue	tissue	I-NP	NN	0	_	_	_	_
28	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	controlled	control	I-NP	VBN	0	_	_	_	_
3	trial	trial	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	recombinant	recombinant	B-NP	JJ	:::NOCLASS	_	_	_	_
6	human	human	I-NP	JJ	:::NOCLASS	_	_	_	_
7	granulocyte	granulocyte	I-NP	NN	:::NOCLASS	_	_	_	_
8	-	-	O	HYPH	:::NOCLASS	_	_	_	_
9	macrophage	macrophage	B-NP	NN	:::NOCLASS	_	_	_	_
10	colony	colony	I-NP	NN	:::NOCLASS	_	_	_	_
11	-	-	O	HYPH	:::NOCLASS	_	_	_	_
12	stimulating	stimulate	B-VP	VBG	:::NOCLASS	_	_	_	_
13	factor	factor	B-NP	NN	:::NOCLASS	_	_	_	_
14	after	after	B-PP	IN	0	_	_	_	_
15	total	total	B-NP	JJ	0	_	_	_	_
16	body	body	I-NP	NN	0	_	_	_	_
17	irradiation	irradiation	I-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	high	high	B-NP	JJ	0	_	_	_	_
20	-	-	I-NP	HYPH	0	_	_	_	_
21	dose	dose	I-NP	NN	0	_	_	_	_
22	chemotherapy	chemotherapy	I-NP	NN	0	_	_	_	_
23	,	,	O	,	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	autologous	autologous	B-NP	JJ	0	_	_	_	_
26	bone	bone	I-NP	NN	UMLS:C0262950:T023:ANAT	_	_	_	_
27	marrow	marrow	I-NP	NN	UMLS:C0376152:T023:ANAT	_	_	_	_
28	transplantation	transplantation	I-NP	NN	0	_	_	_	_
29	for	for	B-PP	IN	0	_	_	_	_
30	acute	acute	B-NP	JJ	0	_	_	_	_
31	lymphoblastic	lymphoblastic	I-NP	JJ	0	_	_	_	_
32	leukemia	leukemia	I-NP	NN	0	_	_	_	_
33	or	or	O	CC	0	_	_	_	_
34	malignant	malignant	B-NP	JJ	0	_	_	_	_
35	lymphoma	lymphoma	I-NP	NN	0	_	_	_	_
36	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	data	datum	I-NP	NNS	0	_	_	_	_
3	demonstrate	demonstrate	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	DMVA	DMVA	B-NP	NN	0	_	_	_	_
6	does	do	B-VP	VBZ	0	_	_	_	_
7	not	not	I-VP	RB	0	_	_	_	_
8	cause	cause	I-VP	VB	0	_	_	_	_
9	more	more	B-NP	RBR	0	_	_	_	_
10	myocardial	myocardial	I-NP	JJ	0	_	_	_	_
11	trauma	trauma	I-NP	NN	0	_	_	_	_
12	than	than	B-PP	IN	0	_	_	_	_
13	CPB	CPB	B-NP	NN	0	_	_	_	_
14	when	when	B-ADVP	WRB	0	_	_	_	_
15	used	use	B-VP	VBN	0	_	_	_	_
16	to	to	B-VP	TO	0	_	_	_	_
17	provide	provide	I-VP	VB	0	_	_	_	_
18	resuscitative	resuscitative	B-NP	JJ	0	_	_	_	_
19	circulatory	circulatory	I-NP	JJ	0	_	_	_	_
20	support	support	I-NP	NN	0	_	_	_	_
21	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	IgG	IgG	I-NP	NN	:::NOCLASS	_	_	_	_
3	subclass	subclass	I-NP	NN	0	_	_	_	_
4	profile	profile	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	untreated	untreated	B-NP	JJ	0	_	_	_	_
7	coeliac	coeliac	I-NP	JJ	UMLS:C0007570:T047:DISO	_	_	_	_
8	disease	disease	I-NP	NN	UMLS:C0007570:T047:DISO	_	_	_	_
9	was	be	B-VP	VBD	0	_	_	_	_
10	found	find	I-VP	VBN	0	_	_	_	_
11	to	to	I-VP	TO	0	_	_	_	_
12	be	be	I-VP	VB	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	same	same	I-NP	JJ	0	_	_	_	_
15	as	as	B-PP	IN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	healthy	healthy	B-NP	JJ	0	_	_	_	_
18	controls	control	I-NP	NNS	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	IgG1	IgG1	B-NP	NN	:::NOCLASS	_	_	_	_
21	approximately	approximately	B-NP	RB	0	_	_	_	_
22	IgG2	IgG2	I-NP	NN	:::NOCLASS	_	_	_	_
23	>	>	B-NP	SYM	0	_	_	_	_
24	IgG3	IgG3	I-NP	NN	:::NOCLASS	_	_	_	_
25	>	>	B-NP	SYM	0	_	_	_	_
26	IgG4	IgG4	I-NP	NN	:::NOCLASS	_	_	_	_
27	)	)	O	)	0	_	_	_	_
28	,	,	O	,	0	_	_	_	_
29	with	with	B-PP	IN	0	_	_	_	_
30	only	only	B-NP	RB	0	_	_	_	_
31	the	the	I-NP	DT	0	_	_	_	_
32	magnitude	magnitude	I-NP	NN	0	_	_	_	_
33	of	of	B-PP	IN	0	_	_	_	_
34	the	the	B-NP	DT	0	_	_	_	_
35	individual	individual	I-NP	JJ	0	_	_	_	_
36	subclass	subclass	I-NP	NN	0	_	_	_	_
37	responses	response	I-NP	NNS	0	_	_	_	_
38	being	be	B-VP	VBG	0	_	_	_	_
39	increased	increase	I-VP	VBN	0	_	_	_	_
40	in	in	B-PP	IN	0	_	_	_	_
41	coeliac	coeliac	B-NP	JJ	0	_	_	_	_
42	patients	patient	I-NP	NNS	0	_	_	_	_
43	.	.	O	.	0	_	_	_	_

1	Examination	Examination	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	ANCA	ANCA	B-NP	NN	:::NOCLASS	_	_	_	_
4	is	be	B-VP	VBZ	0	_	_	_	_
5	not	not	B-CONJP	RB	0	_	_	_	_
6	only	only	I-CONJP	RB	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	significant	significant	I-NP	JJ	0	_	_	_	_
9	contribution	contribution	I-NP	NN	0	_	_	_	_
10	towards	towards	B-PP	IN	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	more	more	I-NP	RBR	0	_	_	_	_
13	accurate	accurate	I-NP	JJ	0	_	_	_	_
14	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	renal	renal	B-NP	JJ	UMLS:C0152002:T047:DISO|UMLS:C0022646:T023:ANAT	_	_	_	_
17	vasculitis	vasculitis	I-NP	NN	UMLS:C0152002:T047:DISO	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	but	but	B-CONJP	CC	0	_	_	_	_
20	also	also	I-CONJP	RB	0	_	_	_	_
21	an	an	B-NP	DT	0	_	_	_	_
22	indicator	indicator	I-NP	NN	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	activity	activity	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	disease	disease	I-NP	NN	0	_	_	_	_
29	and	and	O	CC	0	_	_	_	_
30	thus	thus	B-ADVP	RB	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	effectiveness	effectiveness	I-NP	NN	0	_	_	_	_
34	of	of	B-PP	IN	0	_	_	_	_
35	immunosuppressive	immunosuppressive	B-NP	JJ	0	_	_	_	_
36	treatment	treatment	I-NP	NN	0	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	On	On	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	other	other	I-NP	JJ	0	_	_	_	_
4	hand	hand	I-NP	NN	UMLS:C0018563:T023:ANAT	_	_	_	_
5	,	,	O	,	0	_	_	_	_
6	total	total	B-NP	JJ	0	_	_	_	_
7	pinealectomy	pinealectomy	I-NP	NN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	these	these	B-NP	DT	0	_	_	_	_
10	already	already	I-NP	RB	0	_	_	_	_
11	sympathectomized	sympathectomize	I-NP	VBN	0	_	_	_	_
12	blinded	blind	I-NP	VBN	0	_	_	_	_
13	rabbits	rabbit	I-NP	NNS	0	_	_	_	_
14	always	always	B-ADVP	RB	0	_	_	_	_
15	resulted	result	B-VP	VBD	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	a	a	B-NP	DT	0	_	_	_	_
18	substantial	substantial	I-NP	JJ	0	_	_	_	_
19	deceleration	deceleration	I-NP	NN	0	_	_	_	_
20	of	of	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	rhythms	rhythm	I-NP	NNS	0	_	_	_	_
23	(	(	O	(	0	_	_	_	_
24	mean	mean	B-NP	NN	0	_	_	_	_
25	delta	delta	O	SYM	0	_	_	_	_
26	tau	tau	B-NP	SYM	0	_	_	_	_
27	=	=	B-VP	SYM	0	_	_	_	_
28	+0	+0	B-NP	CD	0	_	_	_	_
29	.	.	I-NP	SYM	0	_	_	_	_
30	23	23	I-NP	CD	0	_	_	_	_
31	h	h	I-NP	NN	0	_	_	_	_
32	)	)	O	)	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	Cicatricial	Cicatricial	B-NP	JJ	UMLS:C0030804:T047:DISO	_	_	_	_
2	pemphigoid	pemphigoid	I-NP	NN	UMLS:C0030804:T047:DISO	_	_	_	_
3	is	be	B-VP	VBZ	0	_	_	_	_
4	an	an	B-NP	DT	0	_	_	_	_
5	autoimmune	autoimmune	I-NP	JJ	0	_	_	_	_
6	systemic	systemic	I-NP	JJ	UMLS:C0442893:T047:DISO	_	_	_	_
7	disease	disease	I-NP	NN	UMLS:C0442893:T047:DISO	_	_	_	_
8	characterized	characterize	B-VP	VBN	0	_	_	_	_
9	by	by	B-PP	IN	0	_	_	_	_
10	chronic	chronic	B-NP	JJ	0	_	_	_	_
11	conjunctival	conjunctival	I-NP	JJ	0	_	_	_	_
12	cicatrization	cicatrization	I-NP	NN	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	effects	effect	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	two	two	B-NP	CD	0	_	_	_	_
5	levels	level	I-NP	NNS	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	caffeine	caffeine	B-NP	NN	0	_	_	_	_
8	ingestion	ingestion	I-NP	NN	0	_	_	_	_
9	on	on	B-PP	IN	0	_	_	_	_
10	excess	excess	B-NP	JJ	0	_	_	_	_
11	postexercise	postexercise	I-NP	NN	0	_	_	_	_
12	oxygen	oxygen	I-NP	NN	0	_	_	_	_
13	consumption	consumption	I-NP	NN	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	untrained	untrained	B-NP	JJ	0	_	_	_	_
16	women	woman	I-NP	NNS	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	distinguishing	distinguishing	I-NP	JJ	0	_	_	_	_
3	features	feature	I-NP	NNS	0	_	_	_	_
4	involved	involve	B-VP	VBD	0	_	_	_	_
5	eight	eight	B-NP	CD	0	_	_	_	_
6	amino	amino	I-NP	NN	0	_	_	_	_
7	acid	acid	I-NP	NN	0	_	_	_	_
8	changes	change	I-NP	NNS	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	including	include	B-PP	VBG	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	single	single	I-NP	JJ	0	_	_	_	_
13	lysine	lysine	I-NP	NN	0	_	_	_	_
14	deletion	deletion	I-NP	NN	0	_	_	_	_
15	relative	relative	B-ADVP	JJ	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	a	a	B-NP	DT	0	_	_	_	_
18	primate	primate	I-NP	JJ	0	_	_	_	_
19	consensus	consensus	I-NP	NN	0	_	_	_	_
20	sequence	sequence	I-NP	NN	0	_	_	_	_
21	in	in	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	first	first	I-NP	JJ	0	_	_	_	_
24	complementary	complementary	I-NP	JJ	0	_	_	_	_
25	-	-	I-NP	HYPH	0	_	_	_	_
26	determing	determe	B-VP	VBG	0	_	_	_	_
27	region	region	B-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	V1J1	V1J1	B-NP	NN	:::NOCLASS	_	_	_	_
30	.	.	O	.	0	_	_	_	_

1	4	4	B-LST	LS	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	in	in	I-NP	FW	0	_	_	_	_
3	vivo	vivo	I-NP	FW	0	_	_	_	_
4	profile	profile	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	ZFH	ZFH	B-NP	NN	:::NOCLASS	_	_	_	_
7	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
8	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	larval	larval	I-NP	JJ	0	_	_	_	_
12	CNS	CNS	I-NP	NN	0	_	_	_	_
13	shows	show	B-VP	VBZ	0	_	_	_	_
14	intriguing	intriguing	B-NP	JJ	0	_	_	_	_
15	overlap	overlap	I-NP	NN	0	_	_	_	_
16	with	with	B-PP	IN	0	_	_	_	_
17	DDC	DDC	B-NP	NN	:::NOCLASS	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	specific	specific	B-NP	JJ	0	_	_	_	_
20	serotonin	serotonin	I-NP	NN	0	_	_	_	_
21	and	and	I-NP	CC	0	_	_	_	_
22	dopamine	dopamine	I-NP	NN	0	_	_	_	_
23	neurons	neuron	I-NP	NNS	0	_	_	_	_
24	.	.	O	.	0	_	_	_	_

1	Unlike	Unlike	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	introns	intron	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	other	other	B-NP	JJ	0	_	_	_	_
6	duplicated	duplicate	I-NP	VBN	0	_	_	_	_
7	ribosomal	ribosomal	I-NP	JJ	:::NOCLASS	_	_	_	_
8	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
9	genes	gene	I-NP	NNS	:::NOCLASS	_	_	_	_
10	which	which	B-NP	WDT	0	_	_	_	_
11	are	be	B-VP	VBP	0	_	_	_	_
12	highly	highly	I-VP	RB	0	_	_	_	_
13	diverged	diverge	I-VP	VBN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	the	the	B-NP	DT	0	_	_	_	_
16	duplicated	duplicate	I-NP	VBN	0	_	_	_	_
17	S13	S13	I-NP	NN	:::NOCLASS	_	_	_	_
18	genes	gene	I-NP	NNS	:::NOCLASS	_	_	_	_
19	have	have	B-VP	VBP	0	_	_	_	_
20	two	two	B-NP	CD	0	_	_	_	_
21	nearly	nearly	I-NP	RB	0	_	_	_	_
22	identical	identical	I-NP	JJ	0	_	_	_	_
23	DNA	DNA	I-NP	NN	0	_	_	_	_
24	sequences	sequence	I-NP	NNS	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	25	25	B-NP	CD	0	_	_	_	_
27	and	and	I-NP	CC	0	_	_	_	_
28	31	31	I-NP	CD	0	_	_	_	_
29	bp	bp	I-NP	NN	0	_	_	_	_
30	in	in	B-PP	IN	0	_	_	_	_
31	length	length	B-NP	NN	0	_	_	_	_
32	within	within	B-PP	IN	0	_	_	_	_
33	their	their	B-NP	PRP$	0	_	_	_	_
34	introns	intron	I-NP	NNS	0	_	_	_	_
35	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	a	a	B-NP	DT	0	_	_	_	_
3	prospective	prospective	I-NP	JJ	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	randomized	randomize	B-VP	VBN	0	_	_	_	_
6	clinical	clinical	B-NP	JJ	0	_	_	_	_
7	trial	trial	I-NP	NN	0	_	_	_	_
8	we	we	B-NP	PRP	0	_	_	_	_
9	compared	compare	B-VP	VBD	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	efficacy	efficacy	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	subcutaneously	subcutaneously	B-NP	RB	0	_	_	_	_
14	(	(	O	(	0	_	_	_	_
15	SC	SC	B-NP	NN	0	_	_	_	_
16	)	)	O	)	0	_	_	_	_
17	administered	administer	B-VP	VBN	0	_	_	_	_
18	(	(	O	(	0	_	_	_	_
19	every	every	B-NP	DT	0	_	_	_	_
20	8	8	I-NP	CD	0	_	_	_	_
21	h	h	I-NP	NN	0	_	_	_	_
22	)	)	O	)	0	_	_	_	_
23	calcium	calcium	B-NP	NN	0	_	_	_	_
24	heparin	heparin	I-NP	NN	0	_	_	_	_
25	to	to	B-PP	TO	0	_	_	_	_
26	intravenous	intravenous	B-NP	JJ	0	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	IV	IV	O	CD	0	_	_	_	_
29	)	)	O	)	0	_	_	_	_
30	sodium	sodium	B-NP	NN	0	_	_	_	_
31	heparin	heparin	I-NP	NN	0	_	_	_	_
32	in	in	B-PP	IN	0	_	_	_	_
33	the	the	B-NP	DT	0	_	_	_	_
34	treatment	treatment	I-NP	NN	0	_	_	_	_
35	of	of	B-PP	IN	0	_	_	_	_
36	proximal	proximal	B-NP	JJ	0	_	_	_	_
37	deep	deep	I-NP	JJ	UMLS:C0149871:T047:DISO	_	_	_	_
38	-	-	I-NP	HYPH	UMLS:C0149871:T047:DISO	_	_	_	_
39	vein	vein	I-NP	NN	UMLS:C0149871:T047:DISO|UMLS:C0042449:T023:ANAT	_	_	_	_
40	thrombosis	thrombosis	I-NP	NN	UMLS:C0149871:T047:DISO	_	_	_	_
41	(	(	O	(	0	_	_	_	_
42	DVT	DVT	B-NP	NN	UMLS:C0149871:T047:DISO	_	_	_	_
43	)	)	O	)	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	highest	high	I-NP	JJS	0	_	_	_	_
3	prevalence	prevalence	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	reported	report	B-NP	VBN	0	_	_	_	_
6	pet	pet	I-NP	NN	0	_	_	_	_
7	allergy	allergy	I-NP	NN	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	chronic	chronic	B-NP	JJ	0	_	_	_	_
10	cough	cough	I-NP	NN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	wheeze	wheeze	B-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	attacks	attack	B-NP	NNS	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	shortness	shortness	B-NP	NN	0	_	_	_	_
17	of	of	B-PP	IN	0	_	_	_	_
18	breath	breath	B-NP	NN	0	_	_	_	_
19	with	with	B-PP	IN	0	_	_	_	_
20	wheezing	wheezing	B-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	doctor	doctor	B-NP	NN	0	_	_	_	_
24	-	-	O	HYPH	0	_	_	_	_
25	diagnosed	diagnose	B-NP	VBN	0	_	_	_	_
26	asthma	asthma	I-NP	NN	UMLS:C0004096:T047:DISO	_	_	_	_
27	was	be	B-VP	VBD	0	_	_	_	_
28	found	find	I-VP	VBN	0	_	_	_	_
29	in	in	B-PP	IN	0	_	_	_	_
30	children	child	B-NP	NNS	0	_	_	_	_
31	who	who	B-NP	WP	0	_	_	_	_
32	had	have	B-VP	VBD	0	_	_	_	_
33	pets	pet	B-NP	NNS	0	_	_	_	_
34	in	in	B-PP	IN	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	past	past	I-NP	NN	0	_	_	_	_
37	but	but	B-PP	CC	0	_	_	_	_
38	not	not	B-ADVP	RB	0	_	_	_	_
39	anymore	anymore	I-ADVP	RB	0	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	Therefore	Therefore	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	it	it	B-NP	PRP	0	_	_	_	_
4	would	would	B-VP	MD	0	_	_	_	_
5	be	be	I-VP	VB	0	_	_	_	_
6	advantageous	advantageous	B-ADJP	JJ	0	_	_	_	_
7	to	to	B-VP	TO	0	_	_	_	_
8	identify	identify	I-VP	VB	0	_	_	_	_
9	such	such	B-NP	JJ	0	_	_	_	_
10	persons	person	I-NP	NNS	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	treat	treat	B-VP	VB	0	_	_	_	_
13	them	them	B-NP	PRP	0	_	_	_	_
14	preferentially	preferentially	B-ADVP	RB	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	On	On	B-PP	IN	0	_	_	_	_
2	the	the	B-NP	DT	0	_	_	_	_
3	basis	basis	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	these	these	B-NP	DT	0	_	_	_	_
6	unique	unique	I-NP	JJ	0	_	_	_	_
7	properties	property	I-NP	NNS	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	newly	newly	I-NP	RB	0	_	_	_	_
11	characterized	characterize	I-NP	VBN	0	_	_	_	_
12	hemagglutinin	hemagglutinin	I-NP	NN	:::NOCLASS	_	_	_	_
13	has	have	B-VP	VBZ	0	_	_	_	_
14	been	be	I-VP	VBN	0	_	_	_	_
15	termed	term	I-VP	VBN	0	_	_	_	_
16	Limulus	Limulus	B-NP	NN	:::NOCLASS	_	_	_	_
17	18K	18K	I-NP	NN	:::NOCLASS	_	_	_	_
18	agglutination	agglutination	I-NP	NN	:::NOCLASS	_	_	_	_
19	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
20	aggregation	aggregation	I-NP	NN	:::NOCLASS	_	_	_	_
21	factor	factor	I-NP	NN	:::NOCLASS	_	_	_	_
22	(	(	O	(	0	_	_	_	_
23	18K	18K	B-NP	NN	:::NOCLASS	_	_	_	_
24	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
25	LAF	LAF	I-NP	NN	:::NOCLASS	_	_	_	_
26	)	)	O	)	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	shift	shift	I-NP	NN	0	_	_	_	_
3	to	to	B-PP	TO	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	nonpermissive	nonpermissive	I-NP	JJ	0	_	_	_	_
6	temperature	temperature	I-NP	NN	0	_	_	_	_
7	is	be	B-VP	VBZ	0	_	_	_	_
8	accompanied	accompany	I-VP	VBN	0	_	_	_	_
9	by	by	B-PP	IN	0	_	_	_	_
10	the	the	B-NP	DT	0	_	_	_	_
11	loss	loss	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	guanyl	guanyl	B-NP	NN	0	_	_	_	_
14	nucleotide	nucleotide	I-NP	NN	0	_	_	_	_
15	-	-	B-NP	HYPH	0	_	_	_	_
16	dependent	dependent	I-NP	JJ	0	_	_	_	_
17	activity	activity	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	adenylylcyclase	adenylylcyclase	B-NP	NN	:::NOCLASS	_	_	_	_
20	in	in	B-ADVP	FW	0	_	_	_	_
21	vitro	vitro	I-ADVP	FW	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Clin	Clin	B-NP	NN	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	data	datum	I-NP	NNS	0	_	_	_	_
3	indicate	indicate	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	minimal	minimal	I-NP	JJ	0	_	_	_	_
7	catalytic	catalytic	I-NP	JJ	0	_	_	_	_
8	domain	domain	I-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	Nmt1p	Nmt1p	B-NP	NN	:::NOCLASS	_	_	_	_
11	is	be	B-VP	VBZ	0	_	_	_	_
12	located	located	B-ADJP	JJ	0	_	_	_	_
13	between	between	B-PP	IN	0	_	_	_	_
14	Ile59	Ile59	B-NP	NN	0	_	_	_	_
15	-	-	B-NP	HYPH	0	_	_	_	_
16	-	-	I-NP	SYM	0	_	_	_	_
17	>	>	I-NP	SYM	0	_	_	_	_
18	Phe96	Phe96	I-NP	NN	0	_	_	_	_
19	and	and	I-NP	CC	0	_	_	_	_
20	Gly451	Gly451	I-NP	NN	0	_	_	_	_
21	-	-	B-NP	SYM	0	_	_	_	_
22	-	-	B-NP	HYPH	0	_	_	_	_
23	>	>	I-NP	SYM	0	_	_	_	_
24	Leu455	Leu455	I-NP	NN	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	It	It	B-NP	PRP	0	_	_	_	_
2	corresponds	correspond	B-VP	VBZ	0	_	_	_	_
3	to	to	B-PP	TO	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	complete	complete	I-NP	JJ	0	_	_	_	_
6	mitochondrial	mitochondrial	I-NP	JJ	0	_	_	_	_
7	presequence	presequence	I-NP	NN	0	_	_	_	_
8	and	and	O	CC	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	lipoyl	lipoyl	I-NP	NN	0	_	_	_	_
11	-	-	O	HYPH	0	_	_	_	_
12	bearing	bear	B-VP	VBG	0	_	_	_	_
13	domain	domain	B-NP	NN	0	_	_	_	_
14	that	that	B-NP	WDT	0	_	_	_	_
15	are	be	B-VP	VBP	0	_	_	_	_
16	encoded	encode	I-VP	VBN	0	_	_	_	_
17	by	by	B-PP	IN	0	_	_	_	_
18	exons	exon	B-NP	NNS	0	_	_	_	_
19	I	I	B-NP	CD	0	_	_	_	_
20	through	through	B-PP	IN	0	_	_	_	_
21	IV	IV	B-NP	CD	0	_	_	_	_
22	of	of	B-PP	IN	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	functional	functional	I-NP	JJ	0	_	_	_	_
25	E2	E2	I-NP	NN	:::NOCLASS	_	_	_	_
26	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Human	Human	B-NP	JJ	0	_	_	_	_
2	neutrophil	neutrophil	I-NP	NN	0	_	_	_	_
3	response	response	I-NP	NN	0	_	_	_	_
4	to	to	B-PP	TO	0	_	_	_	_
5	short	short	B-NP	JJ	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	term	term	I-NP	NN	0	_	_	_	_
8	exposure	exposure	I-NP	NN	0	_	_	_	_
9	to	to	B-PP	TO	0	_	_	_	_
10	F	F	B-NP	NN	0	_	_	_	_
11	-	-	O	HYPH	0	_	_	_	_
12	75	75	B-NP	CD	0	_	_	_	_
13	cobalt	cobalt	I-NP	NN	0	_	_	_	_
14	-	-	O	HYPH	0	_	_	_	_
15	based	base	B-NP	VBN	0	_	_	_	_
16	alloy	alloy	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Disruption	Disruption	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	microtubules	microtubule	B-NP	NNS	0	_	_	_	_
4	did	do	B-VP	VBD	0	_	_	_	_
5	not	not	I-VP	RB	0	_	_	_	_
6	affect	affect	I-VP	VB	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	fidelity	fidelity	I-NP	NN	0	_	_	_	_
9	or	or	I-NP	CC	0	_	_	_	_
10	kinetics	kinetic	I-NP	NNS	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	vacuolar	vacuolar	B-NP	JJ	0	_	_	_	_
13	protein	protein	I-NP	NN	0	_	_	_	_
14	sorting	sorting	I-NP	NN	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	indicating	indicate	B-VP	VBG	0	_	_	_	_
17	that	that	B-SBAR	IN	0	_	_	_	_
18	Vps1p	Vps1p	B-NP	NN	:::NOCLASS	_	_	_	_
19	function	function	I-NP	NN	0	_	_	_	_
20	is	be	B-VP	VBZ	0	_	_	_	_
21	not	not	O	RB	0	_	_	_	_
22	dependent	dependent	B-ADJP	JJ	0	_	_	_	_
23	on	on	B-PP	IN	0	_	_	_	_
24	microtubules	microtubule	B-NP	NNS	0	_	_	_	_
25	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	mutant	mutant	I-NP	JJ	0	_	_	_	_
3	form	form	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	Vps1p	Vps1p	B-NP	NN	:::NOCLASS	_	_	_	_
6	lacking	lack	B-VP	VBG	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	entire	entire	I-NP	JJ	0	_	_	_	_
9	GTP	GTP	I-NP	NN	0	_	_	_	_
10	-	-	B-PP	HYPH	0	_	_	_	_
11	binding	bind	B-NP	VBG	0	_	_	_	_
12	domain	domain	I-NP	NN	0	_	_	_	_
13	interfered	interfere	B-VP	VBD	0	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	vacuolar	vacuolar	B-NP	JJ	0	_	_	_	_
16	protein	protein	I-NP	NN	0	_	_	_	_
17	sorting	sorting	I-NP	NN	0	_	_	_	_
18	in	in	B-PP	IN	0	_	_	_	_
19	wild	wild	B-NP	JJ	0	_	_	_	_
20	-	-	I-NP	HYPH	0	_	_	_	_
21	type	type	I-NP	NN	0	_	_	_	_
22	cells	cell	I-NP	NNS	0	_	_	_	_
23	.	.	O	.	0	_	_	_	_

1	According	Accord	B-PP	VBG	0	_	_	_	_
2	to	to	B-PP	TO	0	_	_	_	_
3	out	out	B-PRT	RP	0	_	_	_	_
4	field	field	B-NP	NN	0	_	_	_	_
5	research	research	I-NP	NN	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	tick	tick	I-NP	NN	0	_	_	_	_
9	fauna	fauna	I-NP	NN	0	_	_	_	_
10	was	be	B-VP	VBD	0	_	_	_	_
11	very	very	B-ADJP	RB	0	_	_	_	_
12	rich	rich	I-ADJP	JJ	0	_	_	_	_
13	throughout	throughout	B-PP	IN	0	_	_	_	_
14	that	that	B-NP	DT	0	_	_	_	_
15	area	area	I-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	and	and	O	CC	0	_	_	_	_
18	it	it	B-NP	PRP	0	_	_	_	_
19	was	be	B-VP	VBD	0	_	_	_	_
20	permissible	permissible	B-ADJP	JJ	0	_	_	_	_
21	enough	enough	I-ADJP	RB	0	_	_	_	_
22	to	to	B-VP	TO	0	_	_	_	_
23	determine	determine	I-VP	VB	0	_	_	_	_
24	ticks	tick	B-NP	NNS	0	_	_	_	_
25	as	as	B-PP	IN	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	vectors	vector	I-NP	NNS	0	_	_	_	_
28	,	,	O	,	0	_	_	_	_
29	based	base	B-PP	VBN	0	_	_	_	_
30	on	on	B-PP	IN	0	_	_	_	_
31	arising	arise	B-VP	VBG	0	_	_	_	_
32	of	of	B-PP	IN	0	_	_	_	_
33	anti	anti	B-NP	AFX	:::NOCLASS	_	_	_	_
34	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
35	SF	SF	I-NP	NN	:::NOCLASS|UMLS:C0175256:T023:ANAT	_	_	_	_
36	group	group	I-NP	NN	:::NOCLASS	_	_	_	_
37	rickettsiae	rickettsiae	I-NP	NN	:::NOCLASS	_	_	_	_
38	(	(	O	(	0	_	_	_	_
39	SFGR	SFGR	B-NP	NN	:::NOCLASS	_	_	_	_
40	)	)	O	)	0	_	_	_	_
41	antibody	antibody	B-NP	NN	0	_	_	_	_
42	in	in	B-PP	IN	0	_	_	_	_
43	mice	mouse	B-NP	NNS	0	_	_	_	_
44	inoculated	inoculate	B-VP	VBN	0	_	_	_	_
45	with	with	B-PP	IN	0	_	_	_	_
46	some	some	B-NP	DT	0	_	_	_	_
47	tick	tick	I-NP	NN	0	_	_	_	_
48	emulsions	emulsion	I-NP	NNS	0	_	_	_	_
49	,	,	O	,	0	_	_	_	_
50	findings	finding	B-NP	NNS	0	_	_	_	_
51	of	of	B-PP	IN	0	_	_	_	_
52	rickettsiae	rickettsia	B-NP	NNS	0	_	_	_	_
53	reactive	reactive	B-ADJP	JJ	0	_	_	_	_
54	to	to	B-PP	TO	0	_	_	_	_
55	patient	patient	B-NP	NN	0	_	_	_	_
56	sera	serum	I-NP	NNS	0	_	_	_	_
57	or	or	O	CC	0	_	_	_	_
58	a	a	B-NP	DT	0	_	_	_	_
59	species	species	I-NP	NN	0	_	_	_	_
60	-	-	B-NP	HYPH	0	_	_	_	_
61	specific	specific	I-NP	JJ	0	_	_	_	_
62	monoclonal	monoclonal	I-NP	JJ	0	_	_	_	_
63	antibody	antibody	I-NP	NN	0	_	_	_	_
64	to	to	B-PP	TO	0	_	_	_	_
65	JSFR	JSFR	B-NP	NN	:::NOCLASS	_	_	_	_
66	in	in	B-PP	IN	0	_	_	_	_
67	the	the	B-NP	DT	0	_	_	_	_
68	hemolymph	hemolymph	I-NP	NN	0	_	_	_	_
69	cells	cell	I-NP	NNS	0	_	_	_	_
70	of	of	B-PP	IN	0	_	_	_	_
71	some	some	B-NP	DT	0	_	_	_	_
72	ticks	tick	I-NP	NNS	0	_	_	_	_
73	,	,	O	,	0	_	_	_	_
74	and	and	O	CC	0	_	_	_	_
75	electron	electron	B-NP	NN	0	_	_	_	_
76	microscopical	microscopical	I-NP	JJ	0	_	_	_	_
77	observations	observation	I-NP	NNS	0	_	_	_	_
78	of	of	B-PP	IN	0	_	_	_	_
79	SFGR	SFGR	B-NP	NN	:::NOCLASS	_	_	_	_
80	in	in	B-PP	IN	0	_	_	_	_
81	various	various	B-NP	JJ	0	_	_	_	_
82	internal	internal	I-NP	JJ	0	_	_	_	_
83	organs	organ	I-NP	NNS	UMLS:C0178784:T023:ANAT	_	_	_	_
84	including	include	B-PP	VBG	0	_	_	_	_
85	the	the	B-NP	DT	0	_	_	_	_
86	salivary	salivary	I-NP	JJ	UMLS:C0036098:T023:ANAT	_	_	_	_
87	gland	gland	I-NP	NN	UMLS:C0036098:T023:ANAT	_	_	_	_
88	of	of	B-PP	IN	0	_	_	_	_
89	ticks	tick	B-NP	NNS	0	_	_	_	_
90	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	second	second	I-NP	JJ	0	_	_	_	_
3	method	method	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	"	"	I-NP	``	0	_	_	_	_
7	macro	macro	I-NP	NN	0	_	_	_	_
8	"	"	I-NP	''	0	_	_	_	_
9	assay	assay	I-NP	NN	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	has	have	B-VP	VBZ	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	sensitivity	sensitivity	I-NP	NN	0	_	_	_	_
14	range	range	I-NP	NN	0	_	_	_	_
15	of	of	B-PP	IN	0	_	_	_	_
16	0	0	B-NP	CD	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_
18	03	03	B-NP	CD	0	_	_	_	_
19	-	-	I-NP	HYPH	0	_	_	_	_
20	5	5	I-NP	CD	0	_	_	_	_
21	.	.	I-NP	.	0	_	_	_	_
22	0	0	I-NP	CD	0	_	_	_	_
23	micrograms	microgram	I-NP	NNS	0	_	_	_	_
24	phosphorus	phosphorus	I-NP	NN	0	_	_	_	_
25	with	with	B-PP	IN	0	_	_	_	_
26	100	100	B-NP	CD	0	_	_	_	_
27	-	-	I-NP	HYPH	0	_	_	_	_
28	500	500	I-NP	CD	0	_	_	_	_
29	microliters	microliter	I-NP	NNS	0	_	_	_	_
30	HClO4	HClO4	I-NP	NN	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Nucleotide	Nucleotide	B-NP	NN	0	_	_	_	_
2	sequence	sequence	I-NP	NN	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	transcriptional	transcriptional	B-NP	JJ	0	_	_	_	_
5	analysis	analysis	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	polyhedrin	polyhedrin	I-NP	NN	:::NOCLASS	_	_	_	_
9	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	Spodoptera	Spodoptera	B-NP	NN	0	_	_	_	_
12	exigua	exigua	I-NP	NN	0	_	_	_	_
13	nuclear	nuclear	I-NP	JJ	0	_	_	_	_
14	polyhedrosis	polyhedrosis	I-NP	NN	0	_	_	_	_
15	virus	virus	I-NP	NN	0	_	_	_	_
16	.	.	O	.	0	_	_	_	_

1	Validation	Validation	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	automated	automated	B-NP	JJ	0	_	_	_	_
4	systems	system	I-NP	NNS	0	_	_	_	_
5	-	-	B-NP	HYPH	0	_	_	_	_
6	-	-	I-NP	HYPH	0	_	_	_	_
7	system	system	I-NP	NN	0	_	_	_	_
8	definition	definition	I-NP	NN	0	_	_	_	_
9	.	.	O	.	0	_	_	_	_

1	As	As	B-PP	IN	0	_	_	_	_
2	a	a	B-NP	DT	0	_	_	_	_
3	consequence	consequence	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	dark	dark	B-NP	JJ	0	_	_	_	_
6	rearing	rearing	I-NP	NN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	numerical	numerical	I-NP	JJ	0	_	_	_	_
10	density	density	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	cortical	cortical	B-NP	JJ	UMLS:C0001613:T023:ANAT|UMLS:C0007776:T023:ANAT|UMLS:C0022655:T023:ANAT	_	_	_	_
13	neurons	neuron	I-NP	NNS	0	_	_	_	_
14	in	in	B-PP	IN	0	_	_	_	_
15	area	area	B-NP	NN	0	_	_	_	_
16	17	17	I-NP	CD	0	_	_	_	_
17	amounted	amounte	B-VP	VBD	0	_	_	_	_
18	to	to	B-PP	TO	0	_	_	_	_
19	about	about	B-NP	RB	0	_	_	_	_
20	double	double	I-NP	JJ	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	value	value	I-NP	NN	0	_	_	_	_
24	observed	observe	B-VP	VBN	0	_	_	_	_
25	in	in	B-PP	IN	0	_	_	_	_
26	normally	normally	B-NP	RB	0	_	_	_	_
27	reared	rear	I-NP	VBN	0	_	_	_	_
28	kittens	kitten	I-NP	NNS	0	_	_	_	_
29	and	and	O	CC	0	_	_	_	_
30	was	be	B-VP	VBD	0	_	_	_	_
31	also	also	B-ADVP	RB	0	_	_	_	_
32	significantly	significantly	B-ADJP	RB	0	_	_	_	_
33	higher	high	I-ADJP	JJR	0	_	_	_	_
34	in	in	B-PP	IN	0	_	_	_	_
35	area	area	B-NP	NN	0	_	_	_	_
36	18	18	I-NP	CD	0	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	suggest	suggest	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	decreased	decrease	B-NP	VBN	0	_	_	_	_
6	class	class	I-NP	NN	0	_	_	_	_
7	I	I	I-NP	CD	0	_	_	_	_
8	enhancer	enhancer	I-NP	NN	0	_	_	_	_
9	activity	activity	I-NP	NN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	Ad12	Ad12	B-NP	NN	UMLS:C1970209:T047:DISO	_	_	_	_
12	-	-	B-NP	HYPH	0	_	_	_	_
13	transformed	transform	I-NP	VBN	0	_	_	_	_
14	cells	cell	I-NP	NNS	0	_	_	_	_
15	may	may	B-VP	MD	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	at	at	B-ADVP	IN	0	_	_	_	_
18	least	least	I-ADVP	JJS	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	part	part	B-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	be	be	B-VP	VB	0	_	_	_	_
23	due	due	B-ADVP	JJ	0	_	_	_	_
24	to	to	B-PP	TO	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	higher	high	I-NP	JJR	0	_	_	_	_
27	levels	level	I-NP	NNS	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	an	an	B-NP	DT	0	_	_	_	_
30	enhancer	enhancer	I-NP	NN	0	_	_	_	_
31	-	-	B-NP	HYPH	0	_	_	_	_
32	specific	specific	I-NP	JJ	0	_	_	_	_
33	factor	factor	I-NP	NN	0	_	_	_	_
34	,	,	O	,	0	_	_	_	_
35	possibly	possibly	B-ADVP	RB	0	_	_	_	_
36	acting	act	B-VP	VBG	0	_	_	_	_
37	as	as	B-PP	IN	0	_	_	_	_
38	a	a	B-NP	DT	0	_	_	_	_
39	repressor	repressor	I-NP	NN	0	_	_	_	_
40	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	second	second	I-NP	JJ	0	_	_	_	_
3	domain	domain	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	located	located	B-ADJP	JJ	0	_	_	_	_
6	in	in	B-PP	IN	0	_	_	_	_
7	the	the	B-NP	DT	0	_	_	_	_
8	C	C	I-NP	NN	0	_	_	_	_
9	-	-	B-NP	HYPH	0	_	_	_	_
10	terminal	terminal	I-NP	JJ	0	_	_	_	_
11	437	437	I-NP	CD	0	_	_	_	_
12	amino	amino	I-NP	NN	0	_	_	_	_
13	acids	acid	I-NP	NNS	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	IE1	IE1	B-NP	NN	:::NOCLASS	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	is	be	B-VP	VBZ	0	_	_	_	_
18	required	require	I-VP	VBN	0	_	_	_	_
19	for	for	B-PP	IN	0	_	_	_	_
20	inhibitory	inhibitory	B-NP	JJ	0	_	_	_	_
21	and	and	I-NP	CC	0	_	_	_	_
22	DNA	DNA	I-NP	NN	0	_	_	_	_
23	-	-	O	HYPH	0	_	_	_	_
24	binding	bind	B-NP	VBG	0	_	_	_	_
25	activities	activity	I-NP	NNS	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	In	In	B-SBAR	IN	0	_	_	_	_
2	order	order	O	NN	0	_	_	_	_
3	to	to	B-VP	TO	0	_	_	_	_
4	investigate	investigate	I-VP	VB	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	blood	blood	I-NP	NN	0	_	_	_	_
7	compatibility	compatibility	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	autogenous	autogenous	B-NP	JJ	0	_	_	_	_
10	vein	vein	I-NP	NN	UMLS:C0042449:T023:ANAT	_	_	_	_
11	graft	graft	I-NP	NN	0	_	_	_	_
12	(	(	O	(	0	_	_	_	_
13	AVG	AVG	B-NP	NN	0	_	_	_	_
14	)	)	O	)	0	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	changes	change	B-NP	NNS	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	prostacyclin	prostacyclin	B-NP	NN	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	PGI2	PGI2	B-NP	NN	0	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	production	production	B-NP	NN	0	_	_	_	_
23	following	follow	B-PP	VBG	0	_	_	_	_
24	harvesting	harvesting	B-NP	NN	0	_	_	_	_
25	and	and	O	CC	0	_	_	_	_
26	arterial	arterial	B-NP	JJ	UMLS:C0003842:T023:ANAT	_	_	_	_
27	implantation	implantation	I-NP	NN	0	_	_	_	_
28	were	be	B-VP	VBD	0	_	_	_	_
29	studied	study	I-VP	VBN	0	_	_	_	_
30	experimentally	experimentally	B-ADVP	RB	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Subcutaneous	Subcutaneous	B-NP	JJ	0	_	_	_	_
2	administration	administration	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	somatostatin	somatostatin	I-NP	NN	:::NOCLASS	_	_	_	_
6	analogue	analogue	I-NP	NN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	octreotide	octreotide	B-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	100	100	B-NP	CD	0	_	_	_	_
11	micrograms	microgram	I-NP	NNS	0	_	_	_	_
12	thrice	thrice	I-NP	NN	0	_	_	_	_
13	daily	daily	B-ADVP	RB	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	resulted	result	B-VP	VBD	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	a	a	B-NP	DT	0	_	_	_	_
18	sustained	sustained	I-NP	JJ	0	_	_	_	_
19	improvement	improvement	I-NP	NN	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	diarrhoea	diarrhoea	B-NP	NN	0	_	_	_	_
22	and	and	I-NP	CC	0	_	_	_	_
23	disappearance	disappearance	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	faecal	faecal	B-NP	JJ	UMLS:C0015732:T047:DISO	_	_	_	_
26	incontinence	incontinence	I-NP	NN	UMLS:C0015732:T047:DISO	_	_	_	_
27	without	without	B-PP	IN	0	_	_	_	_
28	reducing	reduce	B-VP	VBG	0	_	_	_	_
29	calcitonin	calcitonin	B-NP	NN	:::NOCLASS	_	_	_	_
30	levels	level	I-NP	NNS	0	_	_	_	_
31	.	.	O	.	0	_	_	_	_

1	Anti	Anti	B-NP	AFX	:::NOCLASS	_	_	_	_
2	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
3	CRK	CRK	I-NP	NN	:::NOCLASS	_	_	_	_
4	antibodies	antibody	I-NP	NNS	:::NOCLASS	_	_	_	_
5	detect	detect	B-VP	VBP	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	53kDa	53kDa	I-NP	JJ	0	_	_	_	_
8	protein	protein	I-NP	NN	0	_	_	_	_
9	in	in	B-PP	IN	0	_	_	_	_
10	extracts	extract	B-NP	NNS	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	C	C	B-NP	NN	0	_	_	_	_
13	.	.	O	.	0	_	_	_	_
14	fasciculata	fasciculata	B-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	agreement	agreement	B-NP	NN	0	_	_	_	_
17	with	with	B-PP	IN	0	_	_	_	_
18	the	the	B-NP	DT	0	_	_	_	_
19	size	size	I-NP	NN	0	_	_	_	_
20	predicted	predict	B-VP	VBN	0	_	_	_	_
21	from	from	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	nucleotide	nucleotide	I-NP	NN	0	_	_	_	_
24	sequence	sequence	I-NP	NN	0	_	_	_	_
25	of	of	B-PP	IN	0	_	_	_	_
26	the	the	B-NP	DT	0	_	_	_	_
27	cloned	clone	I-NP	VBN	0	_	_	_	_
28	gene	gene	I-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	205	205	B-NP	CD	0	_	_	_	_
2	,	,	I-NP	,	0	_	_	_	_
3	285	285	I-NP	CD	0	_	_	_	_
4	-	-	I-NP	HYPH	0	_	_	_	_
5	290	290	I-NP	CD	0	_	_	_	_
6	]	]	O	)	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	was	be	B-VP	VBD	0	_	_	_	_
9	subsequently	subsequently	I-VP	RB	0	_	_	_	_
10	cloned	clone	I-VP	VBN	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	sequenced	sequence	B-VP	VBN	0	_	_	_	_
13	[	[	O	(	0	_	_	_	_
14	J	J	B-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Nonreplicating	Nonreplicate	B-VP	VBG	0	_	_	_	_
2	vaccinia	vaccinia	B-NP	NN	UMLS:C0042214:T047:DISO	_	_	_	_
3	vector	vector	I-NP	NN	0	_	_	_	_
4	efficiently	efficiently	B-ADVP	RB	0	_	_	_	_
5	expresses	express	B-VP	VBZ	0	_	_	_	_
6	recombinant	recombinant	B-NP	JJ	0	_	_	_	_
7	genes	gene	I-NP	NNS	0	_	_	_	_
8	.	.	O	.	0	_	_	_	_

1	Use	Use	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	free	free	B-NP	JJ	0	_	_	_	_
4	-	-	I-NP	HYPH	0	_	_	_	_
5	access	access	I-NP	NN	0	_	_	_	_
6	minerals	mineral	I-NP	NNS	0	_	_	_	_
7	.	.	O	.	0	_	_	_	_

1	Interferon	Interferon	B-NP	NN	:::NOCLASS	_	_	_	_
2	type	type	I-NP	NN	:::NOCLASS	_	_	_	_
3	I	I	I-NP	CD	:::NOCLASS	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	protective	protective	B-NP	JJ	0	_	_	_	_
6	body	body	I-NP	NN	0	_	_	_	_
7	reactions	reaction	I-NP	NNS	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	an	an	B-NP	DT	0	_	_	_	_
10	experimental	experimental	I-NP	JJ	0	_	_	_	_
11	Klebsiella	Klebsiella	I-NP	NN	UMLS:C0022729:T047:DISO	_	_	_	_
12	infection	infection	I-NP	NN	UMLS:C0022729:T047:DISO	_	_	_	_

1	No	No	B-NP	DT	0	_	_	_	_
2	other	other	I-NP	JJ	0	_	_	_	_
3	changes	change	I-NP	NNS	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	hematopoietic	hematopoietic	B-NP	JJ	0	_	_	_	_
6	differentiation	differentiation	I-NP	NN	0	_	_	_	_
7	status	status	I-NP	NN	0	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	observed	observe	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	association	association	B-NP	NN	0	_	_	_	_
12	with	with	B-PP	IN	0	_	_	_	_
13	Id	Id	B-NP	NN	:::NOCLASS	_	_	_	_
14	-	-	O	HYPH	:::NOCLASS	_	_	_	_
15	SCL	SCL	B-NP	NN	:::NOCLASS	_	_	_	_
16	expression	expression	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Respiratory	Respiratory	B-NP	JJ	0	_	_	_	_
2	interaction	interaction	I-NP	NN	0	_	_	_	_
3	after	after	B-PP	IN	0	_	_	_	_
4	spinal	spinal	B-NP	JJ	0	_	_	_	_
5	anesthesia	anesthesia	I-NP	NN	0	_	_	_	_
6	and	and	I-NP	CC	0	_	_	_	_
7	sedation	sedation	I-NP	NN	0	_	_	_	_
8	with	with	B-PP	IN	0	_	_	_	_
9	midazolam	midazolam	B-NP	NN	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	For	For	B-PP	IN	0	_	_	_	_
2	pressure	pressure	B-NP	NN	0	_	_	_	_
3	greater	great	B-NP	JJR	0	_	_	_	_
4	than	than	I-NP	IN	0	_	_	_	_
5	121	121	I-NP	CD	0	_	_	_	_
6	atm	atm	I-NP	NN	0	_	_	_	_
7	abs	ab	I-NP	NNS	0	_	_	_	_
8	,	,	O	,	0	_	_	_	_
9	an	an	B-NP	DT	0	_	_	_	_
10	increased	increase	I-NP	VBN	0	_	_	_	_
11	excitability	excitability	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	the	the	B-NP	DT	0	_	_	_	_
14	tadpoles	tadpole	I-NP	NNS	0	_	_	_	_
15	made	make	B-VP	VBD	0	_	_	_	_
16	it	it	B-NP	PRP	0	_	_	_	_
17	difficult	difficult	B-ADJP	JJ	0	_	_	_	_
18	to	to	B-VP	TO	0	_	_	_	_
19	distinguish	distinguish	I-VP	VB	0	_	_	_	_
20	the	the	B-NP	DT	0	_	_	_	_
21	righting	righting	I-NP	JJ	0	_	_	_	_
22	reflex	reflex	I-NP	NN	0	_	_	_	_
23	from	from	B-PP	IN	0	_	_	_	_
24	involuntary	involuntary	B-NP	JJ	0	_	_	_	_
25	movements	movement	I-NP	NNS	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	One	One	B-NP	CD	0	_	_	_	_
2	air	air	I-NP	NN	0	_	_	_	_
3	embolism	embolism	I-NP	NN	0	_	_	_	_
4	occurred	occur	B-VP	VBD	0	_	_	_	_
5	;	;	O	:	0	_	_	_	_
6	this	this	B-NP	DT	0	_	_	_	_
7	was	be	B-VP	VBD	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	only	only	I-NP	JJ	0	_	_	_	_
10	filter	filter	I-NP	NN	0	_	_	_	_
11	-	-	B-NP	HYPH	0	_	_	_	_
12	or	or	I-NP	CC	0	_	_	_	_
13	retrieval	retrieval	I-NP	NN	0	_	_	_	_
14	-	-	O	HYPH	0	_	_	_	_
15	related	relate	B-NP	VBN	0	_	_	_	_
16	complication	complication	I-NP	NN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	5	5	I-NP	CD	0	_	_	_	_
3	'	'	I-NP	SYM	0	_	_	_	_
4	region	region	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	ADH5	ADH5	B-NP	NN	:::NOCLASS	_	_	_	_
7	contains	contain	B-VP	VBZ	0	_	_	_	_
8	consensus	consensus	B-NP	NN	0	_	_	_	_
9	binding	binding	I-NP	NN	0	_	_	_	_
10	sites	site	I-NP	NNS	0	_	_	_	_
11	for	for	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	transcriptional	transcriptional	I-NP	JJ	0	_	_	_	_
14	regulatory	regulatory	I-NP	JJ	0	_	_	_	_
15	proteins	protein	I-NP	NNS	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	Sp1	Sp1	B-NP	NN	:::NOCLASS	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	AP2	AP2	B-NP	NN	:::NOCLASS	_	_	_	_
20	,	,	O	,	0	_	_	_	_
21	LF	LF	B-NP	NN	:::NOCLASS	_	_	_	_
22	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
23	A1	A1	I-NP	NN	:::NOCLASS|UMLS:C0933653:T023:ANAT	_	_	_	_
24	,	,	O	,	0	_	_	_	_
25	NF	NF	B-NP	NN	:::NOCLASS	_	_	_	_
26	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
27	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
28	,	,	O	,	0	_	_	_	_
29	NF	NF	B-NP	NN	:::NOCLASS	_	_	_	_
30	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
31	A2	A2	I-NP	NN	:::NOCLASS|UMLS:C0935080:T023:ANAT	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	and	and	O	CC	0	_	_	_	_
34	NF	NF	B-NP	NN	:::NOCLASS	_	_	_	_
35	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
36	E1	E1	I-NP	NN	:::NOCLASS	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	V	V	B-NP	NN	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	data	datum	I-NP	NNS	0	_	_	_	_
3	indicate	indicate	B-VP	VBP	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	RNK	RNK	B-NP	NN	:::NOCLASS	_	_	_	_
6	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
7	Met	Met	I-NP	NN	:::NOCLASS	_	_	_	_
8	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
9	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
10	is	be	B-VP	VBZ	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	serine	serine	I-NP	NN	:::NOCLASS	_	_	_	_
13	protease	protease	I-NP	NN	:::NOCLASS	_	_	_	_
14	with	with	B-PP	IN	0	_	_	_	_
15	unique	unique	B-NP	JJ	0	_	_	_	_
16	activity	activity	I-NP	NN	0	_	_	_	_
17	that	that	B-NP	WDT	0	_	_	_	_
18	is	be	B-VP	VBZ	0	_	_	_	_
19	expressed	express	I-VP	VBN	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	granules	granule	I-NP	NNS	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	large	large	B-NP	JJ	0	_	_	_	_
25	granular	granular	I-NP	JJ	0	_	_	_	_
26	lymphocytes	lymphocyte	I-NP	NNS	0	_	_	_	_
27	.	.	O	.	0	_	_	_	_

1	Purification	Purification	B-NP	NN	0	_	_	_	_
2	and	and	I-NP	CC	0	_	_	_	_
3	cloning	cloning	I-NP	NN	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	a	a	B-NP	DT	0	_	_	_	_
6	novel	novel	I-NP	JJ	0	_	_	_	_
7	serine	serine	I-NP	NN	:::NOCLASS	_	_	_	_
8	protease	protease	I-NP	NN	:::NOCLASS	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	RNK	RNK	B-NP	NN	:::NOCLASS	_	_	_	_
11	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
12	Met	Met	I-NP	NN	:::NOCLASS	_	_	_	_
13	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
14	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
15	,	,	O	,	0	_	_	_	_
16	from	from	B-PP	IN	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	granules	granule	I-NP	NNS	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	a	a	B-NP	DT	0	_	_	_	_
21	rat	rat	I-NP	NN	0	_	_	_	_
22	natural	natural	I-NP	JJ	0	_	_	_	_
23	killer	killer	I-NP	NN	0	_	_	_	_
24	cell	cell	I-NP	NN	0	_	_	_	_
25	leukemia	leukemia	I-NP	NN	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	We	We	B-NP	PRP	0	_	_	_	_
2	describe	describe	B-VP	VBP	0	_	_	_	_
3	here	here	B-ADVP	RB	0	_	_	_	_
4	17	17	B-NP	CD	0	_	_	_	_
5	dominant	dominant	I-NP	JJ	:::NOCLASS	_	_	_	_
6	GCN2	GCN2	I-NP	NN	:::NOCLASS	_	_	_	_
7	mutations	mutation	I-NP	NNS	:::NOCLASS	_	_	_	_
8	that	that	B-NP	WDT	0	_	_	_	_
9	lead	lead	B-VP	VBP	0	_	_	_	_
10	to	to	B-PP	TO	0	_	_	_	_
11	derepression	derepression	B-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	GCN4	GCN4	B-NP	NN	:::NOCLASS	_	_	_	_
14	expression	expression	I-NP	NN	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	absence	absence	I-NP	NN	0	_	_	_	_
18	of	of	B-PP	IN	0	_	_	_	_
19	amino	amino	B-NP	JJ	0	_	_	_	_
20	acid	acid	I-NP	NN	0	_	_	_	_
21	starvation	starvation	I-NP	NN	0	_	_	_	_
22	.	.	O	.	0	_	_	_	_

1	Administration	Administration	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	growth	growth	B-NP	NN	:::NOCLASS	_	_	_	_
4	hormone	hormone	I-NP	NN	:::NOCLASS	_	_	_	_
5	leads	lead	B-VP	VBZ	0	_	_	_	_
6	to	to	B-PP	TO	0	_	_	_	_
7	faster	fast	B-NP	JJR	0	_	_	_	_
8	growth	growth	I-NP	NN	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	but	but	B-CONJP	CC	0	_	_	_	_
11	also	also	I-CONJP	RB	0	_	_	_	_
12	faster	fast	B-NP	JJR	0	_	_	_	_
13	bone	bone	I-NP	NN	UMLS:C0262950:T023:ANAT	_	_	_	_
14	maturation	maturation	I-NP	NN	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Comparisons	Comparison	B-NP	NNS	0	_	_	_	_
2	with	with	B-PP	IN	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	available	available	I-NP	JJ	0	_	_	_	_
5	amino	amino	I-NP	NN	0	_	_	_	_
6	acid	acid	I-NP	NN	0	_	_	_	_
7	residue	residue	I-NP	NN	0	_	_	_	_
8	(	(	O	(	0	_	_	_	_
9	aa	aa	B-NP	NN	UMLS:C1862382:T047:DISO	_	_	_	_
10	)	)	O	)	0	_	_	_	_
11	sequence	sequence	B-NP	NN	0	_	_	_	_
12	information	information	I-NP	NN	0	_	_	_	_
13	from	from	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	complete	complete	I-NP	JJ	0	_	_	_	_
16	CPMV	CPMV	I-NP	NN	:::NOCLASS	_	_	_	_
17	RNA	RNA	I-NP	NN	:::NOCLASS	_	_	_	_
18	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
19	sequence	sequence	I-NP	NN	:::NOCLASS	_	_	_	_
20	and	and	O	CC	0	_	_	_	_
21	the	the	B-NP	DT	0	_	_	_	_
22	partial	partial	I-NP	JJ	0	_	_	_	_
23	sequence	sequence	I-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	red	red	B-NP	JJ	:::NOCLASS	_	_	_	_
26	clover	clover	I-NP	NN	:::NOCLASS	_	_	_	_
27	mottle	mottle	I-NP	NN	:::NOCLASS	_	_	_	_
28	virus	virus	I-NP	NN	:::NOCLASS	_	_	_	_
29	RNA	RNA	I-NP	NN	:::NOCLASS	_	_	_	_
30	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
31	suggest	suggest	B-VP	VBP	0	_	_	_	_
32	that	that	B-SBAR	IN	0	_	_	_	_
33	CPSMV	CPSMV	B-NP	NN	:::NOCLASS	_	_	_	_
34	RNA	RNA	I-NP	NN	:::NOCLASS	_	_	_	_
35	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
36	specifies	specify	B-VP	VBZ	0	_	_	_	_
37	the	the	B-NP	DT	0	_	_	_	_
38	expected	expect	I-NP	VBN	0	_	_	_	_
39	set	set	I-NP	NN	0	_	_	_	_
40	of	of	B-PP	IN	0	_	_	_	_
41	five	five	B-NP	CD	0	_	_	_	_
42	mature	mature	I-NP	JJ	0	_	_	_	_
43	proteins	protein	I-NP	NNS	0	_	_	_	_
44	:	:	O	:	0	_	_	_	_
45	32K	32K	B-NP	NN	:::NOCLASS	_	_	_	_
46	proteinase	proteinase	I-NP	NN	:::NOCLASS	_	_	_	_
47	cofactor	cofactor	I-NP	NN	:::NOCLASS	_	_	_	_
48	,	,	O	,	0	_	_	_	_
49	58K	58K	B-NP	NN	:::NOCLASS	_	_	_	_
50	presumed	presume	B-VP	VBD	:::NOCLASS	_	_	_	_
51	helicase	helicase	B-NP	NN	:::NOCLASS	_	_	_	_
52	,	,	O	,	0	_	_	_	_
53	VPg	VPg	B-NP	NN	:::NOCLASS	_	_	_	_
54	5	5	I-NP	CD	:::NOCLASS	_	_	_	_
55	'	'	B-NP	SYM	:::NOCLASS	_	_	_	_
56	-	-	B-VP	HYPH	:::NOCLASS	_	_	_	_
57	linked	link	B-NP	VBN	:::NOCLASS	_	_	_	_
58	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
59	of	of	B-PP	IN	0	_	_	_	_
60	the	the	B-NP	DT	0	_	_	_	_
61	genomic	genomic	I-NP	JJ	0	_	_	_	_
62	RNAs	RNA	I-NP	NNS	0	_	_	_	_
63	,	,	O	,	0	_	_	_	_
64	24K	24K	B-NP	NN	:::NOCLASS	_	_	_	_
65	proteinase	proteinase	I-NP	NN	:::NOCLASS	_	_	_	_
66	,	,	O	,	0	_	_	_	_
67	and	and	O	CC	0	_	_	_	_
68	87K	87K	B-NP	NN	:::NOCLASS	_	_	_	_
69	presumed	presume	B-VP	VBD	:::NOCLASS	_	_	_	_
70	polymerase	polymerase	B-NP	NN	:::NOCLASS	_	_	_	_
71	,	,	O	,	0	_	_	_	_
72	separated	separate	B-VP	VBN	0	_	_	_	_
73	by	by	B-PP	IN	0	_	_	_	_
74	four	four	B-NP	CD	0	_	_	_	_
75	cleavage	cleavage	I-NP	NN	0	_	_	_	_
76	sites	site	I-NP	NNS	0	_	_	_	_
77	.	.	O	.	0	_	_	_	_

1	Rice	Rice	B-NP	NN	:::NOCLASS	_	_	_	_
2	dwarf	dwarf	I-NP	NN	:::NOCLASS|UMLS:C0013336:T047:DISO	_	_	_	_
3	phytoreovirus	phytoreovirus	I-NP	NN	:::NOCLASS	_	_	_	_
4	segment	segment	I-NP	NN	:::NOCLASS	_	_	_	_
5	S12	S12	I-NP	NN	:::NOCLASS	_	_	_	_
6	transcript	transcript	I-NP	NN	:::NOCLASS	_	_	_	_
7	is	be	B-VP	VBZ	0	_	_	_	_
8	tricistronic	tricistronic	B-ADJP	JJ	0	_	_	_	_
9	in	in	B-ADVP	FW	0	_	_	_	_
10	vitro	vitro	I-ADVP	FW	0	_	_	_	_
11	.	.	O	.	0	_	_	_	_

1	In	In	B-PP	IN	0	_	_	_	_
2	addition	addition	B-NP	NN	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	utility	utility	I-NP	NN	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	beta	beta	B-NP	SYM	:::NOCLASS	_	_	_	_
8	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
9	transferrin	transferrin	I-NP	NN	:::NOCLASS	_	_	_	_
10	assay	assay	I-NP	NN	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	diagnosis	diagnosis	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	cerebrospinal	cerebrospinal	B-NP	JJ	UMLS:C0007814:T047:DISO	_	_	_	_
16	fluid	fluid	I-NP	NN	UMLS:C0007814:T047:DISO	_	_	_	_
17	otorrhea	otorrhea	I-NP	NN	UMLS:C0007814:T047:DISO	_	_	_	_
18	is	be	B-VP	VBZ	0	_	_	_	_
19	presented	present	I-VP	VBN	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	Cold	Cold	B-NP	JJ	UMLS:C0009443:T047:DISO|UMLS:C0024117:T047:DISO	_	_	_	_
2	cardioplegia	cardioplegia	I-NP	NN	0	_	_	_	_
3	was	be	B-VP	VBD	0	_	_	_	_
4	administered	administer	I-VP	VBN	0	_	_	_	_
5	at	at	B-PP	IN	0	_	_	_	_
6	45	45	B-NP	CD	0	_	_	_	_
7	mm	mm	I-NP	NN	0	_	_	_	_
8	Hg	Hg	I-NP	NN	0	_	_	_	_
9	every	every	B-NP	DT	0	_	_	_	_
10	20	20	I-NP	CD	0	_	_	_	_
11	minutes	minute	I-NP	NNS	0	_	_	_	_
12	for	for	B-PP	IN	0	_	_	_	_
13	2	2	B-NP	CD	0	_	_	_	_
14	hours	hour	I-NP	NNS	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	addition	addition	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	diatrizoate	diatrizoate	B-NP	NN	0	_	_	_	_
5	to	to	B-PP	TO	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	IPRK	IPRK	I-NP	NN	0	_	_	_	_
8	led	lead	B-VP	VBD	0	_	_	_	_
9	to	to	B-PP	TO	0	_	_	_	_
10	a	a	B-NP	DT	0	_	_	_	_
11	dose	dose	I-NP	NN	0	_	_	_	_
12	-	-	B-NP	HYPH	0	_	_	_	_
13	dependent	dependent	I-NP	JJ	0	_	_	_	_
14	biphasic	biphasic	I-NP	JJ	0	_	_	_	_
15	change	change	I-NP	NN	0	_	_	_	_
16	in	in	B-PP	IN	0	_	_	_	_
17	RPF	RPF	B-NP	NN	0	_	_	_	_
18	and	and	I-NP	CC	0	_	_	_	_
19	GFR	GFR	I-NP	NN	0	_	_	_	_
20	characterized	characterize	B-VP	VBN	0	_	_	_	_
21	by	by	B-PP	IN	0	_	_	_	_
22	an	an	B-NP	DT	0	_	_	_	_
23	initial	initial	I-NP	JJ	0	_	_	_	_
24	transient	transient	I-NP	JJ	0	_	_	_	_
25	increase	increase	I-NP	NN	0	_	_	_	_
26	followed	follow	B-VP	VBN	0	_	_	_	_
27	by	by	B-PP	IN	0	_	_	_	_
28	a	a	B-NP	DT	0	_	_	_	_
29	marked	marked	I-NP	JJ	0	_	_	_	_
30	and	and	I-NP	CC	0	_	_	_	_
31	sustained	sustained	I-NP	JJ	0	_	_	_	_
32	decrease	decrease	I-NP	NN	0	_	_	_	_
33	.	.	O	.	0	_	_	_	_

1	To	To	B-VP	TO	0	_	_	_	_
2	prepare	prepare	I-VP	VB	0	_	_	_	_
3	for	for	B-PP	IN	0	_	_	_	_
4	analyses	analysis	B-NP	NNS	0	_	_	_	_
5	with	with	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	family	family	I-NP	NN	0	_	_	_	_
8	variables	variable	I-NP	NNS	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	we	we	B-NP	PRP	0	_	_	_	_
11	next	next	B-NP	JJ	0	_	_	_	_
12	present	present	I-NP	JJ	0	_	_	_	_
13	descriptive	descriptive	I-NP	JJ	0	_	_	_	_
14	data	datum	I-NP	NNS	0	_	_	_	_
15	based	base	B-PP	VBN	0	_	_	_	_
16	on	on	B-PP	IN	0	_	_	_	_
17	separate	separate	B-NP	JJ	0	_	_	_	_
18	principal	principal	I-NP	JJ	0	_	_	_	_
19	components	component	I-NP	NNS	0	_	_	_	_
20	analysis	analysis	I-NP	NN	0	_	_	_	_
21	(	(	O	(	0	_	_	_	_
22	PCA	PCA	B-NP	NN	UMLS:C0268398:T047:DISO|UMLS:C0220723:T047:DISO|UMLS:C0149576:T023:ANAT	_	_	_	_
23	)	)	O	)	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	multidimensional	multidimensional	B-NP	JJ	0	_	_	_	_
26	scaling	scaling	I-NP	NN	0	_	_	_	_
27	analysis	analysis	I-NP	NN	0	_	_	_	_
28	(	(	O	(	0	_	_	_	_
29	MDS	MDS	B-NP	NN	UMLS:C0265219:T047:DISO	_	_	_	_
30	)	)	O	)	0	_	_	_	_
31	of	of	B-PP	IN	0	_	_	_	_
32	14	14	B-NP	CD	0	_	_	_	_
33	self	self	I-NP	NN	0	_	_	_	_
34	-	-	O	HYPH	0	_	_	_	_
35	reported	report	B-NP	VBN	0	_	_	_	_
36	health	health	I-NP	NN	0	_	_	_	_
37	scores	score	I-NP	NNS	0	_	_	_	_
38	for	for	B-PP	IN	0	_	_	_	_
39	husbands	husband	B-NP	NNS	0	_	_	_	_
40	and	and	B-PP	CC	0	_	_	_	_
41	for	for	B-PP	IN	0	_	_	_	_
42	wives	wife	B-NP	NNS	0	_	_	_	_
43	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	structural	structural	I-NP	JJ	0	_	_	_	_
3	genes	gene	I-NP	NNS	0	_	_	_	_
4	encoding	encode	B-VP	VBG	0	_	_	_	_
5	glyceraldehyde	glyceraldehyde	B-NP	NN	:::NOCLASS	_	_	_	_
6	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
7	3	3	I-NP	CD	:::NOCLASS	_	_	_	_
8	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
9	phosphate	phosphate	I-NP	NN	:::NOCLASS	_	_	_	_
10	dehydrogenase	dehydrogenase	I-NP	NN	:::NOCLASS	_	_	_	_
11	(	(	O	(	0	_	_	_	_
12	GAPDH	GAPDH	B-NP	NN	:::NOCLASS	_	_	_	_
13	)	)	O	)	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	3	3	B-NP	CD	:::NOCLASS	_	_	_	_
16	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
17	phosphoglycerate	phosphoglycerate	I-NP	NN	:::NOCLASS	_	_	_	_
18	kinase	kinase	I-NP	NN	:::NOCLASS	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	PGK	PGK	B-NP	NN	:::NOCLASS	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	the	the	B-NP	DT	0	_	_	_	_
24	N	N	I-NP	NN	0	_	_	_	_
25	-	-	B-NP	HYPH	0	_	_	_	_
26	terminal	terminal	I-NP	JJ	0	_	_	_	_
27	part	part	I-NP	NN	0	_	_	_	_
28	of	of	B-PP	IN	0	_	_	_	_
29	triosephosphate	triosephosphate	B-NP	NN	:::NOCLASS	_	_	_	_
30	isomerase	isomerase	I-NP	NN	:::NOCLASS	_	_	_	_
31	(	(	O	(	0	_	_	_	_
32	TIM	TIM	B-NP	NN	:::NOCLASS	_	_	_	_
33	)	)	O	)	0	_	_	_	_
34	from	from	B-PP	IN	0	_	_	_	_
35	mesophilic	mesophilic	B-NP	JJ	0	_	_	_	_
36	Bacillus	Bacillus	I-NP	NN	0	_	_	_	_
37	megaterium	megaterium	I-NP	NN	0	_	_	_	_
38	DSM319	DSM319	I-NP	NN	0	_	_	_	_
39	have	have	B-VP	VBP	0	_	_	_	_
40	been	be	I-VP	VBN	0	_	_	_	_
41	cloned	clone	I-VP	VBN	0	_	_	_	_
42	as	as	B-PP	IN	0	_	_	_	_
43	a	a	B-NP	DT	0	_	_	_	_
44	gene	gene	I-NP	NN	0	_	_	_	_
45	cluster	cluster	I-NP	NN	0	_	_	_	_
46	(	(	O	(	0	_	_	_	_
47	gap	gap	B-NP	NN	:::NOCLASS	_	_	_	_
48	operon	operon	I-NP	NN	:::NOCLASS	_	_	_	_
49	)	)	O	)	0	_	_	_	_
50	by	by	B-PP	IN	0	_	_	_	_
51	complementation	complementation	B-NP	NN	0	_	_	_	_
52	of	of	B-PP	IN	0	_	_	_	_
53	an	an	B-NP	DT	0	_	_	_	_
54	Escherichia	Escherichia	I-NP	FW	0	_	_	_	_
55	coli	coli	I-NP	FW	0	_	_	_	_
56	gap	gap	I-NP	NN	:::NOCLASS	_	_	_	_
57	amber	amber	I-NP	NN	:::NOCLASS	_	_	_	_
58	mutant	mutant	I-NP	NN	:::NOCLASS	_	_	_	_
59	.	.	O	.	0	_	_	_	_

1	Pseudomonas	Pseudomonas	B-NP	NN	:::NOCLASS	_	_	_	_
2	aeruginosa	aeruginosa	I-NP	NN	:::NOCLASS	_	_	_	_
3	exotoxin	exotoxin	I-NP	NN	:::NOCLASS	_	_	_	_
4	A	A	I-NP	NN	:::NOCLASS	_	_	_	_
5	:	:	O	:	0	_	_	_	_
6	its	its	B-NP	PRP$	0	_	_	_	_
7	role	role	I-NP	NN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	retardation	retardation	B-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	wound	wound	B-NP	NN	0	_	_	_	_
12	healing	healing	I-NP	NN	0	_	_	_	_
13	:	:	O	:	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	1992	1992	I-NP	CD	0	_	_	_	_
16	Lindberg	Lindberg	I-NP	NNP	0	_	_	_	_
17	Award	Award	I-NP	NNP	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	Laboratory	Laboratory	B-NP	NN	0	_	_	_	_
2	studies	study	I-NP	NNS	0	_	_	_	_
3	showed	show	B-VP	VBD	0	_	_	_	_
4	that	that	B-SBAR	IN	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	direct	direct	I-NP	JJ	0	_	_	_	_
7	fluorescent	fluorescent	I-NP	JJ	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	antibody	antibody	I-NP	NN	0	_	_	_	_
10	kits	kit	I-NP	NNS	0	_	_	_	_
11	were	be	B-VP	VBD	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	least	least	I-NP	JJS	0	_	_	_	_
14	sensitive	sensitive	I-NP	JJ	0	_	_	_	_
15	in	in	B-PP	IN	0	_	_	_	_
16	this	this	B-NP	DT	0	_	_	_	_
17	case	case	I-NP	NN	0	_	_	_	_
18	and	and	O	CC	0	_	_	_	_
19	did	do	B-VP	VBD	0	_	_	_	_
20	not	not	I-VP	RB	0	_	_	_	_
21	detect	detect	I-VP	VB	0	_	_	_	_
22	fewer	few	B-NP	JJR	0	_	_	_	_
23	than	than	I-NP	IN	0	_	_	_	_
24	10	10	I-NP	CD	0	_	_	_	_
25	(	(	O	(	0	_	_	_	_
26	4	4	B-NP	CD	0	_	_	_	_
27	)	)	O	)	0	_	_	_	_
28	elementary	elementary	B-NP	JJ	0	_	_	_	_
29	bodies	body	I-NP	NNS	0	_	_	_	_
30	per	per	B-PP	IN	0	_	_	_	_
31	ml	ml	B-NP	NN	0	_	_	_	_
32	,	,	O	,	0	_	_	_	_
33	while	while	B-SBAR	IN	0	_	_	_	_
34	most	most	B-NP	JJS	0	_	_	_	_
35	ELISA	ELISA	I-NP	NN	0	_	_	_	_
36	kits	kit	I-NP	NNS	0	_	_	_	_
37	detected	detect	B-VP	VBN	0	_	_	_	_
38	between	between	B-PP	IN	0	_	_	_	_
39	130	130	B-NP	CD	0	_	_	_	_
40	and	and	I-NP	CC	0	_	_	_	_
41	600	600	I-NP	CD	0	_	_	_	_
42	elementary	elementary	I-NP	JJ	0	_	_	_	_
43	bodies	body	I-NP	NNS	0	_	_	_	_
44	per	per	B-PP	IN	0	_	_	_	_
45	ml	ml	B-NP	NN	0	_	_	_	_
46	.	.	O	.	0	_	_	_	_

1	To	To	B-VP	TO	0	_	_	_	_
2	study	study	I-VP	VB	0	_	_	_	_
3	the	the	B-NP	DT	0	_	_	_	_
4	significance	significance	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	these	these	B-NP	DT	0	_	_	_	_
7	domains	domain	I-NP	NNS	0	_	_	_	_
8	and	and	O	CC	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	overall	overall	I-NP	JJ	0	_	_	_	_
11	evolutionary	evolutionary	I-NP	JJ	0	_	_	_	_
12	conservation	conservation	I-NP	NN	0	_	_	_	_
13	of	of	B-PP	IN	0	_	_	_	_
14	the	the	B-NP	DT	0	_	_	_	_
15	gene	gene	I-NP	NN	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	the	the	B-NP	DT	0	_	_	_	_
18	homolog	homolog	I-NP	NN	0	_	_	_	_
19	from	from	B-PP	IN	0	_	_	_	_
20	Drosophila	Drosophila	B-NP	FW	0	_	_	_	_
21	melanogaster	melanogaster	I-NP	NN	0	_	_	_	_
22	was	be	B-VP	VBD	0	_	_	_	_
23	isolated	isolate	I-VP	VBN	0	_	_	_	_
24	by	by	B-PP	IN	0	_	_	_	_
25	low	low	B-NP	JJ	0	_	_	_	_
26	stringency	stringency	I-NP	NN	0	_	_	_	_
27	hybridizations	hybridization	I-NP	NNS	0	_	_	_	_
28	using	use	B-VP	VBG	0	_	_	_	_
29	two	two	B-NP	CD	0	_	_	_	_
30	flanking	flanking	I-NP	NN	0	_	_	_	_
31	probes	probe	I-NP	NNS	0	_	_	_	_
32	of	of	B-PP	IN	0	_	_	_	_
33	the	the	B-NP	DT	0	_	_	_	_
34	human	human	I-NP	JJ	:::NOCLASS	_	_	_	_
35	ERCC3	ERCC3	I-NP	NN	:::NOCLASS	_	_	_	_
36	cDNA	cDNA	I-NP	NN	:::NOCLASS	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	Mono	Mono	B-NP	AFX	UMLS:C0021345:T047:DISO	_	_	_	_
2	-	-	I-NP	HYPH	0	_	_	_	_
3	ADP	ADP	I-NP	NN	0	_	_	_	_
4	-	-	O	HYPH	0	_	_	_	_
5	ribosylation	ribosylation	B-NP	NN	0	_	_	_	_
6	is	be	B-VP	VBZ	0	_	_	_	_
7	a	a	B-NP	DT	0	_	_	_	_
8	reversible	reversible	I-NP	JJ	0	_	_	_	_
9	modification	modification	I-NP	NN	0	_	_	_	_
10	of	of	B-PP	IN	0	_	_	_	_
11	proteins	protein	B-NP	NNS	0	_	_	_	_
12	,	,	O	,	0	_	_	_	_
13	with	with	B-PP	IN	0	_	_	_	_
14	NAD	NAD	B-NP	NN	UMLS:C1850380:T047:DISO	_	_	_	_
15	:	:	O	:	0	_	_	_	_
16	arginine	arginine	B-NP	NN	:::NOCLASS	_	_	_	_
17	ADP	ADP	I-NP	NN	:::NOCLASS	_	_	_	_
18	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
19	ribosyltransferases	ribosyltransferas	I-NP	NNS	:::NOCLASS	_	_	_	_
20	(	(	O	(	0	_	_	_	_
21	EC	EC	B-NP	NNP	:::NOCLASS	_	_	_	_
22	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
23	.	.	O	.	:::NOCLASS	_	_	_	_
24	4	4	B-NP	CD	:::NOCLASS	_	_	_	_
25	.	.	I-NP	.	:::NOCLASS	_	_	_	_
26	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
27	.	.	I-NP	.	:::NOCLASS	_	_	_	_
28	31	31	I-NP	CD	:::NOCLASS	_	_	_	_
29	)	)	O	)	0	_	_	_	_
30	and	and	O	CC	0	_	_	_	_
31	ADP	ADP	B-NP	NN	:::NOCLASS	_	_	_	_
32	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
33	ribosylarginine	ribosylarginine	I-NP	NN	:::NOCLASS	_	_	_	_
34	hydrolases	hydrolas	I-NP	NNS	:::NOCLASS	_	_	_	_
35	(	(	O	(	0	_	_	_	_
36	EC	EC	B-NP	NNP	:::NOCLASS	_	_	_	_
37	3	3	I-NP	CD	:::NOCLASS	_	_	_	_
38	.	.	O	.	:::NOCLASS	_	_	_	_
39	2	2	B-NP	CD	:::NOCLASS	_	_	_	_
40	.	.	I-NP	.	:::NOCLASS	_	_	_	_
41	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
42	.	.	I-NP	.	:::NOCLASS	_	_	_	_
43	19	19	I-NP	CD	:::NOCLASS	_	_	_	_
44	)	)	O	)	0	_	_	_	_
45	catalyzing	catalyze	B-VP	VBG	0	_	_	_	_
46	the	the	B-NP	DT	0	_	_	_	_
47	opposing	oppose	I-NP	VBG	0	_	_	_	_
48	reactions	reaction	I-NP	NNS	0	_	_	_	_
49	in	in	B-PP	IN	0	_	_	_	_
50	an	an	B-NP	DT	0	_	_	_	_
51	ADP	ADP	I-NP	NN	0	_	_	_	_
52	-	-	B-NP	HYPH	0	_	_	_	_
53	ribosylation	ribosylation	I-NP	NN	0	_	_	_	_
54	cycle	cycle	I-NP	NN	0	_	_	_	_
55	.	.	O	.	0	_	_	_	_

1	For	For	B-PP	IN	0	_	_	_	_
2	this	this	B-NP	DT	0	_	_	_	_
3	reason	reason	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	the	the	B-NP	DT	0	_	_	_	_
6	particle	particle	I-NP	NN	0	_	_	_	_
7	forming	form	B-VP	VBG	0	_	_	_	_
8	capacity	capacity	B-NP	NN	0	_	_	_	_
9	of	of	B-PP	IN	0	_	_	_	_
10	derivatives	derivative	B-NP	NNS	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	HIV	HIV	I-NP	NN	:::NOCLASS|UMLS:C0019693:T047:DISO	_	_	_	_
14	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
15	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
16	group	group	I-NP	NN	:::NOCLASS	_	_	_	_
17	specific	specific	I-NP	JJ	:::NOCLASS	_	_	_	_
18	core	core	I-NP	NN	:::NOCLASS	_	_	_	_
19	antigen	antigen	I-NP	NN	:::NOCLASS	_	_	_	_
20	p55	p55	I-NP	NN	:::NOCLASS	_	_	_	_
21	gag	gag	I-NP	NN	:::NOCLASS	_	_	_	_
22	was	be	B-VP	VBD	0	_	_	_	_
23	assayed	assay	I-VP	VBN	0	_	_	_	_
24	and	and	O	CC	0	_	_	_	_
25	compared	compare	B-VP	VBN	0	_	_	_	_
26	dependent	dependent	B-ADJP	JJ	0	_	_	_	_
27	on	on	B-PP	IN	0	_	_	_	_
28	various	various	B-NP	JJ	0	_	_	_	_
29	expression	expression	I-NP	NN	0	_	_	_	_
30	systems	system	I-NP	NNS	0	_	_	_	_
31	:	:	O	:	0	_	_	_	_
32	recombinant	recombinant	B-NP	JJ	0	_	_	_	_
33	bacteria	bacteria	I-NP	NNS	0	_	_	_	_
34	,	,	O	,	0	_	_	_	_
35	vaccinia	vaccinia	B-NP	NN	UMLS:C0042214:T047:DISO	_	_	_	_
36	-	-	B-ADJP	HYPH	0	_	_	_	_
37	and	and	O	CC	0	_	_	_	_
38	baculoviruses	baculovirus	B-NP	NNS	0	_	_	_	_
39	were	be	B-VP	VBD	0	_	_	_	_
40	established	establish	I-VP	VBN	0	_	_	_	_
41	encoding	encode	B-VP	VBG	0	_	_	_	_
42	the	the	B-NP	DT	0	_	_	_	_
43	entire	entire	I-NP	JJ	0	_	_	_	_
44	core	core	I-NP	NN	:::NOCLASS	_	_	_	_
45	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
46	p55	p55	I-NP	NN	:::NOCLASS	_	_	_	_
47	either	either	B-PP	CC	0	_	_	_	_
48	in	in	B-PP	IN	0	_	_	_	_
49	its	its	B-NP	PRP$	0	_	_	_	_
50	authentic	authentic	I-NP	JJ	0	_	_	_	_
51	sequence	sequence	I-NP	NN	0	_	_	_	_
52	or	or	O	CC	0	_	_	_	_
53	lacking	lack	B-VP	VBG	0	_	_	_	_
54	the	the	B-NP	DT	0	_	_	_	_
55	myristylation	myristylation	I-NP	NN	0	_	_	_	_
56	consensus	consensus	I-NP	NN	0	_	_	_	_
57	signal	signal	I-NP	NN	0	_	_	_	_
58	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	tramtrack	tramtrack	I-NP	NN	:::NOCLASS	_	_	_	_
3	(	(	O	(	0	_	_	_	_
4	ttk	ttk	B-NP	NN	:::NOCLASS	_	_	_	_
5	)	)	O	)	0	_	_	_	_
6	gene	gene	B-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	Drosophila	Drosophila	B-NP	NNP	0	_	_	_	_
9	encodes	encode	B-VP	VBZ	0	_	_	_	_
10	69	69	B-NP	CD	0	_	_	_	_
11	-	-	I-NP	HYPH	0	_	_	_	_
12	kDa	kDa	I-NP	NN	0	_	_	_	_
13	and	and	I-NP	CC	0	_	_	_	_
14	88	88	I-NP	CD	0	_	_	_	_
15	-	-	I-NP	HYPH	0	_	_	_	_
16	kDa	kDa	I-NP	NN	0	_	_	_	_
17	proteins	protein	I-NP	NNS	0	_	_	_	_
18	through	through	B-PP	IN	0	_	_	_	_
19	alternative	alternative	B-NP	JJ	0	_	_	_	_
20	splicing	splicing	I-NP	NN	0	_	_	_	_
21	of	of	B-PP	IN	0	_	_	_	_
22	the	the	B-NP	DT	0	_	_	_	_
23	primary	primary	I-NP	JJ	0	_	_	_	_
24	ttk	ttk	I-NP	NN	:::NOCLASS	_	_	_	_
25	transcript	transcript	I-NP	NN	:::NOCLASS	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	Removal	Removal	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	beta	beta	B-NP	SYM	:::NOCLASS	_	_	_	_
4	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
5	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
6	microglobulin	microglobulin	I-NP	NN	:::NOCLASS	_	_	_	_
7	by	by	B-PP	IN	0	_	_	_	_
8	hemodialysis	hemodialysis	B-NP	NN	0	_	_	_	_
9	and	and	I-NP	CC	0	_	_	_	_
10	hemofiltration	hemofiltration	I-NP	NN	0	_	_	_	_
11	:	:	O	:	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	four	four	I-NP	CD	0	_	_	_	_
14	year	year	I-NP	NN	0	_	_	_	_
15	follow	follow	B-VP	VB	0	_	_	_	_
16	up	up	B-PRT	IN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Removal	Removal	B-NP	NN	0	_	_	_	_
2	of	of	B-PP	IN	0	_	_	_	_
3	beta	beta	B-NP	SYM	:::NOCLASS	_	_	_	_
4	2	2	I-NP	CD	:::NOCLASS	_	_	_	_
5	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
6	microglobulin	microglobulin	I-NP	NN	:::NOCLASS	_	_	_	_
7	by	by	B-PP	IN	0	_	_	_	_
8	hemodialysis	hemodialysis	B-NP	NN	0	_	_	_	_
9	and	and	I-NP	CC	0	_	_	_	_
10	hemofiltration	hemofiltration	I-NP	NN	0	_	_	_	_
11	:	:	O	:	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	four	four	I-NP	CD	0	_	_	_	_
14	year	year	I-NP	NN	0	_	_	_	_
15	follow	follow	B-VP	VB	0	_	_	_	_
16	up	up	B-PRT	IN	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	Adapromine	Adapromine	B-NP	NN	0	_	_	_	_
2	was	be	B-VP	VBD	0	_	_	_	_
3	established	establish	I-VP	VBN	0	_	_	_	_
4	to	to	I-VP	TO	0	_	_	_	_
5	evoke	evoke	I-VP	VB	0	_	_	_	_
6	a	a	B-NP	DT	0	_	_	_	_
7	decrease	decrease	I-NP	NN	0	_	_	_	_
8	of	of	B-PP	IN	0	_	_	_	_
9	the	the	B-NP	DT	0	_	_	_	_
10	amplitude	amplitude	I-NP	NN	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	dominant	dominant	I-NP	JJ	0	_	_	_	_
14	peak	peak	I-NP	NN	0	_	_	_	_
15	and	and	O	CC	0	_	_	_	_
16	dominant	dominant	B-NP	JJ	0	_	_	_	_
17	theta	theta	I-NP	NN	0	_	_	_	_
18	-	-	B-NP	HYPH	0	_	_	_	_
19	activity	activity	I-NP	NN	0	_	_	_	_
20	in	in	B-PP	IN	0	_	_	_	_
21	power	power	B-NP	NN	0	_	_	_	_
22	spectra	spectrum	I-NP	NNS	0	_	_	_	_
23	of	of	B-PP	IN	0	_	_	_	_
24	the	the	B-NP	DT	0	_	_	_	_
25	EEG	EEG	I-NP	NN	0	_	_	_	_
26	in	in	B-PP	IN	0	_	_	_	_
27	the	the	B-NP	DT	0	_	_	_	_
28	cortex	cortex	I-NP	NN	UMLS:C1176472:T023:ANAT|UMLS:C0007776:T023:ANAT	_	_	_	_
29	and	and	I-NP	CC	0	_	_	_	_
30	hippocamp	hippocamp	I-NP	NN	0	_	_	_	_
31	,	,	O	,	0	_	_	_	_
32	with	with	B-PP	IN	0	_	_	_	_
33	an	an	B-NP	DT	0	_	_	_	_
34	increase	increase	I-NP	NN	0	_	_	_	_
35	of	of	B-PP	IN	0	_	_	_	_
36	rapid	rapid	B-NP	JJ	0	_	_	_	_
37	wave	wave	I-NP	NN	0	_	_	_	_
38	activity	activity	I-NP	NN	0	_	_	_	_
39	in	in	B-PP	IN	0	_	_	_	_
40	the	the	B-NP	DT	0	_	_	_	_
41	beta	beta	I-NP	SYM	0	_	_	_	_
42	2	2	I-NP	CD	0	_	_	_	_
43	range	range	I-NP	NN	0	_	_	_	_
44	in	in	B-PP	IN	0	_	_	_	_
45	the	the	B-NP	DT	0	_	_	_	_
46	right	right	I-NP	JJ	0	_	_	_	_
47	cortex	cortex	I-NP	NN	UMLS:C1176472:T023:ANAT|UMLS:C0007776:T023:ANAT	_	_	_	_
48	and	and	I-NP	CC	0	_	_	_	_
49	hippocamp	hippocamp	I-NP	NN	0	_	_	_	_
50	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	sequences	sequence	I-NP	NNS	0	_	_	_	_
3	were	be	B-VP	VBD	0	_	_	_	_
4	then	then	I-VP	RB	0	_	_	_	_
5	used	use	I-VP	VBN	0	_	_	_	_
6	to	to	B-VP	TO	0	_	_	_	_
7	clone	clone	I-VP	VB	0	_	_	_	_
8	the	the	B-NP	DT	0	_	_	_	_
9	full	full	I-NP	JJ	0	_	_	_	_
10	-	-	I-NP	HYPH	0	_	_	_	_
11	length	length	I-NP	NN	0	_	_	_	_
12	genes	gene	I-NP	NNS	0	_	_	_	_
13	from	from	B-PP	IN	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	yeast	yeast	I-NP	NN	0	_	_	_	_
16	genomic	genomic	I-NP	JJ	0	_	_	_	_
17	library	library	I-NP	NN	0	_	_	_	_
18	.	.	O	.	0	_	_	_	_

1	GAL4	GAL4	B-NP	NN	:::NOCLASS	_	_	_	_
2	-	-	B-NP	HYPH	0	_	_	_	_
3	VP16	VP16	I-NP	NN	:::NOCLASS	_	_	_	_
4	-	-	O	HYPH	0	_	_	_	_
5	mediated	mediate	B-NP	VBN	0	_	_	_	_
6	antirepression	antirepression	I-NP	NN	0	_	_	_	_
7	required	require	B-VP	VBD	0	_	_	_	_
8	an	an	B-NP	DT	0	_	_	_	_
9	auxiliary	auxiliary	I-NP	JJ	0	_	_	_	_
10	factor	factor	I-NP	NN	0	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	denoted	denote	B-VP	VBN	0	_	_	_	_
13	as	as	B-PP	IN	0	_	_	_	_
14	a	a	B-NP	DT	0	_	_	_	_
15	co	co	I-NP	AFX	0	_	_	_	_
16	-	-	I-NP	HYPH	0	_	_	_	_
17	antirepressor	antirepressor	I-NP	NN	0	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	which	which	B-NP	WDT	0	_	_	_	_
20	was	be	B-VP	VBD	0	_	_	_	_
21	partially	partially	I-VP	RB	0	_	_	_	_
22	purified	purify	I-VP	VBN	0	_	_	_	_
23	from	from	B-PP	IN	0	_	_	_	_
24	Drosophila	Drosophila	B-NP	FW	0	_	_	_	_
25	embryos	embryo	I-NP	NNS	0	_	_	_	_
26	.	.	O	.	0	_	_	_	_

1	After	After	B-PP	IN	0	_	_	_	_
2	28	28	B-NP	CD	0	_	_	_	_
3	days	day	I-NP	NNS	0	_	_	_	_
4	of	of	B-PP	IN	0	_	_	_	_
5	haloperidol	haloperidol	B-NP	NN	0	_	_	_	_
6	treatment	treatment	I-NP	NN	0	_	_	_	_
7	,	,	O	,	0	_	_	_	_
8	similar	similar	B-NP	JJ	0	_	_	_	_
9	changes	change	I-NP	NNS	0	_	_	_	_
10	were	be	B-VP	VBD	0	_	_	_	_
11	observed	observe	I-VP	VBN	0	_	_	_	_
12	for	for	B-PP	IN	0	_	_	_	_
13	delta	delta	B-NP	NN	0	_	_	_	_
14	,	,	O	,	0	_	_	_	_
15	together	together	B-ADVP	RB	0	_	_	_	_
16	with	with	B-PP	IN	0	_	_	_	_
17	an	an	B-NP	DT	0	_	_	_	_
18	increase	increase	I-NP	NN	0	_	_	_	_
19	of	of	B-PP	IN	0	_	_	_	_
20	alpha	alpha	B-NP	SYM	0	_	_	_	_
21	1	1	I-NP	CD	0	_	_	_	_
22	,	,	O	,	0	_	_	_	_
23	and	and	O	CC	0	_	_	_	_
24	a	a	B-NP	DT	0	_	_	_	_
25	decrease	decrease	I-NP	NN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	fast	fast	B-NP	JJ	0	_	_	_	_
28	beta	beta	I-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	Four	Four	B-NP	CD	0	_	_	_	_
2	ruminally	ruminally	I-NP	RB	0	_	_	_	_
3	and	and	O	CC	0	_	_	_	_
4	duodenally	duodenally	B-NP	RB	0	_	_	_	_
5	cannulated	cannulate	I-NP	VBN	0	_	_	_	_
6	Hampshire	Hampshire	I-NP	NNP	0	_	_	_	_
7	wethers	wether	I-NP	NNS	0	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	used	use	I-VP	VBN	0	_	_	_	_
10	in	in	B-PP	IN	0	_	_	_	_
11	a	a	B-NP	DT	0	_	_	_	_
12	4	4	I-NP	CD	0	_	_	_	_
13	x	x	I-NP	NN	0	_	_	_	_
14	4	4	B-NP	CD	0	_	_	_	_
15	Latin	Latin	I-NP	NN	0	_	_	_	_
16	square	square	I-NP	JJ	0	_	_	_	_
17	experiment	experiment	I-NP	NN	0	_	_	_	_
18	to	to	B-VP	TO	0	_	_	_	_
19	determine	determine	I-VP	VB	0	_	_	_	_
20	whether	whether	B-SBAR	IN	0	_	_	_	_
21	linoleoyl	linoleoyl	B-NP	NN	0	_	_	_	_
22	methionine	methionine	I-NP	NN	0	_	_	_	_
23	and	and	O	CC	0	_	_	_	_
24	calcium	calcium	B-NP	NN	0	_	_	_	_
25	linoleate	linoleate	I-NP	NN	0	_	_	_	_
26	would	would	B-VP	MD	0	_	_	_	_
27	increase	increase	I-VP	VB	0	_	_	_	_
28	duodenal	duodenal	B-NP	JJ	0	_	_	_	_
29	flow	flow	I-NP	NN	0	_	_	_	_
30	of	of	B-PP	IN	0	_	_	_	_
31	unsaturated	unsaturated	B-NP	JJ	0	_	_	_	_
32	fatty	fatty	I-NP	JJ	0	_	_	_	_
33	acids	acid	I-NP	NNS	0	_	_	_	_
34	(	(	O	(	0	_	_	_	_
35	C18	C18	B-NP	NN	0	_	_	_	_
36	:	:	O	:	0	_	_	_	_
37	2	2	B-NP	CD	0	_	_	_	_
38	+	+	I-NP	SYM	0	_	_	_	_
39	cis	cis	I-NP	NN	0	_	_	_	_
40	C18	C18	I-NP	NN	0	_	_	_	_
41	:	:	O	:	0	_	_	_	_
42	1	1	B-LST	LS	0	_	_	_	_
43	)	)	O	)	0	_	_	_	_
44	.	.	O	.	0	_	_	_	_

1	Truncated	Truncate	B-NP	VBN	:::NOCLASS	_	_	_	_
2	ICSBP	ICSBP	I-NP	NN	:::NOCLASS	_	_	_	_
3	lacking	lack	B-VP	VBG	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	first	first	I-NP	JJ	0	_	_	_	_
6	33	33	I-NP	CD	0	_	_	_	_
7	amino	amino	I-NP	JJ	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	terminal	terminal	I-NP	JJ	0	_	_	_	_
10	amino	amino	I-NP	JJ	0	_	_	_	_
11	acids	acid	I-NP	NNS	0	_	_	_	_
12	fails	fail	B-VP	VBZ	0	_	_	_	_
13	to	to	I-VP	TO	0	_	_	_	_
14	bind	bind	I-VP	VB	0	_	_	_	_
15	to	to	B-PP	TO	0	_	_	_	_
16	the	the	B-NP	DT	0	_	_	_	_
17	ICS	ICS	I-NP	NN	UMLS:C0022521:T047:DISO|:::NOCLASS	_	_	_	_
18	,	,	O	,	0	_	_	_	_
19	indicating	indicate	B-VP	VBG	0	_	_	_	_
20	that	that	B-SBAR	IN	0	_	_	_	_
21	at	at	B-ADVP	IN	0	_	_	_	_
22	least	least	I-ADVP	JJS	0	_	_	_	_
23	part	part	B-NP	NN	0	_	_	_	_
24	of	of	B-PP	IN	0	_	_	_	_
25	the	the	B-NP	DT	0	_	_	_	_
26	DNA	DNA	I-NP	NN	0	_	_	_	_
27	binding	binding	I-NP	NN	0	_	_	_	_
28	domain	domain	I-NP	NN	0	_	_	_	_
29	is	be	B-VP	VBZ	0	_	_	_	_
30	located	located	B-ADJP	JJ	0	_	_	_	_
31	within	within	B-PP	IN	0	_	_	_	_
32	the	the	B-NP	DT	0	_	_	_	_
33	well	well	I-NP	RB	0	_	_	_	_
34	conserved	conserve	I-NP	VBN	0	_	_	_	_
35	amino	amino	I-NP	JJ	0	_	_	_	_
36	terminus	terminus	I-NP	NN	0	_	_	_	_
37	.	.	O	.	0	_	_	_	_

1	Therefore	Therefore	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	ICSBP	ICSBP	B-NP	NN	:::NOCLASS	_	_	_	_
4	may	may	B-VP	MD	0	_	_	_	_
5	be	be	I-VP	VB	0	_	_	_	_
6	involved	involve	I-VP	VBN	0	_	_	_	_
7	in	in	B-PP	IN	0	_	_	_	_
8	maintaining	maintain	B-VP	VBG	0	_	_	_	_
9	submaximal	submaximal	B-NP	JJ	0	_	_	_	_
10	transcriptional	transcriptional	I-NP	JJ	0	_	_	_	_
11	activity	activity	I-NP	NN	0	_	_	_	_
12	of	of	B-PP	IN	0	_	_	_	_
13	IFN	IFN	B-NP	NN	:::NOCLASS	_	_	_	_
14	-	-	B-NP	HYPH	0	_	_	_	_
15	inducible	inducible	I-NP	JJ	0	_	_	_	_
16	genes	gene	I-NP	NNS	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	hematopoietic	hematopoietic	B-NP	JJ	0	_	_	_	_
19	cells	cell	I-NP	NNS	0	_	_	_	_
20	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	case	case	I-NP	NN	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	chronic	chronic	B-NP	JJ	UMLS:C0524910:T047:DISO	_	_	_	_
5	hepatitis	hepatitis	I-NP	NN	UMLS:C0524910:T047:DISO	_	_	_	_
6	C	C	I-NP	NN	UMLS:C0524910:T047:DISO	_	_	_	_
7	with	with	B-PP	IN	0	_	_	_	_
8	primary	primary	B-NP	JJ	UMLS:C0700502:T047:DISO	_	_	_	_
9	hypothyroidism	hypothyroidism	I-NP	NN	UMLS:C0700502:T047:DISO	_	_	_	_
10	manifested	manifest	B-VP	VBN	0	_	_	_	_
11	during	during	B-PP	IN	0	_	_	_	_
12	interferon	interferon	B-NP	NN	:::NOCLASS	_	_	_	_
13	treatment	treatment	I-NP	NN	0	_	_	_	_

1	Dynamic	Dynamic	B-NP	JJ	0	_	_	_	_
2	decision	decision	I-NP	NN	0	_	_	_	_
3	making	making	I-NP	NN	0	_	_	_	_
4	:	:	O	:	0	_	_	_	_
5	human	human	B-NP	JJ	0	_	_	_	_
6	control	control	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	complex	complex	B-NP	JJ	0	_	_	_	_
9	systems	system	I-NP	NNS	0	_	_	_	_
10	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	coiled	coil	I-NP	VBN	:::NOCLASS	_	_	_	_
3	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
4	coil	coil	I-NP	NN	:::NOCLASS	_	_	_	_
5	related	relate	I-NP	VBN	:::NOCLASS	_	_	_	_
6	protein	protein	I-NP	NN	:::NOCLASS	_	_	_	_
7	specific	specific	B-ADJP	JJ	0	_	_	_	_
8	for	for	B-PP	IN	0	_	_	_	_
9	synapsed	synapse	B-NP	VBN	0	_	_	_	_
10	regions	region	I-NP	NNS	0	_	_	_	_
11	of	of	B-PP	IN	0	_	_	_	_
12	meiotic	meiotic	B-NP	JJ	0	_	_	_	_
13	prophase	prophase	I-NP	NN	0	_	_	_	_
14	chromosomes	chromosome	I-NP	NNS	0	_	_	_	_
15	.	.	O	.	0	_	_	_	_

1	Comparable	Comparable	B-NP	JJ	0	_	_	_	_
2	amounts	amount	I-NP	NNS	0	_	_	_	_
3	of	of	B-PP	IN	0	_	_	_	_
4	alpha	alpha	B-NP	SYM	:::NOCLASS	_	_	_	_
5	5	5	B-NP	CD	:::NOCLASS	_	_	_	_
6	beta	beta	I-NP	SYM	:::NOCLASS	_	_	_	_
7	1	1	I-NP	CD	:::NOCLASS	_	_	_	_
8	integrin	integrin	I-NP	NN	:::NOCLASS	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	isolated	isolate	I-VP	VBN	0	_	_	_	_
11	from	from	B-PP	IN	0	_	_	_	_
12	these	these	B-NP	DT	0	_	_	_	_
13	cells	cell	I-NP	NNS	0	_	_	_	_
14	by	by	B-PP	IN	0	_	_	_	_
15	chromatography	chromatography	B-NP	NN	0	_	_	_	_
16	of	of	B-PP	IN	0	_	_	_	_
17	detergent	detergent	B-NP	JJ	0	_	_	_	_
18	extracts	extract	I-NP	NNS	0	_	_	_	_
19	on	on	B-PP	IN	0	_	_	_	_
20	a	a	B-NP	DT	0	_	_	_	_
21	fibronectin	fibronectin	I-NP	NN	:::NOCLASS	_	_	_	_
22	cell	cell	I-NP	NN	0	_	_	_	_
23	-	-	B-VP	HYPH	0	_	_	_	_
24	binding	bind	I-VP	VBG	0	_	_	_	_
25	fragment	fragment	B-NP	NN	0	_	_	_	_
26	affinity	affinity	I-NP	NN	0	_	_	_	_
27	column	column	I-NP	NN	UMLS:C1185738:T023:ANAT	_	_	_	_
28	and	and	O	CC	0	_	_	_	_
29	elution	elution	B-NP	NN	0	_	_	_	_
30	with	with	B-PP	IN	0	_	_	_	_
31	EDTA	EDTA	B-NP	NN	0	_	_	_	_
32	.	.	O	.	0	_	_	_	_

1	Abstracts	Abstract	B-NP	NNS	0	_	_	_	_
2	.	.	O	.	0	_	_	_	_

1	These	These	B-NP	DT	0	_	_	_	_
2	results	result	I-NP	NNS	0	_	_	_	_
3	indicate	indicate	B-VP	VBP	0	_	_	_	_
4	a	a	B-NP	DT	0	_	_	_	_
5	possible	possible	I-NP	JJ	0	_	_	_	_
6	involvement	involvement	I-NP	NN	0	_	_	_	_
7	of	of	B-PP	IN	0	_	_	_	_
8	endogenous	endogenous	B-NP	JJ	0	_	_	_	_
9	opioid	opioid	I-NP	JJ	0	_	_	_	_
10	peptides	peptide	I-NP	NNS	0	_	_	_	_
11	in	in	B-PP	IN	0	_	_	_	_
12	the	the	B-NP	DT	0	_	_	_	_
13	cardiac	cardiac	I-NP	JJ	UMLS:C0018787:T023:ANAT	_	_	_	_
14	effects	effect	I-NP	NNS	0	_	_	_	_
15	due	due	B-ADJP	JJ	0	_	_	_	_
16	to	to	B-PP	TO	0	_	_	_	_
17	myocardial	myocardial	B-NP	JJ	UMLS:C0151744:T047:DISO|UMLS:C0010054:T047:DISO	_	_	_	_
18	ischaemia	ischaemia	I-NP	NN	UMLS:C0151744:T047:DISO|UMLS:C0010054:T047:DISO	_	_	_	_
19	and	and	I-NP	CC	0	_	_	_	_
20	reperfusion	reperfusion	I-NP	NN	0	_	_	_	_
21	,	,	O	,	0	_	_	_	_
22	mediated	mediate	B-VP	VBN	0	_	_	_	_
23	by	by	B-PP	IN	0	_	_	_	_
24	opiate	opiate	B-NP	JJ	:::NOCLASS	_	_	_	_
25	receptors	receptor	I-NP	NNS	:::NOCLASS	_	_	_	_
26	through	through	B-PP	IN	0	_	_	_	_
27	opiate	opiate	B-NP	NN	0	_	_	_	_
28	antagonism	antagonism	I-NP	NN	0	_	_	_	_
29	.	.	O	.	0	_	_	_	_

1	From	From	B-PP	IN	0	_	_	_	_
2	this	this	B-NP	DT	0	_	_	_	_
3	library	library	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	LEU2	LEU2	B-NP	NN	:::NOCLASS	_	_	_	_
6	and	and	I-NP	CC	0	_	_	_	_
7	HIS3	HIS3	I-NP	NN	:::NOCLASS	_	_	_	_
8	cDNAs	cDNA	I-NP	NNS	0	_	_	_	_
9	were	be	B-VP	VBD	0	_	_	_	_
10	recovered	recover	I-VP	VBN	0	_	_	_	_
11	at	at	B-PP	IN	0	_	_	_	_
12	a	a	B-NP	DT	0	_	_	_	_
13	frequency	frequency	I-NP	NN	0	_	_	_	_
14	of	of	B-PP	IN	0	_	_	_	_
15	about	about	B-NP	IN	0	_	_	_	_
16	1	1	I-NP	CD	0	_	_	_	_
17	in	in	B-PP	IN	0	_	_	_	_
18	10	10	B-NP	CD	0	_	_	_	_
19	(	(	O	(	0	_	_	_	_
20	4	4	B-NP	CD	0	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	and	and	O	CC	0	_	_	_	_
23	in	in	B-PP	IN	0	_	_	_	_
24	12	12	B-NP	CD	0	_	_	_	_
25	out	out	B-PP	IN	0	_	_	_	_
26	of	of	B-PP	IN	0	_	_	_	_
27	13	13	B-NP	CD	0	_	_	_	_
28	cases	case	I-NP	NNS	0	_	_	_	_
29	these	these	B-NP	DT	0	_	_	_	_
30	were	be	B-VP	VBD	0	_	_	_	_
31	expressed	express	I-VP	VBN	0	_	_	_	_
32	in	in	B-PP	IN	0	_	_	_	_
33	a	a	B-NP	DT	0	_	_	_	_
34	galactose	galactose	I-NP	NN	0	_	_	_	_
35	-	-	B-NP	HYPH	0	_	_	_	_
36	dependent	dependent	I-NP	JJ	0	_	_	_	_
37	manner	manner	I-NP	NN	0	_	_	_	_
38	.	.	O	.	0	_	_	_	_

1	Among	Among	B-PP	IN	0	_	_	_	_
2	these	these	B-NP	DT	0	_	_	_	_
3	,	,	O	,	0	_	_	_	_
4	ACT1	ACT1	B-NP	NN	:::NOCLASS	_	_	_	_
5	was	be	B-VP	VBD	0	_	_	_	_
6	isolated	isolate	I-VP	VBN	0	_	_	_	_
7	four	four	B-NP	CD	0	_	_	_	_
8	times	time	I-NP	NNS	0	_	_	_	_
9	,	,	O	,	0	_	_	_	_
10	and	and	O	CC	0	_	_	_	_
11	NSR1	NSR1	B-NP	NN	:::NOCLASS	_	_	_	_
12	three	three	B-NP	CD	0	_	_	_	_
13	times	time	I-NP	NNS	0	_	_	_	_
14	.	.	O	.	0	_	_	_	_

1	Since	Since	B-SBAR	IN	0	_	_	_	_
2	CENP	CENP	B-NP	NN	:::NOCLASS	_	_	_	_
3	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
4	B	B	I-NP	NN	:::NOCLASS	_	_	_	_
5	gene	gene	I-NP	NN	:::NOCLASS	_	_	_	_
6	is	be	B-VP	VBZ	0	_	_	_	_
7	conserved	conserve	I-VP	VBN	0	_	_	_	_
8	in	in	B-PP	IN	0	_	_	_	_
9	mammalian	mammalian	B-NP	JJ	0	_	_	_	_
10	species	specie	I-NP	NNS	0	_	_	_	_
11	and	and	O	CC	0	_	_	_	_
12	CENP	CENP	B-NP	NN	:::NOCLASS	_	_	_	_
13	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
14	B	B	I-NP	NN	:::NOCLASS	_	_	_	_
15	boxes	box	I-NP	NNS	:::NOCLASS	_	_	_	_
16	are	be	B-VP	VBP	0	_	_	_	_
17	found	find	I-VP	VBN	0	_	_	_	_
18	also	also	B-ADVP	RB	0	_	_	_	_
19	in	in	B-PP	IN	0	_	_	_	_
20	mouse	mouse	B-NP	NN	0	_	_	_	_
21	centromere	centromere	I-NP	NN	0	_	_	_	_
22	satellite	satellite	I-NP	NN	0	_	_	_	_
23	DNA	DNA	I-NP	NN	0	_	_	_	_
24	(	(	O	(	0	_	_	_	_
25	minor	minor	B-NP	JJ	0	_	_	_	_
26	satellite	satellite	I-NP	NN	0	_	_	_	_
27	)	)	O	)	0	_	_	_	_
28	,	,	O	,	0	_	_	_	_
29	this	this	B-NP	DT	0	_	_	_	_
30	sequence	sequence	I-NP	NN	0	_	_	_	_
31	-	-	O	HYPH	0	_	_	_	_
32	specific	specific	B-NP	JJ	0	_	_	_	_
33	DNA	DNA	I-NP	NN	0	_	_	_	_
34	-	-	B-NP	HYPH	0	_	_	_	_
35	protein	protein	I-NP	NN	0	_	_	_	_
36	interaction	interaction	I-NP	NN	0	_	_	_	_
37	may	may	B-VP	MD	0	_	_	_	_
38	be	be	I-VP	VB	0	_	_	_	_
39	important	important	B-ADJP	JJ	0	_	_	_	_
40	for	for	B-PP	IN	0	_	_	_	_
41	some	some	B-NP	DT	0	_	_	_	_
42	kind	kind	I-NP	NN	0	_	_	_	_
43	of	of	B-PP	IN	0	_	_	_	_
44	common	common	B-NP	JJ	0	_	_	_	_
45	centromere	centromere	I-NP	NN	0	_	_	_	_
46	function	function	I-NP	NN	0	_	_	_	_
47	.	.	O	.	0	_	_	_	_

1	Interestingly	Interestingly	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	a	a	B-NP	DT	0	_	_	_	_
4	portion	portion	I-NP	NN	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	tail	tail	I-NP	NN	UMLS:C0039259:T023:ANAT	_	_	_	_
8	domain	domain	I-NP	NN	0	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	aa	aa	B-NP	NN	UMLS:C1862382:T047:DISO	_	_	_	_
11	,	,	O	,	0	_	_	_	_
12	1	1	B-NP	CD	0	_	_	_	_
13	,	,	I-NP	,	0	_	_	_	_
14	094	094	I-NP	CD	0	_	_	_	_
15	-	-	B-NP	HYPH	0	_	_	_	_
16	1	1	I-NP	CD	0	_	_	_	_
17	,	,	I-NP	,	0	_	_	_	_
18	830	830	I-NP	CD	0	_	_	_	_
19	)	)	O	)	0	_	_	_	_
20	shares	share	B-NP	NNS	0	_	_	_	_
21	58	58	B-NP	CD	0	_	_	_	_
22	%	%	I-NP	NN	0	_	_	_	_
23	amino	amino	I-NP	JJ	0	_	_	_	_
24	acid	acid	I-NP	NN	0	_	_	_	_
25	sequence	sequence	I-NP	NN	0	_	_	_	_
26	identity	identity	I-NP	NN	0	_	_	_	_
27	with	with	B-PP	IN	0	_	_	_	_
28	a	a	B-NP	DT	0	_	_	_	_
29	723	723	I-NP	CD	0	_	_	_	_
30	-	-	I-NP	HYPH	0	_	_	_	_
31	aa	aa	I-NP	NN	UMLS:C1862382:T047:DISO	_	_	_	_
32	protein	protein	I-NP	NN	0	_	_	_	_
33	from	from	B-PP	IN	0	_	_	_	_
34	mouse	mouse	B-NP	NN	0	_	_	_	_
35	brain	brain	I-NP	NN	UMLS:C0006104:T023:ANAT	_	_	_	_
36	reported	report	B-VP	VBN	0	_	_	_	_
37	to	to	I-VP	TO	0	_	_	_	_
38	be	be	I-VP	VB	0	_	_	_	_
39	a	a	B-NP	DT	0	_	_	_	_
40	glutamic	glutamic	I-NP	JJ	:::NOCLASS	_	_	_	_
41	acid	acid	I-NP	NN	:::NOCLASS	_	_	_	_
42	decarboxylase	decarboxylase	I-NP	NN	:::NOCLASS	_	_	_	_
43	.	.	O	.	0	_	_	_	_

1	However	However	B-ADVP	RB	0	_	_	_	_
2	,	,	O	,	0	_	_	_	_
3	in	in	B-PP	IN	0	_	_	_	_
4	the	the	B-NP	DT	0	_	_	_	_
5	subgroup	subgroup	I-NP	NN	0	_	_	_	_
6	with	with	B-PP	IN	0	_	_	_	_
7	normal	normal	B-NP	JJ	0	_	_	_	_
8	Ht	Ht	I-NP	NN	UMLS:C0677607:T047:DISO	_	_	_	_
9	(	(	O	(	0	_	_	_	_
10	<	<	B-NP	SYM	0	_	_	_	_
11	0	0	I-NP	CD	0	_	_	_	_
12	.	.	I-NP	SYM	0	_	_	_	_
13	45	45	I-NP	CD	0	_	_	_	_
14	l	l	I-NP	NN	0	_	_	_	_
15	/	/	B-NP	SYM	0	_	_	_	_
16	l	l	I-NP	NN	0	_	_	_	_
17	;	;	O	:	0	_	_	_	_
18	n	n	B-NP	NN	0	_	_	_	_
19	=	=	B-VP	SYM	0	_	_	_	_
20	201	201	B-NP	CD	0	_	_	_	_
21	)	)	O	)	0	_	_	_	_
22	there	there	B-NP	EX	0	_	_	_	_
23	was	be	B-VP	VBD	0	_	_	_	_
24	a	a	B-NP	DT	0	_	_	_	_
25	significant	significant	I-NP	JJ	0	_	_	_	_
26	reduction	reduction	I-NP	NN	0	_	_	_	_
27	(	(	O	(	0	_	_	_	_
28	p	p	B-NP	NN	0	_	_	_	_
29	<	<	B-ADJP	SYM	0	_	_	_	_
30	0	0	B-NP	CD	0	_	_	_	_
31	.	.	I-NP	.	0	_	_	_	_
32	05	05	I-NP	CD	0	_	_	_	_
33	)	)	O	)	0	_	_	_	_
34	of	of	B-PP	IN	0	_	_	_	_
35	the	the	B-NP	DT	0	_	_	_	_
36	mortality	mortality	I-NP	NN	0	_	_	_	_
37	after	after	B-PP	IN	0	_	_	_	_
38	3	3	B-NP	CD	0	_	_	_	_
39	months	month	I-NP	NNS	0	_	_	_	_
40	(	(	O	(	0	_	_	_	_
41	27	27	B-NP	CD	0	_	_	_	_
42	%	%	I-NP	NN	0	_	_	_	_
43	and	and	O	CC	0	_	_	_	_
44	16	16	B-NP	CD	0	_	_	_	_
45	%	%	I-NP	NN	0	_	_	_	_
46	,	,	O	,	0	_	_	_	_
47	respectively	respectively	B-ADVP	RB	0	_	_	_	_
48	)	)	O	)	0	_	_	_	_
49	and	and	O	CC	0	_	_	_	_
50	an	an	B-NP	DT	0	_	_	_	_
51	increase	increase	I-NP	NN	0	_	_	_	_
52	of	of	B-PP	IN	0	_	_	_	_
53	independence	independence	B-NP	NN	0	_	_	_	_
54	at	at	B-PP	IN	0	_	_	_	_
55	home	home	B-NP	NN	0	_	_	_	_
56	(	(	O	(	0	_	_	_	_
57	35	35	B-NP	CD	0	_	_	_	_
58	%	%	I-NP	NN	0	_	_	_	_
59	and	and	O	CC	0	_	_	_	_
60	48	48	B-NP	CD	0	_	_	_	_
61	%	%	I-NP	NN	0	_	_	_	_
62	,	,	O	,	0	_	_	_	_
63	respectively	respectively	B-ADVP	RB	0	_	_	_	_
64	)	)	O	)	0	_	_	_	_
65	due	due	B-PP	IN	0	_	_	_	_
66	to	to	B-PP	TO	0	_	_	_	_
67	a	a	B-NP	DT	0	_	_	_	_
68	reduction	reduction	I-NP	NN	0	_	_	_	_
69	of	of	B-PP	IN	0	_	_	_	_
70	the	the	B-NP	DT	0	_	_	_	_
71	viscosity	viscosity	I-NP	NN	0	_	_	_	_
72	by	by	B-PP	IN	0	_	_	_	_
73	means	mean	B-NP	NNS	0	_	_	_	_
74	of	of	B-PP	IN	0	_	_	_	_
75	haemodilution	haemodilution	B-NP	NN	0	_	_	_	_
76	with	with	B-PP	IN	0	_	_	_	_
77	albumin	albumin	B-NP	NN	:::NOCLASS	_	_	_	_
78	(	(	O	(	0	_	_	_	_
79	a	a	B-NP	DT	0	_	_	_	_
80	specific	specific	I-NP	JJ	0	_	_	_	_
81	viscosity	viscosity	I-NP	NN	0	_	_	_	_
82	effect	effect	I-NP	NN	0	_	_	_	_
83	in	in	B-PP	IN	0	_	_	_	_
84	the	the	B-NP	DT	0	_	_	_	_
85	normovolaemic	normovolaemic	I-NP	JJ	0	_	_	_	_
86	group	group	I-NP	NN	0	_	_	_	_
87	)	)	O	)	0	_	_	_	_
88	.	.	O	.	0	_	_	_	_

1	Distribution	Distribution	B-NP	NN	0	_	_	_	_
2	and	and	O	CC	0	_	_	_	_
3	changing	change	B-VP	VBG	0	_	_	_	_
4	morphological	morphological	B-NP	JJ	0	_	_	_	_
5	course	course	I-NP	NN	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	appropriate	appropriate	I-NP	JJ	0	_	_	_	_
3	use	use	I-NP	NN	0	_	_	_	_
4	and	and	I-NP	CC	0	_	_	_	_
5	benefits	benefit	I-NP	NNS	0	_	_	_	_
6	of	of	B-PP	IN	0	_	_	_	_
7	bile	bile	B-NP	NN	0	_	_	_	_
8	acid	acid	I-NP	NN	0	_	_	_	_
9	sequestrants	sequestrant	I-NP	NNS	0	_	_	_	_
10	,	,	O	,	0	_	_	_	_
11	nicotinic	nicotinic	B-NP	JJ	0	_	_	_	_
12	acid	acid	I-NP	NN	0	_	_	_	_
13	,	,	O	,	0	_	_	_	_
14	fibric	fibric	B-NP	JJ	0	_	_	_	_
15	acids	acid	I-NP	NNS	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	3	3	B-NP	CD	:::NOCLASS	_	_	_	_
18	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
19	hydroxy	hydroxy	I-NP	NN	:::NOCLASS	_	_	_	_
20	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
21	3	3	I-NP	CD	:::NOCLASS	_	_	_	_
22	-	-	I-NP	HYPH	:::NOCLASS	_	_	_	_
23	methylglutaryl	methylglutaryl	I-NP	NN	:::NOCLASS	_	_	_	_
24	coenzyme	coenzyme	I-NP	NN	:::NOCLASS	_	_	_	_
25	A	A	I-NP	NN	:::NOCLASS	_	_	_	_
26	(	(	O	(	:::NOCLASS	_	_	_	_
27	HMG	HMG	B-NP	NN	:::NOCLASS	_	_	_	_
28	-	-	B-NP	HYPH	:::NOCLASS	_	_	_	_
29	CoA	CoA	I-NP	NN	:::NOCLASS|UMLS:C2678439:T047:DISO	_	_	_	_
30	)	)	O	)	:::NOCLASS	_	_	_	_
31	reductase	reductase	B-NP	NN	:::NOCLASS	_	_	_	_
32	inhibitors	inhibitor	I-NP	NNS	0	_	_	_	_
33	,	,	O	,	0	_	_	_	_
34	and	and	O	CC	0	_	_	_	_
35	probucol	probucol	B-NP	NN	0	_	_	_	_
36	are	be	B-VP	VBP	0	_	_	_	_
37	individually	individually	I-VP	RB	0	_	_	_	_
38	discussed	discuss	I-VP	VBN	0	_	_	_	_
39	,	,	O	,	0	_	_	_	_
40	whereas	whereas	O	IN	0	_	_	_	_
41	nonpharmacologic	nonpharmacologic	B-NP	JJ	0	_	_	_	_
42	approaches	approach	I-NP	NNS	0	_	_	_	_
43	used	use	B-VP	VBN	0	_	_	_	_
44	in	in	B-PP	IN	0	_	_	_	_
45	conjunction	conjunction	B-NP	NN	0	_	_	_	_
46	with	with	B-PP	IN	0	_	_	_	_
47	the	the	B-NP	DT	0	_	_	_	_
48	drugs	drug	I-NP	NNS	0	_	_	_	_
49	are	be	B-VP	VBP	0	_	_	_	_
50	recommended	recommend	I-VP	VBN	0	_	_	_	_
51	emphatically	emphatically	B-ADVP	RB	0	_	_	_	_
52	.	.	O	.	0	_	_	_	_

1	This	This	B-NP	DT	0	_	_	_	_
2	may	may	B-VP	MD	0	_	_	_	_
3	result	result	I-VP	VB	0	_	_	_	_
4	in	in	B-PP	IN	0	_	_	_	_
5	more	more	B-NP	JJR	0	_	_	_	_
6	reabsorption	reabsorption	I-NP	NN	0	_	_	_	_
7	and	and	O	CC	0	_	_	_	_
8	hence	hence	B-NP	RB	0	_	_	_	_
9	reduced	reduce	I-NP	VBN	0	_	_	_	_
10	renal	renal	I-NP	JJ	UMLS:C0022646:T023:ANAT	_	_	_	_
11	clearance	clearance	I-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	The	The	B-NP	DT	0	_	_	_	_
2	major	major	I-NP	JJ	0	_	_	_	_
3	pathological	pathological	I-NP	JJ	0	_	_	_	_
4	findings	finding	I-NP	NNS	0	_	_	_	_
5	of	of	B-PP	IN	0	_	_	_	_
6	the	the	B-NP	DT	0	_	_	_	_
7	placenta	placenta	I-NP	NN	0	_	_	_	_
8	were	be	B-VP	VBD	0	_	_	_	_
9	prematuration	prematuration	B-NP	NN	0	_	_	_	_
10	and	and	I-NP	CC	0	_	_	_	_
11	hypoplasia	hypoplasia	I-NP	NN	0	_	_	_	_
12	.	.	O	.	0	_	_	_	_

1	Green	Green	B-NP	JJ	0	_	_	_	_
2	pepper	pepper	I-NP	NN	0	_	_	_	_
3	significantly	significantly	B-ADVP	RB	0	_	_	_	_
4	inhibited	inhibit	B-VP	VBD	0	_	_	_	_
5	N	N	B-NP	NN	0	_	_	_	_
6	-	-	B-NP	HYPH	0	_	_	_	_
7	nitrosothiazolidine	nitrosothiazolidine	I-NP	NN	0	_	_	_	_
8	-	-	I-NP	HYPH	0	_	_	_	_
9	carboxylic	carboxylic	I-NP	JJ	0	_	_	_	_
10	acid	acid	I-NP	NN	0	_	_	_	_
11	formation	formation	I-NP	NN	0	_	_	_	_
12	relative	relative	B-ADVP	JJ	0	_	_	_	_
13	to	to	B-PP	TO	0	_	_	_	_
14	ascorbic	ascorbic	B-NP	JJ	0	_	_	_	_
15	acid	acid	I-NP	NN	0	_	_	_	_
16	alone	alone	B-ADVP	RB	0	_	_	_	_
17	.	.	O	.	0	_	_	_	_

1	A	A	B-NP	DT	0	_	_	_	_
2	genomic	genomic	I-NP	JJ	0	_	_	_	_
3	clone	clone	I-NP	NN	0	_	_	_	_
4	,	,	O	,	0	_	_	_	_
5	pTt21	pTt21	B-NP	NN	0	_	_	_	_
6	,	,	O	,	0	_	_	_	_
7	containing	contain	B-VP	VBG	0	_	_	_	_
8	DNA	DNA	B-NP	NN	0	_	_	_	_
9	apparently	apparently	B-VP	RB	0	_	_	_	_
10	transcribed	transcribe	I-VP	VBN	0	_	_	_	_
11	specifically	specifically	B-ADVP	RB	0	_	_	_	_
12	in	in	B-PP	IN	0	_	_	_	_
13	Trypanosoma	Trypanosoma	B-NP	NN	0	_	_	_	_
14	cruzi	cruzi	I-NP	NN	0	_	_	_	_
15	trypomastigotes	trypomastigote	I-NP	NNS	0	_	_	_	_
16	,	,	O	,	0	_	_	_	_
17	was	be	B-VP	VBD	0	_	_	_	_
18	obtained	obtain	I-VP	VBN	0	_	_	_	_
19	by	by	B-PP	IN	0	_	_	_	_
20	differentially	differentially	B-VP	RB	0	_	_	_	_
21	screening	screen	I-VP	VBG	0	_	_	_	_
22	a	a	B-NP	DT	0	_	_	_	_
23	genomic	genomic	I-NP	JJ	0	_	_	_	_
24	library	library	I-NP	NN	0	_	_	_	_
25	with	with	B-PP	IN	0	_	_	_	_
26	trypomastigote	trypomastigote	B-NP	NN	0	_	_	_	_
27	and	and	I-NP	CC	0	_	_	_	_
28	epimastigote	epimastigote	I-NP	NN	0	_	_	_	_
29	cDNA	cDNA	I-NP	NN	0	_	_	_	_
30	.	.	O	.	0	_	_	_	_

